<SEC-DOCUMENT>0001171843-15-004476.txt : 20150807
<SEC-HEADER>0001171843-15-004476.hdr.sgml : 20150807
<ACCEPTANCE-DATETIME>20150807163921
ACCESSION NUMBER:		0001171843-15-004476
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		28
CONFORMED PERIOD OF REPORT:	20150630
FILED AS OF DATE:		20150807
DATE AS OF CHANGE:		20150807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arbutus Biopharma Corp
		CENTRAL INDEX KEY:			0001447028
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980597776
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34949
		FILM NUMBER:		151038026

	BUSINESS ADDRESS:	
		STREET 1:		100-8900 GLENLYON PARKWAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5J 5J8
		BUSINESS PHONE:		604-419-3200

	MAIL ADDRESS:	
		STREET 1:		100-8900 GLENLYON PARKWAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5J 5J8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS Corp
		DATE OF NAME CHANGE:	20110607

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20081003
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gfpf10q_080515.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<p style="margin: 0"></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0"><b>UNITED STATES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>Washington, D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>Form 10-Q</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; font-size: 10pt"><font style="font: 10pt Wingdings"><b>x</b></font></td>
    <td style="width: 94%; font-size: 10pt"><font style="font-size: 10pt"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>For the quarterly period ended June 30, 2015</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>OR</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; font-size: 10pt"><font style="font: 10pt Wingdings"><b>o</b></font></td>
    <td style="width: 94%; font-size: 10pt"><font style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>For the Transition Period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>Commission File Number: 001-34949</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in"><b>Arbutus Biopharma Corporation</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 50%; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>British Columbia, Canada</b></font></td>
    <td style="vertical-align: bottom; width: 50%; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>980597776</b></font></td></tr>
<tr style="vertical-align: top">
    <td>
        <p style="font-size: 10pt; text-align: center; margin: 0 3.2pt 0 0">(State or Other Jurisdiction of</p>
        <p style="font-size: 10pt; text-align: center; margin: 0 3.2pt 0 0">Incorporation or Organization)</p></td>
    <td>
        <p style="font-size: 10pt; text-align: center; margin: 0 3.2pt 0 0">(I.R.S. Employer</p>
        <p style="font-size: 10pt; text-align: center; margin: 0 3.2pt 0 0">Identification No.)</p></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>100-8900 Glenlyon Parkway, Burnaby, BC, Canada V5J 5J8</b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: center; font-size: 10pt"><font style="font-size: 10pt">(Address of Principal Executive Offices)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: center; font-size: 10pt"><font style="font-size: 10pt">604-419-3200</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: center; font-size: 10pt"><font style="font-size: 10pt">(Registrant&#8217;s Telephone Number, Including Area Code)</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements
for the past 90 days. Yes [x] No [&nbsp;]</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and
post such files). Yes [x] No [&nbsp;]</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated
filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check
one):</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 28%; text-align: left; font-size: 10pt"><font style="font-size: 10pt">Large accelerated filer [&nbsp; ]</font></td>
    <td style="width: 24%; font-size: 10pt"><font style="font-size: 10pt">Accelerated filer [&nbsp;x ]</font></td>
    <td style="width: 24%">
        <p style="font-size: 10pt; margin: 0 0.8pt 0 0">Non-accelerated filer [&nbsp;&nbsp;&nbsp;]</p>
        <p style="font-size: 10pt; margin: 0 0.8pt 0 0">(Do not check if a smaller reporting company)</p></td>
    <td style="width: 24%; text-align: left; font-size: 10pt"><font style="font-size: 10pt">Smaller reporting company [&nbsp; ]</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes [&nbsp; ] No [x]</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0">As of July 31, 2015, the registrant had 54,328,414&nbsp;common shares,
no par value,&nbsp;outstanding.<font style="background-color: yellow"></font></p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0 0 8pt"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in"><b>ARBUTUS BIOPHARMA CORP.</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>TABLE OF CONTENTS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; margin: 0"><b><u>Page</u></b></p>

<p style="font-size: 10pt; text-align: right; margin: 0">&nbsp;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 90%; text-align: left"><a href="#p1">PART I. FINANCIAL INFORMATION</a></td>
    <td style="width: 10%; text-align: right; padding-bottom: 0pt"><a href="#p1">3</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p1i1">ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p1i1">3</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p1i2">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p1i2">21</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p1i3">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#p1i3">39</A><b></b></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p1i4">ITEM 4. DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROLS OVER FINANCIAL REPORTING</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p1i4">39</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in">&nbsp;</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left"><a href="#p2">PART II. OTHER INFORMATION</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2">40</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p2i1">ITEM 1. LEGAL PROCEEDINGS</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i1">40</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p2i1a">ITEM 1A. RISK FACTORS</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i1a">40</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 30pt; text-indent: -10pt"><a href="#p2i2">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i2">41</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p2i3">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i3">41</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p2i4">ITEM 4. MINE SAFETY DISCLOSURES</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i4">41</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p2i5">ITEM 5. OTHER INFORMATION</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i5">41</a></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt"><a href="#p2i6">ITEM 6. EXHIBITS</a></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 0in"><a href="#p2i6">41<u></u></a></td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0"></p>

<p style="margin: 12pt 0 0; font-size: 10pt; text-align: center"><a name="p1"></a><b>PART I.&nbsp;&nbsp;&nbsp;FINANCIAL INFORMATION</b></p>

<p style="margin: 12pt 0 0; font-size: 10pt"><a name="p1i1"></a><b>ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><b>Condensed Consolidated Balance Sheets</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Expressed in US Dollars and in thousands, except share and per share
amounts)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Prepared in accordance with US GAAP)</p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">June 30 <br>2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">December 31 <br>2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Current assets:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-size: 10pt; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">207,205</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">72,187</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Short-term investments (note 2)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">39,974</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">6,332</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,903</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accrued revenue</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">323</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">538</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Investment tax credits receivable</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">55</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">86</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Prepaid expenses and other assets</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,787</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,730</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total current assets</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">215,702</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">116,418</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Long-term investments (note 2)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">10,012</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">12,469</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,959</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Less accumulated depreciation</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(10,433</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(11,199</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net of accumulated depreciation</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,036</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,760</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Intangible assets (note 3)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">390,017</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Goodwill (note 3)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">156,053</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total assets</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">773,820</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">118,178</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and stockholders' equity</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Current liabilities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued liabilities (note 5)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">6,920</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,328</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred revenue (note 4)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,605</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,779</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Warrants (note 2)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,606</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,099</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 0pt">Total current liabilities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">16,131</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,206</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred revenue, net of current portion (note 4)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">8,045</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,937</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Contingent consideration (note 8)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,136</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Deferred tax liability (note 3)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">156,007</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Total liabilities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">185,319</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,143</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Common shares (note 3 and note 6)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 30pt">Authorized - unlimited number with no par value</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">Issued and outstanding:<br> <font style="font-size: 10pt; font-weight: normal; font-style: normal">54,303,402 (December 31, 2014 - 22,438,169)</font></td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">821,660</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">290,004</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Additional paid-in capital</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">27,844</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,208</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Deficit</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(232,739</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(205,864</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Accumulated other comprehensive loss</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(28,264</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(22,313</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Total stockholders' equity</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">588,501</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">88,035</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total liabilities and stockholders' equity</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">773,820</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">118,178</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Nature of business and future operations (note 1)</p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Contingencies and commitments (note 8)</p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the condensed consolidated financial statements. </p>





<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><b>Condensed Consolidated Statements of Operations and Comprehensive
Loss</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Expressed in US Dollars and in thousands, except share and per share
amounts)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Prepared in accordance with US GAAP)</p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><p style="margin-top: 0; margin-bottom: 0">Three months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30</p></td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><p style="margin-top: 0; margin-bottom: 0">Six months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30</p></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Revenue (note 4)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; font-size: 10pt; text-align: left">Collaborations and contracts</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">2,310</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">1,144</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">5,830</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">4,833</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Licensing fees, milestone and royalty payments</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">1,130</td><td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">667</td><td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2,292</td><td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">1,408</td><td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Total revenue</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,440</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,811</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,122</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,241</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Research, development, collaborations and contracts</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">9,690</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,298</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">20,247</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,502</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,662</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,787</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">10,378</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,837</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Depreciation of property and equipment</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">147</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">267</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">283</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Acquisition costs (note 3)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">361</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">9,656</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Total expenses</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">17,860</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">11,234</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">40,548</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,622</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(14,420</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9,423</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(32,426</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15,381</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other income (losses)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">81</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">257</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">283</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">404</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Foreign exchange gains (losses)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(2,571</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,728</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,467</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,285</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Increase) decrease in fair value of warrant liability (note 2)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,024</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,813</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">801</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(7,803</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Net loss</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(14,886</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(6,081</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(26,875</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(24,065</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Loss per common share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic and diluted</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.27</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.28</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.64</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(1.15</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Weighted average number of common shares</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic and diluted</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">54,255,804</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,063,438</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">42,297,517</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,938,503</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Cumulative translation adjustment</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,223</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,774</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(5,951</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,616</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Comprehensive loss</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(11,663</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(2,307</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(32,826</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(22,449</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">)</td></tr>
</table></div>




<p style="margin: 0">&nbsp;</p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the condensed consolidated financial statements.</p>




<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<P STYLE="font-size: 10pt; text-align: left; margin-right: 0pt; margin-bottom: 0pt; margin-left: 0pt"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><b>Condensed Consolidated Statement of Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)<br>
(Expressed in US Dollars and in thousands, except share and per share amounts)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Prepared in accordance with US GAAP)</p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">Number <br>of shares</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">Share <br>capital</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">Additional paid-in <br>capital</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">Deficit</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">Accumulated <br>other comprehensive <br>loss</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">Total <br>stockholders' <br>equity</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; font-weight: bold">Balance, December 31, 2014</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">22,438,169</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">290,004</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">26,208</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">(205,864</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">(22,313</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">88,035</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Stock-based compensation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,324</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,906</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,230</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt; text-indent: -10pt">Issuance of common shares pursuant to exercise of options</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">373,168</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,956</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,397</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,559</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt; text-indent: -10pt">Issuance of common shares pursuant to exercise of warrants</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">18,750</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">384</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">384</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of common shares in conjunction with the private offering, net of
    issuance costs of $9,700,000</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,500,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">142,177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">142,177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of equity instruments in
    conjunction with the acquisition of Arbutus Inc.     (note 3)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,973,315</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">380,815</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,127</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">381,942</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Currency translation adjustment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,951</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,951</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(26,875</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(26,875</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">Balance, June 30, 2015</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">54,303,402</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">821,660</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">27,844</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(232,739</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(28,264</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">588,501</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the condensed consolidated financial statements.</p>




<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><b>Condensed Consolidated Statements of Cash Flow</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)<br>
(Expressed in US Dollars and in thousands)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Prepared in accordance with US GAAP)</p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="margin: 0"></p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three months ended<br> June 30</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Six months ended<br> June 30</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">OPERATING ACTIVITIES</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; font-size: 10pt; text-align: left">Net loss for the period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">(14,886</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">(6,081</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">(26,875</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">(24,065</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Items not involving cash:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation of property and equipment</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">147</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">267</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">283</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation - research, development, collaborations<br> and contract expenses</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,377</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">792</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,705</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,640</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation - general and administrative expenses</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,046</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">289</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,525</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">629</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Unrealized foreign exchange (gains) losses</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,639</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,391</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(4,418</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,332</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(2,024</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,813</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(801</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,803</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net change in non-cash operating items:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(1,738</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,231</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(4,624</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(178</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accrued revenue</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,304</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">220</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">178</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(519</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(298</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">725</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(7,351</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(943</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(5,343</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">108</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred revenue</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">334</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">455</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(957</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,744</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Net cash provided by (used in) operating activities</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(16,671</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(8,010</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(35,641</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,145</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">INVESTING ACTIVITIES</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Disposition (acquisition) of short and long-term investments</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(9,944</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(42,992</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">27,419</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(42,992</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash acquired through acquisition (note 3)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">324</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Acquisition of property and equipment</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(383</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(246</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(524</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(581</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Net cash provided by (used) in investing activities</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(10,327</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(43,238</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">27,219</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(43,573</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">FINANCING ACTIVITIES</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Proceeds from issuance of common shares, net of issuance costs</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">142,177</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">56,477</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Issuance of common shares pursuant to exercise of options</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">939</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">148</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,559</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,072</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Issuance of common shares pursuant to exercise of warrants</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">19</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">86</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">44</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">974</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Net cash provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">960</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">234</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">143,780</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">59,523</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Effect of foreign exchange rate changes on cash and cash equivalents</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">967</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,924</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(340</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(545</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Increase in cash and cash equivalents</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(25,071</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(49,090</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">135,018</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,550</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Cash and cash equivalents, beginning of period</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">232,276</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">134,357</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">72,187</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">68,717</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Cash and cash equivalents, end of period</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">207,205</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">85,267</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">207,205</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">85,267</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental cash flow information</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Non-cash transactions:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair value of warrants exercised on a cashless basis</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(116</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(116</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Investment tax credits received</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">25</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">25</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Acquisition of Arbutus Inc. excluding cash acquired</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">381,618</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the condensed consolidated financial
statements.</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 0pt"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left"><td style="width: 15pt; text-align: left"><b>1.</b></td><td style="width: 5pt"></td><td style="text-align: left"><b>Nature of business and future operations</b></td>
</tr></table>
<P STYLE="font-size: 10pt; text-align: left; margin: 6pt 0 0">Arbutus Biopharma Corporation (the &#8220;Company&#8221; or &#8220;Arbutus&#8221;)
is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering
from chronic hepatitis B infection (&#8220;HBV&#8221;), a disease of the liver caused by hepatitis B virus (&#8220;HBV&#8221;).
The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company&#8217;s
expertise in Lipid Nanoparticle (&#8220;LNP&#8221;) technology.</p>

<P STYLE="font-size: 10pt; text-align: left; margin: 6pt 0 0">Effective July 31, 2015, the corporate name changed from Tekmira
Pharmaceuticals Corporation (&#8220;Tekmira&#8221;) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate
name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (&#8220;OnCore&#8221;) changed to Arbutus Biopharma Inc. (&#8220;Arbutus
Inc.&#8221;). Including Arbutus Inc., the Company has five wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (&#8220;Protiva&#8221;),
Protiva Biotherapeutics (USA) Inc. (&#8220;Protiva USA&#8221;), Protiva Agricultural Development Company Inc. (&#8220;PADCo&#8221;),
and Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;).</p>

<P STYLE="font-size: 10pt; text-align: left; margin: 6pt 0 0">The success of the Company is dependent on obtaining the necessary
regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development
activities and the commercialization of its products are dependent on the Company&#8217;s ability to successfully complete these
activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to
predict either the outcome of future research and development programs or the Company&#8217;s ability to fund these programs in
the future.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p></div><p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left"><b>2.</b></td><td style="width: 5pt"></td><td style="text-align: left"><b>Significant accounting policies</b></td>
</tr></table>
<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><b><i>Basis of presentation</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">These unaudited condensed consolidated financial statements have
been prepared in accordance with generally accepted accounting principles of the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These
statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for
the year ended December 31, 2014 and included in the Company&#8217;s 2014 annual report on Form 10-K. The unaudited condensed consolidated
financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the
financial position, results of operations and cash flows at June 30, 2015 and for all periods presented. The results of operations
for the three and six months ended June 30, 2015 and June 30, 2014 are not necessarily indicative of the results for the full year.
These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes
to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b><i>Principles of Consolidation</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0">These condensed consolidated financial statements include the
accounts of the Company and four of its wholly-owned subsidiaries, Arbutus Inc., Protiva, Protiva USA, and Enantigen. All intercompany
transactions and balances have been eliminated on consolidation.</p>

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0">The Company records its investment in PADCo using the equity method.
The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;) of which it is not the primary beneficiary.
The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic
performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could
potentially be significant to the VIE. PADCo is described further in note 4(b).</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b><i>Replacement awards </i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">Replacement awards are share-based payment awards exchanged for awards
held by employees of Arbutus Inc. As part of the Company&#8217;s acquisition of Arbutus Inc. (formerly OnCore), Arbutus (formerly
Tekmira) shares were exchanged for Arbutus Inc.&#8217;s shares subject to repurchase rights held by Arbutus Inc.&#8217;s employees
&#8211; see note 3.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">As at the date of acquisition of Arbutus Inc., the Company determined
the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part
of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense
over the expiry period of repurchase provision rights subsequent to the acquisition date.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 6pt 0 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 6pt 0 0">The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense
related to these awards is recognized, share capital is increased by a corresponding amount.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>


<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b><i>Goodwill and intangible assets</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">The costs incurred in establishing and maintaining patents for intellectual
property developed internally are expensed in the period incurred.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">Intangible assets consist of in-process research and
development arising from the Company&#8217;s acquisition of Arbutus Inc. &#8211; see note 3. In-process research and
development (IPR&amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;D becomes
definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets
with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective
patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event
indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and
if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written
down to their fair values.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">Goodwill represents the excess of purchase price over the value assigned
to the net tangible and identifiable intangible assets of Arbutus Inc. &#8211; see note 3. Goodwill has an indefinite accounting
life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the
Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting
unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount,
goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If
the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss.
If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.</p>

<p style="font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><b><i>Income or loss per share</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">Income or loss per share is calculated based on the weighted average
number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company&#8217;s
stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses
the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially
issuable common shares from outstanding, in-the-money stock options and warrants. During the six months ended June 30, 2015, potential
common shares of 2,774,398 (June 30, 2014 &#8211; 2,558,925) were excluded from the calculation of income per common share because
their inclusion would be anti-dilutive.</p>

<p style="font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><b><i>Fair value of financial instruments</i></b></p>

<P STYLE="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The Company measures certain financial instruments and other
items at fair value.</p>

<P STYLE="font-size: 10pt; text-align: left; margin: 9pt 0 0">To determine the fair value, the Company uses the fair value hierarchy
for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs
by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use
to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are
inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of
inputs that may be used to measure fair value are as follows:</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; text-align: left">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-align: left">&#8226;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; text-align: left">Level 1 inputs are quoted market prices for identical instruments available in active markets.</td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0 4.5pt 0 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; text-align: left">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-align: left">&#8226;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; text-align: left">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 2.5pt 0.8pt 0 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; text-align: left">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; text-align: left">&#8226;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; text-align: left">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>



<p style="font-size: 10pt; margin: 0 0 8pt"></p>


<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0">The following tables present information about the Company&#8217;s
assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy
of the valuation techniques used to determine such fair value:</p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 1</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 2</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 3</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">207,205</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">207,205</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Term deposit</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Total</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">217,217</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">217,217</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Liabilities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrants</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,606</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,606</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Contingent consideration</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,136</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,136</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Total</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,742</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,742</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 1</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 2</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 3</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td><td nowrap style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">December 31, 2014</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">72,187</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">72,187</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Guaranteed investment certificates</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Total</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">112,161</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">112,161</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Liabilities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warrants</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Total</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The Company acquired a term deposit in May 2015 with an original
maturity of 24-months and it has been classified as a long-term investment on the balance sheet. For the period ended June 30,
2015, the fair value of the term deposit is $10,012,000 which includes the principal and accrued interest earned as at the balance
sheet date.</p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The Company used a discounted cash flow model to determine
the fair value of the financial instrument, related to Monsanto&#8217;s call option to acquire the equity or all of the assets
of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The
initial fair value of the financial liability was nil, and there has been no change to its fair value as at June 30, 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">Contingent consideration is a liability assumed by the Company
from its acquisition of Arbutus Inc. &#8211; see notes 3 and 8. The Company used a discounted cash flow model to determine the
fair value of the contingent consideration as at the acquisition date, and at each subsequent reporting date. The Company&#8217;s
preliminary estimate of the contingent consideration was $4,736,000 for the reporting date of March 31, 2015. As at June 30, 2015,
the Company has reassessed the preliminary initial fair value of the contingent consideration to be $5,136,000.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>




<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0">The following table presents the changes in fair value of the
Company&#8217;s warrants, in thousands:</p>

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Liability at beginning of the period</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Opening liability of warrants issued in the period</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Fair value of warrants exercised in the period</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><p style="margin-top: 0; margin-bottom: 0">Increase (decrease) in fair</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">value of warrants</p></td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><p style="margin-top: 0; margin-bottom: 0">Foreign exchange&nbsp;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(gain) loss</p></td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><p style="margin-top: 0; margin-bottom: 0">Liability at end</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">of the period</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td nowrap style="width: 12%; font-size: 10pt; text-align: left">Six months ended June 30, 2014</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">5,379</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(6,607</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">7,803</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">15</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">6,590</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">Six months ended June 30, 2015</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,099</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(341</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(801</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(351</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,606</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The change in fair value of warrant liability for the
six months ended June 30, 2015 is recorded in the statement of operations and comprehensive loss.</p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The weighted average Black-Scholes option-pricing assumptions
and the resultant fair values, in thousands, for warrants outstanding at June 30, 2015 and at December 31, 2014 are as follows:</p>

<p style="font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-size: 10pt; text-align: left">Dividend yield</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">0.00</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt; text-align: right">0.00</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">69.32</td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">85.22</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">0.59</td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.00</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Expected average term (years)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">0.4</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of warrants outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">9.50</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">12.80</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Aggregate fair value of warrants outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,606</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Number of warrants outstanding</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">379,500</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">398,250</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><b><i>Foreign currency translation and reporting currency</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><b>Functional currency</b></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The functional currency of the Company and its integrated subsidiaries
(Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian
dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical
exchange rates. The previous month&#8217;s average rate of exchange is used to translate revenue and expense transactions. Exchange
gains and losses are included in income or loss for the period.</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The local currency of Arbutus Inc. (including its subsidiary, Enantigen)
is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic
environment in which Arbutus Inc. operates and expends cash. Foreign currency monetary assets and liabilities are translated into
United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated
at historical exchange rates. The previous month&#8217;s average rate of exchange is used to translate revenue and expense transactions.
Exchange gains and losses are included in income or loss for the period.</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><b>Reporting currency</b></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The Company is using United States dollars as its reporting currency.
All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income
(losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the
date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the
Company&#8217;s functional currency to the Company&#8217;s reporting currency of U.S. dollars are unrealized gains and losses;
therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss
per Share.</p>

<p style="font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>


<p style="font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><b><i>Recent accounting pronouncements</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">From time to time, new accounting pronouncements are issued by
the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified
effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet
effective will not have a material impact on its financial position or results of operations upon adoption.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers
(ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard
for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue
recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue
Recognition &#8211; Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity
recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1)
retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying
this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date
of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December
15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective
date if they choose. The Company has not yet determined the extent of the impact of adoption.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial
Statements &#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as
a Going Concern. The update is intended to provide guidance in GAAP about management&#8217;s responsibility to evaluate whether
there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures.
Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or
available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company
means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does
not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p></div><p style="font-size: 10pt; text-align: left; margin: 0"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left"><b>3.</b></td><td style="width: 5pt"></td><td style="text-align: left"><b>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</b></td>
</tr></table>


<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">On January 11, 2015, the Company entered into a Merger Agreement to acquire
100% of the outstanding shares of Arbutus Inc. and its wholly-owned subsidiary, Enantigen (see note 8). Arbutus Inc. was a privately
owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The
merger was approved by the Company&#8217;s shareholders on March 3, 2015 and consummated on March 4, 2015. Arbutus Inc.&#8217;s
results of operations and fair value of assets acquired and liabilities assumed are included in the Company&#8217;s consolidated
financial statements from the date of acquisition.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The transaction has been accounted for using the acquisition method based
on ASC 805, Business Combinations, on the basis that Arbutus (formerly Tekmira) is the acquirer, based on managements&#8217; analysis
and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and
the relative number of shares issued by the Company on acquisition of Arbutus Inc.. Under the acquisition method, the consideration
transferred is measured at the market price as at the acquisition date. The excess of the purchase price over the preliminary value
assigned to the net assets acquired has been recorded as goodwill. Acquisition costs are expensed as incurred. The company recorded
$9,656,000 of acquisition costs for the six-months ended June 30, 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The Company issued a total of 23,973,315 common shares with a total
value of $381,942,000 as consideration, which is comprised of 20,347,906 common shares issued without subjects and 3,625,412
common shares issued to Arbutus Inc.&#8217;s founding executives and subject to repurchase provision. The fair value of the
common shares issued without subjects has been determined to be the Company&#8217;s NASDAQ closing price of $18.26 on the
date prior to the acquisition&#8217;s consummation, March 4, 2015. The total fair value of the common shares issued subject
to repurchase provision has been determined to be $66,196,000, using the Black-Scholes pricing model with assumed risk-free
interest rate of 0.74%, volatility of 81%, a zero dividend yield and an expected life of 4 years. Of the total fair value,
$9,262,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The
post-combination attribution of $56,934,000 will be recognized as compensation expense over the period of expiry of
repurchase provision rights through to August 2018. The Company has included $5,324,000 compensation expense related to the
expiration of repurchase provision rights from the acquisition date through to June 30, 2015. In July 2015, in conjunction
with amendments to the the employment contracts of Arbutus Inc.&#8217;s founding executives, the Company amended the
repurchase provision rights period of expiry from August 2018 to August 2017. This amendment results in an acceleration of
compensation expense recognized in each subsequent period by approximately $1,893,000 per quarter, effective Q3 2015.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">As at June 30, 2015, 3,625,412 shares were issued and outstanding
which are subject to repurchase provision. Subsequent to the acquisition date, the repurchase rights expire at a rate of
453,177 shares every 3 months commencing on November 30, 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>





<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The Company has further reserved 184,332 shares for the future exercise
of Arbutus Inc. stock options. The total fair value of Arbutus Inc. stock options has been determined to be $3,287,000, using the
Black-Scholes pricing model with the same assumption inputs used by the Company to determine the fair value of Arbutus options.
Of the total fair value, $1,127,000 has been attributed as pre-combination service and included as part of the total acquisition
consideration. The post-combination attribution of $2,160,000 will be recognized as compensation expense over the vesting period
of the stock options through to December 2018. The Company has included $190,000 compensation expense related to the vesting of
Arbutus Inc. stock options from the acquisition date through to June 30, 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The aggregate fair value of consideration transferred to acquire Arbutus
Inc.&#8217;s outstanding shares has been determined to be $381,942,000, and has been attributed to preliminary fair values of assets
acquired and liabilities assumed as summarized in the following table, in thousands:</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Consideration paid:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 89%; font-size: 10pt; text-align: left; padding-left: 10pt">Common shares issued without subjects</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">371,553</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Common shares issued subject to repurchase provision</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,262</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Common shares issuable for Arbutus Inc. stock options</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,127</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">381,942</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Identifiable assets acquired and liabilities assumed:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">324</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">116</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">147</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acquired intangible assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">390,017</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Goodwill</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">156,053</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,580</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Other noncurrent liabilities (note 8)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,136</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Deferred income tax liability</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(156,017</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total purchase price allocation</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">381,942</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The preliminary fair value of intangible assets is estimated to be $390,017,000
using the income approach. The income approach uses valuation techniques to discount future economic benefits attributed to the
subject intangible asset to a present value. Present value is based on current market expectations about those future amounts
and includes management&#8217;s estimates of risk-adjusted future incremental earnings that may be achieved upon regulatory approval,
promotion, and distribution associated with the rights and includes estimated cash flows of approximately 20 years and a discount
rate of approximately 13.8%. The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;D)
HBV assets, as summarized in the table below:</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">$</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 89%; font-size: 10pt; text-align: left">IPR&amp;D &#8211; Cyclophilins</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt; text-align: right">35,124</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">IPR&amp;D &#8211; Immune Modulator</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">189,182</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">IPR&amp;D &#8211; Antigen Inhibitors</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">35,520</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">IPR&amp;D &#8211; cccDNA</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">130,191</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Total IPR&amp;D</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">390,017</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>






<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">All IPR&amp;D acquired are currently classified as indefinite-lived
and so is not currently being amortized. IRP&amp;D becomes definite-lived upon the completion or abandonment of the
associated research and development efforts, and will be amortized from that time over an estimated useful life based on
respective patent terms. The fair value of each IPR&amp;D asset will continue to be evaluated on a quarterly basis for
indicators of impairment.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Based on the preliminary fair values above, an amount of $156,053,000 has
been allocated to goodwill, which represents the excess of the purchase price over the final value assigned to the net assets acquired.
Goodwill is attributable to synergies expected to arise after the Company&#8217;s acquisition of Arbutus Inc. The full amount of
the goodwill has been assigned to Arbutus, which is the reporting unit management has determined the goodwill to be associated
with. The goodwill is not deductible for tax purposes, and is not amortized, but will be evaluated for impairment on an annual
basis.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The amount of net loss of Arbutus Inc. included in the consolidated statements
of operations from the acquisition date, through the period ended June 30, 2015 was $4,072,000. Arbutus Inc. did not earn any
revenues from the acquisition date through the period ended June 30, 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<p style="font-size: 10pt; text-align: left; margin: 0">The following table presents the unaudited pro forma results for the three
and six months ended June 30, 2015 and 2014. The pro forma financial information combines the results of operations of Arbutus,
Arbutus Inc., Protiva, Protiva USA, and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014. The pro forma financial information is presented for informational purposes only, and is not indicative of the results
of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014. The pro forma
financial information presented includes acquisition costs, amortization charges for acquired tangible assets, but does not include
amortization charges for acquired intangible assets as these assets have not yet been put in use.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended <br>June&nbsp;30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended <br>June&nbsp;30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Pro forma information</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; font-size: 10pt; text-align: left">Gross Revenue</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">3,440</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">1,811</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">8,122</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">6,241</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(14,420</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13,844</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(39,491</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(24,278</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(14,886</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(10,479</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(33,940</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(32,962</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Basic and diluted loss per share</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.27</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.23</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.67</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.73</td><td style="font-size: 10pt; text-align: left">)</td></tr>
</table></div>


<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p></div><p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><font style="background-color: yellow"></font></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left"><td style="width: 15pt; text-align: left"><b>4.</b></td><td style="width: 5pt"></td><td style="text-align: left"><b>Collaborations, contracts and licensing agreements</b></td>
</tr></table>


<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The following tables set forth revenue recognized under collaborations,
contracts and licensing agreements, in thousands:</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three months ended June 30</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Six months ended June 30</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Collaborations and contracts</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">DoD (a)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">1,862</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">861</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">4,907</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">4,101</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto (b)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">269</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">283</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">517</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">526</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">BMS (d)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">206</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Dicerna (e)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">179</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">406</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total research and development collaborations and contracts</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,310</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,144</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,830</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,833</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Licensing fees, milestone and royalty payments</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto licensing fees and milestone payments (b)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">805</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">626</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,647</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,171</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acuitas milestone payments (c)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">150</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Dicerna licensing fee (e)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">263</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">526</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Spectrum royalty payments (f)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">62</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">41</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">119</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">87</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Total licensing fees, milestone and royalty payments</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,130</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">667</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,292</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,408</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Total revenue</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,440</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,811</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,122</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,241</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>





<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0">The following table sets forth deferred collaborations and contracts
revenue:</p>

<p style="font-size: 10pt; text-align: left; margin: 9pt 0 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2015</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left">DoD (a)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">563</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">313</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Monsanto current portion (b)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,746</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,245</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Dicerna current portion (e)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,296</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,221</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred revenue, current portion</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,605</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,785</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Monsanto long-term portion (b)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,336</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,666</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Dicerna long-term portion (e)</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">709</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total deferred revenue</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,650</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">15,722</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>(a) Contract with United States Government&#8217;s Department of Defense
(&#8220;DoD&#8221;) to develop TKM-Ebola</b></p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">On July&nbsp;14, 2010, the Company signed a contract with the DoD
to advance TKM-Ebola, an RNAi therapeutic utilizing the Company&#8217;s lipid nanoparticle technology to treat Ebola virus infection.</p>

<p style="font-size: 10pt; text-align: left; margin: 4.5pt 0 0">In the initial phase of the contract, funded as part of the Transformational
Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development
of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States
Food and Drug Administration (&#8220;FDA&#8221;) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company
announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle
(&#8220;LNP&#8221;) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding
by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the
stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads
related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required.
In May 2015, the Company and the DoD signed a contract modification to further increase stage one funding by up to $1,000,000.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The DoD has the option of extending the contract beyond the initial funding
period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the
contract&#8217;s budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014,
the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the &#8220;Ebola-Guinea
Amendment&#8221;), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">In March 2015, the Company and the DoD signed a contract modification to provide up to $2,250,000
to fund the Company for TKM-Ebola-Guinea IND submission expenses.</P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Under the contract, the Company is reimbursed for costs incurred, including
an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour
and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is
adjusted accordingly. The Company&#8217;s actual labour and overhead rates will differ from its estimated rates based on actual
costs incurred and the proportion of the Company&#8217;s efforts on contracts and internal products versus indirect activities.
Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred
versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management&#8217;s
estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June
30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive
fee which has been earned to date.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">On July 20, 2015, the Company announced given
the unclear development path for TKM-Ebola, development activities will be suspended and a joint re-evaluation of the development
contract with the DoD is underway.</P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>






<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0 0"><B>(b)</b> <b>Option and Services Agreements with Monsanto Company
(&#8220;Monsanto&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b></b>&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">On January 13, 2014, the Company and Monsanto signed an Option Agreement
and a Services Agreement (together, the &#8220;Agreements&#8221;). Under the Agreements, Monsanto has an option to obtain a license
to use the Company&#8217;s proprietary delivery technology and related intellectual property for use in agriculture. Over the option
period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto&#8217;s research
and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential
value of the transaction, following the successful completion of milestones, is $86,200,000.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In May 2015, the arrangement was amended to extend the option period by
approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30,
2015, the Company had received $18,550,000 from MonsantoThe amounts received relate to research services and use of the Company&#8217;s
technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Under the Agreements, the Company has established a wholly-owned subsidiary,
PADCo. The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;); however, Monsanto is the primary
beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by
Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period,
Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive
a worldwide, exclusive right to use the Company&#8217;s proprietary delivery technology in the field of agriculture. Monsanto may
elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual
property and intellectual property developed under the Agreements. The Company&#8217;s initial investment is not significant, and
has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The
Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June
30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.25in; margin: 6pt 0 0 0.25in"></p>

<p style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"> (c) License and collaboration with Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) and Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;, formerly AlCana Technologies Inc.)</p>



<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b>Milestone receipts and payments </b></p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">In the six months ended June 30, 2014, the Company earned a $150,000
milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase
III trial for ALN-TTR02.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b>Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou)
Co. Ltd. (&#8220;Ascletis&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">On June 21, 2013, the Company transferred manufacturing process technology
to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under
the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam
to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company
disputes Alnylam&#8217;s position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided
for under the agreement.&nbsp;The hearing date for this arbitration took place in May 2015, and a decision of the arbitrator is
pending. The Company has not recorded any revenue in respect of this milestone.</p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0">(d) Bristol-Myers Squibb (&#8220;BMS&#8221;) collaboration</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">On May 10, 2010 the Company announced the expansion of its research
collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (&#8220;siRNA&#8221;) molecules formulated by the
Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function
of certain genes and share the data with the Company. The Company could use the preclinical data to develop RNAi therapeutic drugs
against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement
and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the
four-year agreement. BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company
that evolve from BMS validated gene targets.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">Revenue from the May 10, 2010 agreement with BMS was being recognized
as the Company produces the related LNP batches.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The revenue earned for the six months ended June 30, 2014 was related
to BMS batches shipped during the period. In August 2014, the agreement expired and both companies&#8217; obligations under the
agreement ended.</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b></b></p>

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>







<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>(e)&nbsp;License and Development and Supply Agreement with Dicerna
Pharmaceuticals, Inc. (&#8220;Dicerna&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">On November 16, 2014, the Company signed a License Agreement and a Development
and Supply Agreement (together, the &#8220;Agreements&#8221;) with Dicerna to develop, manufacture, and commercialize products
directed to the treatment of Primary Hyperoxaluria 1 (&#8220;PH1&#8221;). In consideration for the rights granted under the Agreements,
Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on
manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones
of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee
has been established to provide guidance and direction on the progression of the collaboration.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The Company determined the deliverables under the Agreements included the
rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed
under the joint development committee. The Company has determined that manufacturing services and other services provided have
standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative
fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures
charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time
of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders
is recognized as the services are performed. The license and participation in the joint development committee have been determined
by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these
deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has
estimated to be approximately 28 months.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The Company believes the development and regulatory milestones are substantive,
due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development
and regulatory events are based, in part, on the Company&#8217;s performance and the occurrence of a specific outcome resulting
from performance. The Company has not received any milestone payments to date.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0">(f) Agreements with Spectrum
Pharmaceuticals, Inc. (&#8220;Spectrum&#8221;)</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">On May 6, 2006, the Company signed a number of agreements with Talon
Therapeutics, Inc. (&#8220;Talon&#8221;, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the &#8220;Talon
License Agreement&#8221;) for three of the Company&#8217;s chemotherapy products, Marqibo&#174;, Alocrest<sup>TM</sup> (Optisomal
Vinorelbine) and Brakiva<sup>TM</sup> (Optisomal Topotecan).</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">On August 9, 2012, the Company announced that Talon had received
accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic
leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is
a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company
is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.</p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"><font style="font-weight: normal">Talon was acquired
by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company.</font> <font style="font-weight: normal">On
September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three and six months
ended June 30, 2015, the Company recorded $62,000 and $119,000 in Marqibo royalty revenue (three and six months ended June 30,
2014 - $41,000 and $87,000 respectively). For the six months ended June 30, 2015, the Company accrued 2.5% in royalties due to
TPC in respect of the Marqibo royalty earned by the Company &#8211; see note 8, contingencies and commitments.</font></p></div><p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"><font style="font-weight: normal"></font></p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>






<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left"><td style="width: 15pt; text-align: left">5.</td><td style="width: 5pt"></td><td style="text-align: left">Accounts payable and accrued liabilities</td>
</tr></table>

<p style="font-size: 10pt; text-align: left; text-indent: 0in; margin: 6pt 0 0">Accounts payable and accrued liabilities is comprised
of the following, in thousands:</p>



<p style="font-size: 10pt; text-align: left; text-indent: 0in; margin: 6pt 0 0"></p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0; text-indent: 0.25in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2015</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Trade accounts payable</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,802</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,044</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Research and development accruals</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,914</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,391</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">License fee accruals</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">250</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Professional fee accruals</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">604</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,294</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred lease inducements</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">364</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">250</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Payroll accruals</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">491</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,873</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Other accrued liabilities</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">745</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">226</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">6,920</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">9,328</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0; text-indent: 0.25in"></p>

</div><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left">6.</td><td style="width: 5pt"></td><td style="text-align: left">Financing</td>
</tr></table>

<p style="font-size: 10pt; margin: 6pt 0 0; text-align: left"><font style="font-weight: normal">On March 25, 2015, the Company
announced that it had completed an underwritten public offering of 7,500,000 common shares, at a price of $20.25 per share, representing
gross proceeds of $151,875,000. The Company also granted the underwriters a 30-day option to purchase an additional 1,125,000 shares
for an additional $22,781,000 to cover any over-allotments. The underwriters did not exercise the option. The cost of financing,
including commissions and professional fees, was $9,700,000, resulting in net proceeds of $142,177,000.</font></p>

<p style="font-size: 10pt; margin: 6pt 0 0; text-align: left"><font style="font-weight: normal">&nbsp;</font></p></div><p style="font-size: 10pt; margin: 6pt 0 0; text-align: left"><font style="font-weight: normal"></font></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left"><td style="width: 15pt; text-align: left">7<font style="font-weight: normal">.</font></td><td style="width: 5pt"></td><td style="text-align: left">Concentrations of credit risk</td>
</tr></table>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">Credit risk is defined by the Company as an unexpected loss in cash
and earnings if a collaborative partner is unable to pay its obligations in due time. The Company&#8217;s main source of credit
risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners
in the normal course of operations.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">The Company does not currently maintain a provision for bad debts as
the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">The carrying amount of financial assets represents the maximum credit
exposure. The maximum exposure to credit risk at June 30, 2015 was the accounts receivable balance of $6,332,000 (December 31,
2014 - $1,903,000).</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">All accounts receivable balances were current as at June 30, 2015
and at December 31, 2014.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">&nbsp;</p></div><p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 15pt; text-align: left">8.</td><td style="width: 5pt"></td><td style="text-align: left">Contingencies and commitments</td>
</tr></table>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0"><b>Product development partnership with the Canadian Government</b></p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0 0">The Company entered into a Technology Partnerships Canada ("TPC")
agreement with the Canadian Federal Government on November 12, 1999. Under this agreement, TPC agreed to fund 27% of the costs
incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum
contribution from TPC of $7,179,000 <font style="font-size: 10pt; color: red">&nbsp;</font>(C$9,323,000). As at June 30, 2015,
a cumulative contribution of $2,965,000 <font style="font-size: 10pt; color: red">&nbsp;</font>(C$3,702,000) has been received
and the Company does not expect any further funding under this agreement. In return for the funding provided by TPC, the Company
agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain
non-siRNA oligonucleotide product candidates covered by the funding under the agreement. These royalties are payable until a certain
cumulative payment amount is achieved or until a pre-specified date. In addition, until a cumulative amount equal to the funding
actually received under the agreement has been paid to TPC, the Company agreed to pay 2.5% royalties on any royalties the Company
receives for Marqibo. For the three and six months ended June 30, 2015, the Company earned royalties on Marqibo sales in the amount
of $62,000 and $119,000<b> </b>respectively<b> </b>(three and six months ended June 30, 2014 &#8211; $41,000 and $87,000 respectively)
(see note 4(f)), resulting in $3,000 being recorded by the Company as royalty payable to TPC (June 30, 2014 - $2,000). The cumulative
amount paid or accrued up to June 30, 2015 was $9,000, resulting in the contingent amount due to TPC being $2,956,000 (C$3,692,000).</p>

<p style="font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0">License agreement with Marina Biotech, Inc. (&#8220;Marina&#8221;)</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">On November 29, 2012 the Company announced a worldwide, non-exclusive
license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&#8220;UNA&#8221;) from Marina for the development
of RNAi therapeutics.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>







<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">UNA technology can be used in the development of RNAi therapeutics,
which treats disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential
to improve them by increasing their stability and reducing off-target effects.</p>

<p style="font-size: 10pt; text-align: left; margin: 6pt 0">Under the license agreement the Company paid Marina an upfront fee
of $300,000 during the year ended December 31, 2012. A further license payment of $200,000 was paid in 2013 and the Company will
make milestone payments of up to $3,250,000 and royalties on each product developed by the Company that uses Marina&#8217;s UNA
technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Effective August 9, 2013, Marina&#8217;s UNA technology was acquired by
Arcturus Therapeutics, Inc. (&#8220;Arcturus&#8221;) and the UNA license agreement between the Company and Marina was assigned
to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health
Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus&#8217; UNA technology. This triggered the accrual
of $250,000 as at December 31, 2014 related to the milestone payable to Arcturus upon the dosing of first subject in a Phase I
clinical trial of TKM-HBV, which occurred and was paid by the Company in January 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Arbitration with the University of British Columbia (&#8220;UBC&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Certain early work on lipid nanoparticle delivery systems and related inventions
was undertaken at UBC. These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998
as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Spectrum.&nbsp;&nbsp;Alnylam
has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of
RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate
research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement
signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of
all obligations under such supplemental agreement as between and among all litigants.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">On November 10, 2014, UBC filed a notice of arbitration against the Company
and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to $3,500,000 in allegedly unpaid royalties based
on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs,
including legal fees. The Company is currently disputing UBC&#8217;s allegations, and no dates have been scheduled for this arbitration.
The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related
to both the likelihood and amount of any possible loss or range of loss. Costs related to the arbitration have been recorded by
the Company as incurred.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>








<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Contingent consideration from Arbutus Inc. acquisition of Enantigen
and License Agreements between Enantigen and Blumberg and Drexel</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In October 2014, Arbutus Inc. acquired all of the outstanding shares
of Enantigen pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion
inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&#8217;s
merger with Arbutus Inc. &#8211; see note 3.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Under the stock purchase agreement, Arbutus Inc. agreed to pay up to a
total of $21,000,000 to Enantigen&#8217;s selling stockholders upon the achievement of certain triggering events related to Enantigen&#8217;s
two programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient
in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The regulatory milestone payments have an estimated fair value of approximately
$5,136,000 and have been treated as contingent consideration payable in the preliminary purchase price allocation (note 3), based
on information available at the date of acquisition, using a probability
weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential
contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the
early stage nature of the development program, time to complete the program development, and overall biotech indices.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The Company is currently undertaking valuation assessments of assets acquired
and liabilities assumed from Arbutus Inc., which includes a valuation assessment of the contingent consideration.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Drexel and Blumberg:</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">In February 2014, Arbutus Inc. entered into a license agreement with Blumberg
and Drexel that granted an exclusive, worldwide, sub-licensable license to three different compound series: cccDNA inhibitors,
capsid assembly inhibitors and HCC inhibitors.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In partial consideration for this license, Arbutus Inc. paid a license
initiation fee of $150,000 and issued warrants to Blumberg and Drexel. Under this license agreement, Arbutus Inc. also agreed to
pay up to $3,500,000 in development and regulatory milestones per licensed compound series, up to $92,500,000 in sales performance
milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products
in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts
received from the sub-licensees, subject to customary exclusions.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In November 2014, Arbutus Inc. entered into an additional license agreement
with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents
and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for
these exclusive licenses, Arbutus Inc. made an upfront payment of $50,000. Under this agreement, the Company will be required to
pay up to $1,000,000 for each licensed product upon the achievement of a specified regulatory milestone and a low single digit
royalty, based upon the proportionate&nbsp;net sales of compounds covered by this intellectual property&nbsp;in any commercialized
combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its
sub-licensees, subject to exclusions.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Research Collaboration and Funding Agreement with Blumberg</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In October 2014, Arbutus Inc. entered into a research collaboration and
funding agreement with Blumberg under which the Company will provide $1,000,000 per year of research funding for three years, renewable
at the Company&#8217;s option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer
pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV
research funded under the agreement. In addition, the Company has the right to match any third party offer to fund HBV research
that falls outside the scope of the research being funded under the agreement. Blumberg has granted the Company the right to obtain
an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the
Company elects to exercise its right to obtain such a license, the Company will have a specified period of time to negotiate and
enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated
upfront, milestone and royalty payments: an upfront payment in the amount of $100,000; up to $8,100,000 upon the achievement of
specified development and regulatory milestones; up to $92,500,000 upon the achievement of specified commercialization milestones;
and royalties at a low single to mid-single digit rates based upon the proportionate&nbsp;net sales of licensed&nbsp;products from
any commercialized combination.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 12pt 0 0"><b>ARBUTUS BIOPHARMA CORPORATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(formerly Tekmira Pharmaceuticals Corporation)</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Notes to condensed consolidated financial statements</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">(Unaudited)</p>

<p style="font-size: 10pt; text-align: left; margin: 0; border-bottom: Black 1.1pt solid">(Expressed in US dollars &#8211; tabular
amounts in thousands)</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>








<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>NeuroVive Pharmaceutical AB (&#8220;NeuroVive&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In September 2014, Arbutus Inc. entered into a license agreement with NeuroVive
that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment
of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company
has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory
approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment
of HBV. Under this license agreement, the Company has (1)&nbsp;an option to expand its exclusive license to include treatment of
viral diseases other than HBV and (2)&nbsp;an option, exercisable upon specified conditions, to expand its exclusive license to
include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases
other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products
and non-oral variations of licensed products for all indications (other than HBV) for which the Company has not exercised its option.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In partial consideration for this license, Arbutus Inc. paid NeuroVive
a license fee of $1,000,000. The Company is also obligated to pay up to $47,000,000 in clinical development and regulatory milestones
per indication and up to $102,500,000 in sales performance milestones per licensed product and indication. If the Company is acquired
by a third party in a transaction that meets certain criteria, then the Company or its acquiror will be obligated to pay all remaining
development, regulatory and sales milestone payments, regardless of whether the applicable milestone events have been achieved,
for each licensed product that entered clinical development before such acquisition. As describe in note 3, the acquisition of
Arbutus Inc. by the Company was completed by way of a Merger Agreement, which does not trigger any of the aforementioned milestone
payments. The Company has agreed to pay NeuroVive tiered royalties in the mid-single to low-double digit range based upon the proportionate&nbsp;gross
sales of patented licensed products from any commercialized combination. If the Company terminates this license agreement in its
entirety for convenience prior to the first commercial sale of any licensed product, the Company will be obligated to pay NeuroVive
a termination fee of $2,000,000.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Cytos Biotechnology Ltd (&#8220;Cytos&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">On December&nbsp;30, 2014, Arbutus Inc. entered into an exclusive, worldwide,
sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to six
different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I
agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&nbsp; The Company has
an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for
influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In partial consideration for this license, the Company is obligated to
pay Cytos up to a total of $67,000,000 for each of the six licensed compound series upon the achievement of specified development
and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of $110,000,000 upon the achievement
of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the
proportionate&nbsp;net sales of licensed products in any&nbsp;commercialized combination.</p></div><p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; margin: 0 0 8pt"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; font-size: 10pt"><a name="p1i2"></a><font style="font-size: 10pt"><b>ITEM 2.</b></font></td>
    <td style="width: 91%; font-size: 10pt"><font style="font-size: 10pt"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><i>You should read the following discussion and analysis by our management of our financial
position and results of operations in conjunction with our audited consolidated financial statements and related notes thereto
included as part of our Annual Report on Form 10-K for the year ended December 31, 2014 and our unaudited condensed consolidated
financial statements for the three and six month periods ended June 30, 2015. Our consolidated financial statements have been prepared
in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars.</i></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0"><i>The information in this report contains forward-looking information and
forward-looking statements (collectively, forward-looking statements) within the meaning of applicable securities laws.
Forward-looking statements in this report include statements about our strategy, future operations, clinical trials,
prospects and the plans of management; the discovery, development and commercialization of a cure for HBV; the formation of a
discrete business unit to manage, develop and maximize the value (both short-term and long term) of our non-HBV assets
(including new product development and partnering opportunities); our beliefs and development path and strategy to achieve a
cure for HBV; our intention to conduct a rolling Phase II clinical program for HBV (using an iterative process of combination
drug candidates), the use of results from this program to design additional treatment regimens for next cohorts and to
conduct a Phase III clinical trial intended to ultimately support regulatory filings for marketing approval; our intention to
continue expanding our HBV pipeline through internal development, acquisitions and in-licenses; the research benefits of the
collaboration with The Baruch S. Blumberg Institute, including expansion of our HBV pipeline through internal development,
acquisitions and in-licenses; expected results from our TKM-HBV Phase I clinical trial in the second half of 2015; our plans
to modify the clinical program for TKM-PLK1 to study the effect on viral parameters in chronic HBV patients enrolled in the
HCC trial; the completion of our OCB-030 studies in order to file an IND, or equivalent, by year end 2015; the direct
progression of CYT-003 into patients; expectations of filing an IND, or equivalent, and initial Phase I studies with one of
two core protein inhibitors as oral therapeutics for the treatment of chronic HBV infection in 2016; expectations of filing
an IND, or equivalent, for our HBV surface antigen secretion inhibitors in 2016; expectations of filing an IND, or
equivalent, for cccDNA formation inhibitors in 2016; our belief in the significant value of our non-HBV assets and the
maximization of these asset values; our expanded Phase I/II clinical trial with TKM-PLK1 and expected reporting of final data
in the second half of 2015; Fast Track designation from the US FDA for the development of TKM-Ebola; the partial clinical
hold on TKM-Ebola by the FDA, our response to the partial clinical hold and expectations of resolving the matter; the joint
re-evaluation of our Ebola related DoD development contract; partnering or external funding opportunities to maximize
TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG, TKM-ALDH; the effects of our products on the treatment of chronic Hepatitis B
infection, cancer, infectious disease, alcohol use disorder, and other diseases; the potential of RNAi to generate a new
class of therapies; our RNAi pipeline and the advancement thereof with a focus on realizing the value of these assets; new
product development and partnering opportunities in LNP technology; the expected efficacy of our various HBV therapies; our
continued commitment to our non-HBV assets, both clinical and preclinical, and realization of value for these non-HBV assets;
the quantum and triggering of payments to our partners, including payments to Dicerna, Cytos, Blumberg, Drexel,
Enantigen&#8217;s selling stockholders and NeuroVive; future changes in the fair value of our warrant liability; the expected
return from strategic alliances, licensing agreements, and research collaborations, such as the potential value of a
transaction with the DoD, Monsanto Company and a grant from the U.S. National Institutes of Health; our intent to retain
earnings, if any, to finance the growth and development of their business and not to pay dividends or to make any other
distributions in the near future; arbitration proceedings with Alnylam Pharmaceuticals, Inc. in connection with ALN-VSP;
arbitration proceedings with the University of British Columbia in connection with alleged unpaid royalties; anticipated
royalty receipts; statements with respect to revenue and expense fluctuation and guidance; and the quantum and timing of
potential funding. </i></p>

<p style="font-size: 10pt; margin: 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0"><i></i></p>

<p style="font-size: 10pt; margin: 0"><i>With respect to the forward-looking statements contained in this report, we have made
numerous assumptions regarding, among other things: LNP&rsquo;s status as a leading RNAi delivery technology; our research and
development capabilities and resources; the effectiveness of our products as a treatment for chronic Hepatitis B infection, cancer,
infectious disease, alcohol use disorder, or other diseases; the timing<font style="color: #002060"> </font>and quantum of payments
to be received under contracts with our partners including Alnylam, Spectrum, Dicema, Monsanto and the DoD; assumptions related
to our share price volatility, expected lives of warrants and warrant issuances and/or exercises; and our financial position and
our ability to execute our business strategy. While we consider these assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and social uncertainties and contingencies.</i></p>



<p style="font-size: 10pt; margin: 0"><i></i></p>

<p style="font-size: 10pt; margin: 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0"><i>Our actual results could differ materially from those discussed in the forward-looking
statements as a result of a number of important factors, including the risk factors discussed in this report and the risk factors
discussed in our Annual Report on Form 10-K under the heading &#8220;Risk Factors,&#8221; and the risks discussed in our other
filings with the Securities and Exchange Commission and Canadian Securities Regulators. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management&#8217;s analysis, judgment, belief or expectation only as
of the date hereof. We explicitly disclaim any obligation to update these forward-looking statements to reflect events or circumstances
that arise after the date hereof, except as required by law.</i></p>



<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><font style="background-color: yellow"><i></i></font></p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>OVERVIEW</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;, &#8220;we&#8221;, &#8220;us&#8221;,
and &#8220;our&#8221;) is a publicly traded industry-leading therapeutic solutions company focused on discovering, developing and
commercializing a cure for patients suffering from chronic hepatitis B (HBV) infection, a disease of the liver caused by hepatitis
B. Effective July 31st, 2015, our corporate name changed from Tekmira Pharmaceuticals Corporation to Arbutus Biopharma Corporation.
Also effective July 31st, 2015, the corporate name of our wholly owned subsidiary,
OnCore Biopharma, Inc. changed to Arbutus Biopharma Inc. (&#8220;Arbutus Inc.&#8221;).&nbsp; Including Arbutus Inc., we have five
wholly owned subsidiaries: Protiva Biotherapeutics Inc. (&#8220;Protiva&#8221;), Protiva Agricultural Development Company Inc.
(&#8220;PADCo&#8221;), Protiva Biotherapeutics (USA) Inc. (&#8220;Protiva USA&#8221;) and Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;).&nbsp;
Unless stated otherwise or the context otherwise requires, references herein to &#8220;Arbutus&#8221;, &#8220;we&#8221;, &#8220;us&#8221;
and &#8220;our&#8221;&nbsp;&nbsp;refer to Arbutus Biopharma Corporation, and, unless the context requires otherwise, one or more
subsidiaries through which we conduct business.</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">In March of 2015, we completed
a merger whereby Arbutus Inc. became our wholly owned subsidiary. The transaction was approved by 99.5% of votes cast by our shareholders
voting at a Special Meeting held on Tuesday, March 3, 2015, and representing 51.2% of our common shareholders. In connection with
the transaction, we issued 23,973,315 common shares to the shareholders of Arbutus Inc. in exchange for their Arbutus Inc. securities,
and Arbutus Inc. became our wholly-owned subsidiary.</p>



<p style="font-size: 10pt; margin: 0">

</p><p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Together with our subsidiaries, we have an industry leading pipeline focused on finding a
cure for chronic HBV infection. This HBV pipeline consists of multiple drug candidates, with complementary mechanisms of action.
Our unique strategy is to target the three pillars we believe are necessary to deliver an HBV cure, including: (i)&nbsp; suppressing
HBV viral replication, (ii)&nbsp;restoring host response by suppressing HBV surface antigen (HBsAg) or activating/stimulating the
host immune system directed at HBV, and (iii)&nbsp;eliminating covalently closed circular DNA (cccDNA), the reservoir of viral
genomic material.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We believe our chances for success in HBV are increased and risk is mitigated by having a
portfolio of assets targeting these three strategies. More importantly, we believe combination therapies are the key to HBV treatment
and a potential cure, and clinical development can be accelerated when multiple components of a combination therapy regimen are
controlled by the same company. This is why, together with our subsidiaries, we have retained exclusive worldwide development and
commercialization rights to all of our drug candidates and programs in HBV.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0">Arbutus is also recognized as a world leader in RNA interference (RNAi) delivery technology.
We have focused on advancing novel RNAi-based therapeutics. RNA interference is considered one of the most important discoveries
in the field of biomedical science in the last decade. RNAi has the potential to generate a new class of therapies that take advantage
of the body&#8217;s own natural processes to silence genes and, by extension, treat serious human diseases that often rely on the
production of certain proteins at the genetic level. With this ability to eliminate disease-causing proteins from cells, RNAi therapies
represent opportunities for therapeutic intervention that have not been achievable with conventional therapeutics.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In addition to our HBV pipeline, we also have an RNAi product pipeline which is focused on
anti-virals, oncology and metabolic product platforms, in areas where there is a significant medical need and commercial opportunity.
Our proprietary LNP Delivery Platform allows for the delivery of RNAi drugs. By encapsulating the RNAi trigger molecules in lipid
nanoparticles (LNP) our LNP technology enables efficient delivery and uptake into target cells. Our LNP technology represents the
most widely adopted delivery method in RNAi. To date, it has enabled nine clinical trials and has been administered to more than
250 patients.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We have formed a discrete business unit to manage, develop and maximize the value
of our non-HBV assets.  This business unit will be independently financed through current and potential collaborations and
partnerships, and includes preclinical RNAi product candidates, intellectual property and related know how of the LNP
delivery technology platform and strategic partnerships exploiting the LNP technology. Because LNP can enable a wide variety
of nucleic acid triggers, including mRNA, we continue to seek new product development and partnering opportunities based on
what we believe is our industry-leading delivery expertise. &nbsp;</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We remain committed to continuing to support the work of our product development partners
and intellectual property licensees with the goal of realizing the short-term and long term financial potential of these partnerships.</p>


<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"><b><i>Voluntary Delisting from the Toronto Stock Exchange (TSX)</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Our common shares were voluntarily delisted from the Toronto Stock Exchange ("TSX")&nbsp;as
of the close of business on Tuesday, March 3, 2015. Prior to the voluntary delisting, our common shares traded on the TSX under
the symbol &#8220;TKM&#8221;. We continue to be listed on the NASDAQ. In conjunction with our name change to Arbutus Biopharma
Corporation our ticker symbol was changed to &#8220;ABUS&#8221;.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Public Offering of Common Shares</i></b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">On March 25, 2015, we completed an underwritten public offering of 7.5 million common shares
at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions
and other offering expenses. We also granted the underwriters a 30-day option to purchase up to an additional 1.125 million common
shares, which, if exercised, would have resulted in additional gross proceeds of US$22.8 million. The 30-day option was not exercised
and is no longer available.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><u>Our Product Candidates</u></b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We have what we believe is an industry-leading pipeline focused on curing HBV. Our belief
is that to achieve an HBV cure, a combination of products that affect the main drivers of HBV need to be utilized. Specifically,
this means that to be successful, we believe we need to have products that address HBV persistence &#8212; in antiviral replication,
immune reactivation and the presence of cccDNA.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Once multiple compounds within the portfolio with sufficient anti-HBV activity have been
identified, we intend, subject to discussions with regulatory authorities, to conduct a rolling Phase II clinical program. These
studies will likely evaluate combinations of two or more drug candidates in small cohorts of patients with chronic HBV infection
to identify active combinations and those that do not have sufficient antiviral activity. We also plan to evaluate different treatment
durations to determine the optimal duration for a finite duration therapy. We expect to use these results to design additional
treatment regimens for the next cohorts. We plan to continue this iterative process until we select combination therapy regimens
and treatment durations to conduct Phase III clinical trials intended to ultimately support regulatory filings for marketing approval.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We intend to continue to expand our HBV pipeline through internal development, acquisitions
and in-licenses. We believe that a major engine for internal innovation is our collaboration with The Baruch S. Blumberg Institute
(&#8220;Blumberg&#8221;<b>)</b>, one of the leading non-profit research institutes in the world focused on HBV.&nbsp;We believe
that this collaboration will provide us with access to cutting-edge research in new target identification, assay development, mechanism
of action studies and lead generation efforts focused on hepatitis B virus. This relationship also provides us with access to research
that we believe is equal to, or surpasses that of other biotechnology or pharmaceutical companies, and can add value to our current
and future R&amp;D efforts in HBV.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><u>HBV Product Pipeline</u></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-HBV</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">HBV causes the most common serious liver infection in the world. The World Health Organization
(WHO) estimates that 350 million people worldwide are chronically infected with the virus, and other estimates suggest this could
include up to 1.4 million people in the United States. Individuals chronically infected with HBV are at an increased risk of developing
significant liver disease, including cirrhosis, or permanent scarring of the liver, as well as liver failure and hepatocellular
carcinoma (HCC) or liver cancer. According to the Hepatitis B Foundation, HBV is the cause of up to 80% of liver cancers. Individuals
with liver cancer typically have a five-year survival rate of about 15%. The WHO estimates that more than 780,000 people die every
year due to the consequences of hepatitis B infection.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Our extensive experience in antiviral drug development has been applied to our TKM-HBV program
to develop an RNAi therapeutic for chronic hepatitis B infection. Small molecule nucleotide therapy has been the standard of care
for chronic HBV infected patients. However, many of these patients continue to express a viral protein called HBV surface antigen
(HBsAg). This protein causes inflammation in the liver leading to cirrhosis and, in some cases, HCC and death.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">TKM-HBV is designed to address an unmet medical need and reduce HBsAg expression in patients
chronically infected with HBV. Reducing HBsAg is thought to be a key prerequisite to enable a patient&#8217;s immune system to
raise an adequate antibody response against the virus. The ability of TKM-HBV to inhibit numerous viral elements in addition to
HBsAg increases the likelihood of successfully controlling the viral infection.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">TKM-HBV is being developed as a multi-component RNAi therapeutic that simultaneously targets
three sites on the HBV genome. Targeting three distinct and highly conserved sites on the HBV genome is intended to facilitate
potent knockdown of all viral messenger RNA (mRNA) transcripts and viral antigens across a broad range of HBV genotypes and reduce
the risk of developing antiviral resistance.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We presented results from our preclinical studies at the 10th Annual Meeting of the Oligonucleotide
Therapeutics Society Meeting held in San Diego, California, on October 15, 2014. Among the results reported was the potent and
rapid reduction in HBsAg demonstrated by TKM-HBV in several well-validated models. In these models, TKM-HBV treatment resulted
in reductions in both intrahepatic and serum HBsAg, as well as reductions in HBV DNA, covalently closed circular DNA (cccDNA),
Hepatitis B e antigen&nbsp;(HBeAg) and HBcAg (Hepatitis B c antigen). A rapid 1 log reduction in serum HBsAg was achieved with
a single 1 mg/kg dose of TKM-HBV in the humanized mouse model, which closely mimics chronic human hepatitis B infection. 1-2 log
viral reductions from similar single-dose LNP treatments in two other true-infection animal models were also demonstrated.</p>


<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Preclinical studies conducted on infected primary human hepatocytes showed that TKM-HBV had
robust and consistent activity against different viral strains representing the major clinical genotypes A, B, C and D. Our data
shows that inclusion of three RNAi triggers results in a more broadly effective knockdown of hepatitis B viral elements than a
single trigger alone. The mode of action of TKM-HBV complements standard of care nucleoside/nucleotide (NUC) therapy, and lack
of drug antagonism has been demonstrated with entecavir, lamivudine and tenofovir on infected primary human hepatocytes, making
combination therapy a viable option.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Our data supports the utility of TKM-HBV as a potential new therapeutic option for treating
patients with chronic HBV infection. In early 2015, we advanced two TKM-HBV product candidates into a Phase I trial. Both product
candidates&nbsp;employ the same unique combination of three RNAi trigger molecules. However, they differ in their LNP composition.&nbsp;One
formulation employs a third generation LNP, and the other employs a new, fourth generation LNP, which incorporates novel lipid
chemistry and demonstrates improved potency. The multi-component RNAi therapeutic is expected to result in broad and effective
inhibition of HBV.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">The TKM-HBV Phase I clinical trial is a randomized, single-blind, placebo-controlled study,
involving single ascending doses of TKM-HBV. The study will assess the safety, tolerability and pharmacokinetics of intravenous
administration of two formulations of TKM-HBV in healthy adult subjects. For each formulation, there are five planned cohorts for
a total of 20 subjects (40 in total for both formulations). Four subjects will be enrolled per cohort with three subjects receiving
TKM-HBV, and one receiving placebo. We expect the results from&nbsp;the Phase I clinical trial in healthy human volunteers to determine
which product formulation will advance into chronically infected patients in a multi-dosing trial in the second half of 2015.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>TKM-PLK1</i></b></p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0; background-color: white">Our oncology product platform, TKM-PLK1, targets polo-like kinase
1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. Inhibition of PLK1 expression prevents
the tumor cell from completing cell division, resulting in cell cycle arrest and death of the cancer cell. We are currently evaluating
our oncology product candidate, TKM-PLK1, in clinical trials with patients who have Gastrointestinal Neuroendocrine Tumors (GI-NET),
Adrenocortical Carcinoma (ACC) and&nbsp;Hepatocellular Carcinoma (HCC). Based on a hypothesis that inhibition of PLK-1 could have
utility in treating HBV, we  have modified the clinical program for TKM-PLK1 to study the effect of PLK1 on viral parameters
in chronic HBV patients enrolled in the HCC trial.</p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0"><b><i>Cyclophilin Inhibitor &#8212; OCB-030</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Cyclophilins are proteins that have been shown to play a role in several biological processes,
including viral infection. By inhibiting cyclophilin, we believe the ability of HBV to replicate can be impaired and the host immune
response toward HBV may be enhanced. We have licensed from NeuroVive Pharmaceutical AB, or (&#8220;NeuroVive&#8221;), the exclusive
rights to develop and commercialize cyclophilin inhibitor drug candidates, including OCB-030, for the treatment of hepatitis B.
We are engaged in pre-clinical studies which we expect to be completed in order to file an IND, or an equivalent filing with foreign
regulatory authorities, by year end 2015.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>TLR9 Agonist (CYT-003)</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Pharmaceutical activation of toll-like receptors (TLRs) is a novel and attractive approach
for the treatment of chronic HBV because agonism of these receptors triggers innate immune responses and also stimulates adaptive
immunity.&nbsp;&nbsp;It is hoped that immune stimulation by TLR agonists can overcome the multiple immunologic blocks that allows
chronic HBV infection, including direct activation of the host&#8217;s innate antiviral response, to overcome the functional weakness
in HBV-specific immune cell responses.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Licensed from Cytos Biotechnology Ltd., (&#8220;Cytos&#8221;), CYT003 is a biological carrier
which is filled with the immunostimulatory oligonucleotide called G10. G10 a toll-like receptor-9 (TLR-9) agonist. CYT-003 has
been shown to directly activate B cells and stimulates human (plasmacytoid dendritic cells)<b>&nbsp;</b>pDC to secrete Interferon
alpha. CYT-003 also activates other antigen presenting cells indirectly and promotes the development of TH1 type cytokine response.
This is thought to be potentially beneficial in promoting anti-HBV T cell immunity. CYT-003 has previously been utilised in human
trials in other indications and therefore could move quickly into the clinic in HBV infected patients. We initiated preclinical
studies to demonstrate proof of concept first half of 2015. If the preclinical studies show utility in HBV, we will progress straight
into patients given the existing safety database and the open INDs.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Core Protein/ Capsid Assembly Inhibitors</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are developing two core protein inhibitors (also known as capsid assembly inhibitors)
as oral therapeutics for the treatment of chronic HBV infection. By inhibiting assembly of the viral capsid, the ability of hepatitis
B virus to replicate is impaired, which subsequently reduces the amount of new virus produced, and which may have an effect on
cccDNA. We acquired exclusive, worldwide rights to these drug candidates through an in-license from Blumberg and Drexel University,
or (&#8220;Drexel&#8221;), and through Arbutus Inc.&#8217;s recent acquisition of Enantigen Therapeutics, Inc., or (&#8220;Enantigen&#8221;).
We expect to file an IND with the FDA, or an equivalent filing with foreign regulatory authorities, and initiate Phase 1 studies
with one of these compounds in 2016.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0"><B><I>Surface Antigen Secretion Inhibitors</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are developing multiple small molecule orally bioavailable HBV surface antigen secretion
inhibitors. By inhibiting the secretion of HBV surface antigen from infected cells, we expect that the immune response of patients
treated with this therapy can re-engage and thereby mount a more robust response to a hepatitis B virus infection. We acquired
these drug candidates from Enantigen. We expect to file an IND, or its equivalent in another territory, for a lead compound in
2016.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>STING Agonists</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are developing STING (stimulator of interferon genes) agonists. By activating interferon
genes, we anticipate that the body can produce additional interferon alpha and beta, which have antiviral properties. Our development
program, which is currently in the discovery research stage, is based on proof of concept data in mice generated by Blumberg which
showed that STING agonists can elicit an antiviral response and inhibit HBV replication in mouse liver cells. In collaboration
with Blumberg, our plan is to identify potent, orally active small molecule human STING agonists that possess the desired characteristics
to progress into human clinical studies.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>cccDNA Formation Inhibitors</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are developing multiple series of cccDNA formation inhibitors. The inhibition of cccDNA
formation would reduce the amount of cccDNA in the infected liver cell and could ultimately eliminate the reservoir of HBV genomic
material required for continued viral replication. We acquired the exclusive, worldwide rights to this program through an in-license
from Blumberg. This program is currently in early optimization and we anticipate filing an IND with the FDA, or its equivalent
in another territory, in 2016.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>cccDNA Epigenetic Modifiers</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In addition to cccDNA formation inhibitors, we are developing cccDNA epigenetic modifiers.
By controlling cccDNA transcription, we anticipate that we may be able to inhibit the formation of new virus and sub viral particles
from cccDNA. This development program, which is currently in the discovery research stage, is based on proof of concept data generated
by Blumberg using known inhibitors of enzymes involved in DNA information processing.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><u>Non-HBV Assets Clinical Programs&nbsp;TKM-PLK1, TKM-Ebola, TKM-Ebola-Guinea</u> <i><u>(LNP
Enabled)</u></i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We believe there is significant value in our non-HBV assets and we remain committed to maximizing
this value. We intend to continue our clinical programs to the appropriate stage to support this objective. We also remain interested
in advancing our ongoing metabolic and rare disease preclinical programs to maximize their value, and in continuing to leverage
our knowledge and expertise in LNP technology, where applicable.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-PLK1</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Our oncology product platform, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation
and a validated oncology target. Inhibition of PLK1 expression prevents the tumor cell from completing cell division, resulting
in cell cycle arrest and death of the cancer cell. Evidence that patients with elevated levels of PLK1 in their tumors exhibit
poorer prognosis and survival rates has been documented in the medical literature. TKM-PLK1 is being evaluated in the following
oncology indications where there are limited or ineffective therapies available: Gastrointestinal Neuroendocrine Tumors (GI-NET),
Adrenocortical Carcinoma (ACC) and&nbsp;Hepatocellular Carcinoma (HCC).</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>GI-NET and ACC</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">GI-NET is the gastrointestinal subset of neuroendocrine tumors. According to a paper by Yao
et al., (2008), a historical analysis of the U.S. National Cancer Institute, SEER database reveals the incidence of neuroendocrine
tumors has increased faster in the last few decades than any other neoplasm, with a growth rate of greater than 3% expected to
continue in the near term. The prevalence of GI-NET in the U.S. is estimated to be approximately 55,000 individuals. Prognosis for
advanced or metastatic GI-NET, the target population for TKM-PLK1, is poor with 25-54% of patients surviving less than one year.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">ACC is an ultra-rare form of cancer that develops in the adrenal gland. Data from the U.S.
National Cancer Institute indicates there are approximately 500 patients in the U.S. with ACC. Survival prognosis for patients with
ACC is poor. A large percentage of patients are not good surgical candidates and there is a lack of effective systemic therapies.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We presented updated Phase I TKM-PLK1 data at the 6th Annual NET Conference hosted by the
North American Neuroendocrine Tumor Society (NA-NETS) in Charleston, South Carolina on October 4, 2013. This data set included
a total of 36 patients in a population of advanced cancer patients with solid tumors. Doses ranged from 0.15 mg/kg to 0.90 mg/kg
during the dose escalation portion of the trial, with the maximum tolerated dose (MTD) of 0.75 mg/kg. Serious adverse events (SAEs)
were experienced by four subjects in this heavily pre-treated, advanced cancer patient population, with three of four subjects
continuing on study. Forty percent (6 out of 15) of patients evaluable for response, treated at a dose equal to or greater than
0.6 mg/kg, showed clinical benefit. Three out of the four ACC patients (75%) treated with TKM-PLK1 achieved stable disease, including
one patient who saw a 19.3% reduction in target tumor size after two cycles of treatment. This subject is still in the study receiving
TKM-PLK1. Of the two GI-NET patients enrolled, both experienced clinical benefit: one patient had a partial response based on Response
Evaluation Criteria in Solid Tumors <b>(</b>RECIST) criteria, and the other GI-NET patient achieved stable disease and showed a
greater than 50% reduction in Chromogranin-A (CgA) levels, a key biomarker used to predict clinical outcome and tumor response.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">Based on encouraging results from the dose escalation portion and expansion cohort from our
Phase I TKM-PLK1 clinical trial, we expanded into a Phase I/II clinical trial with TKM-PLK1, which is specifically enrolling patients
within the two therapeutic indications: advanced GI-NET or ACC. This multi-center, single arm, open label study is designed to
measure efficacy using RECIST criteria for GI-NET patients and ACC patients as well as evaluate the safety, tolerability and pharmacokinetics
of TKM-PLK1. TKM-PLK1 is administered weekly with each four-week cycle consisting of three once-weekly doses followed by a rest
week. In the fall of 2014, we achieved our enrollment target of patients with advanced GI-NET or ACC tumors. These patients will
continue treatment and be followed to determine if TKM-PLK1 produces a meaningful clinical benefit.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We provided an update on this Phase I/II clinical study in December 2014. To date, 55 patients,
in both the Phase I and Phase I/II studies have been treated at doses of &#8805; 0.6 mg/kg, which is considered to be in the efficacious
dose range based on preclinical studies. Of these, 31 patients comprise the target population of GI-NET or ACC patients.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">While we are still awaiting maturation of data, we continue to see evidence of anti-tumor
activity in some treated subjects, including one ACC patient with an almost complete resolution of their disease. We expect to
report final data from these studies in the second half of 2015.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>HCC</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">HCC is one of the most common cancers, one of the most deadly and a common outcome of chronic
HBV infection, with over 650,000 deaths each year worldwide according to the Globocan 2012 database.&nbsp;&nbsp;US incidence is
estimated at 27,000 individuals with annual growth rates greater than 2%. HCC is an aggressive, hard-to-treat disease with one-year
survival rates of less than 50% and five-year rates as low as 4% (National Cancer Institute). To date, Nexavar (sorafenib) is the
only agent approved to treat HCC with an improvement in overall survival of just two to three months.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In May 2014, we initiated another Phase I/II clinical trial with TKM-PLK1, enrolling patients
with advanced HCC. Patient dosing has commenced and we have completed the first treatment in cohorts one and two with HCC. This
Phase I/II clinical trial is a multi-center, single arm, open label dose escalation study designed to evaluate the safety, tolerability
and pharmacokinetics of TKM-PLK1 as well as determine the maximum tolerated dose in patients with advanced HCC. It will also include
a preliminary assessment of the anti-tumor activity of TKM-PLK1 in this patient population. It is expected that approximately 38
patients with advanced HCC tumors will be enrolled in this Phase I/II clinical trial. Based on a hypothesis that inhibition of
PLK-1 could have utility in treating HBV, we are planning to modify the clinical program for TKM-PLK1 to study the effect of PLK1
on viral parameters in chronic HBV patients enrolled in the HCC trial.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-Ebola</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">TKM-Ebola, an anti-Ebola RNAi therapeutic, is being developed under a $140 million contract,
signed in July 2010, with the U.S. Department of Defense (DoD) Joint Project Manager Medical Countermeasure Systems BioDefense
Therapeutics (JPM-MCS-BDTX). Preclinical studies published in the medical journal <i>The Lancet</i> in 2010 demonstrated that when
RNAi triggers targeting the Ebola virus and delivered by our LNP technology were used to treat previously infected non-human primates,
the result was 100 percent protection from an otherwise lethal dose of Zaire Ebola virus (Geisbert et al., <i>The Lancet,</i> Vol.
375, May 29, 2010).</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In May 2013, our collaboration with the JPM-MCS-BDTX was modified and expanded to include
advances in LNP formulation technology. The contract modification increased the first stage of funding from $34.7 million to $41.7
million. In April 2014, we signed a second contract modification to increase this funding by $2.1 million to a total of $43.8
million to compensate&nbsp;Arbutus for unrecovered costs that occurred in 2012 and to provide additional funding should it be
required. In May 2015 a further $1.0 million of funding was made available for stage one of the contract.</P>



<P STYLE="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">TKM-Ebola is being developed under specific U.S. Food and Drug Administration (FDA) regulatory
guidelines called the &#8220;Animal Rule.&#8221; This allows, in circumstances where it is unethical or not feasible to conduct
human efficacy studies, marketing approval to be granted based on adequate and well-controlled animal studies when the results
of those studies establish that the drug is reasonably likely to produce clinical benefit in humans.&nbsp;&nbsp;Demonstration of
the product&#8217;s safety in humans is still required.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We were granted Fast Track designation from the FDA for the development of TKM-Ebola in March
2014. The FDA&#8217;s Fast Track is a process designed to facilitate the development and expedite the review of drugs in order
to get important new therapies to the patient earlier.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In May 2014, we successfully completed the single ascending dose portion of the TKM-Ebola
Phase I clinical trial in healthy human volunteers. Results demonstrated that administration of the TKM-Ebola therapeutic, in the
absence of any steroid containing pre-medication, was well-tolerated at a dose level of 0.3 mg/kg, determined to be the maximum
tolerated dose.</p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0"></p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">In July 2014, we received notice from the FDA placing the IND for TKM-Ebola on clinical
hold until additional information is supplied, and the multiple ascending dose portion of the trial protocol is modified to ensure
the safety of healthy volunteers. The clinical hold was subsequently modified to a partial clinical hold to permit the administration
of TKM-Ebola to patients with a suspected or confirmed Ebola virus infection. Under the FDA&#8217;s expanded access program, several
patients with a confirmed or suspected Ebola virus infection were treated with TKM-Ebola. Data are being collected and will be
provided to the FDA under our IND. Health Canada also established a similar framework for the potential use of TKM-Ebola in the
same group of patients.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In December 2014, the U.S. Congress amended the Rare and Tropical Disease list to include Ebola
as a candidate for a potential Accelerated Review Voucher.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In April 2015, the FDA notified us that the partial clinical hold had been modified
to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. However, the IND remains on partial clinical
hold with regard to doses above 0.24 mg/kg/day in healthy volunteers. Given the unclear development path for TKM-Ebola,
development activities  have been suspended and a joint re-evaluation of the development contract with
the U.S. DoD is underway.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-Ebola-Guinea, an Anti-Ebola RNAi Therapeutic Targeting Ebola-Guinea Strain of Ebola
Virus</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In September 2014, we joined an international consortium led by the International Severe
Acute Respiratory and Emerging Infection Consortium (ISARIC) at the University of Oxford, UK, to potentially provide an RNAi based
investigational therapeutic for expedited clinical studies in West Africa.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In October 2014, the genomic sequence of the virus responsible for the recent outbreak in
West Africa was determined from several viral isolates and the strain was called Ebola-Guinea. The results of this work were published
in the New England Journal of Medicine (Baize S., et al. Emergence of Zaire Ebola Virus Disease in Guinea; <i>New England Journal
of Medicine</i> , October 9, 2014, vol. 371 No. 15). In November 2014, the nomenclature for the strain was further refined and
is now known as Ebola-Makona. (Kuhn, JH., et al. Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that
Emerged in Guinea and the Democratic Republic of the Congo in 2014; <i>Viruses</i> , Nov 24, 2014, 6, 4760-4799).&nbsp;&nbsp;We
rapidly developed a modified RNAi therapeutic to target the strain responsible for the epidemic in West Africa. The new product,
TKM-Ebola-Guinea, is designed to exactly match the genomic sequence of the Makona strain with two RNAi molecule triggers.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In December 2014, we entered into a Manufacturing and Clinical Trial Agreement with the University
of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. GMP manufacture of TKM-Ebola-Guinea
has been completed and up to 100 treatment courses are available.&nbsp;&nbsp;In March 2015, a Phase II&nbsp;single arm trial called
RAPIDE (Rapid Assessment of Potential Interventions &amp; Drugs for Ebola), was initiated in Sierra Leone, with TKM-Ebola-Guinea.&nbsp;&nbsp;The
study was led by ISARIC with funding from the Wellcome Trust. In June 2015 we announced closing of the enrollment for the trial
as it reached a futility boundary, which was a predefined statistical endpoint. Data analysis is ongoing and the full results are
pending.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">The U.S. Department of Defense JPM-MCS-BDTX has also exercised an option, valued at $7.0
million, in our current contract to manufacture TKM-Ebola-Guinea.&nbsp;We have been awarded the option for scale-up and GMP manufacture
of the product for approximately 500 treatment courses. This development activity together with other DoD funded Ebola related
activities has been suspended and a joint re-evaluation of the development contract is underway.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">In March 2015, we signed a contract modification to provide up to $2,250,000 to fund TKM-Ebola-Guinea IND
submission expenses.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In April 2015, we, along with our collaborators at the University of
Texas Medical Branch (UTMB) at Galveston, USA, published positive Ebola treatment data in the journal Nature (Thi EP., et al <i>.</i>
Lipid Nanoparticle siRNA Treatment of Ebola-Virus-Makona-Infected Nonhuman Primates; <i>Nature,</i> April 22, 2015). Data demonstrated
100% survival of nonhuman primates previously infected with the West African Makona strain of Ebola virus even when treatment did
not begin until three days after viral exposure a time point at which animals were five to six days away from death. These efficacy
results are comparable to those obtained with TKM-Ebola, which also demonstrated up to 100% protection from an otherwise lethal
dose of the virus.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are exploring partnering or external funding opportunities to maximize the value of our
Ebola related assets.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><u>Non-HBV Preclinical Candidates</u> <i><u>(LNP enabled)</u></i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are currently evaluating several additional preclinical candidates with potential in diverse
therapeutic areas. Given the extremely high efficiency of delivery for third and fourth generation liver-centric LNP formulations,
we are focused on rare diseases where the molecular target is found in the liver, early clinical proof-of-concept can be achieved
and development opportunities may be accelerated. Our research team intends to continue to generate preclinical data to support
the advancement of the most promising of these targets.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-Marburg</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Like Ebola, Marburg is a member of the filovirus family of hemorrhagic fever viruses. Natural
outbreaks with the Marburg-Angola strain have resulted in mortality in approximately 90% of infected individuals. Currently, there
are no approved therapeutics for the treatment of Marburg infection.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">In 2010, along with UTMB, we were awarded a National Institutes of Health (NIH) grant to
support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections. In November 2013,
we announced data showing 100% survival in non-human primates infected with the Angola strain of the Marburg virus in two separate
studies. These results build upon a study published earlier in the Journal of Infectious Disease showing 100% protection in guinea
pig models of infection with Angola, Ci67 and Ravn strains of the Marburg virus using a broad spectrum RNAi therapeutic enabled
by Arbutus&#8217; LNP.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In February 2014, along with UTMB, and other collaborators, we were awarded additional funding
from the NIH in support of this research. Data was published demonstrating complete protection of non-human primates against lethal
Marburg-Angola strain, (<i>Science Translational Medicine</i>. Thi EP., et al. Marburg Virus Infection in Nonhuman Primates: Therapeutic
Treatment by Lipid-Encapsulated siRNA. 2014 Aug 20; 6 (250))</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are exploring partnering or external funding opportunities to maximize the value of this
asset.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-HTG</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">The most advanced program in our metabolic product platform is TKM-HTG targeted towards the
rapid and sustained reductions of triglycerides to address the limitations of existing Hypertriglyceridemia (HTG) treatments. Hypertriglyceridemia
is a type of dyslipidemia where there are high blood levels of triglycerides. Patients with severe HTG, (classified as triglyceride
levels greater than 1000 mg/dL) are at risk of acute pancreatitis as well as the risk of cardiovascular disease. Approximately
one million adults in the U.S. and 18 million worldwide suffer from severe HTG<i>. (National Health and Nutrition Examination Survey,
Centre for Disease Control,</i> NHANES 2003-2004 data). High triglyceride levels are medically linked to an increased risk of cardiovascular
disease, fatty liver disease, insulin resistance and pancreatitis.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Currently in preclinical studies, TKM-HTG is a dual component RNAi investigational therapeutic
that simultaneously targets two important genes - Apolipoprotein C3 (ApoC3) and Angiopoietin like protein 3 (ANGPTL3) &#8211; which
are expressed in the liver and are known to play a significant and complementary role in triglyceride metabolism. The most important
findings obtained in our pre-clinical studies are the super-additive effects on plasma triglycerides by silencing ApoC3 and ANGPTL3
genes in a well validated model of HTG. We presented this and related data at the Keystone Symposia Conference: Liver Metabolism
and Nonalcoholic Fatty Liver Diseases, in Whistler, Canada, March 22-27, 2015.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In our preclinical studies, we employed two well validated models of HTG including a human
ApoC3 transgenic (Tg) mouse model and a high-fat containing diet fed mouse model. In the human ApoC3-Tg mouse model, silencing
of ApoC3 gene was accomplished, which resulted in rapid, potent and sustained plasma triglyceride (TG) lowering, with the lowest
effective dose at 0.03 mg/kg. Duration of gene silencing and TG lowering effects from a single administration of the ApoC3 RNAi
trigger lasted for more than two weeks. In addition, beneficial cholesterol profile changes and significant glucose lowering effects
were also observed. In the high-fat containing diet fed mouse model, silencing of both the ApoC3 and ANGPTL3 genes, resulted in
super-additive plasma triglycerides lowering effects. Doses of 0.125 mg/kg + 0.125 mg/kg in combination were superior to either
0.25 mg/kg or 0.5 mg/kg for the individual RNAi-triggers.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are exploring partnering or external funding opportunities to maximize the value of this
asset.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>TKM-ALDH</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">TKM-ALDH is designed to knockdown or silence aldehyde dehydrogenase (ALDH) to induce long
term acute sensitivity to ethanol, for use in severe alcohol use disorder. Aldehyde dehydrogenase is a key enzyme in ethanol metabolism.
Inhibition of ALDH activity, through the silencing of ALDH results in the build-up of acetaldehyde leading to adverse physiological
effects. Human proof of concept for ALDH inhibition already exists in the form of the approved drug disulfiram. However, disulfiram&#8217;s
efficacy is compromised by poor compliance because it has to be taken daily. We believe TKM-ALDH will induce prolonged ethanol
sensitivity that will enable it to overcome the compliance limitations associated with daily dosing.</p>

<p style="font-size: 10pt; margin: 0 0 0 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We are exploring partnering or external funding opportunities to maximize the value of this
asset.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Ongoing Advancements in LNP Technology</i></b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We plan to continue to develop our proprietary LNP delivery technology and receive clinical
validation from LNP-based products currently in clinical trials. The most advanced LNP-enabled therapeutic, which is being developed
by Alnylam Pharmaceuticals, Inc., has entered a Phase III clinical trial. Our LNP technology remains an important element of our
business development activities moving forward. We recently announced the latest (fourth) generation of the platform which comprises
a rational re-design of the lipid architecture, as well as formulation and process advances. These attributes can be utilized in
programs entering the clinic and are expected to yield significant increases in potency and therapeutic index.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Because LNP can enable a wide variety of nucleic acid triggers, including messenger RNA (mRNA),
we continue to see new product development and partnering opportunities based on what we believe is our industry-leading delivery
expertise. In February 2014, we presented new preclinical data at the AsiaTIDES scientific symposium in Tokyo, Japan demonstrating
that mRNA can be effectively delivered to target proteins expressed.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>Technology, Product Development and Licensing Agreements</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In the field of RNAi therapeutics, we have licensed our LNP delivery technology to Alnylam,
and to Merck &amp; Co., Inc. (which has since been acquired by Alnylam). Alnylam has provided royalty bearing access of our LNP
delivery technology to some of its partners. We have a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc.&nbsp;&nbsp;In
addition, we have ongoing research relationships with Monsanto, U.S. government grants and contracts and other undisclosed pharmaceutical
and biotechnology companies. Outside the field of RNAi, we have a legacy licensing agreement with Spectrum Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We have rights under the RNAi intellectual property of Alnylam to develop 13 RNAi therapeutic
products. In addition, we have a broad non-exclusive license to use Unlocked Nucleobase Analogs (UNAs) from Arcturus Therapeutics,
Inc., for the development of RNAi therapeutic products directed to any target in any therapeutic indication.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><u>Strategic Alliances</u></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Alnylam has a license to use our Intellectual Property (IP) to develop and commercialize
products and may only grant access to our LNP technology to its partners if it is part of a product sublicense. Alnylam&#8217;s
license rights are limited to patents that we have filed, or that claim priority to a patent that was filed, before April 15, 2010.
Alnylam does not have rights to our patents filed after April 15, 2010 unless they claim priority to a patent filed before that
date. Alnylam will pay low single digit royalties as Alnylam&#8217;s LNP-enabled products are commercialized. Alnylam currently
has three LNP-based products in clinical development: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In November 2013, Alnylam presented positive results from its Phase II clinical trial with
patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR),
which is enabled by our LNP technology. Alnylam also announced the initiation of the APOLLO Phase III trial of patisiran, with
the study now open for enrollment to evaluate efficacy and safety of patisiran in ATTR patients with Familial Amyloidotic Polyneuropathy
(FAP).</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In December 2013, we received a $5 million milestone from Alnylam, triggered by the initiation
of the APOLLO Phase III trial of patisiran. We have entered an arbitration proceeding with Alnylam, as provided for under our licensing
agreement, to resolve a matter related to a disputed $5 million milestone payment to us by Alnylam for its ALN-VSP product. We
have not recorded any revenue in respect of this milestone.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In April 2014, Alnylam presented positive new data from its Phase II clinical trial with
patisiran. These results provide support for Alnylam's Phase III APOLLO trial in which patisiran is being evaluated for its potential
efficacy and safety in ATTR patients with FAP. Alnylam has disclosed that it continues to enroll patients in its APOLLO Phase III
trial, with over 20 sites in nine countries, which are now open and active. The Phase III trial is intended to demonstrate the
efficacy and safety of patisiran in support of marketing authorization in countries around the world.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In October 2014, Alnylam reported positive clinical data for the ongoing patisiran Phase
II Open Label Extension (OLE) study in patients with FAP, which is also enabled by our LNP technology. The results demonstrated
sustained knockdown of serum TTR of up to 90% and a favorable tolerability profile out to one year of treatment.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In April 2015, Alnylam announced positive data from the ongoing open-label study with patisiran
which demonstrated continued evidence for possible halting of neuropathy progression after the first 12 months of treatment. In
addition, patisiran treatment showed robust mean knockdown of serum TTR of up to 88%.&nbsp;&nbsp;Alnylam's ongoing OLE study is
an open-label, multi-center trial designed to evaluate the long-term safety and tolerability of patisiran administration in FAP
patients that were previously enrolled in a Phase 2 study.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In July 2015, Alnylam announced initiation of a Phase III open label OLE study with patisiran
(&#8220;APOLLO-OLE&#8221;) to evaluate the long-term safety and tolerability of patisiran in ATTR amyloidosis patients with FAP
who were previously enrolled in the APOLLO Phase III study.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">The patisiran program represents the most clinically advanced application of our LNP delivery
technology. Furthermore, Alnylam&#8217;s results demonstrate that multi-dosing with our LNP has been well-tolerated with treatments
out to 17 months.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Our licensing agreement with Alnylam grants us IP rights for the development and commercialization
of RNAi therapeutics for specified targets. In consideration for these three exclusive and 10 non-exclusive licenses, we have agreed
to pay single-digit royalties to Alnylam on product sales, with milestone obligations of up to $8.5 million on the non-exclusive
licenses and no milestone obligations on the three exclusive licenses.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Consistent with the terms of the settlement agreement signed in November 2012, we finalized
and entered a cross-license agreement with Acuitas (formerly AlCana Technologies, Inc.) in December 2013. The terms of the cross-license
agreement provide Acuitas with access to certain of our earlier IP generated prior to April 2010. At the same time, the terms provide
us with certain access to Acuitas&#8217; technology and licenses in the RNAi field, along with a percentage of each milestone and
royalty payment with respect to certain products. Acuitas has agreed that it will not compete in the RNAi field for a period of
five years, ending in November 2017.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>Spectrum Pharmaceuticals, Inc. (&#8220;Spectrum&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In September 2013, we announced that our licensee, Spectrum, had launched Marqibo&#174; through
its existing hematology sales force in the United States. Since then commercial sales have occurred. Arbutus is entitled to mid-single
digit royalty payments based on Marqibo&#174;&#8217;s commercial sales. Marqibo&#174;, which is a novel sphingomyelin/cholesterol
liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine, was originally developed by Arbutus. We out-licensed
the product to Talon Therapeutics in 2006, and in July 2013, Talon was acquired by Spectrum. Marqibo&#174;&#8217;s approved indication
is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) in second or
greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. Spectrum has ongoing trials
evaluating Marqibo&#174; in three additional indications, which are: first line use in patients with Ph-ALL, Pediatric ALL and Non-Hodgkin&#8217;s
lymphoma.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Monsanto Company (&#8220;Monsanto&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In January 2014, we signed an Option Agreement and a Service Agreement with Monsanto, and
granted Monsanto an option to obtain a license to use our proprietary LNP delivery technology. The transaction supports the application
of LNP technology and related IP for use in agriculture. The potential value of the transaction could reach $86.2 million following
the successful completion of milestones. In January 2014, we received $14.5 million of the $17.5 million in near term payments.
We received additional payments of $1.5 million each in June 2014 and October 2014 following the achievement of specific program
objectives, and $1.05 million in May 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Marina Biotech, Inc.&nbsp;&nbsp;(&#8220;Marina&#8221;) / Arcturus Therapeutics, Inc. (&#8220;Arcturus&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In November 2012, we disclosed that we had obtained a worldwide, non-exclusive license to
a novel RNAi trigger technology called Unlocked Nucleobase Analog (UNA) from Marina for the development of RNAi therapeutics. UNAs
can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target
effects. In August 2013, Marina assigned its UNA technology to Arcturus and the UNA license agreement was then assigned to Arcturus.
The terms of the license are otherwise unchanged.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">To date, we have paid Marina $0.5 million in license fees and there are milestones of up
to $3.2 million plus royalties for each product that we develop using UNA technology licensed from Marina.&nbsp;&nbsp;We announced
on January 21, 2015, that we had initiated a Phase I clinical trial with TKM-HBV.&nbsp;As TKM-HBV utilizes UNA technology in-licensed
from Arcturus,&nbsp;the initiation of the trial triggered a single milestone payment of $250,000 paid by us to Arcturus.&nbsp;</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Merck &amp; Co., Inc. ("Merck") and Alnylam license agreement</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">As a result of the settlement between Protiva and Merck in 2008, we acquired a non-exclusive
royalty-bearing world-wide license agreement with Merck. Under the license, Merck will pay up to $17 million in milestones for
each product they develop covered by our IP, except for the first product for which Merck will pay up to $15 million in milestones,
and will pay royalties on product sales. Merck&#8217;s license rights are limited to patents that Protiva filed, or that claim
priority to one of Protiva&#8217;s patents that was filed, before October 9, 2008. Merck does not have rights to Protiva patents
filed after October 9, 2008 unless they claim priority to a patent filed before that date. On March 6, 2014, Alnylam announced
that they acquired all assets and licenses from Merck, which included our license agreement.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Bristol-Myers Squibb Company (&#8220;BMS&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In May 2010, we announced a research collaboration with BMS. Under this agreement, BMS conducted
preclinical work to validate the function of certain genes and shared the data with us to potentially develop RNAi therapeutic
drugs against therapeutic targets of interest. We formulated the required RNAi trigger molecules enabled by our LNP technology
to silence target genes of interest.&nbsp;&nbsp;BMS paid us $3.0 million concurrent with the signing of the agreement. We provided
a predetermined number of LNP batches over the four-year agreement.&nbsp;&nbsp;In May 2011, we announced a further expansion of
the collaboration to include broader applications of our LNP technology and additional target validation work. In May 2014, the
collaboration expired and all parties&#8217; obligations ended.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>U.S. National Institutes of Health (&#8220;NIH&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">On October 13, 2010 we announced that together with collaborators at UTMB, we were awarded
a new NIH grant, worth $2.4 million, to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever
viral infections using our LNP delivery technology.&nbsp;In February 2014, we along with UTMB and other collaborators were awarded
additional funding of $3.4 million over five years from the NIH in support of this research.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>Halo-Bio RNAi Therapeutics, Inc. ("Halo-Bio")</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In August 2011, Protiva entered into a license and collaboration agreement with Halo-Bio.
Under the agreement, Halo-Bio granted to Protiva an exclusive license to its multivalent ribonucleic acid MV-RNA technology. The
agreement was amended on August 8, 2012 to adjust future license fees and other contingent payments. To date, we have recorded
$0.5 million in fees under the Protiva license from Halo-Bio. Protiva terminated the agreement with Halo-Bio in July 2013. There
are no further payments due or contingently payable to Halo-Bio.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Dicerna Pharmaceuticals, Inc. (&#8220;Dicerna&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In November 2014, we signed a licensing agreement and a development and
supply agreement with Dicerna to license our LNP delivery technology for exclusive use in Dicerna's primary hyperoxaluria
type 1 (PH1) development program. Dicerna will use our third generation LNP technology for delivery of DCR-PH1, Dicerna's
product incorporating its Dicer substrate RNA (DsiRNA) molecule, for the treatment of PH1, a rare, inherited liver disorder
that often results in kidney failure and for which there are no approved therapies. Under the agreements, Dicerna paid a
$2.5 million upfront and will potentially make payments of $22 million in aggregate development milestones, plus
tiered mid-single-digit royalty payments on future PH1 sales. This partnership also includes a supply agreement under which
we will provide clinical drug supply and regulatory support for the rapid advancement of this product candidate.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Cytos Biotechnology Ltd (&#8220;Cytos&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">On December&nbsp;30, 2014, Arbutus Inc., our wholly owned subsidiary, entered into an exclusive,
worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license
to six different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7
or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&nbsp; We have
an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for
influenza, all non-viral infections, and all viral infections (other than hepatitis) for which we have not exercised an option.&nbsp;</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In partial consideration for this license, we will be obligated to pay Cytos up to a total
of $67 million for each of the six licensed compound series upon the achievement of specified development and regulatory milestones;
for hepatitis and each additional licensed viral infection, up to a total of $110 million upon the achievement of specified sales
performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&nbsp;net
sales of licensed products in any&nbsp;commercialized combination.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>The Baruch S. Blumberg Institute (&#8220;Blumberg&#8221;) and Drexel University (&#8220;Drexel&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In February 2014, Arbutus Inc., our wholly owned subsidiary, entered into a license agreement
with Blumberg and Drexel that granted an exclusive (except as to certain know-how and subject to retained non-commercial research
rights), worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and
HCC inhibitors.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In partial consideration for this license, Arbutus Inc. paid a license initiation fee of
$150,000 and issued warrants to Blumberg and Drexel. No warrants were outstanding as at the date Arbutus merged with Arbutus Inc.
Under this license agreement, Arbutus Inc. also agreed to pay up to $3.5 million in development and regulatory milestones per licensed
compound series, up to $92.5 million in sales performance milestones per licensed product, and royalties in the mid-single digits
based upon the proportionate net sales of licensed products in any commercialized combination. We are obligated to pay Blumberg
and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In November 2014, Arbutus Inc. entered into an additional license agreement with Blumberg
and Drexel pursuant to which it&nbsp;received an exclusive (subject to retained non-commercial research rights), worldwide, sub-licensable
license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING
agonists. In consideration for these exclusive licenses, Arbutus Inc. made an upfront payment of $50,000. Under this agreement,
we will be required to pay up to $1.0 million for each licensed product upon the achievement of a specified regulatory milestone
and a low single digit royalty, based upon the proportionate&nbsp;net sales of compounds covered by this intellectual property&nbsp;in
any commercialized combination. We are also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received
from its sub-licensees, subject to exclusions.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>License Agreements between Enantigen (&#8220;Enantigen&#8221;) and Blumberg and Drexel</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In October 2014, Arbutus Inc., our wholly owned subsidiary, acquired all of the outstanding
shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen
secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following our merger
with Arbutus Inc.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Under the stock purchase agreement, we agreed to pay up to a total of $21.0 million to Enantigen&#8217;s
selling stockholders upon the achievement of specified development and regulatory milestones, for the first two products that contain
either a capsid compound, or a HBV surface antigen compound that is covered by a patent acquired under this agreement; or a capsid
compound from an agreed upon list of compounds. The amount paid could be up to a total of $101.5 million in sales performance milestones
in connection with the sale of the first commercialized product by us for the treatment of HBV, regardless of whether such product
is based upon assets acquired under this agreement; and low single digit royalty on net sales of such first commercialized HBV
product, up to a maximum royalty payment of $1.0 million that, if paid, would be offset against our milestone payment obligations.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Under the stock purchase agreement, we also agreed that Enantigen would fulfill its obligations
as they relate to the three patent license agreements with Blumberg and Drexel. Pursuant to each patent license agreement, Enantigen
is obligated to pay Blumberg and Drexel up to approximately $500,000 in development and regulatory milestones per licensed product,
royalties in the low single digits, and a percentage of revenue it receives from its sub-licensees.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>Research Collaboration and Funding Agreement with Blumberg</b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In October 2014, Arbutus Inc., our wholly owned subsidiary, entered into a research collaboration
and funding agreement with Blumberg under which we will provide $1.0 million per year of research funding for three years, renewable
at our option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research
plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under
the agreement. In addition, we have the right to match any third party offer to fund HBV research that falls outside the scope
of the research being funded under the agreement. Blumberg has granted us the right to obtain an exclusive, royalty bearing, worldwide
license to any intellectual property generated by any funded research project. If we elect to exercise our right to obtain such
a license, we will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg.
This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in
the amount of $100,000; up to $8.1 million upon the achievement of specified development and regulatory milestones; up to $92.5
million upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates
based upon the proportionate&nbsp;net sales of licensed&nbsp;products from any commercialized combination.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>NeuroVive Pharmaceutical AB (&#8220;NeuroVive&#8221;)</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0">In September 2014, Arbutus Inc., our wholly owned subsidiary, entered into a license agreement
with NeuroVive that granted us an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the
treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement
we have been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory
approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment
of HBV. Under this license agreement, we have (1)&nbsp;an option to expand our exclusive license to include treatment of viral
diseases other than HBV and (2)&nbsp;an option, exercisable upon specified conditions, to expand our exclusive license to include
development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other
than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and
non-oral variations of licensed products for all indications (other than HBV) for which we have not exercised our option.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of
$1 million. We are also obligated to pay up to $47.0 million in clinical development and regulatory milestones per indication
and up to $102.5 million in sales performance milestones per licensed product and indication. If we are acquired by a third party
in a transaction that meets certain criteria, then we or our acquirer will be obligated to pay all remaining development, regulatory
and sales milestone payments, regardless of whether the applicable milestone events have been achieved, for each licensed product
that entered clinical development before such acquisition. As described in &#8220;Overview&#8221;, Arbutus Inc. became our wholly
owned subsidiary  by way of a Merger Agreement, which does not trigger any of the aforementioned milestone payment We agreed to
pay NeuroVive tiered royalties in the mid-single to low-double digit range based upon the proportionate&nbsp;gross sales of patented
licensed products from any commercialized combination. If we terminate this license agreement in its entirety for convenience
prior to the first commercial sale of any licensed product, we will be obligated to pay NeuroVive a termination fee of $2 million.</p>



<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>CRITICAL ACCOUNTING POLICIES AND ESTIMATES</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Share purchase warrant valuation</b> / The valuation of share purchase
warrants is a critical accounting estimate due to the value of liabilities recorded and the many assumptions that are required
to calculate the liability, resulting in the classification of our warrant liability as a level 3 financial instrument.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We classify warrants in our consolidated balance sheet as liabilities and revalue them at
each balance sheet date. Any change in valuation is recorded in our statement of operations. We use the Black-Scholes pricing model
to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires
considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. Due
to ongoing changes in our business and general stock market conditions, we continuously assess our warrant fair value assumptions.
We adjust the estimated expected life as appropriate, based on the pattern of exercises of our warrants. As at December 31, 2014,
for the purpose of calculating the fair value, the expected life of outstanding warrants was three months for warrants expiring
in June 2016, and nine months for warrants expiring in February 2017. Based on the pattern of decreasing exercises of warrants,
we have increased the expected life to nine months and twelve nine months for outstanding warrants expiring in June 2016 and February
2017, respectively, effective January 1, 2015. The remaining expected life is three months and six months for outstanding warrants
expiring in June 2016 and February 2017, respectively, as at June 30, 2015. For the three and six month period ended June 30, 2015,
we recorded a gain to earnings due to the decrease in fair value of warrant liability of $2,024,000 and $801,000 respectively.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Business combination</b> / The purchase price allocation is a critical
accounting estimates due to the many assumptions that are required to calculate the fair value of assets acquired and liabilities
assumed during a business combination.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">We account for our business combination using the acquisition method.
Under this method, estimates we make to determine the fair values of assets acquired and liabilities assumed include judgments
in our determinations of acquired intangible assets and assessment of the fair value of existing property and equipment. Assumed
liabilities can include other contingency reserves existing at the time of acquisition. Goodwill is recognized as of the acquisition
date as the excess of the purchase price over the estimated fair values of net identifiable assets acquired and liabilities assumed
at their acquisition date. Acquisition related expenses are separately recognized from business combination and are expensed as
incurred.</p>

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">When establishing fair values, we make significant estimates and assumptions,
especially with respect to intangible assets. Intangible assets acquired and recorded by us may include patents, intellectual property,
and in-process research and development. Estimates include, but are not limited to the forecasting of future cash flows and discount
rates. Our estimates for the fair values of assets acquired and liabilities assumed are preliminary for the period ended June 30,
2015. We are currently undertaking a valuation assessment by engaging a third-party firm to assist us to determine the fair values.
Our preliminary estimates of fair values are based upon assumptions that we believe to be reasonable, but which are inherently
uncertain and unpredictable; therefore, actual results may differ from estimates impacting our earnings.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">There are no other changes to our critical accounting policies and estimates
from those disclosed in our annual MD&amp;A contained in our 2014 Annual Report filed on Form 10-K.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">From time to time, new accounting pronouncements are issued by the Financial
Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise
discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on
our financial position or results of operations upon adoption.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with
Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue
standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the
revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35,
Revenue Recognition &#8211; Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that
an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1)
retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying
this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date
of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December
15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective
date if they choose. We have not yet determined the extent of the impact of adoption.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial
Statements &#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as
a Going Concern. The update is intended to provide guidance in GAAP about management&#8217;s responsibility to evaluate whether
there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures.
Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or
available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company
means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted.&nbsp;&nbsp;We do
not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>SUMMARY OF QUARTERLY RESULTS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">The following table presents our unaudited quarterly results of operations for each of our
last eight quarters. These data have been derived from our unaudited condensed consolidated financial statements, which were prepared
on the same basis as our annual audited financial statements and, in our opinion, include all adjustments necessary, consisting
solely of normal recurring adjustments, for the fair presentation of such information.</p>

<p style="font-size: 10pt; margin: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">(in millions $ except per share data) &#8211; unaudited</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q2</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q1</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q4</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q3</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q2</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q1</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q4</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">Q3</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Collaborations and contracts:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%; font-size: 10pt; text-align: left; padding-left: 10pt">DoD</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">1.8</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">3.0</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">2.8</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">1.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">0.9</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">3.2</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">2.6</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">2.8</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Dicerna</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1.6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.2</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(0.1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.4</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.6</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.7</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.6</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.9</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Alnylam milestone payments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5.0</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Monsanto licensing fees and milestone payments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.8</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.8</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.9</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.7</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.6</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dicerna licensing fee</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Spectrum milestone and royalty payments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.0</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.0</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.0</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total revenue</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3.4</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4.7</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4.4</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4.4</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1.8</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4.4</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7.6</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2.9</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(17.9</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22.7</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15.1</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(11.2</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(11.2</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(10.4</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9.9</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6.6</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other income (losses)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.5</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6.0</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1.8</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12.0</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.2</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2.2</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(14.9</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(12.0</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(6.2</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(8.6</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(6.1</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(18.0</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(2.6</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(5.9</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Basic and diluted net loss per share</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.27</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.40</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.27</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.39</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.28</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.91</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.15</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.41</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
</table>


<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0"><b>Quarterly Trends</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Revenue</b> / Our revenue is derived from research and development
collaborations and contracts, licensing fees, milestone and royalty payments. Over the past two years, our principal source of
ongoing revenue has been our contract with the DoD to advance TKM-Ebola which began in July 2010. We expect revenue to continue
to fluctuate particularly due to the development stage of the TKM-Ebola contract and the irregular nature of licensing and milestone
receipts.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In Q3 2010 we signed a contract with the DoD to develop TKM-Ebola and
have since incurred significant program costs related to equipment, materials and preclinical and clinical studies. These costs
are included in our research, development, collaborations and contracts expenses. These costs are fully reimbursed by the DoD,
and this reimbursement amount is recorded as revenue. DoD revenue from the TKM-Ebola program also compensates us for labor and
overheads and provides an incentive fee. As described in our critical accounting policies in our Annual Report, we estimate the
labor and overhead rates to be charged under our TKM-Ebola contract and update these rate estimates throughout the year. In April
2014, we signed a contract modification to increase the stage one targeted funding by $2.1 million to $43.8 million. The additional
funding is to compensate us for unrecovered costs related to the temporary stop-work period that occurred in 2012 and to provide
additional overhead funding should it be required. In Q1 2014, we earned $3.2 million in DoD revenue, due partially to an increase
in activity as we moved into a Phase I Clinical Trial. In Q2 2014, we earned $0.9 million in DoD revenue due to lower contract
activity as our clinical trial data was with the FDA for review. DoD revenue increased in Q3 2014 with an increase in activity
as we prepared a response to the FDA&#8217;s partial clinical hold on our Phase I Clinical Trial. In October 2014, the DoD exercised
a contract option adding $7.0 million to the contract for the scale-up and manufacture of TKM-Ebola-Guinea, our product targeting
the Ebola-Makona (formerly known as Ebola-Guinea) strain responsible for the current outbreak in West Africa. DoD revenue increased
in Q4 2014 and Q1 2015 as we purchased materials and manufactured TKM-Ebola-Guinea. In Q2 2015, material purchases and subcontract
work related to TKM-Ebola-Guinea were less significant. In July 2015, we announced that activities have been suspended while a
joint re-evaluation of the development contract is conducted.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In January 2014, we signed an Option Agreement and a Services Agreement
with Monsanto for the use of our proprietary delivery technology and related intellectual property in agriculture. Over the option
period, which is expected to be approximately four years, Monsanto will make payments to us to maintain their option rights. In
Q1 2014, we received $14.5 million of the $17.5 million near term payments, of which $4.5 million relates to research services
and $10.0 million for the use of our technology. In June 2014 and October 2014, we received further payments of $1.5 million each,
following the completion of specified program developments. In May 2015, we received an additional $1.05 million related &nbsp;to
research services. The payments are being recognized as revenue on a straight-line basis over the option period.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In November 2014, we signed a License Agreement and a Development and
Supply Agreement with Dicerna for the use of our proprietary delivery technology and related technology intended to develop, manufacture,
and commercialize products related to treatment of PH1. In Q4 2014, we received an upfront payment of $2.5 million, which is being
recognized over the period over which we provide services to Dicerna, estimated to complete in Q1 2017. We recognized collaboration
revenue of $0.2 million in each of Q1 and Q2 2015 which relates to materials and services provided to Dicerna.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In Q4 2013 we earned a $5.0 million milestone from Alnylam following
their initiation of a Phase III trial enabled by our LNP technology.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In Q4 2013, we began to earn royalties from Spectrum with respect to
the commercial sales of Marqibo.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Included in &#8220;other collaborations and contract revenue&#8221;
is revenue from a BMS batch formulation agreement. In Q4 2013, we offered to extend the BMS agreement end date from May 2014 to
December 2014. Extending the agreement would have given BMS more time to order LNP batches. Revenue recognized in 2013 has been
reduced and the balance of deferred revenue as at December 31, 2013 has been increased to account for BMS potentially ordering
more batches under the agreement. This agreement is reflected in the $0.1 million of negative &#8220;other revenue&#8221; in Q4
2013 when the offer was made to extend the agreement and a cumulative revenue adjustment was recorded. In August 2014, we received
notification from BMS that the extension would not occur. As such, the collaboration expired and both parties&#8217; obligations
under the agreement ended. Revenue recognized in Q3 2014 relates to the release of the deferred revenue balance of $1.6 million.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B>Expenses /</b> Expenses consist primarily of clinical and pre-clinical
trial expenses, personnel expenses, consulting and third party expenses, reimbursable collaboration expenses, consumables and materials,
patent filing expenses, facilities, stock-based compensation and general corporate costs.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Our expenses have increased in the past eight quarters due to an increase
in our research and development activities as we seek to move more products into the clinic. In Q3 2013, we initiated a Phase I/II
Clinical Trial for TKM-PLK1 in patients with GI-NET or ACC. In Q1 2014, we dosed the first subject in human clinical trials of
TKM-Ebola. In Q2 2014, we initiated a Phase I/II Clinical Trial for TKM-PLK1 in patients with HCC. In Q4 2014, we filed a Canadian
Clinical Trial Application (CTA) for TKM-HBV and received clearance to conduct a Phase I Clinical Trial, as well as initiated manufacturing
of TKM-Ebola-Guinea for emergency use in West Africa &#8211; see overview. In Q1 2015, we initiated a Phase I Clinical Trial for
TKM-HBV and incurred significant material costs related to the TKM-Ebola-Guinea contract with the DoD. In addition, we incurred
$9.3 million in costs for professional fees related to completing the merger with Arbutus Inc. (formerly OnCore) In Q2 2015, we
incurred an incremental $2.9 million R&amp;D expenses related to our HBV programs acquired through the merger with Arbutus Inc.
(formerly OnCore).</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Other income (losses) /</b> Other income (losses) consist primarily
of changes in the fair value of our warrant liability and foreign exchange differences. Other losses increased in Q3 2013, Q1 2014,
and Q3 2014 due primarily to the increase in fair value of our warrant liability. Increases in our share price from the previous
reporting date result in an increase in the fair value of our warrant liability, and vice versa. We expect to see future changes
in the fair value of our warrant liability and these changes will largely depend on the change in the Company&#8217;s share price,
any change in our assumed rate of share price volatility, our assumptions for the expected lives of the warrants and warrant exercises.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In Q2 2015, we recorded $2.6 million foreign exchange loss, due to the
depreciation of U.S. dollar against Canadian dollar from the previous period. This is offset by a $2.0 million decrease in the
fair value of warrant liability for the period.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Net (loss) income /</b> Fluctuations in our net loss are explained
by changes in revenue, expenses and other income (losses) as discussed above.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">The following summarizes the results of our operations for the periods
shown, in thousands:</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1.1pt solid">
        <p style="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><b>Three Months Ended</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><b>June&nbsp;30,</b></p></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1.1pt solid">
        <p style="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><b>Six Months Ended</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><b>June&nbsp;30,</b></p></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2014</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2014</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; text-align: left"><font style="font-size: 10pt">Total revenue</font></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>3,440</b></font></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">1,811</font></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; text-align: right"><font style="font-size: 10pt"><b>8,122</b></font></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">6,241</font></td>
    <td style="width: 2%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt">Operating expenses</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>17,860</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11,234</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>40,548</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21,622</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><font style="font-size: 10pt">Loss from operations</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(14,420</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9,423</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(32,426</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(15,381</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt">Net loss</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(14,886</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(6,081</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(26,875</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(24,065</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><font style="font-size: 10pt">Basic and diluted loss per share</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(0.27</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(0.28</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(0.64</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1.15</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Revenue</b> / Revenue is summarized in the following table, in thousands:</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="14" style="text-align: center"><font style="font-size: 10pt"><b>Three months ended June 30,</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>% of Total</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">2014</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">% of Total</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">DoD</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>1,862</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>54</b></font></td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">861</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">47</font></td>
    <td style="width: 2%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Monsanto</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>269</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>8</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">283</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">16</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">BMS</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>0</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dicerna&nbsp;</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>179</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>5</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Total collaborations and contracts revenue</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>2,310</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>67</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,144</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">63</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Monsanto licensing fee and milestone payments</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>805</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>23</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">626</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">35</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Acuitas milestone payment</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>0</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dicerna licensing fee</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>263</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>8</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Spectrum milestone and royalty payments</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>62</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>2</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">41</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">2</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Total revenue</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>3,440</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,811</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="14" style="text-align: center"><font style="font-size: 10pt"><b>Six months ended June 30,</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>% of Total</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">2014</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">% of Total</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%"><font style="font-size: 10pt">DoD</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>4,907</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>60</b></font></td>
    <td style="width: 2%"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">4,101</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">66</font></td>
    <td style="width: 2%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Monsanto</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>517</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>6</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">526</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">BMS</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>0</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">206</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dicerna&nbsp;</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>406</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>5</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Total collaborations and contracts revenue</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>5,830</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>72</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,833</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">78</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Monsanto licensing fee and milestone payments</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>1,647</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>20</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,171</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">19</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Acuitas milestone payment</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>0</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dicerna licensing fee</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>526</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>6</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Spectrum milestone and royalty payments</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>119</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>1</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">87</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">1</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Total revenue</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>8,122</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,241</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0"><B><I>Revenue contracts are covered in more detail in the overview section of this discussion.
</i></b></p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0"><b><i>DoD revenue</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0 0 10pt">DoD revenues and related contract expenses were higher in Q2 2015 as compared to Q2
2014 largely due to low contract activity in Q2 2014 as we had completed a Phase I clinical trial and were awaiting FDA review
of our data. DoD revenues and related contract expenses were higher in first half of 2015 as compared to 2014 as we incurred costs
and recorded revenue for the manufacture of TKM-Ebola-Guinea.</p>

<p style="font-size: 10pt; margin: 0">In July 2015, we announced that activities have been suspended while a joint re-evaluation
of the DoD development contract is conducted.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Monsanto revenue</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In January 2014, we received $14.5 million, of which $4.5 million
relates to research services and $10.0 million for the use of our technology. In June and October 2014, we received payments
of $1.5 million each, following the completion of specified program developments. In May 2015, we received $1.05 million for
research services. We are recognizing these payments on a straight-line basis over the option period. In Q2 2015 and
the first half of 2015, we recorded an aggregate of $1.1 million and $2.2 million respectively in revenue for the use of our
technology and for research activities.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Dicerna revenue</i></b></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In November 2014, we signed a License Agreement and a Development and
Supply Agreement with Dicerna for the use of our proprietary delivery technology and related technology intended to develop, manufacture,
and commercialize products related to treatment of PH1. In Q4 2014, we received an upfront payment of $2.5 million, which is being
recognized over the period we provide services to Dicerna, estimated to complete in Q1 2017. We recognized collaboration revenue
of $0.2 million and $0.4 million respectively for the three and six months ended June 30, 2015 earned on materials manufactured
and services provided to Dicerna.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"><b><i>Alnylam revenue</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In Q1 2014, we recognized $0.15 million in milestone revenue from Acuitas
following their receipt of a milestone from Alnylam with the initiation of a Phase III trial enabled by our LNP technology.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0"><B><I>BMS revenue</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In May 2010 we signed a formulation agreement with BMS under which BMS
paid us $3.0 million to make a certain number of LNP formulations over the following four year period. The contract expired in
2014 with no further obligation for either party. Revenue recognized in Q1 2014 relates to the batches shipped to BMS during the
period.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b><i>Spectrum revenue</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In September 2013, Spectrum announced that they had shipped the first
commercial orders of Marqibo. We continue to earn royalties on the sales of Marqibo, which uses a license to our technology.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Expenses</b> / Expenses are summarized in the following table, in thousands:</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="14" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Three months ended June 30,</b></font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>% of Total</b></font></td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">2014</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">% of Total</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1.1pt solid">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Research, development, collaborations and contracts</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>9,690</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>68</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">9,298</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">83</font></td>
    <td colspan="2"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt">General and administrative</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>7,662</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>29</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,787</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">16</font></td>
    <td colspan="2"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Depreciation</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>147</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>1</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">149</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1</font></td>
    <td colspan="2"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt">Acquisition costs</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>361</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>2</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td colspan="2" style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt">%</font></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 61%"><font style="font-size: 10pt"><b>Total operating expenses</b></font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="vertical-align: bottom; width: 6%; text-align: right"><font style="font-size: 10pt"><b>17,860</b></font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 6%; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; width: 6%; text-align: right"><font style="font-size: 10pt">11,234</font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 6%; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="14" style="text-align: center"><font style="font-size: 10pt"><b>Six months ended June 30,</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>% of Total</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">2014</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">% of Total</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><font style="font-size: 10pt">Research, development, collaborations and contracts</font></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>20,247</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>56</b></font></td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">17,502</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">81</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt">General and administrative</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>10,378</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>19</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,837</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Depreciation</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>267</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>1</b></font></td>
    <td><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">283</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt">Acquisition costs</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>9,656</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>24</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>Total operating expenses</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>40,548</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">21,622</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Research, development, collaborations and contracts</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Research, development, collaborations and contracts expenses consist
primarily of clinical and pre-clinical trial expenses, personnel expenses, consulting and third party expenses, consumables and
materials, as well as a portion of stock-based compensation and general corporate costs.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In the first half of 2015, we increased our spending on TKM-HBV as we
initiated a Phase I clinical trial. In addition, we incurred costs for the manufacture of TKM-Ebola-Guinea under our DoD contract
&#8211; see overview. In Q2 2015, we incurred incremental costs related to increase in activities for our HBV programs subsequent
to the merger with Arbutus Inc., as well as incremental costs related to our collaboration programs with Monsanto and Dicerna.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">R&amp;D compensation expense increased in Q2 and in the first half
of 2015 as compared to Q2 and in the first half of 2014 due to an increase in the number of employees in support of our
expanded portfolio of product candidates, as well as from our merger with Arbutus Inc. In addition, in the first half of
2015 we incurred a total of $5.3 million of incremental non-cash compensation expense related to the expiry of repurchase
rights on shares issued as part of the consideration paid for the merger with Arbutus Inc. (refer to notes to the financial
statements), of which $1.3 million has been included as part of research, development, collaborations and contracts expense,
and $4.0 million included as part of general and administrative expense.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">A significant portion of our research, development, collaborations and
contracts expenses are not tracked by project as they benefit multiple projects or our technology platform and because our most-advanced
programs are not yet in late-stage clinical development. However, our collaboration agreements contain cost-sharing arrangements
pursuant to which certain costs incurred under the project are reimbursed. Costs reimbursed under collaborations typically include
certain direct external costs and hourly or full-time equivalent labor rates for the actual time worked on the project. In addition,
we have been reimbursed under government contracts for certain allowable costs including direct internal and external costs. As
a result, although a significant portion of our research, development, collaborations and contracts expenses are not tracked on
a project-by-project basis, we do, however, track direct external costs attributable to, and the actual time our employees worked
on, our collaborations and government contracts.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>General and administrative</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">General and administrative expenses were higher in Q2 and in the first
half of 2015 compared to Q2 and in the first half of 2014 due largely to an increase in compensation expense linked to our increase
in employee base and incremental corporate expenses to support the growth of the Company following the completion of our merger
with Arbutus Inc. This includes an incremental non-cash compensation expense we incurred related to the expiry of repurchase rights
on shares issued as part of consideration paid for the merger with Arbutus Inc. (see above). Expenses were also higher in Q2 2015
and in the first half of 2015 due to legal costs incurred in relation to the May 2015 arbitration hearing against Alnylam.</p>

<p style="font-size: 10pt; margin: 0"><font style="background-color: yellow"></font></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"><font style="background-color: yellow"></font></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"><b><i>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0"><B><I>Depreciation of property and equipment</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Most of our recent property and equipment additions were related to
our TKM-Ebola program and are not recorded as Company assets. As such, a large portion of our property and equipment is reaching
full amortization. In 2015, we spent $0.5 million on property and equipment mostly related to lab equipment and information technology
improvements to support integration following our merger with Arbutus Inc.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b><i>Acquisition costs</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In 2015, we incurred $9.7 million in costs for professional fees related
to completing the merger with Arbutus Inc. &#8211; see overview. This is a one-time cost specific to the merger with Arbutus Inc.,
and we do not expect to incur recurring acquisition costs.</p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0"><b>Other income (losses) /</b> Other income (losses) are summarized in the following table,
in thousands:</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td colspan="7">
        <p style="font-size: 10pt; text-align: center; margin: 0 12.6pt 0 0"><b>Three Months Ended</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0 12.6pt 0 0"><b>June&nbsp;30,</b></p></td>
    <td>&nbsp;</td>
    <td colspan="7">
        <p style="font-size: 10pt; text-align: center; margin: 0 12.6pt 0 0"><b>Six Months Ended</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0 12.6pt 0 0"><b>June&nbsp;30,</b></p></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">2014</font></td>
    <td>&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.1pt solid; text-align: center"><font style="font-size: 10pt">2014</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td colspan="4">&nbsp;</td>
    <td colspan="4">&nbsp;</td>
    <td colspan="4">&nbsp;</td>
    <td colspan="4">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 57%; text-align: left"><font style="font-size: 10pt">Interest income</font></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>81</b></font></td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">257</font></td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt"><b>283</b></font></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">404</font></td>
    <td style="width: 3%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt">Foreign exchange gains (losses)</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(2,571</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;&nbsp;</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(2,728</font></td>
    <td><font style="font-size: 10pt">)&nbsp;&nbsp;</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>4,467</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,285</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><font style="font-size: 10pt">(Increase) decrease in fair value of warrant liability</font></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>2,024</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">5,813</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>801</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">(7,803</font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt">)&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt"><b>Total other income (losses)</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(466</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3,342</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>5,551</b></font></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(8,684</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Foreign exchange gains</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">For the three months ended June 30, 2015, we recorded a foreign exchange
loss of $2.6 million , which is primarily an unrealized loss related to a depreciation in the value of our U.S. dollar funds from
the previous period, when converted to our functional currency of Canadian dollars. In the first half of 2015, we recorded foreign
exchange gains of $4.5 million as the U.S. dollar strengthened by 8% against the Canadian dollar in that period. Cumulative translation
adjustments, which result from converting from our functional currency of Canadian dollars to our reporting currency of U.S. dollars,
do not impact our net loss calculation and are not included in foreign exchange gains (losses).</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b><i>Increase in fair value of warrant liability</i></b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">In conjunction with equity and debt financing transactions in 2011 and
an equity private placement that closed on February 29, 2012, we issued warrants to purchase our common share. We are accounting
for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially
settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered
warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash
settlement. At each balance sheet date the warrants are revalued using the Black-Scholes model and the change in value is recorded
in the consolidated statement of operations and comprehensive income (loss).</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Generally, a decrease in our share price from the previous reporting date results in a decrease
in the fair value of our warrant liability and vice versa.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">We expect to see future changes in the fair value of our warrant liability
and these changes will largely depend on the change in the Company&#8217;s share price, any change in our assumed rate of share
price volatility, our assumptions for the expected lives of the warrants and warrant issuances or exercises.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">The following table summarizes our cash flow activities for the periods indicated, in thousands:</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <TD COLSPAN="7"><P STYLE="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><B>Three Months Ended</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><B>June&nbsp;30,</B></P>

</td>
    <td>&nbsp;</td>
    <TD COLSPAN="7"><P STYLE="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><B>Six Months Ended</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 11.6pt 0 0"><B>June&nbsp;30,</B></P>

</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></td>
    <td>&nbsp;</td>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2014</FONT></td>
    <td>&nbsp;</td>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></td>
    <td>&nbsp;</td>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2014</FONT></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td>
    <td colspan="4">&nbsp;</td>
    <td colspan="4">&nbsp;</td>
    <td colspan="4">&nbsp;</td>
    <td colspan="4">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 53%; text-align: left"><font style="font-size: 10pt">Net loss for the period</font></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; text-align: right"><font style="font-size: 10pt"><b>(14,886</b></font></td>
    <td style="width: 3%"><font style="font-size: 10pt"><b>)&nbsp;&nbsp;</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">(6,081</font></td>
    <td style="width: 3%"><font style="font-size: 10pt">)&nbsp;&nbsp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; text-align: right"><font style="font-size: 10pt"><b>(26,875</b></font></td>
    <td style="width: 3%"><font style="font-size: 10pt"><b>)&nbsp;&nbsp;</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 6%; text-align: right"><font style="font-size: 10pt">(24,065</font></td>
    <td style="width: 3%"><font style="font-size: 10pt">)&nbsp;&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt">Adjustments to reconcile net loss to net cash provided by (used in) operating activities</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>6,185</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(3,192</font></td>
    <td><font style="font-size: 10pt">)&nbsp;&nbsp;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>2,278</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11,687</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><font style="font-size: 10pt">Changes in operating assets and liabilities</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>(7,970</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">1,263</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>(11,044</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">13,523</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 10pt"><font style="font-size: 10pt">Net cash provided by (used in) operating activities</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(16,671</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(8,010</font></td>
    <td><font style="font-size: 10pt">)&nbsp;&nbsp;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(35,641</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,145</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left; padding-left: 10pt"><font style="font-size: 10pt">Net cash provided by (used in) investing activities</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(10,327</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(43,238</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>27,219</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(43,573</font></td>
    <td><font style="font-size: 10pt">)&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 10pt"><font style="font-size: 10pt">Net cash provided by financing activities</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>960</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">234</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>143,780</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">59,523</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left; padding-left: 10pt"><font style="font-size: 10pt">Effect of foreign exchange rate changes on cash &amp; cash equivalents</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>967</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">1,924</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>(340</b></font></td>
    <td style="border-bottom: black 1.1pt solid"><font style="font-size: 10pt"><b>)&nbsp;</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">(545)</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt">Net increase (decrease) in cash and cash equivalents</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(25,071</b></font></td>
    <td><font style="font-size: 10pt"><b>)&nbsp;&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(49,090</font></td>
    <td><font style="font-size: 10pt">)&nbsp;&nbsp;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>135,018</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">16,550</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><font style="font-size: 10pt">Cash and cash equivalents, beginning of period</font></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>232,276</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">134,357</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt"><b>72,187</b></font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; text-align: right"><font style="font-size: 10pt">68,717</font></td>
    <td style="border-bottom: black 1.1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font-size: 10pt"><b>Cash and cash equivalents, end of period</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>207,205</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">85,267</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>207,205</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">85,267</font></td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">Since our incorporation, we have financed our operations through the
sales of shares, units, debt, revenues from research and development collaborations and licenses with corporate partners, interest
income on funds available for investment, and government contracts, grants and tax credits.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">At June 30, 2015, we had an aggregate of approximately $217.2 million
in cash and cash equivalents and long-term investments as compared to an aggregate of $112.2 million in cash and cash equivalents
and short-term investments at December 31, 2014.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">For the six months ended June 30, 215, operating activities used $35.6
million in cash as compared to $1.1 million of cash provided in the six months ended June 30, 2014. The increase in cash used from
operating activities is primarily related to the significant costs incurred related to the acquisition of Arbutus Inc. in March
2015, as well as cash received from Monsanto in January 2014.</p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">For the six months ended June 30, 2015, investing activities provided
$27.2 million in cash as we sold the guaranteed investment certificates we acquired in 2014. In May 2015, we acquired a $10.0 million
term deposit.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">On March 25, 2015, we completed an underwritten public offering of 7,500,000
common shares, at a price of $20.25 per share, representing gross proceeds of $151.9 million. The cost of financing, including
commissions and professional fees, was approximately $9.7 million, which gave us net proceeds of $142.2 million. We plan to use
these proceeds to develop and advance product candidates through clinical trials, as well as for working capital and general corporate
purposes.</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>Cash requirements /</b> At December 31, 2014 we held $72.2 million
in cash and cash equivalents, $40.0 in short-term investments, totaling $112.2 million. On March 25, 2015, we raised net proceeds
of $142.2 million from a public offering. Our aggregate cash and long-term investment balance as at June 30, 2015 was $217.2 million.
We believe we have sufficient cash resources for at least the next 12 months. In the future, substantial additional funds will
be required to continue with the active development of our pipeline products and technologies. In particular, our funding needs
may vary depending on a number of factors including:</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%">&nbsp;</td>
    <td style="width: 3%"><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="width: 91%; text-align: left"><font style="font-size: 10pt">the need for additional capital to fund future business development programs;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">revenues earned form our current collaborative partnership and licensing agreements with Monsanto and Dicerna;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">revenues earned from our DoD contract to develop TKM-Ebola and TKM-Ebola-Guinea;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">revenues earned from our legacy collaborative partnerships and licensing agreements, including milestone payments from Alnylam and royalties from sales of Marqibo from Spectrum;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">the extent to which we continue the development of our product candidates, add new product candidates to our pipeline, or form collaborative relationships to advance our products;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">our decisions to in-license or acquire additional products or technology for development, in particular for our HBV and RNAi therapeutics programs;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">our ability to attract and retain corporate partners, and their effectiveness in carrying out the development and ultimate commercialization of our product candidates;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">whether batches of drugs that we manufacture fail to meet specifications resulting in delays and investigational and remanufacturing costs;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">the decisions, and the timing of decisions, made by health regulatory agencies regarding our technology and products;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">competing technological and market developments; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">costs associated with prosecuting and enforcing our patent claims and other intellectual property rights, including litigation and arbitration arising in the course of our business activities.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">We will seek to obtain funding to maintain and advance our business
from a variety of sources including public or private equity or debt financing, collaborative arrangements with pharmaceutical
companies and government grants and contracts. There can be no assurance that funding will be available at all or on acceptable
terms to permit further development of our products.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">If adequate funding is not available, we may be required to delay, reduce
or eliminate one or more of our research or development programs or reduce expenses associated with non-core activities. We may
need to obtain funds through arrangements with collaborators or others that may require us to relinquish most or all of our rights
to product candidates at an earlier stage of development or on less favorable terms than we would otherwise seek if we were better
funded. Insufficient financing may also mean failing to prosecute our patents or relinquishing rights to some of our technologies
that we would otherwise develop or commercialize.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Material commitments for capital expenditures</b> / As at the date of this discussion
we do not have any material commitments for capital expenditure.</p>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B></B></P>


<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B>OFF-BALANCE SHEET ARRANGEMENTS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">We do not have any off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p>



<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"><b>CONTRACTUAL OBLIGATIONS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Other than as disclosed elsewhere in this MD&amp;A, there have not been
any material changes to our contractual obligations from those disclosed in our Form 10-K for the year ended December 31, 2014.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>IMPACT OF INFLATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">Inflation has not had a material impact on our operations.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>RELATED PARTY TRANSACTIONS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0">We have not entered into any related party transactions in the periods covered by this discussion.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>OUTSTANDING SHARE DATA</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><font>At July 31, 2015, we had 54,328,414
common shares issued and outstanding, outstanding options to purchase an additional 2,369,898 common shares and outstanding warrants
to purchase an additional 379,500 common shares.</font>&nbsp;</p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"><b>&nbsp; </b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%"><a name="p1i3"></a><font style="font-size: 10pt"><b>ITEM 3.</b></font></td>
    <td style="width: 91%"><font style="font-size: 10pt"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">There have been no material changes in our quantitative and qualitative
disclosures about market risk from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.</p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%"><a name="p1i4"></a><font style="font-size: 10pt"><b>ITEM 4.</b></font></td>
    <td style="width: 91%"><font style="font-size: 10pt"><b>CONTROLS AND PROCEDURES</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">As of June 30, 2015, an evaluation of the effectiveness of our &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934)
was carried out by our management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO).
The scope of the effectiveness of disclosure controls and procedures do not include any disclosure controls and procedures of Arbutus
Inc., which was acquired on March 4, 2015, that are also part of Arbutus Inc.&#8217;s internal control over financial reporting.
This exclusion is in accordance with SEC&#8217;s  guidance that a recently acquired business may be omitted from the scope
of the assessment in the year of acquisition. Based upon this evaluation, the CEO and CFO have concluded that as of June 30, 2015,
our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that
we file or submit under the Exchange Act is (i)&nbsp;recorded, processed, summarized and reported within the time periods specified
in Securities and Exchange Commission (the &#8220;Commission&#8221;) rules and forms and (ii)&nbsp;accumulated and communicated
to the management of the registrant, including the CEO and CFO, to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">It should be noted that while the CEO and CFO believe that our disclosure
controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that our disclosure
controls and procedures or internal control over financial reporting will prevent all errors and fraud. A control system, no matter
how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system
are met.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">No change in our internal control over financial reporting (as defined
in Rules&nbsp;13a&#8211;15(f) and 15d&#8211;15(f) under the Exchange Act) occurred during the three months ended June 30, 2015
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0"></p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>

<P STYLE="margin-top: 0pt; margin-right: 0; margin-bottom: 0; font-size: 10pt; text-align: left"></P>

<P STYLE="margin-top: 0pt; margin-right: 0; margin-bottom: 0; font-size: 10pt; text-align: left">&nbsp;</P>

<P STYLE="margin: 0pt 0 0; font-size: 10pt; text-align: center"><a name="p2"></a><b>PART II. &nbsp;&nbsp;OTHER INFORMATION</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="margin: 12pt 0 0; font-size: 10pt"><a name="p2i1"></a><b>ITEM 1. LEGAL PROCEEDINGS&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">We are involved with various legal matters arising
in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred
and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect
the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information
and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various
matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material
adverse effect on our consolidated results of operations, cash flows, or financial condition.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>Alnylam Pharmaceuticals Inc. (&#8220;Alnylam&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">On June 21, 2013, we transferred manufacturing process
technology to Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. (&#8220;Ascletis&#8221;) to enable them to produce ALN-VSP, a product
candidate licensed to them by Alnylam. We believe that under a licensing agreement with Alnylam, the technology transfer to Ascletis
triggers a $5 million&nbsp;milestone obligation from Alnylam to Arbutus. However, Alnylam has demanded a declaration that we have
not yet met our milestone obligations. We dispute Alnylam&#8217;s position. To remedy this dispute, the parties have commenced
arbitration proceedings, as provided for under the agreement.&nbsp; In addition to seeking a declaration that we have met our obligations
under the agreement, we have also stated a claim for breach of contract, breach of the implied covenant of good faith and fair
dealing, and fraud.&nbsp; The hearing for this arbitration took place in May, 2015 and a decision is expected in Q3.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"><b>University of British Columbia (&#8220;UBC&#8221;)</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">Certain early work on lipid nanoparticle delivery
systems and related inventions was undertaken at the University of British Columbia (UBC). These inventions are licensed to us
by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. We have granted sublicenses under
the UBC license to Alnylam as well as to Talon.&nbsp;&nbsp;Alnylam has in turn sublicensed back to us under the licensed UBC patents
for discovery, development and commercialization of RNAi products. In mid-2009, we and our subsidiary Protiva entered into a supplemental
agreement with UBC, Alnylam and AlCana Technologies, Inc., in relation to a separate research collaboration to be conducted among
UBC, Alnylam and AlCana to which we have license rights. The settlement agreement signed in late 2012 to resolve the litigation
among Alnylam, AlCana, Arbutus and Protiva provided for the effective termination of all obligations under such supplemental agreement
as between and among all litigants.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">On November 10, 2014, the University of British
Columbia filed a demand for arbitration against Arbutus Biopharma Corp., BCICAC File No.: DCA-1623.&nbsp; We received UBC&#8217;s
Statement of Claims on January 16, 2015.&nbsp; In its Statement of Claims, UBC alleges that it is entitled to $3.5 million in allegedly
unpaid royalties based on publicly available information, and an unspecified amount based on non-public information.&nbsp; UBC
also seeks interest and costs, including legal fees. We dispute UBC&#8217;s allegation.&nbsp; No dates have been scheduled for
this arbitration.</p>

<p style="margin: 12pt 0 0; font-size: 10pt"><a name="p2i1a"></a><b>ITEM 1A. RISK FACTORS</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">Other than as described below, there have been no
material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December
31, 2014.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0"><i>The FDA may place holds on our clinical trial programs which may
prevent or delay us from completing our clinical trial programs or lead to the imposition of further clinical holds or the failure
of our product candidates to obtain marketing approval.</i></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">In July 2014, we received notice from the FDA that
the TKM-Ebola IND had been placed on clinical hold. The FDA is seeking data to elucidate the mechanism of potential cytokine release
and a modification to the protocol for the multiple ascending dose portion of the trial to ensure the safety of healthy volunteers.
In August 2014, the FDA modified its clinical hold to a &#8220;partial clinical hold,&#8221; allowing for the potential use of
TKM-Ebola in individuals who have confirmed or suspected Ebola infection. In April 2015, the FDA notified us that the partial clinical
hold had been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. However, the IND for TKM-Ebola
remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">There can be no assurance that the FDA will lift
the partial hold with regard to doses above 0.24mg/kg on the TKM-Ebola IND on a timely basis, or at all. Additionally, the FDA
could impose additional requirements that may significantly increase the time and expense of obtaining FDA approval, which could
delay or prevent marketing of the therapeutic.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="color: #2E74B5; font-size: 10pt; margin: 12pt 0 0"><a name="p2i2"></a><font style="color: windowtext"><b>ITEM 2. UNREGISTERED SALES OF EQUITY
SECURITIES AND USE OF PROCEEDS&nbsp;</B></FONT></P>

<P STYLE="color: #2E74B5; font-size: 10pt; margin: 0pt 0 0"><FONT STYLE="color: windowtext"><B>&nbsp;</b></font><b>	</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">None.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</p>

<P STYLE="margin: 0pt 0 0; font-size: 10pt"><a name="p2i3"></a><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</B></P>

<P STYLE="margin: 0pt 0 0; font-size: 10pt"><B>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0">None.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<P STYLE="margin: 0pt 0 0; font-size: 10pt"><a name="p2i4"></a><b>ITEM 4. MINE SAFETY DISCLOSURES&nbsp;</b></P>

<P STYLE="margin: 0pt 0 0; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">Not applicable.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="margin: 0pt 0 0; font-size: 10pt"><a name="p2i5"></a><b>ITEM 5. OTHER INFORMATION&nbsp;</B></P>

<P STYLE="margin: 0pt 0 0; font-size: 10pt"><B>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On July 31, 2015, we
changed our name from Tekmira Pharmaceuticals Corporation to Arbutus Biopharma Corporation and in order to reflect the name change,
we amended our Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Effective
as of May 29, 2015, we entered into an Agreement to Serve as Chief Development Officer with William T. Symonds, who was already
serving in such role for our company. The Agreement provides that Mr. Symonds will serve as our Chief Development Officer,
will receive a salary of $190,000 per year, and will be reimbursed for certain expenses incurred in performing services for
our company. Mr. Symonds&rsquo; employment under the Agreement is &ldquo;at-will&rdquo; employment and may be terminated at
any time with or without cause or notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Symonds Agreement
also provides that during the term of his employment, Mr. Symonds will not work or consult, whether directly or indirectly, on
the research, development or commercialization of any treatment for hepatitis B virus infection in humans with any entity other
than our company. During the term of his employment, Mr. Symonds may also not solicit for employment, interfere with or attempt
to entice away from our company or any of our subsidiaries, any individual who either (x) is employed by us or any of our subsidiaries
at the time of such solicitation, interference or enticement, or (y) has been so employed within three (3) months prior to such
solicitation, interference or enticement, or (ii) solicit, divert, call on, induce or otherwise harm our relationship, or attempt
to solicit, divert, call on, induce, or otherwise harm our relationship, with any person who has had at any time during the term
of the Agreement a business relationship with us or its affiliates, including without limitation, a sales representative, supplier,
lender, borrower, guarantor, landlord, tenant, lessor, lessee, but excluding employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Effective as of August 4, 2015, we entered into
the following executive employment agreements:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an Agreement with Bruce Cousins to serve as Executive Vice
                                                                                                     President and Chief
                                                                                                     Financial Officer,                                                                                                      who
                                                                                                     was already serving in such role for our company. The Agreement provides that Mr. Cousins will serve
                                                                                                     as our Executive Vice
                                                                                                     President and Chief Financial Officer, will receive a base salary of $350,000 per year, and will be reimbursed for certain expenses
                                                                                                     incurred in performing services for our company.</FONT> <FONT STYLE="font-size: 10pt"> In addition, Mr. Cousins is eligible
                                                                                                     to be considered for an annual discretionary bonus of up to 40 percent of base salary; which will be subject to the terms of
                                                                                                     the bonus plan and approval of the our Board of Directors, in their sole discretion, on an annual basis.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">an Agreement with Michael Abrams Ph.D to serve as Managing Director. The Agreement provides
                                                                that Dr. Abrams will serve as our Managing Director, will receive a base salary of $347,000 per year, and will be reimbursed
                                                                for certain expenses incurred in performing services for our company. In addition, Dr. Abrams is eligible to be considered
                                                                for an annual discretionary bonus of up to 40 percent of base salary; which will be subject to the terms of the bonus plan
                                                                and approval of the our Board of Directors, in their sole discretion, on an annual basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">an Agreement with Dr. Mark Kowalski to serve as Chief Medical Officer. The Agreement provides
                                                                that Dr. Kowalski will serve as our Chief Medical Officer, will receive a base salary of $365,000 per year, and will be
                                                                reimbursed for certain expenses incurred in performing services for our company. In addition, Dr. Kowalski is eligible to be
                                                                considered for an annual discretionary bonus of up to 40 percent of base salary; which will be subject to the terms of the
                                                                bonus plan and approval of the our Board of Directors, in their sole discretion, on an annual basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">an Agreement with Peter Lutwyche Ph.D to serve as Chief Technical Operations Officer. The
                                                                Agreement provides that Dr. Lutwyche will serve as our Chief Technical Operations Officer, will receive a base salary of
                                                                $300,000 per year, and will be reimbursed for certain expenses incurred in performing services for our company. In addition,
                                                                Dr. Lutwyche is eligible to be considered for an annual discretionary bonus of up to 40 percent of base salary; which will be
                                                                subject to the terms of the bonus plan and approval of the our Board of Directors, in their sole discretion, on an annual
                                                                basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Each of the foregoing
executive employment agreements also provides that during the term of employment, each of the above will not, for the term of employment
and any restricted period thereafter without the written and informed consent of the company: (i)</FONT> <FONT STYLE="font-size: 10pt">canvass
or solicit the business of (or procure or assist the canvassing or soliciting of the business of) any &ldquo;contact&rdquo; (as
defined in the agreement), or otherwise solicit, induce or encourage any contact to curtail or cease its relationship with the
company, for any purpose which is competitive with our business; (ii) accept (or procure or assist the acceptance of) any business
from any contact which business is competitive with our business; (iii) be employed by or supply (or procure or assist the supply
of) any goods or services to any contact for any purpose which is competitive with our business and (iv) employ, engage, offer
employment or engagement to or solicit the employment or engagement of or otherwise entice away from or solicit, induce or encourage
to leave the employment or engagement of the company, any individual who is employed or engaged by us whether or not such individual
would commit any breach of such executive&rsquo;s contract or terms of employment or engagement by leaving the employ or the engagement
of the company, provided that such executive shall be permitted, solely in a personal capacity, to provide letters of reference
for individuals who are employed by us.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">If the employment of
any of the named executives above is terminated for any reason, other than for death or disability, we shall pay or provide
to such executive (or to their authorized representative or estate) on or before the time required by law, but in no event
more than 30 days after the date of termination: (i) unpaid expense reimbursements; (ii) accrued but unused vacation to the
extent payment is required by law or Company policy; (iii) any vested benefits such executive may have under any employee
benefit plan of the Company; (iv) any earned but unpaid base salary and (v) any earned but unpaid annual bonus for the prior
fiscal year.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">If the employment of any of the named executives above is terminated
without cause, then we shall pay to such executive their accrued benefits as of the date of termination. In addition, subject to
any change of control requirements and such executive providing the Company with a fully effective general release of claims in
a form and manner satisfactory to the Company that includes but is not limited to the terms set forth in Exhibit B to the executive
employment agreements for each of the above within the 60-day period following the date of termination, we shall pay to such executive
an amount calculated as follows: (i) an amount equal to eighteen (18) months&rsquo; base salary, less withholding; plus (ii) a
bonus payment equal to the average of the actual bonus payments, if any, made to such executive from the previous three (3) calendar
years preceding the date of termination, pro-rated for the then current calendar year up to and including the date of termination;
plus (iii) provided that such executive is enrolled in the our insurance benefits plans, for continuation of coverage under our
insurance benefits plans that such executives and their dependents are eligible to receive for the earlier of: (A) a period of
up to 24 months from the date of termination, or (B)&#9;until such executives become eligible to receive health insurance benefits
under any other employer&rsquo;s group health plan, or reimburse such executives for premiums paid, if any, for continuation of
coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We shall pay the severance amount within 60
days after the date of termination, provided that if that 60-day period extends over two calendar years, we shall make the payment
in the second calendar year, and further provided that we, in our sole discretion, in the circumstances, may pay the severance
amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The severance amount
is inclusive of any entitlement to minimum standard severance under the British Columbia Employment Standards Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Each of the executives above are eligible for
certain payments upon their termination or resignation in connection with a change of control of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"></p>

<p style="margin: 12pt 0 0; font-size: 10pt"><a name="p2i6"></a><b>ITEM 6. EXHIBITS</b></P>

<P STYLE="margin: 0pt 0 0; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0">See the Exhibit Index hereto.</p>

<p style="font-size: 10pt; text-align: left; margin: 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: right; margin: 0 0 0 20pt; text-indent: 60pt"></p>

<p style="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; text-indent: 0.5in; margin: 0">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized
on August 6, 2015.</p>

<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: left"><font style="font-size: 10pt"><b>ARBUTUS BIOPHARMA CORPORATION</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 51%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 44%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: black 1.1pt solid; text-align: left"><font style="font-size: 10pt">/s/ Mark Murray</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">Mark Murray</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">President and Chief Executive Officer</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0 0 8pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0 0 8pt">&nbsp;</p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: bottom; width: 11%">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0.8pt 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0.8pt 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Articles of the Registrant, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1&dagger;&dagger;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Amendment to Protiva-Monsanto Services Agreement by and among Protiva Biotherapeutics, Inc., Protiva Agricultural Development Company Inc. and Monsanto Company, dated as of May 22, 2015.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2&dagger;&dagger;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Amendment to Option Agreement by and among Monsanto Canada, Inc., Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics, Inc. and Protiva Agricultural Development Company Inc., dated as of May 22, 2105.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3&dagger;&dagger;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Modification Contract P00035, dated May 1, 2015, to Award Contract previously filed as Exhibit 4.16 to the Registrant&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.4&dagger;&dagger;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Modification Contract P00036, dated May 13, 2015, to Award Contract previously filed as Exhibit 4.16 to the Registrant&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.5&dagger;&dagger;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Modification Contract P00037, dated May 13, 2015, to Award Contract previously filed as Exhibit 4.16 to the Registrant&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.6*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement, dated effective as of July 11, 2015, between OnCore Biopharma, Inc. and Patrick T. Higgins.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.7*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Share Repurchase Agreement, dated effective as of July 11, 2015, between Tekmira Pharmaceuticals Corporation and Patrick T. Higgins.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.8*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement, dated effective as of July 11, 2015, between OnCore Biopharma, Inc. and Michael J. Sofia.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.9*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Share Repurchase Agreement, dated effective as of July 11, 2015, between Tekmira Pharmaceuticals Corporation and Michael J. Sofia.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.10*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Agreement to Serve as Chief Development Officer, dated as of May 29, 2015, between Tekmira Pharmaceuticals Corporation and William T. Symonds.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.11*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement, dated as of August 4, 2015,
    between Arbutus Biopharma Corporation and Bruce Cousins.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.12*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement, dated as of August 4, 2015,
    between  Arbutus Biopharma Corporation and Michael Abrams.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.13*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement, dated as of August 4, 2015,
    between  Arbutus Biopharma Corporation and Mark Kowalski.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.14*&plusmn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement, dated as of August 4, 2015,
    between  Arbutus Biopharma Corporation and Peter Lutwyche.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">31.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">31.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">101</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interactive Data Files</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* Filed herewith.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;&dagger;&dagger; Confidential treatment
has been requested as to portions of this exhibit.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&plusmn; Indicates a management contract or compensatory plan arrangement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exh_31.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="exh31_5.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 123.45pt 0 124.25pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 2.4pt; margin-bottom: 0"><B><I>BUSINESS CORPORATIONS ACT</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 6.1pt; margin-bottom: 0"><B>ARTICLES OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0.35pt; margin-bottom: 0"><B>ARBUTUS BIOPHARMA CORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0.2pt; margin-bottom: 0">(the &ldquo;Company&rdquo;) <B>TABLE OF CONTENTS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 6.05pt 0 0 6.55pt"></P>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <td style="text-align: justify; width: 51%">PART 1 INTERPRETATION</td>
    <td style="text-align: right; width: 49%">1</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 2 SHARES AND SHARE CERTIFICATES</td>
    <td style="text-align: right">2</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 3 ISSUE OF SHARES</td>
    <td style="text-align: right">4</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 4 SHARE REGISTERS</td>
    <td style="text-align: right">4</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART <font style="font-size: 10pt; font-weight: normal"><i>5 </i><font style="font-style: normal">SHARE TRANSFERS</font></font></td>
    <td style="font-style: italic; text-align: right">5</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 6 TRANSMISSION OF SHARES</td>
    <td style="text-align: right">6</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 7 PURCHASE OF SHARES</td>
    <td style="text-align: right">7</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 8 BORROWING POWERS</td>
    <td style="text-align: right">8</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 9 ALTERATIONS</td>
    <td style="text-align: right">8</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 10 MEETINGS OF SHAREHOLDERS</td>
    <td style="text-align: right">10</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 11 PROCEEDINGS AT MEETINGS OF SHAREHOLDERS</td>
    <td style="text-align: right">1 1</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 12 VOTES OF SHAREHOLDERS</td>
    <td style="text-align: right">16</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 13 DIRECTORS</td>
    <td style="text-align: right">20</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 14 ELECTION AND REMOVAL OF DIRECTORS</td>
    <td style="text-align: right">21</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 15 ALTERNATE DIRECTORS</td>
    <td style="text-align: right">24</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 16 POWERS AND DUTIES OF DIRECTORS</td>
    <td style="text-align: right">25</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 17 INTERESTS OF DIRECTORS AND OFFICERS</td>
    <td style="text-align: right">26</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 18 PROCEEDINGS OF DIRECTORS</td>
    <td style="text-align: right">27</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 19 EXECUTIVE AND OTHER COMMITTEES</td>
    <td style="text-align: right">30</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART20 OFFICERS</td>
    <td style="text-align: right">32</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART21 INDEMNIFICATION</td>
    <td style="text-align: right">33</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 22 DIVIDENDS</td>
    <td style="text-align: right">34</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 23 ACCOUNTING RECORDS AND AUDITORS</td>
    <td style="text-align: right">36</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART24 NOTICES</td>
    <td style="text-align: right">36</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART25 SEAL</td>
    <td style="text-align: right">39</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: justify">PART 26 SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO PREFERRED SHARES</td>
    <td style="text-align: right">40</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: justify; margin: 6.05pt 0 0 6.55pt"></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 5.15pt 0 5.5pt"><B>Articles adopted by special resolution deposited at
the records office on April 25, 2007 and Notice of Alteration attaching the share rights to the Preferred shares was filed with
the BC Registrar of Companies on April 25, 2007.</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 5.5pt"><B>Section 13.9 added to the Articles by ordinary resolution
deposited at the records office on May 14, 2013.</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 0 0 5.65pt"><B>Part 18.2, Part 27 and Part 28 added to Articles by ordinary
resolution deposited at the records office on March 4, 2015.</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: -0.4pt; margin: 0 0 0 5.65pt"><B>Section 11.3 of the Articles was deleted and replaced
with section 11.3 by ordinary resolution deposited at the records office on July 10, 2015.</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: -0.2pt; margin: 0 0 0 5.5pt"><B>Change of name of the Company effective at 12:00 a.m. on
July 31, 2015 by Notice of Alteration filed with the BC Registrar of Companies.</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 3.45pt 148.3pt 0 148.5pt"><B><I>BUSINESS CORPORATIONS ACT</I></B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 206.9pt 0 207.85pt"><B>ARTICLES OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0.65pt 0.3pt 0 0"><B>ARBUTUS BIOPHARMA CORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 147pt 0 148.5pt">(the &ldquo;Company&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 3.45pt 5.8pt 0 0">Number: BC0736983</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.1pt; margin: 3.45pt 183.05pt 0 183.4pt"><B>PART l INTERPRETATION</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.6pt"><B>Definitions</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 2pt; margin: 0 12.05pt 0 8.2pt">1.1 In these Articles, unless the context otherwise requires:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(a)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>board</B> <B>of</B> <B>directors</B>&rdquo;, &ldquo;<B>directors</B>&rdquo;
and &ldquo;<B>board</B>&rdquo; mean the directors or sole director of the Company for the time being;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(b)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>Act</B>&rdquo; means the Business Corporations Act (British Columbia) from
time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(c)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>Interpretation</B> <B>Act</B>&rdquo; means the Interpretation Act (British
Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant
to that Act;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(d)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>legal personal representative</B>&rdquo; means the personal or other legal
representative of the shareholder;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(e)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>registered address</B>&rdquo; of a shareholder means the shareholder&rsquo;s
address as recorded in the central securities register;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(f)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>seal</B>&rdquo; means the seal of the Company, if any;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(g)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>share</B>&rdquo; means a share in the share structure of the Company; and</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">(h)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&ldquo;<B>special</B> <B>majority</B>&rdquo; means the majority of votes described
in &sect;11.2 which is required to pass a special resolution.</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0.05in 0 0 7pt"></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 5.3pt 0 6.5pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 208.9pt 0 213.15pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 208.9pt 0 213.15pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 8.75pt"><B>Act and Interpretation Act Definitions Applicable</B></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 2pt; margin: 0 12.05pt 0 8.2pt">1.2&#9;The definitions in the Act and the definitions and
rules of construction in the Interpretation Act, with the necessary changes, so far as applicable, and except as the context requires
otherwise, apply to these Articles as if they were an enactment. If there is a conflict between a definition in the Act and a definition
or rule in the Interpretation Act relating to a term used in these Articles, the definition in the Act will prevail. If there is
a conflict or inconsistency between these Articles and the Act, the Act will prevail.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 8.2pt"><B>Section References</B></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 14.55pt 0 7.7pt">1.3&#9;The symbol &sect; followed by a number or some
combination of numbers and letters refers to the section, paragraph, subparagraph, clause or subclause of these Articles so designated.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 126.45pt 0 126.35pt"><B>PART 2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 127.05pt 0 126.35pt"><B>SHARES AND SHARE CERTIFICATES</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 7.15pt"><B>Authorized Share Structure</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 7.15pt">2.1&#9;The authorized share structure of the Company consists of shares of
the class or classes and series, if any, described in the Notice of Articles of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 6.8pt"><B>Form of Share Certificate</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 10.45pt 0 6.6pt">2.2&#9;Each share certificate issued by the Company must
comply with, and be signed as required by, the Act.</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 6.6pt"><B>Shareholder Entitled to Certificate or Acknowledgment</B></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.6pt">2.3&#9;Each shareholder is entitled, without charge, to (a) one share certificate
representing the shares of each class or series of shares registered in the shareholder&rsquo;s name or</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 12.05pt 0 6.4pt">(b) a non-transferable written acknowledgment of the
shareholder&rsquo;s right to obtain such a share certificate, provided that in respect of a share held jointly by several persons,
the Company is not bound to issue more than one share certificate or acknowledgment and delivery of a share certificate or an acknowledgment
to one of several joint shareholders or to a duly authorized agent of one of the joint shareholders will be sufficient delivery
to all.</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 6.4pt"><B>Delivery by Mail</B></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 25.25pt 0 6.25pt">2.4&#9;Any share certificate or non-transferable written
acknowledgment of a shareholder&rsquo;s right to obtain a share certificate may be sent to the shareholder by mail at the shareholder&rsquo;s
registered address and neither the Company nor any director, officer or agent of the Company is liable for any loss to the shareholder
because the share certificate or acknowledgement is lost in the mail or stolen.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.05pt 212.3pt 0 213.9pt"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.05pt 212.3pt 0 213.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 8.2pt"><B>Replacement of Worn Out or Defaced Certificate or Acknowledgement</B></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 28.35pt 0 7.7pt">2.5&#9;If a share certificate or a non-transferable
written acknowledgment of the shareholder&rsquo;s right to obtain a share certificate is worn out or defaced, the Company must,
on production of the share certificate or acknowledgment, as the case may be, and on such other terms, if any, as are deemed fit:</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 34.45pt; margin: 0 0 0 7.15pt">(a)&#9;cancel the share certificate or acknowledgment; and</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 34.45pt; margin: 0 95.6pt 0 7.15pt">(b)&#9;issue a replacement share certificate or acknowledgment.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 95.6pt 0 8.1pt"><B>Replacement of Lost, Stolen or Destroyed Certificate or Acknowledgment</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0.25pt 28.35pt 0 6.95pt">2.6&#9;If a share certificate or a non-transferable
written acknowledgment of a shareholder&rsquo;s right to obtain a share certificate is lost, stolen or destroyed, the Company must
issue a replacement share certificate or acknowledgment, as the case may be, to the person entitled to that share certificate or
acknowledgment, if it receives:</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.7pt"></TD><TD STYLE="width: 33.4pt">(a)</TD><TD>proof satisfactory to it of the loss, theft or destruction; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.7pt"></TD><TD STYLE="width: 33.4pt">(b)</TD><TD>any indemnity the directors consider adequate.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.4pt"><B>Splitting Share Certificates</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 18.4pt 0 6.05pt">2.7&#9;If a shareholder surrenders a share certificate to the Company with
a written request that the Company issue in the shareholder&rsquo;s name two or more share certificates, each representing a specified
number of shares and in the aggregate representing the same number of shares as the share certificate so surrendered, the Company
must cancel the surrendered share certificate and issue replacement share certificates in accordance with that request.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.4pt"><B>Certificate Fee</B></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 36.3pt 0 5.9pt">2.8&#9;There must be paid to the Company, in relation to the issue of any
share certificate under &sect;2.5, &sect;2.6 or &sect;2.7, the amount, if any, not exceeding the amount prescribed under the Act,
determined by the directors.</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.7pt"><B>Recognition of Trusts</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 18.4pt 0 5.5pt">2.9&#9;Except as required by law or statute or these Articles,
no person will be recognized by the Company as holding any share upon any trust, and the Company is not bound by or compelled in
any way to recognize (even when having notice thereof) any equitable, contingent, future or partial interest in any share or fraction
of a share or (except as required by law or statute or these Articles or as ordered by a court of competent jurisdiction) any other
rights in respect of any share except an absolute right to the entirety thereof in the shareholder.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.65pt 175.2pt 0 177pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.65pt 175.2pt 0 177pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 176.3pt 0 177pt"><B>PART 3</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 176.85pt 0 177pt"><B>ISSUE OF SHARES</B></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.5pt 21.2pt 0 7.4pt"><B>Directors Authorized</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 8.8pt 0 6.7pt">3.1&#9;<FONT STYLE="font-size: 10pt">Subject to the Act
and the rights, if any, of the holders of issued shares of the Company, the Company may allot, issue, sell or otherwise dispose
of the unissued shares, and issued shares held by the Company, at the times, to the persons, including directors, in the manner,
on the terms and conditions and for the consideration (including any premium at which shares with par value may be issued) that
the directors may determine. The issue price for a share with par value must be equal to or greater than the par value of the share.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 6.85pt"><B>Commissions and Discounts</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 31.15pt 0 6.15pt">3.2&#9;<FONT STYLE="font-size: 10pt">The Company may
at any time pay a reasonable commission or allow a reasonable discount to any person in consideration of that person&rsquo;s purchase
or agreement to purchase shares of the Company from the Company or any other person&rsquo;s procurement or agreement to procure
purchasers for shares of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 10.75pt 21.2pt 0 6.3pt"><B>Brokerage</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 38.15pt 0 6.15pt">3.3&#9;<FONT STYLE="font-size: 10pt">The Company may
pay such brokerage fee or other consideration as may be lawful for or in connection with the sale or placement of its securities.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 6.15pt"><B>Share Purchase Warrants and Rights</B></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 14.75pt 0 5.6pt">3.4&#9;<FONT STYLE="font-size: 10pt">Subject to the Act,
the Company may issue share purchase warrants, options and rights upon such terms and conditions as the directors determine, which
share purchase warrants, options and rights may be issued alone or in conjunction with debentures, debenture stock, bonds, shares
or any other securities issued or created by the Company from time to time.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>



<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 9.15pt; margin-bottom: 0"><B>PART 4</B><BR>
<B>SHARE REGISTERS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 9.15pt; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 5.8pt"><B>Central Securities Register</B></P>

<P STYLE="font-size: 10pt; margin: 10.7pt 22.75pt 0 5.4pt">4.1&#9;As required by and subject to the Act, the Company must maintain
in British Columbia a central securities register and may appoint an agent to maintain such register. The directors may appoint
one or more agents, including the agent appointed to keep the central securities register, as transfer agent for shares or any
class or series of shares and the same or another agent as registrar for shares or such class or series of shares, as the case
may be. The directors may terminate such appointment of any agent at any time and may appoint another agent in its place.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 172pt 0 173.3pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 172pt 0 173.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 8.2pt 172pt 0 173.3pt"><B>PART 5</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 173pt 0 173.3pt"><B>SHARE TRANSFERS</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.5pt 12.05pt 0 7.85pt"><B>Registering Transfers</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 25.1pt 0 7.7pt">5.1&#9;<FONT STYLE="font-size: 10pt">A transfer of a
share must not be registered unless the Company or the transfer agent or registrar for the class or series of shares to be transferred
has received:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 33.3pt 0 41.15pt">(a)&#9;<FONT STYLE="font-size: 10pt">except as exempted
by the Act, a duly signed proper instrument of transfer in respect of the share;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 0 15.3pt 0 40.8pt">(b)&#9;<FONT STYLE="font-size: 10pt">if a share certificate
has been issued by the Company in respect of the share to be transferred, that share certificate;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 15.3pt 0 40.6pt">(c)&#9;<FONT STYLE="font-size: 10pt">if a non-transferable
written acknowledgment of the shareholder&rsquo;s right to obtain a share certificate has been issued by the Company in respect
of the share to be transferred, that acknowledgment; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 12.9pt 0 40.45pt">(d)&#9;<FONT STYLE="font-size: 10pt">such other evidence,
if any, as the Company or the transfer agent or registrar for the class or series of share to be transferred may require to prove
the title of the transferor or the transferor&rsquo;s right to transfer the share, the due signing of the instrument of transfer
and the right of the transferee to have the transfer registered.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.6pt"><B>Form of Instrument of Transfer</B></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 16.35pt 0 6.6pt">5.2&#9;<FONT STYLE="font-size: 10pt">The instrument of
transfer in respect of any share of the Company must be either in the form, if any, on the back of the Company&rsquo;s share certificates
of that class or series or in some other form that may be approved by the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.25pt"><B>Transferor Remains Shareholder</B></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 0 25.1pt 0 5.9pt">5.3&#9;<FONT STYLE="font-size: 10pt">Except to the extent
that the Act otherwise provides, the transferor of a share is deemed to remain the holder of it until the name of the transferee
is entered in a securities register of the Company in respect of the transfer.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.25pt"><B>Signing of Instrument of Transfer</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 0 15.3pt 0 5.5pt">5.4&#9;<FONT STYLE="font-size: 10pt">If a shareholder,
or his or her duly authorized attorney, signs an instrument of transfer in respect of shares registered in the name of the shareholder,
the signed instrument of transfer constitutes a complete and sufficient authority to the Company and its directors, officers and
agents to register the number of shares specified in the instrument of transfer or specified in any other manner, or, if no number
is specified, all the shares represented by the share certificates or set out in the written acknowledgments deposited with the
instrument of transfer:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.25pt"></TD><TD STYLE="width: 33.65pt">(a)</TD><TD STYLE="padding-right: 12.05pt"><FONT STYLE="font-size: 10pt">in the name of the person named as transferee in that instrument
of transfer; or</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.85pt 0 0 4.35pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.85pt 0 0 4.35pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 8.35pt 18.6pt 0 42.25pt">(b)&#9;if no person is named as transferee in
that instrument of transfer, in the name of the person on whose behalf the instrument is deposited for the purpose of having the
transfer registered.</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 22.2pt 0 8.05pt"><B>Enquiry as to Title Not Required</B></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.1pt; margin: 0 11.25pt 0 6.95pt">5.5&#9;<FONT STYLE="font-size: 10pt">Neither the Company
nor any director, officer or agent of the Company is bound to inquire into the title of the person named in the instrument of transfer
as transferee or, if no person is named as transferee in the instrument of transfer, of the person on whose behalf the instrument
is deposited for the purpose of having the transfer registered or is liable for any claim related to registering the transfer by
the shareholder or by any intermediate owner or holder of the shares transferred, of any interest in such shares, of any share
certificate representing such shares or of any written acknowledgment of a right to obtain a share certificate for such shares.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 22.2pt 0 6.95pt"><B>Transfer Fee</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 24.45pt 0 6.6pt">5.6&#9;<FONT STYLE="font-size: 10pt">There must be paid
to the Company, in relation to the registration of a transfer, the amount, if any, determined by the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 9.35pt; margin-bottom: 0"><B>PART 6</B><BR>
<B>TRANSMISSION</B> <B>OF SHARES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 9.35pt; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 22.2pt 0 6.25pt"><B>Legal Personal Representative Recognized on Death</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 0 11.25pt 0 5.5pt">6.1&#9;<FONT STYLE="font-size: 10pt">In case of the
death of a shareholder, the legal personal representative of the shareholder, or in the case of shares registered in the shareholder&rsquo;s
name and the name of another person in joint tenancy, the surviving joint holder, will be the only person recognized by the Company
as having any title to the shareholder&rsquo;s interest in the shares. Before recognizing a person as a legal personal representative
of a shareholder, the directors may require proof of appointment by a court of competent jurisdiction, a grant of letters probate,
letters of administration or such other evidence or documents as the directors consider appropriate.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 22.2pt 0 5.5pt"><B>Rights of Legal Personal Representative</B></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 11.25pt 0 5.5pt">6.2&#9;<FONT STYLE="font-size: 10pt">The legal personal
representative of a shareholder has the same rights, privileges and obligations that attach to the shares held by the shareholder,
including the right to transfer the shares in accordance with these Articles, provided the documents required by the Act and the
directors have been deposited with the Company. This &sect;6.2 does not apply in the case of the death of a shareholder with respect
to shares registered in the name of the shareholder and the</FONT></P>

<P STYLE="font-size: 10pt; margin: 0 22.2pt 0 5.15pt">name of another person in joint tenancy.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 103.75pt 0 106.95pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 103.75pt 0 106.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0"><B>PART 7<BR>
PURCHASE OF SHARES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 16.85pt 0 8.3pt"><B>Company Authorized to Purchase Shares</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 14.55pt 0 7.4pt">7.1&#9;<FONT STYLE="font-size: 10pt">Subject to &sect;7.2,
to the special rights and restrictions attached to the shares of any class or series and to the Act, the Company may, if authorized
by the directors, purchase or otherwise acquire any of its shares at the price and upon the terms determined by the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 16.85pt 0 7.4pt"><B>Purchase When Insolvent</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 11.5pt 0 6.9pt">7.2&#9;<FONT STYLE="font-size: 10pt">The Company must
not make a payment or provide any other consideration to purchase or otherwise acquire any of its shares if there are reasonable
grounds for believing that:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 11.7pt 0 40.7pt">(a)&#9;<FONT STYLE="font-size: 10pt">the Company is insolvent;
or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 23.5pt 0 40.7pt">(b)&#9;<FONT STYLE="font-size: 10pt">making the payment
or providing the consideration would render the Company insolvent.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 16.85pt 0 6.9pt"><B>Sale and Voting of Purchased Shares</B></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 11.5pt 0 6.5pt">7.3&#9;<FONT STYLE="font-size: 10pt">If the Company retains
a share redeemed, purchased or otherwise acquired by it, the Company may sell, gift or otherwise dispose of the share, but, while
such share is held by the Company, it:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 34.35pt; margin: 0 0 0 6.35pt">(a)&#9;<FONT STYLE="font-size: 10pt">is not entitled to
vote the share at a meeting of its shareholders;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.35pt"></TD><TD STYLE="width: 33.5pt">(b)</TD><TD STYLE="padding-right: 16.85pt"><FONT STYLE="font-size: 10pt">must not pay a dividend in respect of the share; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 34.2pt; margin: 0 109.8pt 0 6.35pt"><B>(c)&#9;</B><FONT STYLE="font-size: 10pt">must not
make any other distribution in respect of the share. <B>Company Entitled to Purchase or Redeem Share Fractions</B></FONT></P>

<P STYLE="font-size: 10pt; text-indent: 34.2pt; margin: 0 109.8pt 0 6.35pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 0 10.75pt 0 5.8pt">7.4&#9;<FONT STYLE="font-size: 10pt">The Company
may, without prior notice to the holders, purchase or redeem for fair value any and all outstanding share fractions of any
class or kind of shares in its authorized share structure as may exist at any time and from time to time. Upon the Company
delivering the purchase funds and confirmation of purchase or redemption of the share fractions to the holders&rsquo;
registered or last known address, or if the Company has a transfer agent then to such agent for the benefit of and forwarding
to such holders, the Company will thereupon amend its central securities register to reflect the purchase or redemption of
such share fractions and if the Company has a transfer agent, will direct the transfer agent to amend the central securities
register accordingly. Any holder of a share fraction, who upon receipt of the funds and confirmation of purchase or
redemption of same, disputes the fair value paid for the fraction, will have the right to apply to the court to request that
it set the price and terms of payment and make consequential orders and give directions the court considers appropriate, as
if the Company were </FONT>the &ldquo;acquiring person&rdquo; as contemplated by Division 6, Compulsory Acquisitions, under
the Act and the holder were an &ldquo;offeree&rdquo; subject to the provisions contained in such Division, <I>mutatis
mutandis.</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 203.75pt 0 207pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 203.75pt 0 207pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 11.7pt 0 8.05pt"></P>

<P STYLE="font-size: 10pt; margin: 0"><I></I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.8pt 206.05pt 0 207pt"><B>PART 8</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0.1pt 0 0"><B>BORROWING POWERS</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 0 0 6.4pt">8.1&#9;<FONT STYLE="font-size: 10pt">The Company, if authorized
by the directors, may:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 21.15pt 0 41.35pt">(a)&#9;<FONT STYLE="font-size: 10pt">borrow money
in the manner and amount, on the security, from the sources and on the terms and conditions that they consider appropriate;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 18.2pt 0 41.15pt">(b)&#9;<FONT STYLE="font-size: 10pt">issue bonds, debentures
and other debt obligations either outright or as security for any liability or obligation of the Company or any other person and
at such discounts or premiums and on such other terms as the directors consider appropriate;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.7pt 0 41pt">(c)&#9;<FONT STYLE="font-size: 10pt">guarantee the repayment of money by any
other person or the performance of any obligation of any other person; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.7pt 0 40.8pt">(d)&#9;<FONT STYLE="font-size: 10pt">mortgage, charge, whether by way of
specific or floating charge, grant a security interest in, or give other security on, the whole or any part of the present and
future assets and undertaking of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 17.4pt 0 6.4pt">8.2&#9;<FONT STYLE="font-size: 10pt">The powers conferred
under this Part 8 will be deemed to include the powers conferred on a company by Division VII of the <I>Special Corporations Powers
Act </I>being chapter P-16 of the Revised Statutes of Quebec, 1988, and every statutory provision that may be substituted therefor
or for any provision therein.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 1.45pt; margin: 0 188.45pt 0 185.5pt"><B>PART 9</B> <B>ALTERATIONS</B></P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.25pt"><B>Alteration of Authorized Share Structure</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 42.05pt 0 6.25pt">9.1&#9;<FONT STYLE="font-size: 10pt">Subject to &sect;9.2
and the Act, the Company may by ordinary resolution (or a resolution of the directors in the case of &sect;9.l(c) or &sect;9.l(f)):</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.6pt 0 40.45pt">(a)&#9;<FONT STYLE="font-size: 10pt">create one or more classes or series
of shares or, if none of the shares of a class or series of shares are allotted or issued, eliminate that class or series of shares;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 11.7pt 0 40.1pt">(b)&#9;<FONT STYLE="font-size: 10pt">increase, reduce
or eliminate the maximum number of shares that the Company is authorized to issue out of any class or series of shares or establish
a maximum number of shares that the Company is authorized to issue out of any class or series of shares for which no maximum is
established;</FONT></P>

<P STYLE="font-size: 10pt; margin: 2.7pt 169.55pt 0 173.3pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 2.7pt 169.55pt 0 173.3pt; text-align: center"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 7.8pt 8.4pt 0 41.35pt">(c)&#9;<FONT STYLE="font-size: 10pt">subdivide or
consolidate all or any of its unissued, or fully paid issued, shares;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 7.8pt 8.4pt 0 41.35pt">(d)&#9;<FONT STYLE="font-size: 10pt">if the Company is authorized to issue shares of a class of shares with par value:</FONT></P>



<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 10.5pt 0 0 75.55pt">(i)&#9;decrease the par value of those shares; or</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 15.3pt 0 75.55pt">(ii)&#9;if none of the shares of that class of shares
are allotted or issued, increase the par value of those shares;</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55pt; margin: 0 17.5pt 0 41.35pt">(e)&#9;<FONT STYLE="font-size: 10pt">change
all or any of its unissued, or fully paid issued, shares with par value into shares without par value or any of its unissued shares
without par value into shares with par value;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 41.5pt">(f)&#9;alter the identifying name of any of its shares; or</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 12.9pt 0 41.15pt">(g)&#9;otherwise alter its shares or authorized share
structure when required or permitted to do so by the Act where it does not specify by a special resolution;</P>

<P STYLE="font-size: 10pt; margin: 10.6pt 12.05pt 0 7.3pt">and, if applicable, alter its Notice of Articles and, if applicable,
its Articles accordingly.</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 7.15pt"><B>Special Rights and Restrictions</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 12.9pt 0 6.6pt">9.2&#9;<FONT STYLE="font-size: 10pt">Subject to the Act
and in particular those provisions of the Act relating to the rights of holders of outstanding shares to vote if their rights are
prejudiced or interfered with, the Company may by ordinary resolution:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 33.3pt 0 40.45pt">(a)&#9;<FONT STYLE="font-size: 10pt">create special
rights or restrictions for, and attach those special rights or restrictions to, the shares of any class or series of shares, whether
or not any or all of those shares have been issued; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 16.35pt 0 40.45pt">(b)&#9;vary or delete any special rights or restrictions attached to the
shares of any class or series of shares, whether or not any or all of those shares have been issued,</P>

<P STYLE="font-size: 10pt; margin: 10.65pt 12.05pt 0 6.25pt">and alter its Notice of Articles and Articles accordingly.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.6pt"><B>Change of Name</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 25.1pt 0 5.7pt">9.3&#9;<FONT STYLE="font-size: 10pt">The Company may
by resolution of the directors authorize an alteration of its Notice of Articles in order to change its name or adopt or change
any translation of that name.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.25pt"><B>Other Alterations</B></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.9pt 0 6.25pt">9.4&#9;<FONT STYLE="font-size: 10pt">If the Act does not specify the type
of resolution and these Articles do not specify another type of resolution, the Company may by ordinary resolution alter these
Articles.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.8pt 137.05pt 0 139.3pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.8pt 137.05pt 0 139.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.6pt 137.15pt 0 139.3pt"><B>PART 10</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 139.25pt 0 139.3pt"><B>MEETINGS OF SHAREHOLDERS</B></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.55pt 0 0 7.4pt"><B>Annual General Meetings</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 22.2pt 0 7.05pt">10.1&#9;<FONT STYLE="font-size: 10pt">Unless an annual
general meeting is deferred or waived in accordance with the Act, the Company must hold an annual general meeting at least once
in each calendar year and not more than 15 months after its last annual general meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.05pt"><B>Calling of Meetings of Shareholders</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.75pt"></TD><TD STYLE="width: 66.8pt">10.2</TD><TD><FONT STYLE="font-size: 10pt">The directors may, at any time, call a meeting of shareholders.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.7pt"><B>Notice for Meetings of Shareholders</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.8pt; margin: 0 16.95pt 0 5.8pt">10.3&#9;<FONT STYLE="font-size: 10pt">The Company must
send notice of the date, time and location of any meeting of shareholders (including, without limitation, any notice specifying
the intention to propose a resolution as an exceptional resolution, a special resolution or a special separate resolution, and
any notice to consider approving an amalgamation into a foreign jurisdiction, an arrangement or the adoption of an amalgamation
agreement, and any notice of a general meeting, class meeting or series meeting), in the manner provided in these Articles, or
in such other manner, if any, as may be prescribed by ordinary resolution (whether previous notice of the resolution has been given
or not), to each shareholder entitled to attend the meeting, to each director and to the auditor of the Company, unless these Articles
otherwise provide, at least 21 days before the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.95pt"><B>Record Date for Notice</B></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 12.1pt 0 5.6pt">10.4&#9;<FONT STYLE="font-size: 10pt">The directors may
set a date as the record date for the purpose of determining shareholders entitled to notice of any meeting of shareholders. The
record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting
requisitioned by shareholders under the Act, by more than four months. The record date must not precede the date on which the meeting
is held by fewer than 21 days. If no record date is set, the record date is 5:00 p.m. on the day immediately preceding the first
date on which the notice is sent or, if no notice is sent, the beginning of the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.6pt"><B>Record Date for Voting</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.3pt; margin: 0 16.95pt 0 5.4pt">10.5&#9;<FONT STYLE="font-size: 10pt">The directors may
set a date as the record date for the purpose of determining shareholders entitled to vote at any meeting of shareholders. The
record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0.05pt 12pt 0 5.4pt">meeting requisitioned by shareholders under the Act,
by more than four months. If no record date is set, the record date is 5:00 p.m. on the day immediately preceding the first date
on which the notice is sent or, if no notice is sent, the beginning of the meeting.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.7pt 138.5pt 0 139.3pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.7pt 138.5pt 0 139.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 7.65pt 0 0 7.05pt"><B>Failure to Give Notice and Waiver of Notice</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.8pt; margin: 0 18.4pt 0 6.3pt">10.6&#9;<FONT STYLE="font-size: 10pt">The accidental omission
to send notice of any meeting of shareholders to, or the non-receipt of any notice by, any of the persons entitled to notice does
not invalidate any proceedings at that meeting. Any person entitled to notice of a meeting of shareholders may, in writing or otherwise,
waive that entitlement or may agree to reduce the period of that notice. Attendance of a person at a meeting of shareholders is
a waiver of entitlement to notice of the meeting unless that person attends the meeting for the express purpose of objecting to
the transaction of any business on the grounds that the meeting is not lawfully called.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.3pt"><B>Notice of Special Business at Meetings of Shareholders</B></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.4pt"></TD><TD STYLE="width: 66.6pt">10.7</TD><TD><FONT STYLE="font-size: 10pt">If a meeting of shareholders is to consider special business within the meaning of</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">&sect;11.1, the notice of meeting must:</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 0 0 39.8pt">(a)&#9;<FONT STYLE="font-size: 10pt">state the general nature
of the special business; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 30.5pt 0 39.8pt">(b)&#9;<FONT STYLE="font-size: 10pt">if the special
business includes considering, approving, ratifying, adopting or authorizing any document or the signing of or giving of effect
to any document, have attached to it a copy of the document or state that a copy of the document will be available for inspection
by shareholders:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 27.3pt 0 73.65pt">(i)&#9;<FONT STYLE="font-size: 10pt">at the Company&rsquo;s records office,
or at such other reasonably accessible location in British Columbia as is specified in the notice; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 18.4pt 0 73.3pt">(ii)&#9;during statutory business hours on any one or
more specified days before the day set for the holding of the meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.4pt"><B>Place of Meetings</B></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 16.95pt 0 5.6pt">10.8&#9;<FONT STYLE="font-size: 10pt">In addition to
any location in British Columbia, any general meeting may be held in any location outside British Columbia approved by a resolution
of the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.05pt 86.85pt 0 85.55pt"><B>PART 11</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 90.15pt 0 85.55pt"><B>PROCEEDINGS AT MEETINGS OF SHAREHOLDERS</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.25pt"><B>Special Business</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.95pt"></TD><TD STYLE="width: 66.8pt">11.1</TD><TD><FONT STYLE="font-size: 10pt">At a meeting of shareholders, the following business is special business:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 16.95pt 0 39.1pt">(a)&#9;<FONT STYLE="font-size: 10pt">at a meeting of shareholders that is
not an annual general meeting, all business is special business except business relating to the conduct of or voting at the meeting;
and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 43.95pt 0 39.1pt">(b)&#9;<FONT STYLE="font-size: 10pt">at an annual general meeting, all business
is special business except for the following:</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 3pt 210.85pt 0 214.2pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 3pt 210.85pt 0 214.2pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 0 24.4pt 0 75.65pt">(i)&#9;business relating to the conduct of or voting
at the meeting;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 10.1pt 0 75.65pt">(ii)&#9;consideration of any financial statements of
the Company presented to the meeting;</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 75.8pt">(iii)&#9;consideration of any reports of the directors or auditor;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 75.8pt"> (iv)&#9;the setting or changing of the number of directors;</P>



<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 75.8pt"> (v)&#9;the election or appointment of directors;</P>



<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 75.45pt">(vi)&#9;the appointment of an auditor;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 0 0 74.9pt">(vii)&#9;the setting of the remuneration of an auditor;</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 8.4pt 0 74.9pt">(viii)&#9;business arising out of a report of the directors
not requiring the passing of a special resolution or an exceptional resolution; and</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 0.2in 0 74.2pt">(ix)&#9;any other business which, under these Articles
or the Act, may be transacted at a meeting of shareholders without prior notice of the business being given to the shareholders.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">Special Majority</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 12.55pt 0 6.85pt">11.2&#9;<FONT STYLE="font-size: 10pt">The majority of
votes required to pass a special resolution at a general meeting of shareholders is two-thirds of the votes cast on the resolution.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">Quorum</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.8pt; margin: 0 12.55pt 0 5.95pt">11.3&#9;<FONT STYLE="font-size: 10pt">Subject to the
special rights and restrictions attached to the shares of any class or series of shares, and to &sect;11.4, the quorum for the
transaction of business at a meeting of shareholders is at least two people who are, or who represent by proxy, one or more shareholders
who, in the aggregate, hold at least five percent (5%) of the issued shares entitled to be voted at the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.95pt">One Shareholder May Constitute Quorum</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.8pt; margin: 0 0 0 5.4pt">11.4&#9;If there is only one shareholder entitled to vote at
a meeting of shareholders:</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.15pt 0 39.9pt">(a)&#9;the quorum is one person who is, or who represents by proxy, that
shareholder; and</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.15pt 0 39.9pt"> (b)&#9;that shareholder, present in person or by proxy, may constitute the meeting.</P>



<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.95pt">Persons Entitled to Attend Meeting</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.3pt; margin: 0 15.05pt 0 5.4pt">11.5&#9;In addition to those persons who are entitled
to vote at a meeting of shareholders, the only other persons entitled to be present at the meeting are the directors, the president
(if</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.95pt 209.9pt 0 213.15pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.95pt 209.9pt 0 213.15pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 9.7pt 10.4pt 0 7.3pt">any), the secretary (if any), the assistant secretary
(if any), any lawyer for the Company, the auditor of the Company, any persons invited to be present at the meeting by the directors
or by the chair of the meeting and any persons entitled or required under the Act or these Articles to be present at the meeting;
but if any of those persons does attend the meeting, that person is not to be counted in the quorum and is not entitled to vote
at the meeting unless that person is a shareholder or proxy holder entitled to vote at the meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 7.3pt">Requirement of Quorum</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 10.4pt 0 6.95pt">11.6&#9;No business, other than the election of a chair
of the meeting and the adjournment of the meeting, may be transacted at any meeting of shareholders unless a quorum of shareholders
entitled to vote is present at the commencement of the meeting, but such quorum need not be present throughout the meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 6.95pt">Lack of Quorum</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.1pt; margin: 0 52.5pt 0 6.95pt">11.7&#9;If, within one-half hour from the time set for
the holding of a meeting of shareholders, a quorum is not present:</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 32.05pt 0 40.6pt">(a)&#9;in the case of a general meeting requisitioned by shareholders, the
meeting is dissolved; and</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 14.55pt 0 40.45pt">(b)&#9;in the case of any other meeting of shareholders,
the meeting stands adjourned to the same day in the next week at the same time and place.</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 6.25pt">Lack of Quorum at Succeeding Meeting</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 12.05pt 0 5.9pt">11.8&#9;If, at the meeting to which the meeting referred
to in &sect;11.7(b) was adjourned, a quorum is not present within one-half hour from the time set for the holding of the meeting,
the person or persons present and being, or representing by proxy, two or more shareholders entitled to attend and vote at the
meeting will be deemed to constitute a quorum.</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 6.25pt">Chair</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 65.3pt 0 6.25pt">11.9&#9;The following individual is entitled to preside
as chair at a meeting of shareholders:</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.15pt 0 39.9pt"> (a)&#9;the chair of the board, if any; or</P>



<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 21.8pt 0 39.7pt">(b)&#9;if the chair of the board is absent or unwilling
to act as chair of the meeting, the president, if any.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.6pt 0 5.9pt">Selection of Alternate Chair</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.3pt; margin: 0 16pt 0 5.5pt">11.10&#9;If, at any meeting of shareholders, there is no
chair of the board or president present within 15 minutes after the time set for holding the meeting, or if the chair of the board
and the president are unwilling to act as chair of the meeting, or if the chair of the board and the</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.7pt 0 0 4.75pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.7pt 0 0 4.75pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 7.75pt 11.65pt 0 7.6pt">president have advised the secretary, if any, or
any director present at the meeting, that they will not be present at the meeting, the directors present may choose either one
of their number or the solicitor of the Company to be chair of the meeting. If all of the directors present decline to take the
chair or fail to so choose or if no director is present or the solicitor of the Company declines to take the chair, the shareholders
entitled to vote at the meeting who are present in person or by proxy may choose any person present at the meeting to chair the
meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 7.6pt">Adjournments</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 17.9pt 0 0.1in">11.11&#9;<FONT STYLE="font-size: 10pt">The chair of a
meeting of shareholders may, and if so directed by the meeting must, adjourn the meeting from time to time and from place to place,
but no business may be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the
adjournment took place.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 0.1in">Notice of Adjourned Meeting</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 17.9pt 0 6.7pt">11.12&#9;<FONT STYLE="font-size: 10pt">It is not necessary
to give any notice of an adjourned meeting of shareholders or of the business to be transacted at an adjourned meeting of shareholders
except that, when a meeting is adjourned for 30 days or more, notice of the adjourned meeting must be given as in the case of the
original meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 6.85pt">Decisions by Show of Hands or Poll</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.8pt; margin: 0 10pt 0 6.15pt">11.13&#9;<FONT STYLE="font-size: 10pt">Subject to the Act,
every motion put to a vote at a meeting of shareholders will be decided on a show of hands unless a poll, before or on the declaration
of the result of the vote by show of hands, is directed by the chair or demanded by any shareholder entitled to vote who is present
in person or by proxy.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 6.5pt">Declaration of Result</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 12.75pt 0 6.15pt">11.14&#9;<FONT STYLE="font-size: 10pt">The chair of
a meeting of shareholders must declare to the meeting the decision on every question in accordance with the result of the show
of hands or the poll, as the case may be, and that decision must be entered in the minutes of the meeting. A declaration of the
chair that a resolution is carried by the necessary majority or is defeated is, unless a poll is directed by the chair or demanded
under &sect;11.13, conclusive evidence without proof of the number or proportion of the votes recorded in favour of or against
the resolution.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 6.15pt">Motion Need Not be Seconded</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 20.55pt 0 5.8pt">11.15&#9;<FONT STYLE="font-size: 10pt">No motion proposed
at a meeting of shareholders need be seconded unless the chair of the meeting rules otherwise, and the chair of any meeting of
shareholders is entitled to propose or second a motion.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 116.7pt 0 116.6pt"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 116.7pt 0 116.6pt"></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 8pt">Casting Vote</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.45pt; margin: 0 26.1pt 0 7.45pt">11.16&#9;<FONT STYLE="font-size: 10pt">In
case of an equality of votes, the chair of a meeting of shareholders does not, either on a show of hands or on a poll, have a second
or casting vote in addition to the vote or votes to which the chair may be entitled as a shareholder.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 7.45pt">Manner of Taking Poll</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.45pt; margin: 0 26.1pt 0 7.45pt"> 11.17&#9;<FONT STYLE="font-size: 10pt">Subject to &sect;11.18, if a poll is duly demanded at a meeting of shareholders:</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 15.25pt 0 40.7pt">(a)&#9;the poll must be taken:</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 3.55pt 23.9pt 0 74.45pt">(i)&#9;<FONT STYLE="font-size: 10pt">at the meeting,
or within seven days after the date of the meeting, as the chair of the meeting directs; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 30.2pt 0 74.45pt">(ii)&#9;<FONT STYLE="font-size: 10pt">in the manner, at the time and at
the place that the chair of the meeting directs;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 15.25pt 0 40.7pt">(b)&#9;<FONT STYLE="font-size: 10pt">the result of the poll is deemed to
be the decision of the meeting at which the poll is demanded; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 33.95pt; margin: 0 42.35pt 0 6.55pt">(c)&#9;<FONT STYLE="font-size: 10pt">the demand for
the poll may be withdrawn by the person who demanded it. Demand for Poll on Adjournment</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0.15pt 15.25pt 0 6.55pt">11.18&#9;<FONT STYLE="font-size: 10pt">A poll demanded
at a meeting of shareholders on a question of adjournment must be taken immediately at the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.55pt">Chair Must Resolve Dispute</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 23.9pt 0 6.2pt">11.19&#9;<FONT STYLE="font-size: 10pt">In the case of
any dispute as to the admission or rejection of a vote given on a poll, the chair of the meeting must determine the dispute, and
his or her determination made in good faith is final and conclusive.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.75pt">Casting of Votes</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 17.9pt 0 6.2pt">11.20&#9;<FONT STYLE="font-size: 10pt">On a poll, a shareholder
entitled to more than one vote need not cast all the votes in the same way.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.2pt">No Demand for Poll on Election of Chair</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 16.85pt 0 6.2pt">11.21&#9;<FONT STYLE="font-size: 10pt">No poll may be
demanded in respect of the vote by which a chair of a meeting of shareholders is elected.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.55pt 145.6pt 0 148.9pt"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.55pt 145.6pt 0 148.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 17.45pt 0 8.2pt">Demand for Poll Not to Prevent Continuance of Meeting</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 18.8pt 0 7.85pt">11.22&#9;<FONT STYLE="font-size: 10pt">The demand for
a poll at a meeting of shareholders does not, unless the chair of the meeting so rules, prevent the continuation of a meeting for
the transaction of any business other than the question on which a poll has been demanded.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 17.45pt 0 7.3pt">Retention of Ballots and Proxies</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 11.65pt 0 6.75pt">11.23&#9;<FONT STYLE="font-size: 10pt">The Company must,
for at least three months after a meeting of shareholders, keep each ballot cast on a poll and each proxy voted at the meeting,
and, during that period, make them available for inspection during normal business hours by any shareholder or proxy holder entitled
to vote at the meeting. At the end of such three month period, the Company may destroy such ballots and proxies.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0.05pt 0 0"><B>PART 12</B></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 148.6pt 0 148.9pt; text-align: center"><B>VOTESOF SHAREHOLDERS</B></P>

<P STYLE="font-size: 10pt; margin: 10.15pt 17.45pt 0 6.4pt">Number of Votes by Shareholder or by Shares</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 37.8pt 0 6.2pt">12.1&#9;<FONT STYLE="font-size: 10pt">Subject to any
special rights or restrictions attached to any shares and to the restrictions imposed on joint shareholders under &sect;12.3:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 20.9pt 0 40pt">(a)&#9;<FONT STYLE="font-size: 10pt">on a vote by show
of hands, every person present who is a shareholder or proxy holder and entitled to vote on the matter has one vote; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 16.6pt 0 39.8pt">(b)&#9;<FONT STYLE="font-size: 10pt">on a poll, every
shareholder entitled to vote on the matter has one vote in respect of each share entitled to be voted on the matter and held by
that shareholder and may exercise that vote either in person or by proxy.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 17.45pt 0 5.7pt">Votes of Persons in Representative Capacity</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 11.65pt 0 5.5pt">12.2&#9;<FONT STYLE="font-size: 10pt">A person who is
not a shareholder may vote at a meeting of shareholders, whether on a show of hands or on a poll, and may appoint a proxy holder
to act at the meeting, if, before doing so, the person satisfies the chair of the meeting, or the directors, that the person is
a legal personal representative or a trustee in bankruptcy for a shareholder who is entitled to vote at the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 17.45pt 0 5.5pt">Votes by Joint Holders</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 11.65pt 0 5.5pt"> 12.3&#9;<FONT STYLE="font-size: 10pt">If there are joint shareholders registered in respect of any share:</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 0.45in 0 39.1pt">(a)&#9;<FONT STYLE="font-size: 10pt">any one of the
joint shareholders may vote at any meeting of shareholders, personally or by proxy, in respect of the share as if that joint shareholder
were solely entitled to it; or</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 0 0 0.75pt"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 0 0 0.75pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 17.9pt 0 41.5pt">(b)&#9;if more than one of the joint shareholders is
present at any meeting of shareholders, personally or by proxy, and more than one of them votes in respect of that share, then
only the vote of the joint shareholder present whose name stands first on the central securities register in respect of the share
will be counted.</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.65pt">Legal Personal Representatives as Joint Shareholders</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.1pt; margin: 0 16.9pt 0 7.45pt">12.4&#9;<FONT STYLE="font-size: 10pt">Two
or more legal personal representatives of a shareholder in whose sole name any share is registered are, for the purposes of &sect;12.3,
deemed to be joint shareholders registered in respect of that share.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.1pt">Representative of a Corporate Shareholder</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 23.9pt 0 6.55pt">12.5&#9;<FONT STYLE="font-size: 10pt">If a corporation,
that is not a subsidiary of the Company, is a shareholder, that corporation may appoint a person to act as its representative at
any meeting of shareholders of the Company, and:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.6pt"></TD><TD STYLE="width: 33.65pt">(a)</TD><TD><FONT STYLE="font-size: 10pt">for that purpose, the instrument appointing a representative must be received:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 14.65pt 0 73.55pt">(i)&#9;<FONT STYLE="font-size: 10pt">at the registered
office of the Company or at any other place specified, in the notice calling the meeting, for the receipt of proxies, at least
the number of business days specified in the notice for the receipt of proxies, or if no number of days is specified, two business
days before the day set for the holding of the meeting or any adjourned meeting; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 26.25pt 0 73.7pt">(ii)&#9;<FONT STYLE="font-size: 10pt">at the meeting or any adjourned meeting,
by the chair of the meeting or adjourned meeting or by a person designated by the chair of the meeting or adjourned meeting; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.25pt"></TD><TD STYLE="width: 33.45pt">(b)</TD><TD>if a representative is appointed under this &sect;12.5:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 21.25pt 0 73.35pt">(i)&#9;<FONT STYLE="font-size: 10pt">the representative
is entitled to exercise in respect of and at that meeting the same rights on behalf of the corporation that the representative
represents as that corporation could exercise if it were a shareholder who is an individual, including, without limitation, the
right to appoint a proxy holder; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 15.25pt 0 73pt">(ii)&#9;<FONT STYLE="font-size: 10pt">the representative,
if present at the meeting, is to be counted for the purpose of forming a quorum and is deemed to be a shareholder present in person
at the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 15.25pt 0 5.65pt">Evidence of the appointment of any such representative may be sent to the
Company by written instrument, fax or any other method of transmitting legibly recorded messages.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.65pt">Proxy Provisions Do Not Apply to All Companies</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 16.85pt 0 5.5pt">12.6&#9;<FONT STYLE="font-size: 10pt">If and for so
long as the Company is a public company, then &sect;12.7 to &sect;12.15 are not mandatory, however the directors of the Company
are authorized to apply all or part of such</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 202.85pt 0 207pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 202.85pt 0 207pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 7.4pt 11.7pt 0 8.4pt">sections or to adopt alternative procedures for proxy
form, deposit and revocation procedures to the extent that the directors deem necessary in order to comply with securities laws
applicable to the Company.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 8.05pt">Appointment of Proxy Holders</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.4pt; margin: 0 20.8pt 0 7.7pt">12.7&#9;<FONT STYLE="font-size: 10pt">Every
shareholder of the Company entitled to vote at a meeting of shareholders may, by proxy, appoint one or more (but not more than
two) proxy holders to attend and act at the meeting in the manner, to the extent and with the powers conferred by the proxy.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 7.7pt">Alternate Proxy Holders</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 11.7pt 0 7.7pt">12.8&#9;<FONT STYLE="font-size: 10pt">A shareholder may
appoint one or more alternate proxy holders to act in the place of an absent proxy holder.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 7.3pt">Proxy Holder Need Not Be Shareholder</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 11.7pt 0 7.7pt"> 12.9&#9;<FONT STYLE="font-size: 10pt">A proxy holder need not be a shareholder of the Company.</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.95pt">Deposit of Proxy</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 11.7pt 0 7.7pt"> 12.10&#9;<FONT STYLE="font-size: 10pt">A proxy for a meeting of shareholders must:</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 14.6pt 0 40.8pt">(a)&#9;<FONT STYLE="font-size: 10pt">be received at the
registered office of the Company or at any other place specified, in the notice calling the meeting, for the receipt of proxies,
at least the number</FONT></P>

<P STYLE="font-size: 10pt; text-indent: -0.2pt; margin: 0.2pt 10pt 0 40.8pt">of business days specified in the notice, or if no
number of days is specified, two business days before the day set for the holding of the meeting or any adjourned meeting; or</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 11.7pt 0 40.45pt">(b)&#9;unless the notice provides otherwise, be received,
at the meeting or any adjourned meeting, by the chair of the meeting or adjourned meeting or by a person designated by the chair
of the meeting or adjourned meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 51.95pt 0 6.25pt">A proxy may be sent to the Company by written instrument,
fax or any other method of transmitting legibly recorded messages, including through Internet voting or by email if permitted by
the notice calling the meeting or the information circular for the meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.25pt">Validity of Proxy Vote</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 11.7pt 0 5.9pt">12.11&#9;<FONT STYLE="font-size: 10pt">A vote given in
accordance with the terms of a proxy is valid notwithstanding the death or incapacity of the shareholder giving the proxy and despite
the revocation of the proxy or the revocation of the authority under which the proxy is given, unless notice in writing of that
death, incapacity or revocation is received:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 20.3pt 0 39.9pt">(a)&#9;<FONT STYLE="font-size: 10pt">at the registered
office of the Company, at any time up to and including the last business day before the day set for the holding of the meeting
or any adjourned meeting at which the proxy is to be used; or</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 0 0 2.85pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 0 0 2.85pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 8.4pt 12.4pt 0 41.7pt">(b)&#9;at the meeting or any adjourned meeting by
the chair of the meeting or adjourned meeting, before any vote in respect of which the proxy has been given has been taken.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.4pt 0 7.4pt">Form of Proxy</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 36.5pt 0 0.1in">12.12&#9;<FONT STYLE="font-size: 10pt">A proxy, whether
for a specified meeting or otherwise, must be either in the following form or in any other form approved by the directors or the
chair of the meeting:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 182.85pt 0 183.4pt">[name of company]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 182.85pt 0 183.4pt">(the &ldquo;Company&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 32.55pt 0 40.8pt">The undersigned, being a shareholder of the Company,
hereby appoints [name] or, failing that person, [name], as proxy holder for the undersigned to attend, act and vote for and on
behalf of the undersigned at the meeting of shareholders of the Company to be held on [month, day, year] and at any adjournment
of that</P>

<P STYLE="font-size: 10pt; margin: 0 24.4pt 0 40.8pt">meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -0.2pt; margin: 0 41.2pt 0 40.45pt">Number of shares in respect of which this proxy is
given (if no number is specified, then this proxy if given in respect of all shares registered in the name of the undersigned):_________</P>

<P STYLE="font-size: 10pt; margin: 9.05pt 49.3pt 0 243.2pt">Signed [month, day, year]</P>

<P STYLE="font-size: 10pt; margin-right: 49.3pt; margin-bottom: 0pt; margin-left: 243.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-right: 49.3pt; margin-bottom: 0pt; margin-left: 243.2pt">________________________________</P>

<P STYLE="font-size: 10pt; margin-right: 49.3pt; margin-bottom: 0pt; margin-left: 243.2pt">[Signature of shareholder]</P>

<P STYLE="font-size: 10pt; margin: 1.1pt 24.4pt 0 243.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 1.1pt 24.4pt 0 243.2pt">________________________________</P>

<P STYLE="font-size: 10pt; margin: 1.1pt 24.4pt 0 243.2pt">[Name of shareholder-printed]</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.4pt 0 5.95pt">Revocation of Proxy</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 10.2pt 0 5.6pt">12.13&#9;<FONT STYLE="font-size: 10pt">Subject to &sect;12.14,
every proxy may be revoked by an instrument in writing that is received:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 18.4pt 0 39.7pt">(a)&#9;<FONT STYLE="font-size: 10pt">at the registered
office of the Company at any time up to and including the last business day before the day set for the holding of the meeting or
any adjourned meeting at which the proxy is to be used; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 11.9pt 0 39.55pt">(b)&#9;<FONT STYLE="font-size: 10pt">at the meeting
or any adjourned meeting, by the chair of the meeting or adjourned meeting, before any vote in respect of which the proxy has been
given has been taken.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.4pt 0 5.4pt">Revocation of Proxy Must Be Signed</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 10.2pt 0 5.6pt"> 12.14&#9;<FONT STYLE="font-size: 10pt">An instrument referred to in &sect;12.13 must be signed as follows:</FONT></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 2.1pt 175.5pt 0 177pt"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.1pt 175.5pt 0 177pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 22.75pt 0 42.1pt">(a)&#9;<FONT STYLE="font-size: 10pt">if the shareholder
for whom the proxy holder is appointed is an individual, the instrument must be signed by the shareholder or his or her legal personal
representative or trustee in bankruptcy; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 26.9pt 0 41.75pt">(b)&#9;<FONT STYLE="font-size: 10pt">if the shareholder
for whom the proxy holder is appointed is a corporation, the instrument must be signed by the corporation or by a representative
appointed for the corporation under &sect;12.5.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 7.75pt">Production of Evidence of Authority to Vote</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 22.75pt 0 7.55pt">12.15&#9;<FONT STYLE="font-size: 10pt">The chair of
any meeting of shareholders may, but need not, inquire into the authority of any person to vote at the meeting and may, but need
not, demand from that person production of evidence as to the existence of the authority to vote.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 19.35pt 0 18.9pt"><B>PART 13</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 20.75pt 0 18.1pt"><B>DIRECTORS</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 0.1in">Number of Directors</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 14.75pt 0 0.1in">13.1&#9;<FONT STYLE="font-size: 10pt">The number of
directors, excluding additional directors appointed under &sect;14.8, is set at the greater of three and the most recently set
of:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 47.15pt 0 40.5pt">(a)&#9;<FONT STYLE="font-size: 10pt">the number of
directors set by a resolution of the directors (whether or not previous notice of the resolution was given); and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 33.85pt; margin: 0 149.75pt 0 7pt">(b)&#9;<FONT STYLE="font-size: 10pt">the number of directors
in office pursuant to &sect;14.4. Change in Number of Directors</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 33.85pt; margin: 0 149.75pt 0 7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 14.75pt 0 0.1in"> 13.2&#9;<FONT STYLE="font-size: 10pt">If the number of directors is set under &sect;13.l(a):</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 14.75pt 0 40.5pt">(a)&#9;<FONT STYLE="font-size: 10pt">the shareholders
may elect or appoint the directors needed to fill any vacancies in the board of directors up to that number; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 0 16.6pt 0 39.95pt">(b)&#9;<FONT STYLE="font-size: 10pt">if the shareholders
do not elect or appoint the directors needed to fill any vacancies in the board of directors up to that number then the directors,
subject to &sect;14.8, may appoint directors to fill those vacancies.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 6.1pt">Directors&rsquo; Acts Valid Despite Vacancy</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 14.75pt 0 5.95pt">13.3&#9;<FONT STYLE="font-size: 10pt">An act or proceeding
of the directors is not invalid merely because fewer than the number of directors set or otherwise required under these Articles
is in office.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.45pt 0 0 2.1pt"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.45pt 0 0 2.1pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 8.5pt">Qualifications of Directors</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 16.85pt 0 7.75pt">13.4&#9;<FONT STYLE="font-size: 10pt">A director is
not required to hold a share as qualification for his or her office but must be qualified as required by the Act to become, act
or continue to act as a director.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.75pt">Remuneration of Directors</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 11.6pt 0 7.4pt">13.S&#9;The directors are entitled to the remuneration
for acting as directors, if any, as the directors may from time to time determine.</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.4pt">Reimbursement of Expenses of Directors</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 0 9.1pt 0 7.4pt">13.6&#9;<FONT STYLE="font-size: 10pt">The Company must
reimburse each director for the reasonable expenses that he or she may incur in and about the business of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.05pt">Special Remuneration for Directors</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 12.05pt 0 6.7pt">13.7&#9;<FONT STYLE="font-size: 10pt">If any director
performs any professional or other services for the Company that in the opinion of the directors are outside the ordinary duties
of a director, he or she may be paid remuneration fixed by the directors, or at the option of the directors, fixed by ordinary
resolution, and such remuneration will be in addition to any other remuneration that he or she may be entitled to receive.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.7pt">Gratuity, Pension or Allowance on Retirement of Director</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.25pt; margin: 0 11.55pt 0 6.15pt">13.8&#9;<FONT STYLE="font-size: 10pt">Unless
otherwise determined by ordinary resolution, the directors on behalf of the Company may pay a gratuity or pension or allowance
on retirement to any director who has held any salaried office or place of profit with the Company or to his or her spouse or dependants
and may make contributions to any fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.7pt 110.3pt 0 106.95pt"><B>PART 14</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 111.25pt 0 106.95pt"><B>ELECTION AND REMOVAL OF DIRECTORS</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.6pt">Election at Annual General Meeting</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 12.05pt 0 6.7pt"> 14.1 <FONT STYLE="font-size: 10pt">At every annual general meeting:</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 12.05pt 0 39.45pt">(a)&#9;<FONT STYLE="font-size: 10pt">the shareholders
entitled to vote at the annual general meeting for the election of directors must elect a board of directors consisting of the
number of directors for the time being set under these Articles; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 29.95pt 0 39.45pt">(b)&#9;all the directors cease to hold office immediately before the election
or appointment of directors under &sect;(a), but are eligible for re-election or re-appointment.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.45pt 137.15pt 0 139.3pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.45pt 137.15pt 0 139.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 3.55pt 0 0 8.45pt">Consent to be a Director</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 31.65pt 0 8.3pt">14.2&#9;<FONT STYLE="font-size: 10pt">No election, appointment
or designation of an individual as a director is valid unless:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.25pt"></TD><TD STYLE="width: 33.4pt">(a)</TD><TD><FONT STYLE="font-size: 10pt">that individual consents to be a director in the manner provided for in the Act; or</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 34.3pt 0 41.7pt">(b)&#9;that individual is elected or appointed at a
meeting at which the individual is present and the individual does not refuse, at the meeting, to be a director.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.75pt">Failure to Elect or Appoint Directors</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8.65pt"></TD><TD STYLE="width: 66.45pt">14.3</TD><TD>If:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 31.65pt 0 41.5pt">(a)&#9;<FONT STYLE="font-size: 10pt">the Company fails
to hold an annual general meeting on or before the date by which the annual general meeting is required to be held under the Act;
or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 43.95pt 0 41.15pt">(b)&#9;the shareholders fail, at the annual general
meeting to elect or appoint any directors;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">then each director then in office continues to hold office until the earlier of
the time when:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 10.65pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.35pt"></TD><TD STYLE="width: 33.4pt">(c)</TD><TD><FONT STYLE="font-size: 10pt">his or her successor is elected or appointed; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 33.55pt">(d)</TD><TD><FONT STYLE="font-size: 10pt">he or she otherwise ceases to hold office under the Act or these Articles.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">Places of Retiring Directors Not Filled</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.65pt; margin: 0 12pt 0 6.3pt">14.4&#9;<FONT STYLE="font-size: 10pt">If, at any meeting
of shareholders at which there should be an election of directors, the places of any of the retiring directors are not filled by
that election, those retiring directors who are not re-elected and who are asked by the newly elected directors to continue in
office will, if willing to do so, continue in office to complete the number of directors for the time being set pursuant to these
Articles but their term of office will expire when new directors are elected at a meeting of shareholders convened for that purpose.
If any such election or continuance of directors does not result in the election or continuance of the number of directors for
the time being set pursuant to these Articles, the number of directors of the Company is deemed to be set at the number of directors
actually elected or continued in office.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.5pt">Directors May Fill Casual Vacancies</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 41.1pt 0 6.15pt">14.5&#9;<FONT STYLE="font-size: 10pt">Any casual vacancy
occurring in the board of directors may be filled by the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.15pt">Remaining Directors Power to Act</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.1pt; margin: 0 12pt 0 5.95pt">14.6&#9;<FONT STYLE="font-size: 10pt">The directors may
act notwithstanding any vacancy in the board of directors, but if the Company has fewer directors in office than the number set
pursuant to these Articles as the quorum of directors, the directors may only act for the purpose of appointing directors up to
that</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 212.3pt 0 216.3pt"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 212.3pt 0 216.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 8.05pt 18.4pt 0 9.65pt">number or of calling a meeting of shareholders for the purpose of filling
any vacancies on the board of directors or, subject to the Act, for any other purpose.</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 9.85pt">Shareholders May Fill Vacancies</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 18.4pt 0 9.5pt">14.7&#9;<FONT STYLE="font-size: 10pt">If the Company
has no directors or fewer directors in office than the number set pursuant to these Articles as the quorum of directors, the shareholders
may elect or appoint directors to fill any vacancies on the board of directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 9.3pt">Additional Directors</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 11.55pt 0 9.1pt">14.8&#9;<FONT STYLE="font-size: 10pt">Notwithstanding
&sect;13.1 and &sect;13.2, between annual general meetings, the directors may appoint one or more additional directors, but the
number of additional directors appointed under this &sect;14.8 must not at any time exceed one-third of the number of the current
directors who were elected or appointed as directors other than under this &sect;14.8.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.55pt 0 9.1pt">Any director so appointed ceases to hold office immediately before the next
election or appointment of directors under &sect;14.l(a), but is eligible for re-election or re-appointment.</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 9.1pt">Ceasing to be a Director</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10pt"></TD><TD STYLE="width: 66.45pt">14.9</TD><TD><FONT STYLE="font-size: 10pt">A director ceases to be a director when:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 31.65pt 0 41.5pt">(a)&#9; the term of office of the director
expires;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 31.65pt 0 41.5pt">(b )&#9; the
director dies;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 31.65pt 0 41.5pt">(c)&#9; the director resigns as a director by
notice in writing provided to the Company;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 31.65pt 0 41.5pt">(d)&#9; or the director is removed from office
pursuant to &sect;14.I 0 or &sect;14.11.</P>

<P STYLE="font-size: 10pt; margin: 1.5pt 0 0 8.4pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 1.5pt 0 0 8.4pt">Removal of Director by Shareholders</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.65pt; margin: 0 9.85pt 0 7.85pt">14.10&#9;<FONT STYLE="font-size: 10pt">The Company may
remove any director before the expiration of his or her term of office by special resolution. In that event, the shareholders may
elect, or appoint by ordinary resolution, a director to fill the resulting vacancy. If the shareholders do not elect or appoint
a director to fill the resulting vacancy contemporaneously with the removal, then the directors may appoint or the shareholders
may elect, or appoint by ordinary resolution, a director to fill that vacancy.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.85pt">Removal of Director by Directors</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 13.3pt 0 7.7pt">14.11&#9;<FONT STYLE="font-size: 10pt">The directors
may remove any director before the expiration of his or her term of office if the director is convicted of an indictable offence,
or if the director ceases to be qualified to act as a director of a company and does not promptly resign, and the directors may
appoint a director to fill the resulting vacancy.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 157.6pt 0 155.55pt"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 157.6pt 0 155.55pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 157.6pt 0 155.5pt"><B>PART 15</B></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 157.6pt 0 155.55pt; text-align: center"><B>ALTERNATE DIRECTORS</B></P>

<P STYLE="font-size: 10pt; margin: 10.15pt 19.3pt 0 7.05pt">Appointment of Alternate Director</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 16.1pt 0 6.5pt">15.1&#9;Any director (an &ldquo;appointor&rdquo;) may
by notice in writing received by the Company appoint any person (an &ldquo;appointee&rdquo;) who is qualified to act as a director
to be his or her alternate to act in his or her place at meetings of the directors or committees of the directors at which the
appointor is not present unless (in the case of an appointee who is not a director) the directors have reasonably disapproved the
appointment of such person as an alternate director and have given notice to that effect to his or her appointor within a reasonable
time after the notice of appointment is received by the Company.</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 6.35pt">Notice of Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 28.2pt 0 6.15pt">15.2&#9;Every alternate director so appointed is entitled
to notice of meetings of the directors and of committees of the directors of which his or her appointor is a member and to attend
and vote as a director at any such meetings at which his or her appointor is not present.</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 6.15pt">Alternate for More than One Director Attending Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 13.35pt 0 5.95pt">15.3&#9;A person may be appointed as an alternate director
by more than one director, and an alternate director:</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 18.1pt 0 39.8pt">(a)&#9;<FONT STYLE="font-size: 10pt">will be counted
in determining the quorum for a meeting of directors once for each of his or her appointors and, in the case of an appointee who
is also a director, once more in that capacity;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 18.1pt 0 40.2pt">(b)&#9;<FONT STYLE="font-size: 10pt">has a separate vote at a meeting of
directors for each of his or her appointors and, in the case of an appointee who is also a director, an additional vote in that
capacity;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.7pt; margin: 0 22.05pt 0 39.3pt">(c)&#9;<FONT STYLE="font-size: 10pt">will be counted
in determining the quorum for a meeting of a committee of directors once for each of his or her appointors who is a member of that
committee and, in the case of an appointee who is also a member of that committee as a directors, once more in that capacity; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 19.5pt 0 39.45pt">(d)&#9;<FONT STYLE="font-size: 10pt">has a separate
vote at a meeting of a committee of directors for each of his or her appointors who is a member of that committee and, in the case
of an appointee who is also a member of that committee as a director, an additional vote in that capacity.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 5.8pt">Consent Resolutions</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 0 28.2pt 0 5.95pt">15.4&#9;Every alternate director, if authorized by the
notice appointing him or her, may sign in place of his or her appointor any resolutions to be consented to in writing.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.3pt 211.9pt 0 213.2pt"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.3pt 211.9pt 0 213.2pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.75pt">Alternate Director an Agent</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 49.45pt 0 7.4pt">15.5&#9;Every alternate director is deemed to be the
agent of his or her appointor. Revocation or Amendment of Appointment of Alternate Director</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 19.95pt 0 6.85pt">15.6&#9;<FONT STYLE="font-size: 10pt">An appointor
may at any time, by notice in writing received by the Company, revoke or amend the terms of the appointment of an alternate director
appointed by him or her.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 0.1in">Ceasing to be an Alternate Director</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.95pt"></TD><TD STYLE="width: 66.45pt">15.7</TD><TD><FONT STYLE="font-size: 10pt">The appointment of an alternate director ceases when:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.15pt 0 40.8pt">(a)&#9;<FONT STYLE="font-size: 10pt">his or her appointor ceases to be a
director and is not promptly re-elected or re- appointed;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.8pt"></TD><TD STYLE="width: 33.6pt">(b)</TD><TD><FONT STYLE="font-size: 10pt">the alternate director dies;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 0.2in 0 40.25pt">(c)&#9;<FONT STYLE="font-size: 10pt">the alternate director
resigns as an alternate director by notice in writing provided to the Company or a lawyer for the Company;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.6pt"></TD><TD STYLE="width: 33.25pt">(d)</TD><TD><FONT STYLE="font-size: 10pt">the alternate director ceases to be qualified to act as a director; or</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 59.65pt 0 40.1pt">(e)&#9;<FONT STYLE="font-size: 10pt">the term of his
appointment expires, or his or her appointor revokes the appointment of the alternate directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.8pt">Remuneration and Expenses of Alternate Director</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.25pt; margin: 0 26.6pt 0 5.6pt">15.8&#9;<FONT STYLE="font-size: 10pt">The Company may
reimburse an alternate director for the reasonable expenses that would be properly reimbursed if he or she were a director, and
the alternate director is entitled to receive from the Company such proportion, if any, of the remuneration otherwise payable to
the appointor as the appointor may from time to time direct.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 3.05pt 0 0"><B>PART 16</B></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 3.85pt 0 0"><B>POWERS AND DUTIES OF DIRECTORS</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.6pt">Powers of Management</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 0.2in 0 5.4pt">16.I&#9;The directors must, subject to the Act and these
Articles, manage or supervise the management of the business and affairs of the Company and have the authority to exercise all
such powers of the Company as are not, by the Act or by these Articles, required to be exercised by the shareholders of the Company.
Notwithstanding the generality of the foregoing, the directors may set the remuneration of the auditor of the Company.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 173.05pt 0 177pt"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 173.05pt 0 177pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 3.55pt 21.2pt 0 9pt">Appointment of Attorney of Company</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.95pt; margin: 0 14.75pt 0 7.95pt">16.2&#9;The directors may from time to time, by power
of attorney or other instrument, under seal if so required by law, appoint any person to be the attorney of the Company for such
purposes, and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the directors under
these Articles and excepting the power to fill vacancies in the board of directors, to remove a director, to change the membership
of, or fill vacancies in, any committee of the directors, to appoint or remove officers appointed by the directors and to declare
dividends) and for such period, and with such remuneration and subject to such conditions as the directors may think fit. Any such
power of attorney may contain such provisions for the protection or convenience of persons dealing with such attorney as the directors
think fit. Any such attorney may be authorized by the directors to sub-delegate all or any of the powers, authorities and discretions
for the time being vested in him or her.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9pt 176.05pt 0 177pt"><B>PART 17</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 19.4pt 0 18.9pt"><B>INTERESTS OF DIRECTORS AND OFFICERS</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 7.95pt">Obligation to Account for Profits</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 16.6pt 0 7.4pt">17.1&#9;<FONT STYLE="font-size: 10pt">A director or senior
officer who holds a disclosable interest (as that term is used in the Act) in a contract or transaction into which the Company
has entered or proposes to enter is liable to account to the Company for any profit that accrues to the director or senior officer
under or as a result of the contract or transaction only if and to the extent provided in the Act.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 7.4pt">Restrictions on Voting by Reason of Interest</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.75pt; margin: 0 0.2in 0 6.7pt">17.2&#9;<FONT STYLE="font-size: 10pt">A
director who holds a disclosable interest in a contract or transaction into which the Company has entered or proposes to enter
is not entitled to vote on any directors&rsquo; resolution to approve that contract or transaction, unless all the directors have
a disclosable interest in that contract or transaction, in which case any or all of those directors may vote on such resolution.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 6.7pt">Interested Director Counted in Quorum</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.1pt; margin: 0 14.75pt 0 6.85pt">17.3&#9;<FONT STYLE="font-size: 10pt">A director who
holds a disclosable interest in a contract or transaction into which the Company has entered or proposes to enter and who is present
at the meeting of directors at which the contract or transaction is considered for approval may be counted in the quorum at the
meeting whether or not the director votes on any or all of the resolutions considered at the meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 6.85pt">Disclosure of Conflict of Interest or Property</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 16.6pt 0 6.5pt">17.4&#9;<FONT STYLE="font-size: 10pt">A director or senior
officer who holds any office or possesses any property, right or interest that could result, directly or indirectly, in the creation
of a duty or interest that materially conflicts with that individual&rsquo;s duty or interest as a director or senior officer,
must disclose the nature and extent of the conflict as required by the Act.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.3pt 0 0 0.05pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.3pt 0 0 0.05pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 7.5pt 0 0 7.15pt">Director Holding Other Office in the Company</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.25pt; margin: 0 8.2pt 0 7pt">17.5&#9;<FONT STYLE="font-size: 10pt">A
director may hold any office or place of profit with the Company, other than the office of auditor of the Company, in addition
to his or her office of director for the period and on the terms (as to remuneration or otherwise) that the directors may determine.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.15pt">No Disqualification</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 24.4pt 0 6.65pt">17.6&#9;<FONT STYLE="font-size: 10pt">No director or
intended director is disqualified by his or her office from contracting with the Company either with regard to the holding of any
office or place of profit the director holds with the Company or as vendor, purchaser or otherwise, and no contract or transaction
entered into by or on behalf of the Company in which a director is in any way interested is liable to be voided for that reason.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.65pt">Professional Services by Director or Officer</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.3pt; margin: 0 19.1pt 0 6.25pt">17.7&#9;<FONT STYLE="font-size: 10pt">Subject to the
Act, a director or officer, or any person in which a director or officer has an interest, may act in a professional capacity for
the Company, except as auditor of the Company, and the director or officer or such person is entitled to remuneration for professional
services as if that director or officer were not a director or officer.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.25pt">Director or Officer in Other Corporations</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 16.15pt 0 5.9pt">17.8&#9;<FONT STYLE="font-size: 10pt">A director or
officer may be or become a director, officer or employee of, or otherwise interested in, any person in which the Company may be
interested as a shareholder or otherwise, and, subject to the Act, the director or officer is not accountable to the Company for
any remuneration or other benefits received by him or her as director, officer or employee of, or from his or her interest in,
such other person.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 8.2pt 142.55pt 0 139.6pt"><B>PART 18</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 143.6pt 0 139.6pt"><B>PROCEEDINGS OF DIRECTORS</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.9pt">Meetings of Directors</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 12.9pt 0 5.75pt">18.1&#9;<FONT STYLE="font-size: 10pt">The directors
may meet together for the conduct of business, adjourn and otherwise regulate their meetings as they think fit, and meetings of
the directors held at regular intervals may be held at the place, at the time and on the notice, if any, as the directors may from
time to time determine.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.55pt">Voting at Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 24.45pt 0 5.4pt">18.2&#9;<FONT STYLE="font-size: 10pt">Questions arising
at any meeting of directors are to be decided by a majority of votes and, in the case of an equality of votes, the chair of the
meeting has a second or casting vote.</FONT></P>

<P STYLE="font-size: 10pt; margin: 2.1pt 0 0 1.05pt; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 2.1pt 0 0 1.05pt; text-align: center"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 3.55pt 0 0 7.9pt">Chair of Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8.4pt"></TD><TD STYLE="width: 66.45pt">18.3</TD><TD><FONT STYLE="font-size: 10pt">The following individual is entitled to preside as chair at a meeting of directors:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 10.6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.4pt"></TD><TD STYLE="width: 32.95pt">(a)</TD><TD>the chair of the board, if any;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 10.6pt; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 41.4pt; text-align: right"></TD><TD STYLE="width: 32.95pt">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in the absence of the chair of the board, the president,
if any, if the president is a director; or</FONT></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.85pt"></TD><TD STYLE="width: 33.3pt">(c)</TD><TD><FONT STYLE="font-size: 10pt">any other director chosen by the directors if:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 19.3pt 0 73.95pt">(i)&#9;<FONT STYLE="font-size: 10pt">neither the chair
of the board nor the president, if a director, is present at the meeting within 15 minutes after the time set for holding the meeting;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 19.75pt 0 74.15pt">(ii)&#9;neither the chair of the board nor the president,
ifa director, is willing to chair the meeting; or</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 10.65pt 0 74.35pt">(iii)&#9;the chair of the board and the president, if a director, have
advised the secretary, if any, or any other director, that they will not be present at the meeting.</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.25pt">Meetings by Telephone or Other Communications Medium</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.1pt; margin: 0 10.65pt 0 6.45pt">18.4&#9;<FONT STYLE="font-size: 10pt">A director may
participate in a meeting of the directors or of any committee of the directors:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 10.75pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.3pt"></TD><TD STYLE="width: 33.3pt">(a)</TD><TD><FONT STYLE="font-size: 10pt">In person;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 10.75pt 0 0 40.1pt">(b)&#9;by telephone; or</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 32.5pt 0 39.75pt">(c)&#9;with the consent of all the directors who wish
to participate in the meeting by other communications medium;</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 19.3pt 0 5.55pt">if all directors participating in the meeting, whether
in person or by telephone or other communications medium, are able to communicate with each other. A director who participates
in a meeting ina manner contemplated by this &sect;18.4 is deemed for all purposes of the Act and these Articles to be present
at the meeting and to have agreed to participate in that manner.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.1pt">Calling of Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.1pt; margin: 0 10.65pt 0 5.9pt">18.5&#9;<FONT STYLE="font-size: 10pt">A director may,
and the secretary or an assistant secretary of the Company, if any, on the request of a director must, call a meeting of the directors
at any time.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.55pt">Notice of Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 12.4pt 0 5.4pt">18.6&#9;<FONT STYLE="font-size: 10pt">Other than for meetings
held at regular intervals as determined by the directors pursuant to &sect;18.1, 48 hours&rsquo; notice of each meeting of the
directors, specifying the place, day and time of that meeting must be given to each of the directors by any method set out in &sect;24.1
or orally or by telephone.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.3pt 0 0 0.55pt"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.3pt 0 0 0.55pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 3.5pt 0 0 6.95pt">When Notice Not Required</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.95pt; margin: 0 0 0 6.05pt">18.7&#9;<FONT STYLE="font-size: 10pt">It is not necessary
to give notice of a meeting of the directors to a director if:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 21.2pt 0 40.6pt">(a)&#9;<FONT STYLE="font-size: 10pt">the meeting is
to be held immediately following a meeting of shareholders at which that director was elected or appointed, or is the meeting of
the directors at which that director is appointed; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 21.2pt 0 40.6pt"> (b)&#9;<FONT STYLE="font-size: 10pt">the director has waived notice of the meeting.</FONT></P>



<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.75pt">Meeting Valid Despite Failure to Give Notice</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.6pt; margin: 0 14.6pt 0 6.05pt">18.8&#9;<FONT STYLE="font-size: 10pt">The accidental
omission to give notice of any meeting of directors to, or the non- receipt of any notice by, any director, does not invalidate
any proceedings at that meeting.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.05pt">Waiver of Notice of Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 11.9pt 0 5.7pt">18.9&#9;<FONT STYLE="font-size: 10pt">Any director may
send to the Company a document signed by him or her waiving notice of any past, present or future meeting or meetings of the directors
and may at any time withdraw that waiver with respect to meetings held after that withdrawal. After sending a waiver with respect
to all future meetings and until that waiver is withdrawn, no notice of any meeting of the directors need be given to that director
and all meetings of the directors so held are deemed not to be improperly called or constituted by reason of notice not having
been given to such director. Attendance of a director or alternate director at a meeting of the directors is a waiver of notice
of the meeting unless that director or alternate director attends the meeting for the express purpose of objecting to the transaction
of any business on the grounds that the meeting is not lawfully called.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.85pt">Quorum</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 17.85pt 0 5.85pt">18.10&#9;<FONT STYLE="font-size: 10pt">The quorum necessary
for the transaction of the business of the directors may be set by the directors and, if not so set, is deemed to be a majority
of the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.7pt">Validity of Acts Where Appointment Defective</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 17.85pt 0 5.3pt">18.11&#9;<FONT STYLE="font-size: 10pt">Subject to the
Act, an act of a director or officer is not invalid merely because of an irregularity in the election or appointment or a defect
in the qualification of that director or officer.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.3pt">Consent Resolutions in Writing</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 21.2pt 0 5.15pt">18.12&#9;<FONT STYLE="font-size: 10pt">A resolution
of the directors or of any committee of the directors may be passed without a meeting:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.65pt 0 39.15pt">(a)&#9;<FONT STYLE="font-size: 10pt">in all cases, if each of the directors
entitled to vote on the resolution consents to it in writing; or</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 200.4pt 0 203.55pt"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 200.4pt 0 203.55pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 8.25pt 12.35pt 0 41.3pt">(b)&#9;in the case of a resolution to approve
a contract or transaction in respect of which a director has disclosed that he or she has or may have a disclosable interest, if
each of the other directors who have not made such a disclosure consents in writing to the resolution.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 12.35pt 0 6.75pt">A consent in writing under this Part 18 may be by signed
document, fax, email or any other method of transmitting legibly recorded messages. A consent in writing may be in two or more
counterparts which together are deemed to constitute one consent in writing. A resolution of the directors or of any committee
of the directors passed in accordance with this &sect;18.12 is effective on the date stated in the consent in writing or on the
latest date stated on any counterpart and is deemed to be a proceeding at a meeting of directors or of the committee of the directors
and to be as valid and effective as if it had been passed at a meeting of the directors or of the committee of the directors that
satisfies all the requirements of the Act and all the requirements of these Articles relating to meetings of the directors or of
a committee of the directors.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.15pt 203.25pt 0 203.55pt"><B>PART 19</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 117.35pt 0 116.6pt"><B>EXECUTIVE AND OTHER COMMITTEES</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.05pt">Appointment and Powers of Executive Committee</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.45pt; margin: 0 23.9pt 0 6.05pt">19.1&#9;<FONT STYLE="font-size: 10pt">The directors
may, by resolution, appoint an executive committee consisting of the director or directors that they consider appropriate, and
this committee has, during the intervals between meetings of the board of directors, all of the directors&rsquo; powers, except:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.25pt"></TD><TD STYLE="width: 33.45pt">(a)</TD><TD><FONT STYLE="font-size: 10pt">the power to fill vacancies in the board of directors;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40.25pt; text-align: right"></TD><TD STYLE="width: 33.45pt">(b)</TD><TD STYLE="text-align: justify">the power to remove a director;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.25pt"></TD><TD STYLE="width: 33.45pt">(c)</TD><TD STYLE="padding-right: 12.35pt"><FONT STYLE="font-size: 10pt">the power to change the membership of, or fill vacancies in, any
committee of the directors; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40.25pt; text-align: right"></TD><TD STYLE="width: 33.45pt">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">such other powers, if any, as may be set out in the
resolution or any subsequent directors&rsquo; resolution.</FONT></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.7pt">Appointment and Powers of Other Committees</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.6pt"></TD><TD STYLE="width: 66.75pt">19.2</TD><TD><FONT STYLE="font-size: 10pt">In addition to any executive committee, the directors may, by resolution:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40.25pt; text-align: right"></TD><TD STYLE="width: 33.45pt">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appoint one or more committees consisting of the director
or directors that they consider appropriate;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.25pt"></TD><TD STYLE="width: 33.45pt">(b)</TD><TD>delegate to a committee appointed under &sect;(a) any of the directors&rsquo; powers, except:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 10.3pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 73pt"></TD><TD STYLE="width: 33.85pt">(i)</TD><TD>the power to fill vacancies in the board of directors;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 136.6pt 0 139.6pt"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 136.6pt 0 139.6pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6.95pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75.9pt"></TD><TD STYLE="width: 33.4pt">(ii)</TD><TD STYLE="padding-right: 24.45pt">the power to remove a director;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 54.75pt 0 75.7pt">(iii)&#9;the power to change the membership of, or fill vacancies in, any
committee of the directors; and</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.45pt 0 75.35pt">(iv)&#9;the power to appoint or remove officers appointed by the directors;
and</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 30.5pt 0 41.4pt">(c)&#9;make any delegation referred to in &sect;(b)
subject to the conditions set out in the resolution or any subsequent directors&rsquo; resolution.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.45pt 0 7.45pt">Obligations of Committees</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.4pt; margin: 0 30.5pt 0 6.95pt">19.3&#9;<FONT STYLE="font-size: 10pt">Any committee appointed
under &sect;19.1 or &sect;19.2, in the exercise of the powers delegated to it, must:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 8.1pt 0 41.25pt">(a)&#9;<FONT STYLE="font-size: 10pt">conform to any rules that may from time
to time be imposed on it by the directors; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 30.5pt 0 40.9pt">(b)&#9;<FONT STYLE="font-size: 10pt">report every act or thing done in exercise
of those powers at such times as the directors may require.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.45pt 0 6.95pt">Powers of Board</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.45pt 0 0 7.65pt">19.4</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.6pt">or &sect;19.2:</P>

<P STYLE="font-size: 10pt; margin: 3.8pt 0 0 6.6pt">The directors may, at any time, with respect to a committee appointed under
&sect;19.1</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 4.15pt 13.2pt 0 40.35pt">(a)&#9;<FONT STYLE="font-size: 10pt">revoke or
alter the authority given to the committee, or override a decision made by the committee, except as to acts done before such revocation,
alteration or overriding;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 4.15pt 13.2pt 0 40.35pt"> (b)&#9; <FONT STYLE="font-size: 10pt">terminate the appointment of, or change the membership of, the committee; and</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 4.15pt 13.2pt 0 40.35pt"> (c)&#9; <FONT STYLE="font-size: 10pt">fill vacancies in the committee.</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.45pt 0 6.2pt">Committee Meetings</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 13.2pt 0 6.05pt">19.5&#9;<FONT STYLE="font-size: 10pt">Subject to &sect;19.3(a)
and unless the directors otherwise provide in the resolution appointing the committee or in any subsequent resolution, with respect
to a committee appointed under &sect;19.1 or &sect;19.2:</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 1.05pt; margin: 0 13.2pt 0 6.05pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 19.55pt 0 39.45pt"> (a)&#9; <FONT STYLE="font-size: 10pt">the committee may meet and adjourn as it thinks proper;</FONT></P>



<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 19.55pt 0 39.45pt">(b)&#9;the committee may elect a chair of its meetings
but, if no chair of a meeting is elected, or if at a meeting the chair of the meeting is not present within 15 minutes after the
time set for holding the meeting, the directors present who are members of the committee may choose one of their number to chair
the meeting;</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 57.35pt 0 39.45pt">(c)&#9;<FONT STYLE="font-size: 10pt">a majority of the members of the committee
constitutes a quorum of the committee; and</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.7pt 137.4pt 0 139.3pt"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.7pt 137.4pt 0 139.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.7pt; margin: 7.85pt 8.85pt 0 41.25pt">(d)&#9;<FONT STYLE="font-size: 10pt">questions
arising at any meeting of the committee are determined by a majority of votes of the members present, and in case of an equality
of votes, the chair of the meeting does not have a second or casting vote.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.3pt 85.75pt 0 85.55pt"><B>PART 20</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.3pt 85.75pt 0 85.55pt"><B>OFFICERS</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">Directors May Appoint Officers</P>

<P STYLE="font-size: 10pt; margin: 3.45pt 0 0 6.85pt"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 4pt 49.05pt 0 6.85pt">20.l&#9;The directors may, from time to time, appoint
such officers, if any, as the directors determine and the directors may, at any time, terminate any such appointment.</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.85pt">Functions, Duties and Powers of Officers</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 10.1pt 0 5.95pt">20.2&#9;<FONT STYLE="font-size: 10pt">The directors may,
for each officer:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 18.6pt 0 40.7pt">(a)&#9;determine the functions and duties of the officer;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14pt 0 40.7pt">(b)&#9;entrust to and confer on the officer any of the powers exercisable by
the directors on such terms and conditions and with such restrictions as the directors think fit; and</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 22.2pt 0 40.15pt">(c)&#9;revoke, withdraw, alter or vary all or any of
the functions, duties and powers of the officer.</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.3pt">Qualifications</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 16.95pt 0 5.95pt">20.3&#9;<FONT STYLE="font-size: 10pt">No person may be appointed as an officer
unless that person is qualified in accordance with the Act. One person may hold more than one position as an officer of the Company.
An officer will not be a director, except that a person appointed the chair of the board or as a managing director must be a director.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.95pt">Remuneration and Terms of Appointment</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 12pt 0 5.8pt">20.4&#9;<FONT STYLE="font-size: 10pt">All appointments
of officers are to be made on the terms and conditions and at the remuneration (whether by way of salary, fee, commission, participation
in profits or otherwise) that the directors thinks fit and are subject to termination at the pleasure of the directors, and an
officer may in addition to such remuneration be entitled to receive, after he or she ceases to hold such office or leaves the employment
of the Company, a pension or gratuity.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.55pt 203.85pt 0 205.3pt"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.55pt 203.85pt 0 205.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 203.85pt 0 205.35pt"><B>PART 21</B></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 1.15pt 0 0; text-align: center"><B>INDEMNIFICATION</B></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.55pt 0 0 8.45pt">Definitions</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 2.35pt; margin: 0 0 0 6.3pt">21.1&#9;In this Part 21:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 11.7pt 0 41.5pt">(a)&#9;<FONT STYLE="font-size: 10pt">&ldquo;eligible
party&rdquo; means an individual who:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75.8pt"></TD><TD STYLE="width: 33.8pt">(i)</TD><TD><FONT STYLE="font-size: 10pt">is or was a director or officer of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75.8pt"></TD><TD STYLE="width: 33.4pt">(ii)</TD><TD><FONT STYLE="font-size: 10pt">is or was a director or officer of another corporation</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 109.4pt; text-align: right"></TD><TD STYLE="width: 33.75pt">(A)</TD><TD STYLE="text-align: justify">at a time when the corporation is or was an affiliate of the Company, or</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 109.4pt"></TD><TD STYLE="width: 33.75pt">(B)</TD><TD>at the request of the Company; or</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 22.35pt 0 75.3pt">(iii)&#9;at the request of the Company, is or was,
or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated
entity;</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.55pt 0 41.5pt">(b)&#9;<FONT STYLE="font-size: 10pt">&ldquo;eligible penalty&rdquo; means
a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.35pt; margin: 0 23pt 0 41.15pt">(c)&#9;<FONT STYLE="font-size: 10pt">&ldquo;eligible
proceeding&rdquo; means a legal proceeding or investigative action, whether current, threatened, pending or completed, in which
a director or former director of the Company or any of the heirs and legal personal representatives of the eligible party, by reason
of the eligible party being or having been a director of the Company:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 74.9pt"></TD><TD STYLE="width: 33.4pt">(i)</TD><TD><FONT STYLE="font-size: 10pt">is or may be joined as a party; or</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 26.3pt 0 74.55pt">(ii)&#9;is or may be liable for or in respect of a
judgment, penalty or fine in, or expenses related to, the proceeding;</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.8pt">and will include any other proceeding or action contemplated by the Act; and</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 15.75pt 0 40.6pt">(d)&#9;<FONT STYLE="font-size: 10pt">&ldquo;expenses&rdquo;
has the meaning set out in the Act and includes costs, charges and expenses, including legal and other fees, but does not include
judgments, penalties, fines or amounts paid in settlement of a proceeding.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.5pt">Mandatory Indemnification of Eligible Parties</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 11.55pt 0 6.3pt">21.2&#9;Subject to the Act, the Company must indemnify
each eligible party and his or her heirs and legal personal representatives against all eligible penalties to which such person
is or may be liable, and the Company must, after the final disposition of an eligible proceeding, pay the expenses actually and
reasonably incurred by such person in respect of that proceeding. Each</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 0 0 0.85pt"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 0 0 0.85pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 8.3pt 20.45pt 0 8.05pt">eligible party is deemed to have contracted with the Company on the
terms of the indemnity contained in this &sect;21.2.</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.85pt">Indemnification of Other Persons</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 20.45pt 0 7.7pt">21.3&#9;<FONT STYLE="font-size: 10pt">Subject to any restrictions in the
Act, the Company may agree to indemnify and may indemnify any person (including an eligible party) against eligible penalties and
pay expenses incurred in connection with the performance of services by that person for the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.7pt">Authority to Advance Expenses</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.85pt 0 7.3pt">21.4&#9;<FONT STYLE="font-size: 10pt">The Company may advance expenses to
an eligible party to the extent permitted by and in accordance with the Act.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.95pt">Non-Compliance with Act</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 11.2pt 0 6.95pt">21.5&#9;<FONT STYLE="font-size: 10pt">Subject to the
Act, the failure of an eligible party of the Company to comply with the Act or these Articles or, if applicable, any former <I>Companies
Act </I>or former Articles does not, of itself, invalidate any indemnity to which he or she is entitled under this Part 21.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.95pt">Company May Purchase Insurance</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 11.3pt 0 6.4pt">21.6&#9;<FONT STYLE="font-size: 10pt">The Company may
purchase and maintain insurance for the benefit of any eligible party person (or his or her heirs or legal personal representatives)
against any liability incurred</FONT></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.6pt">by him or her as such director, officer or person who holds or held such equivalent
position.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 196.8pt 0 193.6pt"><B>PART 22</B></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 197.9pt 0 193.6pt"><B>DIVIDENDS</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.4pt">Payment of Dividends Subject to Special Rights</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 34.55pt 0 5.85pt">22.l&#9;The provisions of this Part 22 are subject
to the rights, if any, of shareholders holding shares with special rights as to dividends.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.85pt">Declaration of Dividends</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.4pt; margin: 0 36.35pt 0 5.5pt">22.2&#9;<FONT STYLE="font-size: 10pt">Subject to the
Act, the directors may from time to time declare and authorize payment of such dividends as they may deem advisable.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.85pt">Record Date</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.3pt 0 5.5pt">22.3&#9;<FONT STYLE="font-size: 10pt">The directors must set a date as the
record date for the purpose of determining shareholders entitled to receive payment of a dividend. The record date must not precede
the date on which the dividend is to be paid by more than two months.</FONT></P>

<P STYLE="font-size: 10pt; margin: 2.4pt 0 0 2.75pt; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 2.4pt 0 0 2.75pt; text-align: center"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 8.1pt">Manner of Paying Dividend</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 11.3pt 0 7.75pt">22.4&#9;<FONT STYLE="font-size: 10pt">A resolution declaring
a dividend may direct payment of the dividend wholly or partly in money or by the distribution of specific assets or of fully paid
shares or of bonds, debentures or other securities of the Company or any other corporation, or in any one or more of those ways.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.75pt">Settlement of Difficulties</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.4pt"></TD><TD STYLE="width: 0.2pt">22.5</TD><TD STYLE="padding-right: 21.8pt">If any difficulty arises in regard to a distribution under &sect;22.4, the directors may settle
the difficulty as they deem advisable, and, in particular, may:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 0 0 41.25pt">(a)&#9;set the value for distribution of specific assets;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 20.7pt 0 41.25pt">(b)&#9;determine that money in substitution for all or any part of the specific
assets to which any shareholders are entitled may be paid to any shareholders on the basis of the value so fixed in order to adjust
the rights of all parties; and</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 34.2pt; margin: 0 24.25pt 0 6.85pt">(c)&#9;vest any such specific assets in trustees for
the persons entitled to the dividend. When Dividend Payable</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 34.65pt 0 6.7pt">22.6&#9;Any dividend may be made payable on such date as is fixed by
the directors. Dividends to be Paid in Accordance with Number of Shares</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0.2in 0 6.7pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0.2in 0 6.7pt">22.7&#9;All dividends on shares of any class or series of shares must
be declared and paid according to the number of such shares held.</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.5pt">Receipt by Joint Shareholders</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.3pt">22.8&#9;If several persons are joint shareholders of any share, any one of
them may give an effective receipt for any dividend, bonus or other money payable in respect of the share.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.3pt">Dividend Bears No Interest</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0.35pt 18.5pt 0 5.6pt"> 22.9&#9;No dividend bears interest against the Company. Fractional Dividends</P>



<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0.35pt 18.5pt 0 5.6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0.35pt 18.5pt 0 5.6pt">22.10&#9;If a dividend to which a shareholder is
entitled includes a fraction of the smallest monetary unit of the currency of the dividend, that fraction may be disregarded in
making payment of the dividend and that payment represents full payment of the dividend.</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.6pt">Payment of Dividends</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 18.5pt 0 5.25pt">22.11&#9;Any dividend or other distribution payable
in money in respect of shares may be paid by cheque, made payable to the order of the person to whom it is sent, and mailed to
the</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 171.25pt 0 173.3pt"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 171.25pt 0 173.3pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 8.05pt 25.1pt 0 8.2pt">registered address of the shareholder, or in the case of joint shareholders,
to the registered address of the joint shareholder who is first named on the central securities register, or to the person and
to the address the shareholder or joint shareholders may direct in writing. The mailing of such cheque will, to the extent of the
sum represented by the cheque (plus the amount of the tax required by law to be deducted), discharge all liability for the dividend
unless such cheque is not paid on presentation or the amount of tax so deducted is not paid to the appropriate taxing authority.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 8.2pt">Capitalization of Retained Earnings or Surplus</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 8.6pt 0 7.7pt">22.12&#9;Notwithstanding anything contained in these Articles,
the directors may from time to time capitalize any retained earnings or surplus of the Company and may from time to time issue,
as fully paid, shares or any bonds, debentures or other securities of the Company as a dividend representing the retained earnings
or surplus so capitalized or any part thereof.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9.25pt 114.55pt 0 113.9pt"><B>PART 23</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 116.5pt 0 113.9pt"><B>ACCOUNTING RECORDS AND AUDITORS</B></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 7.15pt">Recording of Financial Affairs</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 47.2pt 0 6.95pt">23. I&#9;The directors must cause adequate accounting
records to be kept to record properly the financial affairs and condition of the Company and to comply with the Act.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.95pt">Inspection of Accounting Records</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.8pt"></TD><TD STYLE="width: 0.5pt">23.2</TD><TD STYLE="padding-right: 15.3pt">Unless the directors determine otherwise, or unless otherwise determined by ordinary resolution,
no shareholder of the Company is entitled to inspect or obtain a copy of any accounting records of the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.95pt">Remuneration of Auditor</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.8pt"></TD><TD STYLE="width: 67.5pt">23.3</TD><TD STYLE="padding-right: 12.05pt">The directors may set the remuneration of the auditor of the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 9pt 116.45pt 0 113.9pt"><B>PART 24</B></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 116.5pt 0 112.4pt"><B>NOTICES</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 12.05pt 0 6.05pt">Method of Giving Notice</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.9pt"></TD><TD STYLE="width: 0.35pt">24.1</TD><TD STYLE="text-align: justify; padding-right: 20.05pt">Unless the Act or these Articles provide otherwise, a notice, statement,
report or other record required or permitted by the Act or these Articles to be sent by or to a person may be sent by:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 10.25pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.2pt"></TD><TD STYLE="width: 33.2pt">(a)</TD><TD STYLE="padding-right: 12.05pt"><FONT STYLE="font-size: 10pt">mail addressed to the person at the applicable address for that
person as follows:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 204.3pt 0 207pt"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.4pt 204.3pt 0 207pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.35pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.25pt"></TD><TD STYLE="width: 33.65pt">(i)</TD><TD><FONT STYLE="font-size: 10pt">for a record mailed to a shareholder, the shareholder&rsquo;s registered address;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 0 20.3pt 0 75.35pt">(ii)&#9;for a record mailed to a director or officer,
the prescribed address for mailing shown for the director or officer in the records kept by the Company or the mailing address
provided by the recipient for the sending of that record or records of that class;</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75.7pt"></TD><TD STYLE="width: 33.7pt">(iii)</TD><TD STYLE="padding-right: 21.8pt">in any other case, the mailing address of the intended recipient;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 33.2pt 0 41pt">(b)&#9;delivery at the applicable address for that person
as follows, addressed to the person:</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 44.15pt 0 75.2pt">(i)&#9;<FONT STYLE="font-size: 10pt">for a record delivered
to a shareholder, the shareholder&rsquo;s registered address;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 20.3pt 0 74.8pt">(ii)&#9;for a record delivered to a director or officer,
the prescribed address for delivery shown for the director or officer in the records kept by the Company or the delivery address
provided by the recipient for the sending of that record or records of that class;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75pt"></TD><TD STYLE="width: 33.65pt">(iii)</TD><TD STYLE="padding-right: 21.8pt">in any other case, the delivery address of the intended recipient;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 10pt 0 40.45pt">(c)&#9;<FONT STYLE="font-size: 10pt">sending the record
by fax to the fax number provided by the intended recipient for the sending of that record or records of that class;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 48pt 0 40.45pt">(d)&#9;<FONT STYLE="font-size: 10pt">sending the record
by email to the email address provided by the intended recipient for the sending of that record or records of that class; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.45pt"></TD><TD STYLE="width: 33.45pt">(e)</TD><TD STYLE="padding-right: 21.8pt"><FONT STYLE="font-size: 10pt">physical delivery to the intended recipient.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.25pt">Deemed Receipt of Mailing</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.05pt"></TD><TD STYLE="width: 1.8pt">24.2</TD><TD STYLE="padding-right: 21.8pt"><FONT STYLE="font-size: 10pt">A notice, statement, report or other record that is:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75pt; margin: 0 24.05pt 0 39.7pt">(a)&#9;<FONT STYLE="font-size: 10pt">mailed to a person
by ordinary mail to the applicable address for that person referred to in &sect;24.1 i is deemed to be received by the person to
whom it was mailed on the day (Saturdays, Sundays and holidays excepted) following the date of mailing;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 11.7pt 0 39.9pt">(b)&#9;faxed to a person to the fax number provided by that person referred
to in &sect;24.1 is deemed to be received by the person to whom it was faxed on the day it was faxed; and</P>

<P STYLE="font-size: 10pt; margin: 10.5pt 21.8pt 0 39.7pt">(c)&#9;emailed to a person to the e-mail address provided by that person
referred to in &sect;24.l is deemed to be received by the person to whom it was e-mailed on the day that it was emailed.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 206pt 0 207pt"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.15pt 206pt 0 207pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 3.55pt 21.8pt 0 8.05pt">Certificate of Sending</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.7pt"></TD><TD STYLE="width: 0.15pt">24.3</TD><TD STYLE="padding-right: 11.7pt"><FONT STYLE="font-size: 10pt">A certificate signed by the secretary, if any, or other officer
of the Company or of any other corporation acting in that capacity on behalf of the Company stating that a notice, statement, report
or other record was sent in accordance with &sect;24.1 is conclusive evidence of that fact.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 7.3pt">Notice to Joint Shareholders</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 18.2pt 0 7.15pt">24.4&#9;<FONT STYLE="font-size: 10pt">A notice, statement, report or other
record may be provided by the Company to the joint shareholders of a share by providing such record to the joint shareholder first
named in the central securities register in respect of the share.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 7.15pt">Notice to Legal Personal Representatives and Trustees</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 24.05pt 0 6.95pt">24.5&#9;<FONT STYLE="font-size: 10pt">A notice, statement, report or other
record may be provided by the Company to the persons entitled to a share in consequence of the death, bankruptcy or incapacity
of a shareholder by:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 0 0 40.2pt">(a)&#9;<FONT STYLE="font-size: 10pt">mailing the record, addressed
to them:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 10pt 0 74.1pt">(i)&#9;by name, by the title of the legal personal representative
of the deceased or incapacitated shareholder, by the title of trustee of the bankrupt shareholder or by any similar description;
and</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 30.9pt 0 73.95pt">(ii)&#9;at the address, if any, supplied to the Company
for that purpose by the persons claiming to be so entitled; or</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 21.15pt 0 40.2pt">(b)&#9;<FONT STYLE="font-size: 10pt">if an address
referred to in &sect;(a)(ii) has not been supplied to the Company, by giving the notice in a manner in which it might have been
given if the death, bankruptcy or incapacity had not occurred.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.8pt 0 6.05pt">Undelivered Notices</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 11.7pt 0 5.7pt">24.6&#9;<FONT STYLE="font-size: 10pt">If on two consecutive
occasions, a notice, statement, report or other record is sent to a shareholder pursuant to &sect;24.1 and on each of those occasions
any such record is returned because the shareholder cannot be located , the Company will not be required to send any further records
to the shareholder until the shareholder informs the Company in writing of his or her new address.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 85.9pt 0 85.55pt"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.75pt 85.9pt 0 85.55pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 8.2pt 86.8pt 0 85.55pt"><B>PART 25</B></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 87.05pt 0 85.55pt"><B>SEAL</B></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.5pt 0 0 6.7pt">Who May Attest Seal</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.7pt"></TD><TD STYLE="width: 0.15pt">25.1</TD><TD STYLE="padding-right: 23pt"><FONT STYLE="font-size: 10pt">Except as provided in &sect;25.2 and &sect;25.3, the Company&rsquo;s
seal, if any, must not be impressed on any record except when that impression is attested by the signatures of:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.6pt"></TD><TD STYLE="width: 33.6pt">(a)</TD><TD><FONT STYLE="font-size: 10pt">any two directors;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.6pt">(b)&#9;any officer, together with any director;</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 16.95pt 0 40.1pt">(c)&#9;<FONT STYLE="font-size: 10pt">if the Company
only has one director, that director; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 34.3pt 0 40.1pt">(d)&#9;<FONT STYLE="font-size: 10pt">any one or more
directors or officers or persons as may be determined by the directors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 6.15pt">Sealing Copies</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 14pt 0 5.25pt">25.2&#9; <FONT STYLE="font-size: 10pt">For the purpose of
certifying under seal a certificate of incumbency of the directors or officers of the Company or a true copy of any
resolution or other document, despite</FONT> &sect;25.1, the impression of the seal may be attested by the signature of any
director or officer or the signature of any other person as may be determined by the directors.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.8pt">Mechanical Reproduction of Seal</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 14pt 0 5.25pt">25.3&#9;<FONT STYLE="font-size: 10pt">The directors may
authorize the seal to be impressed by third parties on share certificates or bonds, debentures or other securities of the Company
as they may determine appropriate from time to time. To enable the seal to be impressed on any share certificates or bonds, debentures
or other securities of the Company, whether in definitive or interim form, on which facsimiles of any of the signatures of the
directors or officers of the Company are, in accordance with the Act or these Articles, printed or otherwise mechanically reproduced,
there may be delivered to the person employed to engrave, lithograph or print such definitive or interim share certificates or
bonds, debentures or other securities one or more unmounted dies reproducing the seal and such persons as are authorized under
&sect;25.1 to attest the Company&rsquo;s seal may in writing authorize such person to cause the seal to be impressed on such definitive
or interim share certificates or bonds, debentures or other securities by the use of such dies. Share certificates or bonds, debentures
or other securities to which the seal has been so impressed are for all purposes deemed to be under and to bear the seal impressed
on them.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 212.25pt 0 211pt"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 212.25pt 0 211pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 20.75pt 0 18.35pt"><B>PART 26</B></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 20.75pt 0 18.9pt"><B>SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO PREFERRED
SHARES</B></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 21.2pt 0 6.3pt">Attachment of Special Rights and Restrictions</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 22.75pt 0 6.15pt">26.1&#9;<FONT STYLE="font-size: 10pt">There are attached to the Preferred
Shares as a class the following special rights and restrictions:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 14.75pt 0 39.9pt">(a)&#9;<FONT STYLE="font-size: 10pt">the board may
at any time and from time to time issue Preferred Shares in one or more series, each series to consist of such number of shares
as is determined by the board before the issue of any thereof;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5pt; margin: 0 14.75pt 0 39.35pt">(b)&#9;a holder of a Preferred Share will as such be
entitled to receive notice of, attend, speak and vote at a general meeting of the members of the Company, except as otherwise provided
in the special rights and restrictions attached to the share by the board;</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.9pt; margin: 0 0 0 38.8pt">(c)&#9;<FONT STYLE="font-size: 10pt">holders of Preferred
Shares will be entitled to:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 1.65pt; margin: 0 22.75pt 0 71.85pt">(i)&#9;<FONT STYLE="font-size: 10pt">preference with
respect to payment of dividends on such shares over the payment of dividends on the Common Shares and on any other shares ranking
junior to the Preferred Shares with respect to the payment of dividends; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 14.75pt 0 72.95pt">(ii)&#9;in the event of the liquidation, dissolution or winding-up of the
Company, whether voluntary or involuntary, or other distribution of the assets of the Company among its members for the purpose
of winding up its affairs, preference on a distribution of assets:</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.55pt; margin: 0 16.6pt 0 106.15pt">(A)&#9;<FONT STYLE="font-size: 10pt">in repayment
of capital, over any distribution to holders of Common Shares or to holders of other shares not ranking with respect to such distribution
equally with or in priority to the repayment of capital on the Preferred Shares; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 0 12.4pt 0 106.35pt">(B)&#9;<FONT STYLE="font-size: 10pt">on account of
undeclared accumulated dividends, over any distribution to holders of Common Shares or any distribution to holders of other shares
not ranking with respect to such distribution equally with or in priority to the payment of dividends on the Preferred Shares;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 16.6pt 0 38.8pt">(d)&#9;<FONT STYLE="font-size: 10pt">the Company will not without, but may
from time to time with, the approval by a separate class resolution of the holders of the Preferred Shares given in accordance
with</FONT> &sect;26.3:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 10.25pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72.4pt"></TD><TD STYLE="width: 33.75pt">(i)</TD><TD STYLE="padding-right: 21.2pt"><FONT STYLE="font-size: 10pt">increase the authorized number of Preferred Shares;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 10.7pt 22.05pt 0 72.4pt">(ii) attach special rights and restrictions to,
or alter or vary the special rights and restrictions attached to, shares of any other class whereby such shares rank equally with
or in priority to the Preferred Shares with respect to the declaration</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 0 0 1.1pt"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.5pt 0 0 1.1pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.15pt; margin: 7.4pt 16.1pt 0 75.55pt">or payment of dividends or the distribution of
the assets of the Company among its members for any reason;</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.2pt; margin: 0 19.7pt 0 75.35pt">(iii)&#9;create or increase the authorized number of
shares of any class ranking equally with or in priority to the Preferred Shares with respect to the declaration or payment of dividends
or the distribution of the assets of the Company among its members for any reason; and</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 0 30.5pt 0 75pt">(iv)&#9;alter, vary or abrogate the special rights or
restrictions attaching to the Preferred Shares as a class.</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.3pt 0 7.3pt">26.2&#9;<FONT STYLE="font-size: 10pt">The board will, before the first issue
of Preferred Shares of any series, alter the Memorandum or Articles of the Company or both to fix the number of Preferred Shares
in, and to determine the designation of and the special rights and restrictions to be attached to, the Preferred Shares of that
series.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 7.3pt">Separate Class Resolution</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 19.7pt 0 6.95pt">26.3&#9;<FONT STYLE="font-size: 10pt">Approval by separate class resolution
of the holders of Preferred Shares must be by a separate resolution:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 33.65pt">(a)</TD><TD><FONT STYLE="font-size: 10pt">consented to in writing by all holders of Preferred Shares; or</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 41pt; text-align: right"></TD><TD STYLE="width: 33.65pt">(b)</TD><TD STYLE="text-align: justify">presented at a meeting of holders of Preferred Shares, called for such purpose in
accordance with these Articles, at which one or more persons are present representing in person or by proxy at least 33 1/3% of
the issued and outstanding Preferred Shares, and passed by the affirmative vote of at least 66 2/3% of the votes cast.&rdquo;.</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -8.3pt; margin: 0 75.9pt 0 338.05pt"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><I>RECEIVED FOR DEPOSIT AT THE RECORDS OFFICE ON
MAY 14, 2013.</I></P>

<P STYLE="font-size: 10pt; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 71.35pt 0 0">TEKMIRA PHARMACEAUTICALS CORPORATION</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0.3pt 70.8pt 0 0">(the &ldquo;Company&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 150.3pt 0 79.1pt">ORDINARY RESOLUTION PASSED BY THE SHAREHOLDERS OF THE
CO:MPANY AT THE ANNUAL AND SPECIAL MEETING OF THE SHAREHOLDERS CO:MPANY HELD ON MAY 14, 2013</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 41.2pt">&ldquo;BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT:</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.1pt"></TD><TD STYLE="width: 34.65pt">1.</TD><TD STYLE="text-align: justify; padding-right: 77.05pt">the Articles of the Company be altered by adding the text substantially
in the form attached as Exhibit &ldquo;B&rdquo; to the Information Circular of Tekmira Pharmaceuticals Corporation dated March
27, 2013 as and at Section 13.9 of the Articles of the Company; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.2pt"></TD><TD STYLE="width: 35pt">2.</TD><TD STYLE="text-align: justify; padding-right: 76.4pt">any one or more of the directors or officers of the Company be authorized
to take all such actions, do such things and execute and deliver, whether under the common seal of the Company or otherwise, all
such agreements, instruments, statements, forms and other documents as they may be advised by counsel so to do in connection with
this alteration of the Articles.&rdquo;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 9.15pt 0 0 40.85pt">CERTIFIED A TRUE COPY as of the 14th day of May, 2013.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in"><U>/s/ Hector MacKay-Dunn</U></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in">Hector MacKay-Dunn</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in">Title: Corporate Secretary</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 253.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.55pt 0 0 2.35pt"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.55pt 0 0 2.35pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT &ldquo;B&rdquo; TO THE INFORMATION
CIRCULAR OF TEKMIRA PHARMACEUTICALS CORPORATION</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 3.75pt 0 0 5.95pt">Nominations of Directors</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.85pt"></TD><TD STYLE="width: 35.2pt">13.9</TD><TD STYLE="text-align: justify; padding-right: 5.8pt">Only persons who are nominated in accordance with the following procedures
shall be eligible for election as directors of the Company. Nominations of persons for election to the board of directors of the
Company may be made at any annual general meeting of shareholders, or at any special meeting of shareholders if one of the purposes
for which the special meeting was called was the election of directors:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.8pt"></TD><TD STYLE="width: 17.6pt">(a)</TD><TD>by or at the direction of the board, including pursuant to a notice of meeting;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.65pt"></TD><TD STYLE="width: 17.75pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 6.45pt">by or at the direction or request of one or more shareholders pursuant to
a proposal made in accordance with the Act, or a requisition of the shareholders made in accordance with the provisions of the
Act; or</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.8pt"></TD><TD STYLE="width: 17.25pt">(c)</TD><TD STYLE="text-align: justify; padding-right: 5.95pt">by any person (a &ldquo;Nominating Shareholder&rdquo;): (A) who, at the
close of business on the date of the giving by the Nominating Shareholder of the notice provided for below in this Section 13.9
and at the close of business on the record date for notice of such meeting, is entered in the securities register of the Company
as a holder of one or more shares carrying the right to vote at such meeting or who beneficially owns shares that are entitled
to be voted at such meeting; and (B) who complies with the notice procedures set forth below in this Section 13.9.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5pt; margin: 0 6.2pt 0 41.85pt">In addition to any other requirements
under applicable laws, for a nomination to be made by a Nominating Shareholder, the Nominating Shareholder must have given notice
thereof that is both timely (in accordance with this Section 13.9) and in proper written form (in accordance with this Section
13.9) to the Secretary of the Company at the principal executive offices of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 42.2pt">To be timely, a Nominating Shareholder&rsquo;s notice to
the Secretary of the Company must be made:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.45pt"></TD><TD STYLE="width: 17.6pt">(a)</TD><TD STYLE="text-align: justify; padding-right: 6.2pt">in the case of an annual general meeting of shareholders, not less than 30
nor more than 65 days prior to the date of the annual general meeting of shareholders; provided, however, that in the event that
the annual general meeting of shareholders is to be held on a date that is less than 50 days after the date (the &lsquo;&lsquo;Notice
Date&rdquo;) on which the first public announcement of the date of the annual general meeting was made, notice by the Nominating
Shareholder may be made not later than the close of business on the tenth (10th) day following the Notice Date; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.25pt"></TD><TD STYLE="width: 17.8pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 6.5pt">in the case of a special meeting (which is not also an annual general meeting)
of shareholders called for the purpose of electing directors (whether or not called for other purposes), not later than the close
of business on the fifteenth (15th) day following the day on which the first public announcement of the date of the special meeting
of shareholders was made.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.2pt; margin: 0 6.55pt 0 42.05pt">The time periods for the giving
of a Nominating Shareholder&rsquo;s notice set forth above shall in all cases be determined based on the original date of the applicable
annual meeting or special meeting of shareholders,</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.1pt 123.5pt 0 124.25pt"></P>

<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.1pt 123.5pt 0 124.25pt"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.35pt; margin: 9.75pt 6.85pt 0 41.4pt">and in no event shall any
adjournment or postponement of a meeting of shareholders or the announcement thereof commence a new time period for the giving
of such notice.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 41.55pt">To be in proper written form, a Nominating Shareholder&rsquo;s
notice to the Secretary of the Company must set</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0.3pt 0 0 41.55pt">forth:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.9pt"></TD><TD STYLE="width: 17.6pt">(a)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">as to each person whom the Nominating Shareholder proposes to nominate for
election as a director: (A) the name, age, business address and residential address of the person; (B) the principal occupation
or employment of the person, and the principal occupation or employment of the person for the past 5 years; (C) the citizenship
of such person; (D) the class or series and number of shares in the capital of the Company which are controlled or which are owned
beneficially or of record by the person as of the record date for the meeting of shareholders (if such date shall then have been
made publicly available and shall have occurred) and as of the date of such notice; and (E) any other information relating to the
person that would be required to be disclosed in a dissident&rsquo;s proxy circular in connection with solicitations of proxies
for election of directors pursuant to the Act and Applicable Securities Laws (as defined below); and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.9pt"></TD><TD STYLE="width: 17.75pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 5.9pt">as to the Nominating Shareholder giving the notice, full particulars regarding
any proxy, contract, agreement, arrangement or understanding pursuant to which such Nominating Shareholder has a right to vote
or direct the voting of any shares of the Company and any other information relating to such Nominating Shareholder that would
be required to be made in a dissident&rsquo;s proxy circular in connection with solicitations of proxies for election of directors
pursuant to the Act and Applicable Securities Laws (as defined below).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 6.25pt 0 41.4pt">The Company may require any proposed nominee to furnish
such other information as may reasonably be required by the Company to determine the eligibility of such proposed nominee to serve
as an independent director of the Company or that could be material to a reasonable shareholder&rsquo;s understanding of the independence,
or lack thereof, of such proposed nominee.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.4pt; margin: 0 5.95pt 0 41.2pt">No person shall be eligible for
election as a director of the Company unless nominated in accordance with the provisions of this Section 13.9; provided, however,
that nothing in this Section 13.9 shall be deemed to preclude discussion by a shareholder (as distinct from the nomination of directors)
at a meeting of shareholders of any matter that is properly before such meeting pursuant to the provisions of the Act or the discretion
of the Chairman. The Chairman of the meeting shall have the power and duty to determine whether a nomination was made in accordance
with the procedures set forth in the foregoing provisions and, if any proposed nomination is not in compliance with such foregoing
provisions, to declare that such defective nomination shall be disregarded.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 41.05pt">For purposes of this Section 13.9:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.7pt"></TD><TD STYLE="width: 17.8pt">(a)</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">&ldquo;public announcement&rdquo; shall mean disclosure in a press release
reported by a national news service in Canada, or in a document publicly filed by the Company under its profile on the System for
Electronic Document Analysis and Retrieval at www.sedar.com; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.5pt"></TD><TD STYLE="width: 17.8pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 6.4pt">&ldquo;Applicable Securities Laws&rdquo; means the applicable securities
legislation of each relevant province and territory of Canada, as amended from time to time, the rules, regulations and forms made
or promulgated under any such statute and the published national instruments, multilateral</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 122pt 0 124.25pt"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 2.6pt 122pt 0 124.25pt"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 9.8pt 0 0 77.3pt">instruments, policies, bulletins and notices of the securities commission
and similar regulatory authority of each province and territory of Canada.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 5.25pt 0 41.3pt">Notwithstanding any other provision of this Section
13.9 and the Articles, notice given to the Secretary of the Company pursuant to this Section 13.9 may only be given by personal
delivery, facsimile transmission or by email (at such email address as may be stipulated from time to time by the Secretary of
the Company for purposes of this notice), and shall be deemed to have been given and made only at the time it is served by personal
delivery to the Secretary of the Company at the principal executive offices of the Company, email (at the address as aforesaid)
or sent by facsimile transmission (provided that receipt of confirmation of such transmission has been received); provided that
if such delivery or electronic communication is made on a day which is a not a business day or later than 5:00 p.m. (Vancouver
time) on a day which is a business day, then such delivery or electronic communication shall be deemed to have been made on the
next following day that is a business day.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -1.45pt; margin: 0 5.9pt 0 42.7pt">Notwithstanding the foregoing,
the Board may, in its sole discretion, waive any requirement in this Section 13.9.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: right">RECEIVED FOR DEPOSIT AT THE RECORDS OFFICE ON MARCH 4, 2015.</P>

<P STYLE="font-size: 10pt; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 141.05pt 0 133.8pt">TEKMIRA PHARMACEUTICALS CORPORATION</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 6.55pt 0 0">(&ldquo;Tekmira&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 1.4pt; margin: 0.35pt 139.6pt 0 132.35pt">ORDINARY RESOLUTION PASSED
BY THE SHAREHOLDERS OF TEKMIRA AT THE SPECIAL MEETING OF THE SHAREHOLDERS HELD ON MARCH 3, 2015 CALLED TO CONSIDER AND APPROVE
AN AGREEMENT AND PLAN OF MERGER, DATED JANUARY 11, 2015 (THE &ldquo;MERGER AGREEMENT&rdquo;), BY AND AMONG TEKMIRA, TKM ACQUISITION
CORPORATION, A WHOLLY OWNED SUBSIDIARY OF TEKMIRA, AND ONCORE BIOPHARMA, INC. ALL AS MORE PARTICULARLY DESCRIBED IN THE NOTICE
OF MEETING DATED FEBRUARY 4, 2015 AND THE PROXY STATEMENT/INFORMATION CIRCULAR ATTACHED THERETO, AND AN AMENDMENT TO THE ARTICLES
OF TEKMIRA AS SET OUT IN ANNEX C TO THE NOTICE OF MEETING, A COPY OF WHICH IS ATTACHED TO AND FORMS PART OF THIS CERTIFIED RESOLUTION</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 31.9pt; margin: 0 76.6pt 0 68.55pt">&ldquo;BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT,
UPON THE MERGER BECOMING EFFECTIVE AS CONTEMPLATED IN THE MERGER AGREEMENT:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 101.85pt"></TD><TD STYLE="width: 14.3pt">1.</TD><TD STYLE="text-align: justify; padding-right: 76.2pt">the Articles of Tekmira be altered by adding the text substantially in the
form attached as Annex C to this proxy statement/information circular;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.3pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 100.3pt"></TD><TD STYLE="width: 15.65pt">2.</TD><TD STYLE="text-align: justify; padding-right: 76.4pt"><FONT STYLE="font-size: 10pt">the Articles of Tekmira be altered by removing
the right of the chair to a second or casting vote at a meeting of the board of directors of Tekmira; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99.95pt"></TD><TD STYLE="width: 15.85pt">3.</TD><TD STYLE="text-align: justify; padding-right: 76.2pt"><FONT STYLE="font-size: 10pt">any one or more of the directors or officers
of Tekmira be authorized to take all such actions, do such things and execute and deliver, whether under the common seal of Tekmira
or otherwise, all such agreements, instruments, forms and other documents as they may be advised by counsel so to do in connection
with this alteration of the Articles.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 2.6pt 0 0 99.95pt">CERTIFIED A TRUE COPY as of the 4th day of March, 2015</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 362.8pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 289.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in"><U>/s/ Hector MacKay-Dunn</U></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in">Hector MacKay-Dunn</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in">Title: Corporate Secretary</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0.4pt; text-align: center; margin-bottom: 0">AMENDMENT TO TEKMIRA PHARMACEUTICALS CORPORATION ARTICLES OF INCORPORATION</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 3.15pt 92.2pt 0 87pt">Part 18.2</P>

<P STYLE="font-size: 10pt; margin: 8.05pt 83.7pt 0 78.1pt">Questions arising at any meeting of directors are to be decided by a
majority of votes (subject to Part 27), and, in the case of an equality of votes, the chair of the meeting shall not have a second
(or casting) vote.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 8.05pt 93.1pt 0 86.85pt">Part 27 &ndash; Transitional Governance Matters</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.15pt; margin: 7.7pt 83.45pt 0 77.75pt">Notwithstanding any other
provision of the Articles, for a period commencing upon the effective date of the merger (the &ldquo;Merger&rdquo;) between TKM
Acquisition Corporation, a wholly-owned subsidiary of the Company, and OnCore Biopharma, Inc., a Delaware corporation, undertaken
pursuant to an Agreement and Plan of Merger and Reorganization dated January 11, 2015, and ending upon the earlier of (i) thirty
six (36) months following the effective date of the Merger and (ii) when RS no longer has a right to nominate one or more directors
under Section 1 of this Part 28, the following provisions shall apply:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 7.65pt 0 0 77.9pt"><U>Supermajority Matters</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.5pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.15pt"></TD><TD STYLE="width: 13.9pt">l.</TD><TD STYLE="text-align: justify; padding-right: 83.2pt">Any one of the following matters shall require the approval of at least
seventy percent (70%) of the number of directors then in office, whether such approval is given by way of a vote at a meeting of
directors or by written consent:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 8.25pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.4pt"></TD><TD STYLE="width: 16.05pt">(a)</TD><TD>the removal or replacement of the chair of the board of directors of the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.75pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.4pt"></TD><TD STYLE="width: 15.7pt">(b)</TD><TD>the removal or replacement of the chief executive officer of the Company,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.4pt"></TD><TD STYLE="width: 16.05pt">(c)</TD><TD STYLE="text-align: justify; padding-right: 83.55pt">subject to Part 28, the nomination of a director for election to the board
of directors of the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.75pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.7pt"></TD><TD STYLE="width: 15.85pt">(d)</TD><TD STYLE="text-align: justify; padding-right: 83.5pt">subject to Part 28, the appointment of a director to the board of directors
of the Company to fill a vacancy created by the resignation or death of a director;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.95pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.05pt"></TD><TD STYLE="width: 16.05pt">(e)</TD><TD STYLE="text-align: justify; padding-right: 83.95pt">subject to Part 28, the appointment of an additional director to the board
of directors of the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 7.7pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108pt"></TD><TD STYLE="width: 15.7pt">(f)</TD><TD STYLE="text-align: justify; padding-right: 83.95pt">any take-over bid, issuer bid, amalgamation, plan of arrangement, business
combination, merger, tender offer, exchange offer, consolidation, recapitalization, reorganization, liquidation, dissolution or
winding-up in respect of, or involving, the Company or any subsidiary of the Company;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.05pt"></TD><TD STYLE="width: 15.85pt">(g)</TD><TD STYLE="text-align: justify; padding-right: 83.7pt">any sale or issuance of shares of the Company or other equity interests
in the Company (or rights, interests or securities convertible into or exercisable for such shares or other equity interests),
in one or more connected transactions, which would be greater than 5% of the outstanding shares of stock of the company, other
than the grant or issuance of such equity interests in connection with any stock-based compensation plan or plans approved by the
board of directors of the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 8.45pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.2pt"></TD><TD STYLE="width: 15.9pt">(h)</TD><TD STYLE="text-align: justify; padding-right: 83.9pt">any sale of assets (or any strategic alliance, joint venture, license or
other arrangement having the same economic effect as a sale) of the Company or any subsidiary of the Company representing a transaction
value and/or payments greater than $10 million;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 8.75pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.2pt"></TD><TD STYLE="width: 16.05pt">(i)</TD><TD STYLE="text-align: justify; padding-right: 84pt">ceasing or abandoning any research, development or commercialization efforts
that were publicly disclosed by the Company as having been underway as at the effective date of the</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 4.65pt 0 0 14.8pt"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 60.25pt 0 124.1pt"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 60.25pt 0 124.1pt">Merger, or declining to advance the development or commercialization of
such programs, whether by failing to continue to fund such programs or otherwise;</P>

<P STYLE="font-size: 10pt; margin: 7.45pt 0 0 108.65pt">(j) incurring any indebtedness or third party guarantees in excess of $5,000,000
individually or</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 123.7pt">$10,000,000 in the aggregate; or</P>

<P STYLE="font-size: 10pt; text-indent: 0.35pt; margin: 7.3pt 60.25pt 0 108.5pt">(k) any amendment or proposed amendment to the
Articles or Notice of Articles of the Company, (collectively referred to as &ldquo;Supermajority Matters&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0.8pt 0 0 78.6pt">Inconsistencies</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 93.2pt"></TD><TD STYLE="width: 15.45pt">2.</TD><TD STYLE="padding-right: 85.5pt">In the event of an inconsistency between a provision of this Part 27 and any other provision
of these Articles, the provision of this Part 27 shall prevail.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 8.45pt 0 0 78.05pt">Alterations of Part 27 and Section 18.2</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 8.3pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 93.45pt"></TD><TD STYLE="width: 14.7pt">3.</TD><TD>This Part 27 and Section 18.2 may only be amended by special resolution.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Part 28- Director Election Matters</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 3.65pt 0 0 108.5pt">In this Part, the following terms shall have the meaning
assigned to them below:</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.15pt; margin: 0 85.8pt 0 108.15pt">&ldquo;Calculated on an Undiluted
Basis&rdquo; means calculated before giving effect to the exercise, conversion or exchange of any securities exercisable for, convertible
into, or exchangeable for, Company Shares;</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 86.3pt 0 108.3pt">&ldquo;Company Shares&rdquo; means the common shares
in the capital of the Company as constituted on the date hereof;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 86.5pt 0 108.3pt">&ldquo;Record Date Notice&rdquo; means the date of
the letter filed on SEDAR by the Company&rsquo;s registrar and transfer agent giving notice of the record date for determination
of the shareholders entitled to notice of and to vote at any Shareholder Meeting; and &middot;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.2pt; margin: 0 85.7pt 0 108.3pt">&ldquo;Shareholder Meeting&rdquo;
means an annual general meeting of shareholders or special meeting of shareholders of the Company called for the purpose of electing
directors to the board of directors of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 77.6pt"><U>Election of Directors</U></P>

<P STYLE="font-size: 10pt; text-indent: 12.9pt; margin: 8.75pt 104.65pt 0 96.4pt">1.&#9;For so long as Roivant Sciences Ltd. ((the
&ldquo;Nominating Shareholder&rdquo; or &ldquo;RS&rdquo;) has &ldquo;beneficial ownership&rdquo; (as defined pursuant Rule 13d-3
under&middot;the United States, Securities Exchange Act of 1934, as amended) (&ldquo;Beneficial Ownership&rsquo;&rsquo;) owns or
exercises control or direction over not less than:</P>

<P STYLE="font-size: 10pt; text-indent: 11.6pt; margin: 8.15pt 95pt 0 96.6pt">(a)&#9;twenty- percent (20%) of the issued and outstanding
Company Shares Calculated on an Undiluted Basis as at the Record Date Notice, RS has the right to nominate two (2) individuals
for election to the board of directors at the Company at each Shareholder Meeting; and</P>

<P STYLE="font-size: 10pt; text-indent: 11.45pt; margin: 8.3pt 99.4pt 0 96.8pt">(b )&#9;ten percent (10%) of the issued and outstanding
Company Shares Calculated on an Undiluted Basis as at the Record Date Notice, RS has the right to nominate one (1) individual for
election to the board of directors of the Company at each Shareholder Meeting,</P>

<P STYLE="font-size: 10pt; margin: 7.45pt 0 0 96.6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 11.45pt; margin: 8.3pt 99.4pt 0 96.8pt">(where such designee directors are referred to as the &ldquo;RS Nominated Directors&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 30.95pt; margin: 8.85pt 1.2in 0 77.1pt">2.&#9;Upon the Nominating Shareholder having Beneficial
Ownership or exercising control or direction over less than ten percent (10%) of the outstanding Company Shares Calculated on an
Undiluted Basis as at the Record Date Notice, the nomination rights provided under Section 1 will be of no further force and effect.</P>

<P STYLE="font-size: 10pt; margin: 7.75pt 0 0 77.8pt"><U>Number of Directors</U></P>

<P STYLE="font-size: 10pt; text-indent: 30.8pt; margin: 7.7pt 90.05pt 0 77.1pt">3.&#9;For so long a. the Nominating Shareholder
has the right to nominate one or more directors under Section 1 of this Part 28, the number of directors of the Company shall not
exceed seven (7) directors without the prior written consent of the Nominating Shareholder.</P>

<P STYLE="font-size: 10pt; margin: 8.8pt 0 0 77.25pt">Nomination Procedure</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 4.4pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 92.5pt"></TD><TD STYLE="width: 15.75pt">4.</TD><TD STYLE="padding-right: 1.2in">For so long as the Nominating Shareholder has a right to nominate one or more directors under
Section I of this Part 28:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.05pt"></TD><TD STYLE="width: 30.65pt">(a)</TD><TD STYLE="text-align: justify; padding-right: 84.85pt">No earlier than ninety (90) days and no later than sixty (60) days prior
to the date of each Shareholder Meeting, the Company shall notify RS in writing of the date of the Shareholder Meeting (the &ldquo;Company
Notice&rdquo;). The Company Notice shall specify the total number of Company Shares issued and outstanding Calculated on an Undiluted
Basis as at the Record Date Notice.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108.25pt"></TD><TD STYLE="width: 30.25pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 84.55pt">RS shall have the right and option, exercisable within fifteen (15) days
from receipt of the Company Notice (the &ldquo;Nomination Right Notice Period&rdquo;) by written notice to the Company (the &ldquo;Nomination
Notice&rdquo;) to exercise the Nomination Right. If RS wishes to exercise the Nomination Right, RS must specify in the Nomination
Notice (i) the number of Company Shares beneficially owned by the Nominating Shareholder as at the date of the Nomination Notice,
(ii) the name of the individual(s) RS wishes to nominate for election to the board of directors of the Company, and (iii) confirm
that the nominee(s) are eligible to act as director(s) under the Act or, if the Company is otherwise governed by another statue
or regime, that the nominee(s) arc eligible to act as a director under such statute or regime. As soon as reasonably possible after
the request by the Company, duly completed forms and only other information in respect of the RS Nominated Directors, as required
by the relevant stock exchange, shall be provided by the RS Nominated Directors.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 5.1pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.85pt; margin: 5pt 86.95pt 0 137.25pt">(c)&#9;If RS fails to deliver
a Nomination Notice in response to a Company Notice within the Nomination Right Notice Period, then the Company will not be required
to nominate individuals identified by RS for election to the board of directors of the Company at the Shareholder Meeting with
respect to which RS failed to deliver the Nomination Notice,and RS shall have the right to nominate person(s) for election to the
board of directors of the Company at the next Shareholder Meeting in accordance with this Part 28.</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 106.65pt"></TD><TD STYLE="width: 30.45pt">(d)</TD><TD STYLE="text-align: justify; padding-right: 86.1pt">If RS delivers a Nomination Notice in response to a Company Notice within
the Nomination Right Notice Period then, subject only to the nominee(s) identified in the Nomination Notice being eligible to act
as director(s) of the Company, the Company shall (i) nominate the RS nominee(s) to stand for election to the board of directors
of the Company at the Shareholder Meeting, and (ii) solicit proxies from the holders of Company Shares in respect thereof which
will be satisfied by delivery of a form of proxy to the holders of Company Shares following standard procedures consistent with
past practice. For greater certainty, the Company (x) shall not be required to retain a third party solicitation agent, and (y)
shall include the name of the RS nominee(s) to stand for election to the board of directors of the Company in the proxy to be delivered
to each holder of Company Shares in respect of the Shareholder Meeting. The Nominating Shareholder shall also provide to the Company
such other information regarding the RS nominee(s) as may be reasonably requested by the Company so as to comply with applicable
proxy disclosure requirements under applicable securities laws, together with such other information, including a biography of
the RS Nominated Directors, that is consistent with the information the Company intends to publish about management nominees as
directors of the Company in the information circular to be prepared by the Company in connection with the election of directors
at a Shareholder Meeting.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 76.2pt">Casual Vacancies</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 91.05pt"></TD><TD STYLE="width: 15.05pt">5.</TD><TD STYLE="text-align: justify; padding-right: 87.05pt">In the event that an RS Nominated Director resigns, dies, becomes incapacitated
or otherwise ceases to be a director prior to the expiration of his or her term as a director, such vacancy on the board of directors
shall be filled by the remaining directors with the nominee identified by RS promptly. The Company shall use all commercially reasonable
steps, promptly upon receipt by it of a written notice from RS to fill such vacancy, as are necessary to call (no later than five
(5) days following notice of such identified nominee by RS) a meeting of the board of directors to vote on the appointment of such
Shareholder Designee to fill such vacancy (or to obtain a vote of the directors by way of unanimous written resolution) and take
all such other steps as are required by the Act with respect to such appointment.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 75.65pt">Transitional Period</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 90.5pt"></TD><TD STYLE="width: 15.75pt">6.</TD><TD STYLE="text-align: justify; padding-right: 87.5pt">This Part 28 shall remain in effect until the date that is the earlier of
(i) thirty-six (36) months following the effective date of the Merger and (ii) when RS no longer has a right to nominate one or
more directors under Section 1 of this Part 28.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 8.25pt 0 0 76pt">Inconsistencies</P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 90.7pt"></TD><TD STYLE="width: 15.4pt">7.</TD><TD STYLE="text-align: justify; padding-right: 87.3pt">In the event of an inconsistency between a provision of this Part 28 and
any other provision of these Articles, the provision of this Part 28 shall prevail.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"></P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: -7.5pt; margin: 3.75pt 9.5pt 0 323.35pt"><I>RECEIVED FOR DEPOSIT AT
THE RECORDS OFFICE ON</I></P>

<P STYLE="font-size: 10pt; text-indent: 244.55pt; margin: 0.05pt 0 0 102.6pt"><I>JULY 1O, 2015</I></P>

<P STYLE="font-size: 10pt; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 79.85pt 0 77.5pt">TEKMIRA PHARMACEUTICALS CORPORATION</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0.1pt 80.45pt 0 77.5pt">(the &ldquo;Company&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 80.75pt 0 77.5pt">ORDINARY RESOLUTION PASSED BY THE SHAREHOLDERS OF THE
COMPANY AT THE ANNUAL MEETING OF THE SHAREHOLDERS COMPANY HELD ON .JU LY 9, 2015</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 7.35pt">&ldquo;Section 1 1.3 of the Articles of Tekmira be deleted
and replaced in entirety with the following:</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.4pt; margin: 0 11.05pt 0 7.15pt">I 1 .3 Subject to the special rights
and restrictions attached to the shares of any class or series of shares, and to &sect;I 1 .4, the quorum for the transaction of
business at a meeting of shareholders is at least two people who arc, or who represent by proxy, one or more shareholders who,
in the aggregate, hold at least five percent (5%) of the issued shares entitled to be voted at the meeting: provided, however,
that for so long as any class or series of shares is listed for trading on NASDAQ. then:</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -33.95pt; margin: 0 11.15pt 0 40.75pt">(a) the quorum for the transaction
of business at a meeting of shareholders of the Company is at least two people who are, or who represent by proxy, one or more
shareholders who, in the aggregate, hold at least thirty three and one-third percent (33 1/3%) of the issued shares entitled to
be voted at the meeting (the &ldquo;NASDAQ Quorum&rsquo;&ldquo;), and all references in the Articles to a &lsquo;&lsquo;quorum&rdquo;
in Part 1 1 shall be deemed to refer to the NASDAQ Quorum:</P>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.8pt"></TD><TD STYLE="width: 33.95pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 11.1pt">where a separate vote by class or series or classes or series of shares
is required at a meeting of shareholders of the Company. the presence. in person or by proxy, of the holders of at least the NASDAQ
Quorum of the issued and outstanding shares of each such class or series shall also be required to constitute a NASDAQ Quorum:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.65pt"></TD><TD STYLE="width: 34.1pt">(c)</TD><TD STYLE="text-align: justify; padding-right: 12.15pt">if a NASDAQ Quorum is present at an original meeting. a NASDAQ Quorum need
not be present at an adjourned session of that meeting: and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.45pt"></TD><TD STYLE="width: 34.3pt">(d)</TD><TD STYLE="text-align: justify">Neither &sect;l l.7(b) nor &sect;1 1.8 shall have any force or effect.&rdquo;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.6pt">CERTIFIED A TRUE COPY as of the 10th day of July, 2015.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in"><U>/s/ Hector MacKay-Dunn</U></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in">Hector MacKay-Dunn</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3.5in">Title: Corporate Secretary</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 243.65pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 243.65pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 243.65pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">- 10 -</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0 0 12pt; background-color: white">Exhibit 10.1</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">Confidential treatment has been requested for
portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated
as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0; background-color: white">EXECUTION VERSION</P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"><B><U>FIRST AMENDMENT TO <FONT STYLE="font-variant: small-caps">PROTIVA-MONSANTO
SERVICES AGREEMENT</FONT></U></B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 20pt; margin: 0 0 12pt; background-color: white">This FIRST AMENDMENT
TO PROTIVA-MONSANTO SERVICES AGREEMENT (this &ldquo;<B><U>First Amendment</U></B>&rdquo;), dated as of May 22, 2015, is by and
among <B>Protiva Biotherapeutics, Inc.</B>, a British Columbia corporation and a wholly-owned subsidiary of Tekmira Pharmaceuticals
Corporation, a British Columbia corporation, (&ldquo;<B><U>Protiva</U></B>&rdquo;), <B>Protiva Agricultural Development Company
Inc. </B>(&ldquo;<B>PadCo&rdquo;)</B>, a British Columbia<B> </B>corporation and a wholly-owned subsidiary of Protiva (the &ldquo;<B><U>Company</U></B>&rdquo;),
and <B>Monsanto Company</B>, a Delaware corporation (&ldquo;<B><U>Monsanto</U></B>&rdquo;). Protiva, the Company and Monsanto are
sometimes referred to herein individually as a &ldquo;<B><U>Party</U></B>&rdquo; and collectively as the &ldquo;<B><U>Parties</U></B>&rdquo;.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: transparent">WHEREAS, the
Parties are parties to that certain Protiva-Monsanto Services Agreement, dated as of January 12, 2014 (the &ldquo;<B><U>Services
Agreement</U></B>&rdquo;) pursuant to which Monsanto agreed to provide Services relating to the evaluation of Compounds and/or
Formulations according to the Research Plan in in exchange for payment for such Services from Protiva; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: transparent">WHEREAS, concurrent
with the execution of this First Amendment, the Parties are entering into an amendment of that certain Option Agreement dated as
of January 12, 2014 (the &ldquo;<B><U>Third Amendment to Option Agreement</U></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: transparent">NOW, THEREFORE,
in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and
subject to the conditions set forth herein, the Parties agree as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><FONT STYLE="text-transform: uppercase"><B>1.</B></FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><B><U>Amendment
                                         to Article 3</U></B>.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 75pt; text-align: right">(a)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><U>Section 3.1(a)</U> of the Services Agreement is hereby amended by restating such
Section to read in its entirety as follows:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">&ldquo;</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">(a)&#9;Protiva will make the following payments to Monsanto:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 75pt; text-align: right">(i)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">[***] in research funding during Phase A of the Services as described in the Research
Plan, such amount to be paid by Protiva in four equal installments, with the first such installment due within fifteen (15) days
of the Effective Date, and the remaining three installments payable within fifteen (15) days of the end of the third, sixth, and
ninth full month, respectively, immediately following the Effective Date, an additional [***] in research funding during either
the Phase A Extension Election Period or the Phase A Extension Period (in each case, as defined in the Third Amendment to Option
Agreement) of the Services as described in the Amended Research Plan, such amount to be paid by Protiva within fifteen (15) Business
Days of the receipt of an invoice for such amount;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 75pt; text-align: right">(ii)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">[***] in research funding during Phase B as described in the Research Plan, if Phase
B is initiated pursuant to Section 2(e)(iii) of the Option Agreement, such amount to be paid by Protiva in four equal installments,
with the first such installment due within fifteen (15) days of Monsanto&rsquo;s payment to Protiva of the Option Phase B Initiation
Payment, and the remaining three installments payable within fifteen (15) days of the end of the third, sixth, and ninth full
month, respectively, immediately following the date of such Option Phase B Initiation Payment; and</TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 0.5in; background-color: transparent"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 75pt; text-align: right">(iii)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">[***] in research funding during Phase C as described in the Research Plan, if Phase
C is initiated pursuant to Section 2(e)(iv) of the Option Agreement, such amount to be paid by Protiva in four equal installments,
with the first such installment due within fifteen (15) days of Monsanto&rsquo;s payment to Protiva of the Option Phase C Initiation
Payment, and the remaining three installments payable within fifteen (15) days of the end of the third, sixth, and ninth full
month, respectively, immediately following the date of such Option Phase C Initiation Payment.&rdquo;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><B><U>Amendment
                                         to Exhibit C</U></B>.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 12pt; font-size: 10pt; text-align: left; background-color: white; text-indent: 60pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>EXHIBIT C &ndash; <FONT STYLE="font-variant: small-caps">MATERIALS TRANSFER TRANSMITTAL</FONT></U> attached to the Services
Agreement is hereby amended, restated and replaced by <U>EXHIBIT C &ndash; <FONT STYLE="font-variant: small-caps">MATERIALS TRANSFER
TRANSMITTAL</FONT></U> attached to this First Amendment.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><U>Miscellaneous</U></TD>
</TR></TABLE>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For all purposes of this First Amendment, all capitalized terms not otherwise defined herein shall
have the meanings given to them in the Services Agreement.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Amendments</U>. Except as set forth in this First Amendment, the Services Agreement, as modified by this First
Amendment, remains in full force and effect.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interpretation</U>. When a reference is made in this First Amendment to an Exhibit or Section, such reference shall be
to an Exhibit attached to or a Section included in the Services Agreement unless otherwise indicated. The headings contained in
this First Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this First
Amendment.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This First Amendment may be executed in one or more counterparts, all of which shall be considered
one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties
and delivered to the other Parties. Delivery of an executed counterpart of this First Amendment by facsimile or other electronic
image scan transmission shall be effective as delivery of an original counterpart hereof.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. <FONT STYLE="color: black">If any one or more of the provisions contained in this First Amendment or
the application of any such provision to any person or circumstance is held invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired
thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties
will in such an instance use their reasonable best efforts to replace the invalid, illegal or unenforceable provision(s) with valid,
legal and enforceable provision(s) which, insofar as practical, implement the purposes of this First Amendment.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; background-color: transparent"></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments and Waivers</U>. Except as otherwise set forth in this First Amendment, this First Amendment may not be modified,
amended or rescinded, in whole or part, except by a written instrument signed by the Parties. No delay or omission by any Party
hereto in exercising any right or power occurring upon any noncompliance or default by any other Party with respect to any of the
terms of this First Amendment will impair any such right or power or be construed to be a waiver thereof. A waiver by any of the
Parties of any of the covenants, conditions or agreements to be performed by the other will not be construed to be a waiver of
any succeeding breach thereof or of any other covenant, condition or agreement herein contained.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 60pt; background-color: transparent">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Applicable Law; Jurisdiction</U>. This First Amendment shall be governed and interpreted in accordance with the substantive
laws of the State of New York, excluding its conflicts of laws principles. In the event any action shall be brought to enforce
or interpret the terms of this First Amendment, the Parties agree that such action will be brought in the State or Federal courts
located in New York, New York. Each of the Parties hereby irrevocably submits with regard to any action or proceeding for itself
and in respect to its property, generally and unconditionally, to the nonexclusive jurisdiction of the aforesaid courts. Each of
the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in
any action or proceeding with respect to this First Amendment, (a) any claim that it is not personally subject to the jurisdiction
of the above-named courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt
or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest
extent permitted by Applicable Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum,
(ii) the venue of such suit, action or proceeding is improper, and (iii) this First Amendment, or the subject matter hereof, may
not be enforced in or by such courts.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent; text-indent: 0.5in">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 24pt; background-color: transparent"><B>IN WITNESS
WHEREOF, </B>the Parties hereto by their duly authorized representatives have caused this First Amendment to be executed and delivered
as of the date first shown above.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PROTIVA Biotherapeutics, Inc.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="width: 29%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>MONSANTO COMPANY</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Robert M. McCarroll, Ph. D.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Vice President, Chemistry Technology</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0 0 48pt 3in; background-color: transparent"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 3in; background-color: transparent">[<I>Signature Page to First Amendment to Services
Agreement</I>]</P>



<P STYLE="font-size: 10pt; margin: 0; background-color: transparent"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent"></P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><FONT STYLE="font-variant: small-caps"><B><U>EXHIBIT
C &ndash; MATERIALS TRANSFER TRANSMITTAL</U></B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 48pt; background-color: transparent"><B>[Attached]</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 10pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 10pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 10pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 10pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 10pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"><B><U>MATERIALS TRANSFER TRANSMITTAL</U></B></P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">[_________] [__], 20[__]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Providing Party:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[Name]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[Address 1]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[Address 2]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Receiving Party:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[Name]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[Address 1]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[Address 2]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">The following list of materials (the &ldquo;<U>Materials</U>&rdquo;) and a description of each
is herewith provided by the Providing Party (named below) to the Receiving Party (named below) along with this Materials Transfer
Transmittal (this &ldquo;<U>Transmittal</U>&rdquo;). These materials are being provided pursuant to the Protiva-Monsanto Services
Agreement (the &ldquo;<U>Agreement</U>&rdquo;), dated as of [____], 2013, by and among Protiva Biotherapeutics, Inc., a Delaware
corporation and a wholly-owned subsidiary of [Tekmira], a Canadian corporation, (&ldquo;<U>Protiva</U>&rdquo;), [AGNEW-CO], a Canadian
[___] and a wholly-owned subsidiary of Protiva (&ldquo;<U>Company</U>&rdquo;), and Monsanto Company, a Delaware corporation (&ldquo;<U>Monsanto</U>&rdquo;).
The Receiving Party acknowledges and agrees that the materials described herein shall be used solely in connection with the performance
of the Services contemplated by the Agreement and the PadCo-Protiva Services Agreement and the licenses for such use provided by
one party to the other. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Agreement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white"><I>[List here the materials and a brief description
of each, including a marking that materials are believed by Providing Party to be confidential information of the providing party
or a third party or any combination thereof, or otherwise. Attach additional pages if needed. </I>]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">The Receiving Party acknowledges receipt of the Materials. The Receiving Party may refuse to accept
the Materials from a Providing Party by promptly returning all applicable Materials to the Providing Party without any use thereof
being made and providing written notice of such return to the Providing Party.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">This Transmittal shall become effective upon the date first written above and shall continue in
full force and effect thereafter and be co-extensive and subject to the Agreement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">This Transmittal may only be terminated in accordance with the provisions of the Agreement. In
the event that the Agreement and this Transmittal are terminated, the Receiving Party will give the Providing Party an inventory
of the Materials in the Receiving Party&rsquo;s possession and at the time of such termination and such remaining Materials shall
be treated as specified in the Agreement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 0.5in; background-color: white"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white"><I>[Note: The materials shipment should be
addressed to, and receipt acknowledged by, the Receiving Party's designee by initialing or executing either (i) duplicate originals
of this Transmittal or (ii) a scanned copy of this Transmittal in &ldquo;PDF&rdquo; or similar digital format, in either case,
with a copy returned to the Providing Party to the attention of the undersigned designee of the Providing Party]</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Providing Party:</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[<B>NAME]</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">By: &#9;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Name:</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Title:</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Address:</P></TD>
    <TD STYLE="width: 52%">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Receiving Party:</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">[<B>NAME]</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">By: &#9;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Name:</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Title:</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0; background-color: white">Address:</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 48pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0; background-color: white"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>exh_102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0 0 12pt; background-color: white">Exhibit 10.2<B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: transparent">Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0; background-color: transparent">EXECUTION VERSION</P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"><B><U>THIRD AMENDMENT TO OPTION AGREEMENT</U></B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">This THIRD AMENDMENT
TO OPTION AGREEMENT (this &ldquo;<B><U>Third Amendment</U></B>&rdquo;), dated as of May 22, 2015, is by and among <B>Monsanto Canada,
Inc.</B>, a Canadian corporation (&ldquo;<B><U>Monsanto Canada</U></B>&rdquo;), <B>Tekmira Pharmaceuticals Corporation</B>, a British
Columbia corporation (&ldquo;<B><U>Tekmira</U></B>&rdquo;), <B>Protiva Biotherapeutics Inc.</B>, a British Columbia corporation
(&ldquo;<B><U>Protiva</U></B>&rdquo;), and <B>Protiva Agricultural Development Company Inc.</B>, a British Columbia corporation
(the &ldquo;<B><U>Company</U></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">WHEREAS, Monsanto
Canada, Tekmira, Protiva and the Company (each a &ldquo;<B><U>Party</U></B>&rdquo; and collectively, the &ldquo;<B><U>Parties</U></B>&rdquo;)
are parties to that certain Option Agreement, dated as of January 12, 2014 (the &ldquo;<B><U>Option Agreement</U></B>&rdquo;) pursuant
to which Protiva granted to Monsanto Canada an option for Monsanto Canada to acquire all of the outstanding capital stock of the
Company from Protiva, and also provided that at the request of Monsanto Canada at the time of giving notice of exercise of that
option, Monsanto Canada may instead elect to be assigned the PadCo-Protiva License and Services Agreement, the Protiva License,
the Company Owned Intellectual Property and the other Company Licensed &nbsp;Intellectual Property, if any, in the manner described
in the Option Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">WHEREAS, in connection
with the signing of the Option Agreement, the Parties attached an exhibit titled &ldquo;Exhibit A, Research Plan&rdquo; (the &ldquo;<B><U>Original
Research Plan</U></B>&rdquo;) to the Option Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">WHEREAS, the Parties
desire to amend, restate and replace the Original Research Plan as hereinafter set forth with a revised research plan attached
hereto as <U>Annex A</U> (the &ldquo;<B><U>Amended and Restated Research Plan</U></B>&rdquo;);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">WHEREAS, the Parties
desire to extend the period during which Phase A of the Original Research Plan <B>is to </B>be completed and to adjust the time
at which certain payments are to be made under the Option Agreement, in each case, as set forth in this Third Amendment;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">WHEREAS, concurrent
with the execution of this Third Amendment, the Parties are entering into an amendment of that certain Protiva-Monsanto Services
Agreement dated as of January 12, 2014.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white">NOW, THEREFORE,
in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and
subject to the conditions set forth herein, the Parties agree as follows:</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="text-transform: uppercase"><B>1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Amendment and Restatement of Exhibit A</U></B>. The Amended and Restated Research Plan attached as <U>Annex
A</U> to this Third Amendment hereby amends, restates and replaces the Original Research Plan in its entirety.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; background-color: white"></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="text-transform: uppercase"><B>2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Amendment to Section 1</U>.</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 1 of the Option Agreement is hereby amended by inserting the following text on the line immediately before the defined
term &ldquo;Board&rdquo;:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;&ldquo;<B><U>Amendment
Effective Date</U></B>&rdquo; means May 22, 2015.&rdquo;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 1 of the Option Agreement is hereby amended by restating the defined term &ldquo;Initiation Payment&rdquo; to read
in its entirety as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;&ldquo;<B><U>Initiation
Payment</U></B>&rdquo; means the Option Phase A Initiation Payment, the Option Phase A-1 Initiation Payment, the Option Phase A-2
Initiation Payment, the Option Phase B Initiation Payment and the Option Phase C Initiation Payment.&rdquo;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="text-transform: uppercase"><B>3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Amendment to Section 2(e)</U>.</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 2(e)(ii)</U> of the Option Agreement is hereby amended by inserting the following text after the final sentence
of such Section:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;No later
than five (5) Business Days following the Amendment Effective Date, Monsanto Canada shall pay to Protiva [***] (the &ldquo;<B><U>Option</U></B><U>
<B>Phase A-1 Initiation Payment</B></U>&rdquo;) by electronic wire as arranged with Protiva to continue Phase A of the Research
Program. No later than five (5) Business Days following [***] Monsanto Canada shall pay to Protiva [***] (the &ldquo;<B><U>Option</U></B><U>
<B>Phase A-2 Initiation Payment</B></U>&rdquo;) by electronic wire as arranged with Protiva to continue Phase A of the Research
Program. The Parties hereby agree that the Research Plan, as amended as of the Amendment Effective Date, provides (i) an option
for Monsanto Canada to extend the date by which Phase A was to have been completed (originally, [***]) by up to an additional [***]
from the Amendment Effective Date (the &ldquo;<B><U>Phase A</U></B><U> <B>Extension</B> <B>Election Period</B></U>&rdquo;), and
(ii) if Monsanto Canada so elects, an extension of an additional [***] commencing from the end of the Phase A Extension Election
Period in which to complete Phase A (the &ldquo;<B><U>Phase A Extension</U></B><U> <B>Period</B></U>&rdquo;).&rdquo;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 2(e)(iii)</U> of the Option Agreement is hereby amended by inserting the following text after the final sentence
of such Section:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;The Parties
agree that the Research Plan, as amended as of the Amendment Effective Date, provides for an extension of the date by which Phase
A is to be completed and as a result also provides for a corresponding adjustment for the date by which Phase B is to<B> </B>be
completed.&rdquo;<B> </B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 2(e)(iv)</U> of the Option Agreement is hereby amended by inserting the following text after the final sentence
of such Section:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;The Parties
agree that the Research Plan, as amended as of the Amendment Effective Date, provides for an extension of the date by which Phase
A is to be completed and as a result also provides for a corresponding adjustment for the date by which Phase C is to be completed.&rdquo;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="text-transform: uppercase"><B>4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Amendment to Section 3(b)</U>.</B></P>



<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; background-color: white"></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 3(b)(v)</U> of the Option Agreement is hereby amended by restating such Section to read in its entirety as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;Monsanto
Canada shall pay to Protiva, within thirty (30) days after receipt of a Milestone Achievement Notice with respect to the Option
Plant Milestone A, [***] (the &ldquo;<B><U>Option</U></B><U> <B>Plant Milestone A Payment</B></U>&rdquo;) by electronic wire as
arranged with Protiva; provided, that upon the payment of the Option Phase A-1 Initiation Payment, the Option Plant Milestone A
Payment shall be reduced to [***].&rdquo;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 3(b)(vi)</U> of the Option Agreement is hereby amended by restating such Section to read in its entirety as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0 0.5in 12pt; background-color: white">&ldquo;Monsanto
Canada shall pay to Protiva, within thirty (30) days after receipt of a Milestone Achievement Notice with respect to the Option
Insect Milestone A, [***] (the &ldquo;<B><U>Option</U></B><U> <B>Insect Milestone A Payment</B></U>&rdquo;) by electronic wire
as arranged with Protiva; provided, that upon the payment of the Option Phase A-1 Initiation Payment, the Option Insect Milestone
A Payment shall be reduced to [***].&rdquo;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="text-transform: uppercase">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Miscellaneous</U></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For all purposes of this Third Amendment, all capitalized terms not otherwise defined herein shall have
the meanings given to them in the Option Agreement.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Amendments</U>. Except as set forth in this Third Amendment, the Option Agreement, as modified by this Third
Amendment, remains in full force and effect.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interpretation</U>. When a reference is made in this Third Amendment to an Exhibit or Section, such reference shall be
to an Exhibit attached to or a Section included in the Option Agreement unless otherwise indicated. The headings contained in this
Third Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Third Amendment.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Third Amendment may be executed in one or more counterparts, all of which shall be considered
one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties
and delivered to the other Parties. Delivery of an executed counterpart of this Third Amendment by facsimile or other electronic
image scan transmission shall be effective as delivery of an original counterpart hereof.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. <FONT STYLE="color: black">If any one or more of the provisions contained in this Third Amendment or
the application of any such provision to any person or circumstance is held invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired
thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties
will in such an instance use their reasonable best efforts to replace the invalid, illegal or unenforceable provision(s) with valid,
legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Third Amendment.</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; background-color: white"><FONT STYLE="color: black"></FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments and Waivers</U>. Except as otherwise set forth in this Third Amendment, this Third Amendment may not be modified,
amended or rescinded, in whole or part, except by a written instrument signed by the Parties. No delay or omission by any Party
hereto in exercising any right or power occurring upon any noncompliance or default by any other Party with respect to any of the
terms of this Third Amendment will impair any such right or power or be construed to be a waiver thereof. A waiver by any of the
Parties of any of the covenants, conditions or agreements to be performed by the other will not be construed to be a waiver of
any succeeding breach thereof or of any other covenant, condition or agreement herein contained.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in; background-color: white">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Applicable Law; Jurisdiction</U>. This Third Amendment shall be governed and interpreted in accordance with the substantive
laws of the State of New York, excluding its conflicts of laws principles. In the event any action shall be brought to enforce
or interpret the terms of this Third Amendment, the Parties agree that such action will be brought in the State or Federal courts
located in New York, New York. Each of the Parties hereby irrevocably submits with regard to any action or proceeding for itself
and in respect to its property, generally and unconditionally, to the nonexclusive jurisdiction of the aforesaid courts. Each of
the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in
any action or proceeding with respect to this Third Amendment, (a) any claim that it is not personally subject to the jurisdiction
of the above-named courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt
or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest
extent permitted by Applicable Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum,
(ii) the venue of such suit, action or proceeding is improper, and (iii) this Third Amendment, or the subject matter hereof, may
not be enforced in or by such courts.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0 0 12pt; background-color: white">[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK]</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: white"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0 0 12pt; background-color: white"><B>IN WITNESS WHEREOF</B>,
the Parties have caused this Third Amendment to be duly executed under seal as of the date first above written.</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>PROTIVA BIOTHERAPEUTICS INC.</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">By: <U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Name:</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Title:</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Address:&#9;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P></TD>
    <TD STYLE="width: 51%">
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">By: <U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Name:</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Title:</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Address:&#9;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>TEKMIRA PHARMACEUTICALS CORPORATION</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">By: <U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Name:</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Title:</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Address:&#9;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P></TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>MONSANTO CANADA, INC.</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">By: <U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>
        <P STYLE="font-size: 10pt; text-indent: -48.9pt; margin: 0 0 0 48.9pt; background-color: white">Name:&nbsp;&nbsp;&nbsp;&nbsp;Robert M. McCarroll, Ph.
        D.</P>
        <P STYLE="font-size: 10pt; text-indent: -48.9pt; margin: 0 0 0 48.9pt; background-color: white">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized Signatory</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">Address:&#9;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0; background-color: white"><B>&nbsp;</B></P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: transparent">[<I>Signature Page to Third Amendment
to Option Agreement</I>]</P>



<P STYLE="font-size: 10pt; margin: 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0; background-color: white"></P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"><FONT STYLE="text-transform: uppercase"><B><U>ANNEX
A</U></B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"><FONT STYLE="text-transform: uppercase"><B>AMENDED
AND RESTATED RESEARCH PLAN</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">(See Attached)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0; background-color: white">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0.15pt 0 0"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 13.95pt 0 0"><FONT STYLE="text-transform: uppercase"><B><U>Amended and Restated
Research Plan</U></B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">[***]<IMG SRC="image_001.gif" ALT="" STYLE="height: 20px; width: 839px"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>exh_103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.</P>



<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"></P>


<DIV STYLE="text-align: right"><FONT STYLE="font: bold 10pt Times New Roman"></FONT></DIV>

<DIV></DIV>

<DIV ALIGN="CENTER">
<TABLE BGCOLOR="white" CELLPADDING="1" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<TR>
<TD COLSPAN="5" WIDTH="72%" STYLE="border-left: black 1.1pt solid; border-top: black 1.1pt solid">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: bold 12pt times new roman">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</FONT></FONT></DIV>
</TD>
<TD WIDTH="3%" STYLE="border-top: black 1.1pt solid">&#160;</TD>
<TD COLSPAN="2" VALIGN="TOP" WIDTH="15%" STYLE="border-left: black 1.1pt solid; border-top: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">1. CONTRACT&#160;ID CODE</FONT></FONT></DIV>
</TD>
<TD COLSPAN="2" WIDTH="10%" STYLE="border-left: black 1.1pt solid; border-top: black 1.1pt solid">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">PAGE OF PAGES</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">&#160;</TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="20%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="2" WIDTH="15%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center"><FONT STYLE="font: 10pt times new roman">&#160;V</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; border-right: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">1</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid; text-align: center; border-left-style: none; border-left-width: medium"><FONT STYLE="font: 10pt times new roman">3</FONT></TD>
</TR><TR>
<TD COLSPAN="3" WIDTH="33%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">2. AMENDMENT/MODIFICATION NO</FONT></FONT></DIV>
</TD>
<TD WIDTH="19%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">3. EFFECTIVE DATE</FONT></FONT></DIV>
</TD>
<TD COLSPAN="2" WIDTH="23%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 8pt times new roman"><FONT STYLE="font: 8pt times new roman">4. <FONT STYLE="display: inline; font: 8pt times new roman">REQUISITION/PURCHASE REQ. NO.</FONT></FONT></FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="3" WIDTH="20%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">5. PROJECT NO. (If applicable)</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD COLSPAN="2" WIDTH="28%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-indent: 0pt; display: block; margin-left: 9pt"><FONT STYLE="display: inline; font: 10pt times new roman"></FONT></DIV>
</TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-align: left; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt">

<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">01-May-2015</FONT></FONT></FONT></DIV>
</DIV>
</TD>
<TD WIDTH="20%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-align: left; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman">&#160;SEE
SCHEDULE</FONT></DIV>
</TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="10%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD COLSPAN="2" WIDTH="28%" STYLE="border-left: black 1.1pt solid; padding-bottom: 2px">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">6. ISSUED BY</FONT></FONT></DIV>
</TD>
<TD WIDTH="5%" STYLE="padding-bottom: 2px">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">CODE</FONT></FONT></DIV>
</TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; padding-bottom: 2px">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">W911QY</FONT></FONT></DIV>
</TD>
<TD COLSPAN="3" WIDTH="28%" STYLE="border-left: black 1.1pt solid; padding-bottom: 2px">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">7.&#160;ADMINISTERED&#160;BY&#160;(If other&#160;than item&#160;6)</FONT></FONT></DIV>
</TD>
<TD WIDTH="10%" STYLE="padding-bottom: 2px">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">CODE</FONT></FONT></DIV>
</TD>
<TD COLSPAN="2" WIDTH="5%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman">W911QY</FONT></DIV>
</TD>
</TR><TR>
<TD COLSPAN="4" VALIGN="TOP" WIDTH="52%" STYLE="border-left: black 1.1pt solid">
<DIV STYLE="text-indent: 0pt; display: block; margin-left: 9pt"><DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">W6QK ACC-APG NATICK</DIV>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><P STYLE="margin: 0"><FONT STYLE="font-size: 8pt">CONTRACTING DIVISION BLDG 1KANSAS STREET</FONT></P>
</DIV>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><P STYLE="margin: 0"><FONT STYLE="font-size: 8pt">NATICK MA01760-5011</FONT></P>


</DIV>
</DIV>
</DIV>
</DIV>
</TD>
<TD COLSPAN="3" VALIGN="TOP" WIDTH="28%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt">W6QK ACC-APG NATICK</FONT><DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 8pt times new roman">110
                                                                                                                          THOMAS JOHNSON DR SUITE#240</FONT>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 8pt times new roman">FREDERICK
                                         MD 21702</FONT><FONT STYLE="font: 10pt times new roman; color: #464249"> </FONT><DIV STYLE="text-indent: 0pt; display: block"></DIV>
</DIV>
</DIV>
</DIV>

<DIV><FONT STYLE="font: 10pt times new roman">&#160;</FONT></DIV>
</TD>
<TD WIDTH="10%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid">&#160;</TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="20%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="10%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD COLSPAN="5" WIDTH="72%" STYLE="border-left: black 1.1pt solid"><DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 12pt times new roman">8.
NAME AND ADDRESS OF CONTRACTOR&#160;&#160;(No., Street, County, State and Zip Code)</FONT></DIV>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt"></DIV>
</DIV>
</TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="4" VALIGN="TOP" WIDTH="25%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">9A. AMENDMENT OF SOLICITATION NO.</FONT></FONT></DIV>
</TD>
</TR>     <TR>
<TD COLSPAN="5" STYLE="border-left: black 1.1pt solid; padding-bottom: 2px; text-indent: 9pt; padding-left: 0pt; margin-left: 9pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">TEKMIRA PHARMACEUTICALS CORPORATION</FONT></FONT></TD>
<TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">&nbsp;</TD>
<TD COLSPAN="4" STYLE="vertical-align: top; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">9B. DATED (SEE ITEM 11)</TD></TR>
<TR STYLE="text-align: left; vertical-align: top">
<TD COLSPAN="5" WIDTH="72%" STYLE="border-left: black 1.1pt solid; padding-bottom: 2px; text-indent: 9pt; padding-left: 0pt; margin-left: 9pt"><FONT STYLE="font: 8pt times new roman">8900 GLENLYON PKY SUITE 100 </FONT>

<DIV STYLE="text-indent: 0pt; display: block; margin-left: 9pt"><FONT STYLE="font: 8pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">BURNABY V5J 5J8</FONT></FONT></DIV>
</TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center"><FONT STYLE="font: 10pt times new roman">&#160;</FONT><FONT STYLE="font: 10pt times new roman">X</TD>
<TD COLSPAN="4" WIDTH="25%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">


</FONT> <FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">10A. MOD. OF CONTRACT/ORDER NO.<DIV STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></DIV>
</FONT></FONT>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; color: #010101">W9113M-10-C-0057</P>



<FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"></TD>
</TR><TR>
<TD COLSPAN="5" VALIGN="TOP" WIDTH="72%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">&#160;</TD>
<TD VALIGN="TOP" WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center"><FONT STYLE="font: 10pt times new roman">X</FONT></TD>
<TD COLSPAN="4" WIDTH="25%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
10B. DATED (SEE ITEM 13)

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">1<FONT STYLE="font-size: 10pt; color: #010101">4
Jul 2010</FONT></FONT></FONT></DIV>
</TD>
</TR><TR>
<TD COLSPAN="5" VALIGN="TOP" WIDTH="72%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="3%" STYLE="text-align: center; border-left: black 1.1pt solid; padding-bottom: 2px"><FONT STYLE="font: 10pt times new roman"></FONT></TD>
<TD COLSPAN="4" WIDTH="25%" STYLE="border-left: black 1.1pt solid; padding-bottom: 2px"><FONT STYLE="font: 10pt times new roman"></FONT></TD>
</TR><TR>
<TD COLSPAN="2" VALIGN="BOTTOM" WIDTH="28%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">CODE&#160;&#160;&#160; </FONT><FONT STYLE="display: inline; font: 10pt times new roman">L8144</FONT></FONT></DIV>
</TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="2" VALIGN="BOTTOM" WIDTH="39%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">FACILITY CODE</FONT></FONT></DIV>
</TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center">&#160;</TD>
<TD COLSPAN="4" WIDTH="25%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"></FONT></FONT></DIV>
</TD>
</TR><TR>
<TD COLSPAN="10" WIDTH="100%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="text-align: center; border-left: black 1.1pt solid"></TD>
<TD COLSPAN="4" WIDTH="69%">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer</FONT></FONT></DIV>
</TD>
<TD WIDTH="3%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="4" WIDTH="15%">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman"><FONT STYLE="display: inline; font-family: wingdings">o </FONT>is extended&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman"><FONT STYLE="display: inline; font-family: wingdings">o</FONT>&#160;&#160; is not extended.</FONT></FONT></FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="8" WIDTH="92%" STYLE="border-bottom: black 1.1pt solid; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt">
<DIV STYLE="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 8pt times new roman"></FONT>

<P STYLE="font-size: 10pt; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-size: 8pt">Offer
must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the
following methods:</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 2.25pt; margin-right: 86.7pt; margin-bottom: 0; text-align: left"><FONT STYLE="font-size: 8pt">(a)
By completing Items 8 and 15, and returning. <U>&#9; </U>copies of the amendment; (b) By acknowledging receipt of this amendment
on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and
amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE
HOUR AND DATE SPECIFIED MAY RESULT IN</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 1.2pt; margin-right: 96.25pt; margin-bottom: 0; text-align: left"><FONT STYLE="font-size: 8pt">REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram
or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the
opening hour and date specified.</FONT></P>



<FONT STYLE="font: 8pt times new roman"></FONT></DIV>
</TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD COLSPAN="8" WIDTH="90%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">12. ACCOUNTING AND APPROPRIATION DATA (If required)</FONT></FONT></DIV>
<DIV STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><B>See Schedule</B></DIV>
</TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="20%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="10%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD COLSPAN="10" WIDTH="100%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center">
<DIV><FONT STYLE="font: 11pt times new roman">13.&#160; THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. </FONT></DIV>

<DIV><FONT STYLE="font: 11pt times new roman">IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.</FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="width: 3%; border-left: black 1.1pt solid; border-right: black 1.1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="9" STYLE="width: 97%; border-bottom: Black 1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:&#160;&#160;(Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; border-right: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="9" WIDTH="97%" STYLE="border-bottom: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriate date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY
OF FAR 43.103.B.</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; border-right: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">X</FONT></TD>
<TD COLSPAN="9" WIDTH="97%" STYLE="border-bottom: black 1.1pt solid">
<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:</FONT></FONT></DIV>
<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">Mutual Agreement by Both Parties</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="text-align: center; border-left: black 1.1pt solid; border-right: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman"></FONT></TD>
<TD COLSPAN="9" WIDTH="97%">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">D. OTHER (Specify type of modification and authority)</FONT></FONT></DIV>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"></FONT></DIV>
</DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; border-right: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="20%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="10%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD COLSPAN="10" WIDTH="100%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman">E.
IMPORTANT:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Contractor&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT><FONT STYLE="font: 10pt wingdings">o</FONT><FONT STYLE="font: 10pt times new roman">&#160;&#160;is
not,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9746;</FONT><FONT STYLE="font: 10pt wingdings"></FONT><FONT STYLE="font: 10pt times new roman">&#160;&#160;
is required to sign this document and return&#160;&#160;&#160;&#160;___<U>&#160;</U>&#160;&#160;&#160;&#160;copies to the issuing
office.</FONT></DIV>
</TD>
</TR><TR>
<TD COLSPAN="10" WIDTH="100%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV ALIGN="JUSTIFY" STYLE="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)</FONT></FONT></DIV>

<DIV ALIGN="JUSTIFY" STYLE="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><P STYLE="font-size: 10pt; margin: 0.15pt 0 0 13.5pt; color: #050705">Modification Control Number:&#9;mmitchel151777</P>
                                                                                   <P STYLE="font-size: 10pt; margin: 0.15pt 0 0 13.5pt; color: #050705">&nbsp;</P>


</DIV>

<DIV STYLE="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"></FONT></FONT></FONT>

<P STYLE="font-size: 10pt; margin: 1.35pt 0 0 13.45pt; color: #010101">The purpose of this modification is to extend the
delivery date of CLIN 0001 to 31 December 2015 at an additional cost and fee of $183,500, as shown in the attached summary of changes.</P>
<P STYLE="font-size: 10pt; margin: 1.35pt 0 0 13.45pt; color: #010101">Proposal dated 08 April 2015 is hereby incorporated in its entirety by
reference.</P>
<P STYLE="font-size: 10pt; margin: 1.35pt 0 0 13.45pt; color: #010101">All other terms and conditions remain the same and in full force and effect.</P>



<FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman"></FONT></FONT></FONT></DIV>
</DIV>

<DIV STYLE="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></DIV>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></DIV>

<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">Except as provided herein, all terms and conditions ofthe document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</FONT></FONT></DIV>
</DIV>
</DIV>
</DIV>
</TD>
</TR><TR>
<TD COLSPAN="4" VALIGN="TOP" WIDTH="52%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">15A. NAME AND TITLE OF SIGNER (Type or print)</FONT></FONT></DIV>
</TD>
<TD COLSPAN="5" WIDTH="43%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</FONT></FONT></DIV>

<DIV STYLE="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><P STYLE="font-size: 10pt; margin-top: 1.3pt; text-align: left; margin-bottom: 0; color: #050705"><FONT STYLE="font-size: 8pt"></FONT></P>



<FONT STYLE="font: 10pt times new roman"></FONT></DIV>
</TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="20%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"></FONT><P STYLE="margin: 0">TEL:
                                         <FONT STYLE="font-size: 8pt"></FONT></P>


</DIV>
</TD>
<TD COLSPAN="4" WIDTH="23%" STYLE="border-bottom: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman">EMAIL:&#160;</FONT><FONT STYLE="font: 8pt times new roman"> </FONT></DIV>
</TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD COLSPAN="3" WIDTH="33%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">15B. CONTRACTOR/OFFEROR</FONT></FONT></DIV>
</TD>
<TD WIDTH="19%" STYLE="border-left: black 1.1pt solid">
<DIV ALIGN="LEFT" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">15C. DATE SIGNED</FONT></FONT></DIV>
</TD>
<TD COLSPAN="3" WIDTH="28%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">16B. <FONT STYLE="display: inline; font: 10pt times new roman">UNITED STATES OF AMERICA</FONT></FONT></TD>
<TD COLSPAN="3" WIDTH="10%" STYLE="text-align: left; border-left: black 1.1pt solid">
<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">16C. DATE SIGNED</FONT></FONT></DIV>
</TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="20%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="3%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="10%" STYLE="border-left: black 1.1pt solid">

<P STYLE="margin: 0"></P>


</DIV>
</TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid; text-align: left">&#160;</TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="3" WIDTH="28%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: left"><FONT STYLE="font: 10pt times new roman">BY</FONT></TD>
<TD WIDTH="10%" STYLE="border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR><TR>
<TD WIDTH="3%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="25%" STYLE="border-bottom: black 1.1pt solid">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block"><FONT STYLE="font: 8pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">(Signature of person authorized to sign)</FONT></FONT></DIV>
</TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="19%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD COLSPAN="3" WIDTH="28%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
<DIV STYLE="text-align: center"><FONT STYLE="font: 8pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">(Signature of Contracting Officer)</FONT></FONT></DIV>
</TD>
<TD WIDTH="10%" STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
<TD WIDTH="5%" STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font: 10pt times new roman">&#160;</FONT></TD>
</TR></TABLE>
</DIV>

<DIV>&#160;</DIV>

<DIV ALIGN="CENTER">
<TABLE BGCOLOR="white" CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<TR>
<TD VALIGN="TOP" WIDTH="25%"><FONT STYLE="font: 10pt times new roman">E<FONT STYLE="display: inline; font: 10pt times new roman">XCEPTION TO SF 30</FONT> </FONT>

<DIV ALIGN="JUSTIFY" STYLE="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">APPROVED BY OIRM 11-84</FONT></FONT></DIV>
</TD>
<TD VALIGN="TOP" WIDTH="50%" STYLE="text-align: center">
<DIV STYLE="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">30-105-04</FONT></FONT></DIV>
</TD>
<TD WIDTH="25%">
<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">STANDARD FORM 30 (Rev. 10-83)</FONT></FONT></DIV>

<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">Prescribed by GSA </FONT></FONT></DIV>

<DIV STYLE="text-indent: 0pt; display: block"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">FAR (48 CFR) 53.243</FONT></FONT></DIV>
</TD>
</TR></TABLE>
</DIV>

<DIV></DIV>

<DIV></DIV>
</DIV>



<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.8pt"></TD><TD STYLE="width: 6.55pt"></TD><TD></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 2.8pt 0 0 55.8pt"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P>



<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 3.65pt 0 0 45pt"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 0 1pt; text-align: right">W9113M-10-C-0057</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 11.55pt; text-align: right">(mmitchel151777)</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">Page 2 of 3</P>


<P STYLE="font-size: 10pt; margin: 3.65pt 0 0 45pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0"><B>SUMMARY OF CHANGES</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0.3pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION A - SOLICITATION/CONTRACT FORM</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 40pt">The total cost of this contract was increased by $183,500.00 from $121,363,697.24
to $121,547,197.24.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">SECTION B - SUPPLIES OR SERVICES AND PRICES</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 20pt">CLIN 0001</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 40pt">The target cost has increased by $[***] from $[***] to $[***]. The target
profit/fee has increased by $[***] from $[***] to $[***].</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 40pt">The total cost of this line item has increased by $183,500.00 from $[***] to
$[***].</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 20pt">SUBCLIN 000107 is added as follows:</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 11%"><font style="font-size: 10pt">ITEM NO</font></td>
    <td style="width: 20%"><font style="font-size: 10pt">SUPPLIES/SERVICES</font></td>
    <td style="width: 13%"><font style="font-size: 10pt">QUANTITY</font></td>
    <td style="width: 11%"><font style="font-size: 10pt">UNIT</font></td>
    <td style="width: 18%"><font style="font-size: 10pt">UNIT PRICE</font></td>
    <td style="width: 27%"><font style="font-size: 10pt">AMOUNT</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">000107</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Job</font></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$0.00</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="6">
        <P STYLE="font-size: 10pt; margin: 0 379.45pt 0 67.95pt">Funding for CLIN 0001 FFP</P>
        <P STYLE="font-size: 10pt; margin: 0 0 0 67.95pt">FOB: Destination</P>
        <P STYLE="font-size: 10pt; margin: 0 0 0 67.95pt">PURCHASE REQUEST NUMBER: 0010618769-0001</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>
        <P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0 0 0 15.65pt">NET AMT</P></td>
    <td style="border-top: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0.2pt 0 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: right; margin: 0 5.25pt 0 0">$0.00</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">
        <P STYLE="font-size: 10pt; margin: 5.2pt 0 0 6.05pt">ACRN AJ</P>
        <P STYLE="font-size: 10pt; margin: 0 0 0 6.05pt">CIN: GFEBS001061876900002</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$183,500.00</font></td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">SECTION E - INSPECTION AND ACCEPTANCE</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"></P>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
</table>
<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 22%"><font style="font-size: 10pt">INSPECT AT</font></td>
    <TD STYLE="width: 17%"><font style="font-size: 10pt">INSPECT BY</font></td>
    <TD STYLE="width: 35%"><font style="font-size: 10pt">ACCEPT AT</font></td>
    <TD STYLE="width: 17%"><font style="font-size: 10pt">ACCEPT BY</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">N/A</td>
    <TD>N/A</td>
    <TD>
        <P STYLE="font-size: 10pt; margin-top: 5.15pt; text-align: left; margin-bottom: 0">N/A</P>
        <P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></P></td>
    <TD>Government</td></tr>
</table>
<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; text-indent: 0.5in"></P>

<P STYLE="margin: 0">The following Acceptance/Inspection Schedule was added for SUBCLIN 000107:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION F - DELIVERIES OR PERFORMANCE</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">The following Delivery Schedule item for CLIN 0001 has been changed from:</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 22%"><font style="font-size: 10pt">DELIVERY DATE</font></td>
    <TD STYLE="width: 17%"><font style="font-size: 10pt">QUANTITY</font></td>
    <TD STYLE="width: 35%"><font style="font-size: 10pt">SHIP TO ADDRESS</font></td>
    <TD STYLE="width: 17%"><font style="font-size: 10pt">UIC</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">30-APR-2015</font></td>
    <TD>&nbsp;</td>
    <TD>
        <P STYLE="font-size: 10pt; margin-top: 5.15pt; text-align: left; margin-bottom: 0">N/A</P>
        <P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">FOB: Destination</P></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 3.65pt 0 0 5pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 1pt; text-align: right">W9113M-10-C-0057</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 11.55pt; text-align: right">(mmitchel151777)</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">Page 3 of 3</P>



<P STYLE="font-size: 10pt; margin: 3.65pt 0 0 5pt"></P>

<P STYLE="font-size: 10pt; margin: 3.65pt 0 0 5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">To:</P>

<P STYLE="font-size: 10pt; margin: 0.1pt 0 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: left"><font style="font-size: 10pt">DELIVERY DATE</font></td>
    <TD STYLE="width: 17%; text-align: left"><font style="font-size: 10pt">QUANTITY</font></td>
    <TD STYLE="width: 35%; text-align: left"><font style="font-size: 10pt">SHIP TO ADDRESS</font></td>
    <TD STYLE="width: 17%; text-align: left"><font style="font-size: 10pt">UIC</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">31-DEC-2015</font></td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">
        <P STYLE="font-size: 10pt; margin-top: 5.15pt; margin-bottom: 0; text-align: left">N/A</P>
        <P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; text-align: left">FOB: Destination</P></td>
    <TD STYLE="text-align: left">&nbsp;</td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; margin-bottom: 0; text-align: left">SECTION G - CONTRACT ADMINISTRATION DATA</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Accounting and Appropriation</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Summary for the Payment Office</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0 25.15pt">As a result of this modification, the total funded amount for this document
was increased by $183,500.00 from $53,069,126.24 to $53,252,626.24.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SUBCLIN 000107:</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Funding on SUBCLIN 000107 is initiated as follows:</P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">ACRN: AJ</font></td>
    <td colspan="2" rowspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">CIN: GFEBS001061876900002</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 53%"><font style="font-size: 10pt">Acctng &nbsp;Data: 097201520160400000265Y0550506255</font></td>
    <TD STYLE="width: 20%"><font style="font-size: 10pt">A.0011315.4.1.3.1</font></td>
    <TD STYLE="width: 18%"><font style="font-size: 10pt">6100.9000021001</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">Increase: $183,500.00</font></td>
    <td colspan="2" rowspan="3">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">Total: $183,500.00</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><font style="font-size: 10pt">Cost Code: A5XAH</font></td></tr>
</table>
<P STYLE="font-size: 10pt; margin-top: 6.6pt; text-align: left; margin-bottom: 0">(End of Summary of Changes)</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>exh_104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<div style="TEXT-ALIGN: right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.4</FONT></DIV>

<DIV>&#160;</DIV>

<DIV>&#160;<P STYLE="font-size: 10pt; margin: 0">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</p></div>


<table bgcolor="white" cellpadding="1" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="5" width="72%" style="BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</font></font></div>
</td>
<td width="3%" style="BORDER-TOP: black 1.1pt solid">&#160;</td>
<td colspan="2" valign="top" width="15%" style="BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1. CONTRACT&#160;ID CODE</font></font></div>
</td>
<td colspan="2" width="10%" style="BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PAGE OF PAGES</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">&#160;</td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="15%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: medium none"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></td>
</tr><tr>
<td colspan="3" width="33%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2. AMENDMENT/MODIFICATION NO</font></font></div>
</td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3. EFFECTIVE DATE</font></font></div>
</td>
<td colspan="2" width="23%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">4. <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">REQUISITION/PURCHASE REQ. NO.</font></font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="20%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">5. PROJECT NO. (If applicable)</font></font></div>
</td>
</tr><tr>
<td colspan="2" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">P00036</font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13-May-2015</font></font></font></div>
</div>
</td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;SEE
SCHEDULE</font></div>
</td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="28%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">6. ISSUED BY</font></font></div>
</td>
<td width="5%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE</font></font></div>
</td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">W911QY</font></font></div>
</td>
<td colspan="3" width="28%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">7.&#160;ADMINISTERED&#160;BY&#160;(If other&#160;than item&#160;6)</font></font></div>
</td>
<td width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE</font></font></div>
</td>
<td colspan="2" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">W9 <font style="font-size: 10pt; color: #0F2844">11</font><font style="font-size: 10pt; color: #2A2326">Q</font><font style="font-size: 10pt; color: #464249">Y</font></font></div>
</td>
</tr><tr>
<td colspan="4" valign="top" width="52%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">W3QKACC-APG
NATICK</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><p style="margin: 0"><font style="font-size: 8pt">CONTRACTING DIVISION BLDG 1KANSAS STREET</font></p>


</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><p style="margin: 0"><font style="font-size: 8pt">NATICK MA 01760-5011</font></p>


</font></font></font></div>
</div>
</div>
</div>
</td>
<td colspan="3" valign="top" width="28%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">W6QKACC-APG
NATICK</font><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">110
             THOMAS JOHNSON DR SUITE #240</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">FREDERICK
                                         MD 21702</font><font style="font: 10pt times new roman; color: #464249"> </font><div style="TEXT-INDENT: 0pt; DISPLAY: block"></div>
</div>
</div>
</div>

<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="5" width="72%" style="BORDER-LEFT: black 1.1pt solid"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 12pt times new roman">8.
NAME AND ADDRESS OF CONTRACTOR&#160;&#160;(No., Street, County, State and Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"></div>
</div>
</td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" valign="top" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9A. AMENDMENT OF SOLICITATION NO.</font></font></div>
</td>
</tr>     <TR>
<TD COLSPAN="5" STYLE="border-left: black 1.1pt solid; padding-bottom: 2px; text-indent: 9pt; padding-left: 0pt; margin-left: 9pt"><FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 8pt times new roman">TEKMIRA PHARMACEUTICALS CORPORATION</FONT></FONT></TD>
<TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">&nbsp;</TD>
<TD COLSPAN="4" STYLE="vertical-align: top; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">9B. DATED (SEE ITEM 11)</TD></TR>
<tr style="text-align: left; vertical-align: top">
<td colspan="5" width="72%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px; TEXT-INDENT: 9pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">8900 GLENLYON PKY SUITE 100 </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">BURNABY V5J 5J8</font></font></div>
</td>
<td width="3%" style="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center"><FONT STYLE="font: 10pt times new roman"></FONT>X</td>
<td colspan="4" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">


</FONT> <FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">10A. MOD. OF CONTRACT/ORDER NO.<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div>
</font></font>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; color: #010101">W191 13M-1O-C-0057</p>



<font style="font: 10pt times new roman"><font style="display: inline; font: 10pt times new roman"></td>
</tr><tr>
<td colspan="5" valign="top" width="72%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">&#160;</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></td>
<td colspan="4" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
10B. DATED (SEE ITEM 13)

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1<font style="font-size: 10pt; color: #010101">4-Jul-2010</font></font></font></div>
</td>
</tr><tr>
<td colspan="5" valign="top" width="72%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></td>
<td colspan="4" width="25%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></td>
</tr><tr>
<td colspan="2" valign="bottom" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CODE&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">L8144</font></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="39%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FACILITY CODE</font></font></div>
</td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid">&#160;</td>
<td colspan="4" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></font></div>
</td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></font></div>
</td>
</tr><tr>
<td width="3%" style="TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid"></td>
<td colspan="4" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer</font></font></div>
</td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o </font>is extended&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&#160;&#160; is not extended.</font></font></font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="8" width="92%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="font: 8pt times new roman"></font>

<p style="font-size: 10pt; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><font style="font-size: 8pt">Offer
must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the
following methods:</font></p>

<p style="font-size: 10pt; margin-top: 2.25pt; margin-right: 86.7pt; margin-bottom: 0; text-align: left"><font style="font-size: 8pt">(a)
By completing Items 8 and 15, and returning. <u>&#9; </u>copies of the amendment; (b) By acknowledging receipt of this amendment
on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and
amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE
HOUR AND DATE SPECIFIED MAY RESULT IN</font></p>

<p style="font-size: 10pt; margin-top: 1.2pt; margin-right: 96.25pt; margin-bottom: 0; text-align: left"><font style="font-size: 8pt">REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram
or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the
opening hour and date specified.</font></p>



<font style="font: 8pt times new roman"></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" width="90%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></font></div>
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left">See Schedule</div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid">
<div><font style="font: 11pt times new roman">13.&#160; THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. </font></div>

<div><font style="font: 11pt times new roman">IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.</font></div>
</td>
</tr><tr>
<td style="width: 3%; border-left: black 1.1pt solid; border-right: black 1.1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="9" style="width: 97%; border-bottom: Black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:&#160;&#160;(Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="9" width="97%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriate date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY
OF FAR 43.103(B).</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="9" width="97%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:</font></font></div>
</td>
</tr><tr>
<td width="3%" style="TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font>X</td>
<td colspan="9" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">D. OTHER (Specify type of modification and authority)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman"></font></div>
</div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FAR52-232-22, Limitation of Funds</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman">E.
IMPORTANT:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Contractor&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font: 10pt wingdings">x</font><font style="font: 10pt times new roman">&#160;&#160;is
not,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font: 10pt wingdings">o</font><font style="font: 10pt times new roman">&#160;&#160;
is required to sign this document and return&#160;&#160;&#160;&#160;___<u>&#160;</u>&#160;&#160;&#160;&#160;copies to the issuing
office.</font></div>
</td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)</font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><p style="font-size: 10pt; margin: 0.15pt 0 0 13.5pt; color: #050705">Modification Control Number:&#9;soconnel151958</p>
                                                                                   <p style="font-size: 10pt; margin: 0.15pt 0 0 13.5pt; color: #050705">&nbsp;</p>


</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></font></font>

<P STYLE="font-size: 10pt; margin: 1pt 0 0 13.45pt; color: #050705">See attached summary of changes for incremental funding for
tasks 6.1, 6.2, 6.3, and 6.4 of the Statement of Work (SOW), dated 20 Mar 2015, for CLIN0002.</P>




<font style="font: 10pt times new roman"><font style="display: inline; font: 10pt times new roman"><font style="display: inline; font: 10pt times new roman"></font></font></font></div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Except
as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
unchanged and in full force and effect.</font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td colspan="4" valign="top" width="52%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15A. NAME AND TITLE OF SIGNER (Type or print)</font></font></div>
</td>
<td colspan="5" width="43%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><p style="font-size: 10pt; margin-top: 1.3pt; text-align: left; margin-bottom: 0; color: #050705"><font style="font-size: 8pt">SANDRA
OCONNELL/ CONTRACT SPECIALIST /GRANTS 0</font></p>



<font style="font: 10pt times new roman"></font></div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman"></font><p style="margin: 0">TEL:
                                         <font style="font-size: 8pt">301.619.21195</font></p>


</div>
</td>
<td colspan="4" width="23%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman">EMAIL:&#160;</font><font style="font: 8pt times new roman">sandra.ocomell@usarmy.mil
</font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" width="33%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15B. CONTRACTOR/OFFEROR</font></font></div>
</td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15C. DATE SIGNED</font></font></div>
</td>
<td colspan="3" width="28%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16B. <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">UNITED STATES OF AMERICA</font></font></td>
<td colspan="3" width="10%" style="TEXT-ALIGN: left; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16C. DATE SIGNED</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid">

<p style="margin: 0">13-May-2015</p>


</div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left">&#160;</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BY
&nbsp;&nbsp;&nbsp;&nbsp;/s/ Sandra O&rsquo;Connell</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Signature of person authorized to sign)</font></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Signature of Contracting Officer)</font></font></div>
</td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
<P STYLE="margin: 0">&nbsp;</P>

<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">E<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XCEPTION TO SF 30</font> </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">APPROVED BY OIRM 11-84</font></font></div>
</td>
<td valign="top" width="50%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30-105-04</font></font></div>
</td>
<td width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">STANDARD FORM 30 (Rev. 10-83)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prescribed by GSA </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FAR (48 CFR) 53_243</font></font></div>
</td>
</tr></table>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: right; margin-bottom: 0">W9113M-10-C-0057</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 55.35pt; text-align: right">P00036</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">Page 2 of 3</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</P>

<P STYLE="font-size: 10pt; margin-top: 0.3pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"><B>SUMMARY OF CHANGES</B></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin-top: 0.3pt; text-align: left; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION B - SUPPLIES OR SERVICES AND PRICES</P>

<P STYLE="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 20pt">SUBCLIN 000202 is added as follows:</P>

<P STYLE="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="text-align: left"><font style="font-size: 10pt">ITEM NO</font></td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">SUPPLIES/SERVICES</font></td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">QUANTITY</font></td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">UNIT</font></td>
    <TD COLSPAN="3" STYLE="text-align: left"><font style="font-size: 10pt">UNIT PRICE</font></td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">AMOUNT</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left"><font style="font-size: 10pt">000202</font></td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">Job</font></td>
    <TD COLSPAN="3" STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">$[***]</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Funding for CLIN 0002 CPIF</P>
        <P STYLE="font-size: 10pt; margin-top: 0.1pt; text-align: left; margin-bottom: 0">FOB: Destination</P>
        <P STYLE="font-size: 10pt; margin-top: 3pt; text-align: left; margin-bottom: 0">PURCHASE REQUEST NUMBER: 0010618769-0002</P>

</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD COLSPAN="8" STYLE="text-align: left">
        <P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">TARGET COST</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">$[***]</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">TARGET FEE&#9;<U> &#9;</U></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: left"><font style="font-size: 10pt"><u>$[***]&#9;</u></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 40pt"></TD>
    <TD NOWRAP STYLE="text-align: right; padding-left: 40pt">TOTAL TGT COS<FONT STYLE="font-size: 10pt">T + FEE</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; padding-left: 40pt">&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">$[***]</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">MINIMUM FEE</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">$[***]</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; width: 11%">&nbsp;</td>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</td>
    <TD STYLE="text-align: left; width: 11%">&nbsp;</td>
    <TD STYLE="text-align: left; width: 11%">&nbsp;</td>
    <TD STYLE="text-align: right; width: 6%"><FONT STYLE="font-size: 10pt">MAXIMU</FONT>M FEE</TD>
    <TD STYLE="text-align: left; width: 6%"><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: left; width: 11%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 24%"><font style="font-size: 10pt">$[***]</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">SHARE RATIO ABOVE TARGET</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">SHARE RATIO BELOW TARGET</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD COLSPAN="8" STYLE="text-align: left"><font style="font-size: 10pt"></font></td></tr>
<tr style="vertical-align: top">
    <TD COLSPAN="8" STYLE="text-align: left"><font style="font-size: 10pt"></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD COLSPAN="2" STYLE="text-align: left">
        <P STYLE="font-size: 10pt; margin-top: 0.95pt; text-align: left; margin-bottom: 0">ACRN AJ</P>
        <P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">CIN: GFEBS001061876900003</P></td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD COLSPAN="3" STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">$14,988,769.00</font></td></tr>
<tr>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td></tr>
</table>
<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">SECTION E - INSPECTION AND ACCEPTANCE</P>

<P STYLE="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
</table>
<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">The following Acceptance/Inspection Schedule was added for SUBCLIN 000202:</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt"></font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">INSPECT AT</font></td>
    <td colspan="2" style="font-size: 10pt; text-align: left"><font style="font-size: 10pt"></font></td>
    <td style="font-size: 10pt; text-align: left">INSPECT BY</td>
    <td style="font-size: 10pt; text-align: left">ACCEPT AT<font style="font-size: 10pt"></font></td>
    <td style="font-size: 10pt; text-align: left">ACCEPT BY<font style="font-size: 10pt"></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">N/A<div></div>

</td>
    <td colspan="2" style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">N/A</td>
    <td style="font-size: 10pt; text-align: left">N/A</td>
    <td style="font-size: 10pt; text-align: left">Government</td></tr>
</table>
<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION G - CONTRACT ADMINISTRATION DATA</P>

<P STYLE="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Accounting and Appropriation</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Summary for the Payment Office</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0.55pt; margin-bottom: 0; margin-left: 20pt">As a result of this modification, the total funded
amount for this document was increased by $14,988,769.00 from $53,252,626.24 to $68,241,395.24.</P>

<P STYLE="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SUBCLIN 000202:</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">Funding on SUBCLIN 000202 is initiated as follows:</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; margin-left: 20pt">ACRN: AJ</P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid; text-align: left"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; text-align: left"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; text-align: right">W9113M-10-C-0057</P>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; text-align: right">P00036</P>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; text-align: right">Page 3 of 3</P>



<P STYLE="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">CIN: GFEBS001061876900003</font></td>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 53%; text-align: left"><font style="font-size: 10pt">Acctng Data: 097201520160400000265Y0550506255</font></td>
    <TD STYLE="width: 20%; text-align: left"><font style="font-size: 10pt">A.0011315.4.1.3.1</font></td>
    <TD STYLE="width: 18%; text-align: left"><font style="font-size: 10pt">6100.9000021001</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">Increase: $14,988,769.00</font></td>
    <TD COLSPAN="2" ROWSPAN="3" STYLE="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">Total: $14,988,769.00</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">Cost Code: A5XAH</font></td></tr>
</table>
<P STYLE="font-size: 10pt; margin-top: 6.65pt; text-align: left; margin-bottom: 0">(End of Summary of Changes)</P>



<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>exh_105.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<html>
<head>
    <title>exh_1055.htm</title>
    <!--Licensed to: NASDAQ OMX-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-ALIGN: right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.5</font></div>

<div>&#160;<p style="font-size: 10pt; margin: 0">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.</p>



</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="1" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="5" width="72%" style="BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</font></font></div>
</td>
<td width="3%" style="BORDER-TOP: black 1.1pt solid">&#160;</td>
<td colspan="2" valign="top" width="15%" style="BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1. CONTRACT&#160;ID CODE</font></font></div>
</td>
<td colspan="2" width="10%" style="BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PAGE OF PAGES</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">&#160;</td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="15%" style="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; padding-left: -10pt"><font style="font: 10pt times new roman">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: medium none"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></td>
</tr><tr>
<td colspan="3" width="33%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2. AMENDMENT/MODIFICATION NO</font></font></div>
</td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3. EFFECTIVE DATE</font></font></div>
</td>
<td colspan="2" width="23%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">4. <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">REQUISITION/PURCHASE REQ. NO.</font></font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="20%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">5. PROJECT NO. (If applicable)</font></font></div>
</td>
</tr><tr>
<td colspan="2" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">P00037</font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22-May-2015</font></font></font></div>
</div>
</td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;SEE
SCHEDULE</font></div>
</td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="28%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">6. ISSUED BY</font></font></div>
</td>
<td width="5%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE</font></font></div>
</td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">W911QY</font></font></div>
</td>
<td colspan="3" width="28%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">7.&#160;ADMINISTERED&#160;BY&#160;(If other&#160;than item&#160;6)</font></font></div>
</td>
<td width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE</font></font></div>
</td>
<td colspan="2" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">W9 <font style="font-size: 10pt; color: #0F2844">11</font><font style="font-size: 10pt; color: #2A2326">Q</font><font style="font-size: 10pt; color: #464249">Y</font></font></div>
</td>
</tr><tr>
<td colspan="4" valign="top" width="52%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">WQKACC-APG
NATICK</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><p style="margin: 0"><font style="font-size: 8pt">CONTRACTING DIVISION BLDG 1KANSAS STREET</font></p>


</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><p style="margin: 0"><font style="font-size: 8pt">NATICK MA01760-5011</font></p>


</font></font></font></div>
</div>
</div>
</div>
</td>
<td colspan="3" valign="top" width="28%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">W6QKACC-APG
NATICK</font><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">110
             THOMAS JOHNSON DR SUITE #240</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 8pt times new roman">FREDERICK
                                         MD 21702</font><font style="font: 10pt times new roman; color: #464249"> </font><div style="TEXT-INDENT: 0pt; DISPLAY: block"></div>
</div>
</div>
</div>

<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="5" width="72%" style="BORDER-LEFT: black 1.1pt solid"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 12pt times new roman">8.
NAME AND ADDRESS OF CONTRACTOR&#160;&#160;(No., Street, County, State and Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">TEKMIRA PHARMACEUTICALS CORPORATION</font></font></div>
</div>
</td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" valign="top" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9A. AMENDMENT OF SOLICITATION NO.</font></font></div>
</td>
</tr><tr style="text-align: left; vertical-align: top">
<td colspan="5" width="72%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px; TEXT-INDENT: 9pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">8900 GLENLYON PKY SUITE 100 </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">BURNABY V5J 5J8</font></font></div>
</td>
<td width="3%" style="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font><FONT STYLE="font: 10pt times new roman">X</td>
<td colspan="4" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">


</FONT> <FONT STYLE="font: 10pt times new roman"><FONT STYLE="display: inline; font: 10pt times new roman">10A. MOD. OF CONTRACT/ORDER NO.<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div>
</font></font>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; color: #010101">V\19113M-1O-C-0057</p>



<font style="font: 10pt times new roman"><font style="display: inline; font: 10pt times new roman"></td>
</tr><tr>
<td colspan="5" valign="top" width="72%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">&#160;</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></td>
<td colspan="4" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
10B. DATED (SEE ITEM 13)

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1<font style="font-size: 10pt; color: #010101">4-Jul-2010</font></font></font></div>
</td>
</tr><tr>
<td colspan="5" valign="top" width="72%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></td>
<td colspan="4" width="25%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></td>
</tr><tr>
<td colspan="2" valign="bottom" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CODE&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">L8144</font></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="39%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FACILITY CODE</font></font></div>
</td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid">&#160;</td>
<td colspan="4" width="25%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></font></div>
</td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></font></div>
</td>
</tr><tr>
<td width="3%" style="TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid"></td>
<td colspan="4" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer</font></font></div>
</td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o </font>is extended&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&#160;&#160; is not extended.</font></font></font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="8" width="92%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="font: 8pt times new roman"></font>

<p style="font-size: 10pt; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><font style="font-size: 8pt">Offer
must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the
following methods:</font></p>

<p style="font-size: 10pt; margin-top: 2.25pt; margin-right: 86.7pt; margin-bottom: 0; text-align: left"><font style="font-size: 8pt">(a)
By completing Items 8 and 15, and returning. <u>&#9; </u>Copies of the amendment; (b) By acknowledging receipt of this amendment
on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and
amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE
HOUR AND DATE SPECIFIED MAY RESULT IN</font></p>

<p style="font-size: 10pt; margin-top: 1.2pt; margin-right: 96.25pt; margin-bottom: 0; text-align: left"><font style="font-size: 8pt">REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram
or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the
opening hour and date specified.</font></p>



<font style="font: 8pt times new roman"></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" width="90%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></font></div>
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left">See Schedule</div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid">
<div><font style="font: 11pt times new roman">13.&#160; THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. </font></div>

<div><font style="font: 11pt times new roman">IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.</font></div>
</td>
</tr><tr>
<td style="width: 3%; border-left: black 1.1pt solid; border-right: black 1.1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;X</font></td>
<td colspan="9" style="width: 97%; border-bottom: Black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:&#160;&#160;(Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="9" width="97%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriate date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY
OF FAR 43.103.B.</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="9" width="97%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:</font></font></div>
</td>
</tr><tr>
<td width="3%" style="TEXT-ALIGN: center; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></td>
<td colspan="9" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">D. OTHER (Specify type of modification and authority)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman"></font></div>
</div>
</td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman">E.
IMPORTANT:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Contractor&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font: 10pt wingdings">x</font><font style="font: 10pt times new roman">&#160;&#160;is
not,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font: 10pt wingdings">o</font><font style="font: 10pt times new roman">&#160;&#160;
is required to sign this document and return&#160;&#160;&#160;&#160;___<u>&#160;</u>&#160;&#160;&#160;&#160;copies to the issuing
office.</font></div>
</td>
</tr><tr>
<td colspan="10" width="100%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)</font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><p style="font-size: 10pt; margin: 0.15pt 0 0 13.5pt; color: #050705">Modification Control Number:&#9;soconnel151958</p>
                                                                                   <p style="font-size: 10pt; margin: 0.15pt 0 0 13.5pt; color: #050705">&nbsp;</p>


</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"></font></font></font>

<p style="font-size: 10pt; margin: 1.35pt 0 0 13.45pt; color: #010101">See attached summary of changes for this change order.</p>



<font style="font: 10pt times new roman"><font style="display: inline; font: 10pt times new roman"><font style="display: inline; font: 10pt times new roman"></font></font></font></div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Except as provided herein, all terms and conditions ofthe document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td colspan="4" valign="top" width="52%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15A. NAME AND TITLE OF SIGNER (Type or print)</font></font></div>
</td>
<td colspan="5" width="43%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><p style="font-size: 10pt; margin-top: 1.3pt; text-align: left; margin-bottom: 0; color: #050705"><font style="font-size: 8pt">SANDRA
OCONNELL/ CONTRACT SPECIALIST /GRANTS 0</font></p>



<font style="font: 10pt times new roman"></font></div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman"></font><p style="margin: 0">TEL:
                                         <font style="font-size: 8pt">301 619.21!15</font></p>


</div>
</td>
<td colspan="4" width="23%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="font: 10pt times new roman">EMAIL:&#160;</font><font style="font: 8pt times new roman">sandra.ocomell@usarmy.mil
</font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" width="33%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15B. CONTRACTOR/OFFEROR</font></font></div>
</td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15C. DATE SIGNED</font></font></div>
</td>
<td colspan="3" width="28%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16B. <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">UNITED STATES OF AMERICA</font></font></td>
<td colspan="3" width="10%" style="TEXT-ALIGN: left; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16C. DATE SIGNED</font></font></div>
</td>
</tr><tr>
<td width="3%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid">

<p style="margin: 0">26-May-2015</p>


</div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left">&#160;</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BY</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Signature of person authorized to sign)</font></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="19%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Signature of Contracting Officer)</font></font></div>
</td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">E<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XCEPTION TO SF 30</font> </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">APPROVED BY OIRM 11-84</font></font></div>
</td>
<td valign="top" width="50%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30-105-04</font></font></div>
</td>
<td width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">STANDARD FORM 30 (Rev. 10-83)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prescribed by GSA </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FAR (48 CFR) 53.243</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;&#160;&#160;</div>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<div><p style="font-size: 10pt; margin: 0 0 0 1pt; text-align: right">W9113M-10-C-0057</p>

<p style="font-size: 10pt; margin: 0 0 0 55.35pt; text-align: right">P00037</p>

<p style="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">Page 2 of 3</p>

<p style="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">&nbsp;</p>

<p style="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">&nbsp;</p>



</div>

<div><p style="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</p>

<p style="font-size: 10pt; margin-top: 0.3pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"><b>SUMMARY OF CHANGES</b></p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin-top: 0.3pt; text-align: left; margin-bottom: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0.1pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">The following have been added by full text:</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; margin-left: 20pt"><u>P00037</u></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">A.<font style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</font>The purpose of this change order is to direct the Contractor to execute and accomplish the remaining activities related
to resolution of the partial clinical hold imposed by the FDA under CLIN 0001. Prior to receipt and negotiation of a proposed equitable
adjustment resulting from this change order, Tekmira shall not be allowed to incur costs exceeding $[***].</p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All other terms and conditions of this contract remain the same and in full force and effect.</p>



<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0.55pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION B - SUPPLIES OR SERVICES AND PRICES</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; margin-left: 20pt">SUBCLIN 000108 is added as follows:</p>

<p style="font-size: 10pt; margin-top: 0.1pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">ITEM NO</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">SUPPLIES/SERVICES</font></td>
    <td colspan="2" style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">QUANTITY</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">UNIT</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">UNIT PRICE</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">AMOUNT</font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">000108</font></td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td colspan="2" style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">$0.00</font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left"><div><p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Funding for CLIN 0001 FFP</P>
        <P STYLE="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">FOB: Destination</p></div>

</td>
    <td colspan="2" style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="7" style="text-align: left">
        <p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></p></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td colspan="2" style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="text-align: left">
        <p style="font-size: 10pt; margin-top: 0.2pt; text-align: left; margin-bottom: 0">&nbsp;</p>
        <p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">NET AMT</p></td>
    <td style="border-top: black 1pt solid; text-align: left">
        <p style="font-size: 10pt; margin-top: 0.2pt; text-align: left; margin-bottom: 0">&nbsp;</p>
        <p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">$0.00</p></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td colspan="2" style="text-align: left">
        <p style="font-size: 10pt; margin-top: 5.2pt; text-align: left; margin-bottom: 0">ACRN AK</p>
        <p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">CIN: 000000000000000000000000000000</p></td>
    <td style="text-align: left">
        <p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</p>
        <p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></p></td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">$1,000,000.00</font></td></tr>
<tr>
    <td style="width: 11%; text-align: left">&nbsp;</td>
    <td style="width: 20%; text-align: left">&nbsp;</td>
    <td style="width: 7%; text-align: left">&nbsp;</td>
    <td style="width: 7%; text-align: left">&nbsp;</td>
    <td style="width: 9%; text-align: left">&nbsp;</td>
    <td style="width: 19%; text-align: left">&nbsp;</td>
    <td style="width: 27%; text-align: left">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0.45pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">SECTION E - INSPECTION AND ACCEPTANCE</p>

<p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%">
</table>
<p style="margin-top: 0; text-align: left; margin-bottom: 0"></p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">The following Acceptance/Inspection Schedule was added for SUBCLIN 000108:</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt"></font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">INSPECT AT</font></td>
    <td colspan="2" style="font-size: 10pt; text-align: left"><font style="font-size: 10pt"></font></td>
    <td style="font-size: 10pt; text-align: left">INSPECT BY</td>
    <td style="font-size: 10pt; text-align: left">ACCEPT AT<font style="font-size: 10pt"></font></td>
    <td style="font-size: 10pt; text-align: left">ACCEPT BY<font style="font-size: 10pt"></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">N/A<div></div>

</td>
    <td colspan="2" style="font-size: 10pt; text-align: left">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">N/A</td>
    <td style="font-size: 10pt; text-align: left">N/A</td>
    <td style="font-size: 10pt; text-align: left">Government</td></tr>
</table>
<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0"></p>

<p style="font-size: 10pt; margin-top: 0.45pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SECTION G - CONTRACT ADMINISTRATION DATA</p>

<p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Accounting and Appropriation</p>

<p style="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</p></div>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid; text-align: left"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: left; width: 100%">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; text-align: left"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"><tr><td style="text-align: left; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<div><P STYLE="font-size: 10pt; margin: 0 0 0 1pt; text-align: right">W9113M-10-C-0057</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 55.35pt; text-align: right">P00037</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 40.7pt; text-align: right">Page 3 of 3</p></div>


<div style="text-align: left"><p style="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0"></p>

<p style="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">Summary for the Payment Office</p>

<p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">As a result of this modification, the total funded
amount for this document was increased by $1,690,592.00 from $68,241,395.24 to $69,931,987.24.</p>

<p style="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SUBCLIN 000108:</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">Funding on SUBCLIN 000108 is initiated as follows:</p>

<p style="font-size: 10pt; margin-top: 0.4pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">ACRN: AK</font></td>
    <td colspan="2" rowspan="2" style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td colspan="2" rowspan="2" style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">CIN:&nbsp;&nbsp;&nbsp;000000000000000000000000000000</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 9%">&nbsp;</td>
    <td style="width: 53%; text-align: left"><font style="font-size: 10pt">Acctng Data: 097201520160400000265Y0550506255</font></td>
    <td style="width: 20%; text-align: left"><font style="font-size: 10pt">A.0011315.4.1.3.4</font></td>
    <td style="width: 18%; text-align: left"><font style="font-size: 10pt">6100.9000021001</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">Increase: $1,000,000.00</font></td>
    <td colspan="2" rowspan="3" style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td colspan="2" rowspan="3" style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">Total: $1,000,000.00</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: left"><font style="font-size: 10pt">Cost Code: A5XAH</font></td></tr>
</table>
<p style="font-size: 10pt; margin-top: 0.2pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 3.65pt; text-align: left; margin-bottom: 0">SUBCLIN 000201:</p>

<p style="font-size: 10pt; margin-top: 0.5pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; margin-left: 20pt">AK: 097201520160400000265Y0550506255&#9;A.0011315.4.1.3.4&#9;6100.9000021001
A5XAH (CIN GFEBS001066272300001) was increased by $[***] from $[***] to $[***]</p>

<p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">SUBCLIN 000202:</p>

<p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0; margin-left: 20pt">AJ: 097201520160400000265Y0550506255&#9;A.0011315.4.1.3.1&#9;6100.9000021001
A5XAH (CIN GFEBS001061876900003) was decreased by $[***] from $[***] to $[***]</p>

<p style="font-size: 10pt; margin-top: 0.05pt; text-align: left; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0; text-align: left; margin-bottom: 0">(End of Summary of Changes)</p>



</div>

<div style="text-align: left"></div>
</div>

<div style="text-align: left; display: block"></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>8
<FILENAME>exh_106.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">EXECUTIVE EMPLOYMENT AGREEMENT</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This Executive Employment Agreement (&ldquo;<B><U>Agreement</U></B>&rdquo;)
is made effective as of July 11, 2015 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;) by and between OnCore Biopharma, Inc. (the
&ldquo;<B><U>Company</U></B>&rdquo;), and Patrick T. Higgins (the &ldquo;<B><U>Executive</U></B>&rdquo;) (together the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">RECITALS</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">A.</TD><TD>As of the Effective Date, the Company and the Executive have agreed to terminate any and all existing employment agreements
(including any amendments thereto) between the Executive and the Company and set forth their mutual rights and obligations in this
Agreement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">B.</TD><TD>In connection with and as a condition to the execution of this Agreement, Tekmira Pharmaceuticals Corporation, the parent of
the Company (&ldquo;<B><U>Tekmira</U></B>&rdquo;), and the Executive have also agreed to the terms of that certain Share Repurchase
Agreement, dated as of the date hereof (the &ldquo;<B><U>Share Repurchase Agreement</U></B>&rdquo;), whereby certain common shares
of Tekmira owned by the Executive are subject to a repurchase right of Tekmira, pursuant to the terms and conditions thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">THEREFORE, the Parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Position and Duties</U>. The Executive will serve as Chief Business &amp; Commercial Operations Officer (&amp; US Site Head)
of the Company, and will have powers and duties consistent with such position as may from time to time be prescribed by the Chief
Executive Officer of the Company. As Chief Business &amp; Commercial Operations Officer (&amp; US Site Head) of the Company, the
Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing,
the Executive may manage his personal investments or engage charitable or other community activities. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><U>Section 2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Compensation and Related Matters.</FONT></U>(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Base Salary</U>. The Executive&rsquo;s base salary will be US$360,000 per year. The Executive&rsquo;s base salary will be reviewed
annually by the Chief Executive Officer of the Company and is subject to increase but not decrease except for an across-the-board
salary reduction affecting all senior executives of the Company. The base salary in effect at any given time is referred to as
&ldquo;<B><U>Base Salary</U></B>&rdquo; and this Agreement need not be modified to reflect a change in Base Salary. Notwithstanding
the foregoing, for the purposes of determining the &ldquo;Base Salary&rdquo; for a termination by the Executive for &ldquo;Good
Reason&rdquo; solely under Section 4(d)(iv), the Base Salary shall be the amount set forth in the first sentence of this Section
2(a). The Base Salary is subject to withholding and payable in a manner that is consistent with the Company&rsquo;s usual payroll
practices for senior executives.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Bonus</U>. The Executive is eligible to be considered for an annual discretionary bonus of up to 40% of Base Salary (such bonus,
the &ldquo;<B>Target Bonus</B>&rdquo;); however, notwithstanding the foregoing, for the purposes of determining the &ldquo;Target
Bonus&rdquo; for a termination by the Executive for &ldquo;Good Reason&rdquo; solely under Section 4(d)(iv), the Target Bonus shall
be 40% of Base Salary). The Target Bonus shall be subject to the terms of the bonus plan and the approval of the Company&rsquo;s
Board of Directors (the &ldquo;<B><U>Board</U></B>&rdquo;), in its sole discretion, on an annual basis.<U> </U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Expenses</U>. The Executive is entitled to receive prompt reimbursement for all reasonable expenses incurred by him in performing
services under this Agreement, in accordance with the policies and procedures then in effect and established by the Company for
its senior executives.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Other Benefits</U>. The Executive is entitled to participate in or receive benefits under the Company&rsquo;s employee benefit
plans as they may be adopted and amended from time to time, subject to the terms and conditions of those employee benefit plans.
</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Equity Compensation</U>. Subject to the discretionary approval of the Company&rsquo;s Board of Directors, and in accordance
with the Company&rsquo;s annual performance and compensation review process, the Executive shall be eligible to receive equity
awards under the Tekmira Pharmaceuticals Corporation Share Incentive Plan and or any other similar equity incentive plan </FONT>to
the same extent as other executives of the Company<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Vacations</U>. The Executive is entitled to paid holidays and vacation days each year, in an amount determined in accordance
with and subject to the Company&rsquo;s applicable policies in effect, and as may be amended from time to time. Unless a different
number is established by the Board in its sole discretion, the Executive will be entitled to 20 days of vacation per calendar year,
which will be pro-rated for any year in which the Executive is only employed with the Company for a portion of the year or for
any period in which the Executive is not a full-time employee. Carry-over of vacation days will be according to Company policy,
and any accrued but unused vacation days will be paid out upon termination. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Competition and Non-Solicitation</U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Executive acknowledges that the Company&rsquo;s industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company&rsquo;s interests if they join a competing business immediately upon
leaving the Company. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions:</U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Affiliate&rdquo; means any person or entity directly or indirectly controlling, controlled by or under common control with
the Company, where control may be by either management authority or equity interest.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Business&rdquo; or &ldquo;Business of the Company&rdquo; means (a) researching, developing, producing and marketing any
treatment for hepatitis B virus infection in humans or (b) any other treatment area in which the Company has an active research
and development program on the date this Agreement terminates and in connection with which the Executive directly provided service
or had direct supervisory responsibilities.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Competing Business&rdquo; means any endeavor, activity or business which is competitive in any material way with the Business
of the Company worldwide.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Contact&rdquo; means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder,
investor, collaborator, strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates)
with whom the Executive dealt or otherwise became aware of during the term of his employment in any capacity with the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Restricted Period&rdquo; means: (a) with respect to Section 3(d) the eighteen (18) month period commencing immediately after
the Executive&rsquo;s employment terminates and (b) with respect to Section 3(f), the twelve (12) month period commencing immediately
after the Executive&rsquo;s employment terminates.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Reasonableness</U>. The Executive hereby acknowledges and agrees that:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
both before and since the Effective Date the Company has operated and competed and will operate and compete worldwide, with respect
to the Business of the Company;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
competitors of the Company and the Business are located worldwide; </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in order to protect the Company adequately, any enjoinder of competition would have to apply to any country in which the Company,
during the term of the Executive&rsquo;s employment, had material business relationships; </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during the course of the Executive&rsquo;s employment with the Company, on behalf of the Company, the Executive will acquire knowledge
of, and will come into contact with, initiate and establish relationships with, both existing and new clients, customers, suppliers,
principals, contacts and prospects of the Company, and that in some circumstances the Executive may become the senior or sole representative
of the Company dealing with such persons; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper protection of the Business
of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Restrictive Covenant</U>. During the term of the Executive&rsquo;s employment and for the Restricted Period after the termination
thereof, the Executive shall not, without the advance written consent of the Board, such consent to be granted or withheld in the
Board&rsquo;s sole discretion, within the geographic scope of any country in which the Company, during the term of the Executive&rsquo;s
employment, had material business relationships, carry on or be employed by or engaged in or have any financial or other interest
in or be otherwise commercially involved in a Competing Business, directly or indirectly, either individually or in partnership
or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee,
shareholder or in any manner whatsoever.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exception</U>. The Executive shall not be in default of Section 3(d) by virtue of the Executive:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
following the termination of employment, holding, strictly for portfolio purposes and as a passive investor, no more than five
percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or other entity that is a Competing
Business; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during the term of his employment, holding, strictly for portfolio purposes and as a passive investor, issued and outstanding shares
of, or any other interest in, any corporation or other entity, the business of which corporation or other entity is in the same
Business as the Company provided such corporation is not a Competing Business, and provided further that the Executive first obtains
the Company&rsquo;s written consent, which consent will not be unreasonably withheld.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">If the Executive holds issued and outstanding shares or any other interest in a corporation
or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares or other interest the business
of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose of the Executive&rsquo;s shares
or other interest in such corporation or other entity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Solicitation</U>. The Executive shall not, during the term of his employment and for the Restricted Period after the termination
thereof for any reason, whether legal or illegal, either individually or in partnership or jointly or in conjunction with any person,
firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever,
without the prior written and informed consent of the Company, directly or indirectly:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for any purpose which is competitive
with the Business; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
accept (or procure or assist the acceptance of) any business from any Contact if such business is competitive with the Business;
or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
be employed by or supply (or procure or assist the supply of) any goods or services to any Contact for any purpose which the Executive
knows or has reason to know is competitive with the Business; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise entice away from or solicit,
induce or encourage to leave the employment or engagement of the Company, any individual who is employed or engaged by the Company
at the time of any such offer, solicitation or enticement whether or not such individual would commit any breach of his contract
or terms of employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall
be permitted, solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Validity</U>. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&rsquo;s
activities following the termination of the Executive&rsquo;s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive acknowledges and agrees that, simultaneous with and as a condition to this Agreement, Tekmira and the Executive have
agreed to enter into the Share Repurchase Agreement</FONT>, in order to <FONT STYLE="font-size: 10pt">accelerate the termination
of certain of Tekmira&rsquo;s rights to repurchase common shares of Tekmira owned by the Executive, and that such Agreement shall
be considered as a portion of the consideration received by the Executive on account of the Executive&rsquo;s obligations under
this Section 3. The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable
to any extent by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of
the restriction, the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that
which is in fact declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration,
in order to ensure that the intention of the parties is given the greatest possible effect.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination</U>. The Executive&rsquo;s employment by the Company may be terminated without any breach of this Agreement under
the following circumstances:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Death</U>. The Executive&rsquo;s employment hereunder terminates upon his death.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Disability</U>. The Company may terminate the Executive&rsquo;s employment if he is disabled (as determined by the Chief Executive
Officer) in a manner that renders the Executive unable to perform the essential functions of his then existing position or positions
under this Agreement with or without reasonable accommodation for a period of six months or more. Nothing in this Section 4(b)
is to be construed to waive the Executive&rsquo;s rights, if any, under existing law including, without limitation, the Family
and Medical Leave Act of 1993, 29 U.S.C. &sect;2601 et seq., and the Americans with Disabilities Act, 42 U.S.C. &sect;12101 et
seq. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by Company for Cause</U>. For purposes of this Agreement, &ldquo;For Cause&rdquo; shall mean: (i) Employee is charged
with a felony (excluding a DUI) or any violation of state or federal securities laws; (ii) Employee willfully engages in conduct
that is in bad faith and materially injurious to the Company, including but not limited to, misappropriation of trade secrets,
fraud or embezzlement; (iii) Employee commits a material breach of this Agreement; (iv) Employee willfully refuses to implement
or follow a lawful policy or directive of the Company; or (v) Employee engages in misfeasance or malfeasance demonstrated by a
pattern of failure to perform job duties diligently and professionally. The Company may terminate Employee&rsquo;s employment For
Cause at any time, without any advance notice. The Company shall pay Employee all compensation to which Employee is entitled up
through the date of termination, subject to any other rights or remedies of the Company under law; and thereafter all obligations
of the Company under this Agreement shall cease. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by the Company Without Cause or by the Executive for Good Reason</U>. The Company may terminate the Executive&rsquo;s
employment under this Agreement at any time without Cause and the Executive may terminate his employment with Good Reason. For
purposes of this Agreement, &ldquo;Good Reason&rdquo; means</FONT> <FONT STYLE="font-size: 10pt">the occurrence of any of the following
events without the Executive's prior written consent: (i) the failure of the Executive to be appointed to the position set forth
in Section 1, if not promptly cured after written notice; (ii) a reduction by the Company of the Executive's Base Salary or Target
Bonus percentage, except for an across-the-board salary reduction affecting all senior executives of the Company; (iii) a relocation
of Employee&rsquo;s principal place of employment by more than fifty (50) miles; (iv) a termination of the Executive&rsquo;s employment
by the Company or the Executive with OnCore for any reason during the period from April 1, 2016 until April 30, 2016 and (v) a
substantial and adverse change to the Executive&rsquo;s duties and responsibilities. For purposes of this Agreement, termination
for Good Reason requires Executive to comply with the &ldquo;Good Reason Process,&rdquo; which means that (i) the Executive reasonably
determines in good faith that a Good Reason condition has occurred; (ii) the Executive notifies the Company in writing of the first
occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (iii) the Executive cooperates
in good faith with the Company&rsquo;s efforts, for a period of not less than 30 days following that notice (the &ldquo;<B><U>Cure
Period</U></B>&rdquo;) to remedy the condition; (iv) notwithstanding the Company&rsquo;s efforts, the Good Reason condition continues
to exist; and (v) the Executive terminates his employment within 30 days after the end of the Cure Period. If the Company cures
the Good Reason condition during the Cure Period, Good Reason is deemed not to have occurred. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Any termination by the Company of the Executive&rsquo;s employment under this Agreement
that does not constitute a termination for Cause under Section 4(c) and does not result from the death or disability of the Executive
under Section 4(a) or (b) is a termination without Cause.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by the Executive</U>. Executive may terminate employment with the Company without Good Reason at any time for any
reason or no reason at all, upon thirty (30) days&rsquo; advance written notice. The Company shall have the option, in its sole
discretion, to make Executive&rsquo;s termination effective or to direct the Executive to perform no work and/or remain off premises
at any time prior to the end of such notice period as long as the Company pays Executive all compensation to which Executive is
entitled up through the last day of the 30 day notice period. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice of Termination</U>. Except for termination as specified in Section 4(a), any termination of the Executive&rsquo;s employment
by the Company or any termination of his employment by the Executive must be communicated by written Notice of Termination to the
other party. For purposes of this Agreement, a &ldquo;<B><U>Notice of Termination</U></B>&rdquo; means a notice that indicates
the specific termination provision in this Agreement that the termination is based upon.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Date of Termination</U>. &ldquo;<B><U>Date of Termination</U></B>&rdquo; means: (i) if the Executive&rsquo;s employment is terminated
by his death, the date of his death; (ii) if the Executive&rsquo;s employment is terminated on account of disability under Section
4(b) or by the Company for Cause under Section 4(c), or by the Company without Cause under Section 4(d) on the date the Notice
of Termination is given; (iii) if the Executive terminates his employment under Section 4(e) without Good Reason, on the date specified
by the Executive in the notice (which shall be at least thirty (30) days after the date of the Notice of Termination) and, if no
such date is specified, 30 days after the date of the Notice of Termination; and (iv) if the Executive terminates his employment
under Section 4(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding
the foregoing, if the Executive gives a Notice of Termination to the Company that takes effect at a future date, the Company may
unilaterally accelerate the Date of Termination and that acceleration will not be deemed a termination by the Company for purposes
of this Agreement. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compensation Upon Termination</U>. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination Generally</U>. If the Executive&rsquo;s employment with the Company is terminated for any reason, the Company shall
pay or provide to the Executive (or to his authorized representative or estate), (i) unpaid expense reimbursements; (ii) accrued
but unused vacation to the extent payment is required by law or Company policy; (iii) any vested benefits the Executive may have
under any employee benefit plan of the Company; (iv) any earned but unpaid base salary and (v) any earned but unpaid annual bonus
for the prior fiscal year (collectively the &ldquo;<B><U>Accrued Benefit</U></B>&rdquo;) on or before the time required by law,
but in no event more than 30 days after the Executive&rsquo;s Date of Termination. The Executive shall not be entitled to any other
salary, compensation, bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically
provided hereunder, under the Company&rsquo;s employee benefit plans or as expressly required by applicable law. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by the Company Without Cause or by the Executive for Good Reason</U>. If the Executive&rsquo;s employment is terminated
by the Company without Cause or by the Executive for Good Reason, then the Company shall pay the Executive his Accrued Benefit
as of the Date of Termination. In addition, subject to the Executive providing the Company with a fully effective general release
of claims in a form and manner satisfactory to the Company that includes but is not limited to the terms set forth in the attached
<U>Exhibit A</U> (the &ldquo;<B><U>Release</U></B>&rdquo;) within the 60-day period following the Date of Termination, the Company
shall pay the Executive (i) severance pay in a lump sum in cash in an amount equal to (y) in the event of a termination during
the period of April 1, 2016 until April 30, 2016, the Executive&rsquo;s Base Salary multiplied by 2.0, less withholding or (z)
in the event of a termination at any other time other than as set forth in clause (y) above, one and one-half times the Executive&rsquo;s
Base Salary, less withholding (as applicable, &ldquo;<B><U>Severance Amount</U></B>&rdquo;), payable within 60 days after the Date
of Termination, but if that 60-day period extends over two calendar years, the Company shall make the payment in the second calendar
year, (ii) a bonus payment equal to (y) if the termination occurs on or before March 31, 2018, the Target Bonus pro-rated for the
portion of the year the Executive was employed by the Company prior to the termination or (z) if the termination occurs on or after
April 1, 2018, the average of the bonus payments, if any, made to the Executive with respect to the previous three (3) calendar
years preceding the date of termination of employment, pro-rated for the portion of the year that Executive is employed, and (iii)
provided that the Executive timely elects COBRA coverage, reimburse the Executive for the COBRA premiums paid by the Executive,
if any, for the continuation of coverage under the Executive&rsquo;s then-existing group company health plan that the Executive
and his dependents are eligible to receive for the earlier of (x) a period of up to 24 months from the date of the Executive&rsquo;s
termination of employment, or (y) until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Change in Control Provisions</U>. The provisions of this Section 6 set forth the Executive&rsquo;s rights and obligations upon
the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&rsquo;s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. The provisions of this Section 6 apply in addition to, and/or modify, the provisions of Section 5(b) regarding
severance pay and benefits upon a termination of employment, if applicable, if the termination of employment occurs within 12 months
after the occurrence of a Change in Control. These provisions are subject to the Executive providing (and not revoking) the Company
with a fully effective Release. These provisions terminate and are of no further force or effect beginning 12 months after the
occurrence of such a Change in Control.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severance</U>. If within 12 months following a Change of Control (i) the Company terminates the Executive&rsquo;s employment
with the Company other than for Cause, or (ii) the Executive resigns from his employment with the Company for Good Reason, within
the 60-day period following the Date of Termination, then, in lieu of paying the Executive the Severance Amount and in addition
to paying the Accrued Benefit, Company shall: (i) pay the Executive severance pay in a lump sum in cash (less applicable withholdings)
in an amount equal to the Executive&rsquo;s Base Salary multiplied by 2.0 (&ldquo;<B><U>Change in Control Severance Amount</U></B>&rdquo;),
payable within 60 days after the Date of Termination, but if that 60-day period extends over two calendar years, the Company shall
make the payment in the second calendar year; (ii) pay the Executive a bonus payment equal to the Target Bonus pro-rated for that
portion of the year that Executive is employed, (iii) provided that the Executive timely elects COBRA coverage, reimburse the Executive
for the COBRA premiums paid by the Executive, if any, for the continuation of coverage under the Executive&rsquo;s then-existing
group company health plan that the Executive and his dependents are eligible to receive for the earlier of (x) a period of up to
24 months from the date of the Executive&rsquo;s termination of employment, or (y) until the Executive becomes eligible to receive
health insurance benefits under any other employer&rsquo;s group health plan; and (iv) cause all stock options and other stock-based
awards granted after the Effective Date and held by the Executive to immediately accelerate, vest, and become fully exercisable
or nonforfeitable.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Additional Limitation.</U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Anything in this Agreement to the contrary notwithstanding, if the amount of any compensation, payment, acceleration, benefit,
or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable
pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue
Code of 1986, as amended (the &ldquo;<B><U>Code</U></B>&rdquo;) and the applicable regulations thereunder (the &ldquo;<B><U>Severance
Payments</U></B>&rdquo;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Severance Payments will
be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments does not exceed the Threshold
Amount (defined below), but if the after-tax amount the Executive would receive if there were no reduction pursuant to this section
(including any federal, state, and local taxes) exceeds the after-tax amount the Executive would receive if the Severance Payments
were reduced below the Threshold Amount, the Severance Payments will no longer be so reduced. If Severance Payments are required
to be reduced, the Severance Payments will be reduced in the following order: (1) cash payments not subject to Section 409A of
the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms
of benefits.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For the purposes of this Section 6(c), &ldquo;<B><U>Threshold Amount</U></B>&rdquo; means three times the Executive&rsquo;s &ldquo;base
amount&rdquo; within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00).</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The determinations under this Section 6(c) will be made by a nationally recognized accounting firm selected by the Company (the
&ldquo;<B><U>Accounting Firm</U></B>&rdquo;), which must provide detailed supporting calculations both to the Company and the Executive
within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company
or the Executive.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Change in Control Definition</U>. For purposes of this Section 6, &ldquo;<B><U>Change in Control</U></B>&rdquo; means the consummation
of any of the following:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the sale of all or substantially all of the assets of the Company or the Parent to an unrelated person or entity;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a merger, reorganization, or consolidation involving the Company or the Parent in which the shares of voting stock outstanding
immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving or resulting
entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power of the surviving
or resulting entity;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the acquisition of all or a majority of the outstanding voting stock of the Company or the Parent in a single transaction or a
series of related transactions by a person or group of persons; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
any other acquisition of the business of the Company or the Parent, as determined by the Board; </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">but the Company&rsquo;s initial public offering, any subsequent public offering, or another
capital raising event, or a merger effected solely to change the Company&rsquo;s domicile does not constitute a Change in Control.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Section 409A Compliance</U>. The following rules shall apply, to the extent necessary, with respect to distribution of the payments
and benefits, if any, to be provided to the Executive under this Agreement. Subject to the provisions in this Section, the severance
payments pursuant to this Agreement shall begin only upon the date of the Executive's &ldquo;separation from service&rdquo; (determined
as set forth below) which occurs on or after the date of the Executive's termination of employment.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Agreement is intended to comply with Code Section 409A (to the extent applicable) and the parties hereto agree to interpret,
apply and administer this Agreement in the least restrictive manner necessary to comply therewith and without resulting in any
increase in the amounts owed hereunder by the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a
separate &ldquo;payment&rdquo; for purposes of Section 409 A of the Internal Revenue Code of 1986, as amended, and the guidance
issued thereunder (&ldquo;Section 409A&rdquo;). Neither the Executive nor the Company shall have the right to accelerate or defer
the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If, as of the date of the Executive's &ldquo;separation from service&rdquo; from the Company, the Executive is not a &ldquo;specified
employee&rdquo; (within the meaning of Section 409 A), then each installment of the severance payments and benefits shall be made
on the dates and terms set forth in this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If, as of the date of the Executive's &ldquo;separation from service&rdquo; from the Company, the Executive is a &ldquo;specified
employee&rdquo; (within the meaning of Section 409A), then:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set
forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral
period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section
1.409A-l(b)(4) to the maximum extent permissible under Section 409A; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each installment of the severance payments and benefits due under this Agreement that is not described in Section 7(d)(i) above
and that would, absent this subsection, be paid within the six-month period following the Executive's &ldquo;separation from service&rdquo;
from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier,
the Executive's death), with any such installments that are required to be delayed being accumulated during the six-month period
and paid in a lump sum on the date that is six months and one day following the Executive's separation from service and any subsequent
installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding
provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent
that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by
reason of the application of Treasury Regulation 1.409A-1 (b)(9)(iii) (relating to separation pay upon an involuntary separation
from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid
no later than the last day of the second taxable year following the taxable year in which the separation from service occurs.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The determination of whether and when the Executive's separation from service from the Company has occurred shall be made in a
manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h). Solely for purposes
of this Section, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered a single employer as
determined under Treasury Regulation Section 1.409A-l(h)(3).</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements
of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable,
the requirements that (i) any reimbursement is for expenses incurred during the Executive's lifetime (or during a shorter period
of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect
the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made
on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement
is not subject to set off or liquidation or exchange for any other benefit.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding anything herein to the contrary, the Company shall have no liability to the Executive or to any other person if
the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not
so exempt or compliant.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Confidential Information</U>. Employee agrees to enter into the Company&rsquo;s standard Employee Confidentiality and Proprietary
Rights Agreement (the &ldquo;Confidential Information Agreement&rdquo;). Employee&rsquo;s receipt of any benefits in connection
with or following Employee&rsquo;s termination will be subject to Employee continuing to comply with the terms of Confidential
Information Agreement. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Cooperation; Other Documents; Non-Disclosure</U>. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Litigation
and Regulatory Cooperation</U>. During and after the Executive&rsquo;s employment, the Executive shall reasonably cooperate
with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the
future against or on behalf of the Company which relate to events or occurrences that took place while the Executive was
employed by the Company. The Executive&rsquo;s reasonable cooperation in connection with such claims or actions includes, but
is not limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf
of the Company at mutually convenient times. During and after the Executive&rsquo;s employment, the Executive also shall
reasonably cooperate with the Company in connection with any investigation or review of any federal, state, or local
regulatory authority as any such investigation or review relates to events or occurrences that took place while the Executive
was employed by the Company. The Company shall compensate Executive for his time spent, and reimburse the Executive for any
reasonable out-of-pocket expenses incurred, in connection with the Executive&rsquo;s performance of obligations pursuant to
this Section 9(a). Non-Disclosure. The Executive shall use his reasonable efforts to maintain the confidentiality of the terms
of this Agreement to the extent permitted by law, but the Executive may disclose the terms to his immediate family members
and to his legal, tax, and other advisors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Arbitration of Disputes</U>. <U> </U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Scope of Arbitration Requirement</U>. The Executive hereby waives his right to a trial before a judge or jury and agrees to
arbitrate before a neutral arbitrator skilled in hearing similar disputes any and all claims or disputes arising out of this Agreement
and any and all claims arising from or relating to his employment, including but not limited to claims against any current or former
employee, director, or agent of the Company, claims of wrongful termination, retaliation, discrimination, harassment, breach of
contract (including but not limited to disputes pertaining to the formation, validity, interpretation or effect of this Agreement),
breach of the covenant of good faith and fair dealing, defamation, invasion of privacy, fraud, misrepresentation, constructive
discharge or failure to provide a leave of absence, or claims regarding commissions, stock options or bonuses, infliction of emotional
distress, or unfair business practices (each an &ldquo;<B><U>Arbitrable Dispute</U></B>&rdquo;). Arbitration is the exclusive remedy
for any Arbitrable Dispute, instead of any court or administrative action, unless the waiver of a certain court or administrative
action is prohibited by law.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Procedure</U>. Any arbitration will be administered by the American Arbitration Association (&ldquo;<B><U>AAA</U></B>&rdquo;)
and the neutral arbitrator will be selected in a manner consistent with AAA&rsquo;s National Rules For The Resolution of Employment
Disputes (&ldquo;<B><U>Applicable Arbitration Rules</U></B>&rdquo;). Any arbitration under this Agreement must be conducted in
the Commonwealth of Pennsylvania, and the arbitrator must administer and conduct the arbitration in accordance with the Applicable
Arbitration Rules, except that (i) the arbitrator must allow for the discovery authorized by the Pennsylvania Rules of Civil Procedure
or the discovery that the arbitrator decides is necessary for the Parties to vindicate their respective claims or defenses, and
(ii) presentation of evidence will be governed by the Pennsylvania Rules of Evidence. Within a reasonable time after the conclusion
the arbitration proceedings, the arbitrator shall issue a written decision and must include the findings of fact and law that support
that decision. The arbitrator has the power to award any remedies available under applicable law, and the arbitrator&rsquo;s decision
is final and binding on both Parties, except to the extent applicable law allows for judicial review of arbitration awards.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Costs</U>. The Company shall bear all the costs of arbitration, except that the Executive shall pay the first $125.00 of any
filing fees associated with any arbitration the Executive initiates. Both Parties are responsible for their own attorneys&rsquo;
fees, and the arbitrator may not award attorneys&rsquo; fees unless a statute or contract at issue specifically authorizes such
an award.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Applicability</U>. This Section 10, does not apply to (i) workers&rsquo; compensation or unemployment insurance claims or (ii)
claims concerning ownership, validity, infringement, misappropriation, disclosure, misuse, or enforceability of any confidential
information, patent right, copyright, mask work, trademark, or any other trade secret or intellectual property held or sought by
either the Executive or the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Remedy</U>. Should any party institute any legal action or administrative proceeding against the other with respect to any claim
waived by this Agreement or pursue any Arbitrable Dispute by any method other than as set forth above, except to enforce the arbitration
provisions and as expressly provided for in this Section 9, the responding party is entitled to recover from the initiating party
all damages, costs, expenses, and attorneys&rsquo; fees incurred as a result of that action.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Consent to Jurisdiction</U>. To the extent that any court action is initiated to enforce Section 10 of this Agreement, the Parties
hereby consent to the jurisdiction of any state court in the Commonwealth of Pennsylvania and any U.S. District Court sitting in
the Commonwealth of Pennsylvania. Accordingly, with respect to any such court action, the Executive (a) submits to the personal
jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute,
rule of court, or otherwise) with respect to personal jurisdiction or service of process.<SUP> </SUP></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Integration</U>. This Agreement, together with the Share Repurchase Agreement and the Confidential Information Agreement executed
concurrently herewith, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersedes
all prior agreements between the Parties concerning such subject matter, but any indemnification agreement between the Parties,
and all plans and agreements related to stock options and other stock-based awards held by the Executive remain in full force and
effect except to the extent specifically modified by this Agreement. Without limiting the foregoing, the parties agree that any
employment agreement, other than this Agreement, existing between the Parties as of the date hereof is hereby terminated and shall
be of no force of effect. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 13.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Withholding</U>. All payments made by the Company to the Executive under this Agreement will be net of any tax or other amounts
required to be withheld by the Company under applicable law. Nothing in this Agreement is to be construed to obligate the Company
to design or implement any compensation arrangement in a way that minimizes tax consequences for the Executive.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 14.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successor to the Executive</U>. This Agreement inures to the benefit of and is enforceable by the Executive&rsquo;s personal
representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the Executive dies after his termination
of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue
the payments to the Executive&rsquo;s beneficiary designated in writing to the Company prior to his death (or to his estate, if
the Executive fails to make such a designation).</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 15.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Enforceability</U>. If any portion or provision of this Agreement is declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of that portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, will not be affected by that declaration, and each portion and provision
of this Agreement will continue to be valid and enforceable to the fullest extent permitted by law. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 16.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Survival</U>. The provisions of this Agreement survive the termination of this Agreement and/or the termination of the Executive&rsquo;s
employment to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 17.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver</U>. No waiver of any provision of this Agreement is effective unless made in writing and signed by the waiving party,
and, in the case of the Company only after the waiver has been specifically approved by the Board. The failure of either party
to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement,
will not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 18.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement are sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage
prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or,
in the case of the Company, at its main offices, attention to the Corporate Secretary.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 19.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly
authorized representative of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 20.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law</U>. This is a Pennsylvania contract and is to be construed under and be governed in all respects by the laws
of the Commonwealth of Pennsylvania without giving effect to the conflict of laws principles of that state.<SUP> </SUP></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 21.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each party on separate counterparts,
each of which counterparts, when so executed and delivered is to be taken to be an original; but those counterparts together constitute
one and the same document. PDF, facsimile, scanned, and electronic signatures have the same legal effect as original ink signatures.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 22.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation,
or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this
Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the
Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession is a material breach of this
Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 23.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Voluntary Nature of Agreement</U>. The Executive acknowledges and agrees that he is executing this Agreement voluntarily and
without any duress or undue influence by the Company or anyone else. The Executive further acknowledges and agrees that he has
carefully read this Agreement and that he has asked any questions needed for him to fully understand the terms, consequences, and
binding effect of this Agreement. The Executive agrees that he has been provided an opportunity to seek the advice of an attorney
of his choice before signing this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">[Signature Page Follows]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Parties are executing this Executive Agreement as of the date
set forth in the introductory paragraph.<BR></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>ONCORE BIOPHARMA, INC.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">By: <U>/s/ Mark Murray &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Printed Name: Mark Murray</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Title: Chief Executive Officer</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>EXECUTIVE</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><U>/s/ Patrick T. Higgins&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Printed Name: Patrick T. Higgins</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">[Signature Page to Executive Employment Agreement]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>GENERAL RELEASE LANGUAGE</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the &ldquo;<B><U>Executive&rsquo;s
Parties</U></B>&rdquo;), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates,
subsidiaries, directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns,
insurers, attorneys, benefit plans sponsored by the Company, and said plans&rsquo; fiduciaries, agents and trustees (the &ldquo;<B><U>Company&rsquo;s
Parties</U></B>&rdquo;), from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions,
damages, judgments, levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive&rsquo;s
Parties have, have had, or may in the future claim to have against the Company&rsquo;s Parties by reason of, arising out of, related
to, or resulting from the Executive&rsquo;s employment with the Company or the termination of that employment. This release specifically
includes without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach
of contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. This specifically includes, without limitation, any claim that the Executive
has or has had under Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment Act, as amended,
the Americans with Disabilities Act, as amended, and the Employee Retirement Income Security Act of 1974, as amended. It is understood
and agreed that the waiver of benefits and claims contained in this section does not include a waiver of the right to payment of
any vested, nonforfeitable benefits to which the Executive or a beneficiary of the Executive may be entitled under the terms and
provisions of any employee benefit plan of the company which have accrued as of the Date of Termination, and does not include a
waiver of the right to benefits and payment of consideration to which the Executive may be entitled under this Agreement or any
of the agreements contemplated by this Agreement (including the indemnification agreement and the stock option agreement). The
Executive acknowledges that he is entitled to only the severance benefits and compensation set forth in this Agreement, and that
all other claims for any other benefits or compensation are hereby waived, except those expressly stated in the preceding sentence.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>exh_107.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">SHARE REPURCHASE AGREEMENT</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This Share Repurchase Agreement (&ldquo;<B><U>Agreement</U></B>&rdquo;)
is made effective as of July 11, 2015 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;) between Tekmira Pharmaceuticals Corporation
(the &ldquo;<B><U>Company</U></B>&rdquo;), and Patrick T. Higgins (&ldquo;<B><U>Executive</U></B>&rdquo;) (together the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">RECITALS</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">A.</TD><TD>As of the Effective Date, OnCore Biopharma, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&ldquo;<B><U>OnCore</U></B>&rdquo;)
and Executive have agreed to terminate any and all existing employment agreements (including any amendments thereto) and set forth
their mutual rights and obligations in that certain Executive Employment Agreement dated as of the date hereof, whereby Executive
will serve as the Chief Business &amp; Commercial Operations Officer (&amp; US Site Head) of OnCore (the &ldquo;<B><U>Employment
Agreement</U></B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">B.</TD><TD>This Agreement is being entered into by and between the Parties in connection with and as a condition to the execution of the
Employment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">THEREFORE, the Parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Right of Repurchase</U>. Executive and/or his affiliates own 1,764,815 Common Shares of the Company (the &ldquo;<B><U>Shares</U></B>&rdquo;).
906,355 of the Shares (the &ldquo;<B><U>Buyback Shares</U></B>&rdquo;) will be subject to repurchase by the Company under the
circumstances and at the prices described below (collectively, the &ldquo;<B><U>Repurchase Right</U></B>&rdquo;). </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Employment</U>. Except as otherwise set forth herein, in the event that OnCore terminates the Executive's employment
with OnCore for Cause (as defined in the Employment Agreement) or the Executive terminates his employment other than for Good Reason
(as defined in the Employment Agreement), the Company may, during the 60-day period following such termination, repurchase any
or all of the Buyback Shares that have not previously been released from the Repurchase Right (pursuant to Section 2 hereof) as
of the date of termination of Executive&rsquo;s employment, at a purchase price of $0.001 per share.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice of Repurchase</U>. In the event that the Company elects to exercise its Repurchase Right pursuant to this Section 1,
it shall provide the Executive with written notice of such election within the 60-day period following the termination date. The
closing shall occur within ten (10) business days following delivery of the written notice, at which time the Company shall deliver
to the Executive an amount equal to the purchase price, by cash, check or wire transfer, and the Executive shall deliver to the
Company the stock certificate(s) evidencing the Buyback Shares that are the subject of the repurchase, together with executed stock
powers. Failure by the Executive to deliver the stock certificates shall not affect the transfer of ownership of the Buyback Shares
to the Company. Upon payment of the purchase price, the stock ledger of the Company shall reflect the Company as the owner of the
Buyback Shares and the Executive will have no rights whatsoever in the Buyback Shares.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Repurchase Right</U>. The Company&rsquo;s Repurchase Right shall terminate as set forth below. The schedule
of termination of the Repurchase Right described in Section 2(a) is shown graphically in <U>Exhibit A</U> attached hereto. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination Schedule</U>. For the period commencing as of Effective Date and ending August 31, 2017, the right of the Company
to purchase the Buyback Shares shall terminate:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as to 113,294 of the Buyback Shares, subject to adjustment to reflect stock splits, reverse stock splits or combinations, on each
of (i) November 30, 2015, (ii) February 29, 2016, (iii) May 31, 2016, (iv) August 31, 2016 and (v) November 30, 2016; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as to 113,295 of the Buyback Shares, subject to adjustment to reflect stock splits, reverse stock splits or combinations, on each
of (i) February 28, 2017, (ii) May 31, 2017 and (iii) August 31, 2017.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Other Termination Events</U>. The right of the Company to repurchase Buyback Shares shall terminate with respect to all Buyback
Shares which have not previously been released (pursuant to Section 2 hereof) from the right of repurchase if: </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Executive's employment with OnCore terminates as a result of a termination without Cause (as defined in the Employment Agreement),
by the Executive for Good Reason (as defined in the Employment Agreement), or as a result of the death or Disability (as defined
in the Employment Agreement) of the Executive; or </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during the period from April 1, 2016 until April 30, 2016, the Executive&rsquo;s employment with OnCore is terminated for any reason.
</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0in">Notwithstanding the foregoing, the Parties agree that Executive waives
any right to claim a &ldquo;Good Reason&rdquo; under this Section 2(b) for any event, change or other circumstance which exists,
has occurred, or is otherwise disclosed to Executive prior to the Effective Date. The Parties further agree that Executive hereby
waives and releases any rights to terminate OnCore&rsquo;s right to repurchase Buyback Shares of OnCore or the Company under any
agreement entered into prior to the date hereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Enforceability</U>. If any portion or provision of this Agreement is declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of that portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, will not be affected by that declaration, and each portion and provision
of this Agreement will continue to be valid and enforceable to the fullest extent permitted by law. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Survival</U>. The provisions of this Agreement survive the termination of this Agreement and/or the termination of the Executive&rsquo;s
employment to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver</U>. No waiver of any provision of this Agreement is effective unless made in writing and signed by the waiving party,
and, in the case of the Company only after the waiver has been specifically approved by the Board. The failure of either party
to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement,
will not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement are sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage
prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or,
in the case of the Company, at its main offices, attention to the Corporate Secretary.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly
authorized representative of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law</U>. This is a Delaware contract and is to be construed under and be governed in all respects by the laws of the
State of Delaware without giving effect to the conflict of laws principles of that state.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each party on separate counterparts,
each of which counterparts, when so executed and delivered is to be taken to be an original; but those counterparts together constitute
one and the same document. PDF, facsimile, scanned, and electronic signatures have the same legal effect as original ink signatures.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation,
or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this
Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the
Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession is a material breach of this
Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Voluntary Nature of Agreement</U>. Executive acknowledges and agrees that he is executing this Agreement voluntarily and without
any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that he has carefully read
this Agreement and that he has asked any questions needed for him to fully understand the terms, consequences, and binding effect
of this Agreement. Executive agrees that he has been provided an opportunity to seek the advice of an attorney of his choice before
signing this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Parties are executing this Executive Agreement as of the date
set forth in the introductory paragraph.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>TEKMIRA PHARMACEUTICALS CORPORATION </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">By: <U>/s/ Mark Murray &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Printed Name: Mark Murray</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Title: Chief Executive Officer</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>EXECUTIVE</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><U>/s/ Patrick T. Higgins&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Printed Name: Patrick T. Higgins</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>Termination of Repurchase Rights</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Repurchase Right Termination Date</U></B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Number of Common Shares</U></B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Shares Subject to Repurchase</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Effective Date</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">906,355</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">November 30, 2015</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">793,061</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">February 29, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">679,767</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">May 31, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">566,473</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">August 31, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">453,179</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">November 30, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">339,885</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">February 28, 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">226,590</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">May 31, 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">August 31, 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>10
<FILENAME>exh_108.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.8</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">EXECUTIVE EMPLOYMENT AGREEMENT</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This Executive Employment Agreement (&ldquo;<B><U>Agreement</U></B>&rdquo;)
is made effective as of July 11, 2015 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;) by and between OnCore Biopharma, Inc. (the
&ldquo;<B><U>Company</U></B>&rdquo;), and Michael J. Sofia (the &ldquo;<B><U>Executive</U></B>&rdquo;) (together the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">RECITALS</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">A.</TD><TD>As of the Effective Date, the Company and the Executive have agreed to terminate any and all existing employment agreements
(including any amendments thereto) between the Executive and the Company and set forth their mutual rights and obligations in this
Agreement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">B.</TD><TD>In connection with and as a condition to the execution of this Agreement, Tekmira Pharmaceuticals Corporation, the parent of
the Company (&ldquo;<B><U>Tekmira</U></B>&rdquo;), and the Executive have also agreed to the terms of that certain Share Repurchase
Agreement, dated as of the date hereof (the &ldquo;<B><U>Share Repurchase Agreement</U></B>&rdquo;), whereby certain common shares
of Tekmira owned by the Executive are subject to a repurchase right of Tekmira, pursuant to the terms and conditions thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">THEREFORE, the Parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Position and Duties</U>. The Executive will serve as Chief Scientific Officer of the Company, and will have powers and duties
consistent with such position as may from time to time be prescribed by the Chief Executive Officer of the Company. As Chief Scientific
Officer of the Company, the Executive shall devote his full working time and efforts to the business and affairs of the Company.
Notwithstanding the foregoing, the Executive may manage his personal investments or engage charitable or other community activities
and may engage in the publishing of scientific articles, speaking engagements and scientific advisory panels except as restricted
or prohibited by the terms of a confidentiality agreement between the Executive and the Company and as long as those engagements,
services and activities, individually or in the aggregate, do not interfere with the Executive&rsquo;s performance of his duties
to the Company. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><U>Section 2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Compensation and Related Matters.</FONT></U>(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Base Salary</U>. The Executive&rsquo;s base salary will be US$350,000 per year. The Executive&rsquo;s base salary will be reviewed
annually by the Chief Executive Officer of the Company and is subject to increase but not decrease except for an across-the-board
salary reduction affecting all senior executives of the Company. The base salary in effect at any given time is referred to as
&ldquo;<B><U>Base Salary</U></B>&rdquo; and this Agreement need not be modified to reflect a change in Base Salary. Notwithstanding
the foregoing, for the purposes of determining the &ldquo;Base Salary&rdquo; for a termination by the Executive for &ldquo;Good
Reason&rdquo; solely under Section 4(d)(iv), the Base Salary shall be the amount set forth in the first sentence of this Section
2(a). The Base Salary is subject to withholding and payable in a manner that is consistent with the Company&rsquo;s usual payroll
practices for senior executives.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Bonus</U>. The Executive is eligible to be considered for an annual discretionary bonus of up to 40% of Base Salary (such bonus,
the &ldquo;<B>Target Bonus</B>&rdquo;); however, notwithstanding the foregoing, for the purposes of determining the &ldquo;Target
Bonus&rdquo; for a termination by the Executive for &ldquo;Good Reason&rdquo; solely under Section 4(d)(iv), the Target Bonus shall
be 40% of Base Salary). The Target Bonus shall be subject to the terms of the bonus plan and the approval of the Company&rsquo;s
Board of Directors (the &ldquo;<B><U>Board</U></B>&rdquo;), in its sole discretion, on an annual basis.<U> </U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Expenses</U>. The Executive is entitled to receive prompt reimbursement for all reasonable expenses incurred by him in performing
services under this Agreement, in accordance with the policies and procedures then in effect and established by the Company for
its senior executives.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Other Benefits</U>. The Executive is entitled to participate in or receive benefits under the Company&rsquo;s employee benefit
plans as they may be adopted and amended from time to time, subject to the terms and conditions of those employee benefit plans.
</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Equity Compensation</U>. Subject to the discretionary approval of the Company&rsquo;s Board of Directors, and in accordance
with the Company&rsquo;s annual performance and compensation review process, the Executive shall be eligible to receive equity
awards under the Tekmira Pharmaceuticals Corporation Share Incentive Plan and or any other similar equity incentive plan </FONT>to
the same extent as other executives of the Company<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Vacations</U>. The Executive is entitled to paid holidays and vacation days each year, in an amount determined in accordance
with and subject to the Company&rsquo;s applicable policies in effect, and as may be amended from time to time. Unless a different
number is established by the Board in its sole discretion, the Executive will be entitled to 20 days of vacation per calendar year,
which will be pro-rated for any year in which the Executive is only employed with the Company for a portion of the year or for
any period in which the Executive is not a full-time employee. Carry-over of vacation days will be according to Company policy,
and any accrued but unused vacation days will be paid out upon termination. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Competition and Non-Solicitation</U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Executive acknowledges that the Company&rsquo;s industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company&rsquo;s interests if they join a competing business immediately upon
leaving the Company. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions:</U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Affiliate&rdquo; means any person or entity directly or indirectly controlling, controlled by or under common control with
the Company, where control may be by either management authority or equity interest.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Business&rdquo; or &ldquo;Business of the Company&rdquo; means (a) researching, developing, producing and marketing any
treatment for hepatitis B virus infection in humans or (b) any other treatment area in which the Company has an active research
and development program on the date this Agreement terminates and in connection with which the Executive directly provided service
or had direct supervisory responsibilities.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Competing Business&rdquo; means any endeavor, activity or business which is competitive in any material way with the Business
of the Company worldwide.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Contact&rdquo; means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder,
investor, collaborator, strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates)
with whom the Executive dealt or otherwise became aware of during the term of his employment in any capacity with the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Restricted Period&rdquo; means: (a) with respect to Section 3(d) the eighteen (18) month period commencing immediately after
the Executive&rsquo;s employment terminates and (b) with respect to Section 3(f), the twelve (12) month period commencing immediately
after the Executive&rsquo;s employment terminates.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Reasonableness</U>. The Executive hereby acknowledges and agrees that:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
both before and since the Effective Date the Company has operated and competed and will operate and compete worldwide, with respect
to the Business of the Company;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
competitors of the Company and the Business are located worldwide; </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in order to protect the Company adequately, any enjoinder of competition would have to apply to any country in which the Company,
during the term of the Executive&rsquo;s employment, had material business relationships; </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during the course of the Executive&rsquo;s employment with the Company, on behalf of the Company, the Executive will acquire knowledge
of, and will come into contact with, initiate and establish relationships with, both existing and new clients, customers, suppliers,
principals, contacts and prospects of the Company, and that in some circumstances the Executive may become the senior or sole representative
of the Company dealing with such persons; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper protection of the Business
of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Restrictive Covenant</U>. Except as set forth on <U>Exhibit B</U> attached hereto, during the term of the Executive&rsquo;s
employment and for the Restricted Period after the termination thereof, the Executive shall not, without the advance written consent
of the Board, such consent to be granted or withheld in the Board&rsquo;s sole discretion, within the geographic scope of any country
in which the Company, during the term of the Executive&rsquo;s employment, had material business relationships, carry on or be
employed by or engaged in or have any financial or other interest in or be otherwise commercially involved in a Competing Business,
directly or indirectly, either individually or in partnership or jointly or in conjunction with any person, firm, corporation or
other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exception</U>. The Executive shall not be in default of Section 3(d) by virtue of the Executive:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
following the termination of employment, holding, strictly for portfolio purposes and as a passive investor, no more than five
percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or other entity that is a Competing
Business; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during the term of his employment, holding, strictly for portfolio purposes and as a passive investor, issued and outstanding shares
of, or any other interest in, any corporation or other entity, the business of which corporation or other entity is in the same
Business as the Company provided such corporation is not a Competing Business, and provided further that the Executive first obtains
the Company&rsquo;s written consent, which consent will not be unreasonably withheld.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">If the Executive holds issued and outstanding shares or any other interest in a corporation
or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares or other interest the business
of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose of the Executive&rsquo;s shares
or other interest in such corporation or other entity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Solicitation</U>. The Executive shall not, during the term of his employment and for the Restricted Period after the termination
thereof for any reason, whether legal or illegal, either individually or in partnership or jointly or in conjunction with any person,
firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever,
without the prior written and informed consent of the Company, directly or indirectly:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for any purpose which is competitive
with the Business; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
accept (or procure or assist the acceptance of) any business from any Contact if such business is competitive with the Business;
or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
be employed by or supply (or procure or assist the supply of) any goods or services to any Contact for any purpose which the Executive
knows or has reason to know is competitive with the Business; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise entice away from or solicit,
induce or encourage to leave the employment or engagement of the Company, any individual who is employed or engaged by the Company
at the time of any such offer, solicitation or enticement whether or not such individual would commit any breach of his contract
or terms of employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall
be permitted, solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Validity</U>. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&rsquo;s
activities following the termination of the Executive&rsquo;s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive acknowledges and agrees that, simultaneous with and as a condition to this Agreement, Tekmira and the Executive have
agreed to enter into the Share Repurchase Agreement</FONT>, in order to <FONT STYLE="font-size: 10pt">accelerate the termination
of certain of Tekmira&rsquo;s rights to repurchase common shares of Tekmira owned by the Executive, and that such Agreement shall
be considered as a portion of the consideration received by the Executive on account of the Executive&rsquo;s obligations under
this Section 3. The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable
to any extent by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of
the restriction, the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that
which is in fact declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration,
in order to ensure that the intention of the parties is given the greatest possible effect.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination</U>. The Executive&rsquo;s employment by the Company may be terminated without any breach of this Agreement under
the following circumstances:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Death</U>. The Executive&rsquo;s employment hereunder terminates upon his death.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Disability</U>. The Company may terminate the Executive&rsquo;s employment if he is disabled (as determined by the Chief Executive
Officer) in a manner that renders the Executive unable to perform the essential functions of his then existing position or positions
under this Agreement with or without reasonable accommodation for a period of six months or more. Nothing in this Section 4(b)
is to be construed to waive the Executive&rsquo;s rights, if any, under existing law including, without limitation, the Family
and Medical Leave Act of 1993, 29 U.S.C. &sect;2601 et seq., and the Americans with Disabilities Act, 42 U.S.C. &sect;12101 et
seq. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by Company for Cause</U>. For purposes of this Agreement, &ldquo;For Cause&rdquo; shall mean: (i) Employee is charged
with a felony (excluding a DUI) or any violation of state or federal securities laws; (ii) Employee willfully engages in conduct
that is in bad faith and materially injurious to the Company, including but not limited to, misappropriation of trade secrets,
fraud or embezzlement; (iii) Employee commits a material breach of this Agreement; (iv) Employee willfully refuses to implement
or follow a lawful policy or directive of the Company; or (v) Employee engages in misfeasance or malfeasance demonstrated by a
pattern of failure to perform job duties diligently and professionally. The Company may terminate Employee&rsquo;s employment For
Cause at any time, without any advance notice. The Company shall pay Employee all compensation to which Employee is entitled up
through the date of termination, subject to any other rights or remedies of the Company under law; and thereafter all obligations
of the Company under this Agreement shall cease. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by the Company Without Cause or by the Executive for Good Reason</U>. The Company may terminate the Executive&rsquo;s
employment under this Agreement at any time without Cause and the Executive may terminate his employment with Good Reason. For
purposes of this Agreement, &ldquo;Good Reason&rdquo; means</FONT> <FONT STYLE="font-size: 10pt">the occurrence of any of the following
events without the Executive's prior written consent: (i) the failure of the Executive to be appointed to the position set forth
in Section 1, if not promptly cured after written notice; (ii) a reduction by the Company of the Executive's Base Salary or Target
Bonus percentage, except for an across-the-board salary reduction affecting all senior executives of the Company; (iii) a relocation
of Employee&rsquo;s principal place of employment by more than fifty (50) miles; (iv) a termination of the Executive&rsquo;s employment
by the Company or the Executive with OnCore for any reason during the period from April 1, 2016 until April 30, 2016 and (v) a
substantial and adverse change to the Executive&rsquo;s duties and responsibilities. For purposes of this Agreement, termination
for Good Reason requires Executive to comply with the &ldquo;Good Reason Process,&rdquo; which means that (i) the Executive reasonably
determines in good faith that a Good Reason condition has occurred; (ii) the Executive notifies the Company in writing of the first
occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (iii) the Executive cooperates
in good faith with the Company&rsquo;s efforts, for a period of not less than 30 days following that notice (the &ldquo;<B><U>Cure
Period</U></B>&rdquo;) to remedy the condition; (iv) notwithstanding the Company&rsquo;s efforts, the Good Reason condition continues
to exist; and (v) the Executive terminates his employment within 30 days after the end of the Cure Period. If the Company cures
the Good Reason condition during the Cure Period, Good Reason is deemed not to have occurred. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Any termination by the Company of the Executive&rsquo;s employment under this Agreement
that does not constitute a termination for Cause under Section 4(c) and does not result from the death or disability of the Executive
under Section 4(a) or (b) is a termination without Cause.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by the Executive</U>. Executive may terminate employment with the Company without Good Reason at any time for any
reason or no reason at all, upon thirty (30) days&rsquo; advance written notice. The Company shall have the option, in its sole
discretion, to make Executive&rsquo;s termination effective or to direct the Executive to perform no work and/or remain off premises
at any time prior to the end of such notice period as long as the Company pays Executive all compensation to which Executive is
entitled up through the last day of the 30 day notice period. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice of Termination</U>. Except for termination as specified in Section 4(a), any termination of the Executive&rsquo;s employment
by the Company or any termination of his employment by the Executive must be communicated by written Notice of Termination to the
other party. For purposes of this Agreement, a &ldquo;<B><U>Notice of Termination</U></B>&rdquo; means a notice that indicates
the specific termination provision in this Agreement that the termination is based upon.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Date of Termination</U>. &ldquo;<B><U>Date of Termination</U></B>&rdquo; means: (i) if the Executive&rsquo;s employment is terminated
by his death, the date of his death; (ii) if the Executive&rsquo;s employment is terminated on account of disability under Section
4(b) or by the Company for Cause under Section 4(c), or by the Company without Cause under Section 4(d) on the date the Notice
of Termination is given; (iii) if the Executive terminates his employment under Section 4(e) without Good Reason, on the date specified
by the Executive in the notice (which shall be at least thirty (30) days after the date of the Notice of Termination) and, if no
such date is specified, 30 days after the date of the Notice of Termination; and (iv) if the Executive terminates his employment
under Section 4(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding
the foregoing, if the Executive gives a Notice of Termination to the Company that takes effect at a future date, the Company may
unilaterally accelerate the Date of Termination and that acceleration will not be deemed a termination by the Company for purposes
of this Agreement. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compensation Upon Termination</U>. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination Generally</U>. If the Executive&rsquo;s employment with the Company is terminated for any reason, the Company shall
pay or provide to the Executive (or to his authorized representative or estate), (i) unpaid expense reimbursements; (ii) accrued
but unused vacation to the extent payment is required by law or Company policy; (iii) any vested benefits the Executive may have
under any employee benefit plan of the Company; (iv) any earned but unpaid base salary and (v) any earned but unpaid annual bonus
for the prior fiscal year (collectively the &ldquo;<B><U>Accrued Benefit</U></B>&rdquo;) on or before the time required by law,
but in no event more than 30 days after the Executive&rsquo;s Date of Termination. The Executive shall not be entitled to any other
salary, compensation, bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically
provided hereunder, under the Company&rsquo;s employee benefit plans or as expressly required by applicable law. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination by the Company Without Cause or by the Executive for Good Reason</U>. If the Executive&rsquo;s employment is terminated
by the Company without Cause or by the Executive for Good Reason, then the Company shall pay the Executive his Accrued Benefit
as of the Date of Termination. In addition, subject to the Executive providing the Company with a fully effective general release
of claims in a form and manner satisfactory to the Company that includes but is not limited to the terms set forth in the attached
<U>Exhibit A</U> (the &ldquo;<B><U>Release</U></B>&rdquo;) within the 60-day period following the Date of Termination, the Company
shall pay the Executive (i) severance pay in a lump sum in cash in an amount equal to (y) in the event of a termination during
the period of April 1, 2016 until April 30, 2016, the Executive&rsquo;s Base Salary multiplied by 2.0, less withholding or (z)
in the event of a termination at any other time other than as set forth in clause (y) above, one and one-half times the Executive&rsquo;s
Base Salary, less withholding (as applicable, &ldquo;<B><U>Severance Amount</U></B>&rdquo;), payable within 60 days after the Date
of Termination, but if that 60-day period extends over two calendar years, the Company shall make the payment in the second calendar
year, (ii) a bonus payment equal to (y) if the termination occurs on or before March 31, 2018, the Target Bonus pro-rated for the
portion of the year the Executive was employed by the Company prior to the termination or (z) if the termination occurs on or after
April 1, 2018, the average of the bonus payments, if any, made to the Executive with respect to the previous three (3) calendar
years preceding the date of termination of employment, pro-rated for the portion of the year that Executive is employed, and (iii)
provided that the Executive timely elects COBRA coverage, reimburse the Executive for the COBRA premiums paid by the Executive,
if any, for the continuation of coverage under the Executive&rsquo;s then-existing group company health plan that the Executive
and his dependents are eligible to receive for the earlier of (x) a period of up to 24 months from the date of the Executive&rsquo;s
termination of employment, or (y) until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Change in Control Provisions</U>. The provisions of this Section 6 set forth the Executive&rsquo;s rights and obligations upon
the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&rsquo;s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. The provisions of this Section 6 apply in addition to, and/or modify, the provisions of Section 5(b) regarding
severance pay and benefits upon a termination of employment, if applicable, if the termination of employment occurs within 12 months
after the occurrence of a Change in Control. These provisions are subject to the Executive providing (and not revoking) the Company
with a fully effective Release. These provisions terminate and are of no further force or effect beginning 12 months after the
occurrence of such a Change in Control.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severance</U>. If within 12 months following a Change of Control (i) the Company terminates the Executive&rsquo;s employment
with the Company other than for Cause, or (ii) the Executive resigns from his employment with the Company for Good Reason, within
the 60-day period following the Date of Termination, then, in lieu of paying the Executive the Severance Amount and in addition
to paying the Accrued Benefit, Company shall: (i) pay the Executive severance pay in a lump sum in cash (less applicable withholdings)
in an amount equal to the Executive&rsquo;s Base Salary multiplied by 2.0 (&ldquo;<B><U>Change in Control Severance Amount</U></B>&rdquo;),
payable within 60 days after the Date of Termination, but if that 60-day period extends over two calendar years, the Company shall
make the payment in the second calendar year; (ii) pay the Executive a bonus payment equal to the Target Bonus pro-rated for that
portion of the year that Executive is employed, (iii) provided that the Executive timely elects COBRA coverage, reimburse the Executive
for the COBRA premiums paid by the Executive, if any, for the continuation of coverage under the Executive&rsquo;s then-existing
group company health plan that the Executive and his dependents are eligible to receive for the earlier of (x) a period of up to
24 months from the date of the Executive&rsquo;s termination of employment, or (y) until the Executive becomes eligible to receive
health insurance benefits under any other employer&rsquo;s group health plan; and (iv) cause all stock options and other stock-based
awards granted after the Effective Date and held by the Executive to immediately accelerate, vest, and become fully exercisable
or nonforfeitable.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Additional Limitation.</U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Anything in this Agreement to the contrary notwithstanding, if the amount of any compensation, payment, acceleration, benefit,
or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable
pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue
Code of 1986, as amended (the &ldquo;<B><U>Code</U></B>&rdquo;) and the applicable regulations thereunder (the &ldquo;<B><U>Severance
Payments</U></B>&rdquo;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Severance Payments will
be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments does not exceed the Threshold
Amount (defined below), but if the after-tax amount the Executive would receive if there were no reduction pursuant to this section
(including any federal, state, and local taxes) exceeds the after-tax amount the Executive would receive if the Severance Payments
were reduced below the Threshold Amount, the Severance Payments will no longer be so reduced. If Severance Payments are required
to be reduced, the Severance Payments will be reduced in the following order: (1) cash payments not subject to Section 409A of
the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms
of benefits.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For the purposes of this Section 6(c), &ldquo;<B><U>Threshold Amount</U></B>&rdquo; means three times the Executive&rsquo;s &ldquo;base
amount&rdquo; within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00).</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The determinations under this Section 6(c) will be made by a nationally recognized accounting firm selected by the Company (the
&ldquo;<B><U>Accounting Firm</U></B>&rdquo;), which must provide detailed supporting calculations both to the Company and the Executive
within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company
or the Executive.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Change in Control Definition</U>. For purposes of this Section 6, &ldquo;<B><U>Change in Control</U></B>&rdquo; means the consummation
of any of the following:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the sale of all or substantially all of the assets of the Company or the Parent to an unrelated person or entity;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a merger, reorganization, or consolidation involving the Company or the Parent in which the shares of voting stock outstanding
immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving or resulting
entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power of the surviving
or resulting entity;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the acquisition of all or a majority of the outstanding voting stock of the Company or the Parent in a single transaction or a
series of related transactions by a person or group of persons; or</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
any other acquisition of the business of the Company or the Parent, as determined by the Board; </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">but the Company&rsquo;s initial public offering, any subsequent public offering, or another
capital raising event, or a merger effected solely to change the Company&rsquo;s domicile does not constitute a Change in Control.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Section 409A Compliance</U>. The following rules shall apply, to the extent necessary, with respect to distribution of the payments
and benefits, if any, to be provided to the Executive under this Agreement. Subject to the provisions in this Section, the severance
payments pursuant to this Agreement shall begin only upon the date of the Executive's &ldquo;separation from service&rdquo; (determined
as set forth below) which occurs on or after the date of the Executive's termination of employment.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Agreement is intended to comply with Code Section 409A (to the extent applicable) and the parties hereto agree to interpret,
apply and administer this Agreement in the least restrictive manner necessary to comply therewith and without resulting in any
increase in the amounts owed hereunder by the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a
separate &ldquo;payment&rdquo; for purposes of Section 409 A of the Internal Revenue Code of 1986, as amended, and the guidance
issued thereunder (&ldquo;Section 409A&rdquo;). Neither the Executive nor the Company shall have the right to accelerate or defer
the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If, as of the date of the Executive's &ldquo;separation from service&rdquo; from the Company, the Executive is not a &ldquo;specified
employee&rdquo; (within the meaning of Section 409 A), then each installment of the severance payments and benefits shall be made
on the dates and terms set forth in this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If, as of the date of the Executive's &ldquo;separation from service&rdquo; from the Company, the Executive is a &ldquo;specified
employee&rdquo; (within the meaning of Section 409A), then:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set
forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral
period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section
1.409A-l(b)(4) to the maximum extent permissible under Section 409A; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each installment of the severance payments and benefits due under this Agreement that is not described in Section 7(d)(i) above
and that would, absent this subsection, be paid within the six-month period following the Executive's &ldquo;separation from service&rdquo;
from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier,
the Executive's death), with any such installments that are required to be delayed being accumulated during the six-month period
and paid in a lump sum on the date that is six months and one day following the Executive's separation from service and any subsequent
installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding
provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent
that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by
reason of the application of Treasury Regulation 1.409A-1 (b)(9)(iii) (relating to separation pay upon an involuntary separation
from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid
no later than the last day of the second taxable year following the taxable year in which the separation from service occurs.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The determination of whether and when the Executive's separation from service from the Company has occurred shall be made in a
manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h). Solely for purposes
of this Section, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered a single employer as
determined under Treasury Regulation Section 1.409A-l(h)(3).</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements
of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable,
the requirements that (i) any reimbursement is for expenses incurred during the Executive's lifetime (or during a shorter period
of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect
the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made
on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement
is not subject to set off or liquidation or exchange for any other benefit.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding anything herein to the contrary, the Company shall have no liability to the Executive or to any other person if
the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not
so exempt or compliant.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Confidential Information</U>. Employee agrees to enter into the Company&rsquo;s standard Employee Confidentiality and Proprietary
Rights Agreement (the &ldquo;Confidential Information Agreement&rdquo;). Employee&rsquo;s receipt of any benefits in connection
with or following Employee&rsquo;s termination will be subject to Employee continuing to comply with the terms of Confidential
Information Agreement. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Cooperation; Other Documents; Non-Disclosure</U>. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Litigation
and Regulatory Cooperation</U>. During and after the Executive&rsquo;s employment, the Executive shall reasonably cooperate
with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the
future against or on behalf of the Company which relate to events or occurrences that took place while the Executive was
employed by the Company. The Executive&rsquo;s reasonable cooperation in connection with such claims or actions includes, but
is not limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf
of the Company at mutually convenient times. During and after the Executive&rsquo;s employment, the Executive also shall
reasonably cooperate with the Company in connection with any investigation or review of any federal, state, or local
regulatory authority as any such investigation or review relates to events or occurrences that took place while the Executive
was employed by the Company. The Company shall compensate Executive for his time spent, and reimburse the Executive for any
reasonable out-of-pocket expenses incurred, in connection with the Executive&rsquo;s performance of obligations pursuant to
this Section 9(a). Non-Disclosure. The Executive shall use his reasonable efforts to maintain the confidentiality of the
terms of this Agreement to the extent permitted by law, but the Executive may disclose the terms to his immediate family
members and to his legal, tax, and other advisors.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Arbitration of Disputes</U>. <U> </U></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Scope of Arbitration Requirement</U>. The Executive hereby waives his right to a trial before a judge or jury and agrees to
arbitrate before a neutral arbitrator skilled in hearing similar disputes any and all claims or disputes arising out of this Agreement
and any and all claims arising from or relating to his employment, including but not limited to claims against any current or former
employee, director, or agent of the Company, claims of wrongful termination, retaliation, discrimination, harassment, breach of
contract (including but not limited to disputes pertaining to the formation, validity, interpretation or effect of this Agreement),
breach of the covenant of good faith and fair dealing, defamation, invasion of privacy, fraud, misrepresentation, constructive
discharge or failure to provide a leave of absence, or claims regarding commissions, stock options or bonuses, infliction of emotional
distress, or unfair business practices (each an &ldquo;<B><U>Arbitrable Dispute</U></B>&rdquo;). Arbitration is the exclusive remedy
for any Arbitrable Dispute, instead of any court or administrative action, unless the waiver of a certain court or administrative
action is prohibited by law.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Procedure</U>. Any arbitration will be administered by the American Arbitration Association (&ldquo;<B><U>AAA</U></B>&rdquo;)
and the neutral arbitrator will be selected in a manner consistent with AAA&rsquo;s National Rules For The Resolution of Employment
Disputes (&ldquo;<B><U>Applicable Arbitration Rules</U></B>&rdquo;). Any arbitration under this Agreement must be conducted in
the Commonwealth of Pennsylvania, and the arbitrator must administer and conduct the arbitration in accordance with the Applicable
Arbitration Rules, except that (i) the arbitrator must allow for the discovery authorized by the Pennsylvania Rules of Civil Procedure
or the discovery that the arbitrator decides is necessary for the Parties to vindicate their respective claims or defenses, and
(ii) presentation of evidence will be governed by the Pennsylvania Rules of Evidence. Within a reasonable time after the conclusion
the arbitration proceedings, the arbitrator shall issue a written decision and must include the findings of fact and law that support
that decision. The arbitrator has the power to award any remedies available under applicable law, and the arbitrator&rsquo;s decision
is final and binding on both Parties, except to the extent applicable law allows for judicial review of arbitration awards.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Costs</U>. The Company shall bear all the costs of arbitration, except that the Executive shall pay the first $125.00 of any
filing fees associated with any arbitration the Executive initiates. Both Parties are responsible for their own attorneys&rsquo;
fees, and the arbitrator may not award attorneys&rsquo; fees unless a statute or contract at issue specifically authorizes such
an award.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Applicability</U>. This Section 10, does not apply to (i) workers&rsquo; compensation or unemployment insurance claims or (ii)
claims concerning ownership, validity, infringement, misappropriation, disclosure, misuse, or enforceability of any confidential
information, patent right, copyright, mask work, trademark, or any other trade secret or intellectual property held or sought by
either the Executive or the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Remedy</U>. Should any party institute any legal action or administrative proceeding against the other with respect to any claim
waived by this Agreement or pursue any Arbitrable Dispute by any method other than as set forth above, except to enforce the arbitration
provisions and as expressly provided for in this Section 9, the responding party is entitled to recover from the initiating party
all damages, costs, expenses, and attorneys&rsquo; fees incurred as a result of that action.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Consent to Jurisdiction</U>. To the extent that any court action is initiated to enforce Section 10 of this Agreement, the Parties
hereby consent to the jurisdiction of any state court in the Commonwealth of Pennsylvania and any U.S. District Court sitting in
the Commonwealth of Pennsylvania. Accordingly, with respect to any such court action, the Executive (a) submits to the personal
jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute,
rule of court, or otherwise) with respect to personal jurisdiction or service of process.<SUP> </SUP></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Integration</U>. This Agreement, together with the Share Repurchase Agreement and the Confidential Information Agreement executed
concurrently herewith, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersedes
all prior agreements between the Parties concerning such subject matter, but any indemnification agreement between the Parties,
and all plans and agreements related to stock options and other stock-based awards held by the Executive remain in full force and
effect except to the extent specifically modified by this Agreement. Without limiting the foregoing, the parties agree that any
employment agreement, other than this Agreement, existing between the Parties as of the date hereof is hereby terminated and shall
be of no force of effect. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 13.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Withholding</U>. All payments made by the Company to the Executive under this Agreement will be net of any tax or other amounts
required to be withheld by the Company under applicable law. Nothing in this Agreement is to be construed to obligate the Company
to design or implement any compensation arrangement in a way that minimizes tax consequences for the Executive.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 14.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successor to the Executive</U>. This Agreement inures to the benefit of and is enforceable by the Executive&rsquo;s personal
representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the Executive dies after his termination
of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue
the payments to the Executive&rsquo;s beneficiary designated in writing to the Company prior to his death (or to his estate, if
the Executive fails to make such a designation).</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 15.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Enforceability</U>. If any portion or provision of this Agreement is declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of that portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, will not be affected by that declaration, and each portion and provision
of this Agreement will continue to be valid and enforceable to the fullest extent permitted by law. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 16.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Survival</U>. The provisions of this Agreement survive the termination of this Agreement and/or the termination of the Executive&rsquo;s
employment to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 17.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver</U>. No waiver of any provision of this Agreement is effective unless made in writing and signed by the waiving party,
and, in the case of the Company only after the waiver has been specifically approved by the Board. The failure of either party
to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement,
will not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 18.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement are sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage
prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or,
in the case of the Company, at its main offices, attention to the Corporate Secretary.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 19.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly
authorized representative of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 20.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law</U>. This is a Pennsylvania contract and is to be construed under and be governed in all respects by the laws
of the Commonwealth of Pennsylvania without giving effect to the conflict of laws principles of that state.<SUP> </SUP></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 21.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each party on separate counterparts,
each of which counterparts, when so executed and delivered is to be taken to be an original; but those counterparts together constitute
one and the same document. PDF, facsimile, scanned, and electronic signatures have the same legal effect as original ink signatures.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 22.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation,
or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this
Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the
Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession is a material breach of this
Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 23.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Voluntary Nature of Agreement</U>. The Executive acknowledges and agrees that he is executing this Agreement voluntarily and
without any duress or undue influence by the Company or anyone else. The Executive further acknowledges and agrees that he has
carefully read this Agreement and that he has asked any questions needed for him to fully understand the terms, consequences, and
binding effect of this Agreement. The Executive agrees that he has been provided an opportunity to seek the advice of an attorney
of his choice before signing this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">[Signature Page Follows]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Parties are executing this Executive Agreement as of the date
set forth in the introductory paragraph.<BR>
<BR>
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ONCORE BIOPHARMA, INC.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">By: <U>/s/ Mark Murray &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Printed Name: Mark Murray</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Title: Chief Executive Officer</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>EXECUTIVE</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><U>/s/ Michael J.
Sofia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">Printed Name: Michael J. Sofia</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">[Signature Page to Executive Employment Agreement]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>GENERAL RELEASE LANGUAGE</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the &ldquo;<B><U>Executive&rsquo;s
Parties</U></B>&rdquo;), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates,
subsidiaries, directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns,
insurers, attorneys, benefit plans sponsored by the Company, and said plans&rsquo; fiduciaries, agents and trustees (the &ldquo;<B><U>Company&rsquo;s
Parties</U></B>&rdquo;), from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions,
damages, judgments, levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive&rsquo;s
Parties have, have had, or may in the future claim to have against the Company&rsquo;s Parties by reason of, arising out of, related
to, or resulting from the Executive&rsquo;s employment with the Company or the termination of that employment. This release specifically
includes without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach
of contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. This specifically includes, without limitation, any claim that the Executive
has or has had under Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment Act, as amended,
the Americans with Disabilities Act, as amended, and the Employee Retirement Income Security Act of 1974, as amended. It is understood
and agreed that the waiver of benefits and claims contained in this section does not include a waiver of the right to payment of
any vested, nonforfeitable benefits to which the Executive or a beneficiary of the Executive may be entitled under the terms and
provisions of any employee benefit plan of the company which have accrued as of the Date of Termination, and does not include a
waiver of the right to benefits and payment of consideration to which the Executive may be entitled under this Agreement or any
of the agreements contemplated by this Agreement (including the indemnification agreement and the stock option agreement). The
Executive acknowledges that he is entitled to only the severance benefits and compensation set forth in this Agreement, and that
all other claims for any other benefits or compensation are hereby waived, except those expressly stated in the preceding sentence.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT B</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXISTING CONFLICTS</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">If applicable, Executive to describe, in specific terms, any ongoing business relationship
with any organization other than Tekmira or OnCore. Please provide a copy of any agreement(s) you might have with said organization(s)
that creates a business relationship described in Section 3 (d).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>11
<FILENAME>exh_109.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.9</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">SHARE REPURCHASE AGREEMENT</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This Share Repurchase Agreement (&ldquo;<B><U>Agreement</U></B>&rdquo;)
is made effective as of July 11, 2015 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;) between Tekmira Pharmaceuticals Corporation
(the &ldquo;<B><U>Company</U></B>&rdquo;), and Michael J. Sofia (&ldquo;<B><U>Executive</U></B>&rdquo;) (together the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">RECITALS</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">A.</TD><TD>As of the Effective Date, OnCore Biopharma, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&ldquo;<B><U>OnCore</U></B>&rdquo;)
and Executive have agreed to terminate any and all existing employment agreements (including any amendments thereto) and set forth
their mutual rights and obligations in that certain Executive Employment Agreement dated as of the date hereof, whereby Executive
will serve as the Chief Scientific Officer of OnCore (the &ldquo;<B><U>Employment Agreement</U></B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">B.</TD><TD>This Agreement is being entered into by and between the Parties in connection with and as a condition to the execution of the
Employment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">THEREFORE, the Parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Right of Repurchase</U>. Executive and/or his affiliates own 1,764,815 Common Shares of the Company (the &ldquo;<B><U>Shares</U></B>&rdquo;).
906,355 of the Shares (the &ldquo;<B><U>Buyback Shares</U></B>&rdquo;) will be subject to repurchase by the Company under the circumstances
and at the prices described below (collectively, the &ldquo;<B><U>Repurchase Right</U></B>&rdquo;). </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Employment</U>. Except as otherwise set forth herein, in the event that OnCore terminates the Executive's employment
with OnCore for Cause (as defined in the Employment Agreement) or the Executive terminates his employment other than for Good Reason
(as defined in the Employment Agreement), the Company may, during the 60-day period following such termination, repurchase any
or all of the Buyback Shares that have not previously been released from the Repurchase Right (pursuant to Section 2 hereof) as
of the date of termination of Executive&rsquo;s employment, at a purchase price of $0.001 per share.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice of Repurchase</U>. In the event that the Company elects to exercise its Repurchase Right pursuant to this Section 1,
it shall provide the Executive with written notice of such election within the 60-day period following the termination date. The
closing shall occur within ten (10) business days following delivery of the written notice, at which time the Company shall deliver
to the Executive an amount equal to the purchase price, by cash, check or wire transfer, and the Executive shall deliver to the
Company the stock certificate(s) evidencing the Buyback Shares that are the subject of the repurchase, together with executed stock
powers. Failure by the Executive to deliver the stock certificates shall not affect the transfer of ownership of the Buyback Shares
to the Company. Upon payment of the purchase price, the stock ledger of the Company shall reflect the Company as the owner of the
Buyback Shares and the Executive will have no rights whatsoever in the Buyback Shares.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Repurchase Right</U>. The Company&rsquo;s Repurchase Right shall terminate as set forth below. The schedule of
termination of the Repurchase Right described in Section 2(a) is shown graphically in <U>Exhibit A</U> attached hereto. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination Schedule</U>. For the period commencing as of Effective Date and ending August 31, 2017, the right of the Company
to purchase the Buyback Shares shall terminate:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as to 113,294 of the Buyback Shares, subject to adjustment to reflect stock splits, reverse stock splits or combinations, on each
of (i) November 30, 2015, (ii) February 29, 2016, (iii) May 31, 2016, (iv) August 31, 2016 and (v) November 30, 2016; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as to 113,295 of the Buyback Shares, subject to adjustment to reflect stock splits, reverse stock splits or combinations, on each
of (i) February 28, 2017, (ii) May 31, 2017 and (iii) August 31, 2017.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Other Termination Events</U>. The right of the Company to repurchase Buyback Shares shall terminate with respect to all Buyback
Shares which have not previously been released (pursuant to Section 2 hereof) from the right of repurchase if: </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Executive's employment with OnCore terminates as a result of a termination without Cause (as defined in the Employment Agreement),
by the Executive for Good Reason (as defined in the Employment Agreement), or as a result of the death or Disability (as defined
in the Employment Agreement) of the Executive; or </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during the period from April 1, 2016 until April 30, 2016, the Executive&rsquo;s employment with OnCore is terminated for any reason.
</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0in">Notwithstanding the foregoing, the Parties agree that Executive waives
any right to claim a &ldquo;Good Reason&rdquo; under this Section 2(b) for any event, change or other circumstance which exists,
has occurred, or is otherwise disclosed to Executive prior to the Effective Date. The Parties further agree that Executive hereby
waives and releases any rights to terminate OnCore&rsquo;s right to repurchase Buyback Shares of OnCore or the Company under any
agreement entered into prior to the date hereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Enforceability</U>. If any portion or provision of this Agreement is declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of that portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, will not be affected by that declaration, and each portion and provision
of this Agreement will continue to be valid and enforceable to the fullest extent permitted by law. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Survival</U>. The provisions of this Agreement survive the termination of this Agreement and/or the termination of the Executive&rsquo;s
employment to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver</U>. No waiver of any provision of this Agreement is effective unless made in writing and signed by the waiving party,
and, in the case of the Company only after the waiver has been specifically approved by the Board. The failure of either party
to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement,
will not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement are sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage
prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or,
in the case of the Company, at its main offices, attention to the Corporate Secretary.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly
authorized representative of the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law</U>. This is a Delaware contract and is to be construed under and be governed in all respects by the laws of the
State of Delaware without giving effect to the conflict of laws principles of that state.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each party on separate counterparts,
each of which counterparts, when so executed and delivered is to be taken to be an original; but those counterparts together constitute
one and the same document. PDF, facsimile, scanned, and electronic signatures have the same legal effect as original ink signatures.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation,
or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this
Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the
Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession is a material breach of this
Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Section 11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Voluntary Nature of Agreement</U>. Executive acknowledges and agrees that he is executing this Agreement voluntarily and without
any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that he has carefully read
this Agreement and that he has asked any questions needed for him to fully understand the terms, consequences, and binding effect
of this Agreement. Executive agrees that he has been provided an opportunity to seek the advice of an attorney of his choice before
signing this Agreement.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Parties are executing this Executive Agreement as of the date
set forth in the introductory paragraph.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>TEKMIRA PHARMACEUTICALS CORPORATION </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">By: <U>/s/ Mark Murray &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Printed Name: Mark Murray</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">Title: Chief Executive Officer</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><B>EXECUTIVE</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 3.5in"><U>/s/ Michael J.
Sofia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">Printed Name: Michael J. Sofia</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>Termination of Repurchase Rights</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Repurchase Right Termination Date</U></B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Number of Common Shares</U></B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Shares Subject to Repurchase</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Effective Date</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">906,355</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">November 30, 2015</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">793,061</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">February 29, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">679,767</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">May 31, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">566,473</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">August 31, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">453,179</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">November 30, 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,294</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">339,885</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">February 28, 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">226,590</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">May 31, 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">August 31, 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">113,295</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>12
<FILENAME>exh_1010.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.10</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">AGREEMENT TO SERVE AS CHIEF DEVELOPMENT OFFICER</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">This Agreement (the &ldquo;<B>Agreement</B>&rdquo;)
is entered into as of May 29, 2015 (the &ldquo;<B>Effective Date</B>&rdquo;) by and between Tekmira Pharmaceuticals Corp., (the
&ldquo;<B>Company</B>&rdquo;), and William T. Symonds (&ldquo;<B>Executive</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">NOW, THEREFORE, in consideration of the mutual
covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duties and Scope of Responsibilities</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Positions and Duties</U>. Executive will serve as the Company&rsquo;s Chief Development Officer, leading the clinical
development strategy of the Company&rsquo;s portfolio of hepatitis B drug combinations. Executive will render such business and
professional services in the performance of his duties, consistent with Executive&rsquo;s position within the Company, and as will
reasonably be assigned to him by the Company&rsquo;s Chief Executive Officer. The period of Executive&rsquo;s employment under
this Agreement is referred to herein as the &ldquo;<B>Term</B>.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Conflict</U>. Executive represents and warrants that Executive&rsquo;s execution of this Agreement and Executive&rsquo;s
performance of proposed duties under this Agreement shall not violate any obligations Executive may have to any other employer,
person or entity, including any obligations with respect to proprietary or confidential information of any other person or entity.
The Company understands, acknowledges and agrees that (i)&nbsp;Executive is currently, and will continue to be, an employee of
Roivant Sciences, Inc. (&ldquo;<B>Roivant</B>&rdquo;) and (ii) the Company and Executive agree that the Executive&rsquo;s duties
hereunder may not interfere with his employment with and/or services to Roivant and his duties in connection therewith. Roivant
is an intended third-party beneficiary of this Section 1(b).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Salary</U>. In consideration of the services to be rendered under this Agreement, the Company shall pay Executive
a salary at the rate of One Hundred and Ninety Thousand Dollars ($190,000) per year (the &ldquo;<B>Base Salary</B>&rdquo;). The
Base Salary will be paid periodically in accordance with the Company&rsquo;s normal payroll practices and be subject to the usual,
required withholdings. Executive's Base Salary will be reviewed from time to time in accordance with the established procedures
of the Company for adjusting salaries for similarly situated employees and may be adjusted in the sole discretion of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by
Executive in the furtherance of or in connection with the performance of Executive&rsquo;s duties hereunder, in accordance with
the Company&rsquo;s expense reimbursement policy as in effect from time to time.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>At-Will Employment</U>. The parties agree that Executive&rsquo;s employment with the Company will be &ldquo;at-will&rdquo;
employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither his
job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis
for modification, amendment, or extension, by implication or otherwise, of his employment with the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidential Information</U>. Executive agrees to enter into the At-Will Employment, Confidential Information, Invention
Assignment Agreement (the &ldquo;<B>Confidential Information Agreement</B>&rdquo;). Executive&rsquo;s receipt of any benefits in
connection with or following Executive&rsquo;s termination will be subject to Executive continuing to comply with the terms of
Confidential Information Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Disclosure of Third Party Information</U>. Executive represents and warrants and covenants that Executive shall not
disclose to the Company, or use, or induce the Company to use, any proprietary information or trade secrets of others at any time,
including but not limited to any proprietary information or trade secrets of Roivant Sciences, Inc., or any former employer, if
any; and Executive acknowledges and agrees that any violation of this provision shall be grounds for termination and could subject
Executive to substantial civil liabilities and criminal penalties. Executive further specifically and expressly acknowledges that
no officer or other employee or representative of the Company has requested or instructed Executive to disclose or use any such
third party proprietary information or trade secrets.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition and Non-Solicitation</U>. During the Term, Executive shall not, without the advance written consent of
the Board, such consent to be granted or withheld in the Board&rsquo;s sole discretion:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a) work or consult, whether directly or indirectly, on
the research, development or commercialization of any treatment for hepatitis B virus infection in humans with any entity other
than the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b) directly or indirectly, on his own behalf or on behalf
of any other person, firm, partnership, corporation or other entity, (i) solicit for employment, interfere with or attempt to entice
away from the Company or any of its subsidiaries, any individual who either (x) is employed by the Company or any of its subsidiaries
at the time of such solicitation, interference or enticement, or (y) has been so employed within three (3) months prior to such
solicitation, interference or enticement, or (ii) solicit, divert, call on, induce or otherwise harm the Company&rsquo;s relationship,
or attempt to solicit, divert, call on, induce, or otherwise harm the Company&rsquo;s relationship, with any person which has had
at any time during the term of this Agreement a business relationship with the Company or its affiliates, including without limitation,
a sales representative, supplier, lender, borrower, guarantor, landlord, tenant, lessor, lessee, but excluding employees.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment</U>. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives
of Executive upon Executive&rsquo;s death and (b) any successor of the Company. Any such successor of the Company will be deemed
substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &ldquo;<B>successor</B>&rdquo;
means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly
or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive
any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent
and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive&rsquo;s right to compensation
or other benefits will be null and void.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Integration</U>. This Agreement, together with the Confidential Information Agreement and the Plan, represents the entire
agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements
whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the
parties that is designated as an amendment to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver of Breach</U>. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will
not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. All captions and section headings used in this Agreement are for convenient reference only and do not form
a part of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Withholding</U>. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement will be governed by the laws of the Commonwealth of Pennsylvania without regard to
its conflict of laws provisions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgment</U>. Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice
from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this
Agreement, and is knowingly and voluntarily entering into this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in counterparts, and each counterpart will have the same force and effect
as an original and will constitute an effective, binding agreement on the part of each of the undersigned.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">IN WITNESS WHEREOF, each of the parties has
executed this Agreement, in the case of the Company by their duly authorized officers, as of the day and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">[<I>Signature page follows</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">COMPANY:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; text-align: justify; text-indent: 0in">TEKMIRA PHARMACEUTICALS CORP. &nbsp;</TD>
    <TD STYLE="width: 53%; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">By:  <U>/s/ Mark Murray &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">Its: <U>Chief Executive Officer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Date:  _________________________________<BR>
<BR></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">EXECUTIVE:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in"><U>/s/ William T. Symonds_</U>_________________</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Date:  _________________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">William T. Symonds</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>13
<FILENAME>exh_1011.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">EXECUTIVE
EMPLOYMENT</FONT> <FONT STYLE="font-size: 12pt">AGREEMENT</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT made this 4<SUP>
</SUP>day of August, 2015</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>ARBUTUS BIOPHARMA CORPORATION</B>, a company
incorporated under the laws of British Columbia (the &ldquo;<B>Company</B>&rdquo;), with offices at 100 &ndash; 8900 Glenlyon
Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>Bruce Cousins </B>(the &ldquo;<B>Executive</B>&rdquo;),
of <B>Victoria</B>, <B>British Columbia,</B> <B>Canada</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Executive has the
expertise, qualifications and required certifications to perform the services contemplated by this Agreement; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">C.&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Company wishes to employ the Executive to perform the
services, on the terms and conditions herein set forth, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree
as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive will be employed by and will serve the Company as its <B>Chief Financial Officer</B>
and will have powers and duties consistent with such position as may from time to time be prescribed by the Chief Executive Officer
of the Company. The Executive will report directly to the <B>Chief Executive Officer</B> of the Company and will perform the duties
and responsibilities assigned to the Executive from time to time by the Chief Executive Officer. The Executive will comply with
all lawful instructions given by the Chief Executive Officer of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The terms and conditions of this Agreement will have effect as and from 4<SUP> </SUP>day of
August, 2015 and the Executive&rsquo;s employment as <B>Chief Financial Officer</B> will continue until terminated as provided
for in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement,
the Executive&rsquo;s employment with the Company is subject to and governed by the Company&rsquo;s policies as established from
time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions
of the Agreement. The Executive will inform himself of the details of such policies and amendments thereto established from time
to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Executive will devote himself exclusively to the Company&rsquo;s business and will not be employed
or engaged in any capacity in any other business without the prior permission of the Company, such permission not to be unreasonably
withheld. Notwithstanding the foregoing, the Executive may manage his personal investments or engage charitable or other community
activities as long as those services and activities do not interfere with the Executive&rsquo;s performance of his duties to the
Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Concurrently with the execution and delivery of this Agreement and in consideration of the Executive&rsquo;s
employment by the Company, the Executive and the Company will enter into a &ldquo;Confidentiality and Assignment of Inventions
Agreement&rdquo; in the form attached hereto as Exhibit A.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>REMUNERATION AND BENEFITS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Base Salary</U>. The Company will pay the Executive an annual salary of US$350,000, less required
deductions (the &ldquo;<B>Base Salary</B>&rdquo;). The Base Salary will be payable semi-monthly. The Executive&rsquo;s Base Salary
will be reviewed annually by the Chief Executive Officer of the Company and is subject to increase but not decrease, except for
an across-the-board salary reduction affecting all or substantially all senior executives of the Company, nor will it necessarily
result in an increase to the Base Salary. The base salary in effect at any given time is referred to as &ldquo;Base Salary&rdquo;
and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable
in a manner that is consistent with the Company&rsquo;s usual payroll practices for senior executives.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Bonus</U>. The Executive is eligible to be considered for an annual discretionary bonus of up
to 40 percent of Base Salary (such bonus, the &ldquo;<B>Target Bonus</B>&rdquo;); which will be subject to the terms of the bonus
plan and approval of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;), in its sole discretion, on an annual
basis. Any bonus payable during the first year of the Executive&rsquo;s employment will be pro-rated. Payment of a bonus in any
one year will not indicate the payment of a bonus in any other year.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Expenses</U>. The Company will reimburse the Executive for all reasonable expenses actually
and properly incurred by the Executive in performing services under this Agreement, in accordance with the policies and procedures
then in effect and established by the Company for its senior executives. The Executive will provide the Company with receipts supporting
the Executive&rsquo;s claims for reimbursement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Other Benefits</U>. The Company will facilitate the Executive&rsquo;s enrolment in the Company&rsquo;s
insurance benefits plans, as amended from time to time by the Company or the insurance carrier. In all cases, eligibility to participate
in the plans and to receive benefits under the plans will be subject to the terms and requirements of the applicable insurance
carrier in accordance with the formal benefits plan documents and policies. Any issues with respect to entitlement to or payment
of benefits under the benefits package will be governed by the terms of such documents and policies. The Company is not responsible
for the payment of benefits in any circumstance. Further, the Company reserves the right, in its sole discretion, to change any
of the insurance benefit plans or providers, however, if the Company is unable to maintain similar coverage as to the insurance
benefits plans or the providers, then the Executive will be provided with compensation to assist in securing the Executive&rsquo;s
own coverage, such compensation to be determined by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Equity Compensation</U>. Subject to the discretionary approval of the Company&rsquo;s Board
of Directors, and in accordance with the Company&rsquo;s annual performance and compensation review process, the Executive shall
be eligible to receive equity awards under the  Arbutus Biopharma Corporation Share Incentive Plan and or any other similar
equity incentive plan to the same extent as other executives of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Vacation</U>. The Executive is entitled to paid holidays and vacation days each year, in an
amount determined in accordance with and subject to the Company&rsquo;s applicable policies in effect, and as may be amended from
time to time. The Executive will be entitled to 25 days of vacation per calendar year, which will be pro-rated for any year in
which the Executive is only employed with the Company for a portion of the year or for any period in which the Executive is not
a full-time employee. Vacation days will be scheduled at times that are mutually acceptable to the Executive and the Company. Carry-over
of vacation days will be according to Company policy, and any accrued but unused vacation days will be paid out upon termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>NON-COMPETITION AND NON-SOLICITATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The biotechnology industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company&rsquo;s interests if they join a competing business immediately upon
leaving the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&ldquo;<B>Affiliate</B>&rdquo;
means, in respect of the Company, a company or other entity which directly or indirectly controls, is controlled by, or is
under common control with, the Company. For the purposes of this definition, &ldquo;control&rdquo; means direct or indirect
beneficial ownership of a greater than 50% interest in the income of such company or entity or such other relationship as, in
fact, constitutes actual control. For greater certainty, without limiting the generality of the foregoing, Protiva
Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc. and Arbutus Biopharma, Inc. are Affiliates of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>researching, developing, producing and marketing any treatment for hepatitis B virus infection in humans; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
other treatment area in which the Company has an active research and development program on the date this Agreement terminates
and in connection with which the Executive directly provided service or had direct supervisory responsibilities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Competing Business</B>&rdquo; means any endeavour, activity or business which is competitive in any material way
with the Business of the Company worldwide.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Contact</B>&rdquo;
means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator,
strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates) with whom the Executive
dealt or otherwise became aware of during the term of the Executive&rsquo;s employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Restricted Period</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive is terminated pursuant to Section 5(d) of this Employment Agreement, a period equivalent
to the amount of notice that the Executive is entitled pursuant to Section 6(b)(i); or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive&rsquo;s employment is terminated pursuant to a Change of Control (as defined below), a period
equivalent to the amount of notice that the Executive is entitled pursuant to Section&nbsp;7(d)(iii)(A).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: left"><U>Reasonableness</U>. The Executive hereby acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">both before and since the commencement of the Executive&rsquo;s employment by the Company, the Company
has operated and competed and will operate and compete worldwide, with respect to the Business of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">competitors of the Company and the Business are located worldwide;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">in order to protect the Company adequately, any enjoinder of competition would have to apply to any
country in which the Company, during the term of the Executive&rsquo;s employment, had material business relationships;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">during the course of the Executive&rsquo;s employment with the Company, on behalf of the Company,
the Executive will acquire knowledge of, and will come into contact with, initiate and establish relationships with, both existing
and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive
may become the senior or sole representative of the Company dealing with such persons; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: left">in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper
protection of the Business of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Restrictive Covenant</U>. Except as set forth on Exhibit C attached hereto, during the term
of the Executive&rsquo;s employment and for the Restricted Period after the termination thereof, the Executive shall not, without
the prior written consent of the Board, such consent to be granted or withheld in the Board&rsquo;s sole discretion, within the
geographic scope of any country in which the Company, during the term of the Executive&rsquo;s employment, had material business
relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially
involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with
any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner
whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: left"><U>Exception</U>. The Executive shall not be in default of Section 3(d) by virtue of the Executive:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">following the termination of employment, holding, strictly for portfolio purposes and as a passive
investor, no more than five percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or
other entity which is listed on any recognized stock exchange, that is a Competing Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">during the term of the Executive&rsquo;s employment, holding, strictly for portfolio purposes and
as a passive investor, issued and outstanding shares of, or any other interest in, any corporation or other entity, the business
of which corporation or other entity is in the same Business as the Company provided such corporation is not a Competing Business,
and provided further that the Executive first obtains the Company&rsquo;s written consent, which consent will not be unreasonably
withheld.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Executive holds issued and outstanding shares or
any other interest in a corporation or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares
or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose
of the Executive&rsquo;s shares or other interest in such corporation or other entity.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: left"><U>Non-Solicitation</U>. The Executive shall not, during the term of the Executive&rsquo;s employment
and for the Restricted Period after the termination thereof for any reason, whether legal or illegal, either individually or in
partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor,
employee, shareholder or in any manner whatsoever, without the prior written and informed consent of the Company, directly or indirectly:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business
of) any Contact, or otherwise solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for
any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">accept (or procure or assist the acceptance of) any business from any Contact which business is competitive
with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">be employed by or supply (or procure or assist the supply of) any goods or services to any Contact
for any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise
entice away from or solicit, induce or encourage to leave the employment or engagement of the Company, any individual who is employed
or engaged by the Company whether or not such individual would commit any breach of the Executive&rsquo;s contract or terms of
employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall be permitted,
solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Validity</U>. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&rsquo;s
activities following the termination of the Executive&rsquo;s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable to any extent
by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction,
the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that which is in fact
declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order
to ensure that the intention of the parties is given the greatest possible effect.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>INJUNCTIVE
RELIEF</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive understands and agrees that the Company has a material interest in preserving the
relationships it has developed with its executives, customers and suppliers against impairment by competitive activities of a former
executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Section 3 are reasonably required
for the protection of the Company and its goodwill and that the Executive&rsquo;s agreement to those restrictions and covenants
by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to
enter into this Agreement and to employ the Executive, and that the Company would not enter into this Agreement absent such an
inducement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Executive understands and acknowledges that if the Executive breaches Section 3, that breach
will give rise to irreparable injury to the Company for which damages are an inadequate remedy, and the Company may pursue injunctive
relief for such breach in a court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive&rsquo;s employment by the Company may be terminated
under the following circumstances:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Death</U>. The Executive&rsquo;s employment hereunder will terminate upon the Executive&rsquo;s
death.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Disability</U>. The Company may terminate the Executive&rsquo;s employment if the Executive
is disabled (as determined by the Chief Executive Officer) by a condition that qualifies Executive for long term disability benefits
under the Company&rsquo;s then-current long term disability plan, in a manner that renders the Executive unable to perform the
essential functions of the Executive&rsquo;s then existing position or positions under this Agreement with or without reasonable
accommodation for a period of six (6) months or more. Nothing in this Section 5(b) will be construed to waive the Executive&rsquo;s
rights, if any, under the Company&rsquo;s insurance benefits plans accruing prior to termination or under applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Termination by Company for Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company may terminate the Executive&rsquo;s employment For Cause at any time, without notice
or payment in lieu thereof. The payment by the Company of the Executive&rsquo;s Accrued Benefits shall be subject to any other
rights or remedies of the Company under law and thereafter all obligations of the Company under this Agreement shall cease.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, &ldquo;<B>For Cause</B>&rdquo; shall mean:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the Executive commits a crime involving dishonesty, breach of trust, or physical harm to any person
(excluding driving while affected by drugs or alcohol) or any violation of provincial, state or federal securities laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Executive willfully engages in conduct that is in bad faith and materially injurious to the
Company or its Affiliates, monetarily or otherwise, including but not limited to, misappropriation of trade secrets, fraud or embezzlement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the Executive commits a material breach of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">the Executive willfully refuses to implement or follow a lawful policy or directive of the Company;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">the Executive willfully and on a continuing basis fails to perform his duties hereunder diligently
and professionally.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company, in its sole discretion, may terminate the Executive&rsquo;s employment under this
Agreement without Cause at any time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, any termination by the Company of the Executive&rsquo;s employment
under this Agreement that does not constitute a termination &ldquo;For Cause&rdquo; under Section 5(c) and does not result from
the death or disability of the Executive under Sections 5(a) or 5(b), respectively, shall be a termination &ldquo;without Cause&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Resignation by Executive</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment by providing to the Company Notice of Termination of
his employment at least three (3) months prior to the effective date of resignation. During such notice period Executive shall
continue to diligently perform all of Executive&rsquo;s duties hereunder, provided that the Company shall have the option, in its
sole discretion, to waive such notice period, in whole or in part, and if it does so, the Executive&rsquo;s resignation will become
effective and the Executive&rsquo;s employment will cease on the date set by the Company in the notice of waiver, and the Executive
shall be entitled to his Accrued Benefits up to and including the Date of Termination (as defined in Section&nbsp;5(g)(iii)). In
the event the Company waives the Executive&rsquo;s notice hereunder, the Company, in its sole discretion, in the circumstances,
may pay the Base Salary portion of the Executive&rsquo;s Accrued Benefits by way of one or more lump sum payments, by way of salary
continuance or by a combination of both.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment for Good Reason within 12 months following a Change
in Control of the Company in accordance with, and subject to, the process set out in Section 7(c).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Notice of Termination</U>. Except for termination as specified in Section 5(a), any termination
of the Executive&rsquo;s employment by the Company or any termination of the Executive&rsquo;s employment by the Executive must
be communicated by written Notice of Termination to the other party. For the purposes of this Agreement, &ldquo;<B>Notice of Termination</B>&rdquo;
means a written notice that indicates the specific termination provision in this Agreement upon which the termination is based.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Date of Termination</U>. For the purposes of this Agreement, &ldquo;<B>Date of Termination</B>&rdquo;
means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated by his death, the date of his death;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated on account of disability under Section 5(b) or
by the Company for Cause under Section 5(c), or by the Company without Cause under Section 5(d) on the date the Notice of Termination
is given;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(i) without Good Reason, on the effective
date of resignation specified by the Executive in the Notice of Termination (which shall be at least three (3) months after the
date of the Notice of Termination) or, if no such date is specified or if the Company waives the notice period, the date that is
three (3) months after the date of the Notice of Termination; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(ii) for Good Reason following a Change
in Control of the Company, the date on which a Notice of Termination is given after the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">Notwithstanding the foregoing, if the Executive gives a
Notice of Termination to the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination
and that acceleration will not be deemed a termination by the Company for purposes of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>COMPENSATION
UPON TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Termination Generally</U>. If the Executive&rsquo;s employment with the Company is terminated
for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) on or before
the time required by law, but in no event more than 30 days after the Executive&rsquo;s Date of Termination:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">unpaid expense reimbursements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">accrued but unused vacation to the extent payment is required by law or Company policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any vested benefits the Executive may have under any employee benefit plan of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any earned but unpaid Base Salary; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any earned but unpaid annual bonus for the prior fiscal year;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">for service up to and including the Date of Termination
(collectively the &ldquo;<B>Accrued Benefits</B>&rdquo;). The Executive shall not be entitled to any other salary, compensation,
bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided in this Agreement,
under the Company&rsquo;s employee benefit plans or as expressly required by applicable law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>. If the Executive&rsquo;s employment is terminated
by the Company without Cause, then the Company shall pay the Executive his Accrued Benefits as of the Date of Termination. In addition,
subject to Section 7 and the Executive providing the Company with a fully effective general release of claims in a form and manner
satisfactory to the Company that includes but is not limited to the terms set forth in the attached Exhibit B (the &ldquo;<B>Release</B>&rdquo;)
within the 60-day period following the Date of Termination (and which shall be countersigned by the Company in respect of the non-disparagement
clause therein), the Company shall pay the Executive an amount (the &ldquo;<B>Severance Amount</B>&rdquo; calculated as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an amount equal to eighteen (18) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">The Company shall pay the Severance Amount within 60 days
after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company shall make the
payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances, may pay
the Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Severance
Amount is inclusive of any entitlement to minimum standard severance under the British Columbia <I>Employment Standards Act</I>.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>CHANGE
IN CONTROL</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The provisions of this Section 7 set forth the Executive&rsquo;s rights and obligations upon the
occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&rsquo;s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. Where the provisions of this Section 7 apply, they shall supersede the payment of the Severance Amount under
Section 6(b). The provisions of this Section 7 are subject to the Executive providing to the Company, and not revoking, a fully
effective Release.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Definitions</U>. For purposes of this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the sale of all or substantially all of the assets of the Company to an unrelated person or entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a merger, reorganization, or consolidation involving the Company in which the shares of voting
stock outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving
or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power
of the surviving or resulting entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the acquisition of all or a majority of the outstanding voting stock of the Company in a single
transaction or a series of related transactions by a person or group of persons; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">any other acquisition of the business of the Company, as determined by the Board;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">but any public offering by the Company, or another capital
raising event, or a merger effected solely to change the Company&rsquo;s domicile does not constitute a Change in Control; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Good Reason</B>&rdquo; shall mean the occurrence of any of the following events without
the Executive's prior written consent:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a change in the Executive&rsquo;s position which materially reduces the Executive&rsquo;s responsibilities
from the responsibilities in effect immediately prior to the Change of Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a reduction by the Company of the Executive&rsquo;s Base Salary or Target Bonus percentage, except
for an across-the-board salary reduction affecting all senior executives of the Company; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">a relocation of Executive&rsquo;s principal place of employment by more than 80 kilometres.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Resignation for Good Reason</U>. If the Executive desires to terminate his employment for Good
Reason within 12 months following a Change in Control, the Executive must comply with, and shall be subject to, the following terms
and conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Executive reasonably determines in good faith that a Good Reason condition has occurred within
12 months following a Change in Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive notifies the Company in writing of the first occurrence of the Good Reason condition
within 30 days of the first occurrence of such condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Executive cooperates in good faith with the Company&rsquo;s efforts, for a period of not less
than 30 days following that notice (the &ldquo;<B>Cure Period</B>&rdquo;) to remedy the condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding the Company&rsquo;s efforts, the Good Reason condition continues to exist; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">the Executive provides to the Company Notice of Termination of his employment within 30 days after
the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Company cures the Good Reason condition during the
Cure Period, the Good Reason condition is deemed not to have occurred and the Executive may not terminate his employment in respect
of such condition.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Change in Control Severance</U>. If within 12 months following a Change in Control:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company terminates the Executive&rsquo;s employment with the Company without Cause; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive resigns from his employment with the Company for Good Reason;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">then,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">in addition to paying the Executive his Accrued Benefits and in lieu of paying the Executive the
Severance Amount, the Company shall pay to the Executive an amount (the &ldquo;<B>Change in Control Severance Amount</B>&rdquo;)
as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">an amount equal to twenty-four (24) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">The Company shall pay the Change in Control Severance
Amount within 60 days after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company
shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances,
may pay the Change in Control Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination
of both. The Change in Control Severance Amount is inclusive of any entitlement to minimum standard severance under the British
Columbia <I>Employment Standards Act</I>; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding anything to the contrary in any applicable option agreement or stock-based award
agreement, all stock options and other stock-based awards held by the Executive shall immediately accelerate, vest, and become
fully exercisable or non-forfeitable as of the Date of Termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The Executive will return to the Company all Company documents,
files, manuals, books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to
Company upon the termination of the executive&rsquo;s employment with the Company for any reason.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>GENERAL PROVISIONS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Withholding</U>. All payments made by the Company to the Executive
under this Agreement will be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing
in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that
minimizes tax consequences for the Executive.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company expressly
to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession
had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession
is a material breach of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Successor to the Executive</U>. This Agreement inures to the benefit of and is enforceable by
the Executive&rsquo;s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the
Executive dies after his termination of employment but prior to the completion by the Company of all payments due to him under
this Agreement, the Company shall continue the payments to the Executive&rsquo;s beneficiary designated in writing to the Company
prior to his death (or to his estate, if the Executive fails to make such a designation).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Non-Waiver</U><B>.</B> Failure on the part of either party to complain of any act or failure
to act of the other of them or to declare the other party in default of this Agreement, irrespective of how long such failure continues,
will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Severability</U><B>. </B>In the event that any provision or part of this Agreement is determined
to be void or unenforceable in whole or in part, the remaining provisions, or parts thereof, will be and remain in full force and
effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U><B>.</B> This Agreement constitutes the entire agreement between the parties
with respect to the employment of the Executive and supersedes any and all agreements, understandings, warranties or representations
of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each
of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claim or demands
whatsoever under or in respect of any agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Survival</U><B>.</B> The provisions of this Agreement survive the termination of this Agreement
and/or the termination of the Executive&rsquo;s employment to the extent necessary to effectuate the intent of the Parties as expressed
in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><U>Modification of Agreement</U><B>.</B> Any modification of this Agreement must be in writing
and signed by both the Company and the Executive or it will have no effect and will be void.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><U>Disputes</U><B>.</B> Except for disputes arising in respect of Section 3, all disputes arising
out of or in connection with this Agreement and the employment relationship between the parties, are to be referred to and finally
resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules.
The place of arbitration will be Vancouver, British Columbia.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify"><U>Governing Law</U><B>.</B> This Agreement will be governed by and construed according to the
laws of the Province of British Columbia, Canada.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement
are sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered
or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing
with the Company or, in the case of the Company, at its main offices, attention to the Corporate Secretary.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify"><U>Independent Legal Advice</U><B>.</B> The Executive agrees that the contents, terms and effect
of this Agreement have been explained to the Executive by a lawyer and are fully understood. The Executive further agrees that
the consideration described aforesaid is accepted voluntarily for the purpose of employment with the Company under the terms and
conditions described above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each
party on separate counterparts, each of which counterparts, when so executed and delivered is to be taken to be an original; but
those counterparts together constitute one and the same document. PDF, facsimile, scanned, and electronic signatures have the same
legal effect as original ink signatures.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="text-align: left; vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0.1in 0pt 0">by <B>Bruce Cousins </B>in
        the presence of:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0.1in 0pt 0.5in; text-indent: -0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">)</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">)</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">)</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">)</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; font-size: 10pt">/s/ Bruce Cousins</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Witness</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><B>Bruce Cousins</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Occupation</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CONFIDENTIALITY</B><BR>
<B>AND ASSIGNMENT OF INVENTIONS AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;)
dated for reference the 4<SUP> </SUP>day of August, 2015.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR>
(the &ldquo;<B>Company</B>&rdquo;), a company incorporated under the laws of British Columbia with offices at 100 &ndash; 8900
Glenlyon Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>Bruce Cousins</B> (the &ldquo;<B>Executive</B>&rdquo;),
of <B>Victoria, British Columbia, Canada</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the
employment of the Executive by the Company, the parties desire to establish the terms and conditions under which the Executive
will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information
confidential, to protect it from disclosure and to use it only in accordance with the terms of this Agreement; and (iii) assign
to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed
or disclosed by the Executive over the course of his work during his employment with the Company, as set out in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of
the employment of the Executive by the Company and the payment by the Company to the Executive of the sum of $10.00 and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;INTERPRETATION</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Definitions.</B> In this Agreement:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; means, in respect of the Company, a company or other entity
                                                               which directly or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of
                                                               this definition, &ldquo;<B>control</B>&rdquo; means direct or indirect beneficial ownership of a greater than 50% interest in
                                                               the income of such company or entity or such other relationship as, in fact, constitutes actual control. For greater
                                                               certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc.
                                                               and  Arbutus Biopharma, Inc. are Affiliates of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">researching, developing, producing and marketing any treatment for hepatitis B virus infection
in humans; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any other treatment area in which the Company has an active research and development program on
the date the Executive&rsquo;s employment with the Company terminates and in connection with which the Executive directly provided
service or had direct supervisory responsibilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo; shall mean all information, knowledge, or data, whether
in written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered
or developed in whole or in part by the Executive, that is not generally known to the public or to other persons who are not bound
by obligations of confidentiality and:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">from which the Company or its Affiliates derive economic value, actual or potential, from the information
not being generally known; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">and which, without limiting the generality of the foregoing,
shall include:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">all proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research and development of RNA interference drugs
and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas, processes,
research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">all information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory, marketing, advertising and
commercial information and strategies, customer lists, compilations, agreements and contractual records and correspondence; programs,
devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate items that is not generally
known and items provided or disclosed to the Company or its Affiliates by third parties subject to restrictions on use or disclosure;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all know-how relating to the Business of the Company, including all biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information,
and all applications, registrations, licenses, authorizations, approvals and correspondence submitted to regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors&rsquo; research and development, intellectual property, operations, financial, clinical, regulatory,
marketing, advertising and commercial strategies, that is not generally known;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">all information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">all information relating to the Executive&rsquo;s compensation and benefits, including his salary,
vacation, stock options, rights to continuing education, perquisites, severance notice, rights on termination and all other compensation
and benefits, except that he shall be entitled to disclose such information to his bankers, advisors, agents, consultants and other
third parties who have a duty of confidence to him and who have a need to know such information in order to provide advice, products
or services to him.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">All Work Product shall be deemed to be the Company&rsquo;s
Confidential Information.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means the 4 day of August, 2015 being the date that the
                                                               Executive started working at the Company, as indicated in his employment agreement with the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo; is used in its broadest sense and means and includes
any statutory, common law, equitable, contractual or proprietary rights or interests, recognized currently or in future, in and
to any Inventions, including, without limitation, rights and interests in and to the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">knowledge, know-how and its embodiments, including trade secret information;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">patents in inventions, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">copyrights in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works
of authorship including technical descriptions for products, user guides, illustrations, advertising materials, computer programs,
source code and object code, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">trademarks, service marks, tradenames, business names and domain names and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">industrial designs and all other industrial or intellectual property and all applications therefor;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all goodwill connected with the foregoing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Inventions</B>&rdquo; shall mean any and all inventions, discoveries, developments, enhancements,
improvements, concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced to practice, and
whether or not protectable under patent, copyright, trade secret or similar laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Work Product</B>&rdquo; shall mean any and all Inventions and possible Inventions relating
to the Business of the Company and which the Executive may make or conceive, alone or jointly with others, during his involvement
in any capacity with the Company, whether during or outside his regular working hours, except those Inventions made or conceived
by the Executive entirely on his own time that do not relate to the Business of the Company and do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or through his involvement
in any capacity with the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">CONFIDENTIALITY</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prior
Business Confidential Information</B>. The Executive represents and warrants to the Company that the Executive has not brought
or used, and the Executive covenants and agrees that the Executive will not use or bring to the Company any confidential information
of any kind whatsoever of any prior party (the &ldquo;<B>Prior Business</B>&rdquo;) with whom the Executive was previously involved,
whether such involvement was as an employee, director or officer of that Prior Business, an investor in that Prior Business, a
partner in that Prior Business, a consultant to that Prior Business or other relationship to that Prior Business (the &ldquo;<B>Prior
Involvement</B>&rdquo;). The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain confidential information relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any and all legal obligations the Executive may have to such Prior Business. The Executive covenants
and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer
as a result of any breach by the Executive of his obligations to such Prior Business in that regard.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Basic Obligation of Confidentiality.</B> The Executive hereby acknowledges and agrees that in the course of his involvement
with the Company, the Company may disclose to him or he may otherwise have access or be exposed to Confidential Information. The
Company hereby agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential
Information on the terms and conditions set out in this Agreement. Except as otherwise set out in this Agreement, the Executive
will keep strictly confidential all Confidential Information and all other information belonging to the Company that he acquires,
observes or is informed of, directly or indirectly, in connection with his involvement, in any capacity, with the Company both
during and after the term of his employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Fiduciary
Capacity.</B> The Executive will be and act toward the Company and its Affiliates as a fiduciary in respect of the Confidential
Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-disclosure.</B> Except with the prior written consent of the Company, the Executive will not at any time, either
during or after his involvement in any capacity with the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">use or copy any Confidential Information or recollections thereof for any purpose other than the
performance of his duties for the benefit of the Company and its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">publish or disclose any Confidential Information or recollections thereof to any person other than
to employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their
duties for the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be used, copied, published, disclosed, translated
or adapted except as otherwise expressly permitted by this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on personal computers, except in accordance
with written procedures of the Company, as amended from time to time in writing.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Taking Precautions.</B> The Executive will take all reasonable precautions necessary or prudent to prevent material in
his possession or control that contains or refers to Confidential Information from being discovered, used or copied by third parties.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>The Company&rsquo;s Ownership of Confidential Information.</B> As between the Executive and the Company, the Company
shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Control of Confidential Information and Return of Information.</B> All physical materials produced or prepared by the
Executive containing Confidential Information, including, without limitation, records, devices, computer files, data, notes, reports,
proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates
and all other materials prepared in the course of his responsibilities to or for the benefit of the Company or its Affiliates,
together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn
over to the Company&rsquo;s possession every original and copy of any and all such items in his possession or control upon request
by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will
provide reasonable evidence that such materials have been destroyed, purged or erased.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Purpose of Use.</B> The Executive agrees that he will use Confidential Information only for purposes authorized or directed
by the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Exemptions. </B>The obligations of confidentiality set out in this Article 2 will not apply to any of the following:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">information that is already known to the Executive, though not due to a prior disclosure by the
Company or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or
its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">information disclosed to the Executive by another person who is not obliged to maintain the confidentiality
of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">information that is developed by the Executive independently of Confidential Information received
from the Company or its Affiliates and such independent development can be documented by the Executive;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">other particular information or material which the Company expressly exempts by written instrument
signed by the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">information or material that is in the public domain through no fault of the Executive; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">information required by operation of law, court order or government agency to be disclosed, provided
that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, the Executive will provide to the Company prompt written notice so that the Company may seek
a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Company agrees that the disclosure is required by law, it will give the Executive written
authorization to disclose the information for the required purposes only;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Company does not agree that the disclosure is required by law, this Agreement will continue
to apply, except to the extent that a Court of competent jurisdiction orders otherwise; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if a protective order or other remedy is not obtained or if compliance with this Agreement is waived,
the Executive will furnish only that portion of the Confidential Information that is legally required and will exercise all reasonable
efforts to obtain confidential treatment of such Confidential Information.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">ASSIGNMENT
OF INTELLECTUAL PROPERTY RIGHTS</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notice
of Invention.</B> The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable,
throughout the course of his involvement, in any capacity, with the Company and from which there is a reasonable basis to believe
that Intellectual Property may be derived therefrom, whether or not developed before or after execution of this Agreement. On
his ceasing to be employed by the Company for any reason whatsoever, the Executive will immediately deliver up to the Company
all Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment
of Rights.</B> Subject only to the exceptions set out in <B>Exhibit I</B> attached to this Agreement, the Executive will assign,
and does hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company&rsquo;s
designee, all of his right, title and interest in and to all Work Product, including all Intellectual Property rights therein.
To the extent that the Executive retains or acquires legal title to any such Intellectual Property rights and interests, the Executive
hereby declares and confirms that such legal title is and will be held by him only as trustee and agent for the Company or the
Company&rsquo;s designee. The Executive agrees that the Company&rsquo;s rights hereunder shall attach to all Intellectual Property
rights in his Work Product, notwithstanding that it may be perfected or reduced to specific form after he has terminated his relationship
with the Company. The Executive further agrees that the Company&rsquo;s rights hereunder are worldwide rights and are not limited
to Canada, but shall extend to every country of the world.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Moral
Rights.</B> Without limiting the foregoing, the Executive hereby irrevocably waives any and all moral rights arising under the
<I>Copyright Act</I> (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in
other applicable jurisdictions or at common law that he may have with respect to all Work Product, and agrees never to assert
any moral rights which he may have in the Work Product, including, without limitation, the right to the integrity of the Work
Product, the right to be associated with the Work Product, the right to restrain or claim damages for any distortion, mutilation
or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product
in any context and in connection with any product, service, cause or institution, and the Executive further confirms that the
Company may use or alter any Work Product as the Company sees fits in its absolute discretion.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Goodwill.</B> The Executive hereby agrees that all goodwill he has established or may establish with clients, customers,
suppliers, principals, shareholders, investors, collaborators, strategic partners, licensees, contacts or prospects of the Company
relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date,
shall, as between the Executive and the Company, be and remain the property of the Company exclusively, for the Company to use,
alter, vary, adapt and exploit as the Company shall determine in its discretion.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance.
</B>The Executive hereby agrees to reasonably assist the Company, at the Company&rsquo;s request and expense, in:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">making patent applications for all Work Product, including instructions to lawyers and/or patent
agents as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification,
to execute all formal documentation incidental to an application for letters patent and to execute assignment documents in favour
of the Company for such applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">making applications for all other forms of Intellectual Property registration relating to all Work
Product;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">prosecuting and maintaining the patent applications and other Intellectual Property relating to
all Work Product; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">registering, maintaining and enforcing the patents and other Intellectual Property registrations
relating to all Work Product.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the Company is unable for any reason to secure the Executive&rsquo;s
signature with respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents
or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and stead to execute
and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal force
and effect as if executed by him.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance with Proceedings.</B> The Executive further agrees to reasonably assist the Company, at the Company&rsquo;s
request and expense, in connection with any defence to an allegation of infringement of another person&rsquo;s intellectual property
rights, claim of invalidity of another person&rsquo;s intellectual property rights, opposition to, or intervention regarding, an
application for letters patent, copyright or trademark or other proceedings relating to Intellectual Property or applications for
registration thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Commercialization.
</B>The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company&rsquo;s
sole discretion and for the Company&rsquo;s sole benefit and that no royalty or other consideration will be due or payable to
him as a result of the Company&rsquo;s efforts to commercialize or market any such Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Business Intellectual Property</B>. The Executive represents and warrants to the Company that he has not brought or used,
and the Executive covenants and agrees that he will not use or bring to the Company any Intellectual Property of any kind
whatsoever of any Prior Business with whom the Executive had a Prior Involvement or any Intellectual Property directly owned
by the Executive. The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain Intellectual Property relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any legal obligations the Executive may have to such Prior Business. The Executive covenants and
agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer as
a result any breach by the Executive of his obligations to such Prior Business in that regard.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Inventions.</B> In order to have them excluded from this Agreement, the Executive has set forth on <B>Exhibit I</B> attached to
this Agreement a complete list of all Inventions for which a patent application has not yet been filed that he has, alone or jointly
with others, conceived, developed or reduced to practice prior to the execution of this Agreement to which he has any right, title
or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive
represents and warrants that there are no such prior Inventions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>General</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Term.
</B>Subject to Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive
is no longer working at or for the Company in any capacity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>No
Conflicting Obligations.</B> The Executive hereby represents and warrants that he has no agreements with or obligations to
any other person with respect to the matters covered by this Agreement or concerning the Confidential Information that are in
conflict with anything in this Agreement, except as disclosed in <B>Exhibit I</B> attached to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Publicity.</B> The Executive shall not, without the prior written consent of the Company, make or give any public announcements,
press releases or statements to the public or the press regarding any Work Product or any Confidential Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Further
Assurances.</B> The parties will execute and deliver to each other such further instruments and assurances and do such further
acts as may be required to give effect to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notices.
</B>All notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand
delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with
receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to
have been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either
party may change its address or its facsimile number by giving the other party written notice, delivered in accordance with this
section.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Equitable
Remedies. </B>The Executive understands and acknowledges that if he breaches any of his obligations under this Agreement,
that breach may give rise to irreparable injury to the Company for which damages are an inadequate remedy. In the event of
any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company
will be entitled as a matter of right to apply to a court of competent jurisdiction for such relief by way of restraining
order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-Waiver</B>.
Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other
party in default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such
party of their rights hereunder or of the right to then or subsequently declare a default.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Severability.
</B>In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the
remaining provisions, or parts thereof, will be and remain in full force and effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Entire Agreement.</B> This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral,
express or implied, including any relating to the nature of the position or its duration, and each of the parties releases and
forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect
of any agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Survival.</B> Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article
2 (including the obligations of confidentiality and to return Confidential Information, which shall endure, with respect to each
item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections
3.2, 3.3, 3.4, 3.5, 3.6 and 3.8 and Article 4 shall survive any expiration or early termination of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Modification of Agreement.</B> Any modification of this Agreement must be in writing and signed by both the
Company and the Executive or it will have no effect and will be void.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>G</B></FONT><B>overning Law.</B> This Agreement will be governed by and construed according to the laws of the Province of
British Columbia, Canada.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Independent Legal Advice.</B> The Executive agrees that he has obtained or has had an opportunity to obtain independent
legal advice in connection with this Agreement, and further acknowledge that he has read, understands, and agrees to be bound by
all of the terms and conditions contained herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">by <B>Bruce Cousins</B> in the
        presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">/s/ Bruce Cousins</P></TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Witness Signature</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><BR></P></TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><B>Bruce Cousins</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Name</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: left; font-size: 10pt"><BR>
<BR>
</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Witness Occupation</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><BR></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT I</B><BR>
<B>to Confidentiality and Assignment of Inventions Agreement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXCLUSIONS FROM WORK PRODUCT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[To be completed as applicable]</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>GENERAL RELEASE LANGUAGE</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the &ldquo;<B>Executive&rsquo;s
Parties</B>&rdquo;), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates, subsidiaries,
directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys,
benefit plans sponsored by the Company, and said plans&rsquo; fiduciaries, agents and trustees (the &ldquo;<B>Company&rsquo;s Parties</B>&rdquo;),
from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments,
levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive&rsquo;s Parties have, have
had, or may in the future claim to have against the Company&rsquo;s Parties by reason of, arising out of, related to, or resulting
from the Executive&rsquo;s employment with the Company or the termination of that employment. This release specifically includes
without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of
contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. It is understood and agreed that the waiver of benefits and claims contained
in this section does not include a waiver of the right to payment of any vested, non-forfeitable benefits to which the Executive
or a beneficiary of the Executive may be entitled under the terms and provisions of any employee benefit plan of the company which
have accrued as of the Date of Termination, and does not include a waiver of the right to benefits and payment of consideration
to which the Executive may be entitled under this Agreement or any of the agreements contemplated by this Agreement (including
the indemnification agreement and the stock option agreement). The Executive acknowledges that he is entitled to only the severance
benefits and compensation set forth in this Agreement, and that all other claims for any other benefits or compensation are hereby
waived, except those expressly stated in the preceding sentence.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Executive agrees that he will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Company&rsquo;s Parties or their products, employees, services, work
and/or employment.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Company agrees that it will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Executive&rsquo;s Parties.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>14
<FILENAME>exh_1012.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.12</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">EXECUTIVE
EMPLOYMENT</FONT> <FONT STYLE="font-size: 12pt">AGREEMENT</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT made this 4<SUP>
</SUP>day of August, 2015</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>ARBUTUS BIOPHARMA CORPORATION</B>, a company incorporated
under the laws of British Columbia (the &ldquo;<B>Company</B>&rdquo;), with offices at 100 &ndash; 8900 Glenlyon Parkway, Burnaby,
British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 40pt"><B>Michael Abrams </B>(the &ldquo;<B>Executive</B>&rdquo;),
of <B>Custer, Washington, USA</B></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Executive has the
expertise, qualifications and required certifications to perform the services contemplated by this Agreement; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">C.&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Company wishes to employ the Executive to perform the
services, on the terms and conditions herein set forth, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree
as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive will be employed by and will serve the Company as its <B>Managing Director</B>
and will have powers and duties consistent with such position as may from time to time be prescribed by the Chief Executive Officer
of the Company. The Executive will report directly to the <B>Chief Executive Officer</B> of the Company and will perform the duties
and responsibilities assigned to the Executive from time to time by the Chief Executive Officer. The Executive will comply with
all lawful instructions given by the Chief Executive Officer of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The terms and conditions of this
                                         Agreement will have effect as and from 4<SUP> </SUP>day of August, 2015 and the Executive&rsquo;s
                                         employment as <B>Managing Director</B> will continue until terminated as provided for
                                         in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement,
the Executive&rsquo;s employment with the Company is subject to and governed by the Company&rsquo;s policies as established from
time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions
of the Agreement. The Executive will inform himself of the details of such policies and amendments thereto established from time
to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The Executive agrees that, as a high technology professional as defined in the Regulations to the Employment
Standards Act of British Columbia, and an executive, his hours of work will vary and may be irregular and will be those hours required
to meet the objectives of his employment. The Executive agrees that the compensation described in Section <FONT STYLE="font-size: 10pt">2
of this Agreement compensates him in full for all hours worked.</FONT></P>


</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The Executive will devote 80% of his time to the Company&rsquo;s business and will not be employed or
engaged in any capacity in any other business without the prior permission of the Company, such permission not to be unreasonably
withheld. Notwithstanding the foregoing, the Executive may manage his personal investments or engage charitable or other community
activities as long as those services and activities do not interfere with the Executive&rsquo;s performance of his duties to the
Company.</P>


</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Concurrently with the execution and delivery of this Agreement and in consideration of the Executive&rsquo;s
employment by the Company, the Executive and the Company will enter into a &ldquo;Confidentiality and Assignment of Inventions
Agreement&rdquo; in the form attached hereto as Exhibit A.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>REMUNERATION AND BENEFITS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Base Salary</U>. The Company will pay the Executive an annual salary of US$347,500, less required
deductions (the &ldquo;<B>Base Salary</B>&rdquo;). The Base Salary will be payable semi-monthly. The Executive&rsquo;s Base Salary
will be reviewed annually by the Chief Executive Officer of the Company and is subject to increase but not decrease, except for
an across-the-board salary reduction affecting all or substantially all senior executives of the Company, nor will it necessarily
result in an increase to the Base Salary. The base salary in effect at any given time is referred to as &ldquo;Base Salary&rdquo;
and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable
in a manner that is consistent with the Company&rsquo;s usual payroll practices for senior executives.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Bonus</U>. The Executive is eligible to be considered for an annual discretionary bonus of up
to 40 percent of Base Salary (such bonus, the &ldquo;<B>Target Bonus</B>&rdquo;); which will be subject to the terms of the bonus
plan and approval of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;), in its sole discretion, on an annual
basis. Any bonus payable during the first year of the Executive&rsquo;s employment will be pro-rated. Payment of a bonus in any
one year will not indicate the payment of a bonus in any other year.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Expenses</U>. The Company will reimburse the Executive for all reasonable expenses actually
and properly incurred by the Executive in performing services under this Agreement, in accordance with the policies and procedures
then in effect and established by the Company for its senior executives. The Executive will provide the Company with receipts supporting
the Executive&rsquo;s claims for reimbursement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Other Benefits</U>. The Company will facilitate the Executive&rsquo;s enrolment in the Company&rsquo;s
insurance benefits plans, as amended from time to time by the Company or the insurance carrier. In all cases, eligibility to participate
in the plans and to receive benefits under the plans will be subject to the terms and requirements of the applicable insurance
carrier in accordance with the formal benefits plan documents and policies. Any issues with respect to entitlement to or payment
of benefits under the benefits package will be governed by the terms of such documents and policies. The Company is not responsible
for the payment of benefits in any circumstance. Further, the Company reserves the right, in its sole discretion, to change any
of the insurance benefit plans or providers, however, if the Company is unable to maintain similar coverage as to the insurance
benefits plans or the providers, then the Executive will be provided with compensation to assist in securing the Executive&rsquo;s
own coverage, such compensation to be determined by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Equity Compensation</U>. Subject to the discretionary approval of the Company&rsquo;s Board
of Directors, and in accordance with the Company&rsquo;s annual performance and compensation review process, the Executive shall
be eligible to receive equity awards under the  Arbutus Biopharma Corporation Share Incentive Plan and or any other similar
equity incentive plan to the same extent as other executives of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Vacation</U>. The Executive is entitled to paid holidays and vacation days each year, in an
amount determined in accordance with and subject to the Company&rsquo;s applicable policies in effect, and as may be amended from
time to time. The Executive will be entitled to 20 days of vacation per calendar year, which will be pro-rated for any year in
which the Executive is only employed with the Company for a portion of the year or for any period in which the Executive is not
a full-time employee. Vacation days will be scheduled at times that are mutually acceptable to the Executive and the Company. Carry-over
of vacation days will be according to Company policy, and any accrued but unused vacation days will be paid out upon termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>NON-COMPETITION AND NON-SOLICITATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The biotechnology industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company&rsquo;s interests if they join a competing business immediately upon
leaving the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Affiliate</B>&rdquo;
means, in respect of the Company, a company or other entity which directly or indirectly controls, is controlled by, or is under
common control with, the Company. For the purposes of this definition, &ldquo;control&rdquo; means direct or indirect beneficial
ownership of a greater than 50% interest in the income of such company or entity or such other relationship as, in fact, constitutes
actual control. For greater certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva
Biotherapeutics (USA) Inc. and Arbutus Biopharma, Inc. are Affiliates of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>researching, developing, producing and marketing any treatment for hepatitis B virus infection in humans; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
other treatment area in which the Company has an active research and development program on the date this Agreement terminates
and in connection with which the Executive directly provided service or had direct supervisory responsibilities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Competing Business</B>&rdquo; means any endeavour, activity or business which is competitive in any material way
with the Business of the Company worldwide.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Contact</B>&rdquo;
means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator,
strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates) with whom the Executive
dealt or otherwise became aware of during the term of the Executive&rsquo;s employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Restricted Period</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive is terminated pursuant to Section 5(d) of this Employment Agreement, a period equivalent
to the amount of notice that the Executive is entitled pursuant to Section 6(b)(i); or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive&rsquo;s employment is terminated pursuant to a Change of Control (as defined below), a period
equivalent to the amount of notice that the Executive is entitled pursuant to Section&nbsp;7(d)(iii)(A).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: left"><U>Reasonableness</U>. The Executive hereby acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">both before and since the commencement of the Executive&rsquo;s employment by the Company, the Company
has operated and competed and will operate and compete worldwide, with respect to the Business of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">competitors of the Company and the Business are located worldwide;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">in order to protect the Company adequately, any enjoinder of competition would have to apply to any
country in which the Company, during the term of the Executive&rsquo;s employment, had material business relationships;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">during the course of the Executive&rsquo;s employment with the Company, on behalf of the Company,
the Executive will acquire knowledge of, and will come into contact with, initiate and establish relationships with, both existing
and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive
may become the senior or sole representative of the Company dealing with such persons; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: left">in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper
protection of the Business of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Restrictive Covenant</U>. Except as set forth on Exhibit C attached hereto, during the term
of the Executive&rsquo;s employment and for the Restricted Period after the termination thereof, the Executive shall not, without
the prior written consent of the Board, such consent to be granted or withheld in the Board&rsquo;s sole discretion, within the
geographic scope of any country in which the Company, during the term of the Executive&rsquo;s employment, had material business
relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially
involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with
any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner
whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: left"><U>Exception</U>. The Executive shall not be in default of Section 3(d) by virtue of the Executive:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">following the termination of employment, holding, strictly for portfolio purposes and as a passive
investor, no more than five percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or
other entity which is listed on any recognized stock exchange, that is a Competing Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">during the term of the Executive&rsquo;s employment, holding, strictly for portfolio purposes and
as a passive investor, issued and outstanding shares of, or any other interest in, any corporation or other entity, the business
of which corporation or other entity is in the same Business as the Company provided such corporation is not a Competing Business,
and provided further that the Executive first obtains the Company&rsquo;s written consent, which consent will not be unreasonably
withheld.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Executive holds issued and outstanding shares or
any other interest in a corporation or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares
or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose
of the Executive&rsquo;s shares or other interest in such corporation or other entity.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: left"><U>Non-Solicitation</U>. The Executive shall not, during the term of the Executive&rsquo;s employment
and for the Restricted Period after the termination thereof for any reason, whether legal or illegal, either individually or in
partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor,
employee, shareholder or in any manner whatsoever, without the prior written and informed consent of the Company, directly or indirectly:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business
of) any Contact, or otherwise solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for
any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">accept (or procure or assist the acceptance of) any business from any Contact which business is competitive
with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">be employed by or supply (or procure or assist the supply of) any goods or services to any Contact
for any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise
entice away from or solicit, induce or encourage to leave the employment or engagement of the Company, any individual who is employed
or engaged by the Company whether or not such individual would commit any breach of the Executive&rsquo;s contract or terms of
employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall be permitted,
solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Validity</U>. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&rsquo;s
activities following the termination of the Executive&rsquo;s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable to any extent
by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction,
the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that which is in fact
declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order
to ensure that the intention of the parties is given the greatest possible effect.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>INJUNCTIVE
RELIEF</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive understands and agrees that the Company has a material interest in preserving the
relationships it has developed with its executives, customers and suppliers against impairment by competitive activities of a former
executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Section 3 are reasonably required
for the protection of the Company and its goodwill and that the Executive&rsquo;s agreement to those restrictions and covenants
by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to
enter into this Agreement and to employ the Executive, and that the Company would not enter into this Agreement absent such an
inducement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Executive understands and acknowledges that if the Executive breaches Section 3, that breach
will give rise to irreparable injury to the Company for which damages are an inadequate remedy, and the Company may pursue injunctive
relief for such breach in a court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive&rsquo;s employment by the Company may be terminated
under the following circumstances:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Death</U>. The Executive&rsquo;s employment hereunder will terminate upon the Executive&rsquo;s
death.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Disability</U>. The Company may terminate the Executive&rsquo;s employment if the Executive
is disabled (as determined by the Chief Executive Officer) by a condition that qualifies Executive for long term disability benefits
under the Company&rsquo;s then-current long term disability plan, in a manner that renders the Executive unable to perform the
essential functions of the Executive&rsquo;s then existing position or positions under this Agreement with or without reasonable
accommodation for a period of six (6) months or more. Nothing in this Section 5(b) will be construed to waive the Executive&rsquo;s
rights, if any, under the Company&rsquo;s insurance benefits plans accruing prior to termination or under applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Termination by Company for Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company may terminate the Executive&rsquo;s employment For Cause at any time, without notice
or payment in lieu thereof. The payment by the Company of the Executive&rsquo;s Accrued Benefits shall be subject to any other
rights or remedies of the Company under law and thereafter all obligations of the Company under this Agreement shall cease.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, &ldquo;<B>For Cause</B>&rdquo; shall mean:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the Executive commits a crime involving dishonesty, breach of trust, or physical harm to any person
(excluding driving while affected by drugs or alcohol) or any violation of provincial, state or federal securities laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Executive willfully engages in conduct that is in bad faith and materially injurious to the
Company or its Affiliates, monetarily or otherwise, including but not limited to, misappropriation of trade secrets, fraud or embezzlement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the Executive commits a material breach of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">the Executive willfully refuses to implement or follow a lawful policy or directive of the Company;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">the Executive willfully and on a continuing basis fails to perform his duties hereunder diligently
and professionally.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company, in its sole discretion, may terminate the Executive&rsquo;s employment under this
Agreement without Cause at any time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, any termination by the Company of the Executive&rsquo;s employment
under this Agreement that does not constitute a termination &ldquo;For Cause&rdquo; under Section 5(c) and does not result from
the death or disability of the Executive under Sections 5(a) or 5(b), respectively, shall be a termination &ldquo;without Cause&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Resignation by Executive</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment by providing to the Company Notice of Termination of
his employment at least three (3) months prior to the effective date of resignation. During such notice period Executive shall
continue to diligently perform all of Executive&rsquo;s duties hereunder, provided that the Company shall have the option, in its
sole discretion, to waive such notice period, in whole or in part, and if it does so, the Executive&rsquo;s resignation will become
effective and the Executive&rsquo;s employment will cease on the date set by the Company in the notice of waiver, and the Executive
shall be entitled to his Accrued Benefits up to and including the Date of Termination (as defined in Section&nbsp;5(g)(iii)). In
the event the Company waives the Executive&rsquo;s notice hereunder, the Company, in its sole discretion, in the circumstances,
may pay the Base Salary portion of the Executive&rsquo;s Accrued Benefits by way of one or more lump sum payments, by way of salary
continuance or by a combination of both.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment for Good Reason within 12 months following a Change
in Control of the Company in accordance with, and subject to, the process set out in Section 7(c).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Notice of Termination</U>. Except for termination as specified in Section 5(a), any termination
of the Executive&rsquo;s employment by the Company or any termination of the Executive&rsquo;s employment by the Executive must
be communicated by written Notice of Termination to the other party. For the purposes of this Agreement, &ldquo;<B>Notice of Termination</B>&rdquo;
means a written notice that indicates the specific termination provision in this Agreement upon which the termination is based.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Date of Termination</U>. For the purposes of this Agreement, &ldquo;<B>Date of Termination</B>&rdquo;
means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated by his death, the date of his death;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated on account of disability under Section 5(b) or
by the Company for Cause under Section 5(c), or by the Company without Cause under Section 5(d) on the date the Notice of Termination
is given;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(i) without Good Reason, on the effective
date of resignation specified by the Executive in the Notice of Termination (which shall be at least three (3) months after the
date of the Notice of Termination) or, if no such date is specified or if the Company waives the notice period, the date that is
three (3) months after the date of the Notice of Termination; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(ii) for Good Reason following a Change
in Control of the Company, the date on which a Notice of Termination is given after the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">Notwithstanding the foregoing, if the Executive gives a
Notice of Termination to the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination
and that acceleration will not be deemed a termination by the Company for purposes of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>COMPENSATION
UPON TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Termination Generally</U>. If the Executive&rsquo;s employment with the Company is terminated
for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) on or before
the time required by law, but in no event more than 30 days after the Executive&rsquo;s Date of Termination:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">unpaid expense reimbursements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">accrued but unused vacation to the extent payment is required by law or Company policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any vested benefits the Executive may have under any employee benefit plan of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any earned but unpaid Base Salary; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any earned but unpaid annual bonus for the prior fiscal year;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">for service up to and including the Date of Termination
(collectively the &ldquo;<B>Accrued Benefits</B>&rdquo;). The Executive shall not be entitled to any other salary, compensation,
bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided in this Agreement,
under the Company&rsquo;s employee benefit plans or as expressly required by applicable law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>. If the Executive&rsquo;s employment is terminated
by the Company without Cause, then the Company shall pay the Executive his Accrued Benefits as of the Date of Termination. In addition,
subject to Section 7 and the Executive providing the Company with a fully effective general release of claims in a form and manner
satisfactory to the Company that includes but is not limited to the terms set forth in the attached Exhibit B (the &ldquo;<B>Release</B>&rdquo;)
within the 60-day period following the Date of Termination (and which shall be countersigned by the Company in respect of the non-disparagement
clause therein), the Company shall pay the Executive an amount (the &ldquo;<B>Severance Amount</B>&rdquo; calculated as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an amount equal to eighteen (18) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">The Company shall pay the Severance Amount within 60 days
after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company shall make the
payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances, may pay
the Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Severance
Amount is inclusive of any entitlement to minimum standard severance under the British Columbia <I>Employment Standards Act</I>.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>CHANGE
IN CONTROL</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The provisions of this Section 7 set forth the Executive&rsquo;s rights and obligations upon the
occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&rsquo;s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. Where the provisions of this Section 7 apply, they shall supersede the payment of the Severance Amount under
Section 6(b). The provisions of this Section 7 are subject to the Executive providing to the Company, and not revoking, a fully
effective Release.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Definitions</U>. For purposes of this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the sale of all or substantially all of the assets of the Company to an unrelated person or entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a merger, reorganization, or consolidation involving the Company in which the shares of voting
stock outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving
or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power
of the surviving or resulting entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the acquisition of all or a majority of the outstanding voting stock of the Company in a single
transaction or a series of related transactions by a person or group of persons; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">any other acquisition of the business of the Company, as determined by the Board;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">but any public offering by the Company, or another capital
raising event, or a merger effected solely to change the Company&rsquo;s domicile does not constitute a Change in Control; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Good Reason</B>&rdquo; shall mean the occurrence of any of the following events without
the Executive's prior written consent:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a change in the Executive&rsquo;s position which materially reduces the Executive&rsquo;s responsibilities
from the responsibilities in effect immediately prior to the Change of Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a reduction by the Company of the Executive&rsquo;s Base Salary or Target Bonus percentage, except
for an across-the-board salary reduction affecting all senior executives of the Company; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">a relocation of Executive&rsquo;s principal place of employment by more than 80 kilometres.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Resignation for Good Reason</U>. If the Executive desires to terminate his employment for Good
Reason within 12 months following a Change in Control, the Executive must comply with, and shall be subject to, the following terms
and conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Executive reasonably determines in good faith that a Good Reason condition has occurred within
12 months following a Change in Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive notifies the Company in writing of the first occurrence of the Good Reason condition
within 30 days of the first occurrence of such condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Executive cooperates in good faith with the Company&rsquo;s efforts, for a period of not less
than 30 days following that notice (the &ldquo;<B>Cure Period</B>&rdquo;) to remedy the condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding the Company&rsquo;s efforts, the Good Reason condition continues to exist; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">the Executive provides to the Company Notice of Termination of his employment within 30 days after
the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Company cures the Good Reason condition during the
Cure Period, the Good Reason condition is deemed not to have occurred and the Executive may not terminate his employment in respect
of such condition.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Change in Control Severance</U>. If within 12 months following a Change in Control:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company terminates the Executive&rsquo;s employment with the Company without Cause; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive resigns from his employment with the Company for Good Reason;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">then,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">in addition to paying the Executive his Accrued Benefits and in lieu of paying the Executive the
Severance Amount, the Company shall pay to the Executive an amount (the &ldquo;<B>Change in Control Severance Amount</B>&rdquo;)
as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">an amount equal to twenty-four (24) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">The Company shall pay the Change in Control Severance
Amount within 60 days after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company
shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances,
may pay the Change in Control Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination
of both. The Change in Control Severance Amount is inclusive of any entitlement to minimum standard severance under the British
Columbia <I>Employment Standards Act</I>; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding anything to the contrary in any applicable option agreement or stock-based award
agreement, all stock options and other stock-based awards held by the Executive shall immediately accelerate, vest, and become
fully exercisable or non-forfeitable as of the Date of Termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The Executive will return to the Company all Company documents,
files, manuals, books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to
Company upon the termination of the executive&rsquo;s employment with the Company for any reason.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>GENERAL PROVISIONS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Withholding</U>. All payments made by the Company to the Executive
under this Agreement will be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing
in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that
minimizes tax consequences for the Executive.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company expressly
to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession
had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession
is a material breach of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Successor to the Executive</U>. This Agreement inures to the benefit of and is enforceable by
the Executive&rsquo;s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the
Executive dies after his termination of employment but prior to the completion by the Company of all payments due to him under
this Agreement, the Company shall continue the payments to the Executive&rsquo;s beneficiary designated in writing to the Company
prior to his death (or to his estate, if the Executive fails to make such a designation).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Non-Waiver</U><B>.</B> Failure on the part of either party to complain of any act or failure
to act of the other of them or to declare the other party in default of this Agreement, irrespective of how long such failure continues,
will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Severability</U><B>. </B>In the event that any provision or part of this Agreement is determined
to be void or unenforceable in whole or in part, the remaining provisions, or parts thereof, will be and remain in full force and
effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U><B>.</B> This Agreement constitutes the entire agreement between the parties
with respect to the employment of the Executive and supersedes any and all agreements, understandings, warranties or representations
of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each
of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claim or demands
whatsoever under or in respect of any agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Survival</U><B>.</B> The provisions of this Agreement survive the termination of this Agreement
and/or the termination of the Executive&rsquo;s employment to the extent necessary to effectuate the intent of the Parties as expressed
in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><U>Modification of Agreement</U><B>.</B> Any modification of this Agreement must be in writing
and signed by both the Company and the Executive or it will have no effect and will be void.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><U>Disputes</U><B>.</B> Except for disputes arising in respect of Section 3, all disputes arising
out of or in connection with this Agreement and the employment relationship between the parties, are to be referred to and finally
resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules.
The place of arbitration will be Vancouver, British Columbia.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify"><U>Governing Law</U><B>.</B> This Agreement will be governed by and construed according to the
laws of the Province of British Columbia, Canada.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement
are sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered
or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing
with the Company or, in the case of the Company, at its main offices, attention to the Corporate Secretary.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify"><U>Independent Legal Advice</U><B>.</B> The Executive agrees that the contents, terms and effect
of this Agreement have been explained to the Executive by a lawyer and are fully understood. The Executive further agrees that
the consideration described aforesaid is accepted voluntarily for the purpose of employment with the Company under the terms and
conditions described above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each
party on separate counterparts, each of which counterparts, when so executed and delivered is to be taken to be an original; but
those counterparts together constitute one and the same document. PDF, facsimile, scanned, and electronic signatures have the same
legal effect as original ink signatures.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">by <B>Michael Abrams </B>in the presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">/s/ Michael Abrams</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Witness</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><P STYLE="margin: 0pt 0"><B>Michael Abrams</B></P>


</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Occupation</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CONFIDENTIALITY</B><BR>
<B>AND ASSIGNMENT OF INVENTIONS AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;)
dated for reference the 4<SUP> </SUP>day of August, 2015.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR>
(the &ldquo;<B>Company</B>&rdquo;), a company incorporated under the laws of British Columbia with offices at 100 &ndash; 8900
Glenlyon Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>Michael Abrams</B> (the &ldquo;<B>Executive</B>&rdquo;),
of <B>Custer, Washington, USA</B></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the
employment of the Executive by the Company, the parties desire to establish the terms and conditions under which the Executive
will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information
confidential, to protect it from disclosure and to use it only in accordance with the terms of this Agreement; and (iii) assign
to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed
or disclosed by the Executive over the course of his work during his employment with the Company, as set out in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of
the employment of the Executive by the Company and the payment by the Company to the Executive of the sum of $10.00 and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;INTERPRETATION</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Definitions.</B> In this Agreement:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; means, in respect of the Company, a company or other entity
                                                               which directly or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of
                                                               this definition, &ldquo;<B>control</B>&rdquo; means direct or indirect beneficial ownership of a greater than 50% interest in
                                                               the income of such company or entity or such other relationship as, in fact, constitutes actual control. For greater
                                                               certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc.
                                                               and  Arbutus Biopharma, Inc. are Affiliates of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">researching, developing, producing and marketing any treatment for hepatitis B virus infection
in humans; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any other treatment area in which the Company has an active research and development program on
the date the Executive&rsquo;s employment with the Company terminates and in connection with which the Executive directly provided
service or had direct supervisory responsibilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo; shall mean all information, knowledge, or data, whether
in written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered
or developed in whole or in part by the Executive, that is not generally known to the public or to other persons who are not bound
by obligations of confidentiality and:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">from which the Company or its Affiliates derive economic value, actual or potential, from the information
not being generally known; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">and which, without limiting the generality of the foregoing,
shall include:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">all proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research and development of RNA interference drugs
and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas, processes,
research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">all information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory, marketing, advertising and
commercial information and strategies, customer lists, compilations, agreements and contractual records and correspondence; programs,
devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate items that is not generally
known and items provided or disclosed to the Company or its Affiliates by third parties subject to restrictions on use or disclosure;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all know-how relating to the Business of the Company, including all biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information,
and all applications, registrations, licenses, authorizations, approvals and correspondence submitted to regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors&rsquo; research and development, intellectual property, operations, financial, clinical, regulatory,
marketing, advertising and commercial strategies, that is not generally known;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">all information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">all information relating to the Executive&rsquo;s compensation and benefits, including his salary,
vacation, stock options, rights to continuing education, perquisites, severance notice, rights on termination and all other compensation
and benefits, except that he shall be entitled to disclose such information to his bankers, advisors, agents, consultants and other
third parties who have a duty of confidence to him and who have a need to know such information in order to provide advice, products
or services to him.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">All Work Product shall be deemed to be the Company&rsquo;s
Confidential Information.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means the 4<SUP> </SUP>day of August, 2015 being the date
that the Executive started working at the Company, as indicated in his employment agreement with the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo; is used in its broadest sense and means and includes
any statutory, common law, equitable, contractual or proprietary rights or interests, recognized currently or in future, in and
to any Inventions, including, without limitation, rights and interests in and to the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">knowledge, know-how and its embodiments, including trade secret information;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">patents in inventions, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">copyrights in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works
of authorship including technical descriptions for products, user guides, illustrations, advertising materials, computer programs,
source code and object code, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">trademarks, service marks, tradenames, business names and domain names and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">industrial designs and all other industrial or intellectual property and all applications therefor;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all goodwill connected with the foregoing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Inventions</B>&rdquo; shall mean any and all inventions, discoveries, developments, enhancements,
improvements, concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced to practice, and
whether or not protectable under patent, copyright, trade secret or similar laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Work Product</B>&rdquo; shall mean any and all Inventions and possible Inventions relating
to the Business of the Company and which the Executive may make or conceive, alone or jointly with others, during his involvement
in any capacity with the Company, whether during or outside his regular working hours, except those Inventions made or conceived
by the Executive entirely on his own time that do not relate to the Business of the Company and do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or through his involvement
in any capacity with the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">CONFIDENTIALITY</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prior
Business Confidential Information</B>. The Executive represents and warrants to the Company that the Executive has not brought
or used, and the Executive covenants and agrees that the Executive will not use or bring to the Company any confidential information
of any kind whatsoever of any prior party (the &ldquo;<B>Prior Business</B>&rdquo;) with whom the Executive was previously involved,
whether such involvement was as an employee, director or officer of that Prior Business, an investor in that Prior Business, a
partner in that Prior Business, a consultant to that Prior Business or other relationship to that Prior Business (the &ldquo;<B>Prior
Involvement</B>&rdquo;). The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain confidential information relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any and all legal obligations the Executive may have to such Prior Business. The Executive covenants
and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer
as a result of any breach by the Executive of his obligations to such Prior Business in that regard.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Basic
Obligation of Confidentiality.</B> The Executive hereby acknowledges and agrees that in the course of <B>his</B> involvement with
the Company, the Company may disclose to him or he may otherwise have access or be exposed to Confidential Information. The Company
hereby agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential Information
on the terms and conditions set out in this Agreement. Except as otherwise set out in this Agreement, the Executive will keep
strictly confidential all Confidential Information and all other information belonging to the Company that he acquires, observes
or is informed of, directly or indirectly, in connection with his involvement, in any capacity, with the Company both during and
after the term of his employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Fiduciary
Capacity.</B> The Executive will be and act toward the Company and its Affiliates as a fiduciary in respect of the Confidential
Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-disclosure.</B> Except with the prior written consent of the Company, the Executive will not at any time, either
during or after his involvement in any capacity with the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">use or copy any Confidential Information or recollections thereof for any purpose other than the
performance of his duties for the benefit of the Company and its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">publish or disclose any Confidential Information or recollections thereof to any person other than
to employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their
duties for the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be used, copied, published, disclosed, translated
or adapted except as otherwise expressly permitted by this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on personal computers, except in accordance
with written procedures of the Company, as amended from time to time in writing.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Taking Precautions.</B> The Executive will take all reasonable precautions necessary or prudent to prevent material in
his possession or control that contains or refers to Confidential Information from being discovered, used or copied by third parties.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>The Company&rsquo;s Ownership of Confidential Information.</B> As between the Executive and the Company, the Company
shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Control of Confidential Information and Return of Information.</B> All physical materials produced or prepared by the
Executive containing Confidential Information, including, without limitation, records, devices, computer files, data, notes, reports,
proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates
and all other materials prepared in the course of his responsibilities to or for the benefit of the Company or its Affiliates,
together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn
over to the Company&rsquo;s possession every original and copy of any and all such items in his possession or control upon request
by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will
provide reasonable evidence that such materials have been destroyed, purged or erased.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Purpose of Use.</B> The Executive agrees that he will use Confidential Information only for purposes authorized or directed
by the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Exemptions. </B>The obligations of confidentiality set out in this Article 2 will not apply to any of the following:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">information that is already known to the Executive, though not due to a prior disclosure by the
Company or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or
its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">information disclosed to the Executive by another person who is not obliged to maintain the confidentiality
of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">information that is developed by the Executive independently of Confidential Information received
from the Company or its Affiliates and such independent development can be documented by the Executive;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">other particular information or material which the Company expressly exempts by written instrument
signed by the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">information or material that is in the public domain through no fault of the Executive; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">information required by operation of law, court order or government agency to be disclosed, provided
that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, the Executive will provide to the Company prompt written notice so that the Company may seek
a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Company agrees that the disclosure is required by law, it will give the Executive written
authorization to disclose the information for the required purposes only;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Company does not agree that the disclosure is required by law, this Agreement will continue
to apply, except to the extent that a Court of competent jurisdiction orders otherwise; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if a protective order or other remedy is not obtained or if compliance with this Agreement is waived,
the Executive will furnish only that portion of the Confidential Information that is legally required and will exercise all reasonable
efforts to obtain confidential treatment of such Confidential Information.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">ASSIGNMENT
OF INTELLECTUAL PROPERTY RIGHTS</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notice
of Invention.</B> The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable,
throughout the course of his involvement, in any capacity, with the Company and from which there is a reasonable basis to believe
that Intellectual Property may be derived therefrom, whether or not developed before or after execution of this Agreement. On
his ceasing to be employed by the Company for any reason whatsoever, the Executive will immediately deliver up to the Company
all Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment
of Rights.</B> Subject only to the exceptions set out in <B>Exhibit I</B> attached to this Agreement, the Executive will assign,
and does hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company&rsquo;s
designee, all of his right, title and interest in and to all Work Product, including all Intellectual Property rights therein.
To the extent that the Executive retains or acquires legal title to any such Intellectual Property rights and interests, the Executive
hereby declares and confirms that such legal title is and will be held by him only as trustee and agent for the Company or the
Company&rsquo;s designee. The Executive agrees that the Company&rsquo;s rights hereunder shall attach to all Intellectual Property
rights in his Work Product, notwithstanding that it may be perfected or reduced to specific form after he has terminated his relationship
with the Company. The Executive further agrees that the Company&rsquo;s rights hereunder are worldwide rights and are not limited
to Canada, but shall extend to every country of the world.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Moral
Rights.</B> Without limiting the foregoing, the Executive hereby irrevocably waives any and all moral rights arising under the
<I>Copyright Act</I> (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in
other applicable jurisdictions or at common law that he may have with respect to all Work Product, and agrees never to assert
any moral rights which he may have in the Work Product, including, without limitation, the right to the integrity of the Work
Product, the right to be associated with the Work Product, the right to restrain or claim damages for any distortion, mutilation
or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product
in any context and in connection with any product, service, cause or institution, and the Executive further confirms that the
Company may use or alter any Work Product as the Company sees fits in its absolute discretion.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Goodwill.</B> The Executive hereby agrees that all goodwill he has established or may establish with clients, customers,
suppliers, principals, shareholders, investors, collaborators, strategic partners, licensees, contacts or prospects of the Company
relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date,
shall, as between the Executive and the Company, be and remain the property of the Company exclusively, for the Company to use,
alter, vary, adapt and exploit as the Company shall determine in its discretion.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance.
</B>The Executive hereby agrees to reasonably assist the Company, at the Company&rsquo;s request and expense, in:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">making patent applications for all Work Product, including instructions to lawyers and/or patent
agents as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification,
to execute all formal documentation incidental to an application for letters patent and to execute assignment documents in favour
of the Company for such applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">making applications for all other forms of Intellectual Property registration relating to all Work
Product;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">prosecuting and maintaining the patent applications and other Intellectual Property relating to
all Work Product; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">registering, maintaining and enforcing the patents and other Intellectual Property registrations
relating to all Work Product.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the Company is unable for any reason to secure the Executive&rsquo;s
signature with respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents
or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and stead to execute
and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal force
and effect as if executed by him.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance with Proceedings.</B> The Executive further agrees to reasonably assist the Company, at the Company&rsquo;s
request and expense, in connection with any defence to an allegation of infringement of another person&rsquo;s intellectual property
rights, claim of invalidity of another person&rsquo;s intellectual property rights, opposition to, or intervention regarding, an
application for letters patent, copyright or trademark or other proceedings relating to Intellectual Property or applications for
registration thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Commercialization.
</B>The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company&rsquo;s
sole discretion and for the Company&rsquo;s sole benefit and that no royalty or other consideration will be due or payable to
him as a result of the Company&rsquo;s efforts to commercialize or market any such Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Business Intellectual Property</B>. The Executive represents and warrants to the Company that he has not brought or used,
and the Executive covenants and agrees that he will not use or bring to the Company any Intellectual Property of any kind
whatsoever of any Prior Business with whom the Executive had a Prior Involvement or any Intellectual Property directly owned
by the Executive. The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain Intellectual Property relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any legal obligations the Executive may have to such Prior Business. The Executive covenants and
agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer as
a result any breach by the Executive of his obligations to such Prior Business in that regard.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Inventions.</B> In order to have them excluded from this Agreement, the Executive has set forth on <B>Exhibit I</B> attached to
this Agreement a complete list of all Inventions for which a patent application has not yet been filed that he has, alone or jointly
with others, conceived, developed or reduced to practice prior to the execution of this Agreement to which he has any right, title
or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive
represents and warrants that there are no such prior Inventions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>General</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Term.
</B>Subject to Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive
is no longer working at or for the Company in any capacity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>No
Conflicting Obligations.</B> The Executive hereby represents and warrants that he has no agreements with or obligations to
any other person with respect to the matters covered by this Agreement or concerning the Confidential Information that are in
conflict with anything in this Agreement, except as disclosed in <B>Exhibit I</B> attached to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Publicity.</B> The Executive shall not, without the prior written consent of the Company, make or give any public announcements,
press releases or statements to the public or the press regarding any Work Product or any Confidential Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Further
Assurances.</B> The parties will execute and deliver to each other such further instruments and assurances and do such further
acts as may be required to give effect to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notices.
</B>All notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand
delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with
receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to
have been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either
party may change its address or its facsimile number by giving the other party written notice, delivered in accordance with this
section.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Equitable
Remedies. </B>The Executive understands and acknowledges that if he breaches any of his obligations under this Agreement,
that breach may give rise to irreparable injury to the Company for which damages are an inadequate remedy. In the event of
any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company
will be entitled as a matter of right to apply to a court of competent jurisdiction for such relief by way of restraining
order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-Waiver</B>.
Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other
party in default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such
party of their rights hereunder or of the right to then or subsequently declare a default.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Severability.
</B>In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the
remaining provisions, or parts thereof, will be and remain in full force and effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Entire Agreement.</B> This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral,
express or implied, including any relating to the nature of the position or its duration, and each of the parties releases and
forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect
of any agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Survival.</B> Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article
2 (including the obligations of confidentiality and to return Confidential Information, which shall endure, with respect to each
item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections
3.2, 3.3, 3.4, 3.5, 3.6 and 3.8 and Article 4 shall survive any expiration or early termination of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Modification of Agreement.</B> Any modification of this Agreement must be in writing and signed by both the
Company and the Executive or it will have no effect and will be void.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>G</B></FONT><B>overning Law.</B> This Agreement will be governed by and construed according to the laws of the Province of
British Columbia, Canada.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Independent Legal Advice.</B> The Executive agrees that he has obtained or has had an opportunity to obtain independent
legal advice in connection with this Agreement, and further acknowledge that he has read, understands, and agrees to be bound by
all of the terms and conditions contained herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">by <B>Michael Abrams</B> in the
        presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">/s/ Michael Abrams</P></TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Witness Signature</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><BR></P></TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><B>Michael Abrams</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Name</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: left; font-size: 10pt"><BR>
<BR>
</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Witness Occupation</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><BR></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT I</B><BR>
<B>to Confidentiality and Assignment of Inventions Agreement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXCLUSIONS FROM WORK PRODUCT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[To be completed as applicable]</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>GENERAL RELEASE LANGUAGE</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the &ldquo;<B>Executive&rsquo;s
Parties</B>&rdquo;), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates, subsidiaries,
directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys,
benefit plans sponsored by the Company, and said plans&rsquo; fiduciaries, agents and trustees (the &ldquo;<B>Company&rsquo;s Parties</B>&rdquo;),
from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments,
levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive&rsquo;s Parties have, have
had, or may in the future claim to have against the Company&rsquo;s Parties by reason of, arising out of, related to, or resulting
from the Executive&rsquo;s employment with the Company or the termination of that employment. This release specifically includes
without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of
contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. It is understood and agreed that the waiver of benefits and claims contained
in this section does not include a waiver of the right to payment of any vested, non-forfeitable benefits to which the Executive
or a beneficiary of the Executive may be entitled under the terms and provisions of any employee benefit plan of the company which
have accrued as of the Date of Termination, and does not include a waiver of the right to benefits and payment of consideration
to which the Executive may be entitled under this Agreement or any of the agreements contemplated by this Agreement (including
the indemnification agreement and the stock option agreement). The Executive acknowledges that he is entitled to only the severance
benefits and compensation set forth in this Agreement, and that all other claims for any other benefits or compensation are hereby
waived, except those expressly stated in the preceding sentence.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Executive agrees that he will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Company&rsquo;s Parties or their products, employees, services, work
and/or employment.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Company agrees that it will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Executive&rsquo;s Parties.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --> &nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXISTING CONFLICTS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">If applicable, Executive to describe, in specific terms,
any ongoing business relationship with any organization other than Arbutus Biopharma Corporation or Arbutus Biopharma Inc. Please provide a
copy of any agreements with said organizations that creates a business relationship described in Section 3(d)</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>15
<FILENAME>exh_1013.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.13</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">EXECUTIVE
EMPLOYMENT</FONT> <FONT STYLE="font-size: 12pt">AGREEMENT</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT made this 4<SUP>
</SUP>day of August, 2015</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>ARBUTUS BIOPHARMA CORPORATION</B>, a company
incorporated under the laws of British Columbia (the &ldquo;<B>Company</B>&rdquo;), with offices at 100 &ndash; 8900 Glenlyon
Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>Mark Kowalski</B> (the &ldquo;<B>Executive</B>&rdquo;),
of <B>Winchester, Massachusetts, USA</B></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Executive has the
expertise, qualifications and required certifications to perform the services contemplated by this Agreement; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">C.&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Company wishes to employ the Executive to perform the
services, on the terms and conditions herein set forth, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree
as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive will be employed by and will serve the Company as its <B>Chief Medical Officer</B>
and will have powers and duties consistent with such position as may from time to time be prescribed by the Chief Executive Officer
of the Company. The Executive will report directly to the <B>Chief Executive Officer</B> of the Company and will perform the duties
and responsibilities assigned to the Executive from time to time by the Chief Executive Officer. The Executive will comply with
all lawful instructions given by the Chief Executive Officer of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The terms and conditions of this Agreement will have effect as and from 4<SUP> </SUP>day
                                                               of August, 2015 and the Executive&rsquo;s employment as <B>Chief Medical Officer</B> will continue until terminated as
                                                               provided for in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement,
the Executive&rsquo;s employment with the Company is subject to and governed by the Company&rsquo;s policies as established from
time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions
of the Agreement. The Executive will inform himself of the details of such policies and amendments thereto established from time
to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The Executive agrees that, as a high technology professional as defined in the Regulations to the Employment
Standards Act of British Columbia, and an executive, his hours of work will vary and may be irregular and will be those hours required
to meet the objectives of his employment. The Executive agrees that the compensation described in Section <FONT STYLE="font-size: 10pt">2
of this Agreement compensates him in full for all hours worked.</FONT></P>


</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Executive will devote himself exclusively to the Company&rsquo;s business and will not be employed
or engaged in any capacity in any other business without the prior permission of the Company, such permission not to be unreasonably
withheld. Notwithstanding the foregoing, the Executive may manage his personal investments or engage charitable or other community
activities as long as those services and activities do not interfere with the Executive&rsquo;s performance of his duties to the
Company.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Concurrently with the execution and delivery of this Agreement and in consideration of the Executive&rsquo;s
employment by the Company, the Executive and the Company will enter into a &ldquo;Confidentiality and Assignment of Inventions
Agreement&rdquo; in the form attached hereto as Exhibit A.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>REMUNERATION AND BENEFITS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Base Salary</U>. The Company will pay the Executive an annual salary of US$365,000, less required
deductions (the &ldquo;<B>Base Salary</B>&rdquo;). The Base Salary will be payable semi-monthly. The Executive&rsquo;s Base Salary
will be reviewed annually by the Chief Executive Officer of the Company and is subject to increase but not decrease, except for
an across-the-board salary reduction affecting all or substantially all senior executives of the Company, nor will it necessarily
result in an increase to the Base Salary. The base salary in effect at any given time is referred to as &ldquo;Base Salary&rdquo;
and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable
in a manner that is consistent with the Company&rsquo;s usual payroll practices for senior executives.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Bonus</U>. The Executive is eligible to be considered for an annual discretionary bonus of up
to 40 percent of Base Salary (such bonus, the &ldquo;<B>Target Bonus</B>&rdquo;); which will be subject to the terms of the bonus
plan and approval of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;), in its sole discretion, on an annual
basis. Any bonus payable during the first year of the Executive&rsquo;s employment will be pro-rated. Payment of a bonus in any
one year will not indicate the payment of a bonus in any other year.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Expenses</U>. The Company will reimburse the Executive for all reasonable expenses actually
and properly incurred by the Executive in performing services under this Agreement, in accordance with the policies and procedures
then in effect and established by the Company for its senior executives. The Executive will provide the Company with receipts supporting
the Executive&rsquo;s claims for reimbursement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Other Benefits</U>. The Company will facilitate the Executive&rsquo;s enrolment in the Company&rsquo;s
insurance benefits plans, as amended from time to time by the Company or the insurance carrier. In all cases, eligibility to participate
in the plans and to receive benefits under the plans will be subject to the terms and requirements of the applicable insurance
carrier in accordance with the formal benefits plan documents and policies. Any issues with respect to entitlement to or payment
of benefits under the benefits package will be governed by the terms of such documents and policies. The Company is not responsible
for the payment of benefits in any circumstance. Further, the Company reserves the right, in its sole discretion, to change any
of the insurance benefit plans or providers, however, if the Company is unable to maintain similar coverage as to the insurance
benefits plans or the providers, then the Executive will be provided with compensation to assist in securing the Executive&rsquo;s
own coverage, such compensation to be determined by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Equity Compensation</U>. Subject to the discretionary approval of the Company&rsquo;s Board
of Directors, and in accordance with the Company&rsquo;s annual performance and compensation review process, the Executive shall
be eligible to receive equity awards under the  Arbutus Biopharma Corporation Share Incentive Plan and or any other similar
equity incentive plan to the same extent as other executives of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Vacation</U>. The Executive is entitled to paid holidays and vacation days each year, in an
amount determined in accordance with and subject to the Company&rsquo;s applicable policies in effect, and as may be amended from
time to time. The Executive will be entitled to 20 days of vacation per calendar year, which will be pro-rated for any year in
which the Executive is only employed with the Company for a portion of the year or for any period in which the Executive is not
a full-time employee. Vacation days will be scheduled at times that are mutually acceptable to the Executive and the Company. Carry-over
of vacation days will be according to Company policy, and any accrued but unused vacation days will be paid out upon termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>NON-COMPETITION AND NON-SOLICITATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The biotechnology industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company&rsquo;s interests if they join a competing business immediately upon
leaving the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Affiliate</B>&rdquo;
means, in respect of the Company, a company or other entity which directly or indirectly controls, is controlled by, or is under
common control with, the Company. For the purposes of this definition, &ldquo;control&rdquo; means direct or indirect beneficial
ownership of a greater than 50% interest in the income of such company or entity or such other relationship as, in fact, constitutes
actual control. For greater certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva
Biotherapeutics (USA) Inc. and Arbutus Biopharma, Inc. are Affiliates of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>researching, developing, producing and marketing any treatment for hepatitis B virus infection in humans; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
other treatment area in which the Company has an active research and development program on the date this Agreement terminates
and in connection with which the Executive directly provided service or had direct supervisory responsibilities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Competing Business</B>&rdquo; means any endeavour, activity or business which is competitive in any material way
with the Business of the Company worldwide.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Contact</B>&rdquo;
means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator,
strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates) with whom the Executive
dealt or otherwise became aware of during the term of the Executive&rsquo;s employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Restricted Period</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive is terminated pursuant to Section 5(d) of this Employment Agreement, a period equivalent
to the amount of notice that the Executive is entitled pursuant to Section 6(b)(i); or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive&rsquo;s employment is terminated pursuant to a Change of Control (as defined below), a period
equivalent to the amount of notice that the Executive is entitled pursuant to Section&nbsp;7(d)(iii)(A).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: left"><U>Reasonableness</U>. The Executive hereby acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">both before and since the commencement of the Executive&rsquo;s employment by the Company, the Company
has operated and competed and will operate and compete worldwide, with respect to the Business of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">competitors of the Company and the Business are located worldwide;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">in order to protect the Company adequately, any enjoinder of competition would have to apply to any
country in which the Company, during the term of the Executive&rsquo;s employment, had material business relationships;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">during the course of the Executive&rsquo;s employment with the Company, on behalf of the Company,
the Executive will acquire knowledge of, and will come into contact with, initiate and establish relationships with, both existing
and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive
may become the senior or sole representative of the Company dealing with such persons; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: left">in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper
protection of the Business of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Restrictive Covenant</U>. Except as set forth on Exhibit C attached hereto, during the term
of the Executive&rsquo;s employment and for the Restricted Period after the termination thereof, the Executive shall not, without
the prior written consent of the Board, such consent to be granted or withheld in the Board&rsquo;s sole discretion, within the
geographic scope of any country in which the Company, during the term of the Executive&rsquo;s employment, had material business
relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially
involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with
any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner
whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: left"><U>Exception</U>. The Executive shall not be in default of Section 3(d) by virtue of the Executive:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">following the termination of employment, holding, strictly for portfolio purposes and as a passive
investor, no more than five percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or
other entity which is listed on any recognized stock exchange, that is a Competing Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">during the term of the Executive&rsquo;s employment, holding, strictly for portfolio purposes and
as a passive investor, issued and outstanding shares of, or any other interest in, any corporation or other entity, the business
of which corporation or other entity is in the same Business as the Company provided such corporation is not a Competing Business,
and provided further that the Executive first obtains the Company&rsquo;s written consent, which consent will not be unreasonably
withheld.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Executive holds issued and outstanding shares or
any other interest in a corporation or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares
or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose
of the Executive&rsquo;s shares or other interest in such corporation or other entity.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: left"><U>Non-Solicitation</U>. The Executive shall not, during the term of the Executive&rsquo;s employment
and for the Restricted Period after the termination thereof for any reason, whether legal or illegal, either individually or in
partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor,
employee, shareholder or in any manner whatsoever, without the prior written and informed consent of the Company, directly or indirectly:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business
of) any Contact, or otherwise solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for
any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">accept (or procure or assist the acceptance of) any business from any Contact which business is competitive
with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">be employed by or supply (or procure or assist the supply of) any goods or services to any Contact
for any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise
entice away from or solicit, induce or encourage to leave the employment or engagement of the Company, any individual who is employed
or engaged by the Company whether or not such individual would commit any breach of the Executive&rsquo;s contract or terms of
employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall be permitted,
solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Validity</U>. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&rsquo;s
activities following the termination of the Executive&rsquo;s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable to any extent
by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction,
the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that which is in fact
declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order
to ensure that the intention of the parties is given the greatest possible effect.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>INJUNCTIVE
RELIEF</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive understands and agrees that the Company has a material interest in preserving the
relationships it has developed with its executives, customers and suppliers against impairment by competitive activities of a former
executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Section 3 are reasonably required
for the protection of the Company and its goodwill and that the Executive&rsquo;s agreement to those restrictions and covenants
by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to
enter into this Agreement and to employ the Executive, and that the Company would not enter into this Agreement absent such an
inducement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Executive understands and acknowledges that if the Executive breaches Section 3, that breach
will give rise to irreparable injury to the Company for which damages are an inadequate remedy, and the Company may pursue injunctive
relief for such breach in a court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive&rsquo;s employment by the Company may be terminated
under the following circumstances:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Death</U>. The Executive&rsquo;s employment hereunder will terminate upon the Executive&rsquo;s
death.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Disability</U>. The Company may terminate the Executive&rsquo;s employment if the Executive
is disabled (as determined by the Chief Executive Officer) by a condition that qualifies Executive for long term disability benefits
under the Company&rsquo;s then-current long term disability plan, in a manner that renders the Executive unable to perform the
essential functions of the Executive&rsquo;s then existing position or positions under this Agreement with or without reasonable
accommodation for a period of six (6) months or more. Nothing in this Section 5(b) will be construed to waive the Executive&rsquo;s
rights, if any, under the Company&rsquo;s insurance benefits plans accruing prior to termination or under applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Termination by Company for Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company may terminate the Executive&rsquo;s employment For Cause at any time, without notice
or payment in lieu thereof. The payment by the Company of the Executive&rsquo;s Accrued Benefits shall be subject to any other
rights or remedies of the Company under law and thereafter all obligations of the Company under this Agreement shall cease.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, &ldquo;<B>For Cause</B>&rdquo; shall mean:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the Executive commits a crime involving dishonesty, breach of trust, or physical harm to any person
(excluding driving while affected by drugs or alcohol) or any violation of provincial, state or federal securities laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Executive willfully engages in conduct that is in bad faith and materially injurious to the
Company or its Affiliates, monetarily or otherwise, including but not limited to, misappropriation of trade secrets, fraud or embezzlement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the Executive commits a material breach of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">the Executive willfully refuses to implement or follow a lawful policy or directive of the Company;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">the Executive willfully and on a continuing basis fails to perform his duties hereunder diligently
and professionally.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company, in its sole discretion, may terminate the Executive&rsquo;s employment under this
Agreement without Cause at any time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, any termination by the Company of the Executive&rsquo;s employment
under this Agreement that does not constitute a termination &ldquo;For Cause&rdquo; under Section 5(c) and does not result from
the death or disability of the Executive under Sections 5(a) or 5(b), respectively, shall be a termination &ldquo;without Cause&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Resignation by Executive</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment by providing to the Company Notice of Termination of
his employment at least three (3) months prior to the effective date of resignation. During such notice period Executive shall
continue to diligently perform all of Executive&rsquo;s duties hereunder, provided that the Company shall have the option, in its
sole discretion, to waive such notice period, in whole or in part, and if it does so, the Executive&rsquo;s resignation will become
effective and the Executive&rsquo;s employment will cease on the date set by the Company in the notice of waiver, and the Executive
shall be entitled to his Accrued Benefits up to and including the Date of Termination (as defined in Section&nbsp;5(g)(iii)). In
the event the Company waives the Executive&rsquo;s notice hereunder, the Company, in its sole discretion, in the circumstances,
may pay the Base Salary portion of the Executive&rsquo;s Accrued Benefits by way of one or more lump sum payments, by way of salary
continuance or by a combination of both.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment for Good Reason within 12 months following a Change
in Control of the Company in accordance with, and subject to, the process set out in Section 7(c).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Notice of Termination</U>. Except for termination as specified in Section 5(a), any termination
of the Executive&rsquo;s employment by the Company or any termination of the Executive&rsquo;s employment by the Executive must
be communicated by written Notice of Termination to the other party. For the purposes of this Agreement, &ldquo;<B>Notice of Termination</B>&rdquo;
means a written notice that indicates the specific termination provision in this Agreement upon which the termination is based.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Date of Termination</U>. For the purposes of this Agreement, &ldquo;<B>Date of Termination</B>&rdquo;
means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated by his death, the date of his death;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated on account of disability under Section 5(b) or
by the Company for Cause under Section 5(c), or by the Company without Cause under Section 5(d) on the date the Notice of Termination
is given;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(i) without Good Reason, on the effective
date of resignation specified by the Executive in the Notice of Termination (which shall be at least three (3) months after the
date of the Notice of Termination) or, if no such date is specified or if the Company waives the notice period, the date that is
three (3) months after the date of the Notice of Termination; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(ii) for Good Reason following a Change
in Control of the Company, the date on which a Notice of Termination is given after the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">Notwithstanding the foregoing, if the Executive gives a
Notice of Termination to the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination
and that acceleration will not be deemed a termination by the Company for purposes of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>COMPENSATION
UPON TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Termination Generally</U>. If the Executive&rsquo;s employment with the Company is terminated
for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) on or before
the time required by law, but in no event more than 30 days after the Executive&rsquo;s Date of Termination:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">unpaid expense reimbursements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">accrued but unused vacation to the extent payment is required by law or Company policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any vested benefits the Executive may have under any employee benefit plan of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any earned but unpaid Base Salary; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any earned but unpaid annual bonus for the prior fiscal year;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">for service up to and including the Date of Termination
(collectively the &ldquo;<B>Accrued Benefits</B>&rdquo;). The Executive shall not be entitled to any other salary, compensation,
bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided in this Agreement,
under the Company&rsquo;s employee benefit plans or as expressly required by applicable law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>. If the Executive&rsquo;s employment is terminated
by the Company without Cause, then the Company shall pay the Executive his Accrued Benefits as of the Date of Termination. In addition,
subject to Section 7 and the Executive providing the Company with a fully effective general release of claims in a form and manner
satisfactory to the Company that includes but is not limited to the terms set forth in the attached Exhibit B (the &ldquo;<B>Release</B>&rdquo;)
within the 60-day period following the Date of Termination (and which shall be countersigned by the Company in respect of the non-disparagement
clause therein), the Company shall pay the Executive an amount (the &ldquo;<B>Severance Amount</B>&rdquo; calculated as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an amount equal to eighteen (18) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">The Company shall pay the Severance Amount within 60 days
after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company shall make the
payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances, may pay
the Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Severance
Amount is inclusive of any entitlement to minimum standard severance under the British Columbia <I>Employment Standards Act</I>.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>CHANGE
IN CONTROL</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The provisions of this Section 7 set forth the Executive&rsquo;s rights and obligations upon the
occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&rsquo;s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. Where the provisions of this Section 7 apply, they shall supersede the payment of the Severance Amount under
Section 6(b). The provisions of this Section 7 are subject to the Executive providing to the Company, and not revoking, a fully
effective Release.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Definitions</U>. For purposes of this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the sale of all or substantially all of the assets of the Company to an unrelated person or entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a merger, reorganization, or consolidation involving the Company in which the shares of voting
stock outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving
or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power
of the surviving or resulting entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the acquisition of all or a majority of the outstanding voting stock of the Company in a single
transaction or a series of related transactions by a person or group of persons; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">any other acquisition of the business of the Company, as determined by the Board;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">but any public offering by the Company, or another capital
raising event, or a merger effected solely to change the Company&rsquo;s domicile does not constitute a Change in Control; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Good Reason</B>&rdquo; shall mean the occurrence of any of the following events without
the Executive's prior written consent:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a change in the Executive&rsquo;s position which materially reduces the Executive&rsquo;s responsibilities
from the responsibilities in effect immediately prior to the Change of Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a reduction by the Company of the Executive&rsquo;s Base Salary or Target Bonus percentage, except
for an across-the-board salary reduction affecting all senior executives of the Company; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">a relocation of Executive&rsquo;s principal place of employment by more than 80 kilometres.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Resignation for Good Reason</U>. If the Executive desires to terminate his employment for Good
Reason within 12 months following a Change in Control, the Executive must comply with, and shall be subject to, the following terms
and conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Executive reasonably determines in good faith that a Good Reason condition has occurred within
12 months following a Change in Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive notifies the Company in writing of the first occurrence of the Good Reason condition
within 30 days of the first occurrence of such condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Executive cooperates in good faith with the Company&rsquo;s efforts, for a period of not less
than 30 days following that notice (the &ldquo;<B>Cure Period</B>&rdquo;) to remedy the condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding the Company&rsquo;s efforts, the Good Reason condition continues to exist; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">the Executive provides to the Company Notice of Termination of his employment within 30 days after
the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Company cures the Good Reason condition during the
Cure Period, the Good Reason condition is deemed not to have occurred and the Executive may not terminate his employment in respect
of such condition.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Change in Control Severance</U>. If within 12 months following a Change in Control:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company terminates the Executive&rsquo;s employment with the Company without Cause; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive resigns from his employment with the Company for Good Reason;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">then,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">in addition to paying the Executive his Accrued Benefits and in lieu of paying the Executive the
Severance Amount, the Company shall pay to the Executive an amount (the &ldquo;<B>Change in Control Severance Amount</B>&rdquo;)
as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">an amount equal to twenty-four (24) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">The Company shall pay the Change in Control Severance
Amount within 60 days after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company
shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances,
may pay the Change in Control Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination
of both. The Change in Control Severance Amount is inclusive of any entitlement to minimum standard severance under the British
Columbia <I>Employment Standards Act</I>; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding anything to the contrary in any applicable option agreement or stock-based award
agreement, all stock options and other stock-based awards held by the Executive shall immediately accelerate, vest, and become
fully exercisable or non-forfeitable as of the Date of Termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The Executive will return to the Company all Company documents,
files, manuals, books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to
Company upon the termination of the executive&rsquo;s employment with the Company for any reason.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>GENERAL PROVISIONS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Withholding</U>. All payments made by the Company to the Executive
under this Agreement will be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing
in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that
minimizes tax consequences for the Executive.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company expressly
to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession
had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession
is a material breach of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Successor to the Executive</U>. This Agreement inures to the benefit of and is enforceable by
the Executive&rsquo;s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the
Executive dies after his termination of employment but prior to the completion by the Company of all payments due to him under
this Agreement, the Company shall continue the payments to the Executive&rsquo;s beneficiary designated in writing to the Company
prior to his death (or to his estate, if the Executive fails to make such a designation).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Non-Waiver</U><B>.</B> Failure on the part of either party to complain of any act or failure
to act of the other of them or to declare the other party in default of this Agreement, irrespective of how long such failure continues,
will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Severability</U><B>. </B>In the event that any provision or part of this Agreement is determined
to be void or unenforceable in whole or in part, the remaining provisions, or parts thereof, will be and remain in full force and
effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U><B>.</B> This Agreement constitutes the entire agreement between the parties
with respect to the employment of the Executive and supersedes any and all agreements, understandings, warranties or representations
of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each
of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claim or demands
whatsoever under or in respect of any agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Survival</U><B>.</B> The provisions of this Agreement survive the termination of this Agreement
and/or the termination of the Executive&rsquo;s employment to the extent necessary to effectuate the intent of the Parties as expressed
in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><U>Modification of Agreement</U><B>.</B> Any modification of this Agreement must be in writing
and signed by both the Company and the Executive or it will have no effect and will be void.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><U>Disputes</U><B>.</B> Except for disputes arising in respect of Section 3, all disputes arising
out of or in connection with this Agreement and the employment relationship between the parties, are to be referred to and finally
resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules.
The place of arbitration will be Vancouver, British Columbia.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify"><U>Governing Law</U><B>.</B> This Agreement will be governed by and construed according to the
laws of the Province of British Columbia, Canada.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement
are sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered
or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing
with the Company or, in the case of the Company, at its main offices, attention to the Corporate Secretary.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify"><U>Independent Legal Advice</U><B>.</B> The Executive agrees that the contents, terms and effect
of this Agreement have been explained to the Executive by a lawyer and are fully understood. The Executive further agrees that
the consideration described aforesaid is accepted voluntarily for the purpose of employment with the Company under the terms and
conditions described above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each
party on separate counterparts, each of which counterparts, when so executed and delivered is to be taken to be an original; but
those counterparts together constitute one and the same document. PDF, facsimile, scanned, and electronic signatures have the same
legal effect as original ink signatures.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">by <B>Mark Kowalski </B>in
        the presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">/s/ Mark
    Kowalski</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Witness</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><B>Mark Kowalski</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Occupation</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CONFIDENTIALITY</B><BR>
<B>AND ASSIGNMENT OF INVENTIONS AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;)
dated for reference the 4<SUP> </SUP>day of August, 2015.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR>
(the &ldquo;<B>Company</B>&rdquo;), a company incorporated under the laws of British Columbia with offices at 100 &ndash; 8900
Glenlyon Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>Mark Kowalski</B> (the &ldquo;<B>Executive</B>&rdquo;),
of <B>Winchester, Massachusetts, USA</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the
employment of the Executive by the Company, the parties desire to establish the terms and conditions under which the Executive
will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information
confidential, to protect it from disclosure and to use it only in accordance with the terms of this Agreement; and (iii) assign
to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed
or disclosed by the Executive over the course of his work during his employment with the Company, as set out in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of
the employment of the Executive by the Company and the payment by the Company to the Executive of the sum of $10.00 and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;INTERPRETATION</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Definitions.</B> In this Agreement:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; means, in respect of the Company, a company or other entity which
directly or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of this definition,
&ldquo;<B>control</B>&rdquo; means direct or indirect beneficial ownership of a greater than 50% interest in the income of such
company or entity or such other relationship as, in fact, constitutes actual control. For greater certainty, without limiting the
generality of the foregoing, Protiva Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc. and Arbutus Biopharma, Inc. are Affiliates
of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">researching, developing, producing and marketing any treatment for hepatitis B virus infection
in humans; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any other treatment area in which the Company has an active research and development program on
the date the Executive&rsquo;s employment with the Company terminates and in connection with which the Executive directly provided
service or had direct supervisory responsibilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo; shall mean all information, knowledge, or data, whether
in written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered
or developed in whole or in part by the Executive, that is not generally known to the public or to other persons who are not bound
by obligations of confidentiality and:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">from which the Company or its Affiliates derive economic value, actual or potential, from the information
not being generally known; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">and which, without limiting the generality of the foregoing,
shall include:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">all proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research and development of RNA interference drugs
and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas, processes,
research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">all information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory, marketing, advertising and
commercial information and strategies, customer lists, compilations, agreements and contractual records and correspondence; programs,
devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate items that is not generally
known and items provided or disclosed to the Company or its Affiliates by third parties subject to restrictions on use or disclosure;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all know-how relating to the Business of the Company, including all biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information,
and all applications, registrations, licenses, authorizations, approvals and correspondence submitted to regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors&rsquo; research and development, intellectual property, operations, financial, clinical, regulatory,
marketing, advertising and commercial strategies, that is not generally known;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">all information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">all information relating to the Executive&rsquo;s compensation and benefits, including his salary,
vacation, stock options, rights to continuing education, perquisites, severance notice, rights on termination and all other compensation
and benefits, except that he shall be entitled to disclose such information to his bankers, advisors, agents, consultants and other
third parties who have a duty of confidence to him and who have a need to know such information in order to provide advice, products
or services to him.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">All Work Product shall be deemed to be the Company&rsquo;s
Confidential Information.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means the 4<SUP> </SUP>day of August, 2015 being the date
that the Executive started working at the Company, as indicated in his employment agreement with the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo; is used in its broadest sense and means and includes
any statutory, common law, equitable, contractual or proprietary rights or interests, recognized currently or in future, in and
to any Inventions, including, without limitation, rights and interests in and to the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">knowledge, know-how and its embodiments, including trade secret information;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">patents in inventions, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">copyrights in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works
of authorship including technical descriptions for products, user guides, illustrations, advertising materials, computer programs,
source code and object code, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">trademarks, service marks, tradenames, business names and domain names and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">industrial designs and all other industrial or intellectual property and all applications therefor;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all goodwill connected with the foregoing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Inventions</B>&rdquo; shall mean any and all inventions, discoveries, developments, enhancements,
improvements, concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced to practice, and
whether or not protectable under patent, copyright, trade secret or similar laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Work Product</B>&rdquo; shall mean any and all Inventions and possible Inventions relating
to the Business of the Company and which the Executive may make or conceive, alone or jointly with others, during his involvement
in any capacity with the Company, whether during or outside his regular working hours, except those Inventions made or conceived
by the Executive entirely on his own time that do not relate to the Business of the Company and do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or through his involvement
in any capacity with the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">CONFIDENTIALITY</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prior
Business Confidential Information</B>. The Executive represents and warrants to the Company that the Executive has not brought
or used, and the Executive covenants and agrees that the Executive will not use or bring to the Company any confidential information
of any kind whatsoever of any prior party (the &ldquo;<B>Prior Business</B>&rdquo;) with whom the Executive was previously involved,
whether such involvement was as an employee, director or officer of that Prior Business, an investor in that Prior Business, a
partner in that Prior Business, a consultant to that Prior Business or other relationship to that Prior Business (the &ldquo;<B>Prior
Involvement</B>&rdquo;). The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain confidential information relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any and all legal obligations the Executive may have to such Prior Business. The Executive covenants
and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer
as a result of any breach by the Executive of his obligations to such Prior Business in that regard.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Basic Obligation of Confidentiality.</B> The Executive hereby acknowledges and agrees that in the course of his involvement
with the Company, the Company may disclose to him or he may otherwise have access or be exposed to Confidential Information. The
Company hereby agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential
Information on the terms and conditions set out in this Agreement. Except as otherwise set out in this Agreement, the Executive
will keep strictly confidential all Confidential Information and all other information belonging to the Company that he acquires,
observes or is informed of, directly or indirectly, in connection with his involvement, in any capacity, with the Company both
during and after the term of his employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Fiduciary
Capacity.</B> The Executive will be and act toward the Company and its Affiliates as a fiduciary in respect of the Confidential
Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-disclosure.</B> Except with the prior written consent of the Company, the Executive will not at any time, either
during or after his involvement in any capacity with the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">use or copy any Confidential Information or recollections thereof for any purpose other than the
performance of his duties for the benefit of the Company and its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">publish or disclose any Confidential Information or recollections thereof to any person other than
to employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their
duties for the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be used, copied, published, disclosed, translated
or adapted except as otherwise expressly permitted by this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on personal computers, except in accordance
with written procedures of the Company, as amended from time to time in writing.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Taking Precautions.</B> The Executive will take all reasonable precautions necessary or prudent to prevent material in
his possession or control that contains or refers to Confidential Information from being discovered, used or copied by third parties.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>The Company&rsquo;s Ownership of Confidential Information.</B> As between the Executive and the Company, the Company
shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Control of Confidential Information and Return of Information.</B> All physical materials produced or prepared by the
Executive containing Confidential Information, including, without limitation, records, devices, computer files, data, notes, reports,
proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates
and all other materials prepared in the course of his responsibilities to or for the benefit of the Company or its Affiliates,
together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn
over to the Company&rsquo;s possession every original and copy of any and all such items in his possession or control upon request
by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will
provide reasonable evidence that such materials have been destroyed, purged or erased.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Purpose of Use.</B> The Executive agrees that he will use Confidential Information only for purposes authorized or directed
by the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Exemptions. </B>The obligations of confidentiality set out in this Article 2 will not apply to any of the following:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">information that is already known to the Executive, though not due to a prior disclosure by the
Company or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or
its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">information disclosed to the Executive by another person who is not obliged to maintain the confidentiality
of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">information that is developed by the Executive independently of Confidential Information received
from the Company or its Affiliates and such independent development can be documented by the Executive;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">other particular information or material which the Company expressly exempts by written instrument
signed by the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">information or material that is in the public domain through no fault of the Executive; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">information required by operation of law, court order or government agency to be disclosed, provided
that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, the Executive will provide to the Company prompt written notice so that the Company may seek
a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Company agrees that the disclosure is required by law, it will give the Executive written
authorization to disclose the information for the required purposes only;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Company does not agree that the disclosure is required by law, this Agreement will continue
to apply, except to the extent that a Court of competent jurisdiction orders otherwise; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if a protective order or other remedy is not obtained or if compliance with this Agreement is waived,
the Executive will furnish only that portion of the Confidential Information that is legally required and will exercise all reasonable
efforts to obtain confidential treatment of such Confidential Information.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">ASSIGNMENT
OF INTELLECTUAL PROPERTY RIGHTS</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notice
of Invention.</B> The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable,
throughout the course of his involvement, in any capacity, with the Company and from which there is a reasonable basis to believe
that Intellectual Property may be derived therefrom, whether or not developed before or after execution of this Agreement. On
his ceasing to be employed by the Company for any reason whatsoever, the Executive will immediately deliver up to the Company
all Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment
of Rights.</B> Subject only to the exceptions set out in <B>Exhibit I</B> attached to this Agreement, the Executive will assign,
and does hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company&rsquo;s
designee, all of his right, title and interest in and to all Work Product, including all Intellectual Property rights therein.
To the extent that the Executive retains or acquires legal title to any such Intellectual Property rights and interests, the Executive
hereby declares and confirms that such legal title is and will be held by him only as trustee and agent for the Company or the
Company&rsquo;s designee. The Executive agrees that the Company&rsquo;s rights hereunder shall attach to all Intellectual Property
rights in his Work Product, notwithstanding that it may be perfected or reduced to specific form after he has terminated his relationship
with the Company. The Executive further agrees that the Company&rsquo;s rights hereunder are worldwide rights and are not limited
to Canada, but shall extend to every country of the world.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Moral
Rights.</B> Without limiting the foregoing, the Executive hereby irrevocably waives any and all moral rights arising under the
<I>Copyright Act</I> (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in
other applicable jurisdictions or at common law that he may have with respect to all Work Product, and agrees never to assert
any moral rights which he may have in the Work Product, including, without limitation, the right to the integrity of the Work
Product, the right to be associated with the Work Product, the right to restrain or claim damages for any distortion, mutilation
or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product
in any context and in connection with any product, service, cause or institution, and the Executive further confirms that the
Company may use or alter any Work Product as the Company sees fits in its absolute discretion.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Goodwill.</B> The Executive hereby agrees that all goodwill he has established or may establish with clients, customers,
suppliers, principals, shareholders, investors, collaborators, strategic partners, licensees, contacts or prospects of the Company
relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date,
shall, as between the Executive and the Company, be and remain the property of the Company exclusively, for the Company to use,
alter, vary, adapt and exploit as the Company shall determine in its discretion.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance.
</B>The Executive hereby agrees to reasonably assist the Company, at the Company&rsquo;s request and expense, in:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">making patent applications for all Work Product, including instructions to lawyers and/or patent
agents as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification,
to execute all formal documentation incidental to an application for letters patent and to execute assignment documents in favour
of the Company for such applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">making applications for all other forms of Intellectual Property registration relating to all Work
Product;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">prosecuting and maintaining the patent applications and other Intellectual Property relating to
all Work Product; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">registering, maintaining and enforcing the patents and other Intellectual Property registrations
relating to all Work Product.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the Company is unable for any reason to secure the Executive&rsquo;s
signature with respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents
or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and stead to execute
and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal force
and effect as if executed by him.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance with Proceedings.</B> The Executive further agrees to reasonably assist the Company, at the Company&rsquo;s
request and expense, in connection with any defence to an allegation of infringement of another person&rsquo;s intellectual property
rights, claim of invalidity of another person&rsquo;s intellectual property rights, opposition to, or intervention regarding, an
application for letters patent, copyright or trademark or other proceedings relating to Intellectual Property or applications for
registration thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Commercialization.
</B>The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company&rsquo;s
sole discretion and for the Company&rsquo;s sole benefit and that no royalty or other consideration will be due or payable to
him as a result of the Company&rsquo;s efforts to commercialize or market any such Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Business Intellectual Property</B>. The Executive represents and warrants to the Company that he has not brought or used,
and the Executive covenants and agrees that he will not use or bring to the Company any Intellectual Property of any kind
whatsoever of any Prior Business with whom the Executive had a Prior Involvement or any Intellectual Property directly owned
by the Executive. The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain Intellectual Property relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any legal obligations the Executive may have to such Prior Business. The Executive covenants and
agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer as
a result any breach by the Executive of his obligations to such Prior Business in that regard.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Inventions.</B> In order to have them excluded from this Agreement, the Executive has set forth on <B>Exhibit I</B> attached to
this Agreement a complete list of all Inventions for which a patent application has not yet been filed that he has, alone or jointly
with others, conceived, developed or reduced to practice prior to the execution of this Agreement to which he has any right, title
or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive
represents and warrants that there are no such prior Inventions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>General</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Term.
</B>Subject to Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive
is no longer working at or for the Company in any capacity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>No
Conflicting Obligations.</B> The Executive hereby represents and warrants that he has no agreements with or obligations to
any other person with respect to the matters covered by this Agreement or concerning the Confidential Information that are in
conflict with anything in this Agreement, except as disclosed in <B>Exhibit I</B> attached to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Publicity.</B> The Executive shall not, without the prior written consent of the Company, make or give any public announcements,
press releases or statements to the public or the press regarding any Work Product or any Confidential Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Further
Assurances.</B> The parties will execute and deliver to each other such further instruments and assurances and do such further
acts as may be required to give effect to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notices.
</B>All notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand
delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with
receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to
have been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either
party may change its address or its facsimile number by giving the other party written notice, delivered in accordance with this
section.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Equitable
Remedies. </B>The Executive understands and acknowledges that if he breaches any of his obligations under this Agreement,
that breach may give rise to irreparable injury to the Company for which damages are an inadequate remedy. In the event of
any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company
will be entitled as a matter of right to apply to a court of competent jurisdiction for such relief by way of restraining
order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-Waiver</B>.
Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other
party in default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such
party of their rights hereunder or of the right to then or subsequently declare a default.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Severability.
</B>In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the
remaining provisions, or parts thereof, will be and remain in full force and effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Entire Agreement.</B> This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral,
express or implied, including any relating to the nature of the position or its duration, and each of the parties releases and
forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect
of any agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Survival.</B> Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article
2 (including the obligations of confidentiality and to return Confidential Information, which shall endure, with respect to each
item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections
3.2, 3.3, 3.4, 3.5, 3.6 and 3.8 and Article 4 shall survive any expiration or early termination of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Modification of Agreement.</B> Any modification of this Agreement must be in writing and signed by both the
Company and the Executive or it will have no effect and will be void.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>G</B></FONT><B>overning Law.</B> This Agreement will be governed by and construed according to the laws of the Province of
British Columbia, Canada.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Independent Legal Advice.</B> The Executive agrees that he has obtained or has had an opportunity to obtain independent
legal advice in connection with this Agreement, and further acknowledge that he has read, understands, and agrees to be bound by
all of the terms and conditions contained herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">by <B><B>Mark Kowalski</B></B> in the
        presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">/s/ Mark Kowalski<B>&nbsp;</B></P></TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Witness Signature</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><BR></P></TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><B>Mark Kowalski</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Name</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: left; font-size: 10pt"><BR>
<BR>
</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Witness Occupation</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><BR></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT I</B><BR>
<B>to Confidentiality and Assignment of Inventions Agreement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXCLUSIONS FROM WORK PRODUCT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[To be completed as applicable]</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>GENERAL RELEASE LANGUAGE</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the &ldquo;<B>Executive&rsquo;s
Parties</B>&rdquo;), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates, subsidiaries,
directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys,
benefit plans sponsored by the Company, and said plans&rsquo; fiduciaries, agents and trustees (the &ldquo;<B>Company&rsquo;s Parties</B>&rdquo;),
from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments,
levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive&rsquo;s Parties have, have
had, or may in the future claim to have against the Company&rsquo;s Parties by reason of, arising out of, related to, or resulting
from the Executive&rsquo;s employment with the Company or the termination of that employment. This release specifically includes
without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of
contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. It is understood and agreed that the waiver of benefits and claims contained
in this section does not include a waiver of the right to payment of any vested, non-forfeitable benefits to which the Executive
or a beneficiary of the Executive may be entitled under the terms and provisions of any employee benefit plan of the company which
have accrued as of the Date of Termination, and does not include a waiver of the right to benefits and payment of consideration
to which the Executive may be entitled under this Agreement or any of the agreements contemplated by this Agreement (including
the indemnification agreement and the stock option agreement). The Executive acknowledges that he is entitled to only the severance
benefits and compensation set forth in this Agreement, and that all other claims for any other benefits or compensation are hereby
waived, except those expressly stated in the preceding sentence.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Executive agrees that he will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Company&rsquo;s Parties or their products, employees, services, work
and/or employment.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Company agrees that it will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Executive&rsquo;s Parties.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXISTING CONFLICTS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">If applicable, Executive to describe, in specific terms, any
ongoing business relationship with any organization other than  Arbutus Biopharma Corporation or Arbutus Biopharma Inc. Please provide
a copy of any agreements with said organizations that creates a business relationship described in Section 3(d)</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>16
<FILENAME>exh_1014.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.14</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">EXECUTIVE
EMPLOYMENT</FONT> <FONT STYLE="font-size: 12pt">AGREEMENT</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT made this 4<SUP>
</SUP>day of August, 2015</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>ARBUTUS BIOPHARMA</B> <B> CORPORATION</B>, a company
incorporated under the laws of British Columbia (the &ldquo;<B>Company</B>&rdquo;), with offices at 100 &ndash; 8900 Glenlyon
Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>Peter Lutwyche</B> (the &ldquo;<B>Executive</B>&rdquo;),
of <B>Vancouver, British Columbia, Canada</B></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B></B></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Executive has the
expertise, qualifications and required certifications to perform the services contemplated by this Agreement; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">C.&#9;&nbsp;&nbsp;&nbsp;&nbsp;The Company wishes to employ the Executive to perform the
services, on the terms and conditions herein set forth, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree
as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive will be employed by and will serve the Company as its <B>Chief Technical
                                                               Operations Officer</B> and will have powers and duties consistent with such position as may from time to time be prescribed
                                                               by the Chief Executive Officer of the Company. The Executive will report directly to the <B>Chief Executive Officer</B> of
                                                               the Company and will perform the duties and responsibilities assigned to the Executive from time to time by the Chief
                                                               Executive Officer. The Executive will comply with all lawful instructions given by the Chief Executive Officer of the
                                                               Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The terms and conditions of this
                                         Agreement will have effect as and from 4<SUP> </SUP>day of August, 2015 and the Executive&rsquo;s
                                         employment as <B>Chief Technical Operations Officer</B> will continue until terminated
                                         as provided for in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement,
the Executive&rsquo;s employment with the Company is subject to and governed by the Company&rsquo;s policies as established from
time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions
of the Agreement. The Executive will inform himself of the details of such policies and amendments thereto established from time
to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The Executive agrees that, as a high technology professional as defined in the Regulations to the Employment
Standards Act of British Columbia, and an executive, his hours of work will vary and may be irregular and will be those hours required
to meet the objectives of his employment. The Executive agrees that the compensation described in Section <FONT STYLE="font-size: 10pt">2
of this Agreement compensates him in full for all hours worked.</FONT></P>


</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Executive will devote himself exclusively to the Company&rsquo;s business and will not be employed
or engaged in any capacity in any other business without the prior permission of the Company, such permission not to be unreasonably
withheld. Notwithstanding the foregoing, the Executive may manage his personal investments or engage charitable or other community
activities as long as those services and activities do not interfere with the Executive&rsquo;s performance of his duties to the
Company.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Concurrently with the execution and delivery of this Agreement and in consideration of the Executive&rsquo;s
employment by the Company, the Executive and the Company will enter into a &ldquo;Confidentiality and Assignment of Inventions
Agreement&rdquo; in the form attached hereto as Exhibit A.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>REMUNERATION AND BENEFITS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Base Salary</U>. The Company will pay the Executive an annual salary of US$300,000, less required
deductions (the &ldquo;<B>Base Salary</B>&rdquo;). The Base Salary will be payable semi-monthly. The Executive&rsquo;s Base Salary
will be reviewed annually by the Chief Executive Officer of the Company and is subject to increase but not decrease, except for
an across-the-board salary reduction affecting all or substantially all senior executives of the Company, nor will it necessarily
result in an increase to the Base Salary. The base salary in effect at any given time is referred to as &ldquo;Base Salary&rdquo;
and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable
in a manner that is consistent with the Company&rsquo;s usual payroll practices for senior executives.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Bonus</U>. The Executive is eligible to be considered for an annual discretionary bonus of up
to 40 percent of Base Salary (such bonus, the &ldquo;<B>Target Bonus</B>&rdquo;); which will be subject to the terms of the bonus
plan and approval of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;), in its sole discretion, on an annual
basis. Any bonus payable during the first year of the Executive&rsquo;s employment will be pro-rated. Payment of a bonus in any
one year will not indicate the payment of a bonus in any other year.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Expenses</U>. The Company will reimburse the Executive for all reasonable expenses actually
and properly incurred by the Executive in performing services under this Agreement, in accordance with the policies and procedures
then in effect and established by the Company for its senior executives. The Executive will provide the Company with receipts supporting
the Executive&rsquo;s claims for reimbursement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Other Benefits</U>. The Company will facilitate the Executive&rsquo;s enrolment in the Company&rsquo;s
insurance benefits plans, as amended from time to time by the Company or the insurance carrier. In all cases, eligibility to participate
in the plans and to receive benefits under the plans will be subject to the terms and requirements of the applicable insurance
carrier in accordance with the formal benefits plan documents and policies. Any issues with respect to entitlement to or payment
of benefits under the benefits package will be governed by the terms of such documents and policies. The Company is not responsible
for the payment of benefits in any circumstance. Further, the Company reserves the right, in its sole discretion, to change any
of the insurance benefit plans or providers, however, if the Company is unable to maintain similar coverage as to the insurance
benefits plans or the providers, then the Executive will be provided with compensation to assist in securing the Executive&rsquo;s
own coverage, such compensation to be determined by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Equity Compensation</U>. Subject to the discretionary approval of the Company&rsquo;s Board
of Directors, and in accordance with the Company&rsquo;s annual performance and compensation review process, the Executive shall
be eligible to receive equity awards under the  Arbutus Biopharma Corporation Share Incentive Plan and or any other similar
equity incentive plan to the same extent as other executives of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Vacation</U>. The Executive is entitled to paid holidays and vacation days each year, in an
amount determined in accordance with and subject to the Company&rsquo;s applicable policies in effect, and as may be amended from
time to time. The Executive will be entitled to 20 days of vacation per calendar year, which will be pro-rated for any year in
which the Executive is only employed with the Company for a portion of the year or for any period in which the Executive is not
a full-time employee. Vacation days will be scheduled at times that are mutually acceptable to the Executive and the Company. Carry-over
of vacation days will be according to Company policy, and any accrued but unused vacation days will be paid out upon termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>NON-COMPETITION AND NON-SOLICITATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The biotechnology industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company&rsquo;s interests if they join a competing business immediately upon
leaving the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Affiliate</B>&rdquo;
means, in respect of the Company, a company or other entity which directly or indirectly controls, is controlled by, or is under
common control with, the Company. For the purposes of this definition, &ldquo;control&rdquo; means direct or indirect beneficial
ownership of a greater than 50% interest in the income of such company or entity or such other relationship as, in fact, constitutes
actual control. For greater certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva
Biotherapeutics (USA) Inc. and  Arbutus Biopharma, Inc. are Affiliates of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>researching, developing, producing and marketing any treatment for hepatitis B virus infection in humans; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
other treatment area in which the Company has an active research and development program on the date this Agreement terminates
and in connection with which the Executive directly provided service or had direct supervisory responsibilities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Competing Business</B>&rdquo; means any endeavour, activity or business which is competitive in any material way
with the Business of the Company worldwide.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Contact</B>&rdquo;
means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator,
strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates) with whom the Executive
dealt or otherwise became aware of during the term of the Executive&rsquo;s employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Restricted Period</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive is terminated pursuant to Section 5(d) of this Employment Agreement, a period equivalent
to the amount of notice that the Executive is entitled pursuant to Section 6(b)(i); or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that the Executive&rsquo;s employment is terminated pursuant to a Change of Control (as defined below), a period
equivalent to the amount of notice that the Executive is entitled pursuant to Section&nbsp;7(d)(iii)(A).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: left"><U>Reasonableness</U>. The Executive hereby acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">both before and since the commencement of the Executive&rsquo;s employment by the Company, the Company
has operated and competed and will operate and compete worldwide, with respect to the Business of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">competitors of the Company and the Business are located worldwide;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">in order to protect the Company adequately, any enjoinder of competition would have to apply to any
country in which the Company, during the term of the Executive&rsquo;s employment, had material business relationships;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">during the course of the Executive&rsquo;s employment with the Company, on behalf of the Company,
the Executive will acquire knowledge of, and will come into contact with, initiate and establish relationships with, both existing
and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive
may become the senior or sole representative of the Company dealing with such persons; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: left">in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper
protection of the Business of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Restrictive Covenant</U>. Except as set forth on Exhibit C attached hereto, during the term
of the Executive&rsquo;s employment and for the Restricted Period after the termination thereof, the Executive shall not, without
the prior written consent of the Board, such consent to be granted or withheld in the Board&rsquo;s sole discretion, within the
geographic scope of any country in which the Company, during the term of the Executive&rsquo;s employment, had material business
relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially
involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with
any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner
whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: left"><U>Exception</U>. The Executive shall not be in default of Section 3(d) by virtue of the Executive:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">following the termination of employment, holding, strictly for portfolio purposes and as a passive
investor, no more than five percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or
other entity which is listed on any recognized stock exchange, that is a Competing Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">during the term of the Executive&rsquo;s employment, holding, strictly for portfolio purposes and
as a passive investor, issued and outstanding shares of, or any other interest in, any corporation or other entity, the business
of which corporation or other entity is in the same Business as the Company provided such corporation is not a Competing Business,
and provided further that the Executive first obtains the Company&rsquo;s written consent, which consent will not be unreasonably
withheld.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Executive holds issued and outstanding shares or
any other interest in a corporation or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares
or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose
of the Executive&rsquo;s shares or other interest in such corporation or other entity.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: left"><U>Non-Solicitation</U>. The Executive shall not, during the term of the Executive&rsquo;s employment
and for the Restricted Period after the termination thereof for any reason, whether legal or illegal, either individually or in
partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor,
employee, shareholder or in any manner whatsoever, without the prior written and informed consent of the Company, directly or indirectly:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business
of) any Contact, or otherwise solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for
any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">accept (or procure or assist the acceptance of) any business from any Contact which business is competitive
with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">be employed by or supply (or procure or assist the supply of) any goods or services to any Contact
for any purpose which is competitive with the Business; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise
entice away from or solicit, induce or encourage to leave the employment or engagement of the Company, any individual who is employed
or engaged by the Company whether or not such individual would commit any breach of the Executive&rsquo;s contract or terms of
employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall be permitted,
solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Validity</U>. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&rsquo;s
activities following the termination of the Executive&rsquo;s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable to any extent
by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction,
the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that which is in fact
declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order
to ensure that the intention of the parties is given the greatest possible effect.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>INJUNCTIVE
RELIEF</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Executive understands and agrees that the Company has a material interest in preserving the
relationships it has developed with its executives, customers and suppliers against impairment by competitive activities of a former
executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Section 3 are reasonably required
for the protection of the Company and its goodwill and that the Executive&rsquo;s agreement to those restrictions and covenants
by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to
enter into this Agreement and to employ the Executive, and that the Company would not enter into this Agreement absent such an
inducement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Executive understands and acknowledges that if the Executive breaches Section 3, that breach
will give rise to irreparable injury to the Company for which damages are an inadequate remedy, and the Company may pursue injunctive
relief for such breach in a court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive&rsquo;s employment by the Company may be terminated
under the following circumstances:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Death</U>. The Executive&rsquo;s employment hereunder will terminate upon the Executive&rsquo;s
death.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Disability</U>. The Company may terminate the Executive&rsquo;s employment if the Executive
is disabled (as determined by the Chief Executive Officer) by a condition that qualifies Executive for long term disability benefits
under the Company&rsquo;s then-current long term disability plan, in a manner that renders the Executive unable to perform the
essential functions of the Executive&rsquo;s then existing position or positions under this Agreement with or without reasonable
accommodation for a period of six (6) months or more. Nothing in this Section 5(b) will be construed to waive the Executive&rsquo;s
rights, if any, under the Company&rsquo;s insurance benefits plans accruing prior to termination or under applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Termination by Company for Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company may terminate the Executive&rsquo;s employment For Cause at any time, without notice
or payment in lieu thereof. The payment by the Company of the Executive&rsquo;s Accrued Benefits shall be subject to any other
rights or remedies of the Company under law and thereafter all obligations of the Company under this Agreement shall cease.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, &ldquo;<B>For Cause</B>&rdquo; shall mean:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the Executive commits a crime involving dishonesty, breach of trust, or physical harm to any person
(excluding driving while affected by drugs or alcohol) or any violation of provincial, state or federal securities laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Executive willfully engages in conduct that is in bad faith and materially injurious to the
Company or its Affiliates, monetarily or otherwise, including but not limited to, misappropriation of trade secrets, fraud or embezzlement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the Executive commits a material breach of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">the Executive willfully refuses to implement or follow a lawful policy or directive of the Company;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">the Executive willfully and on a continuing basis fails to perform his duties hereunder diligently
and professionally.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company, in its sole discretion, may terminate the Executive&rsquo;s employment under this
Agreement without Cause at any time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">For the purposes of this Agreement, any termination by the Company of the Executive&rsquo;s employment
under this Agreement that does not constitute a termination &ldquo;For Cause&rdquo; under Section 5(c) and does not result from
the death or disability of the Executive under Sections 5(a) or 5(b), respectively, shall be a termination &ldquo;without Cause&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Resignation by Executive</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment by providing to the Company Notice of Termination of
his employment at least three (3) months prior to the effective date of resignation. During such notice period Executive shall
continue to diligently perform all of Executive&rsquo;s duties hereunder, provided that the Company shall have the option, in its
sole discretion, to waive such notice period, in whole or in part, and if it does so, the Executive&rsquo;s resignation will become
effective and the Executive&rsquo;s employment will cease on the date set by the Company in the notice of waiver, and the Executive
shall be entitled to his Accrued Benefits up to and including the Date of Termination (as defined in Section&nbsp;5(g)(iii)). In
the event the Company waives the Executive&rsquo;s notice hereunder, the Company, in its sole discretion, in the circumstances,
may pay the Base Salary portion of the Executive&rsquo;s Accrued Benefits by way of one or more lump sum payments, by way of salary
continuance or by a combination of both.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Executive may terminate his employment for Good Reason within 12 months following a Change
in Control of the Company in accordance with, and subject to, the process set out in Section 7(c).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Notice of Termination</U>. Except for termination as specified in Section 5(a), any termination
of the Executive&rsquo;s employment by the Company or any termination of the Executive&rsquo;s employment by the Executive must
be communicated by written Notice of Termination to the other party. For the purposes of this Agreement, &ldquo;<B>Notice of Termination</B>&rdquo;
means a written notice that indicates the specific termination provision in this Agreement upon which the termination is based.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Date of Termination</U>. For the purposes of this Agreement, &ldquo;<B>Date of Termination</B>&rdquo;
means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated by his death, the date of his death;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Executive&rsquo;s employment is terminated on account of disability under Section 5(b) or
by the Company for Cause under Section 5(c), or by the Company without Cause under Section 5(d) on the date the Notice of Termination
is given;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(i) without Good Reason, on the effective
date of resignation specified by the Executive in the Notice of Termination (which shall be at least three (3) months after the
date of the Notice of Termination) or, if no such date is specified or if the Company waives the notice period, the date that is
three (3) months after the date of the Notice of Termination; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if the Executive terminates his employment under Section 5(e)(ii) for Good Reason following a Change
in Control of the Company, the date on which a Notice of Termination is given after the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">Notwithstanding the foregoing, if the Executive gives a
Notice of Termination to the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination
and that acceleration will not be deemed a termination by the Company for purposes of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>COMPENSATION
UPON TERMINATION</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Termination Generally</U>. If the Executive&rsquo;s employment with the Company is terminated
for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) on or before
the time required by law, but in no event more than 30 days after the Executive&rsquo;s Date of Termination:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">unpaid expense reimbursements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">accrued but unused vacation to the extent payment is required by law or Company policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any vested benefits the Executive may have under any employee benefit plan of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any earned but unpaid Base Salary; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any earned but unpaid annual bonus for the prior fiscal year;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">for service up to and including the Date of Termination
(collectively the &ldquo;<B>Accrued Benefits</B>&rdquo;). The Executive shall not be entitled to any other salary, compensation,
bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided in this Agreement,
under the Company&rsquo;s employee benefit plans or as expressly required by applicable law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Termination by the Company without Cause</U>. If the Executive&rsquo;s employment is terminated
by the Company without Cause, then the Company shall pay the Executive his Accrued Benefits as of the Date of Termination. In addition,
subject to Section 7 and the Executive providing the Company with a fully effective general release of claims in a form and manner
satisfactory to the Company that includes but is not limited to the terms set forth in the attached Exhibit B (the &ldquo;<B>Release</B>&rdquo;)
within the 60-day period following the Date of Termination (and which shall be countersigned by the Company in respect of the non-disparagement
clause therein), the Company shall pay the Executive an amount (the &ldquo;<B>Severance Amount</B>&rdquo; calculated as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an amount equal to eighteen (18) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">The Company shall pay the Severance Amount within 60 days
after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company shall make the
payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances, may pay
the Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Severance
Amount is inclusive of any entitlement to minimum standard severance under the British Columbia <I>Employment Standards Act</I>.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>CHANGE
IN CONTROL</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The provisions of this Section 7 set forth the Executive&rsquo;s rights and obligations upon the
occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&rsquo;s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. Where the provisions of this Section 7 apply, they shall supersede the payment of the Severance Amount under
Section 6(b). The provisions of this Section 7 are subject to the Executive providing to the Company, and not revoking, a fully
effective Release.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Definitions</U>. For purposes of this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the sale of all or substantially all of the assets of the Company to an unrelated person or entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a merger, reorganization, or consolidation involving the Company in which the shares of voting
stock outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving
or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power
of the surviving or resulting entity;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the acquisition of all or a majority of the outstanding voting stock of the Company in a single
transaction or a series of related transactions by a person or group of persons; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">any other acquisition of the business of the Company, as determined by the Board;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">but any public offering by the Company, or another capital
raising event, or a merger effected solely to change the Company&rsquo;s domicile does not constitute a Change in Control; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Good Reason</B>&rdquo; shall mean the occurrence of any of the following events without
the Executive's prior written consent:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a change in the Executive&rsquo;s position which materially reduces the Executive&rsquo;s responsibilities
from the responsibilities in effect immediately prior to the Change of Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a reduction by the Company of the Executive&rsquo;s Base Salary or Target Bonus percentage, except
for an across-the-board salary reduction affecting all senior executives of the Company; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">a relocation of Executive&rsquo;s principal place of employment by more than 80 kilometres.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Resignation for Good Reason</U>. If the Executive desires to terminate his employment for Good
Reason within 12 months following a Change in Control, the Executive must comply with, and shall be subject to, the following terms
and conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Executive reasonably determines in good faith that a Good Reason condition has occurred within
12 months following a Change in Control;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive notifies the Company in writing of the first occurrence of the Good Reason condition
within 30 days of the first occurrence of such condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Executive cooperates in good faith with the Company&rsquo;s efforts, for a period of not less
than 30 days following that notice (the &ldquo;<B>Cure Period</B>&rdquo;) to remedy the condition;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding the Company&rsquo;s efforts, the Good Reason condition continues to exist; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">the Executive provides to the Company Notice of Termination of his employment within 30 days after
the end of the Cure Period.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">If the Company cures the Good Reason condition during the
Cure Period, the Good Reason condition is deemed not to have occurred and the Executive may not terminate his employment in respect
of such condition.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Change in Control Severance</U>. If within 12 months following a Change in Control:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company terminates the Executive&rsquo;s employment with the Company without Cause; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Executive resigns from his employment with the Company for Good Reason;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">then,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">in addition to paying the Executive his Accrued Benefits and in lieu of paying the Executive the
Severance Amount, the Company shall pay to the Executive an amount (the &ldquo;<B>Change in Control Severance Amount</B>&rdquo;)
as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">an amount equal to twenty-four (24) months&rsquo; Base Salary, less withholding; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">provided that the Executive is enrolled in the Company&rsquo;s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company&rsquo;s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">a period of up to 24 months from the Date of Termination, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">until the Executive becomes eligible to receive health insurance benefits under any other employer&rsquo;s
group health plan,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">The Company shall pay the Change in Control Severance
Amount within 60 days after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company
shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances,
may pay the Change in Control Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination
of both. The Change in Control Severance Amount is inclusive of any entitlement to minimum standard severance under the British
Columbia <I>Employment Standards Act</I>; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">notwithstanding anything to the contrary in any applicable option agreement or stock-based award
agreement, all stock options and other stock-based awards held by the Executive shall immediately accelerate, vest, and become
fully exercisable or non-forfeitable as of the Date of Termination.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The Executive will return to the Company all Company documents,
files, manuals, books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to
Company upon the termination of the executive&rsquo;s employment with the Company for any reason.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>GENERAL PROVISIONS</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Withholding</U>. All payments made by the Company to the Executive
under this Agreement will be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing
in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that
minimizes tax consequences for the Executive.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Successor to Company</U>. The Company shall require any successor (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company expressly
to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession
had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession
is a material breach of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Successor to the Executive</U>. This Agreement inures to the benefit of and is enforceable by
the Executive&rsquo;s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the
Executive dies after his termination of employment but prior to the completion by the Company of all payments due to him under
this Agreement, the Company shall continue the payments to the Executive&rsquo;s beneficiary designated in writing to the Company
prior to his death (or to his estate, if the Executive fails to make such a designation).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Non-Waiver</U><B>.</B> Failure on the part of either party to complain of any act or failure
to act of the other of them or to declare the other party in default of this Agreement, irrespective of how long such failure continues,
will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Severability</U><B>. </B>In the event that any provision or part of this Agreement is determined
to be void or unenforceable in whole or in part, the remaining provisions, or parts thereof, will be and remain in full force and
effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U><B>.</B> This Agreement constitutes the entire agreement between the parties
with respect to the employment of the Executive and supersedes any and all agreements, understandings, warranties or representations
of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each
of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claim or demands
whatsoever under or in respect of any agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Survival</U><B>.</B> The provisions of this Agreement survive the termination of this Agreement
and/or the termination of the Executive&rsquo;s employment to the extent necessary to effectuate the intent of the Parties as expressed
in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><U>Modification of Agreement</U><B>.</B> Any modification of this Agreement must be in writing
and signed by both the Company and the Executive or it will have no effect and will be void.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><U>Disputes</U><B>.</B> Except for disputes arising in respect of Section 3, all disputes arising
out of or in connection with this Agreement and the employment relationship between the parties, are to be referred to and finally
resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules.
The place of arbitration will be Vancouver, British Columbia.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify"><U>Governing Law</U><B>.</B> This Agreement will be governed by and construed according to the
laws of the Province of British Columbia, Canada.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any notices, requests, demands, and other communications provided for by this Agreement
are sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered
or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing
with the Company or, in the case of the Company, at its main offices, attention to the Corporate Secretary.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify"><U>Independent Legal Advice</U><B>.</B> The Executive agrees that the contents, terms and effect
of this Agreement have been explained to the Executive by a lawyer and are fully understood. The Executive further agrees that
the consideration described aforesaid is accepted voluntarily for the purpose of employment with the Company under the terms and
conditions described above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, and by each
party on separate counterparts, each of which counterparts, when so executed and delivered is to be taken to be an original; but
those counterparts together constitute one and the same document. PDF, facsimile, scanned, and electronic signatures have the same
legal effect as original ink signatures.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.1in 0pt 0">by <B><B>Peter Lutwyche</B> </B>in
        the presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">/s/ Peter
    Lutwyche</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Witness</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><P STYLE="margin: 0pt 0"><B>Peter Lutwyche</B></P>


</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; vertical-align: bottom">Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Occupation</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CONFIDENTIALITY</B><BR>
<B>AND ASSIGNMENT OF INVENTIONS AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">THIS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;)
dated for reference the 4<SUP> </SUP>day of August, 2015.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">BETWEEN:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR>
(the &ldquo;<B>Company</B>&rdquo;), a company incorporated under the laws of British Columbia with offices at 100 &ndash; 8900
Glenlyon Parkway, Burnaby, British Columbia fax:&nbsp;(604)&nbsp;419-3201</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">AND:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>Peter Lutwyche</B> (the &ldquo;<B>Executive</B>&rdquo;),
of <B>Vancouver, British Columbia, Canada</B></P>



<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 1in 0pt 85.05pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">WHEREAS:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">B.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the
employment of the Executive by the Company, the parties desire to establish the terms and conditions under which the Executive
will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information
confidential, to protect it from disclosure and to use it only in accordance with the terms of this Agreement; and (iii) assign
to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed
or disclosed by the Executive over the course of his work during his employment with the Company, as set out in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of
the employment of the Executive by the Company and the payment by the Company to the Executive of the sum of $10.00 and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;INTERPRETATION</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Definitions.</B> In this Agreement:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; means, in respect of the Company, a company or other entity
                                                               which directly or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of
                                                               this definition, &ldquo;<B>control</B>&rdquo; means direct or indirect beneficial ownership of a greater than 50% interest in
                                                               the income of such company or entity or such other relationship as, in fact, constitutes actual control. For greater
                                                               certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc.
                                                               and  Arbutus Biopharma, Inc. are Affiliates of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business</B>&rdquo; or &ldquo;<B>Business of the Company</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">researching, developing, producing and marketing any treatment for hepatitis B virus infection
in humans; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any other treatment area in which the Company has an active research and development program on
the date the Executive&rsquo;s employment with the Company terminates and in connection with which the Executive directly provided
service or had direct supervisory responsibilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo; shall mean all information, knowledge, or data, whether
in written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered
or developed in whole or in part by the Executive, that is not generally known to the public or to other persons who are not bound
by obligations of confidentiality and:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">from which the Company or its Affiliates derive economic value, actual or potential, from the information
not being generally known; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">and which, without limiting the generality of the foregoing,
shall include:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">all proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research and development of RNA interference drugs
and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas, processes,
research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">all information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory, marketing, advertising and
commercial information and strategies, customer lists, compilations, agreements and contractual records and correspondence; programs,
devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate items that is not generally
known and items provided or disclosed to the Company or its Affiliates by third parties subject to restrictions on use or disclosure;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all know-how relating to the Business of the Company, including all biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information,
and all applications, registrations, licenses, authorizations, approvals and correspondence submitted to regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors&rsquo; research and development, intellectual property, operations, financial, clinical, regulatory,
marketing, advertising and commercial strategies, that is not generally known;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">all information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">all information relating to the Executive&rsquo;s compensation and benefits, including his salary,
vacation, stock options, rights to continuing education, perquisites, severance notice, rights on termination and all other compensation
and benefits, except that he shall be entitled to disclose such information to his bankers, advisors, agents, consultants and other
third parties who have a duty of confidence to him and who have a need to know such information in order to provide advice, products
or services to him.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">All Work Product shall be deemed to be the Company&rsquo;s
Confidential Information.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means the 4<SUP> </SUP>day of August, 2015 being the date
that the Executive started working at the Company, as indicated in his employment agreement with the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo; is used in its broadest sense and means and includes
any statutory, common law, equitable, contractual or proprietary rights or interests, recognized currently or in future, in and
to any Inventions, including, without limitation, rights and interests in and to the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">knowledge, know-how and its embodiments, including trade secret information;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">patents in inventions, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">copyrights in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works
of authorship including technical descriptions for products, user guides, illustrations, advertising materials, computer programs,
source code and object code, and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">trademarks, service marks, tradenames, business names and domain names and all applications therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">industrial designs and all other industrial or intellectual property and all applications therefor;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">all goodwill connected with the foregoing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Inventions</B>&rdquo; shall mean any and all inventions, discoveries, developments, enhancements,
improvements, concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced to practice, and
whether or not protectable under patent, copyright, trade secret or similar laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Work Product</B>&rdquo; shall mean any and all Inventions and possible Inventions relating
to the Business of the Company and which the Executive may make or conceive, alone or jointly with others, during his involvement
in any capacity with the Company, whether during or outside his regular working hours, except those Inventions made or conceived
by the Executive entirely on his own time that do not relate to the Business of the Company and do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or through his involvement
in any capacity with the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">CONFIDENTIALITY</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prior
Business Confidential Information</B>. The Executive represents and warrants to the Company that the Executive has not brought
or used, and the Executive covenants and agrees that the Executive will not use or bring to the Company any confidential information
of any kind whatsoever of any prior party (the &ldquo;<B>Prior Business</B>&rdquo;) with whom the Executive was previously involved,
whether such involvement was as an employee, director or officer of that Prior Business, an investor in that Prior Business, a
partner in that Prior Business, a consultant to that Prior Business or other relationship to that Prior Business (the &ldquo;<B>Prior
Involvement</B>&rdquo;). The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain confidential information relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any and all legal obligations the Executive may have to such Prior Business. The Executive covenants
and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer
as a result of any breach by the Executive of his obligations to such Prior Business in that regard.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Basic Obligation of Confidentiality.</B> The Executive hereby acknowledges and agrees that in the course of his involvement
with the Company, the Company may disclose to him or he may otherwise have access or be exposed to Confidential Information. The
Company hereby agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential
Information on the terms and conditions set out in this Agreement. Except as otherwise set out in this Agreement, the Executive
will keep strictly confidential all Confidential Information and all other information belonging to the Company that he acquires,
observes or is informed of, directly or indirectly, in connection with his involvement, in any capacity, with the Company both
during and after the term of his employment in any capacity with the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Fiduciary
Capacity.</B> The Executive will be and act toward the Company and its Affiliates as a fiduciary in respect of the Confidential
Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-disclosure.</B> Except with the prior written consent of the Company, the Executive will not at any time, either
during or after his involvement in any capacity with the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">use or copy any Confidential Information or recollections thereof for any purpose other than the
performance of his duties for the benefit of the Company and its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">publish or disclose any Confidential Information or recollections thereof to any person other than
to employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their
duties for the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be used, copied, published, disclosed, translated
or adapted except as otherwise expressly permitted by this Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">permit or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on personal computers, except in accordance
with written procedures of the Company, as amended from time to time in writing.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Taking Precautions.</B> The Executive will take all reasonable precautions necessary or prudent to prevent material in
his possession or control that contains or refers to Confidential Information from being discovered, used or copied by third parties.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>The Company&rsquo;s Ownership of Confidential Information.</B> As between the Executive and the Company, the Company
shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Control of Confidential Information and Return of Information.</B> All physical materials produced or prepared by the
Executive containing Confidential Information, including, without limitation, records, devices, computer files, data, notes, reports,
proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates
and all other materials prepared in the course of his responsibilities to or for the benefit of the Company or its Affiliates,
together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn
over to the Company&rsquo;s possession every original and copy of any and all such items in his possession or control upon request
by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will
provide reasonable evidence that such materials have been destroyed, purged or erased.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Purpose of Use.</B> The Executive agrees that he will use Confidential Information only for purposes authorized or directed
by the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">2.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Exemptions. </B>The obligations of confidentiality set out in this Article 2 will not apply to any of the following:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">information that is already known to the Executive, though not due to a prior disclosure by the
Company or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or
its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">information disclosed to the Executive by another person who is not obliged to maintain the confidentiality
of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">information that is developed by the Executive independently of Confidential Information received
from the Company or its Affiliates and such independent development can be documented by the Executive;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">other particular information or material which the Company expressly exempts by written instrument
signed by the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">information or material that is in the public domain through no fault of the Executive; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">information required by operation of law, court order or government agency to be disclosed, provided
that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, the Executive will provide to the Company prompt written notice so that the Company may seek
a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Company agrees that the disclosure is required by law, it will give the Executive written
authorization to disclose the information for the required purposes only;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Company does not agree that the disclosure is required by law, this Agreement will continue
to apply, except to the extent that a Court of competent jurisdiction orders otherwise; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if a protective order or other remedy is not obtained or if compliance with this Agreement is waived,
the Executive will furnish only that portion of the Confidential Information that is legally required and will exercise all reasonable
efforts to obtain confidential treatment of such Confidential Information.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-size: 10pt">ASSIGNMENT
OF INTELLECTUAL PROPERTY RIGHTS</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notice
of Invention.</B> The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable,
throughout the course of his involvement, in any capacity, with the Company and from which there is a reasonable basis to believe
that Intellectual Property may be derived therefrom, whether or not developed before or after execution of this Agreement. On
his ceasing to be employed by the Company for any reason whatsoever, the Executive will immediately deliver up to the Company
all Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment
of Rights.</B> Subject only to the exceptions set out in <B>Exhibit I</B> attached to this Agreement, the Executive will assign,
and does hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company&rsquo;s
designee, all of his right, title and interest in and to all Work Product, including all Intellectual Property rights therein.
To the extent that the Executive retains or acquires legal title to any such Intellectual Property rights and interests, the Executive
hereby declares and confirms that such legal title is and will be held by him only as trustee and agent for the Company or the
Company&rsquo;s designee. The Executive agrees that the Company&rsquo;s rights hereunder shall attach to all Intellectual Property
rights in his Work Product, notwithstanding that it may be perfected or reduced to specific form after he has terminated his relationship
with the Company. The Executive further agrees that the Company&rsquo;s rights hereunder are worldwide rights and are not limited
to Canada, but shall extend to every country of the world.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Moral
Rights.</B> Without limiting the foregoing, the Executive hereby irrevocably waives any and all moral rights arising under the
<I>Copyright Act</I> (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in
other applicable jurisdictions or at common law that he may have with respect to all Work Product, and agrees never to assert
any moral rights which he may have in the Work Product, including, without limitation, the right to the integrity of the Work
Product, the right to be associated with the Work Product, the right to restrain or claim damages for any distortion, mutilation
or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product
in any context and in connection with any product, service, cause or institution, and the Executive further confirms that the
Company may use or alter any Work Product as the Company sees fits in its absolute discretion.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Goodwill.</B> The Executive hereby agrees that all goodwill he has established or may establish with clients, customers,
suppliers, principals, shareholders, investors, collaborators, strategic partners, licensees, contacts or prospects of the Company
relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date,
shall, as between the Executive and the Company, be and remain the property of the Company exclusively, for the Company to use,
alter, vary, adapt and exploit as the Company shall determine in its discretion.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance.
</B>The Executive hereby agrees to reasonably assist the Company, at the Company&rsquo;s request and expense, in:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">making patent applications for all Work Product, including instructions to lawyers and/or patent
agents as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification,
to execute all formal documentation incidental to an application for letters patent and to execute assignment documents in favour
of the Company for such applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">making applications for all other forms of Intellectual Property registration relating to all Work
Product;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">prosecuting and maintaining the patent applications and other Intellectual Property relating to
all Work Product; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">registering, maintaining and enforcing the patents and other Intellectual Property registrations
relating to all Work Product.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the Company is unable for any reason to secure the Executive&rsquo;s
signature with respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents
or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and stead to execute
and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal force
and effect as if executed by him.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Assistance with Proceedings.</B> The Executive further agrees to reasonably assist the Company, at the Company&rsquo;s
request and expense, in connection with any defence to an allegation of infringement of another person&rsquo;s intellectual property
rights, claim of invalidity of another person&rsquo;s intellectual property rights, opposition to, or intervention regarding, an
application for letters patent, copyright or trademark or other proceedings relating to Intellectual Property or applications for
registration thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Commercialization.
</B>The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company&rsquo;s
sole discretion and for the Company&rsquo;s sole benefit and that no royalty or other consideration will be due or payable to
him as a result of the Company&rsquo;s efforts to commercialize or market any such Work Product.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Business Intellectual Property</B>. The Executive represents and warrants to the Company that he has not brought or used,
and the Executive covenants and agrees that he will not use or bring to the Company any Intellectual Property of any kind
whatsoever of any Prior Business with whom the Executive had a Prior Involvement or any Intellectual Property directly owned
by the Executive. The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain Intellectual Property relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any legal obligations the Executive may have to such Prior Business. The Executive covenants and
agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer as
a result any breach by the Executive of his obligations to such Prior Business in that regard.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">3.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Prior
Inventions.</B> In order to have them excluded from this Agreement, the Executive has set forth on <B>Exhibit I</B> attached to
this Agreement a complete list of all Inventions for which a patent application has not yet been filed that he has, alone or jointly
with others, conceived, developed or reduced to practice prior to the execution of this Agreement to which he has any right, title
or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive
represents and warrants that there are no such prior Inventions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in"><FONT STYLE="font-weight: normal">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>General</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: justify; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Term.
</B>Subject to Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive
is no longer working at or for the Company in any capacity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>No
Conflicting Obligations.</B> The Executive hereby represents and warrants that he has no agreements with or obligations to
any other person with respect to the matters covered by this Agreement or concerning the Confidential Information that are in
conflict with anything in this Agreement, except as disclosed in <B>Exhibit I</B> attached to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Publicity.</B> The Executive shall not, without the prior written consent of the Company, make or give any public announcements,
press releases or statements to the public or the press regarding any Work Product or any Confidential Information.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Further
Assurances.</B> The parties will execute and deliver to each other such further instruments and assurances and do such further
acts as may be required to give effect to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notices.
</B>All notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand
delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with
receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to
have been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either
party may change its address or its facsimile number by giving the other party written notice, delivered in accordance with this
section.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Equitable
Remedies. </B>The Executive understands and acknowledges that if he breaches any of his obligations under this Agreement,
that breach may give rise to irreparable injury to the Company for which damages are an inadequate remedy. In the event of
any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company
will be entitled as a matter of right to apply to a court of competent jurisdiction for such relief by way of restraining
order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Non-Waiver</B>.
Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other
party in default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such
party of their rights hereunder or of the right to then or subsequently declare a default.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Severability.
</B>In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the
remaining provisions, or parts thereof, will be and remain in full force and effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Entire Agreement.</B> This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral,
express or implied, including any relating to the nature of the position or its duration, and each of the parties releases and
forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect
of any agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Survival.</B> Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article
2 (including the obligations of confidentiality and to return Confidential Information, which shall endure, with respect to each
item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections
3.2, 3.3, 3.4, 3.5, 3.6 and 3.8 and Article 4 shall survive any expiration or early termination of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Modification of Agreement.</B> Any modification of this Agreement must be in writing and signed by both the
Company and the Executive or it will have no effect and will be void.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>G</B></FONT><B>overning Law.</B> This Agreement will be governed by and construed according to the laws of the Province of
British Columbia, Canada.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">4.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Independent Legal Advice.</B> The Executive agrees that he has obtained or has had an opportunity to obtain independent
legal advice in connection with this Agreement, and further acknowledge that he has read, understands, and agrees to be bound by
all of the terms and conditions contained herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">SIGNED, SEALED AND DELIVERED</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0.1in 0pt 0">by <B>Peter Lutwyche </B>in the presence of:</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0.1in 0pt 0.5in"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">/s/ Peter Lutwyche<B>&nbsp;</B></P></TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Witness Signature</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><BR></P></TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><B>Peter Lutwyche</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Name</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Witness Address</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: left; font-size: 10pt"><BR>
<BR>
</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P>
        <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">)</P></TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Witness Occupation</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">)</TD>
    <TD STYLE="text-indent: -0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>ARBUTUS BIOPHARMA CORPORATION</B><BR></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Per:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Mark J. Murray</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark J. Murray</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><BR></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT I</B><BR>
<B>to Confidentiality and Assignment of Inventions Agreement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXCLUSIONS FROM WORK PRODUCT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[To be completed as applicable]</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>GENERAL RELEASE LANGUAGE</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the &ldquo;<B>Executive&rsquo;s
Parties</B>&rdquo;), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates, subsidiaries,
directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys,
benefit plans sponsored by the Company, and said plans&rsquo; fiduciaries, agents and trustees (the &ldquo;<B>Company&rsquo;s Parties</B>&rdquo;),
from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments,
levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive&rsquo;s Parties have, have
had, or may in the future claim to have against the Company&rsquo;s Parties by reason of, arising out of, related to, or resulting
from the Executive&rsquo;s employment with the Company or the termination of that employment. This release specifically includes
without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of
contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. It is understood and agreed that the waiver of benefits and claims contained
in this section does not include a waiver of the right to payment of any vested, non-forfeitable benefits to which the Executive
or a beneficiary of the Executive may be entitled under the terms and provisions of any employee benefit plan of the company which
have accrued as of the Date of Termination, and does not include a waiver of the right to benefits and payment of consideration
to which the Executive may be entitled under this Agreement or any of the agreements contemplated by this Agreement (including
the indemnification agreement and the stock option agreement). The Executive acknowledges that he is entitled to only the severance
benefits and compensation set forth in this Agreement, and that all other claims for any other benefits or compensation are hereby
waived, except those expressly stated in the preceding sentence.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Executive agrees that he will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Company&rsquo;s Parties or their products, employees, services, work
and/or employment.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Company agrees that it will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Executive&rsquo;s Parties.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXISTING CONFLICTS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">If applicable, Executive to describe, in specific terms,
any ongoing business relationship with any organization other than Arbutus Biopharma Corporation or Arbutus Biopharma Inc. Please
provide a copy of any agreements with said organizations that creates a business relationship described in Section 3(d)</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>17
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14
OR 15d-14 OF THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT
TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Mark Murray, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 6, 2015</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 0.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Mark Murray</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark Murray</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>18
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14
OR 15d-14 OF THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT
TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Bruce Cousins, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 6, 2015</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 0.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Bruce Cousins</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Bruce Cousins</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0">Executive Vice President, Finance and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>19
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report
on Form 10-Q of Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, (the &ldquo;Company&rdquo;), for the
quarter ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: August 6, 2015</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 0.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Mark Murray</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark Murray</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>20
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report
on Form 10-Q of Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, (the &ldquo;Company&rdquo;), for the
quarter ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I Bruce Cousins, Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: August 6, 2015</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 0.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Bruce Cousins</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bruce Cousins</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">Executive Vice President, Finance
        and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>21
<FILENAME>tkmr-20150630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:02PM UTC 2015-08-07--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:tkmr="http://www.tekmirapharm.com/20150630" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="tkmr-20150630.xsd" xlink:type="simple"/>
  <dei:AmendmentFlag contextRef="d_2015-01-01_2015-06-30" id="c-13">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2015-01-01_2015-06-30" id="c-3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2015-01-01_2015-06-30" id="c-12">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2015-01-01_2015-06-30" id="c-11">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2015-01-01_2015-06-30" id="c-10">2015-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2015-01-01_2015-06-30" id="c-9">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2015-01-01_2015-06-30" id="c-2">0001447028</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2015-07-31" decimals="INF" id="c-8" unitRef="xbrli-shares">54328414</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2015-01-01_2015-06-30" id="c-5">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2015-01-01_2015-06-30" id="c-4">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2015-01-01_2015-06-30" id="c-1">Arbutus Biopharma Corp</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2015-01-01_2015-06-30" id="c-6">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2015-01-01_2015-06-30" id="c-7">No</dei:EntityWellKnownSeasonedIssuer>
  <tkmr:AccruedContractRevenuePercentage contextRef="i_2015-06-30" decimals="3" id="c1670013" unitRef="xbrli-pure">0.025</tkmr:AccruedContractRevenuePercentage>
  <tkmr:AccruedLicenseFeeAccruals contextRef="i_2015-06-30" id="c1669849" unitRef="iso4217-usd" xs:nil="true"/>
  <tkmr:AccruedLicenseFeeAccruals contextRef="i_2014-12-31" decimals="-3" id="c1669850" unitRef="iso4217-usd">250000</tkmr:AccruedLicenseFeeAccruals>
  <tkmr:AccruedResearchAndDevelopment contextRef="i_2015-06-30" decimals="-3" id="c1669847" unitRef="iso4217-usd">1914000</tkmr:AccruedResearchAndDevelopment>
  <tkmr:AccruedResearchAndDevelopment contextRef="i_2014-12-31" decimals="-3" id="c1669848" unitRef="iso4217-usd">2391000</tkmr:AccruedResearchAndDevelopment>
  <tkmr:ApproximateOptionPeriod contextRef="d_2014-01-13_2014-01-13_CounterpartyNameAxis-MonsantoMember" id="c1669980">P4Y</tkmr:ApproximateOptionPeriod>
  <tkmr:BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares contextRef="d_2015-03-04_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669950" unitRef="iso4217-usd">190000</tkmr:BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares>
  <tkmr:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonStockMember" decimals="INF" id="c1669936" unitRef="iso4217-usd">56934000</tkmr:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense>
  <tkmr:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense contextRef="i_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669949" unitRef="iso4217-usd">2160000</tkmr:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense>
  <tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted contextRef="d_2015-04-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669781" unitRef="iso4217-usd-per-xbrli-shares">-0.27</tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted>
  <tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted contextRef="d_2014-04-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669782" unitRef="iso4217-usd-per-xbrli-shares">-0.23</tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted>
  <tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669783" unitRef="iso4217-usd-per-xbrli-shares">-0.67</tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted>
  <tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted contextRef="d_2014-01-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669784" unitRef="iso4217-usd-per-xbrli-shares">-0.73</tkmr:BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted>
  <tkmr:BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter contextRef="d_2015-07-01_2015-09-30_BusinessAcquisitionAxis-ArbutusIncMember_StatementScenarioAxis-ScenarioForecastMember" decimals="INF" id="c1669939" unitRef="iso4217-usd">1893000</tkmr:BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter>
  <tkmr:BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" decimals="INF" id="c1669935" unitRef="iso4217-usd">9262000</tkmr:BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice>
  <tkmr:BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice contextRef="i_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669948" unitRef="iso4217-usd">1127000</tkmr:BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice>
  <tkmr:BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-SharesIssuableForArbutusStockOptionsMember" decimals="-3" id="c1669750" unitRef="iso4217-usd">1127000</tkmr:BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice>
  <tkmr:BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669759" unitRef="iso4217-usd">3580000</tkmr:BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities>
  <tkmr:ChangesInFairValueOfWarrantsTableTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Liability at beginning of the period&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Opening liability of warrants issued in the period&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Fair value of warrants exercised in the period&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Increase (decrease) in fair&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;value of warrants&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Foreign exchange&amp;nbsp;&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;(gain) loss&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Liability at end&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;of the period&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 12%; font-size: 10pt; text-align: left"&gt;Six months ended June 30, 2014&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,379&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(6,607&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;7,803&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;6,590&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;Six months ended June 30, 2015&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(341&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(801&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(351&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</tkmr:ChangesInFairValueOfWarrantsTableTextBlock>
  <tkmr:CollaborativeArrangementTerm contextRef="d_2010-05-10_2010-05-10_CounterpartyNameAxis-BMSMember" id="c1670155">P4Y</tkmr:CollaborativeArrangementTerm>
  <tkmr:ContractualObligationAmountOfResearchFundingPerYear contextRef="i_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670087" unitRef="iso4217-usd">1000000</tkmr:ContractualObligationAmountOfResearchFundingPerYear>
  <tkmr:CumulativeContributionForProduct contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c1670037" unitRef="iso4217-usd">2965000</tkmr:CumulativeContributionForProduct>
  <tkmr:CumulativeContributionForProduct contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c1670038" unitRef="iso4217-cad">3702000</tkmr:CumulativeContributionForProduct>
  <tkmr:ExtendedOptionPeriod contextRef="d_2015-05-01_2015-05-31_CounterpartyNameAxis-MonsantoMember" id="c1669982">P150D</tkmr:ExtendedOptionPeriod>
  <tkmr:FairValueOfWarrantsExercisedInThePeriod contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669723" unitRef="iso4217-usd">6607000</tkmr:FairValueOfWarrantsExercisedInThePeriod>
  <tkmr:FairValueOfWarrantsExercisedInThePeriod contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669729" unitRef="iso4217-usd">341000</tkmr:FairValueOfWarrantsExercisedInThePeriod>
  <tkmr:FairValueOfWarrantsOutstandingPerWarrant contextRef="i_2015-06-30" decimals="INF" id="c1669741" unitRef="iso4217-usd-per-xbrli-shares">9.50</tkmr:FairValueOfWarrantsOutstandingPerWarrant>
  <tkmr:FairValueOfWarrantsOutstandingPerWarrant contextRef="i_2014-12-31" decimals="INF" id="c1669742" unitRef="iso4217-usd-per-xbrli-shares">12.80</tkmr:FairValueOfWarrantsOutstandingPerWarrant>
  <tkmr:FairValueWarrantsForeignExchangeGainLoss contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669725" unitRef="iso4217-usd">15000</tkmr:FairValueWarrantsForeignExchangeGainLoss>
  <tkmr:FairValueWarrantsForeignExchangeGainLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669731" unitRef="iso4217-usd">-351000</tkmr:FairValueWarrantsForeignExchangeGainLoss>
  <tkmr:IncreaseDecreaseInValueOfWarrants contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669724" unitRef="iso4217-usd">7803000</tkmr:IncreaseDecreaseInValueOfWarrants>
  <tkmr:IncreaseDecreaseInValueOfWarrants contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669730" unitRef="iso4217-usd">-801000</tkmr:IncreaseDecreaseInValueOfWarrants>
  <tkmr:LicenseAgreementEarlyTerminationFee contextRef="i_2014-09-30_CounterpartyNameAxis-NeuroviveMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670104" unitRef="iso4217-usd">2000000</tkmr:LicenseAgreementEarlyTerminationFee>
  <tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="i_2014-02-28_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670083" unitRef="iso4217-usd">3500000</tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
  <tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="i_2014-11-30_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670086" unitRef="iso4217-usd">1000000</tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
  <tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="i_2014-09-30_CounterpartyNameAxis-NeuroviveMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670099" unitRef="iso4217-cad">47000000</tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
  <tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="i_2014-12-30_CounterpartyNameAxis-CytosMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670108" unitRef="iso4217-usd">67000000</tkmr:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
  <tkmr:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense contextRef="i_2014-02-28_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670084" unitRef="iso4217-usd">92500000</tkmr:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense>
  <tkmr:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense contextRef="i_2014-09-30_CounterpartyNameAxis-NeuroviveMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670100" unitRef="iso4217-usd">102500000</tkmr:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense>
  <tkmr:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense contextRef="i_2014-12-30_CounterpartyNameAxis-CytosMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670110" unitRef="iso4217-usd">110000000</tkmr:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense>
  <tkmr:MaturityOfInvestments contextRef="d_2015-05-01_2015-05-31_InvestmentTypeAxis-TermDepositMember" id="c1669891">P2Y</tkmr:MaturityOfInvestments>
  <tkmr:MaximumContributionForProduct contextRef="d_2004-03-01_2004-03-31" decimals="INF" id="c1670035" unitRef="iso4217-usd">7179000</tkmr:MaximumContributionForProduct>
  <tkmr:MaximumContributionForProduct contextRef="d_2004-03-01_2004-03-31" decimals="INF" id="c1670036" unitRef="iso4217-cad">9323000</tkmr:MaximumContributionForProduct>
  <tkmr:MaximumPotentialTransactionValue contextRef="d_2014-01-13_2014-01-13_CounterpartyNameAxis-MonsantoMember" decimals="INF" id="c1669981" unitRef="iso4217-usd">86200000</tkmr:MaximumPotentialTransactionValue>
  <tkmr:MaximumPotentialTransactionValueForExtensionPeriod contextRef="d_2015-05-01_2015-05-31_CounterpartyNameAxis-MonsantoMember" decimals="INF" id="c1669983" unitRef="iso4217-usd">2000000</tkmr:MaximumPotentialTransactionValueForExtensionPeriod>
  <tkmr:MilestonePayments contextRef="d_2014-11-01_2014-11-16_CounterpartyNameAxis-DicernaMember" decimals="INF" id="c1669998" unitRef="iso4217-usd">22000000</tkmr:MilestonePayments>
  <tkmr:MilestonePayments contextRef="d_2013-01-01_2013-12-31_CounterpartyNameAxis-MarinaMember" decimals="INF" id="c1670058" unitRef="iso4217-usd">200000</tkmr:MilestonePayments>
  <tkmr:MilestonePayments contextRef="d_2012-01-01_2012-12-31_CounterpartyNameAxis-MarinaMember_StatementScenarioAxis-ScenarioForecastMember" decimals="INF" id="c1670060" unitRef="iso4217-usd">3250000</tkmr:MilestonePayments>
  <tkmr:MilestonePayments contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-ArcturusMember" decimals="INF" id="c1670061" unitRef="iso4217-usd">250000</tkmr:MilestonePayments>
  <tkmr:NearTermContractPayments contextRef="d_2014-01-14_2015-05-31_CounterpartyNameAxis-MonsantoMember" decimals="INF" id="c1669984" unitRef="iso4217-usd">18550000</tkmr:NearTermContractPayments>
  <tkmr:NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised contextRef="d_2015-04-01_2015-06-30" id="c1669649" unitRef="iso4217-usd" xs:nil="true"/>
  <tkmr:NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669650" unitRef="iso4217-usd">116000</tkmr:NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised>
  <tkmr:NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised contextRef="d_2015-01-01_2015-06-30" id="c1669651" unitRef="iso4217-usd" xs:nil="true"/>
  <tkmr:NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669652" unitRef="iso4217-usd">116000</tkmr:NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised>
  <tkmr:OptionalExcercisedContractualOptionAmount contextRef="i_2014-10-31_CounterpartyNameAxis-DoDMember" decimals="INF" id="c1669977" unitRef="iso4217-usd">7000000</tkmr:OptionalExcercisedContractualOptionAmount>
  <tkmr:PercentOfCostsFundedByTPC contextRef="d_2004-03-01_2004-03-31" decimals="3" id="c1670034" unitRef="xbrli-pure">0.27</tkmr:PercentOfCostsFundedByTPC>
  <tkmr:PotentialContractFundingAmount contextRef="i_2010-07-14_CounterpartyNameAxis-DoDMember" decimals="INF" id="c1669966" unitRef="iso4217-usd">34700000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmount contextRef="i_2013-05-08_CounterpartyNameAxis-DoDMember_StatementScenarioAxis-IncreaseToSupportDevelopmentPlansMember" decimals="INF" id="c1669969" unitRef="iso4217-usd">6970000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmount contextRef="i_2014-04-22_CounterpartyNameAxis-DoDMember_StatementScenarioAxis-IncreasedFundingForStageOneMember" decimals="INF" id="c1669971" unitRef="iso4217-usd">2100000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmount contextRef="i_2014-04-22_CounterpartyNameAxis-DoDMember" decimals="INF" id="c1669972" unitRef="iso4217-usd">43819000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmount contextRef="i_2010-07-14_RangeAxis-MaximumMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ContractExtensionMember" decimals="INF" id="c1669976" unitRef="iso4217-usd">140000000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmount contextRef="i_2015-03-31_CounterpartyNameAxis-DoDMember" decimals="INF" id="c1669978" unitRef="iso4217-usd">2250000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmount contextRef="i_2012-08-09_CounterpartyNameAxis-TalonTherapeuticsMember" decimals="INF" id="c1670004" unitRef="iso4217-usd">18000000</tkmr:PotentialContractFundingAmount>
  <tkmr:PotentialContractFundingAmountIncrease contextRef="d_2015-05-01_2015-05-31_CounterpartyNameAxis-DoDMember_TypeOfArrangementAxis-ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" decimals="INF" id="c1669975" unitRef="iso4217-usd">1000000</tkmr:PotentialContractFundingAmountIncrease>
  <tkmr:PotentialProceedsOfAdditionalSharesAuthorized contextRef="d_2015-03-25_2015-03-25_AwardTypeAxis-UnderwriterOptionsMember" decimals="INF" id="c1670022" unitRef="iso4217-usd">22781000</tkmr:PotentialProceedsOfAdditionalSharesAuthorized>
  <tkmr:ProceedsFromIssuanceOfCommonStockNet contextRef="d_2015-03-25_2015-03-25" decimals="INF" id="c1670024" unitRef="iso4217-usd">142177000</tkmr:ProceedsFromIssuanceOfCommonStockNet>
  <tkmr:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments contextRef="i_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670093" unitRef="iso4217-usd">92500000</tkmr:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments>
  <tkmr:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments contextRef="i_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670092" unitRef="iso4217-usd">8100000</tkmr:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments>
  <tkmr:ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment contextRef="i_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670091" unitRef="iso4217-usd">100000</tkmr:ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment>
  <tkmr:ResearchFundingPeriod contextRef="d_2014-10-31_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember" id="c1670160">P3Y</tkmr:ResearchFundingPeriod>
  <tkmr:RevenueRecognitionPerformancePeriod contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-DicernaMember" id="c1670156">P2Y120D</tkmr:RevenueRecognitionPerformancePeriod>
  <tkmr:RevenueRecognitionPerformancePeriod contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-DicernaMember" id="c1670157">P2Y120D</tkmr:RevenueRecognitionPerformancePeriod>
  <tkmr:RoyaltiesPaidOrAccrued contextRef="d_2015-01-01_2015-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670052" unitRef="iso4217-usd">9000</tkmr:RoyaltiesPaidOrAccrued>
  <tkmr:RoyaltyPayable contextRef="i_2015-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670048" unitRef="iso4217-usd">3000</tkmr:RoyaltyPayable>
  <tkmr:RoyaltyPayable contextRef="i_2014-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670050" unitRef="iso4217-usd">2000</tkmr:RoyaltyPayable>
  <tkmr:RoyaltyguaranteesCommitmentsPercentage contextRef="d_2015-01-01_2015-06-30" decimals="3" id="c1670039" unitRef="xbrli-pure">0.025</tkmr:RoyaltyguaranteesCommitmentsPercentage>
  <tkmr:StockRepurchaseRightsExpirationRateShares contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669943" unitRef="xbrli-shares">453177</tkmr:StockRepurchaseRightsExpirationRateShares>
  <tkmr:UpfrontFee contextRef="d_2012-01-01_2012-12-31_CounterpartyNameAxis-MarinaMember" decimals="INF" id="c1670057" unitRef="iso4217-usd">300000</tkmr:UpfrontFee>
  <tkmr:WhollyOwnedSubsidiaries contextRef="i_2015-06-30" decimals="INF" id="c1669862" unitRef="xbrli-pure">5</tkmr:WhollyOwnedSubsidiaries>
  <tkmr:WhollyOwnedSubsidiariesIncludedInFinancialStatements contextRef="i_2015-06-30" decimals="INF" id="c1669871" unitRef="xbrli-pure">4</tkmr:WhollyOwnedSubsidiariesIncludedInFinancialStatements>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669383" unitRef="iso4217-usd">6920000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669384" unitRef="iso4217-usd">9328000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;5.&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; text-indent: 0in; margin: 6pt 0 0"&gt;Accounts payable and accrued liabilities is comprised of the following, in thousands:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; text-indent: 0in; margin: 6pt 0 0"&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0; text-indent: 0.25in"&gt;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 70%; font-size: 10pt; text-align: left"&gt;Trade accounts payable&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,802&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,044&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Research and development accruals&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,914&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,391&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;License fee accruals&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;250&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fee accruals&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;604&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,294&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred lease inducements&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;364&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;250&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Payroll accruals&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;491&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,873&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;Other accrued liabilities&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;745&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;226&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;6,920&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;9,328&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableTradeCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669845" unitRef="iso4217-usd">2802000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669846" unitRef="iso4217-usd">2044000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNet contextRef="i_2015-06-30" decimals="INF" id="c1670027" unitRef="iso4217-usd">6332000</us-gaap:AccountsReceivableNet>
  <us-gaap:AccountsReceivableNet contextRef="i_2014-12-31" decimals="INF" id="c1670029" unitRef="iso4217-usd">1903000</us-gaap:AccountsReceivableNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669357" unitRef="iso4217-usd">6332000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669358" unitRef="iso4217-usd">1903000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669851" unitRef="iso4217-usd">604000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669852" unitRef="iso4217-usd">1294000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2015-06-30" decimals="-3" id="c1669371" unitRef="iso4217-usd">10433000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2014-12-31" decimals="-3" id="c1669372" unitRef="iso4217-usd">11199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-06-30" decimals="-3" id="c1669408" unitRef="iso4217-usd">-28264000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2014-12-31" decimals="-3" id="c1669409" unitRef="iso4217-usd">-22313000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-06-30" decimals="-3" id="c1669404" unitRef="iso4217-usd">27844000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31" decimals="-3" id="c1669405" unitRef="iso4217-usd">26208000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c1669496" unitRef="iso4217-usd">1906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669499" unitRef="iso4217-usd">7230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c1670124" unitRef="iso4217-usd">9700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember_NatureOfExpenseAxis-RelatedToTheExpirationOfRepurchaseProvisionRightsMember" decimals="INF" id="c1669937" unitRef="iso4217-usd">5324000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c1669881" unitRef="xbrli-shares">2774398</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-06-30" decimals="INF" id="c1669883" unitRef="xbrli-shares">2558925</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2015-06-30" decimals="-3" id="c1669379" unitRef="iso4217-usd">773820000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2014-12-31" decimals="-3" id="c1669380" unitRef="iso4217-usd">118178000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669365" unitRef="iso4217-usd">215702000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669366" unitRef="iso4217-usd">116418000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" decimals="-3" id="c1669670" unitRef="iso4217-usd">217217000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="i_2015-06-30" decimals="-3" id="c1669673" unitRef="iso4217-usd">217217000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" decimals="-3" id="c1669704" unitRef="iso4217-usd">112161000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="i_2014-12-31" decimals="-3" id="c1669707" unitRef="iso4217-usd">112161000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1671775">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&amp;#x2019;s audited consolidated financial statements and notes thereto for the year ended December 31, 2014 and included in the Company&amp;#x2019;s 2014 annual report on Form 10-K. The unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the financial position, results of operations and cash flows at June 30, 2015 and for all periods presented. The results of operations for the three and six months ended June 30, 2015 and June 30, 2014 are not necessarily indicative of the results for the full year. These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" decimals="INF" id="c1669930" unitRef="iso4217-usd">66196000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="i_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669947" unitRef="iso4217-usd">3287000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedWithoutSubjectsMember" decimals="-3" id="c1669748" unitRef="iso4217-usd">371553000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedWithoutSubjectsMember" decimals="INF" id="c1669927" unitRef="xbrli-shares">20347906</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" decimals="INF" id="c1669928" unitRef="xbrli-shares">3625412</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="i_2015-01-11_BusinessAcquisitionAxis-ArbutusIncMember" decimals="4" id="c1669920" unitRef="xbrli-pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Three Months Ended &lt;br /&gt;June&amp;nbsp;30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended &lt;br /&gt;June&amp;nbsp;30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Pro forma information&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Gross Revenue&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;3,440&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;1,811&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;8,122&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;6,241&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Loss from operations&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(14,420&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(13,844&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(39,491&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(24,278&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net loss&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(14,886&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(10,479&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(33,940&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(32,962&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Basic and diluted loss per share&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.27&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.67&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.73&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:BusinessAcquisitionSharePrice contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedWithoutSubjectsMember" decimals="INF" id="c1669929" unitRef="iso4217-usd-per-xbrli-shares">18.26</us-gaap:BusinessAcquisitionSharePrice>
  <us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="d_2015-04-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669773" unitRef="iso4217-usd">-14420000</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
  <us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="d_2014-04-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669774" unitRef="iso4217-usd">-13844000</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
  <us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669775" unitRef="iso4217-usd">-39491000</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
  <us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="d_2014-01-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669776" unitRef="iso4217-usd">-24278000</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="d_2015-04-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669777" unitRef="iso4217-usd">-14886000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="d_2014-04-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669778" unitRef="iso4217-usd">-10479000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669779" unitRef="iso4217-usd">-33940000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="d_2014-01-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669780" unitRef="iso4217-usd">-32962000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="d_2015-04-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669769" unitRef="iso4217-usd">3440000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="d_2014-04-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669770" unitRef="iso4217-usd">1811000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669771" unitRef="iso4217-usd">8122000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="d_2014-01-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669772" unitRef="iso4217-usd">6241000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669924" unitRef="iso4217-usd">9656000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669440" unitRef="iso4217-usd">361000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="d_2014-04-01_2014-06-30" id="c1669441" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669442" unitRef="iso4217-usd">9656000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="d_2014-01-01_2014-06-30" id="c1669443" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669951" unitRef="iso4217-usd">381942000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="d_2015-03-03_2015-03-03" decimals="-3" id="c1669751" unitRef="iso4217-usd">381942000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="i_2014-10-31_BusinessAcquisitionAxis-EnantigenMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670073" unitRef="iso4217-usd">21000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="i_2015-03-31" decimals="INF" id="c1669896" unitRef="iso4217-usd">4736000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="i_2015-06-30" decimals="INF" id="c1669897" unitRef="iso4217-usd">5136000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="i_2014-10-31_BusinessAcquisitionAxis-EnantigenMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670079" unitRef="iso4217-usd">5136000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="-3" id="c1669681" unitRef="iso4217-usd">5136000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="i_2015-06-30" decimals="-3" id="c1669393" unitRef="iso4217-usd">5136000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="i_2014-12-31" id="c1669394" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;3.&lt;/div&gt;&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;On January 11, 2015, the Company entered into a Merger Agreement to acquire 100% of the outstanding shares of Arbutus Inc. and its wholly-owned subsidiary, Enantigen (see note 8). Arbutus Inc. was a privately owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The merger was approved by the Company&amp;#x2019;s shareholders on March 3, 2015 and consummated on March 4, 2015. Arbutus Inc.&amp;#x2019;s results of operations and fair value of assets acquired and liabilities assumed are included in the Company&amp;#x2019;s consolidated financial statements from the date of acquisition.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The transaction has been accounted for using the acquisition method based on ASC 805, Business Combinations, on the basis that Arbutus (formerly Tekmira) is the acquirer, based on managements&amp;#x2019; analysis and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and the relative number of shares issued by the Company on acquisition of Arbutus Inc.. Under the acquisition method, the consideration transferred is measured at the market price as at the acquisition date. The excess of the purchase price over the preliminary value assigned to the net assets acquired has been recorded as goodwill. Acquisition costs are expensed as incurred. The company recorded $9,656,000 of acquisition costs for the six-months ended June 30, 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The Company issued a total of 23,973,315 common shares with a total value of $381,942,000 as consideration, which is comprised of 20,347,906 common shares issued without subjects and 3,625,412 common shares issued to Arbutus Inc.&amp;#x2019;s founding executives and subject to repurchase provision. The fair value of the common shares issued without subjects has been determined to be the Company&amp;#x2019;s NASDAQ closing price of $18.26 on the date prior to the acquisition&amp;#x2019;s consummation, March 4, 2015. The total fair value of the common shares issued subject to repurchase provision has been determined to be $66,196,000, using the Black-Scholes pricing model with assumed risk-free interest rate of 0.74%, volatility of 81%, a zero dividend yield and an expected life of 4 years. Of the total fair value, $9,262,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of $56,934,000 will be recognized as compensation expense over the period of expiry of repurchase provision rights through to August 2018. The Company has included $5,324,000 compensation expense related to the expiration of repurchase provision rights from the acquisition date through to June 30, 2015. In July 2015, in conjunction with amendments to the the employment contracts of Arbutus Inc.&amp;#x2019;s founding executives, the Company amended the repurchase provision rights period of expiry from August 2018 to August 2017. This amendment results in an acceleration of compensation expense recognized in each subsequent period by approximately $1,893,000 per quarter, effective Q3 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;As at June 30, 2015, 3,625,412 shares were issued and outstanding which are subject to repurchase provision. Subsequent to the acquisition date, the repurchase rights expire at a rate of 453,177 shares every 3 months commencing on November 30, 2015.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 11; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The Company has further reserved 184,332 shares for the future exercise of Arbutus Inc. stock options. The total fair value of Arbutus Inc. stock options has been determined to be $3,287,000, using the Black-Scholes pricing model with the same assumption inputs used by the Company to determine the fair value of Arbutus options. Of the total fair value, $1,127,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of $2,160,000 will be recognized as compensation expense over the vesting period of the stock options through to December 2018. The Company has included $190,000 compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to June 30, 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The aggregate fair value of consideration transferred to acquire Arbutus Inc.&amp;#x2019;s outstanding shares has been determined to be $381,942,000, and has been attributed to preliminary fair values of assets acquired and liabilities assumed as summarized in the following table, in thousands:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Consideration paid:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 89%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Common shares issued without subjects&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;371,553&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Common shares issued subject to repurchase provision&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;9,262&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"&gt;Common shares issuable for Arbutus Inc. stock options&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,127&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;381,942&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Identifiable assets acquired and liabilities assumed:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Cash&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;324&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Prepaid expenses and other assets&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;116&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Accounts receivable&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;8&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Property and equipment&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;147&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Acquired intangible assets&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;390,017&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Goodwill&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;156,053&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Accounts payable and accrued liabilities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(3,580&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Other noncurrent liabilities (note 8)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(5,136&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"&gt;Deferred income tax liability&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(156,017&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total purchase price allocation&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;381,942&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The preliminary fair value of intangible assets is estimated to be $390,017,000 using the income approach. The income approach uses valuation techniques to discount future economic benefits attributed to the subject intangible asset to a present value. Present value is based on current market expectations about those future amounts and includes management&amp;#x2019;s estimates of risk-adjusted future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights and includes estimated cash flows of approximately 20 years and a discount rate of approximately 13.8%. The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;amp;D) HBV assets, as summarized in the table below:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid"&gt;$&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 89%; font-size: 10pt; text-align: left"&gt;IPR&amp;amp;D &amp;#x2013; Cyclophilins&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;35,124&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;IPR&amp;amp;D &amp;#x2013; Immune Modulator&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;189,182&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;IPR&amp;amp;D &amp;#x2013; Antigen Inhibitors&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;35,520&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;IPR&amp;amp;D &amp;#x2013; cccDNA&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;130,191&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt"&gt;Total IPR&amp;amp;D&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;390,017&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;        &lt;!-- Field: Page; Sequence: 12; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;All IPR&amp;amp;D acquired are currently classified as indefinite-lived and so is not currently being amortized. IRP&amp;amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts, and will be amortized from that time over an estimated useful life based on respective patent terms. The fair value of each IPR&amp;amp;D asset will continue to be evaluated on a quarterly basis for indicators of impairment.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;Based on the preliminary fair values above, an amount of $156,053,000 has been allocated to goodwill, which represents the excess of the purchase price over the final value assigned to the net assets acquired. Goodwill is attributable to synergies expected to arise after the Company&amp;#x2019;s acquisition of Arbutus Inc. The full amount of the goodwill has been assigned to Arbutus, which is the reporting unit management has determined the goodwill to be associated with. The goodwill is not deductible for tax purposes, and is not amortized, but will be evaluated for impairment on an annual basis.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The amount of net loss of Arbutus Inc. included in the consolidated statements of operations from the acquisition date, through the period ended June 30, 2015 was $4,072,000. Arbutus Inc. did not earn any revenues from the acquisition date through the period ended June 30, 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The following table presents the unaudited pro forma results for the three and six months ended June 30, 2015 and 2014. The pro forma financial information combines the results of operations of Arbutus, Arbutus Inc., Protiva, Protiva USA, and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014. The pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014. The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Three Months Ended &lt;br /&gt;June&amp;nbsp;30,&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended &lt;br /&gt;June&amp;nbsp;30,&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Pro forma information&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Gross Revenue&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;3,440&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;1,811&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;8,122&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;6,241&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Loss from operations&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(14,420&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(13,844&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(39,491&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(24,278&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net loss&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(14,886&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(10,479&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(33,940&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(32,962&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Basic and diluted loss per share&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.27&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.23&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.67&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.73&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="d_2015-03-04_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669958" unitRef="iso4217-usd">4072000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
  <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="d_2015-03-04_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1670151" unitRef="iso4217-usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669753" unitRef="iso4217-usd">324000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669754" unitRef="iso4217-usd">116000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669755" unitRef="iso4217-usd">8000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669761" unitRef="iso4217-usd">156017000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669952" unitRef="iso4217-usd">390017000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-CyclophilinsMember" decimals="-3" id="c1669763" unitRef="iso4217-usd">35124000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-ImmuneModulatorMember" decimals="-3" id="c1669764" unitRef="iso4217-usd">189182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-AntigenInhibitorsMember" decimals="-3" id="c1669765" unitRef="iso4217-usd">35520000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-CccdnaMember" decimals="-3" id="c1669766" unitRef="iso4217-usd">130191000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669760" unitRef="iso4217-usd">5136000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="-3" id="c1669756" unitRef="iso4217-usd">147000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <us-gaap:BusinessCombinationsPolicy contextRef="d_2015-01-01_2015-06-30" id="c1671777">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Replacement awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&amp;#x2019;s acquisition of Arbutus Inc. (formerly OnCore), Arbutus (formerly Tekmira) shares were exchanged for Arbutus Inc.&amp;#x2019;s shares subject to repurchase rights held by Arbutus Inc.&amp;#x2019;s employees &amp;#x2013; see note 3.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <us-gaap:CashAcquiredFromAcquisition contextRef="d_2015-04-01_2015-06-30" id="c1669602" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAcquiredFromAcquisition contextRef="d_2014-04-01_2014-06-30" id="c1669603" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAcquiredFromAcquisition contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669604" unitRef="iso4217-usd">324000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:CashAcquiredFromAcquisition contextRef="d_2014-01-01_2014-06-30" id="c1669605" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-06-30" decimals="-3" id="c1669353" unitRef="iso4217-usd">207205000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="-3" id="c1669354" unitRef="iso4217-usd">72187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-03-31" decimals="-3" id="c1669639" unitRef="iso4217-usd">232276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-03-31" decimals="-3" id="c1669640" unitRef="iso4217-usd">134357000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2013-12-31" decimals="-3" id="c1669642" unitRef="iso4217-usd">68717000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-06-30" decimals="-3" id="c1669644" unitRef="iso4217-usd">85267000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" decimals="-3" id="c1669662" unitRef="iso4217-usd">207205000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-06-30" decimals="-3" id="c1669665" unitRef="iso4217-usd">207205000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" decimals="-3" id="c1669696" unitRef="iso4217-usd">72187000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2014-12-31" decimals="-3" id="c1669699" unitRef="iso4217-usd">72187000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669635" unitRef="iso4217-usd">-25071000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669636" unitRef="iso4217-usd">-49090000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669637" unitRef="iso4217-usd">135018000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669638" unitRef="iso4217-usd">16550000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2015-06-30" decimals="INF" id="c1669745" unitRef="xbrli-shares">379500</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2014-12-31" decimals="INF" id="c1669746" unitRef="xbrli-shares">398250</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;4.&lt;/div&gt;&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Collaborations, contracts and licensing agreements&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The following tables set forth revenue recognized under collaborations, contracts and licensing agreements, in thousands:&lt;/div&gt;      &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Three months ended June 30&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Six months ended June 30&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Collaborations and contracts&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;DoD (a)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,862&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;861&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,907&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;4,101&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Monsanto (b)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;269&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;283&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;517&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;526&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;BMS (d)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;206&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt"&gt;Dicerna (e)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;179&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;406&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Total research and development collaborations and contracts&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,310&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,144&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,830&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,833&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Licensing fees, milestone and royalty payments&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Monsanto licensing fees and milestone payments (b)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;805&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;626&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,647&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,171&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Acuitas milestone payments (c)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;150&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Dicerna licensing fee (e)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;263&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;526&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt"&gt;Spectrum royalty payments (f)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;62&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;41&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;119&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;87&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Total licensing fees, milestone and royalty payments&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,130&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;667&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,292&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,408&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid"&gt;Total revenue&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;3,440&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,811&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;8,122&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;6,241&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;        &lt;!-- Field: Page; Sequence: 13; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                &lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The following table sets forth deferred collaborations and contracts revenue:&lt;/div&gt;      &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 70%; font-size: 10pt; text-align: left"&gt;DoD (a)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;563&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;313&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Monsanto current portion (b)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,746&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,245&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;Dicerna current portion (e)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,296&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,221&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred revenue, current portion&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,605&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,785&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Monsanto long-term portion (b)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,336&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;8,666&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;Dicerna long-term portion (e)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;709&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,271&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total deferred revenue&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;13,650&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;15,722&lt;/td&gt;      &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(a) Contract with United States Government&amp;#x2019;s Department of Defense (&amp;#x201c;DoD&amp;#x201d;) to develop TKM-Ebola&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;On July&amp;nbsp;14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company&amp;#x2019;s lipid nanoparticle technology to treat Ebola virus infection.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (&amp;#x201c;LNP&amp;#x201d;) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. In May 2015, the Company and the DoD signed a contract modification to further increase stage one funding by up to $1,000,000.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract&amp;#x2019;s budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the &amp;#x201c;Ebola-Guinea Amendment&amp;#x201d;), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; margin: 0"&gt;In March 2015, the Company and the DoD signed a contract modification to provide up to $2,250,000 to fund the Company for TKM-Ebola-Guinea IND submission expenses.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company&amp;#x2019;s actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company&amp;#x2019;s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management&amp;#x2019;s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June 30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;On July 20, 2015, the Company announced given the unclear development path for TKM-Ebola, development activities will be suspended and a joint re-evaluation of the development contract with the DoD is underway.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 14; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                  &lt;div style=" font-size: 10pt; text-align: left; margin: 0pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(b)&lt;/div&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Option and Services Agreements with Monsanto Company (&amp;#x201c;Monsanto&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the &amp;#x201c;Agreements&amp;#x201d;). Under the Agreements, Monsanto has an option to obtain a license to use the Company&amp;#x2019;s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto&amp;#x2019;s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from MonsantoThe amounts received relate to research services and use of the Company&amp;#x2019;s technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity (&amp;#x201c;VIE&amp;#x201d;); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company&amp;#x2019;s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company&amp;#x2019;s initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.&lt;/div&gt;    &lt;div style=" font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"&gt; (c) License and collaboration with Alnylam Pharmaceuticals, Inc. (&amp;#x201c;Alnylam&amp;#x201d;) and Acuitas Therapeutics Inc. (&amp;#x201c;Acuitas&amp;#x201d;, formerly AlCana Technologies Inc.)&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Milestone receipts and payments &lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;In the six months ended June 30, 2014, the Company earned a $150,000 milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (&amp;#x201c;Ascletis&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam&amp;#x2019;s position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement.&amp;nbsp;The hearing date for this arbitration took place in May 2015, and a decision of the arbitrator is pending. The Company has not recorded any revenue in respect of this milestone.&lt;/div&gt;  &lt;div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0"&gt;(d) Bristol-Myers Squibb (&amp;#x201c;BMS&amp;#x201d;) collaboration&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (&amp;#x201c;siRNA&amp;#x201d;) molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company could use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the four-year agreement. BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;Revenue from the May 10, 2010 agreement with BMS was being recognized as the Company produces the related LNP batches.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The revenue earned for the six months ended June 30, 2014 was related to BMS batches shipped during the period. In August 2014, the agreement expired and both companies&amp;#x2019; obligations under the agreement ended.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 15; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                    &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(e)&amp;nbsp;License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. (&amp;#x201c;Dicerna&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the &amp;#x201c;Agreements&amp;#x201d;) with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 (&amp;#x201c;PH1&amp;#x201d;). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company&amp;#x2019;s performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"&gt;(f) Agreements with Spectrum Pharmaceuticals, Inc. (&amp;#x201c;Spectrum&amp;#x201d;)&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (&amp;#x201c;Talon&amp;#x201d;, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the &amp;#x201c;Talon License Agreement&amp;#x201d;) for three of the Company&amp;#x2019;s chemotherapy products, Marqibo&amp;reg;, Alocrest&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;TM&lt;/div&gt; (Optisomal Vinorelbine) and Brakiva&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;TM&lt;/div&gt; (Optisomal Topotecan).&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.&lt;/div&gt;  &lt;div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company.&lt;/div&gt; &lt;div style="display: inline; font-weight: normal"&gt;On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three and six months ended June 30, 2015, the Company recorded $62,000 and $119,000 in Marqibo royalty revenue (three and six months ended June 30, 2014 - $41,000 and $87,000 respectively). For the six months ended June 30, 2015, the Company accrued 2.5% in royalties due to TPC in respect of the Marqibo royalty earned by the Company &amp;#x2013; see note 8, contingencies and commitments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;8.&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;Contingencies and commitments&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Product development partnership with the Canadian Government&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The Company entered into a Technology Partnerships Canada (&amp;quot;TPC&amp;quot;) agreement with the Canadian Federal Government on November 12, 1999. Under this agreement, TPC agreed to fund 27% of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of $7,179,000 &lt;div style="display: inline; font-size: 10pt; color: red"&gt;&amp;nbsp;&lt;/div&gt;(C$9,323,000). As at June 30, 2015, a cumulative contribution of $2,965,000 &lt;div style="display: inline; font-size: 10pt; color: red"&gt;&amp;nbsp;&lt;/div&gt;(C$3,702,000) has been received and the Company does not expect any further funding under this agreement. In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement. These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date. In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay 2.5% royalties on any royalties the Company receives for Marqibo. For the three and six months ended June 30, 2015, the Company earned royalties on Marqibo sales in the amount of $62,000 and $119,000&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;respectively&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;(three and six months ended June 30, 2014 &amp;#x2013; $41,000 and $87,000 respectively) (see note 4(f)), resulting in $3,000 being recorded by the Company as royalty payable to TPC (June 30, 2014 - $2,000). The cumulative amount paid or accrued up to June 30, 2015 was $9,000, resulting in the contingent amount due to TPC being $2,956,000 (C$3,692,000).&lt;/div&gt;  &lt;div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"&gt;License agreement with Marina Biotech, Inc. (&amp;#x201c;Marina&amp;#x201d;)&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&amp;#x201c;UNA&amp;#x201d;) from Marina for the development of RNAi therapeutics.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 17; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                &lt;div style=" font-size: 10pt; text-align: left; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0pt 0"&gt;UNA technology can be used in the development of RNAi therapeutics, which treats disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;Under the license agreement the Company paid Marina an upfront fee of $300,000 during the year ended December 31, 2012. A further license payment of $200,000 was paid in 2013 and the Company will make milestone payments of up to $3,250,000 and royalties on each product developed by the Company that uses Marina&amp;#x2019;s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;Effective August 9, 2013, Marina&amp;#x2019;s UNA technology was acquired by Arcturus Therapeutics, Inc. (&amp;#x201c;Arcturus&amp;#x201d;) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus&amp;#x2019; UNA technology. This triggered the accrual of $250,000 as at December 31, 2014 related to the milestone payable to Arcturus upon the dosing of first subject in a Phase I clinical trial of TKM-HBV, which occurred and was paid by the Company in January 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Arbitration with the University of British Columbia (&amp;#x201c;UBC&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at UBC. These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Spectrum.&amp;nbsp;&amp;nbsp;Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to $3,500,000 in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. The Company is currently disputing UBC&amp;#x2019;s allegations, and no dates have been scheduled for this arbitration. The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related to both the likelihood and amount of any possible loss or range of loss. Costs related to the arbitration have been recorded by the Company as incurred.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 18; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contingent consideration from Arbutus Inc. acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In October 2014, Arbutus Inc. acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&amp;#x2019;s merger with Arbutus Inc. &amp;#x2013; see note 3.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;Under the stock purchase agreement, Arbutus Inc. agreed to pay up to a total of $21,000,000 to Enantigen&amp;#x2019;s selling stockholders upon the achievement of certain triggering events related to Enantigen&amp;#x2019;s two programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The regulatory milestone payments have an estimated fair value of approximately $5,136,000 and have been treated as contingent consideration payable in the preliminary purchase price allocation (note 3), based on information available at the date of acquisition, using a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;The Company is currently undertaking valuation assessments of assets acquired and liabilities assumed from Arbutus Inc., which includes a valuation assessment of the contingent consideration.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Drexel and Blumberg:&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In February 2014, Arbutus Inc. entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In partial consideration for this license, Arbutus Inc. paid a license initiation fee of $150,000 and issued warrants to Blumberg and Drexel. Under this license agreement, Arbutus Inc. also agreed to pay up to $3,500,000 in development and regulatory milestones per licensed compound series, up to $92,500,000 in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In November 2014, Arbutus Inc. entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, Arbutus Inc. made an upfront payment of $50,000. Under this agreement, the Company will be required to pay up to $1,000,000 for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate&amp;nbsp;net sales of compounds covered by this intellectual property&amp;nbsp;in any commercialized combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Research Collaboration and Funding Agreement with Blumberg&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In October 2014, Arbutus Inc. entered into a research collaboration and funding agreement with Blumberg under which the Company will provide $1,000,000 per year of research funding for three years, renewable at the Company&amp;#x2019;s option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, the Company has the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted the Company the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the Company elects to exercise its right to obtain such a license, the Company will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of $100,000; up to $8,100,000 upon the achievement of specified development and regulatory milestones; up to $92,500,000 upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate&amp;nbsp;net sales of licensed&amp;nbsp;products from any commercialized combination.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 19; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NeuroVive Pharmaceutical AB (&amp;#x201c;NeuroVive&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In September 2014, Arbutus Inc. entered into a license agreement with NeuroVive that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&amp;#x2019;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, the Company has (1)&amp;nbsp;an option to expand its exclusive license to include treatment of viral diseases other than HBV and (2)&amp;nbsp;an option, exercisable upon specified conditions, to expand its exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which the Company has not exercised its option.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of $1,000,000. The Company is also obligated to pay up to $47,000,000 in clinical development and regulatory milestones per indication and up to $102,500,000 in sales performance milestones per licensed product and indication. If the Company is acquired by a third party in a transaction that meets certain criteria, then the Company or its acquiror will be obligated to pay all remaining development, regulatory and sales milestone payments, regardless of whether the applicable milestone events have been achieved, for each licensed product that entered clinical development before such acquisition. As describe in note 3, the acquisition of Arbutus Inc. by the Company was completed by way of a Merger Agreement, which does not trigger any of the aforementioned milestone payments. The Company has agreed to pay NeuroVive tiered royalties in the mid-single to low-double digit range based upon the proportionate&amp;nbsp;gross sales of patented licensed products from any commercialized combination. If the Company terminates this license agreement in its entirety for convenience prior to the first commercial sale of any licensed product, the Company will be obligated to pay NeuroVive a termination fee of $2,000,000.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cytos Biotechnology Ltd (&amp;#x201c;Cytos&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;On December&amp;nbsp;30, 2014, Arbutus Inc. entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to six different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&amp;nbsp; The Company has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In partial consideration for this license, the Company is obligated to pay Cytos up to a total of $67,000,000 for each of the six licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of $110,000,000 upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&amp;nbsp;net sales of licensed products in any&amp;nbsp;commercialized combination.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669946" unitRef="xbrli-shares">184332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockNoParValue contextRef="i_2015-06-30" decimals="INF" id="c1670115" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:CommonStockNoParValue>
  <us-gaap:CommonStockNoParValue contextRef="i_2014-12-31" decimals="INF" id="c1670116" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:CommonStockNoParValue>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-06-30" id="c1670117" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2014-12-31" id="c1670118" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-06-30" decimals="INF" id="c1670111" unitRef="xbrli-shares">54303402</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2014-12-31" decimals="INF" id="c1670112" unitRef="xbrli-shares">22438169</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember_StatementScenarioAxis-SubjectToRepurchaseMember" decimals="INF" id="c1673018" unitRef="xbrli-shares">3625412</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-06-30" decimals="INF" id="c1670113" unitRef="xbrli-shares">54303402</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2014-12-31" decimals="INF" id="c1670114" unitRef="xbrli-shares">22438169</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember_StatementScenarioAxis-SubjectToRepurchaseMember" decimals="INF" id="c1669942" unitRef="xbrli-shares">3625412</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2015-06-30" decimals="-3" id="c1669402" unitRef="iso4217-usd">821660000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2014-12-31" decimals="-3" id="c1669403" unitRef="iso4217-usd">290004000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669484" unitRef="iso4217-usd">-11663000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669485" unitRef="iso4217-usd">-2307000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669486" unitRef="iso4217-usd">-32826000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669487" unitRef="iso4217-usd">-22449000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;7&lt;div style="display: inline; font-weight: normal"&gt;.&lt;/div&gt;&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;Concentrations of credit risk&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time. The Company&amp;#x2019;s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0"&gt;The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at June 30, 2015 was the accounts receivable balance of $6,332,000 (December 31, 2014 - $1,903,000).&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;All accounts receivable balances were current as at June 30, 2015 and at December 31, 2014.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1671776">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Principles of Consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;These condensed consolidated financial statements include the accounts of the Company and four of its wholly-owned subsidiaries, Arbutus Inc., Protiva, Protiva USA, and Enantigen. All intercompany transactions and balances have been eliminated on consolidation.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&amp;#x201c;VIE&amp;#x201d;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ContractsRevenue contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669415" unitRef="iso4217-usd">2310000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669416" unitRef="iso4217-usd">1144000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669417" unitRef="iso4217-usd">5830000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669418" unitRef="iso4217-usd">4833000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-DoDMember" decimals="-3" id="c1669786" unitRef="iso4217-usd">1862000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-DoDMember" decimals="-3" id="c1669787" unitRef="iso4217-usd">861000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-DoDMember" decimals="-3" id="c1669788" unitRef="iso4217-usd">4907000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-DoDMember" decimals="-3" id="c1669789" unitRef="iso4217-usd">4101000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669790" unitRef="iso4217-usd">269000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669791" unitRef="iso4217-usd">283000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669792" unitRef="iso4217-usd">517000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669793" unitRef="iso4217-usd">526000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-BMSMember" id="c1669794" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ContractsRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-BMSMember" id="c1669795" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ContractsRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-BMSMember" id="c1669796" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ContractsRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-BMSMember" decimals="-3" id="c1669797" unitRef="iso4217-usd">206000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669798" unitRef="iso4217-usd">179000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-DicernaMember" id="c1669799" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ContractsRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669800" unitRef="iso4217-usd">406000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-DicernaMember" id="c1669801" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ContractualObligation contextRef="i_2015-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670053" unitRef="iso4217-usd">2956000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="i_2015-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670054" unitRef="iso4217-cad">3692000</us-gaap:ContractualObligation>
  <us-gaap:DeferredRevenue contextRef="i_2010-05-10_CounterpartyNameAxis-BMSMember" decimals="INF" id="c1669989" unitRef="iso4217-usd">3000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="i_2014-11-16_CounterpartyNameAxis-DicernaMember" decimals="INF" id="c1669997" unitRef="iso4217-usd">2500000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="i_2015-06-30" decimals="-3" id="c1669843" unitRef="iso4217-usd">13650000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="i_2014-12-31" decimals="-3" id="c1669844" unitRef="iso4217-usd">15722000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-size: 10pt; text-align: left"&gt;DoD (a)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;563&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;313&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Monsanto current portion (b)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,746&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,245&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;Dicerna current portion (e)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,296&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,221&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred revenue, current portion&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,605&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,785&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Monsanto long-term portion (b)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,336&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,666&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;Dicerna long-term portion (e)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;709&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,271&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total deferred revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;13,650&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;15,722&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669385" unitRef="iso4217-usd">5605000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669386" unitRef="iso4217-usd">5779000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-06-30_CounterpartyNameAxis-DoDMember" decimals="-3" id="c1669831" unitRef="iso4217-usd">563000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_CounterpartyNameAxis-DoDMember" decimals="-3" id="c1669832" unitRef="iso4217-usd">313000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669833" unitRef="iso4217-usd">3746000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669834" unitRef="iso4217-usd">4245000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-06-30_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669835" unitRef="iso4217-usd">1296000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669836" unitRef="iso4217-usd">1221000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-06-30" decimals="-3" id="c1669391" unitRef="iso4217-usd">8045000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2014-12-31" decimals="-3" id="c1669392" unitRef="iso4217-usd">9937000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669839" unitRef="iso4217-usd">7336000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2014-12-31_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669840" unitRef="iso4217-usd">8666000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-06-30_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669841" unitRef="iso4217-usd">709000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2014-12-31_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669842" unitRef="iso4217-usd">1271000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2015-06-30" decimals="-3" id="c1669395" unitRef="iso4217-usd">156007000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2014-12-31" id="c1669396" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:Depreciation contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669436" unitRef="iso4217-usd">147000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669437" unitRef="iso4217-usd">149000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669438" unitRef="iso4217-usd">267000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669439" unitRef="iso4217-usd">283000</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c1669470" unitRef="iso4217-usd-per-xbrli-shares">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-04-01_2014-06-30" decimals="INF" id="c1669471" unitRef="iso4217-usd-per-xbrli-shares">-0.28</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c1669472" unitRef="iso4217-usd-per-xbrli-shares">-0.64</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-06-30" decimals="INF" id="c1669473" unitRef="iso4217-usd-per-xbrli-shares">-1.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1671779">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income or loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company&amp;#x2019;s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants. During the six months ended June 30, 2015, potential common shares of 2,774,398 (June 30, 2014 &amp;#x2013; 2,558,925) were excluded from the calculation of income per common share because their inclusion would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669631" unitRef="iso4217-usd">967000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669632" unitRef="iso4217-usd">1924000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669633" unitRef="iso4217-usd">-340000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669634" unitRef="iso4217-usd">-545000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669855" unitRef="iso4217-usd">491000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669856" unitRef="iso4217-usd">2873000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-15">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;207,205&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;207,205&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Term deposit&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10,012&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10,012&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;217,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;217,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Warrants&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Contingent consideration&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,136&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,136&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Financial instrument&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,742&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,742&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;72,187&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;72,187&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Guaranteed investment certificates&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;39,974&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;39,974&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;112,161&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;112,161&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Warrants&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Financial instrument&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" decimals="4" id="c1669933" unitRef="xbrli-pure">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-06-30" decimals="4" id="c1669733" unitRef="xbrli-pure">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="d_2014-01-01_2014-12-31" decimals="4" id="c1669734" unitRef="xbrli-pure">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" id="c1669934">P4Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FairValueByAssetClassAxis-FiniteLivedIntangibleAssetsMember" id="c1669953">P20Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="d_2015-01-01_2015-06-30" id="c1669739">P146D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="d_2014-01-01_2014-12-31" id="c1669740">P182D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" decimals="4" id="c1669932" unitRef="xbrli-pure">0.81</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-06-30" decimals="4" id="c1669735" unitRef="xbrli-pure">0.6932</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="d_2014-01-01_2014-12-31" decimals="4" id="c1669736" unitRef="xbrli-pure">0.8522</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember" decimals="4" id="c1669931" unitRef="xbrli-pure">0.0074</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-06-30" decimals="4" id="c1669737" unitRef="xbrli-pure">0.0059</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="d_2014-01-01_2014-12-31" decimals="4" id="c1669738" unitRef="xbrli-pure">0.01</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FairValueByAssetClassAxis-FiniteLivedIntangibleAssetsMember" decimals="4" id="c1669954" unitRef="xbrli-pure">0.138</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1672300">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair value of financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; text-align: left"&gt;&amp;#x2022;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; text-align: left"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 0 4.5pt 0 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; text-align: left"&gt;&amp;#x2022;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; text-align: left"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 2.5pt 0.8pt 0 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; text-align: left"&gt;&amp;#x2022;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; text-align: left"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&amp;#x2019;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The following tables present information about the Company&amp;#x2019;s assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;207,205&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;207,205&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Term deposit&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10,012&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10,012&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;217,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;217,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Warrants&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Contingent consideration&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,136&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,136&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Financial instrument&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,742&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,742&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;72,187&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;72,187&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Guaranteed investment certificates&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;39,974&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;39,974&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;112,161&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;112,161&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;Liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Warrants&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Financial instrument&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The Company acquired a term deposit in May 2015 with an original maturity of 24-months and it has been classified as a long-term investment on the balance sheet. For the period ended June 30, 2015, the fair value of the term deposit is $10,012,000 which includes the principal and accrued interest earned as at the balance sheet date.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The Company used a discounted cash flow model to determine the fair value of the financial instrument, related to Monsanto&amp;#x2019;s call option to acquire the equity or all of the assets of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial liability was nil, and there has been no change to its fair value as at June 30, 2015.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;Contingent consideration is a liability assumed by the Company from its acquisition of Arbutus Inc. &amp;#x2013; see notes 3 and 8. The Company used a discounted cash flow model to determine the fair value of the contingent consideration as at the acquisition date, and at each subsequent reporting date. The Company&amp;#x2019;s preliminary estimate of the contingent consideration was $4,736,000 for the reporting date of March 31, 2015. As at June 30, 2015, the Company has reassessed the preliminary initial fair value of the contingent consideration to be $5,136,000.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The following table presents the changes in fair value of the Company&amp;#x2019;s warrants, in thousands:&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Liability at beginning of the period&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Opening liability of warrants issued in the period&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Fair value of warrants exercised in the period&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Increase (decrease) in fair&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;value of warrants&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Foreign exchange&amp;nbsp;&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;(gain) loss&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Liability at end&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;of the period&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 12%; font-size: 10pt; text-align: left"&gt;Six months ended June 30, 2014&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,379&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(6,607&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;7,803&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;6,590&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;Six months ended June 30, 2015&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(341&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(801&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(351&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The change in fair value of warrant liability for the six months ended June 30, 2015 is recorded in the statement of operations and comprehensive loss.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The weighted average Black-Scholes option-pricing assumptions and the resultant fair values, in thousands, for warrants outstanding at June 30, 2015 and at December 31, 2014 are as follows:&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;0.00&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;0.00&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69.32&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;85.22&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rate&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.59&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.00&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Expected average term (years)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.4&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Fair value of warrants outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;9.50&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;12.80&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Aggregate fair value of warrants outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Number of warrants outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;379,500&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;398,250&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669461" unitRef="iso4217-usd">2024000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669462" unitRef="iso4217-usd">5813000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669463" unitRef="iso4217-usd">801000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669464" unitRef="iso4217-usd">-7803000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669457" unitRef="iso4217-usd">-2571000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669458" unitRef="iso4217-usd">-2728000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669459" unitRef="iso4217-usd">4467000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669460" unitRef="iso4217-usd">-1285000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669560" unitRef="iso4217-usd">-2639000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669561" unitRef="iso4217-usd">-1391000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669562" unitRef="iso4217-usd">4418000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669563" unitRef="iso4217-usd">-1332000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1672301">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign currency translation and reporting currency&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Functional currency&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The functional currency of the Company and its integrated subsidiaries (Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&amp;#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The local currency of Arbutus Inc. (including its subsidiary, Enantigen) is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic environment in which Arbutus Inc. operates and expends cash. Foreign currency monetary assets and liabilities are translated into United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&amp;#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reporting currency&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the Company&amp;#x2019;s functional currency to the Company&amp;#x2019;s reporting currency of U.S. dollars are unrealized gains and losses; therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:GainContingencyUnrecordedAmount contextRef="i_2013-06-21_GainContingenciesByNatureAxis-PositiveOutcomeOfLitigationMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-AlnylamLicenseAgreementMember" decimals="INF" id="c1669987" unitRef="iso4217-usd">5000000</us-gaap:GainContingencyUnrecordedAmount>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669432" unitRef="iso4217-usd">7662000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669433" unitRef="iso4217-usd">1787000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669434" unitRef="iso4217-usd">10378000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669435" unitRef="iso4217-usd">3837000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Goodwill contextRef="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669956" unitRef="iso4217-usd">156053000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2015-06-30" decimals="-3" id="c1669377" unitRef="iso4217-usd">156053000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2014-12-31" id="c1669378" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1671778">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Goodwill and intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Intangible assets consist of in-process research and development arising from the Company&amp;#x2019;s acquisition of Arbutus Inc. &amp;#x2013; see note 3. In-process research and development (IPR&amp;amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written down to their fair values.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. &amp;#x2013; see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxesReceivable contextRef="i_2015-06-30" decimals="-3" id="c1669361" unitRef="iso4217-usd">55000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:IncomeTaxesReceivable contextRef="i_2014-12-31" decimals="-3" id="c1669362" unitRef="iso4217-usd">86000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669585" unitRef="iso4217-usd">-7351000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669586" unitRef="iso4217-usd">-943000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669587" unitRef="iso4217-usd">-5343000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669588" unitRef="iso4217-usd">108000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669569" unitRef="iso4217-usd">1738000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669570" unitRef="iso4217-usd">-1231000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669571" unitRef="iso4217-usd">4624000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669572" unitRef="iso4217-usd">178000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="d_2015-04-01_2015-06-30" id="c1669577" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669578" unitRef="iso4217-usd">57000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="d_2015-01-01_2015-06-30" id="c1669579" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669580" unitRef="iso4217-usd">112000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669589" unitRef="iso4217-usd">334000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669590" unitRef="iso4217-usd">455000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669591" unitRef="iso4217-usd">-957000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669592" unitRef="iso4217-usd">12744000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669581" unitRef="iso4217-usd">519000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669582" unitRef="iso4217-usd">-243000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669583" unitRef="iso4217-usd">298000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669584" unitRef="iso4217-usd">-725000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669573" unitRef="iso4217-usd">-1304000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669574" unitRef="iso4217-usd">-220000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669575" unitRef="iso4217-usd">-178000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669576" unitRef="iso4217-usd">-12000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2015-06-30" decimals="-3" id="c1669375" unitRef="iso4217-usd">390017000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2014-12-31" id="c1669376" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InvestmentIncomeInterest contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669453" unitRef="iso4217-usd">81000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669454" unitRef="iso4217-usd">257000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669455" unitRef="iso4217-usd">283000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669456" unitRef="iso4217-usd">404000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" decimals="-3" id="c1669700" unitRef="iso4217-usd">39974000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" id="c1669702" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="i_2014-12-31" decimals="-3" id="c1669703" unitRef="iso4217-usd">39974000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:LeaseIncentivePayableCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669853" unitRef="iso4217-usd">364000</us-gaap:LeaseIncentivePayableCurrent>
  <us-gaap:LeaseIncentivePayableCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669854" unitRef="iso4217-usd">250000</us-gaap:LeaseIncentivePayableCurrent>
  <us-gaap:Liabilities contextRef="i_2015-06-30" decimals="-3" id="c1669397" unitRef="iso4217-usd">185319000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="i_2014-12-31" decimals="-3" id="c1669398" unitRef="iso4217-usd">30143000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-06-30" decimals="-3" id="c1669412" unitRef="iso4217-usd">773820000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2014-12-31" decimals="-3" id="c1669413" unitRef="iso4217-usd">118178000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669389" unitRef="iso4217-usd">16131000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669390" unitRef="iso4217-usd">20206000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="-3" id="c1669689" unitRef="iso4217-usd">8742000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="i_2015-06-30" decimals="-3" id="c1669690" unitRef="iso4217-usd">8742000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="-3" id="c1669719" unitRef="iso4217-usd">5099000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="i_2014-12-31" decimals="-3" id="c1669720" unitRef="iso4217-usd">5099000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:LicenseCosts contextRef="d_2014-02-01_2014-02-28_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670082" unitRef="iso4217-usd">150000</us-gaap:LicenseCosts>
  <us-gaap:LicenseCosts contextRef="d_2014-11-01_2014-11-30_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670085" unitRef="iso4217-usd">50000</us-gaap:LicenseCosts>
  <us-gaap:LicenseCosts contextRef="d_2014-09-01_2014-09-30_CounterpartyNameAxis-NeuroviveMember_LegalEntityAxis-ArbutusIncMember" decimals="INF" id="c1670098" unitRef="iso4217-cad">1000000</us-gaap:LicenseCosts>
  <us-gaap:LicensesRevenue contextRef="d_2014-01-01_2014-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-AlnylamLicenseAgreementMember" decimals="INF" id="c1669985" unitRef="iso4217-usd">150000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669419" unitRef="iso4217-usd">1130000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669420" unitRef="iso4217-usd">667000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669421" unitRef="iso4217-usd">2292000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669422" unitRef="iso4217-usd">1408000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669807" unitRef="iso4217-usd">805000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669808" unitRef="iso4217-usd">626000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669809" unitRef="iso4217-usd">1647000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-MonsantoMember" decimals="-3" id="c1669810" unitRef="iso4217-usd">1171000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-AcuitasMember" id="c1669811" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LicensesRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-AcuitasMember" id="c1669812" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LicensesRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-AcuitasMember" id="c1669813" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LicensesRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-AcuitasMember" decimals="-3" id="c1669814" unitRef="iso4217-usd">150000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669815" unitRef="iso4217-usd">263000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-DicernaMember" id="c1669816" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LicensesRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-DicernaMember" decimals="-3" id="c1669817" unitRef="iso4217-usd">526000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-DicernaMember" id="c1669818" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LicensesRevenue contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-SpectrumMember" decimals="-3" id="c1669819" unitRef="iso4217-usd">62000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-04-01_2014-06-30_CounterpartyNameAxis-SpectrumMember" decimals="-3" id="c1669820" unitRef="iso4217-usd">41000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-SpectrumMember" decimals="-3" id="c1669821" unitRef="iso4217-usd">119000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="d_2014-01-01_2014-06-30_CounterpartyNameAxis-SpectrumMember" decimals="-3" id="c1669822" unitRef="iso4217-usd">87000</us-gaap:LicensesRevenue>
  <us-gaap:LongTermInvestments contextRef="i_2015-05-31_InvestmentTypeAxis-TermDepositMember" decimals="INF" id="c1669892" unitRef="iso4217-usd">10012000</us-gaap:LongTermInvestments>
  <us-gaap:LongTermInvestments contextRef="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" decimals="-3" id="c1669666" unitRef="iso4217-usd">10012000</us-gaap:LongTermInvestments>
  <us-gaap:LongTermInvestments contextRef="i_2015-06-30" decimals="-3" id="c1669669" unitRef="iso4217-usd">10012000</us-gaap:LongTermInvestments>
  <us-gaap:LongTermInvestments contextRef="i_2014-12-31" id="c1669368" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="d_2015-01-16_2015-01-16_LitigationCaseAxis-ArbitrationWithTheUniversityOfBritishColumbiaMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c1670070" unitRef="iso4217-usd">3500000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:NatureOfOperations contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;1.&lt;/div&gt;&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Nature of business and future operations&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Arbutus Biopharma Corporation (the &amp;#x201c;Company&amp;#x201d; or &amp;#x201c;Arbutus&amp;#x201d;) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (&amp;#x201c;HBV&amp;#x201d;), a disease of the liver caused by hepatitis B virus (&amp;#x201c;HBV&amp;#x201d;). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company&amp;#x2019;s expertise in Lipid Nanoparticle (&amp;#x201c;LNP&amp;#x201d;) technology.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Effective July 31, 2015, the corporate name changed from Tekmira Pharmaceuticals Corporation (&amp;#x201c;Tekmira&amp;#x201d;) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (&amp;#x201c;OnCore&amp;#x201d;) changed to Arbutus Biopharma Inc. (&amp;#x201c;Arbutus Inc.&amp;#x201d;). Including Arbutus Inc., the Company has five wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (&amp;#x201c;Protiva&amp;#x201d;), Protiva Biotherapeutics (USA) Inc. (&amp;#x201c;Protiva USA&amp;#x201d;), Protiva Agricultural Development Company Inc. (&amp;#x201c;PADCo&amp;#x201d;), and Enantigen Therapeutics, Inc. (&amp;#x201c;Enantigen&amp;#x201d;).&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company&amp;#x2019;s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company&amp;#x2019;s ability to fund these programs in the future.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669627" unitRef="iso4217-usd">960000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669628" unitRef="iso4217-usd">234000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669629" unitRef="iso4217-usd">143780000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669630" unitRef="iso4217-usd">59523000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669610" unitRef="iso4217-usd">-10327000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669611" unitRef="iso4217-usd">-43238000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669612" unitRef="iso4217-usd">27219000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669613" unitRef="iso4217-usd">-43573000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669593" unitRef="iso4217-usd">-16671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669594" unitRef="iso4217-usd">-8010000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669595" unitRef="iso4217-usd">-35641000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669596" unitRef="iso4217-usd">1145000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c1669533" unitRef="iso4217-usd">-26875000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669535" unitRef="iso4217-usd">-26875000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669465" unitRef="iso4217-usd">-14886000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669466" unitRef="iso4217-usd">-6081000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669468" unitRef="iso4217-usd">-24065000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-06-30" id="c1672302">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent accounting pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition &amp;#x2013; Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December 15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &amp;#x2013; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&amp;#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="d_2015-04-01_2015-06-30" id="c1669657" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="d_2014-04-01_2014-06-30" id="c1669658" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669659" unitRef="iso4217-usd">381618000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="d_2014-01-01_2014-06-30" id="c1669660" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OperatingExpenses contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669444" unitRef="iso4217-usd">17860000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669445" unitRef="iso4217-usd">11234000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669446" unitRef="iso4217-usd">40548000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669447" unitRef="iso4217-usd">21622000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669448" unitRef="iso4217-usd">-14420000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669449" unitRef="iso4217-usd">-9423000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669450" unitRef="iso4217-usd">-32426000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669451" unitRef="iso4217-usd">-15381000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669857" unitRef="iso4217-usd">745000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669858" unitRef="iso4217-usd">226000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c1669528" unitRef="iso4217-usd">-5951000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669529" unitRef="iso4217-usd">-5951000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669480" unitRef="iso4217-usd">3223000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669481" unitRef="iso4217-usd">3774000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669483" unitRef="iso4217-usd">1616000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:PaymentsForProceedsFromInvestments contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669598" unitRef="iso4217-usd">9944000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsForProceedsFromInvestments contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669599" unitRef="iso4217-usd">42992000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsForProceedsFromInvestments contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669600" unitRef="iso4217-usd">-27419000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsForProceedsFromInvestments contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669601" unitRef="iso4217-usd">42992000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2015-03-25_2015-03-25" decimals="INF" id="c1670023" unitRef="iso4217-usd">9700000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669606" unitRef="iso4217-usd">383000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669607" unitRef="iso4217-usd">246000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669608" unitRef="iso4217-usd">524000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669609" unitRef="iso4217-usd">581000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669363" unitRef="iso4217-usd">1787000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669364" unitRef="iso4217-usd">1730000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669653" unitRef="iso4217-usd">25000</us-gaap:ProceedsFromIncomeTaxRefunds>
  <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="d_2014-04-01_2014-06-30" id="c1669654" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669655" unitRef="iso4217-usd">25000</us-gaap:ProceedsFromIncomeTaxRefunds>
  <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="d_2014-01-01_2014-06-30" id="c1669656" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-03-25_2015-03-25" decimals="INF" id="c1670019" unitRef="iso4217-usd">151875000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669615" unitRef="iso4217-usd">2000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-04-01_2014-06-30" id="c1669616" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669617" unitRef="iso4217-usd">142177000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669618" unitRef="iso4217-usd">56477000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669619" unitRef="iso4217-usd">939000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669620" unitRef="iso4217-usd">148000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669621" unitRef="iso4217-usd">1559000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669622" unitRef="iso4217-usd">2072000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669623" unitRef="iso4217-usd">19000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669624" unitRef="iso4217-usd">86000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669625" unitRef="iso4217-usd">44000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669626" unitRef="iso4217-usd">974000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-06-30" decimals="-3" id="c1669369" unitRef="iso4217-usd">12469000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31" decimals="-3" id="c1669370" unitRef="iso4217-usd">12959000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-06-30" decimals="-3" id="c1669373" unitRef="iso4217-usd">2036000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2014-12-31" decimals="-3" id="c1669374" unitRef="iso4217-usd">1760000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669428" unitRef="iso4217-usd">9690000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669429" unitRef="iso4217-usd">9298000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669430" unitRef="iso4217-usd">20247000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669431" unitRef="iso4217-usd">17502000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-06-30" decimals="-3" id="c1669406" unitRef="iso4217-usd">-232739000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31" decimals="-3" id="c1669407" unitRef="iso4217-usd">-205864000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Revenues contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c1669423" unitRef="iso4217-usd">3440000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c1669424" unitRef="iso4217-usd">1811000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669425" unitRef="iso4217-usd">8122000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-01-01_2014-06-30" decimals="-3" id="c1669426" unitRef="iso4217-usd">6241000</us-gaap:Revenues>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-04-01_2015-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember" decimals="INF" id="c1670007" unitRef="iso4217-usd">62000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember" decimals="INF" id="c1670008" unitRef="iso4217-usd">119000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-04-01_2014-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember" decimals="INF" id="c1670011" unitRef="iso4217-usd">41000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-01-01_2014-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember" decimals="INF" id="c1670012" unitRef="iso4217-usd">87000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-04-01_2015-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670041" unitRef="iso4217-usd">62000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670042" unitRef="iso4217-usd">119000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-04-01_2014-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670045" unitRef="iso4217-usd">41000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-01-01_2014-06-30_ProductOrServiceAxis-MarqiboMember" decimals="INF" id="c1670046" unitRef="iso4217-usd">87000</us-gaap:RoyaltyRevenue>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-size: 10pt; text-align: left"&gt;Trade accounts payable&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,802&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,044&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Research and development accruals&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,914&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,391&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;License fee accruals&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;250&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fee accruals&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;604&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,294&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred lease inducements&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;364&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;250&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Payroll accruals&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;491&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,873&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;Other accrued liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;745&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;226&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;6,920&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;9,328&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Consideration paid:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 89%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Common shares issued without subjects&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;371,553&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Common shares issued subject to repurchase provision&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;9,262&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"&gt;Common shares issuable for Arbutus Inc. stock options&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,127&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;381,942&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Identifiable assets acquired and liabilities assumed:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Cash&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;324&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Prepaid expenses and other assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;116&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Accounts receivable&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Property and equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;147&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Acquired intangible assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;390,017&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Goodwill&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;156,053&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Accounts payable and accrued liabilities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(3,580&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Other noncurrent liabilities (note 8)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(5,136&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"&gt;Deferred income tax liability&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(156,017&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total purchase price allocation&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;381,942&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Three months ended June 30&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Six months ended June 30&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Collaborations and contracts&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;DoD (a)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,862&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;861&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,907&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;4,101&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Monsanto (b)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;269&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;283&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;517&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;526&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;BMS (d)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;206&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt"&gt;Dicerna (e)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;406&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Total research and development collaborations and contracts&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;2,310&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,144&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,830&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,833&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Licensing fees, milestone and royalty payments&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Monsanto licensing fees and milestone payments (b)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;805&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;626&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,647&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,171&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Acuitas milestone payments (c)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;150&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Dicerna licensing fee (e)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;263&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;526&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt"&gt;Spectrum royalty payments (f)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;62&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;41&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;119&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;87&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Total licensing fees, milestone and royalty payments&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,130&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;667&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,292&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,408&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid"&gt;Total revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;3,440&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,811&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;8,122&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;6,241&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid"&gt;$&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 89%; font-size: 10pt; text-align: left"&gt;IPR&amp;amp;D &amp;#x2013; Cyclophilins&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;35,124&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;IPR&amp;amp;D &amp;#x2013; Immune Modulator&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;189,182&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;IPR&amp;amp;D &amp;#x2013; Antigen Inhibitors&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;35,520&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;IPR&amp;amp;D &amp;#x2013; cccDNA&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;130,191&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt"&gt;Total IPR&amp;amp;D&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;390,017&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2015-01-01_2015-06-30" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;0.00&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;0.00&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69.32&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;85.22&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rate&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.59&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.00&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Expected average term (years)&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.4&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Fair value of warrants outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;9.50&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;12.80&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Aggregate fair value of warrants outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,606&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Number of warrants outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;379,500&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;398,250&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-04-01_2015-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c1669552" unitRef="iso4217-usd">1377000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-04-01_2014-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c1669553" unitRef="iso4217-usd">792000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c1669554" unitRef="iso4217-usd">2705000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c1669555" unitRef="iso4217-usd">1640000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-04-01_2015-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c1669556" unitRef="iso4217-usd">4046000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-04-01_2014-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c1669557" unitRef="iso4217-usd">289000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c1669558" unitRef="iso4217-usd">4525000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c1669559" unitRef="iso4217-usd">629000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2015-03-25_2015-03-25_AwardTypeAxis-UnderwriterOptionsMember" decimals="INF" id="c1670021" unitRef="xbrli-shares">1125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharePrice contextRef="i_2015-03-25" decimals="INF" id="c1670018" unitRef="iso4217-usd-per-xbrli-shares">20.25</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2015-03-25_2015-03-25_AwardTypeAxis-UnderwriterOptionsMember" id="c1670158">P30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharesOutstanding contextRef="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1669488" unitRef="xbrli-shares">22438169</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1669536" unitRef="xbrli-shares">54303402</us-gaap:SharesOutstanding>
  <us-gaap:ShortTermInvestments contextRef="i_2015-06-30" id="c1669355" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ShortTermInvestments contextRef="i_2014-12-31" decimals="-3" id="c1669356" unitRef="iso4217-usd">39974000</us-gaap:ShortTermInvestments>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2.&lt;/div&gt;&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Significant accounting policies&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&amp;#x2019;s audited consolidated financial statements and notes thereto for the year ended December 31, 2014 and included in the Company&amp;#x2019;s 2014 annual report on Form 10-K. The unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the financial position, results of operations and cash flows at June 30, 2015 and for all periods presented. The results of operations for the three and six months ended June 30, 2015 and June 30, 2014 are not necessarily indicative of the results for the full year. These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Principles of Consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;These condensed consolidated financial statements include the accounts of the Company and four of its wholly-owned subsidiaries, Arbutus Inc., Protiva, Protiva USA, and Enantigen. All intercompany transactions and balances have been eliminated on consolidation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&amp;#x201c;VIE&amp;#x201d;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Replacement awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&amp;#x2019;s acquisition of Arbutus Inc. (formerly OnCore), Arbutus (formerly Tekmira) shares were exchanged for Arbutus Inc.&amp;#x2019;s shares subject to repurchase rights held by Arbutus Inc.&amp;#x2019;s employees &amp;#x2013; see note 3.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 7; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Goodwill and intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Intangible assets consist of in-process research and development arising from the Company&amp;#x2019;s acquisition of Arbutus Inc. &amp;#x2013; see note 3. In-process research and development (IPR&amp;amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written down to their fair values.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"&gt;Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. &amp;#x2013; see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income or loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company&amp;#x2019;s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants. During the six months ended June 30, 2015, potential common shares of 2,774,398 (June 30, 2014 &amp;#x2013; 2,558,925) were excluded from the calculation of income per common share because their inclusion would be anti-dilutive.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair value of financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; text-align: left"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; text-align: left"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0 4.5pt 0 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; text-align: left"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; text-align: left"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 2.5pt 0.8pt 0 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; text-align: left"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; text-align: left"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&amp;#x2019;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;    &lt;!-- Field: Page; Sequence: 8; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                  &lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The following tables present information about the Company&amp;#x2019;s assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/div&gt;    &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 1&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 2&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Level 3&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;207,205&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;207,205&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Term deposit&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10,012&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10,012&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;217,217&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;217,217&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;Liabilities&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Warrants&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Contingent consideration&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,136&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,136&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Financial instrument&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;8,742&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;8,742&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 1&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 2&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;Level 3&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td nowrap="nowrap" style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;72,187&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;72,187&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Guaranteed investment certificates&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;39,974&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;39,974&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;112,161&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;112,161&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;Liabilities&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Warrants&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Financial instrument&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Total&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The Company acquired a term deposit in May 2015 with an original maturity of 24-months and it has been classified as a long-term investment on the balance sheet. For the period ended June 30, 2015, the fair value of the term deposit is $10,012,000 which includes the principal and accrued interest earned as at the balance sheet date.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The Company used a discounted cash flow model to determine the fair value of the financial instrument, related to Monsanto&amp;#x2019;s call option to acquire the equity or all of the assets of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial liability was nil, and there has been no change to its fair value as at June 30, 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;Contingent consideration is a liability assumed by the Company from its acquisition of Arbutus Inc. &amp;#x2013; see notes 3 and 8. The Company used a discounted cash flow model to determine the fair value of the contingent consideration as at the acquisition date, and at each subsequent reporting date. The Company&amp;#x2019;s preliminary estimate of the contingent consideration was $4,736,000 for the reporting date of March 31, 2015. As at June 30, 2015, the Company has reassessed the preliminary initial fair value of the contingent consideration to be $5,136,000.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 9; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                    &lt;div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0"&gt;The following table presents the changes in fair value of the Company&amp;#x2019;s warrants, in thousands:&lt;/div&gt;      &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Liability at beginning of the period&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Opening liability of warrants issued in the period&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;Fair value of warrants exercised in the period&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Increase (decrease) in fair&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;value of warrants&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Foreign exchange&amp;nbsp;&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;(gain) loss&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&lt;div style=" margin-top: 0; margin-bottom: 0"&gt;Liability at end&lt;/div&gt; &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;of the period&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td nowrap="nowrap" style="width: 12%; font-size: 10pt; text-align: left"&gt;Six months ended June 30, 2014&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,379&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(6,607&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;7,803&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;15&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;6,590&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;Six months ended June 30, 2015&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(341&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(801&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(351&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;3,606&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The change in fair value of warrant liability for the six months ended June 30, 2015 is recorded in the statement of operations and comprehensive loss.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0"&gt;The weighted average Black-Scholes option-pricing assumptions and the resultant fair values, in thousands, for warrants outstanding at June 30, 2015 and at December 31, 2014 are as follows:&lt;/div&gt;      &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;June 30, 2015&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 78%; font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"&gt;0.00&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;0.00&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;69.32&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;85.22&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.59&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1.00&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;Expected average term (years)&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.4&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.5&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Fair value of warrants outstanding&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;9.50&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;12.80&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Aggregate fair value of warrants outstanding&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,606&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,099&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid"&gt;Number of warrants outstanding&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;379,500&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; border-bottom: Black 1.1pt solid"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;398,250&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign currency translation and reporting currency&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Functional currency&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The functional currency of the Company and its integrated subsidiaries (Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&amp;#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The local currency of Arbutus Inc. (including its subsidiary, Enantigen) is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic environment in which Arbutus Inc. operates and expends cash. Foreign currency monetary assets and liabilities are translated into United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&amp;#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reporting currency&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the Company&amp;#x2019;s functional currency to the Company&amp;#x2019;s reporting currency of U.S. dollars are unrealized gains and losses; therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 10; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;                &lt;div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent accounting pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition &amp;#x2013; Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December 15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: left; margin: 0"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &amp;#x2013; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&amp;#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669925" unitRef="xbrli-shares">23973315</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1669518" unitRef="xbrli-shares">23973315</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2015-03-25_2015-03-25" decimals="INF" id="c1670017" unitRef="xbrli-shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1669512" unitRef="xbrli-shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1669506" unitRef="xbrli-shares">18750</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-03-25_2015-03-25_AwardTypeAxis-UnderwriterOptionsMember" decimals="INF" id="c1670159" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1669500" unitRef="xbrli-shares">373168</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember" decimals="INF" id="c1669926" unitRef="iso4217-usd">381942000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c1669519" unitRef="iso4217-usd">380815000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c1669520" unitRef="iso4217-usd">1127000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669523" unitRef="iso4217-usd">381942000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c1669513" unitRef="iso4217-usd">142177000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669517" unitRef="iso4217-usd">142177000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c1669507" unitRef="iso4217-usd">384000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669511" unitRef="iso4217-usd">384000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c1669501" unitRef="iso4217-usd">2956000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c1669502" unitRef="iso4217-usd">-1397000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c1669505" unitRef="iso4217-usd">1559000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c1669489" unitRef="iso4217-usd">290004000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c1669490" unitRef="iso4217-usd">26208000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c1669491" unitRef="iso4217-usd">-205864000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c1669492" unitRef="iso4217-usd">-22313000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31" decimals="-3" id="c1669493" unitRef="iso4217-usd">88035000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c1669537" unitRef="iso4217-usd">821660000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c1669538" unitRef="iso4217-usd">27844000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c1669539" unitRef="iso4217-usd">-232739000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c1669540" unitRef="iso4217-usd">-28264000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-06-30" decimals="-3" id="c1669541" unitRef="iso4217-usd">588501000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2015-01-01_2015-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;       &lt;tr style="vertical-align: top; text-align: left"&gt;     &lt;td style="width: 15pt; text-align: left"&gt;6.&lt;/td&gt;     &lt;td style="width: 5pt"&gt;&lt;/td&gt;     &lt;td style="text-align: left"&gt;Financing&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; margin: 6pt 0 0; text-align: left"&gt;&lt;div style="display: inline; font-weight: normal"&gt;On March 25, 2015, the Company announced that it had completed an underwritten public offering of 7,500,000 common shares, at a price of $20.25 per share, representing gross proceeds of $151,875,000. The Company also granted the underwriters a 30-day option to purchase an additional 1,125,000 shares for an additional $22,781,000 to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was $9,700,000, resulting in net proceeds of $142,177,000.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UnbilledReceivablesCurrent contextRef="i_2015-06-30" decimals="-3" id="c1669359" unitRef="iso4217-usd">323000</us-gaap:UnbilledReceivablesCurrent>
  <us-gaap:UnbilledReceivablesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1669360" unitRef="iso4217-usd">538000</us-gaap:UnbilledReceivablesCurrent>
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax contextRef="d_2015-01-01_2015-06-30_VariableInterestEntitiesByClassificationOfEntityAxis-PADCoMember" decimals="INF" id="c1670154" unitRef="iso4217-usd">0</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax>
  <us-gaap:VariableInterestEntityNonconsolidatedCarryingAmountAssets contextRef="i_2015-06-30_VariableInterestEntitiesByClassificationOfEntityAxis-PADCoMember" decimals="INF" id="c1670152" unitRef="iso4217-usd">0</us-gaap:VariableInterestEntityNonconsolidatedCarryingAmountAssets>
  <us-gaap:VariableInterestEntityNonconsolidatedCarryingAmountLiabilities contextRef="i_2015-06-30_VariableInterestEntitiesByClassificationOfEntityAxis-PADCoMember" decimals="INF" id="c1670153" unitRef="iso4217-usd">0</us-gaap:VariableInterestEntityNonconsolidatedCarryingAmountLiabilities>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="i_2015-06-30" decimals="-3" id="c1669387" unitRef="iso4217-usd">3606000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="i_2014-12-31" decimals="-3" id="c1669388" unitRef="iso4217-usd">5099000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="-3" id="c1669677" unitRef="iso4217-usd">3606000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="i_2015-06-30" decimals="-3" id="c1669678" unitRef="iso4217-usd">3606000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="-3" id="c1669711" unitRef="iso4217-usd">5099000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="i_2014-12-31" decimals="-3" id="c1669712" unitRef="iso4217-usd">5099000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="i_2013-12-31" decimals="-3" id="c1669721" unitRef="iso4217-usd">5379000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="i_2014-06-30" decimals="-3" id="c1669726" unitRef="iso4217-usd">6590000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c1669475" unitRef="xbrli-shares">54255804</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2014-04-01_2014-06-30" decimals="INF" id="c1669476" unitRef="xbrli-shares">22063438</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c1669477" unitRef="xbrli-shares">42297517</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2014-01-01_2014-06-30" decimals="INF" id="c1669478" unitRef="xbrli-shares">20938503</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#c1669813" xlink:label="c1669813" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669813" xlink:to="f-192" xlink:type="arc"/>
    <link:loc xlink:href="#c1669812" xlink:label="c1669812" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669812" xlink:to="f-192" xlink:type="arc"/>
    <link:loc xlink:href="#c1669811" xlink:label="c1669811" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669811" xlink:to="f-192" xlink:type="arc"/>
    <link:loc xlink:href="#c1669810" xlink:label="c1669810" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669810" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669816" xlink:label="c1669816" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669816" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669820" xlink:label="c1669820" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669820" xlink:to="f-195" xlink:type="arc"/>
    <link:loc xlink:href="#c1669817" xlink:label="c1669817" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669817" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669814" xlink:label="c1669814" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669814" xlink:to="f-192" xlink:type="arc"/>
    <link:loc xlink:href="#c1669815" xlink:label="c1669815" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669815" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669821" xlink:label="c1669821" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669821" xlink:to="f-195" xlink:type="arc"/>
    <link:loc xlink:href="#c1669818" xlink:label="c1669818" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669818" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669822" xlink:label="c1669822" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669822" xlink:to="f-195" xlink:type="arc"/>
    <link:loc xlink:href="#c1669819" xlink:label="c1669819" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669819" xlink:to="f-195" xlink:type="arc"/>
    <link:loc xlink:href="#c1669786" xlink:label="c1669786" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669786" xlink:to="f-190" xlink:type="arc"/>
    <link:loc xlink:href="#c1669787" xlink:label="c1669787" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669787" xlink:to="f-190" xlink:type="arc"/>
    <link:loc xlink:href="#c1669788" xlink:label="c1669788" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669788" xlink:to="f-190" xlink:type="arc"/>
    <link:loc xlink:href="#c1669789" xlink:label="c1669789" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669789" xlink:to="f-190" xlink:type="arc"/>
    <link:loc xlink:href="#c1669800" xlink:label="c1669800" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669800" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669801" xlink:label="c1669801" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669801" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669790" xlink:label="c1669790" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669790" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669793" xlink:label="c1669793" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669793" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669807" xlink:label="c1669807" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669807" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669794" xlink:label="c1669794" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669794" xlink:to="f-193" xlink:type="arc"/>
    <link:loc xlink:href="#c1669808" xlink:label="c1669808" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669808" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669791" xlink:label="c1669791" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669791" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669809" xlink:label="c1669809" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669809" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669792" xlink:label="c1669792" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669792" xlink:to="f-191" xlink:type="arc"/>
    <link:loc xlink:href="#c1669797" xlink:label="c1669797" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669797" xlink:to="f-193" xlink:type="arc"/>
    <link:loc xlink:href="#c1669798" xlink:label="c1669798" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669798" xlink:to="f-194" xlink:type="arc"/>
    <link:loc xlink:href="#c1669795" xlink:label="c1669795" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669795" xlink:to="f-193" xlink:type="arc"/>
    <link:loc xlink:href="#c1669796" xlink:label="c1669796" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669796" xlink:to="f-193" xlink:type="arc"/>
    <link:loc xlink:href="#c1669799" xlink:label="c1669799" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669799" xlink:to="f-194" xlink:type="arc"/>
    <link:footnote xlink:label="f-190" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Contract with United States Government's Department of Defense ("DoD") to develop TKM-Ebola  On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection.  In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. In May 2015, the Company and the DoD signed a contract modification to further increase stage one funding by up to $1,000,000.  The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKMEbola-Guinea (the "Ebola-Guinea Amendment"), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.  In March 2015, the Company and the DoD signed a contract modification to provide up to $2,250,000 to fund the Company for TKM-Ebola-Guinea IND submission expenses.  Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June 30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.  On July 20, 2015, the Company announced given the unclear development path for TKM-Ebola, development activities will be suspended and a joint re-evaluation of the development contract with the DoD is underway.</link:footnote>
    <link:footnote xlink:label="f-191" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Option and Services Agreements with Monsanto Company ("Monsanto")  On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.  In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from MonsantoThe amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.  Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</link:footnote>
    <link:footnote xlink:label="f-192" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">License and collaboration with Alnylam Pharmaceuticals, Inc. ("Alnylam") and Acuitas Therapeutics Inc. ("Acuitas", formerly AlCana Technologies Inc.)  Milestone receipts and payments  In the six months ended June 30, 2014, the Company earned a $150,000 milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.  Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. ("Ascletis")  On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam's position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement. The hearing date for this arbitration took place in May 2015, and a decision of the arbitrator is pending. The Company has not recorded any revenue in respect of this milestone.</link:footnote>
    <link:footnote xlink:label="f-193" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb ("BMS") collaboration  On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA ("siRNA") molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company could use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the four-year agreement. BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.  Revenue from the May 10, 2010 agreement with BMS was being recognized as the Company produces the related LNP batches.  The revenue earned for the six months ended June 30, 2014 was related to BMS batches shipped during the period. In August 2014, the agreement expired and both companies' obligations under the agreement ended.</link:footnote>
    <link:footnote xlink:label="f-194" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna") On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.  The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months.  The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</link:footnote>
    <link:footnote xlink:label="f-195" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Agreements with Spectrum Pharmaceuticals, Inc. ("Spectrum")  On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. ("Talon", formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the "Talon License Agreement") for three of the Company's chemotherapy products, Marqibo, AlocrestTM (Optisomal Vinorelbine) and BrakivaTM (Optisomal Topotecan).  On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.  Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three and six months ended June 30, 2015, the Company recorded $62,000 and $119,000 in Marqibo royalty revenue (three and six months ended June 30, 2014 - $41,000 and $87,000 respectively). For the six months ended June 30, 2015, the Company accrued 2.5% in royalties due to TPC in respect of the Marqibo royalty earned by the Company - see note 8, contingencies and commitments.</link:footnote>
    <link:loc xlink:href="#c1669831" xlink:label="c1669831" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669831" xlink:to="f-200" xlink:type="arc"/>
    <link:loc xlink:href="#c1669841" xlink:label="c1669841" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669841" xlink:to="f-202" xlink:type="arc"/>
    <link:loc xlink:href="#c1669832" xlink:label="c1669832" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669832" xlink:to="f-200" xlink:type="arc"/>
    <link:loc xlink:href="#c1669842" xlink:label="c1669842" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669842" xlink:to="f-202" xlink:type="arc"/>
    <link:loc xlink:href="#c1669833" xlink:label="c1669833" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669833" xlink:to="f-201" xlink:type="arc"/>
    <link:loc xlink:href="#c1669834" xlink:label="c1669834" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669834" xlink:to="f-201" xlink:type="arc"/>
    <link:loc xlink:href="#c1669840" xlink:label="c1669840" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669840" xlink:to="f-201" xlink:type="arc"/>
    <link:loc xlink:href="#c1669835" xlink:label="c1669835" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669835" xlink:to="f-202" xlink:type="arc"/>
    <link:loc xlink:href="#c1669836" xlink:label="c1669836" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669836" xlink:to="f-202" xlink:type="arc"/>
    <link:loc xlink:href="#c1669839" xlink:label="c1669839" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c1669839" xlink:to="f-201" xlink:type="arc"/>
    <link:footnote xlink:label="f-200" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Contract with United States Government's Department of Defense ("DoD") to develop TKM-Ebola  On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection.  In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required.   The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the "Ebola-Guinea Amendment"), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.   Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June 30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.   On July 20, 2015, the Company announced that development activities related to TKM-Ebola will be suspended and a joint re-evaluation of the development contract with the DoD is underway.</link:footnote>
    <link:footnote xlink:label="f-201" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Option and Services Agreements with Monsanto Company ("Monsanto")   On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.   In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from Monsanto The amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.   Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</link:footnote>
    <link:footnote xlink:label="f-202" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna")   On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.   The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months as at June 30, 2015 (December 31, 2014 - 28 months).   The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</link:footnote>
  </link:footnoteLink>
  <xbrli:unit id="iso4217-cad">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2004-03-01_2004-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-03-01</xbrli:startDate>
      <xbrli:endDate>2004-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2010-05-10_2010-05-10_CounterpartyNameAxis-BMSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BMSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-05-10</xbrli:startDate>
      <xbrli:endDate>2010-05-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-01-01_2012-12-31_CounterpartyNameAxis-MarinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MarinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-01-01_2012-12-31_CounterpartyNameAxis-MarinaMember_StatementScenarioAxis-ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MarinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_CounterpartyNameAxis-MarinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MarinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_CounterpartyNameAxis-AcuitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:AcuitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_CounterpartyNameAxis-BMSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BMSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_CounterpartyNameAxis-SpectrumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:SpectrumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_ProductOrServiceAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-AlnylamLicenseAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-ArcturusMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:ArcturusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-13_2014-01-13_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-13</xbrli:startDate>
      <xbrli:endDate>2014-01-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-14_2015-05-31_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-14</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-02-01_2014-02-28_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DrexelAndBlumbergMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-01</xbrli:startDate>
      <xbrli:endDate>2014-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_CounterpartyNameAxis-AcuitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:AcuitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_CounterpartyNameAxis-BMSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BMSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_CounterpartyNameAxis-SpectrumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:SpectrumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_ProductOrServiceAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-09-01_2014-09-30_CounterpartyNameAxis-NeuroviveMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:NeuroviveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-10-31_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BlumbergMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-10-31</xbrli:startDate>
      <xbrli:endDate>2014-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-11-01_2014-11-16_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-11-01</xbrli:startDate>
      <xbrli:endDate>2014-11-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-11-01_2014-11-30_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DrexelAndBlumbergMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-11-01</xbrli:startDate>
      <xbrli:endDate>2014-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember_NatureOfExpenseAxis-RelatedToTheExpirationOfRepurchaseProvisionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">tkmr:RelatedToTheExpirationOfRepurchaseProvisionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-AcuitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:AcuitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-BMSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BMSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-SpectrumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:SpectrumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_ProductOrServiceAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_VariableInterestEntitiesByClassificationOfEntityAxis-PADCoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">tkmr:PADCoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-16_2015-01-16_LitigationCaseAxis-ArbitrationWithTheUniversityOfBritishColumbiaMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tkmr:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-16</xbrli:startDate>
      <xbrli:endDate>2015-01-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-03_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-03</xbrli:startDate>
      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-03</xbrli:startDate>
      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">tkmr:CommonSharesIssuedSubjectToRepurchaseProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-03</xbrli:startDate>
      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedWithoutSubjectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">tkmr:CommonSharesIssuedWithoutSubjectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-03</xbrli:startDate>
      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-03_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FairValueByAssetClassAxis-FiniteLivedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-03</xbrli:startDate>
      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-04_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tkmr:ArbutusStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-04</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-04_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-04</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-25_2015-03-25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-25</xbrli:startDate>
      <xbrli:endDate>2015-03-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-25_2015-03-25_AwardTypeAxis-UnderwriterOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tkmr:UnderwriterOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-25</xbrli:startDate>
      <xbrli:endDate>2015-03-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-AcuitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:AcuitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-BMSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BMSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-SpectrumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:SpectrumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_ProductOrServiceAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-05-01_2015-05-31_CounterpartyNameAxis-DoDMember_TypeOfArrangementAxis-ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tkmr:ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-05-01_2015-05-31_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-05-01_2015-05-31_InvestmentTypeAxis-TermDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tkmr:TermDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30_BusinessAcquisitionAxis-ArbutusIncMember_StatementScenarioAxis-ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2010-05-10_CounterpartyNameAxis-BMSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BMSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-05-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2010-07-14_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2010-07-14_RangeAxis-MaximumMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ContractExtensionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:ContractExtensionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-08-09_CounterpartyNameAxis-TalonTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:TalonTherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-05-08_CounterpartyNameAxis-DoDMember_StatementScenarioAxis-IncreaseToSupportDevelopmentPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">tkmr:IncreaseToSupportDevelopmentPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-05-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-06-21_GainContingenciesByNatureAxis-PositiveOutcomeOfLitigationMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-AlnylamLicenseAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">us-gaap:PositiveOutcomeOfLitigationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tkmr:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-02-28_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DrexelAndBlumbergMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-04-22_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-04-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-04-22_CounterpartyNameAxis-DoDMember_StatementScenarioAxis-IncreasedFundingForStageOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">tkmr:IncreasedFundingForStageOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-04-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-06-30_ProductOrServiceAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-09-30_CounterpartyNameAxis-NeuroviveMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:NeuroviveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-10-31_BusinessAcquisitionAxis-EnantigenMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:EnantigenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-10-31_CounterpartyNameAxis-BlumbergMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:BlumbergMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-10-31_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-11-16_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-11-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-11-30_CounterpartyNameAxis-DrexelAndBlumbergMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DrexelAndBlumbergMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-30_CounterpartyNameAxis-CytosMember_LegalEntityAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:CytosMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-01-11_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-01-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedSubjectToRepurchaseProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">tkmr:CommonSharesIssuedSubjectToRepurchaseProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonSharesIssuedWithoutSubjectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">tkmr:CommonSharesIssuedWithoutSubjectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_EquityInterestIssuedOrIssuableByTypeAxis-SharesIssuableForArbutusStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">tkmr:SharesIssuableForArbutusStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-AntigenInhibitorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tkmr:AntigenInhibitorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-CccdnaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tkmr:CccdnaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-CyclophilinsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tkmr:CyclophilinsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03_BusinessAcquisitionAxis-ArbutusIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis-ImmuneModulatorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tkmr:ImmuneModulatorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-05-31_InvestmentTypeAxis-TermDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tkmr:TermDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_AwardTypeAxis-ArbutusStockOptionsMember_BusinessAcquisitionAxis-ArbutusIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tkmr:ArbutusStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_BusinessAcquisitionAxis-ArbutusIncMember_StatementScenarioAxis-SubjectToRepurchaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tkmr:ArbutusIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">tkmr:SubjectToRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_CounterpartyNameAxis-DicernaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DicernaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_CounterpartyNameAxis-DoDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:DoDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_CounterpartyNameAxis-MonsantoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tkmr:MonsantoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_ProductOrServiceAxis-MarqiboMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tkmr:MarqiboMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30_VariableInterestEntitiesByClassificationOfEntityAxis-PADCoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">tkmr:PADCoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-07-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>tkmr-20150630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:02PM UTC 2015-08-07--><xsd:schema xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:tkmr="http://www.tekmirapharm.com/20150630" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.tekmirapharm.com/20150630">
  <xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tkmr-20150630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tkmr-20150630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tkmr-20150630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tkmr-20150630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.tekmirapharm.com/20150630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-unaudited" roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flow-unaudited" roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business-and-future-operations" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Nature of Business and Future Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-collaborations-contracts-and-licensing-agreements" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Collaborations, Contracts and Licensing Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accounts-payable-and-accrued-liabilities" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Document - Note 5 - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-financing" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Financing</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-concentrations-of-credit-risk" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Concentrations of Credit Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-contingencies-and-commitments" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Contingencies and Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.tekmirapharm.com/20150630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-tables" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 2 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-collaborations-contracts-and-licensing-agreements-tables" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 4 - Collaborations, Contracts and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accounts-payable-and-accrued-liabilities-tables" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 5 - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business-and-future-operations-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 1 - Nature of Business and Future Operations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-assets-and-liabilities-measured-at-fair-value-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Statement - Note 2 - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-changes-in-fair-value-of-the-companys-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Statement - Note 2 - Changes in Fair Value of the Company's Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-blackscholes-optionpricing-assumptions-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-blackscholes-optionpricing-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Statement - Note 2 - Black-Scholes Option-pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-business-acquistion-assets-and-liabilities-transferred-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Statement - Note 3 - Business Acquistion Assets and Liabilities Transferred (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-summary-of-acquired-identifiable-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Statement - Note 3 - Summary of Acquired Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-pro-forma-financial-information-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-pro-forma-financial-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Statement - Note 3 - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 4 - Collaborations, Contracts and Licensing Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Statement - Note 4 - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-deferred-collaborations-and-contracts-revenue-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-deferred-collaborations-and-contracts-revenue-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Statement - Note 4 - Deferred Collaborations and Contracts Revenue (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accounts-payable-and-accrued-liabilities-details" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Statement - Note 5 - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-financing-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 6 - Financing (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-concentrations-of-credit-risk-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 7 - Concentrations of Credit Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-contingencies-and-commitments-details-textual" roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 8 - Contingencies and Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tkmr_AccruedContractRevenuePercentage" name="AccruedContractRevenuePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_AccruedLicenseFeeAccruals" name="AccruedLicenseFeeAccruals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="tkmr_AcuitasMember" name="AcuitasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_AlnylamLicenseAgreementMember" name="AlnylamLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_AntigenInhibitorsMember" name="AntigenInhibitorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_ApproximateOptionPeriod" name="ApproximateOptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" name="ArbitrationWithTheUniversityOfBritishColumbiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ArbutusIncMember" name="ArbutusIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ArbutusStockOptionsMember" name="ArbutusStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ArcturusMember" name="ArcturusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_BMSMember" name="BMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_BlumbergMember" name="BlumbergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" name="BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" name="BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" name="BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" name="BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" name="BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="tkmr_CccdnaMember" name="CccdnaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" name="ChangesInFairValueOfWarrantsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_CollaborativeArrangementTerm" name="CollaborativeArrangementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" name="CommonSharesIssuedSubjectToRepurchaseProvisionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_CommonSharesIssuedWithoutSubjectsMember" name="CommonSharesIssuedWithoutSubjectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ContractExtensionMember" name="ContractExtensionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" name="ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_ContractualObligationAmountOfResearchFundingPerYear" name="ContractualObligationAmountOfResearchFundingPerYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_CumulativeContributionForProduct" name="CumulativeContributionForProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_CyclophilinsMember" name="CyclophilinsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_CytosMember" name="CytosMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_DicernaMember" name="DicernaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_DoDMember" name="DoDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_DrexelAndBlumbergMember" name="DrexelAndBlumbergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_EnantigenMember" name="EnantigenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_ExtendedOptionPeriod" name="ExtendedOptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_FairValueOfWarrantsExercisedInThePeriod" name="FairValueOfWarrantsExercisedInThePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_FairValueOfWarrantsOutstandingPerWarrant" name="FairValueOfWarrantsOutstandingPerWarrant" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_FairValueWarrantsForeignExchangeGainLoss" name="FairValueWarrantsForeignExchangeGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_ImmuneModulatorMember" name="ImmuneModulatorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_IncreaseDecreaseInValueOfWarrants" name="IncreaseDecreaseInValueOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_IncreaseToSupportDevelopmentPlansMember" name="IncreaseToSupportDevelopmentPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_IncreasedFundingForStageOneMember" name="IncreasedFundingForStageOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_LicenseAgreementEarlyTerminationFee" name="LicenseAgreementEarlyTerminationFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" name="LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="tkmr_MarinaMember" name="MarinaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_MarqiboMember" name="MarqiboMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_MaturityOfInvestments" name="MaturityOfInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_MaximumContributionForProduct" name="MaximumContributionForProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_MaximumPotentialTransactionValue" name="MaximumPotentialTransactionValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_MaximumPotentialTransactionValueForExtensionPeriod" name="MaximumPotentialTransactionValueForExtensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_MilestonePayments" name="MilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_MonsantoMember" name="MonsantoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_NearTermContractPayments" name="NearTermContractPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_NeuroviveMember" name="NeuroviveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" name="NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_OptionalExcercisedContractualOptionAmount" name="OptionalExcercisedContractualOptionAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="tkmr_PADCoMember" name="PADCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_PercentOfCostsFundedByTPC" name="PercentOfCostsFundedByTPC" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_PotentialContractFundingAmount" name="PotentialContractFundingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_PotentialContractFundingAmountIncrease" name="PotentialContractFundingAmountIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_PotentialProceedsOfAdditionalSharesAuthorized" name="PotentialProceedsOfAdditionalSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" name="RelatedToTheExpirationOfRepurchaseProvisionRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" name="ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" name="ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" name="ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_ResearchFundingPeriod" name="ResearchFundingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_RevenueRecognitionPerformancePeriod" name="RevenueRecognitionPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_RoyaltiesPaidOrAccrued" name="RoyaltiesPaidOrAccrued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_RoyaltyPayable" name="RoyaltyPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_RoyaltyguaranteesCommitmentsPercentage" name="RoyaltyguaranteesCommitmentsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_SharesIssuableForArbutusStockOptionsMember" name="SharesIssuableForArbutusStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_SpectrumMember" name="SpectrumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_StockRepurchaseRightsExpirationRateShares" name="StockRepurchaseRightsExpirationRateShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_SubjectToRepurchaseMember" name="SubjectToRepurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_TalonTherapeuticsMember" name="TalonTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_TermDepositMember" name="TermDepositMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_UnderwriterOptionsMember" name="UnderwriterOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_UpfrontFee" name="UpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="tkmr_WhollyOwnedSubsidiaries" name="WhollyOwnedSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" name="WhollyOwnedSubsidiariesIncludedInFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" name="statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" name="statement-statement-note-2-blackscholes-optionpricing-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" name="statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-2-significant-accounting-policies-tables" name="statement-statement-note-2-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" name="statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" name="statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-3-pro-forma-financial-information-details" name="statement-statement-note-3-pro-forma-financial-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" name="statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" name="statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" name="statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" name="statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" name="statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" name="statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="tkmr_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>tkmr-20150630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:03PM UTC 2015-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:href="tkmr-20150630.xsd#statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-balance-sheets-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicensesRevenue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_ContractsRevenue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedLicenseFeeAccruals" xlink:label="tkmr_AccruedLicenseFeeAccruals" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedResearchAndDevelopment" xlink:label="tkmr_AccruedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="tkmr_AccruedResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="tkmr_AccruedLicenseFeeAccruals" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>tkmr-20150630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:03PM UTC 2015-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-document-and-entity-information" xlink:href="tkmr-20150630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations" xlink:href="tkmr-20150630.xsd#statement-note-1-nature-of-business-and-future-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies" xlink:href="tkmr-20150630.xsd#statement-note-2-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TermDepositMember" xlink:label="tkmr_TermDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tkmr_TermDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" xlink:href="tkmr-20150630.xsd#statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusStockOptionsMember" xlink:label="tkmr_ArbutusStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SubjectToRepurchaseMember" xlink:label="tkmr_SubjectToRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="tkmr_SubjectToRepurchaseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tkmr_ArbutusStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements" xlink:href="tkmr-20150630.xsd#statement-note-4-collaborations-contracts-and-licensing-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AlnylamLicenseAgreementMember" xlink:label="tkmr_AlnylamLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractExtensionMember" xlink:label="tkmr_ContractExtensionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreasedFundingForStageOneMember" xlink:label="tkmr_IncreasedFundingForStageOneMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PADCoMember" xlink:label="tkmr_PADCoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TalonTherapeuticsMember" xlink:label="tkmr_TalonTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PositiveOutcomeOfLitigationMember" xlink:label="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="tkmr_PADCoMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_BMSMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="tkmr_IncreasedFundingForStageOneMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tkmr_ContractExtensionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tkmr_AlnylamLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GainContingenciesByNatureAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingencyNatureDomain" xlink:to="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingencyNatureDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_TalonTherapeuticsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingencyNatureDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing" xlink:href="tkmr-20150630.xsd#statement-note-6-financing" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UnderwriterOptionsMember" xlink:label="tkmr_UnderwriterOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tkmr_UnderwriterOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk" xlink:href="tkmr-20150630.xsd#statement-note-7-concentrations-of-credit-risk" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments" xlink:href="tkmr-20150630.xsd#statement-note-8-contingencies-and-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArcturusMember" xlink:label="tkmr_ArcturusMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BlumbergMember" xlink:label="tkmr_BlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CytosMember" xlink:label="tkmr_CytosMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DrexelAndBlumbergMember" xlink:label="tkmr_DrexelAndBlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_EnantigenMember" xlink:label="tkmr_EnantigenMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarinaMember" xlink:label="tkmr_MarinaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NeuroviveMember" xlink:label="tkmr_NeuroviveMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_BlumbergMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_MarinaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_ArcturusMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_EnantigenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DrexelAndBlumbergMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_NeuroviveMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_CytosMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-significant-accounting-policies-policies" xlink:href="tkmr-20150630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-tables" xlink:href="tkmr-20150630.xsd#statement-note-2-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:label="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:href="tkmr-20150630.xsd#statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:href="tkmr-20150630.xsd#statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-1-nature-of-business-and-future-operations-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_WhollyOwnedSubsidiaries" xlink:label="tkmr_WhollyOwnedSubsidiaries" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_WhollyOwnedSubsidiaries" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-2-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaturityOfInvestments" xlink:label="tkmr_MaturityOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TermDepositMember" xlink:label="tkmr_TermDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:label="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tkmr_TermDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaturityOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusStockOptionsMember" xlink:label="tkmr_ArbutusStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:label="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:label="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:label="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_StockRepurchaseRightsExpirationRateShares" xlink:label="tkmr_StockRepurchaseRightsExpirationRateShares" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SubjectToRepurchaseMember" xlink:label="tkmr_SubjectToRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="tkmr_SubjectToRepurchaseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tkmr_ArbutusStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_StockRepurchaseRightsExpirationRateShares" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedContractRevenuePercentage" xlink:label="tkmr_AccruedContractRevenuePercentage" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AlnylamLicenseAgreementMember" xlink:label="tkmr_AlnylamLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ApproximateOptionPeriod" xlink:label="tkmr_ApproximateOptionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CollaborativeArrangementTerm" xlink:label="tkmr_CollaborativeArrangementTerm" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractExtensionMember" xlink:label="tkmr_ContractExtensionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ExtendedOptionPeriod" xlink:label="tkmr_ExtendedOptionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreasedFundingForStageOneMember" xlink:label="tkmr_IncreasedFundingForStageOneMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumPotentialTransactionValue" xlink:label="tkmr_MaximumPotentialTransactionValue" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:label="tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MilestonePayments" xlink:label="tkmr_MilestonePayments" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NearTermContractPayments" xlink:label="tkmr_NearTermContractPayments" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_OptionalExcercisedContractualOptionAmount" xlink:label="tkmr_OptionalExcercisedContractualOptionAmount" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PADCoMember" xlink:label="tkmr_PADCoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialContractFundingAmount" xlink:label="tkmr_PotentialContractFundingAmount" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialContractFundingAmountIncrease" xlink:label="tkmr_PotentialContractFundingAmountIncrease" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RevenueRecognitionPerformancePeriod" xlink:label="tkmr_RevenueRecognitionPerformancePeriod" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TalonTherapeuticsMember" xlink:label="tkmr_TalonTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PositiveOutcomeOfLitigationMember" xlink:label="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:label="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="tkmr_PADCoMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_BMSMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="tkmr_IncreasedFundingForStageOneMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tkmr_ContractExtensionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tkmr_AlnylamLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GainContingenciesByNatureAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingencyNatureDomain" xlink:to="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingencyNatureDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_TalonTherapeuticsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingencyNatureDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_CollaborativeArrangementTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RevenueRecognitionPerformancePeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PotentialContractFundingAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PotentialContractFundingAmountIncrease" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_OptionalExcercisedContractualOptionAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ApproximateOptionPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaximumPotentialTransactionValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ExtendedOptionPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_NearTermContractPayments" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicensesRevenue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainContingencyUnrecordedAmount" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MilestonePayments" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_AccruedContractRevenuePercentage" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-6-financing-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:label="tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:label="tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UnderwriterOptionsMember" xlink:label="tkmr_UnderwriterOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tkmr_UnderwriterOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-7-concentrations-of-credit-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-8-contingencies-and-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArcturusMember" xlink:label="tkmr_ArcturusMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BlumbergMember" xlink:label="tkmr_BlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CumulativeContributionForProduct" xlink:label="tkmr_CumulativeContributionForProduct" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CytosMember" xlink:label="tkmr_CytosMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DrexelAndBlumbergMember" xlink:label="tkmr_DrexelAndBlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_EnantigenMember" xlink:label="tkmr_EnantigenMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementEarlyTerminationFee" xlink:label="tkmr_LicenseAgreementEarlyTerminationFee" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:label="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarinaMember" xlink:label="tkmr_MarinaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumContributionForProduct" xlink:label="tkmr_MaximumContributionForProduct" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MilestonePayments" xlink:label="tkmr_MilestonePayments" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NeuroviveMember" xlink:label="tkmr_NeuroviveMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PercentOfCostsFundedByTPC" xlink:label="tkmr_PercentOfCostsFundedByTPC" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingPeriod" xlink:label="tkmr_ResearchFundingPeriod" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltiesPaidOrAccrued" xlink:label="tkmr_RoyaltiesPaidOrAccrued" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltyPayable" xlink:label="tkmr_RoyaltyPayable" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:label="tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UpfrontFee" xlink:label="tkmr_UpfrontFee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_BlumbergMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_MarinaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_ArcturusMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_EnantigenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DrexelAndBlumbergMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_NeuroviveMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_CytosMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PercentOfCostsFundedByTPC" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaximumContributionForProduct" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_CumulativeContributionForProduct" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RoyaltyPayable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RoyaltiesPaidOrAccrued" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_UpfrontFee" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MilestonePayments" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicenseCosts" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_LicenseAgreementEarlyTerminationFee" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:href="tkmr-20150630.xsd#statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:label="tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:href="tkmr-20150630.xsd#statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:href="tkmr-20150630.xsd#statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AntigenInhibitorsMember" xlink:label="tkmr_AntigenInhibitorsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CccdnaMember" xlink:label="tkmr_CccdnaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CyclophilinsMember" xlink:label="tkmr_CyclophilinsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ImmuneModulatorMember" xlink:label="tkmr_ImmuneModulatorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tkmr_CyclophilinsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tkmr_ImmuneModulatorMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tkmr_AntigenInhibitorsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tkmr_CccdnaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:href="tkmr-20150630.xsd#statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:label="tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:label="tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseDecreaseInValueOfWarrants" xlink:label="tkmr_IncreaseDecreaseInValueOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_IncreaseDecreaseInValueOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-balance-sheets-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_UnbilledReceivablesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:label="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-pro-forma-financial-information-details" xlink:href="tkmr-20150630.xsd#statement-note-3-pro-forma-financial-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-pro-forma-financial-information-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:label="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:href="tkmr-20150630.xsd#statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AcuitasMember" xlink:label="tkmr_AcuitasMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SpectrumMember" xlink:label="tkmr_SpectrumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_BMSMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_AcuitasMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_SpectrumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_ContractsRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_LicensesRevenue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:href="tkmr-20150630.xsd#statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:label="tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:href="tkmr-20150630.xsd#statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedLicenseFeeAccruals" xlink:label="tkmr_AccruedLicenseFeeAccruals" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedResearchAndDevelopment" xlink:label="tkmr_AccruedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_AccruedResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_AccruedLicenseFeeAccruals" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncentivePayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>tkmr-20150630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:02PM UTC 2015-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DocumentAndEntityInformation" xlink:label="tkmr_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="tkmr_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_DocumentAndEntityInformation" xlink:to="tkmr_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="tkmr_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="tkmr_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PADCoMember" xlink:label="tkmr_PADCoMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_PADCoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PADCo [Member]</link:label>
    <link:label xlink:label="tkmr_PADCoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PADCo, a wholly-owned subsidiary accounted for as a variable interest entity for which the company is not the primary beneficiary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_PADCoMember" xlink:to="tkmr_PADCoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-significant-accounting-policies-policies" xlink:label="tkmr_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-significant-accounting-policies-policies" xlink:to="tkmr_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-significant-accounting-policies-tables" xlink:label="tkmr_statement-statement-note-2-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-2-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2significantaccountingpoliciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-2-significant-accounting-policies-tables" xlink:to="tkmr_statement-statement-note-2-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:label="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote3mergerwitharbutusbiopharmaincformerlyoncorebiopharmainctables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:to="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RevenueRecognitionPerformancePeriod" xlink:label="tkmr_RevenueRecognitionPerformancePeriod" xlink:type="locator"/>
    <link:label xlink:label="tkmr_RevenueRecognitionPerformancePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_RevenueRecognitionPerformancePeriod</link:label>
    <link:label xlink:label="tkmr_RevenueRecognitionPerformancePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Performance Period</link:label>
    <link:label xlink:label="tkmr_RevenueRecognitionPerformancePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the performance period for revenue recognition.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_RevenueRecognitionPerformancePeriod" xlink:to="tkmr_RevenueRecognitionPerformancePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:label="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4collaborationscontractsandlicensingagreementstables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:to="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CollaborativeArrangementTerm" xlink:label="tkmr_CollaborativeArrangementTerm" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CollaborativeArrangementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_CollaborativeArrangementTerm</link:label>
    <link:label xlink:label="tkmr_CollaborativeArrangementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label xlink:label="tkmr_CollaborativeArrangementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the term of a collaborative arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CollaborativeArrangementTerm" xlink:to="tkmr_CollaborativeArrangementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:label="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5accountspayableandaccruedliabilitiestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:to="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:label="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2assetsandliabilitiesmeasuredatfairvaluedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:to="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:label="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2changesinfairvalueofthecompanyswarrantsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:to="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:label="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2blackscholesoptionpricingassumptionsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:to="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromWarrantExercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UnderwriterOptionsMember" xlink:label="tkmr_UnderwriterOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_UnderwriterOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter Options [Member]</link:label>
    <link:label xlink:label="tkmr_UnderwriterOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents underwriter options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_UnderwriterOptionsMember" xlink:to="tkmr_UnderwriterOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDamagesSoughtValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyDamagesSoughtValue</link:label>
    <link:label xlink:label="us-gaap_LossContingencyDamagesSoughtValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:label="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote3businessacquistionassetsandliabilitiestransferreddetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:to="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:label="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote3summaryofacquiredidentifiableintangibleassetsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:to="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-pro-forma-financial-information-details" xlink:label="tkmr_statement-statement-note-3-pro-forma-financial-information-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-3-pro-forma-financial-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote3proformafinancialinformationdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-3-pro-forma-financial-information-details" xlink:to="tkmr_statement-statement-note-3-pro-forma-financial-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:label="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4revenuerecognizedundercollaborationscontractsandlicensingagreementsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:to="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:label="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4deferredcollaborationsandcontractsrevenuedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:to="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:label="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5accountspayableandaccruedliabilitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:to="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="tkmr_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="tkmr_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatements" xlink:label="tkmr_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="tkmr_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_NotesToFinancialStatements" xlink:to="tkmr_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of Arbutus Inc. excluding cash acquired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_WhollyOwnedSubsidiaries" xlink:label="tkmr_WhollyOwnedSubsidiaries" xlink:type="locator"/>
    <link:label xlink:label="tkmr_WhollyOwnedSubsidiaries-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_WhollyOwnedSubsidiaries</link:label>
    <link:label xlink:label="tkmr_WhollyOwnedSubsidiaries-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholly Owned Subsidiaries</link:label>
    <link:label xlink:label="tkmr_WhollyOwnedSubsidiaries-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of subsidiaries wholly owned by an entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_WhollyOwnedSubsidiaries" xlink:to="tkmr_WhollyOwnedSubsidiaries-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledReceivablesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:label="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised</link:label>
    <link:label xlink:label="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised on a cashless basis</link:label>
    <link:label xlink:label="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value of warrants issued and exercised on a cashless basis. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:to="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investments (note 2)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash transactions:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, development, collaborations and contracts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionsProFormaRevenue</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainContingencyNatureDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyNatureDomain" xlink:to="us-gaap_GainContingencyNatureDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PositiveOutcomeOfLitigationMember" xlink:label="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PositiveOutcomeOfLitigationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Positive Outcome of Litigation [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PositiveOutcomeOfLitigationMember" xlink:to="us-gaap_PositiveOutcomeOfLitigationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pro forma information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2014</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, June 30, 2015</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainContingenciesByNatureAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingenciesByNatureAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreasedFundingForStageOneMember" xlink:label="tkmr_IncreasedFundingForStageOneMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_IncreasedFundingForStageOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Funding for Stage One [Member]</link:label>
    <link:label xlink:label="tkmr_IncreasedFundingForStageOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of increased funding for stage one of a contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_IncreasedFundingForStageOneMember" xlink:to="tkmr_IncreasedFundingForStageOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_DoDMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DoD [Member]</link:label>
    <link:label xlink:label="tkmr_DoDMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Name of counterparty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_DoDMember" xlink:to="tkmr_DoDMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NearTermContractPayments" xlink:label="tkmr_NearTermContractPayments" xlink:type="locator"/>
    <link:label xlink:label="tkmr_NearTermContractPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_NearTermContractPayments</link:label>
    <link:label xlink:label="tkmr_NearTermContractPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Near Term Contract Payments</link:label>
    <link:label xlink:label="tkmr_NearTermContractPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments which are near term in a contract agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_NearTermContractPayments" xlink:to="tkmr_NearTermContractPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionSharePrice</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2014 (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, June 30, 2015 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumPotentialTransactionValue" xlink:label="tkmr_MaximumPotentialTransactionValue" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MaximumPotentialTransactionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_MaximumPotentialTransactionValue</link:label>
    <link:label xlink:label="tkmr_MaximumPotentialTransactionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Potential Transaction Value</link:label>
    <link:label xlink:label="tkmr_MaximumPotentialTransactionValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum potential transaction value between entities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MaximumPotentialTransactionValue" xlink:to="tkmr_MaximumPotentialTransactionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional fee accruals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US"/>
    <link:label xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TermDepositMember" xlink:label="tkmr_TermDepositMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_TermDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Deposit [Member]</link:label>
    <link:label xlink:label="tkmr_TermDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A deposit held at a financial institution that has a fixed term. When a term deposit is purchased, the lender (the customer) understands that the money can only be withdrawn after the term has ended or by giving a predetermined number of days notice.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_TermDepositMember" xlink:to="tkmr_TermDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired and liabilities assumed:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseIncentivePayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred lease inducements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentivePayableCurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants (note 2)</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of warrants outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MarqiboMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marqibo [Member]</link:label>
    <link:label xlink:label="tkmr_MarqiboMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MarqiboMember" xlink:to="tkmr_MarqiboMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableTradeCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AlnylamLicenseAgreementMember" xlink:label="tkmr_AlnylamLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_AlnylamLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alnylam License Agreement [Member]</link:label>
    <link:label xlink:label="tkmr_AlnylamLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_AlnylamLicenseAgreementMember" xlink:to="tkmr_AlnylamLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TalonTherapeuticsMember" xlink:label="tkmr_TalonTherapeuticsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_TalonTherapeuticsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Talon Therapeutics [Member]</link:label>
    <link:label xlink:label="tkmr_TalonTherapeuticsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of the counterparty in an agreement with the entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_TalonTherapeuticsMember" xlink:to="tkmr_TalonTherapeuticsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingPeriod" xlink:label="tkmr_ResearchFundingPeriod" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ResearchFundingPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ResearchFundingPeriod</link:label>
    <link:label xlink:label="tkmr_ResearchFundingPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Funding Period</link:label>
    <link:label xlink:label="tkmr_ResearchFundingPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about the research funding period under the research collaboration and funding agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ResearchFundingPeriod" xlink:to="tkmr_ResearchFundingPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BMSMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BMS [Member]</link:label>
    <link:label xlink:label="tkmr_BMSMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Name of counterparty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BMSMember" xlink:to="tkmr_BMSMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AcuitasMember" xlink:label="tkmr_AcuitasMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_AcuitasMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acuitas [Member]</link:label>
    <link:label xlink:label="tkmr_AcuitasMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Name of counterparty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_AcuitasMember" xlink:to="tkmr_AcuitasMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:label="tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MaximumPotentialTransactionValueForExtensionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_MaximumPotentialTransactionValueForExtensionPeriod</link:label>
    <link:label xlink:label="tkmr_MaximumPotentialTransactionValueForExtensionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Potential Transaction Value for Extension Period</link:label>
    <link:label xlink:label="tkmr_MaximumPotentialTransactionValueForExtensionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum potential transaction value for the extended period for the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:to="tkmr_MaximumPotentialTransactionValueForExtensionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MonsantoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monsanto [Member]</link:label>
    <link:label xlink:label="tkmr_MonsantoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of a counterparty in an agreement with the entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MonsantoMember" xlink:to="tkmr_MonsantoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentNet</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill (note 3)</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ExtendedOptionPeriod" xlink:label="tkmr_ExtendedOptionPeriod" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ExtendedOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ExtendedOptionPeriod</link:label>
    <link:label xlink:label="tkmr_ExtendedOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended Option Period</link:label>
    <link:label xlink:label="tkmr_ExtendedOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the extended period for the option agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ExtendedOptionPeriod" xlink:to="tkmr_ExtendedOptionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RoyaltyRevenue</link:label>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:label="tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:type="locator"/>
    <link:label xlink:label="tkmr_FairValueOfWarrantsExercisedInThePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_FairValueOfWarrantsExercisedInThePeriod</link:label>
    <link:label xlink:label="tkmr_FairValueOfWarrantsExercisedInThePeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised in the period</link:label>
    <link:label xlink:label="tkmr_FairValueOfWarrantsExercisedInThePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amounts of gains and losses from fair value changes included in warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:to="tkmr_FairValueOfWarrantsExercisedInThePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseDecreaseInValueOfWarrants" xlink:label="tkmr_IncreaseDecreaseInValueOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="tkmr_IncreaseDecreaseInValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in fair value of warrants</link:label>
    <link:label xlink:label="tkmr_IncreaseDecreaseInValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase decrease in value of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_IncreaseDecreaseInValueOfWarrants" xlink:to="tkmr_IncreaseDecreaseInValueOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CyclophilinsMember" xlink:label="tkmr_CyclophilinsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CyclophilinsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cyclophilins [Member]</link:label>
    <link:label xlink:label="tkmr_CyclophilinsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about the Company's products.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CyclophilinsMember" xlink:to="tkmr_CyclophilinsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities (note 8)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:label="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ChangesInFairValueOfWarrantsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrants [Table Text Block]</link:label>
    <link:label xlink:label="tkmr_ChangesInFairValueOfWarrantsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure on changes in fair value of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:to="tkmr_ChangesInFairValueOfWarrantsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CccdnaMember" xlink:label="tkmr_CccdnaMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CccdnaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cccDNA [Member]</link:label>
    <link:label xlink:label="tkmr_CccdnaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by products and services or groups of similar products and services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CccdnaMember" xlink:to="tkmr_CccdnaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:label="tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:type="locator"/>
    <link:label xlink:label="tkmr_FairValueWarrantsForeignExchangeGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label xlink:label="tkmr_FairValueWarrantsForeignExchangeGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gains and losses from changes in foreign exchanges.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:to="tkmr_FairValueWarrantsForeignExchangeGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ImmuneModulatorMember" xlink:label="tkmr_ImmuneModulatorMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ImmuneModulatorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immune Modulator [Member]</link:label>
    <link:label xlink:label="tkmr_ImmuneModulatorMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by products and services or groups of similar products and services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ImmuneModulatorMember" xlink:to="tkmr_ImmuneModulatorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AntigenInhibitorsMember" xlink:label="tkmr_AntigenInhibitorsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_AntigenInhibitorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antigen Inhibitors [Member]</link:label>
    <link:label xlink:label="tkmr_AntigenInhibitorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by products and services or groups of similar products and services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_AntigenInhibitorsMember" xlink:to="tkmr_AntigenInhibitorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term investments (note 2)</link:label>
    <link:label xlink:label="us-gaap_LongTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="us-gaap_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss per common share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaturityOfInvestments" xlink:label="tkmr_MaturityOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_MaturityOfInvestments</link:label>
    <link:label xlink:label="tkmr_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of Investments</link:label>
    <link:label xlink:label="tkmr_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between issuance and maturity of Investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MaturityOfInvestments" xlink:to="tkmr_MaturityOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:label="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense</link:label>
    <link:label xlink:label="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Post Combination Compensation Expense</link:label>
    <link:label xlink:label="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity, of which will be attributed as post-combination compensation expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:to="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares issued subject to repurchase provision</link:label>
    <link:label xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Pre Combination Service and Included as Part of Total Purchase Price</link:label>
    <link:label xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity, of which has been attributed as pre-combination service and included as part of the total purchase price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:to="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ArbutusIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:label xlink:label="tkmr_ArbutusIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the business Arbutus Inc. (formerly OnCore BioPharma, Inc.).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ArbutusIncMember" xlink:to="tkmr_ArbutusIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:label="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares</link:label>
    <link:label xlink:label="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Compensation Expense Related to Vesting of Shares</link:label>
    <link:label xlink:label="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate amount of compensation expense related to the vesting of shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:to="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:label="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements</link:label>
    <link:label xlink:label="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholly Owned Subsidiaries Included in Financial Statements</link:label>
    <link:label xlink:label="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:to="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:label="tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:type="locator"/>
    <link:label xlink:label="tkmr_FairValueOfWarrantsOutstandingPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_FairValueOfWarrantsOutstandingPerWarrant</link:label>
    <link:label xlink:label="tkmr_FairValueOfWarrantsOutstandingPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants outstanding (in dollars per share)</link:label>
    <link:label xlink:label="tkmr_FairValueOfWarrantsOutstandingPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of the warrants outstanding per warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:to="tkmr_FairValueOfWarrantsOutstandingPerWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ApproximateOptionPeriod" xlink:label="tkmr_ApproximateOptionPeriod" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ApproximateOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ApproximateOptionPeriod</link:label>
    <link:label xlink:label="tkmr_ApproximateOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Approximate Option Period</link:label>
    <link:label xlink:label="tkmr_ApproximateOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The approximate term of options agreed between two entities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ApproximateOptionPeriod" xlink:to="tkmr_ApproximateOptionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:label xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability at end of the period</link:label>
    <link:label xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets (note 3)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialContractFundingAmount" xlink:label="tkmr_PotentialContractFundingAmount" xlink:type="locator"/>
    <link:label xlink:label="tkmr_PotentialContractFundingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_PotentialContractFundingAmount</link:label>
    <link:label xlink:label="tkmr_PotentialContractFundingAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Contract Funding Amount</link:label>
    <link:label xlink:label="tkmr_PotentialContractFundingAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of funding an entity could potentially earn in a contract agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_PotentialContractFundingAmount" xlink:to="tkmr_PotentialContractFundingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment tax credits receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromInvestments</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposition (acquisition) of short and long-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Issued Without Subjects [Member]</link:label>
    <link:label xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the common shares issued without subjects, in relation to the merger with OnCore Biopharma, Inc. (OnCore).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares in conjunction with the private offering, net of issuance costs of $9,700,000</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Issued Subject to Repurchase Provision [Member]</link:label>
    <link:label xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the common shares issued subject to repurchase provision, in relation to the merger with OnCore Biopharma, Inc. (OnCore).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusStockOptionsMember" xlink:label="tkmr_ArbutusStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ArbutusStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbutus Stock Options [Member]</link:label>
    <link:label xlink:label="tkmr_ArbutusStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Arbutus stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ArbutusStockOptionsMember" xlink:to="tkmr_ArbutusStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items not involving cash:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligation</link:label>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net change in non-cash operating items:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:label="tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_SharesIssuableForArbutusStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issuable for Arbutus Stock Options [Member]</link:label>
    <link:label xlink:label="tkmr_SharesIssuableForArbutusStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shares issuable for Arbutus stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:to="tkmr_SharesIssuableForArbutusStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities</link:label>
    <link:label xlink:label="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label xlink:label="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the accrued liabilities and accounts payable assumed in the business acquisition.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:to="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:label="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted</link:label>
    <link:label xlink:label="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share (in dollars per share)</link:label>
    <link:label xlink:label="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:to="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_OptionalExcercisedContractualOptionAmount" xlink:label="tkmr_OptionalExcercisedContractualOptionAmount" xlink:type="locator"/>
    <link:label xlink:label="tkmr_OptionalExcercisedContractualOptionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_OptionalExcercisedContractualOptionAmount</link:label>
    <link:label xlink:label="tkmr_OptionalExcercisedContractualOptionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optional Exercised Contractual Option, Amount</link:label>
    <link:label xlink:label="tkmr_OptionalExcercisedContractualOptionAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of an option exercise that was embedded in a contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_OptionalExcercisedContractualOptionAmount" xlink:to="tkmr_OptionalExcercisedContractualOptionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedContractRevenuePercentage" xlink:label="tkmr_AccruedContractRevenuePercentage" xlink:type="locator"/>
    <link:label xlink:label="tkmr_AccruedContractRevenuePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_AccruedContractRevenuePercentage</link:label>
    <link:label xlink:label="tkmr_AccruedContractRevenuePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Contract Revenue, Percentage</link:label>
    <link:label xlink:label="tkmr_AccruedContractRevenuePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of revenue from accrued contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_AccruedContractRevenuePercentage" xlink:to="tkmr_AccruedContractRevenuePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsExpectedTerm</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to Support Development Plans [Member]</link:label>
    <link:label xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the increase funding potential to support development plans that integrate recent advancements in lipid nanoparticle (&#8220;LNP&#8221;) formulation and manufacturing technologies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:to="tkmr_IncreaseToSupportDevelopmentPlansMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractExtensionMember" xlink:label="tkmr_ContractExtensionMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ContractExtensionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Extension [Member]</link:label>
    <link:label xlink:label="tkmr_ContractExtensionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the contract extension.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ContractExtensionMember" xlink:to="tkmr_ContractExtensionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsExpectedDividendRate</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_DicernaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dicerna [Member]</link:label>
    <link:label xlink:label="tkmr_DicernaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Dicerna Pharmaceuticals.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_DicernaMember" xlink:to="tkmr_DicernaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange (gains) losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedLicenseFeeAccruals" xlink:label="tkmr_AccruedLicenseFeeAccruals" xlink:type="locator"/>
    <link:label xlink:label="tkmr_AccruedLicenseFeeAccruals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License fee accruals</link:label>
    <link:label xlink:label="tkmr_AccruedLicenseFeeAccruals-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for license fee accruals.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_AccruedLicenseFeeAccruals" xlink:to="tkmr_AccruedLicenseFeeAccruals-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAcquiredFromAcquisition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash acquired through acquisition (note 3)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesFairValueDisclosureRecurring</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:label="tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ProceedsFromIssuanceOfCommonStockNet</link:label>
    <link:label xlink:label="tkmr_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock, Net</link:label>
    <link:label xlink:label="tkmr_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:to="tkmr_ProceedsFromIssuanceOfCommonStockNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PercentOfCostsFundedByTPC" xlink:label="tkmr_PercentOfCostsFundedByTPC" xlink:type="locator"/>
    <link:label xlink:label="tkmr_PercentOfCostsFundedByTPC-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_PercentOfCostsFundedByTPC</link:label>
    <link:label xlink:label="tkmr_PercentOfCostsFundedByTPC-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent Of Costs Funded by TPC</link:label>
    <link:label xlink:label="tkmr_PercentOfCostsFundedByTPC-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percent of costs funded by TPC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_PercentOfCostsFundedByTPC" xlink:to="tkmr_PercentOfCostsFundedByTPC-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ContractualObligationAmountOfResearchFundingPerYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ContractualObligationAmountOfResearchFundingPerYear</link:label>
    <link:label xlink:label="tkmr_ContractualObligationAmountOfResearchFundingPerYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Amount of Research Funding Per Year</link:label>
    <link:label xlink:label="tkmr_ContractualObligationAmountOfResearchFundingPerYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research funding the company is obligated to pay per year to a third party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:to="tkmr_ContractualObligationAmountOfResearchFundingPerYear-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:label="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:type="locator"/>
    <link:label xlink:label="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense</link:label>
    <link:label xlink:label="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Maximum Sales Performance Milestone Payments Per License</link:label>
    <link:label xlink:label="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum sales performance milestone payments due per license under a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:to="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueAcquisitions</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:type="locator"/>
    <link:label xlink:label="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense</link:label>
    <link:label xlink:label="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Maximum Development and Regulatory Milestone Payments Per License</link:label>
    <link:label xlink:label="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum development and regulatory milestone payments due per license under a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:to="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractsRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractsRevenue</link:label>
    <link:label xlink:label="us-gaap_ContractsRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborations and contracts</link:label>
    <link:label xlink:label="us-gaap_ContractsRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborations and contracts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue (note 4)</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementEarlyTerminationFee" xlink:label="tkmr_LicenseAgreementEarlyTerminationFee" xlink:type="locator"/>
    <link:label xlink:label="tkmr_LicenseAgreementEarlyTerminationFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_LicenseAgreementEarlyTerminationFee</link:label>
    <link:label xlink:label="tkmr_LicenseAgreementEarlyTerminationFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement Early Termination Fee</link:label>
    <link:label xlink:label="tkmr_LicenseAgreementEarlyTerminationFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of termination fee if the license agreement is terminated prior to the first commercial sale of any licensed product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_LicenseAgreementEarlyTerminationFee" xlink:to="tkmr_LicenseAgreementEarlyTerminationFee-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments</link:label>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right to Obtain Exclusive License, Maximum Commercialization Milestone Payments</link:label>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of commercialization milestone payments due if right to exclusive license is exercised under a research funding agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments</link:label>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right to Obtain Exclusive License Maximum Development and Regulatory Milestone Payments</link:label>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of development and regulatory milestone payments due if right to exclusive license is exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment</link:label>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right to Obtain Exclusive License Upfront Payment</link:label>
    <link:label xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of upfront payment required to exercise a right to an exclusive license under a research funding agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborations and contracts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArcturusMember" xlink:label="tkmr_ArcturusMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ArcturusMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arcturus [Member]</link:label>
    <link:label xlink:label="tkmr_ArcturusMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Arcturus Therapeutics.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ArcturusMember" xlink:to="tkmr_ArcturusMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DrexelAndBlumbergMember" xlink:label="tkmr_DrexelAndBlumbergMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_DrexelAndBlumbergMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drexel and Blumberg [Member]</link:label>
    <link:label xlink:label="tkmr_DrexelAndBlumbergMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The companies, Drexel and Blumberg.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_DrexelAndBlumbergMember" xlink:to="tkmr_DrexelAndBlumbergMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BlumbergMember" xlink:label="tkmr_BlumbergMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BlumbergMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blumberg [Member]</link:label>
    <link:label xlink:label="tkmr_BlumbergMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The company, Blumberg.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BlumbergMember" xlink:to="tkmr_BlumbergMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbitration With the University of British Columbia [Member]</link:label>
    <link:label xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to arbitration with the University of British Columbia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:to="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicensesRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LicensesRevenue</link:label>
    <link:label xlink:label="us-gaap_LicensesRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licensing fees, milestone and royalty payments</link:label>
    <link:label xlink:label="us-gaap_LicensesRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_EnantigenMember" xlink:label="tkmr_EnantigenMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_EnantigenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enantigen [Member]</link:label>
    <link:label xlink:label="tkmr_EnantigenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the company, Enantigen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_EnantigenMember" xlink:to="tkmr_EnantigenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NeuroviveMember" xlink:label="tkmr_NeuroviveMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_NeuroviveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NeuroVive [Member]</link:label>
    <link:label xlink:label="tkmr_NeuroviveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The company, NeuroVive.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_NeuroviveMember" xlink:to="tkmr_NeuroviveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CytosMember" xlink:label="tkmr_CytosMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CytosMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cytos [Member]</link:label>
    <link:label xlink:label="tkmr_CytosMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The company, Cytos Biotechnology Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CytosMember" xlink:to="tkmr_CytosMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarinaMember" xlink:label="tkmr_MarinaMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MarinaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marina [Member]</link:label>
    <link:label xlink:label="tkmr_MarinaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Name of counterparty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MarinaMember" xlink:to="tkmr_MarinaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment tax credits received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities</link:label>
    <link:label xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Nonconsolidated, Carrying Amount, Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:to="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares in conjunction with the private offering, issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets</link:label>
    <link:label xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Nonconsolidated, Carrying Amount, Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:to="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedResearchAndDevelopment" xlink:label="tkmr_AccruedResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="tkmr_AccruedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development accruals</link:label>
    <link:label xlink:label="tkmr_AccruedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_AccruedResearchAndDevelopment" xlink:to="tkmr_AccruedResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SpectrumMember" xlink:label="tkmr_SpectrumMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_SpectrumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spectrum [Member]</link:label>
    <link:label xlink:label="tkmr_SpectrumMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of the counterparty in an agreement with the entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_SpectrumMember" xlink:to="tkmr_SpectrumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:label="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Measure of Activity, Income or Loss before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:to="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesOther</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueOther</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumContributionForProduct" xlink:label="tkmr_MaximumContributionForProduct" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MaximumContributionForProduct-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_MaximumContributionForProduct</link:label>
    <link:label xlink:label="tkmr_MaximumContributionForProduct-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Contribution For Product</link:label>
    <link:label xlink:label="tkmr_MaximumContributionForProduct-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of contribution for a product in an agreement between an entity and the counterparty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MaximumContributionForProduct" xlink:to="tkmr_MaximumContributionForProduct-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CumulativeContributionForProduct" xlink:label="tkmr_CumulativeContributionForProduct" xlink:type="locator"/>
    <link:label xlink:label="tkmr_CumulativeContributionForProduct-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_CumulativeContributionForProduct</link:label>
    <link:label xlink:label="tkmr_CumulativeContributionForProduct-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Contribution for Product</link:label>
    <link:label xlink:label="tkmr_CumulativeContributionForProduct-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amount of contributions from an entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_CumulativeContributionForProduct" xlink:to="tkmr_CumulativeContributionForProduct-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:label="tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="tkmr_PotentialProceedsOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_PotentialProceedsOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="tkmr_PotentialProceedsOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Proceeds of Additional Shares Authorized</link:label>
    <link:label xlink:label="tkmr_PotentialProceedsOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential cash inflow from the additional capital contribution to the entity if an option is exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:to="tkmr_PotentialProceedsOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payroll accruals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used) in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities (note 5)</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:label="tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:type="locator"/>
    <link:label xlink:label="tkmr_RoyaltyguaranteesCommitmentsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_RoyaltyguaranteesCommitmentsPercentage</link:label>
    <link:label xlink:label="tkmr_RoyaltyguaranteesCommitmentsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Guarantees Commitments Percentage</link:label>
    <link:label xlink:label="tkmr_RoyaltyguaranteesCommitmentsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty guarantees commitments percentage.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:to="tkmr_RoyaltyguaranteesCommitmentsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltiesPaidOrAccrued" xlink:label="tkmr_RoyaltiesPaidOrAccrued" xlink:type="locator"/>
    <link:label xlink:label="tkmr_RoyaltiesPaidOrAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_RoyaltiesPaidOrAccrued</link:label>
    <link:label xlink:label="tkmr_RoyaltiesPaidOrAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties Paid or Accrued</link:label>
    <link:label xlink:label="tkmr_RoyaltiesPaidOrAccrued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cumulative amount of royalties paid or accrued of an entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_RoyaltiesPaidOrAccrued" xlink:to="tkmr_RoyaltiesPaidOrAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltyPayable" xlink:label="tkmr_RoyaltyPayable" xlink:type="locator"/>
    <link:label xlink:label="tkmr_RoyaltyPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_RoyaltyPayable</link:label>
    <link:label xlink:label="tkmr_RoyaltyPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Payable</link:label>
    <link:label xlink:label="tkmr_RoyaltyPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of royalty payable from an entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_RoyaltyPayable" xlink:to="tkmr_RoyaltyPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UpfrontFee" xlink:label="tkmr_UpfrontFee" xlink:type="locator"/>
    <link:label xlink:label="tkmr_UpfrontFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_UpfrontFee</link:label>
    <link:label xlink:label="tkmr_UpfrontFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Fee</link:label>
    <link:label xlink:label="tkmr_UpfrontFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of fees due upfront from an entity in an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_UpfrontFee" xlink:to="tkmr_UpfrontFee-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MilestonePayments" xlink:label="tkmr_MilestonePayments" xlink:type="locator"/>
    <link:label xlink:label="tkmr_MilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_MilestonePayments</link:label>
    <link:label xlink:label="tkmr_MilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payments</link:label>
    <link:label xlink:label="tkmr_MilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for milestones reached in an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_MilestonePayments" xlink:to="tkmr_MilestonePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued and outstanding: 54,303,402 (December 31, 2014 - 22,438,169)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNet</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInUnbilledReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:to="us-gaap_IncreaseDecreaseInUnbilledReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockNoParValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, no par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue (note 4)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueInputsDiscountRate</link:label>
    <link:label xlink:label="us-gaap_FairValueInputsDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="us-gaap_FairValueInputsDiscountRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing fees, milestone and royalty payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationContingentConsiderationLiability</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainContingencyUnrecordedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainContingencyUnrecordedAmount</link:label>
    <link:label xlink:label="us-gaap_GainContingencyUnrecordedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SubjectToRepurchaseMember" xlink:label="tkmr_SubjectToRepurchaseMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_SubjectToRepurchaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subject to Repurchase [Member]</link:label>
    <link:label xlink:label="tkmr_SubjectToRepurchaseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents subject to repurchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_SubjectToRepurchaseMember" xlink:to="tkmr_SubjectToRepurchaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related to the Expiration of Repurchase Provision Rights [Member]</link:label>
    <link:label xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expense related to the expiration of repurchase provision rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:to="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherIncomeAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (losses)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_StockRepurchaseRightsExpirationRateShares" xlink:label="tkmr_StockRepurchaseRightsExpirationRateShares" xlink:type="locator"/>
    <link:label xlink:label="tkmr_StockRepurchaseRightsExpirationRateShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_StockRepurchaseRightsExpirationRateShares</link:label>
    <link:label xlink:label="tkmr_StockRepurchaseRightsExpirationRateShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Rights, Expiration Rate, Shares</link:label>
    <link:label xlink:label="tkmr_StockRepurchaseRightsExpirationRateShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stock repurchase rights that expire every three months.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_StockRepurchaseRightsExpirationRateShares" xlink:to="tkmr_StockRepurchaseRightsExpirationRateShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (note 3)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Increase) decrease in fair value of warrant liability (note 2)</link:label>
    <link:label xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LicenseCosts</link:label>
    <link:label xlink:label="us-gaap_LicenseCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialContractFundingAmountIncrease" xlink:label="tkmr_PotentialContractFundingAmountIncrease" xlink:type="locator"/>
    <link:label xlink:label="tkmr_PotentialContractFundingAmountIncrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_PotentialContractFundingAmountIncrease</link:label>
    <link:label xlink:label="tkmr_PotentialContractFundingAmountIncrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Contract Funding Amount Increase</link:label>
    <link:label xlink:label="tkmr_PotentialContractFundingAmountIncrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in amount of funding an entity could potentially earn in a contract agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_PotentialContractFundingAmountIncrease" xlink:to="tkmr_PotentialContractFundingAmountIncrease-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Modification to Fund The Company For TKM-Ebola-Guinea IND Submission Expenses [Member]</link:label>
    <link:label xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents contract modification to fund the Company for TKM-Ebola-Guinea IND submission expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:to="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration (note 8)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:label="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:type="locator"/>
    <link:label xlink:label="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter</link:label>
    <link:label xlink:label="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Acceleration of Share-based Compensation Expense Per Quarter</link:label>
    <link:label xlink:label="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount per quarter of acceleration of share-based compensation expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:to="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion (note 4)</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guaranteed investment certificates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition costs (note 3)</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>tkmr-20150630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:02PM UTC 2015-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-document-and-entity-information" xlink:href="tkmr-20150630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DocumentAndEntityInformation" xlink:label="tkmr_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_DocumentAndEntityInformation" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations" xlink:href="tkmr-20150630.xsd#statement-note-1-nature-of-business-and-future-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies" xlink:href="tkmr-20150630.xsd#statement-note-2-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TermDepositMember" xlink:label="tkmr_TermDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="tkmr_TermDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" xlink:href="tkmr-20150630.xsd#statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusStockOptionsMember" xlink:label="tkmr_ArbutusStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SubjectToRepurchaseMember" xlink:label="tkmr_SubjectToRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="tkmr_SubjectToRepurchaseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="tkmr_ArbutusStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements" xlink:href="tkmr-20150630.xsd#statement-note-4-collaborations-contracts-and-licensing-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AlnylamLicenseAgreementMember" xlink:label="tkmr_AlnylamLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractExtensionMember" xlink:label="tkmr_ContractExtensionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreasedFundingForStageOneMember" xlink:label="tkmr_IncreasedFundingForStageOneMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PADCoMember" xlink:label="tkmr_PADCoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TalonTherapeuticsMember" xlink:label="tkmr_TalonTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PositiveOutcomeOfLitigationMember" xlink:label="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="tkmr_PADCoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_BMSMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="tkmr_IncreasedFundingForStageOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="tkmr_ContractExtensionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="tkmr_AlnylamLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GainContingenciesByNatureAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_TalonTherapeuticsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingencyNatureDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing" xlink:href="tkmr-20150630.xsd#statement-note-6-financing" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UnderwriterOptionsMember" xlink:label="tkmr_UnderwriterOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="tkmr_UnderwriterOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk" xlink:href="tkmr-20150630.xsd#statement-note-7-concentrations-of-credit-risk" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments" xlink:href="tkmr-20150630.xsd#statement-note-8-contingencies-and-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArcturusMember" xlink:label="tkmr_ArcturusMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BlumbergMember" xlink:label="tkmr_BlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CytosMember" xlink:label="tkmr_CytosMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DrexelAndBlumbergMember" xlink:label="tkmr_DrexelAndBlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_EnantigenMember" xlink:label="tkmr_EnantigenMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarinaMember" xlink:label="tkmr_MarinaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NeuroviveMember" xlink:label="tkmr_NeuroviveMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NotesToFinancialStatementsAbstract" xlink:label="tkmr_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_BlumbergMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_MarinaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_ArcturusMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_EnantigenMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DrexelAndBlumbergMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_NeuroviveMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_CytosMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-significant-accounting-policies-policies" xlink:href="tkmr-20150630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-significant-accounting-policies-policies" xlink:label="tkmr_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-tables" xlink:href="tkmr-20150630.xsd#statement-note-2-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:label="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-significant-accounting-policies-tables" xlink:label="tkmr_statement-statement-note-2-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-2-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="tkmr_ChangesInFairValueOfWarrantsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:href="tkmr-20150630.xsd#statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:label="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:href="tkmr-20150630.xsd#statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:label="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-4-collaborations-contracts-and-licensing-agreements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:label="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-1-nature-of-business-and-future-operations-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_WhollyOwnedSubsidiaries" xlink:label="tkmr_WhollyOwnedSubsidiaries-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_WhollyOwnedSubsidiaries-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-2-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaturityOfInvestments" xlink:label="tkmr_MaturityOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TermDepositMember" xlink:label="tkmr_TermDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements" xlink:label="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="tkmr_TermDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaturityOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusStockOptionsMember" xlink:label="tkmr_ArbutusStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares" xlink:label="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense" xlink:label="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:label="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:label="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_StockRepurchaseRightsExpirationRateShares" xlink:label="tkmr_StockRepurchaseRightsExpirationRateShares-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SubjectToRepurchaseMember" xlink:label="tkmr_SubjectToRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="tkmr_SubjectToRepurchaseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="tkmr_ArbutusStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_StockRepurchaseRightsExpirationRateShares-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedContractRevenuePercentage" xlink:label="tkmr_AccruedContractRevenuePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AlnylamLicenseAgreementMember" xlink:label="tkmr_AlnylamLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ApproximateOptionPeriod" xlink:label="tkmr_ApproximateOptionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CollaborativeArrangementTerm" xlink:label="tkmr_CollaborativeArrangementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractExtensionMember" xlink:label="tkmr_ContractExtensionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:label="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ExtendedOptionPeriod" xlink:label="tkmr_ExtendedOptionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:label="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreasedFundingForStageOneMember" xlink:label="tkmr_IncreasedFundingForStageOneMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumPotentialTransactionValue" xlink:label="tkmr_MaximumPotentialTransactionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumPotentialTransactionValueForExtensionPeriod" xlink:label="tkmr_MaximumPotentialTransactionValueForExtensionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MilestonePayments" xlink:label="tkmr_MilestonePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NearTermContractPayments" xlink:label="tkmr_NearTermContractPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_OptionalExcercisedContractualOptionAmount" xlink:label="tkmr_OptionalExcercisedContractualOptionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PADCoMember" xlink:label="tkmr_PADCoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialContractFundingAmount" xlink:label="tkmr_PotentialContractFundingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialContractFundingAmountIncrease" xlink:label="tkmr_PotentialContractFundingAmountIncrease-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RevenueRecognitionPerformancePeriod" xlink:label="tkmr_RevenueRecognitionPerformancePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_TalonTherapeuticsMember" xlink:label="tkmr_TalonTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PositiveOutcomeOfLitigationMember" xlink:label="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax" xlink:label="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets" xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities" xlink:label="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="tkmr_PADCoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_BMSMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="tkmr_IncreaseToSupportDevelopmentPlansMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="tkmr_IncreasedFundingForStageOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="tkmr_ContractExtensionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="tkmr_AlnylamLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GainContingenciesByNatureAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_PositiveOutcomeOfLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_TalonTherapeuticsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingencyNatureDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_CollaborativeArrangementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RevenueRecognitionPerformancePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PotentialContractFundingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PotentialContractFundingAmountIncrease-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_OptionalExcercisedContractualOptionAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ApproximateOptionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaximumPotentialTransactionValue-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ExtendedOptionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaximumPotentialTransactionValueForExtensionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_NearTermContractPayments-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicensesRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainContingencyUnrecordedAmount-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MilestonePayments-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_AccruedContractRevenuePercentage-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-6-financing-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-6-financing-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PotentialProceedsOfAdditionalSharesAuthorized" xlink:label="tkmr_PotentialProceedsOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ProceedsFromIssuanceOfCommonStockNet" xlink:label="tkmr_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UnderwriterOptionsMember" xlink:label="tkmr_UnderwriterOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="tkmr_UnderwriterOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PotentialProceedsOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-7-concentrations-of-credit-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments-details-textual" xlink:href="tkmr-20150630.xsd#statement-note-8-contingencies-and-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArcturusMember" xlink:label="tkmr_ArcturusMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BlumbergMember" xlink:label="tkmr_BlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="tkmr_ContractualObligationAmountOfResearchFundingPerYear-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CumulativeContributionForProduct" xlink:label="tkmr_CumulativeContributionForProduct-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CytosMember" xlink:label="tkmr_CytosMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DrexelAndBlumbergMember" xlink:label="tkmr_DrexelAndBlumbergMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_EnantigenMember" xlink:label="tkmr_EnantigenMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementEarlyTerminationFee" xlink:label="tkmr_LicenseAgreementEarlyTerminationFee-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:label="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarinaMember" xlink:label="tkmr_MarinaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MarqiboMember" xlink:label="tkmr_MarqiboMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MaximumContributionForProduct" xlink:label="tkmr_MaximumContributionForProduct-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MilestonePayments" xlink:label="tkmr_MilestonePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NeuroviveMember" xlink:label="tkmr_NeuroviveMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoteToFinancialStatementDetailsTextual" xlink:label="tkmr_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_PercentOfCostsFundedByTPC" xlink:label="tkmr_PercentOfCostsFundedByTPC-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:label="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ResearchFundingPeriod" xlink:label="tkmr_ResearchFundingPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltiesPaidOrAccrued" xlink:label="tkmr_RoyaltiesPaidOrAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltyPayable" xlink:label="tkmr_RoyaltyPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_RoyaltyguaranteesCommitmentsPercentage" xlink:label="tkmr_RoyaltyguaranteesCommitmentsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_UpfrontFee" xlink:label="tkmr_UpfrontFee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_BlumbergMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="tkmr_MarqiboMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_MarinaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_ArcturusMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_EnantigenMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DrexelAndBlumbergMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_NeuroviveMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_CytosMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_PercentOfCostsFundedByTPC-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MaximumContributionForProduct-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_CumulativeContributionForProduct-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RoyaltyguaranteesCommitmentsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RoyaltyPayable-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_RoyaltiesPaidOrAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_UpfrontFee-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_MilestonePayments-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicenseCosts-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ContractualObligationAmountOfResearchFundingPerYear-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_LicenseAgreementEarlyTerminationFee-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:href="tkmr-20150630.xsd#statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:label="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:label="tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:label="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-3-business-acquistion-assets-and-liabilities-transferred-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_CommonSharesIssuedWithoutSubjectsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="tkmr_SharesIssuableForArbutusStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:href="tkmr-20150630.xsd#statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:label="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-2-assets-and-liabilities-measured-at-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_LongTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:href="tkmr-20150630.xsd#statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AntigenInhibitorsMember" xlink:label="tkmr_AntigenInhibitorsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CccdnaMember" xlink:label="tkmr_CccdnaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_CyclophilinsMember" xlink:label="tkmr_CyclophilinsMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ImmuneModulatorMember" xlink:label="tkmr_ImmuneModulatorMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:label="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-3-summary-of-acquired-identifiable-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="tkmr_CyclophilinsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="tkmr_ImmuneModulatorMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="tkmr_AntigenInhibitorsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="tkmr_CccdnaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:href="tkmr-20150630.xsd#statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueOfWarrantsExercisedInThePeriod" xlink:label="tkmr_FairValueOfWarrantsExercisedInThePeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:label="tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_IncreaseDecreaseInValueOfWarrants" xlink:label="tkmr_IncreaseDecreaseInValueOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:label="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-2-changes-in-fair-value-of-the-companys-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_FairValueOfWarrantsExercisedInThePeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_IncreaseDecreaseInValueOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_FairValueWarrantsForeignExchangeGainLoss" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-balance-sheets-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_UnbilledReceivablesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:href="tkmr-20150630.xsd#statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised" xlink:label="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInUnbilledReceivables-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-3-pro-forma-financial-information-details" xlink:href="tkmr-20150630.xsd#statement-note-3-pro-forma-financial-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-3-pro-forma-financial-information-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_ArbutusIncMember" xlink:label="tkmr_ArbutusIncMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted" xlink:label="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted-1" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-3-pro-forma-financial-information-details" xlink:label="tkmr_statement-statement-note-3-pro-forma-financial-information-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-3-pro-forma-financial-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="tkmr_ArbutusIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:href="tkmr-20150630.xsd#statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AcuitasMember" xlink:label="tkmr_AcuitasMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_BMSMember" xlink:label="tkmr_BMSMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_SpectrumMember" xlink:label="tkmr_SpectrumMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:label="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_BMSMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_AcuitasMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_SpectrumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_ContractsRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_LicensesRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:href="tkmr-20150630.xsd#statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_FairValueOfWarrantsOutstandingPerWarrant" xlink:label="tkmr_FairValueOfWarrantsOutstandingPerWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:label="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-2-blackscholes-optionpricing-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_FairValueOfWarrantsOutstandingPerWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:href="tkmr-20150630.xsd#statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DicernaMember" xlink:label="tkmr_DicernaMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_DoDMember" xlink:label="tkmr_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_MonsantoMember" xlink:label="tkmr_MonsantoMember" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:label="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-4-deferred-collaborations-and-contracts-revenue-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DoDMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_MonsantoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="tkmr_DicernaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:href="tkmr-20150630.xsd#statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedLicenseFeeAccruals" xlink:label="tkmr_AccruedLicenseFeeAccruals" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_AccruedResearchAndDevelopment" xlink:label="tkmr_AccruedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="tkmr-20150630.xsd#tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:label="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tkmr_statement-statement-note-5-accounts-payable-and-accrued-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_AccruedResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tkmr_AccruedLicenseFeeAccruals" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncentivePayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>exh31_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh31_5.jpg
M_]C_X  02D9)1@ ! @$!Q '$  #_X0]%17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  1/A    G
M$ !$^$   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,#<Z
M,S$@,38Z,C Z,3,      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $GP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   X/
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H ![ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M.1N](D[" Z6N;J0'CZ;6_FN14E*22224I))))3__T_54DDTA)2Z2:1(;.IU
M[Z)!S3P0?]B2E.:' M< 6D00=005'T:=?8W60=!K/*0MJ<):]I'B"$^]FGN'
MN$C7D>*2F/H4:_HVZB#[1Q_JU/Z56W;L;M,@B!$'Z7^<GWL@G<(')GP3>K5(
M&]LD @2.#H$E+FMAF6@SSIS(C^"855 R&-!B) ' 3FQ@Y<!VY[\IA;63 >TD
M^824NUC&-#6-#6C@ 0%)1;8QQAK@3Y&?+^"?G4)*723)TE*22224_P#_U/55
MEY_1[,O(]8NQBT$%C;<<6.X:U^ZWU&N=OV_Z[%J))*<?]@ 5FJLX[:]7-8:
MX!\L+';/4#=M?I?0_M_SBA_S=AK0TXH],S6#B@AFK'_HXM9MW6U^I_VW_P ;
M9MI)*<?]@!Y><@8M[B06N., 0?SG/_2.:_=_44?V \LV%V*6R2UOV1FUH,;O
M;N]VYC6UK:224XS?J^UKV6,&*UXV[G#%:./IM9ML#V;V?RU)_1K/3:U@PP6D
MS..Z"TPWTQ^GW-_1^I79^99ZO\TM=))3F.Z/[=E?HM&^235/Z(#TZZ(W_F,;
M7^D_D(7[!9Z9K+,0M#1Z8^S-$/E^][AOV.;Z#O18WT_9^D_TGIK8224Y+NB6
M%^_=C;A8XAQQ@2*W!M;JVN]5NU[JMU;[OS_^MH)^K-1M:2S$-37[BS[.07-(
MV/8_;>VO_B'^E^A_X3](MQ))3E,Z'5ZOZ=F-=CE[K2ST-MAL.W](ZUMOI?F?
MI/U?](KN/T_"Q7[\>EE3MNR6B/;N=;M_[<>YRL))*4DDDDI__]7U5))))2DD
MDDE*22224I))))2DDDDE*22224I))))2DDDDE/\ _];U5,X@ DF -22G6%]=
M.HV]/Z#=92YS+;7-J8]L@M+CJ[>QS',]K?\ U&FSEPQ,CT%LF#$<V6&*.^20
MA_C.+]8OK[Z-UN#TH!SJRZM^2[@.&CO2_?VN]1O_ (+^EJ7)7?6+K=MA>_/O
METGVO+!)W_1:S:UG\X_Z"SF]O <)3!^/"R\F?),V9$> V>UY;X=RW+P$8XXR
M->J<QQ3G]KT'3OKQU[#L;ZMYRJ@27,N ),EQ_G/;9])_[W^CK_FUZ)T/K6+U
MK!;EXX+#]&VIW+']V;A_KL7C6LGS70_4+J+\7K]= ^AE@U/ $F0"^OZ-=MFU
MOYVWT6?GW6;*U+R^>8D(R)E&6FO1I?%?A>&>">7%"./+C''Z!PB<8_.)1B^J
MJC9TFBQ[GF[)&\EQ:V^UK9,_1:UXVM]WT5=3K1>3:8Z90+Q?ZN07-)<&^O;M
M]W;T]^S9_(5>WI[F6555MRK:AN+KAE/#A.[V.WV-?;_(]RU%F==?U?[,S'Z3
M27W9#Q7;D![&>A4?YR]OJ_3M_,JVL?\ Z;])Z7HVI2*O&OL:T.QLBJ; 'SE&
M6-:RMF]GIO=N9]+]%^_ZEO\ A$L?"R'N]*ZC(JI>1N>[+<\CTG>I4\>[<SU/
MS_3L_P",6)T7'^NW3',8[&^U4OKQVV'(R?4=7#G-R&4UFSTVMIK?ZCG[[K;O
MT5/Z5G]%Z/HAZM]CCJP)RR2^QP#!6"\E_H8[:G/?Z&-_,UVW_I[OYQ)3)G2,
M9C2T67F8U==8XB-T;-[W;?II-Z30US'"[)EA!$Y%I!@AVUS?4VN;[?[:O))*
M4DDDDI__U_55S/\ C!Q'Y'U?>]@EV.]MO;1HEKW:L?\ F_\ "4_^B;.F4+&M
M>TM<)!$$)LX\43'N*9N6S'#FQY0+]N0E7>GPQLB4YB01X+I_K%]2LWI]UF3T
MZDWX))<&L.Y]8D>W8?TCF-W?\-[*K+KUS+MH,.T=WG0CY+)G"4)5(4]QR_,X
MN8@,F*0D#_C1\)Q_16TX"V?J;A/R_K%B;6RREWK6&) #1H3NKN:WW_O?];NJ
MN]-ZI=.Z5G]2N95B4NLWN##9!V-),38^/:UOTGKTOZK_ %:IZ)BR^+,VUH]:
MV./SO39J[Z/T/9_/>GZBEY?%*4Q*JB#=M+XKS^+!@GCX@<N2)A& Z<?IXI.Z
M.$Z8)UIO',7NVM+H+MH)VCDQV"Q,S.S,EP^S_;L.&P]K<9KR#[I(?;OK<[^I
MZOYG_7=?)Q,?*:UN0S>&'<S4@AT%FYKFD;7;7.5<='P6'<QMF[W<W6_G-=6?
M\)^X])3G_P"4_0<QV7G M+7BYF-3O]S/YES'MM;8QO\ .6;*OT=_Z/U=GZ"N
M6#F96.2[*=G9A@-VNQ@P ^UCG?H@-WO:]_TE"SHE[I+<+&+M!_2;ZP88RO5E
M=;]N_P!/TW?3]G^E^@M)_2,&QYL>QV]T[HML ,G>[VM>UOTTE-NM^^MKX+=P
M!VN$$3V<W]Y20,3"Q\-CJ\<.:UQW$.>Y^L!FGJN?M]K$=)2DDDDE/__0]547
MSM):-S@-!,2?!2224T!D=5+21@L#PT$!UX@N_.;N;6[_ *E#->1<]_K]+I(
M.UY>QY=(>W:X&OV_S^0W_KS_ /36+322H)!(V)#GLNZH&R,"IDR2T7]R-YXI
MV[GVG_OZ/CVYK[2V_&;37!(>+ XR'0UKF!H^E7[_ *?\A64DD*22224I))))
M2DDDDE*22224I))))3__V?_M$_)0:&]T;W-H;W @,RXP #A"24T$)0
M$                      X0DE- ^T      ! !Q     $  0'$     0 !
M.$))300F       .             #^    X0DE-! T       0    >.$))
M3009       $    'CA"24T#\P      "0           0 X0DE-! H
M  $  #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      U<    &              2?   #CP   !$
M90!X &@ ,P Q %\ 4 !A &< 90!? #4 ( !C &\ < !Y     0
M               !              ./   $GP                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   $GP    !29VAT;&]N9P   X\
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     3_P
M.$))3004       $     3A"24T$#      .*P    $   ![    H    70
M .B    .#P 8  '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B95]#30 !
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ H ![ P$B  (1 0,1 ?_=  0 "/_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M2224I))))3__V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
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M14,@<U)'0@                  ]M8  0    #3+4A0("
M                                                 !%C<')T   !
M4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:
M   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D
M;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^
M !1M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $
M/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(
M97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V
M,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                        6%E:
M(        /-1  $    !%LQ865H@                     %A96B
M  !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*
M  ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                      !D97-C         "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C
M92 M('-21T(                             9&5S8P         L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$                                  '9I97<      !.D_@ 4
M7RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A
M<P         !                         H\    "<VEG(     !#4E0@
M8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H
M3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\
M ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!
M/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A
M >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"
MM@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N
M [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$
MX03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W
M!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'
MT@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/
M":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +
MF NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W#
M#=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"80
M0Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C
M$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5
MX!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ
M&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<
M>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5
M($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D
M'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_
M*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(L
MURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&"
M,;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(V
MKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH
M/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!
MK$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[
M1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--
MW$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"
M5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;
M15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))
M8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II
M\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5
M<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EY
MYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P
M@I*"](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+
M,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@
ME(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=
MTIY GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=N
MI^"H4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"Q
MUK)+LL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PA
MO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'
M0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_
MTL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>
M'-ZBWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0
MZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V
M;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4
M9      !_]L A  &! 0$!00&!04&"08%!@D+" 8&" L,"@H+"@H,$ P,# P,
M#! ,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0<'!PT,#1@0$!@4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" 2? X\# 1$  A$! Q$!_]T ! !R_\0!H@    <! 0$! 0
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M??\ 4.^*O-9/+6MP_EMY _,+RLGJ>9?+&B6?KV0J!?Z:]NC7%H:?M@ R0?\
M%G^7QQ5YVVL6FL_D3Y_UVTY"PO?.@OT9Q0I#+<6L@+^'$-\6*O5_SGUO2+CS
M3^5MI;WD,UQ<>8K6[ACC=7+6X1E]4<2?@)=>+?M8JW^5.FV$OG[\V;F2W1YY
M=42VDD9028?J_+T]_P!@EOB7]K%6%Z+I]BG_ #A?>%+>,&6SNYY3Q'Q2K>N
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MD 7ZI=6-8EM(T%>,42;H69WD5^;O_*JU^4W_ ),/\TO^VQ;?]0JXJC/S&_\
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M4UG^>V_X%_\ FK%74UG^>V_X%_\ FK%74UG^>V_X%_\ FK%74UG^>V_X%_\
MFK%6J:S_ #VW_ R?\U8JC%Y<1RIRI\5.E?;%6\5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BK__T?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5_]+U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5?_3]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_U/5.*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]7U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_6]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%4N\P^8=%\NZ/<ZSK5VEEIMFO.>XD.P%:  "I9F/PJJ
M_$S8J^<-?_YS>TZ*Y:/0?+,MU;J:"XO;@0,P]HXTEI_R,Q5E?Y9_\Y9^4/-N
MJVNBZO8R:!J=XPBMI'D6:U>0FBIZM(V1W.R<X^/+X>>*O2/S3_,"'R!Y,NO,
M\UDVH1VLD,9M4D$1;UI%CKS*O]GE7[.*O#O^AXM)_P"I2G_Z34_ZHXJU_P!#
MQ:5_U*4__2:G_5'%7L?G3\U;?RQ^5\'GV33GNH9H;.<6"RA& O>%!ZA5A\'J
M?R?%BKQW_H>+2?\ J4I_^DU/^J.*HO3O^<W?*LLP74?+=];0D@&2":*<@>/%
MA#_Q+%7K7FK\V=#TC\KY/S#TV/\ 3&DB.&6!(W](R+-,L-*LK<&1G^-67[2\
M,5>-?]#Q:3_U*4__ $FI_P!4<5=_T/%I7_4I3_\ 2:G_ %1Q5FTO_.2EE'^4
ML'YB?H&4PS:B=-&G?65Y @,?4]3TZ?L?9X8JRS\N_P U8/.?Y>7'G*/3GLHH
M/K7^A-*)&/U45/QA5'Q_ZN*O'?\ H>+2J;^49_\ I-3_ *HXJ[_H>+2?^I2G
M_P"DU/\ JCBKU3SK^=5KY7_*_1_/LFE/=0ZN+1EL%F"-']<A,PK(48-PIQ^Q
M\6*IQ^4_YCP_F'Y0C\R0V+:<DD\L MGD$I'I$#ER"IUK_+BK$/S4_P"<F_)7
MD/49=&A@EUO7(?\ >BUMF5(H6_DFF/*C_P"0B2<?V^.*O.=+_P"<X8VO -4\
MJ&.S)W>UNQ)*H_U)(XU;_@TQ5]%^2_.OE[SEY?M]=T"Y%S8SU4U'&2.1?M12
MIU21:[K_ +)?AQ5'ZYJ]KHVBW^KW9I:Z=;RW4].O"%"[4KWHN*O"?)'_ #F!
MH/F7S7IF@7&@RZ8FIS+;)>O<I(J22;1AE]--G?BGVOVL5?0>*O _S#_YRQT[
MR9YSU3RQ+Y;FO9--D2-KI+I8P_.-9*\#$W'[=/M8JQW_ *'BTK_J4I_^DU/^
MJ.*LB_+S_G+'3O.?G/2_+$7EN:RDU*1XQ=-=+($X1M)7B(EY?8I]K%4+YR_Y
MR_TWRSYKU;R])Y8FN7TJZEM&N%NT02&)N/(*8CQKX5Q5)_\ H>+2?^I2G_Z3
M4_ZHXJ])_)7\^;3\T+O5;>WT>32_T7'#(S23K-S]8N*"B)QX\,5>JXJ[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__U_5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\E_\YL>;+\ZMH7E.*0I8K;G4KB,'^\E=
MVABY?\8U23C_ ,9,5>Y_E1^4?E#R;Y3L+:#3;>74YK>-]3U"6-9)9IG0%_B<
M$K&&V2-?AX_Y6*L(_-#_ )Q5T3S;YHM=:T&\B\L@J?TBEO;\A)*K I+&BO$D
M;TKS;]KX6^URQ5,/^<G[>XMOR"O;>YN#=W$+6$<UTP"M*ZSQAI"HV!<CD0,5
M>6_\XT>?ORB\O>1;VR\Y7=C!J<FHR2PI=6S3OZ)AB52&$<GP\U?:N*O7!^<7
M_.-+$*-0TDD[ ?4'[_\ /#%5+_G*M(D_(W4TA4)$LUD(T444*+B.@ '04Q5Y
MO_SBQYB_*_3?(%_!YKOM(MM0;4Y7BCU%K<2F(P0@%?5^+AR#XJM_YRB\Q_DQ
MJ7DFU@\N3:7>>81>1FWDTP1%XX0K>KZCPBGIGX?@8_;^+]G%7H7_ #BGI$[_
M ))VL.KP+/9W=Y<S6D$ZAT,', ?"P(IZR2./^"Q5!?\ .6&@Z'9?E#<3V>G6
MMM-]=M1ZL,,<;4+&HY* <50O_.(FA:)??E1+->Z?;74PU2Y4230QR-Q$<5!5
M@33%5?\ YR\L;*R_)V&"RMXK: :M;L(H46-*F.:IXJ -\54_^<;_ /UG'4/^
MWI_Q XJ\7_YQ5UKR3I/G#5YO-US8VME)IW"!M1]/TS+Z\9HOJ;<N(;%7U#:^
M=OR"N[J&TMM2\O37-PZQ00I]5+.[D*JJ -RS&F*L._YS"ABA_)ZWAA18XH]3
MM5CC0!551%*  !L ,52W\@?,9\M?\XRZGKZ@&333J-Q"IZ&5!^[!KXOQQ5YQ
M_P XJ_E]IOGGSAK?F?S1$-473"DHBN 'CEO;MW<RRJ1QDX!';BWP\GQ5]0>>
MORJ\F></+MQH]]I=LCM$R65W'$B2VTG$A'C=0&7BW['V7^RV*L8_(O\ )"]_
M+!-1637VU2/4A&9;-8/1BCECK2127=B>)XG[/_"XJD7_ #EYYX.A?EPNA6\O
M"^\QS>@P!'(6L-))S\F/IQ'_ (R8J^8?,?Y:ZEY<_+;RAYY7U8Y=:GN"YZ"'
M@P:S8'L94261?]CBK[G_ "K\WCSA^7VA^8"ZO<7ELGUS@00+F/\ =S#;I^\5
MML53JX\N>7KF=Y[G2[2>>0UDED@C=V-*;LRDG%7Q7IUC8G_G+5[(V\1L_P#$
M,Z?5N"^EQ#/1>%./'VIBK[5MO+GEZUG2XMM+M()XS6.6.")'4TILRJ",5?$&
MHZGH>E_\Y2W^H:Z\<>D6VOW#WLDR&2,1AFW90&Y#_8XJ^D/^5R?\XT_]7#2?
M^D!_^J&*LS\@>9_RY\QP7=WY*EM)XH'6&\EM(#!1B.2JU4C+;8JRS%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__0]4XJ[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%7QK_SFOI]S%Y^T342I^KW.F"&-^Q>">1G7
MZ!*G_!8J^L_*&MV.N>5M)U>QD66UOK6*:-E-1\2"J_ZRM56'\V*L*_-+\_/*
M?Y<:[I>E:Q!/<MJ$;S3M:\&>WC#!4=XV*\A(>?1O]UXJQ_\ YR8U6TU?_G'R
M[U6SYFTOSI]S;F1&C<QRSQNA9& 9?A/0XJ\J_P"<;OR*\@>?O)%[J_F&&YDO
M8-1DM8V@G:)?36&)Q50.O*1L5>L+_P XB_DXK!A;7U0:C_2V[?1BJ(_YRN4+
M^2&JJ.BSV0'T7*8J\'_(G_G';R_^97DN^UJ]U6[T^^@O9+.%85C>*B11R!F5
MAR8UD/21<58A#Y<TK\L/S2.C_F/H8UK3+=EJ$DDC1X78%+N(*5]9>(/[E_A^
MU&WQ+BK[\T6?29]'LIM',1TJ2"-K VX"Q>@5!C],+0!.%.(Q5Y#_ ,Y>?^2;
MN?\ F.M/^)'%4+_SAO\ ^2CE_P"VK<_\FX<5=_SF1_Y*.+_MJVW_ ";FQ5"?
M\XW_ /K..H?]O3_B!Q5X%_SCO^5/E[\R/,VI:5KD]U;V]G9?6HFLWC1R_JI'
M1C(D@XT<]L5?1.C_ /.'_P"6^E:O8ZI;ZCJS7%A<174*O+;E"\+B10P$ /$E
M=]\5:_YS(_\ )1Q?]M6V_P"3<V*L9_*71[G6/^<2?,&G6JEKF9-2,*#JS1TD
M"C_6X\<52;_G"+S!90ZAYFT"5U2[NTM[RV4FA=8"Z2@#OQ]1#BKZEUS6;'1=
M&OM7OY!%9V$$EQ.[$ !(U+'<^--L58)^4WY[^4_S*DGM=+MKNSU&TA$]U;7,
M8**I8+59D+(WQ';EP?\ R,5?+7_.57FYO,'YMW=C&YELM!C33XD7_?@_>7%/
M\KU',?\ SSQ5%>>_^<B_\6_E\WDI_*$=E91QP1V$Z7+NUN;;B(V53$O+X%X=
M?LMBK-O^<+?/I2?5O(]U)\,@.I::&/[0XI<1CYCTY!_JR8J^KL5?$.F_^M@/
M_P"!'<?\2?%7V]BKX.U7RYIGF7_G*'4-"U17;3]0U^XAN5C8HQ0LQV8=.F*O
MH?\ Z%#_ ";_ .6:^_Z2V_IBK//RY_*SRG^7ME>6?ER.:."^E6:<3RF4\D7B
M*$@4VQ5EV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__1]4XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%6&?FO^5VB?F-Y7?1M1
M8V]S&WK:=J"*&>WF IR -.2-]F2.OQK_ )7%L5?,>G?E=_SE5Y DGTWRM)</
MII8E&LKFWDMFJ=W6&Y8&-F_:_=(V*ICY'_YQD_,KS5YLCU_\SYWBM%D62[CN
M)UN;RZ"&HBJC2)'$:<6JWPI\,:?RJO=/^<@?)VN>:/RJO_+_ )<LQ<ZA)):F
MWM5:.$<(ID9J&1D10J+XXJ^<_+'Y6?\ .5_E:P?3_+T%SIME)(9Y((+RQ"F1
ME"EC64[\548JG'^&_P#G-7_EIOO^DVP_ZJ8J]8_,?R9^87F;_G'FU\O2VSWW
MG*2&P-_#)+"'::*1'F+2EEB)%&.S_P"KBJO_ ,XP^0_-7DKR)?:7YELOJ-]-
MJ4ES'%ZD4M8FAA0-RB9U^TC=\5;_ .<D?R?G_,#RG%/HT"2>9]*?G8U*(TT+
M[2VYD<JH_P!^)R;CS3_+;%5'_G&S1_S1\M>7)_*WG326M;*Q/JZ/>F>";X)&
M)>W(BD=AP8^I&3_,R?LKBJ:_\Y&^3?,?F_\ +2;1O+UI]=U)[NWE6#U(XO@C
M8ECRE9%V_P!;%4/_ ,XT^2/,_DW\NI-(\R6?U'4&U"><0^I'+^[=(PK<HF==
MRK=\5=_SDMY(\S^<ORZCTCRW9_7M074()S#ZD<7[M$D#-RE9%V++WQ5#?DGY
M#\U^6_R4O/+>M67U769?K_IVOJ125]=2(_CC9D^+_6Q5A'_.+?Y0?F'Y(\W:
MMJ'F?2OJ%I<Z?Z$,GKP2\I/6C?C2*20CX5.*OI?%7E'_ #DMY(\S^<_RZCTC
MRW9_7M074()S#ZD<7[M$D#-RE9%V++WQ57_YQR\F>8_*'Y9PZ+YBM/J6HK=W
M$K0<XY?@D8%3RB9TW_UL5>2_FA_SC#YQTOS5)YM_*VX,;22M<+I\4PM;FVED
M)+_5I"40PFK? 71D7X/WBXJQ;6?R\_YRT\Z11Z1Y@%Y)I_(!TN;JUAM]C4-*
ML+CU>-*_$DC?RXJ^@_RL_*6/\J_(NH1Z7&-7\T7,33W,JTC$]Q&A]&WC+E>$
M*L>*EV_;>1OY55>4_D#^1'G_ $O\SYO-OGK31;B".>XMY'F@G,E[<-0M2)Y*
M<5>5^3?M<<5?4?HP_P B_<,5?*=[^2?YG^6?S[?S?Y4T076@1ZD+V,Q7%O"#
M;W.]S$$DD1AQ$DJ#X>.*OJ_%7RQ9?DM^947_ #D@WG%]'IY=.MS7@O?7M_[A
MRQ5_3]3U>_V>'+%7U/BKXU\\?D?^>3?FQK?FORQI3Q^IJ<]WIE_'=6B-Q=R5
M<*\H9=C^TN*HS_#?_.:O_+5??])MA_U4Q5Z;^0NE?G]9^9-1?\R9;F32FL^-
MF)[BVF7ZQZJ'9869@?3Y[G%7N.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5__TO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
M_]/U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_4]4XJ[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_U?5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5YQ
M^</YX>6ORSL[<7L3ZAJ]Z"UGID+!&**:&21R"(XZ_"/A9F;[*_:XJO!3_P Y
M@_FM>%[S3O+%B=-B/[PB&[G"@;_%,DBJ-O\ )Q5Z9^47_.5'E_SIJEOH.MV7
MZ$UNZ/"T</ZEK/)V16(#1.W["O\ "WV>?/BN*LY_.K\Q;W\OO(TOF.RLXKZ>
M.XA@$$S,J$2D@FJ[[4Q5X)#_ ,YG>>)TYP>4;:5*TY(]PPJ.U0,53GRE_P Y
M7^=];\U:/HUSY3AMK?4KVWM);@&XK&DTBHSBHI\(:N^*OI[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ__6]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%7PSK%L_YH_\ .3\VE:C*\NGOJDMGQJ12RT[GRC3^
M7FD+]/VY.6*OMW3M-T_3+&&PT^VCM+*W01P6T*A(T0; *JT&*OCC_G+?R5I_
ME/SQH_F/08ET\ZNCS2+  BK>6CJ3*@6G%G$D;'_+7E^UBKTK_G(/7F\P?\XS
MZ7KCT]34OT9<RT%!SE7D_P#PQ.*L:_YQJ_.K\M?)GY=2:1YCU?ZEJ#:A/.(/
M0N)?W;I&%;E%&Z[E6_:Q5[GY-_.O\M?.>L'1_+FK?7M0$37!A]"XB_=H0&;E
M+&B]67OBK.,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BK__7]4XJ[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7PL]ZGY:?\Y1SW^J
M!H[&#6)YI96'2TU$/27W"17'/;^7%7W-#-#-"DT+K)#(H>.1"&5E85#*1L01
MBKXX_P"<RO-MGK'G72/+=@XN)=$AD^M>G1J7-VR?NMM^:I''4?\ %F*O0/SZ
MT*;0/^<8-(T6>OKZ>NEV\X/42(M''_!5Q5BW_..'Y%_EOYX_+V36?,5A+<Z@
MM_/;B1+B:(>FB1E1QC95ZNV*O=/(WY%_EOY(UHZUY=L);;4&A>W,CW$TH].0
MJ6'&1F7JBXJS_%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J__]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>4?GA^0>C_F7;
MPWD,XTWS'9H8[:^X\HY(ZU]*=1\14&O!U^*/_+^SBKPJ'_G'O_G)C286TK2]
M7=-,'PJEKJLD4!6O:,F,@?[#%6?_ ).?\XI?H#68/,WG>[BU+5;>03VFG0EI
M($F!Y"6:1P&FD5OB50O#G\7*3%7H_P"?GD'7?/?Y>S>7]$,"W\ES!,#<N8X^
M,3$M\2JYK]&*J/\ SCW^7?F#R!Y"DT+76@:]:^FN0;9S(G"1(U7XF5#6J'MB
MKTS%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7_]'U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5?_2]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_
MT_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]3U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_5]4XJ[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%4H\V>:M%\J>7KW7]:G]#3K%.<S@58DD*J(O[3NQ"(/YL5?*=Y
M^?\ ^?/YC:Y<VGY<Z?)96$-.,-K#%-*J$_"UQ<3*8XV?P7TU_P!?[6*K=/\
M^<A/ST_+K7X+'\Q["6]LI35X+J&."<QU^)[:>$+'(5_RO43]GX/M8J^D?,GG
MJ*?\I-4\Z>6+D.OZ)GO],N60&CI$S+R1A]I'7BZ-^U\.*O.?^<6_S8\[>?\
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M/ZW!]6201$F5J5Y%7Z4\,5>X_P#0\6D_]2E/_P!)J?\ 5'%7N/Y6?F!#Y_\
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ML/KJ7L&EFT]01@2"0Q"3UD^&H(3X/A7^;%7T/>V5I?6<]E>0I<6ES&T5Q!(
MR/&XXLK ]0P.*OG#SC_SA9H5Y=O=>5-:DTI&/(6-VAN(U/@DH9)57_7]5O\
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MVL1_W8Z1[1K_ *[+BJOY1_,SRQYI@OSI[7$%]I8KJ6DWD#V]]!4<EYP/\7Q
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M5=BKL5>4)^7_ .:>E^>_,_F?0-4T2GF.2WJFH6UU-)%#:1F*%%,4L2]#5_\
M*Q5.O+7Y?Z^?-R><O.>JP:GKEM;O9Z7:V,#6]E:0RFLK(LCRRR32THTCO]CX
M,52;2_R]_,WR8+S3?(NKZ5-Y=NKF6ZMK/6X)VFLFG8O(D4ELRB:/F2RK*O\
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MQ5+=!_-KR;K6KP:/#)=V6I708V=OJ-E=6)G]->3B%KB.-9&5?B9%;EQQ5.]
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MU\50?YEZAI_FGS"?,MK2:RTC5?+>C:=<#<,]S<IJ%TP_V,MI'_L&Q5D>N?\
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MO,>?*V6+T>#D_:JFQQ5+?+OY=Z%H5_9WUM)=7%SI^G#1[)[J8S>G:"7U>*U
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M6U7S'KOYB:GIFMW-UJ$UEI=IJ3H88A.ZV<:6:AE;X%CXIQ^/EBKTZR_,C6=
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M8!?\D',8:F415NXS]F:?*1*41Q1_FI<S\@S$5D8DNWN>N8QYN5RV61>I4T
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MV*NQ5V*NQ5V*NQ5V*O+_ ,\/S='DO3(M'T1?KWG?6J0:+IT:^HZM(W 3NH[
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M84VM=>+"IJ *E1W^C"#;*U-CR4,5^$'8#K3) 4K9:H+ $*_PT_#%:W1$(2)
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MF>,^M;RO"XH>2,1NO2N(D8EADA&6Q%O:?RG_ #=UR2:'1]7MY;Z-SPAO8U+
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MV3H,6HG628QC_=/E_P S>;_-&N.R:U<R\ Q=;9@54'Y'-#ERSES?5]#V=I\
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MJA_^<A?(VO><?+>A:?H]B-0-MK=K=7T#/&@%JB2+*Q]5D##X_LCXL59GY?\
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M\]_;LGZ,4AU<;>J?A*FN8N@PW/?^%WOM5KQ'2@0/][_N6:?G+^5K7T?Z<T*
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M@3J)XU^+TY,50%U^4=]J\$&F^:/-VIZ]Y?MW1SI,R6L*W'I$%%O)H(DEN4Y
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1V*NQ5V*NQ5V*NQ5V*NQ5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EA1P,4 '< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
<! $     +      !  $ @     $" P("1 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>29
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`/63!T?G?S$WN0$``)T7```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V8RT[#,!!%?Z7*%C6N'=ZBW5"V@`0_8))I8S6.+=M]_3UV"@BJ@EJ@
MTMWDT3N>>Y-QSJ(WSVM+OK?23>N'61V"O6;,ES5IZ7-CJ8W*Q#@M0[QU4V9E
M.9-38F(P.&>E:0.UH1]2CVQT\[`@YU1%O=N-D'H/,VEMHTH9E&G9HJVVNO;-
M9*)*JDPYUW%)'J(UG40]ZSU*%^ZECBW8JF&=L#GR/.GL?PR]=20K7Q,%W>0^
MK!ORN_PWRKOSF"9RWH2#C-_>7>ZHZ6I\K>R;U=TJ=O'QMV$65;^7P_;"GY(I
MG89FV^F7%>G^E\^R]1(7NAD[N51;!HNCC2F=<RU5NVM42^-F+\;,_G.;4'JJ
MBJJ^=;'0!;5CE\3BQZAZ%EO_R?M]IY3&T5Z&J?"('T4M'55/P<7Y[OXV/A<<
M+T>::W?]W=`[T;/N=$1(')1#@.0H0'*<@N0X`\EQ#I+C`B3')4B.*Y`<?(`2
M!(6H'`6I'(6I'`6J'(6J'`6K'(6K'`6L'(6L`H6L`H6L`H6L`H6L`H6L`H6L
M`H6L`H6L`H6L`H6L!0I9"Q2R%BAD+5#(6J"0M4`A:_%!5M;]*S]Z!5!+`P04
M````"`#UDP='2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_
M)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B
M]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&10IXV+!XUE])"1#M@2[`LRQ7(K8[9
MK.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)4]`'_K,-
M`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C
M-Z."N[_8_`)02P,$%`````@`]9,'1PQUTFF.`0``J18``!H```!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<\782VK#,!#&\:L$'Z#RS.1-DE4WV;:]@'`4
MVR1^(*FTN7U=+XK[T-!%X-O8V(+1?_5#:->&?/ODKC;671NJN@^S]^;:ANWP
M?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9L^-I
MG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ-?U28
MKPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T)VJ2#
M-I`@RA49<TR2AC5&:U*X)HS7I(!-&+%)(9LP9I."-F'4)H5MPKA-"MR$D9L4
MN@EC-REX$T9O5O1FC-ZLZ,V@L[9VV,;HS8K>C-&;%;T9HS<K>C-&;U;T9HS>
MK.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@MBMZ"
MT5L4O06CMTST#I7U[O0<?=V6X=XUWX:K11.\0[Q=W?U3QJEJPT3K..SDS/B\
MNT#CU,\0\^M6^O`!4$L#!!0````(`/63!T?,]%3"]0(``*$*```0````9&]C
M4')O<',O87!P+GAM;+V637/:,!"&_XJ&4P\E!CNA*4,\PT<RS4P^F$#2LY#7
MH(DLN9),(;^^*SNX)@%WS*%<D-?[K+3[+BL&TG3Z4ZU2T):#(9M$2--'XU5K
M96W:]SS#5I!0<X8N$M_&2B?4XJ->>BJ..8.)8ED"TGI^I]/S8&-!1A"UTS)H
M*QRX789I*CBCEBL9WG.FE5&Q)=<;!F+@?73("8P\`Y9I;K=AI_"IFG*?&:,"
MQKA7&%-AH/#Z:\Q]QBI)J=QZQ=,=EZ_F.9VK";50I?9?%-%75$.$F^Y%+XVY
MSX\MYBD<.UY1N82HZOOYY:X6+Z"-R[3KGW7P4Y9@9R]B`XVX7$XIUR8<K&U_
M#<PJ_2[3VIZJ4J28$]V\S/%\ID46U(!;7K765',J;8L8_H:/?JO8MK#F:Y$:
MJ\.?2K^:%8`U`Z\TYLNJ;W7-S\.@EWO@:M_3*S,+W\NVE[>SS+D58![C*=7V
M/Y4BSVE7B*#7JF2_"T&&,B+7TF([DEM9;(7B54M2KL8*?Q?20$1P993@$;99
M1$944,F`G,`$39B9Q2\\\PG,Q0E,[P3FVT'F05D@7=(F#]1F&HB*R2@S7((Q
MA,KH..,C,^-+R5%TZK1B3&6HE5P>9P)D[D$O09/?W*[(4"\RFQDRXL>9<V3&
M2@BZ4#J7WWQUZ5E-CS,7R+R?QY`IW=*%`)<-&1YG>LC<<(G*UZ;P+3\.MH<[
M07X<5[(QCJSCS&7!N-H`AH>\LFA)DH/,X:J2*0KJX.:2=&ND/R9)][*Y)-WO
MS27Q.\W;TN\VKX'OUS-#8W#:YL+<<;K@@MM_UKJX=`SADMS@+"4O5&1'1DW)
MC`1EK^T96RD<N.0Q=>5KI\WU\0^/@)(IJS5DOS)NW#:88STSRY*$ZJTK=DYA
M4Y/;FKYV#$YW<N,F\^['0P7.ZN:]$]3T@6.>8`T2J_L$3*&Z;WBTY[KQY)@)
MQ*!U/@XK&S;OT>#P5?!Y;)`O$["4"T/FL&D^0X+#5T'M#`GV^N#35?_A8O?V
M_Y"&?P!02P,$%`````@`]9,'1Q+8:3X_`0``:0,``!$```!D;V-0<F]P<R]C
M;W)E+GAM;,V334_#,`R&_PKJO4N["AA1UP,@3DQ"8@C$+21>%]9\*/'4]=^3
M95W+@,MNW.K:[^/7<5)R2[EQ\.2,!8<2_,5.-=I3;N?)&M%20CQ?@V)^$BIT
M2*Z,4PQ#Z&IB&=^P&L@TRZZ(`F2"(2-[8&H'8E*5@E/N@*%Q/5[P`6^WKHDP
MP0DTH$"C)_DD)TGUHC?:M+HDH[XJ@^.&>5P8(5<2Q&TWEOU.A<X(3OF#',30
M/O[]TT/,D*2OW'DY5+5M.VF+6!<&SLG;XO$YGDTJM4>F.025EQ0["_/DV/FU
MN+M?/B35-,LOTVR69M?+?$:+G!8W[_O)3OR-AE4_Q+]U?#08MXL2&SASMU$C
MXG+C9P0)\-Q)B]+HLW`1\TT<87[[\0D<SP?UPGC9-M"UQ@E?Q?LU1ON7$U96
M&]<=4C^BDU=5?0%02P,$%`````@`]9,'1YE<G",0!@``G"<``!,```!X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103`9IZ_PP`JE3%ZU6FD`PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW`<!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5`TR``
M6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK`:?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG`LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E`<`J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_`>KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_`[/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z`=-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI`&$P'-E,E$\`*"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP#`4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````
M"`#UDP='06%(`4L"``#<"0``#0```'AL+W-T>6QE<RYX;6S-5EMKVS`4_BM"
M*:.%$=LI35EK&TI&8+"50O.PMR+;LB/0Q9/ES.FOGRZ.E82%M.DN]8N.OG/.
M=SY=?.RX46N*'Y<8*]`QRIL$+I6J;X*@R9>8H68L:LRUIQ22(:6GL@J:6F)4
M-":)T6`2AM.`(<)A&O.6S9EJ0"Y:KA)X.4#`Y<]$@1/X=/[A1RO4[1EPX^CC
M:!0^7=SNX^?6<0&!X_A2)#":7L'@Y:3C\#"O]NU13X]0S^X^'U#L/;_5?&V(
M@WYSTK@4W._1!#H@C9MGL$)4QT<F/!=42*#T(6@%%N&(81<Q0Y1DDABP1(S0
MM8,G!K#GUL<QPH6TM5V%_3KCT%>259;`L']>7B[S['8PRR.4[BY/`VE<(Z6P
MY',]`;V]6-=Z<5QP[$3:N"/1E43K:'*UE6`'73<3LL!RJ!S!#93&%)=*)TA2
M+<VH1&VD"Z4$TT9!4"4XHH9RD]$;FC;'E#Z:M^1[N</=E<#%F#,.(3`J-J;>
MB-[TU\!N:K#-YKBW:<.3>$%7#@5T-JIKNKZCI.(,.[$.FHM^=HP^.D"?QFC#
M"I9"DF<=;RY"K@$L(5AAJ4B^C?R4J%[@3O4W..C*0PI/7?)[U^3KZTOWFN(6
MNF]9AN7<]J+72[J\/KY/]I6`>S+_[5&=(.'/W^?_>4[FH_;7=NFMTJ;O5]I;
MKW?0M]^M'K_3X0<49"VABO"-!F2^R?=&-]UIOKZ[:\ZB\XW=>A7*]*_63A5-
M5N`2M50]D)50UIE`;W\U\J/I$+48*!+H[6^X("W[9!7X_[GT%U!+`P04````
M"`#UDP='*8PQ2^$#``#E#```#P```'AL+W=O<FMB;V]K+GAM;)6647/;*!"`
M_PJCISY<SA:RG<13=\9VFFMFVC03YW+/6%I;3!#H`,5)?WT7'+>KUF2:)PDD
M?0+V8]GW;KHS]F%MS`-[:I1V4SO+:N_;Z6#@RAH:X?XV+6A\MC&V$1Z;=CLP
MFXTLX<*470/:#_AP.!E84,)+HUTM6Y>]T-R?T%QK052N!O"-VL,:(77VX;V;
M;J2">[`.P4RT[;5H8)8]J8PIX?S'2GJH9MD(FV8'O0[;M8M.JM`8#\?9(,`.
M4[VQK#05[&%WM73_O3S(6`4;T2E_AX,]_'>6Y7S$^63/"*_=2]@Y"@P=3)1>
M/L*=6,^R8<9$Y\VE5![LA?#PCS5=*_4661G;2.O\*DPWOME(+1OY+8P;6ZXV
MNT_&RF]&>Z%6I35*Q:_"@_@1_L']Z,$Q>EGV7O1B?1LB,<LF0P0^2B?74DG_
M/,OBO8(PD\$O4XG+__..Z;@XAQ"SN:[81^V1PJ[T/GBX-&$,^/)5%7]LIQ)O
M[%65[Y>*@I9&5Z`=5`SOG%&RPE6IV$(HH4M@!,0)B+\55!!004#%'X-6'B\X
M90(:$=#HK:`Q`8T):/Q6T(2`)@0T>2OHE(!.">CT=]"U\<!R=L*NA>\L,+-A
MB\Y)#<XQH2L".B.@LP2((V@EMUIB\A#!J;(T'3JEMP1T3D#G"5"!H"]@MV#9
M3OJ:S>VZ\YUC"TF%'%(CAPG4"%%+W#EB;>P^??T5%LU;05$]N8_8'5%C1+U,
MR;$;\2QPIX558G.*HGKG1_R.J`FB+J5&H_N+DU.G\R-2QZ]/XYQP-X1IQ#F%
MP"TMT(#EU.K\B-81=;9'A1@!#@9BV+&G:2B*>IT?$?MXT-D-FAF8%$7-SH^H
M_:I(.54[IV[G*;E3*N5G%$7MSE-ZIU3*SRF*^IVG!$^IQ(<T45+!>4KPU.[E
M.451P7E*\-2R<TY1O?R=$CR@YL[AB1.%^BQ%/*+Z,G!J.T_9'E#+6J"@CDG-
M+H6T[%ZHKG^H4-MYRO:`6BA1/IRLRMHH!'YM0R!/6HJBMO,CMK_J%:=IG%/;
M><KV@/H1MWGY?R==&!2N'T51V_EKMJ^ZIA'V.=@089@6V!7-#)S:SE.V!]2-
M->PRU`*'9"445@<416WG*=M3&Z>@MA?4]N*U='X+CZ`Q_+=0&I05"ROV;^^L
M*JCM1<KV@+J`#5@;SU$R/(JBMA<IVU/;N>B5*[UZ)65[[V1@[R[`"ZD<NX,G
MBJ*V%RG;4\=$04N6@MI>I&Q/'1,%M;V@MA>3ER+T9]V)I3<Z7H6JW,7?8%E;
MAE(=+_NC<S0.Z3.TOV#Y/LM"C8WE=*?4$ON^ZL]&Q$IT3SX4YQ^^`U!+`P04
M````"`#UDP='+:6WDED"``!]"```&````'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;(V6VXZ;,!"&7P7Q``LVD),(4I*J:B\JK?:BO782)Z"U,;6=L'W[^@2;
M5*[A)F#S__-YB,=#V3/^+FJ,9?1!22NV<2UEMTD2<:HQ1>*%=;A53RZ,4R35
MD%\3T7&,SL9$20+3=)%0U+1Q59JY5UZ5["9)T^)7'HD;I8C_V6/"^FT,XF'B
MK;G64D\D59F,OG-#<2L:UD8<7[;Q#FP.H-`2H_C9X%X\W$=Z\4?&WO7@^WD;
MIWH-F."3U"&0NMSQ`1.B(RGR;Q?TDZF-C_=#]*\F7;7\(Q+XP,BOYBQKM=HT
MCL[X@FY$OK'^&W8YF!6>&!'F-SK=A&1TL,0111_VVK3FVMLG!70VOP$Z`QP-
M,`L:,F?(1@/(3:9V92:O+TBBJN2LCT2']+\--DK.=1`5.5+)"/6>3$QNWE15
MWJNT3.XZS),"&L7>*L"H2%1L+P#&/CLT=OA_P,$JLFE`]@RPD[O,V',?P"KV
M5E%,`W(O(#?VQ3.@-8K<`JP"Y/DRA:MI3.'%%";(,I"'5<P`++R`A;&O`P"K
M`.DT8>DE+*T?!!!.`J<1*R]B9?U9`.$D^31B[46LK;\((-:S$2#U,LRTBA#8
M50>G*?(,KO)9+.!GN0H.;:U!,V-S`>BGV#(&H?WE-'#&!@/^8@>VEB$(5..@
M2<&,D@?^F@>VI*'WW"H<QVEFG%S`7_+`5C0,'5Z#YM]<DH?3GF)^-5U01"=V
M:Z4][,?9L=/N3#]*/N55V:$K_H'XM6E%=&12]1S3&BZ,2:SPZ8M*ME;?`N.`
MX(O4MTO]%FQWM`/)NJ'9CU\<U5]02P,$%`````@`]9,'1_-+DDOM`P``81(`
M`!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R-F$V3FS@0AO\*Y?L$=4L(
MF/*X*B:5RAY2E<IA]\R,Y;$K8!Q@QME_'Z`;UI/MD74Q'WY;_;8D'@G6EZ;]
MT1V<ZZ-?=77J'E:'OC_?QW'W='!UV7UHSNXT_+-OVKKLA\OV.>[.K2MW4U!=
MQ:B4C>OR>%IMUM.];^UFW;STU?'DOK51]U+79?OOUE7-Y6$%J_G&]^/SH1]O
MQ)MUO,3MCK4[=<?F%+5N_[#Z"/>%QE$R*?X^NDMW=1Z-YA^;YL=X\=?N8:5&
M#ZYR3_W81#D<7EWAJFIL:<C\DQO]+^<8>'T^M_YY*G>P_UAVKFBJ?XZ[_C"X
M5:MHY_;E2]5_;RY?'->0C`T^-54W_49/+UW?U'/(*JK+7W0\GJ;CA?Y)YS`Y
M`#D`EP`PW@#-`?J/@)B<375]*OMRLVZ;2]2=RW&TX7Z0MV,C0\O14$PW]-/4
M9COUU&;]ND&[CE_'=MY(<))L6?*^HF!%NDCB(;]H`M^:L&0"*3Z[':_?QM/-
MCYKB\[<63Y,DI2)8HE)4R?NR@F0I0A90C!'-F*D)K:0LAK*P),]3<SM+(F9)
MJ`GPE$P2JS5ZK)`(<J5O.[&B$TM./$FVLT1[C)`FT0&3(!5]I)3$DV-+DD2<
M`&R#))F][2(3763DPGA<D`32JRGV?Q^SZ&H>O>LD%YWDY,13[)8D"$FJQ.'C
MAX)D`-9`P.B`$NU,MP<_UN.'-:`48$`BD!,1C;2G=[>L`336`XUBD>5)'N`'
M93]$MZN)+?@AS1THXYO`Q:(#R$,<R;@$S?SQ.9J!*0_8W$&:IZD-F*8@\Q*(
MAL8#S"W,Q!QF1@"8068F$.R,",TY$P,QL2H)0"+(3`2BF?%!D35IJC,4:Y_[
MV/+CEPW("'#T!QUYB04"FPFI228;$)*,#VVLL;E<T3R+297KD!4?9+H!0<GX
M\,::<2A];EB5I@%/%,IP0P*7\<$-9P`JCZI@5:)"GF^4"8B$+>,C(&O`@KR'
MF.WPUDZA"E@2428@$K6,CX"LR90\HOPLL"K/=<A>4Z8?$K.,CWZL24"'5"US
M#0V/I"^/66BC0BJ2N88)N_5E8JYEB0;?DL<ZK2`$%6A%V"!OY@(6<90W<\A;
M-=]NCC49@K4^W+`.A\5#!>RW4<8?$K02'_Y8@VGFHV0QRRRJ``"B#$#,;VYF
MMZRY0XVI;[4O%J%*,AO01UK&H&9X^3#(FCO,T/HZ:=&AAH"9J&44:F"X^QRQ
M)LL2Y6,AZ[),76VJWS<DLU`C)_.]JV+8SH!UXLX@OOH8<"Z?W=>R?3Z>NNBQ
MZ?NFGE[_]TW3NZ$=]2%910=7[I:+RNW[\30=SEOZ`D(7?7.>/^@L7Y4VOP%0
M2P,$%`````@`]9,'1^XDF(')`0``S`0``!@```!X;"]W;W)K<VAE971S+W-H
M965T,RYX;6R5E,UNHS`4A5_%X@%JL"%I(X+4,JIF%B-57;1K)UP"JHVI[83.
MV]<_A"81Z<QL\`_GG/O9&.>#5&^Z`3#H0_!.KZ/&F'Z%L=XV()B^D3UT]DTM
ME6#&#M4.ZUX!J[Q)<$SB>($%:[NHR/W<DRIRN3>\[>!)(;T7@JD_#\#EL(Z2
MZ#CQW.X:XR9PD>/)5[4".MW*#BFHU]%]LBHSI_""EQ8&?=)'CGTCY9L;_*K6
M4>P0@,/6N`1FFP.4P+D+LH7?Q\RODLYXVC^F/_K56OH-TU!*_MI6IK&P<80J
MJ-F>FV<Y_(1Q"9YP*[GV3[3=:R/%T1(AP3Y"VW:^'<*;VWBTS1O(:""3(4F_
M-=#10"\,.)#Y=?U@AA6YD@/2/7,?.UE9N7(A-AG9Q6B[3SY3^9TJ\D.1W>7X
MX'+.),1+'H*$7%>4HV(Y2;"M/PM!SB'"Y#WQ_D5\7J+SDC1`!$F6TIBF,;DN
M+(.0D)3>)HN[OQ/162(:B))OB.B_$M'_)$IGB=)`-%MH&8B"9'87@Z*\5%QE
MR&89LL!`+_SXY.#U;`>_F=JUG48;:>P9]D>MEM*`C8AOL@@U]FJ9!AQJX[I+
MVU?A;PL#(_OCW3%=8,4G4$L#!!0````(`/63!T<B?JZ;<00``!H4```8````
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M_Y*_%>VWZORG)PU#A,]5T0Q_H^>WIJW*T601E?DO_#P<A\\S_L<),@L;`!G`
M9#"-$S909*#>#31KH,E`SQW!D('Y-$*,VH?,;?,V7RWKZAPUI[R?3_*AP^O>
M2><YZM+5=&]B\%D/[V*U_+FR>AG_[/U\0&!`UH28Z\@6$3D1<3=^,`A8A$:`
MP1RN#[!!PEHFAIM.LM^<7`U3?0S38JX4VB>W[?5'>X7V&NW=QQ"/`Y)@)A`!
M)<5U:(.0E%I?A[8(&:<83QE"VBEU6Y,):C*H*0T-HE&3H7##D2"T(3\7R?V-
MV2(#D,)U**/1M'"W)=F@)#MX2)AHUX@HK3E)"$DG):,)(2>!TX20!3VCPI+@
MU$U0TPQ[%\R)0WLFR#4BJ4VYG!`$:;`(*"<(@0#-S(8,*9D8`;=5I4%5*:I2
MC"I"K&6D;U(*Q7&SER"A$D9[AI1R:L8J(T50U?"XBSFX.I`L8F0XP[3.3!!3
MW5N"(%RYM,Z,D)NQSD@95H4])C&<*F24Y2J.H-2:&8U`0C@8H&G!!0/CK+#<
M8CYB$A3SPK:$:6$TTS\RPD!:F%$54H758:-+F-F\)N:N:T+`%?S(I1J8,MN.
MF`(-3%*S:5BCW(S%3'YJQ+0:2NQ[R8P6(<-M3V*;2;B^1XQC)N.&&##<RC%"
MCLE@1I`6>H:H<..3U(RXSD?,71<QJVO$$N!6>L*TYOI^-CJ3X,P,<4E87'+S
M;:R)Z3L/IRVAK95D9S2-)Y@!,X+N$B?FK(SAWBRQ$[I@AZ)])3%=N3H7K*]Q
M-2+.BG"B:',Y8F!=>$$>EZ.1T\+.>75IN%RQ*<YI'A!NB8#]QP5?JZ-#"#)W
MXAZ"D]'12>0="\YL1Z>1"?M\MKK$LA&3]W)&?D`&\P/8T>84!X3[&6#;"$\-
M*@YBC`9CG.`*A$@`89567/T3J;L]?6(DMP:,/D6JG)E3+!`^PP$V$#=C>P7A
M4QQ@\W#<,8X8!>&F1\4V4DEXJT:U1M2=20U3DAEATLH9VQH(=S4PGY,3D&9H
MQDIK67'$@1*,N^V(*7#AQC_*&]V!OMB.HL#XXN*C]/7K<.741,_5V['%L_ST
M=+K6^@+]Q<FGYVOYL)&!YUOYD.&EU;O[U?*4O_J_\_KU<&RBIZIMJW*X57FI
MJM9W(8O[+M=[G^^F'X5_:?NO2?\2\.H*?[35:;R)FZX#5_\#4$L#!!0````(
M`/63!T?%Z([D)@,``)L,```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
MC9=+<YLP$,>_"L/=00\D1`9[IGY->^A,IH?V3&S99@+(!3E.OWT%6DC2"MDY
MA(=_N_O?7;&([*J:E_8DI0[>JK)NY^%)Z_-C%+6[DZSR]D&=96U^.:BFRK6Y
M;(Y1>VYDON^-JC(B"/&HRHLZ7&3]O:=FD:F++HM:/C5!>ZFJO/FSE*6ZSD,<
M#C=^%,>3[FY$BRP:[?9%)>NV4'70R,,\_((?MYAW2$_\+.2U_7`>=.*?E7KI
M+K[MYR'J-,A2[G3G(C>'5[F29=EY,I%_@]/WF)WAQ_/!^[9/U\A_SENY4N6O
M8J]/1BT*@[T\Y)=2_U#7KQ)R8)W#G2K;_G^PN[1:58-)&%3YFST6=7^\VE\$
M`C.W`0$#,AH0XC6@8$!'`\J]!C$8Q.\1$J\!`P/V'L%OP,&`CP;8%M\6JR_U
M.M?Y(FO4-6C/>;<`\:/!F\Z)\1R8^K:F=;W/IF_>(GM=B#2+7CL_GQ#2(TN+
MI&@:60&"IY$U(&0:V0!"IY$M(/&(1"939[KD<[K4IDNL/?L<HNZ1V*9K$4)B
M*C!/;P>BSD#4!N*N0(D-9!&2(H3B:6P%&"=(3%-K2\T(8H)[O&T&CE!,I[&M
MQ81`E-VN0.RL0&PKD$R7>F41G")GF2RTM5!"*+JMA#F5,*O$63YHND5H0C$7
MM\-P9QANPZ2>EG-H.?,DO++0#%-?[;:6PHS=L403I][$>D#(4Q=@1,+NJ+YP
MAA$0!GOJ8ADJG"L7$OZ?F122.H6D((1X\K6,R;;[NQT((V>D_G87RO.(+0<H
M)CCQ-=K-34O";DD8)'E*O`2(F)5'*;[CR<?N*8L)!'/.V2%_`@U%`GOF\6IP
MAHFW2H,WG,;D#N'NJ8TI"/<\GQN`9BQESC4]*')ATX+<0Q3;Z2<\:W8-S(QP
M\YCZ!#FY:47N88H9E,C3C25`+*:(QNB>?KA'*H8IYWOU+0$2!'/NG&7P(@6.
M)"+VO"'7@,T()0GU#//-"`KB>^5N@6-",/3O2H@^[-G.^5%^SYMC4;?!L])F
M^]?OT@Y*:6G\H`>S3SR9+X7QHI0'W9TFYKRQ>V=[H=5Y^!08OT<6?P%02P,$
M%`````@`]9,'1[+23]6J`0``M@,``!@```!X;"]W;W)K<VAE971S+W-H965T
M-BYX;6R-4UUOVR`4_2N('U!L)UV6R+'4M)JVATE5'[9G8E_;J,!U`<?=OQ\?
MCIM4D38_&+B<<^ZY7"@G-*^V!W#D74EM][1W;M@Q9NL>%+=W.(#V.RT:Q9U?
MFH[9P0!O(DE)5F39%Z:XT+0J8^S95"6.3@H-SX;842EN_AQ`XK2G.3T'7D37
MNQ!@5<D67B,4:"M0$P/MGC[DN\,Z("+@EX#)7LQ)\'Y$?`V+'\V>9L$"2*A=
M4.!^.,$C2!F$?.*W6?,C92!>SL_JWV*UWOV16WA$^5LTKO=F,TH::/DHW0M.
MWV$NX3X(UBAM_)-ZM`[5F4*)XN]I%#J.4]KYFLVTVX1B)A0+H4C&4Z)H\XD[
M7I4&)V(''GJ7[SS<!!&O3+PWZ\N.FB867I6G*L^V)3L%H2M,(AYFS()@7OUF
MBH+>HA>)GF?_%EA="ZR2QU44V/Z'@?5-_GHVD%_7J"-FDTPFS':3A>]3(G9Q
ML`I,%^^/)36.VJ5S7:++%7TH8F,^X%4Y\`Y^<M,);<D1G6]O[$*+Z,!;R.[N
M*>G](UH6$EH7IAL_-^E>I87#X?Q*EJ=:_0502P,$%`````@`]9,'1\*;Z0B1
M!0``E1T``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6R-F4USXC@0AO\*
MQ9U!:GW9*4+5Q&9K][!54W/8/3O!"=0`9FUGF/WW:UO=$++ZN@1P'K6ZVY+>
M;GMU:=H?W:ZN^]FOX^'4/<YW?7]^6"Z[EUU]K+HOS;D^#?]Y;=ICU0\_V[=E
M=V[K:CL-.AZ6P)A>'JO]:;Y>3=>^M>M5\]X?]J?Z6SOKWH_'JOWWJ3XTE\<Y
MG].%[_NW73]>6*Y7R^NX[?Y8G[I]<YJU]>OC_"M_V(AL1";BKWU]Z3Y\GXW.
M/S?-C_''']O'.1M]J`_U2S^:J(:/GW51'PZCI6'F?]#H;<YQX,?O9/VW*=S!
M_>>JJXOF\/=^V^\&;]E\MJU?J_=#_[VY_%YC#&HT^-(<NNGO[.6]ZYLC#9G/
MCM4O^[D_39\7^Q^=XS#W`,`!<!UPG<<]0.``<1L@@P,D#I"I,R@<H#[-L+2Q
M3YDKJ[Y:K]KF,NO.U;B>^,.`MZ.1P?)L2%<WW(G)9CO=B_7JYYIS6"U_CH;N
M&)B8)\MHY4=*-',EEH,#3B]@[IH!IN$!'PI+:!WP(6ID\S\C7C?%O9O")DM@
MLD3<@+PWH*T!B09DW(!R>J`F`[FY#_(T(<;FTB)<&,,8\W.%Y4P.0:RT&!BF
M@MP&I]62?>2\X6EG>!KSH^(&C#/!)CW!F=.#+)!@:1-L$<FD]F3$<H7E(,N#
M6(GF%/@2;+F-Y33D2?G-G='EF!X=",\R"RZS+!(@DIIE/!PB@J`S$PF22,FT
M2HJ3,V>@T^5A=<M`H,APZ=LH&.:5B]Q(Y$"'[6V(RT1:A-P=(9W<H:6*$&@1
M]KT@:R*/W$H$%U+R+!(FF120%B>XXP2,,PO%";AN&,A(H$BJC(M(I$AF+)R2
M#8(F8XDW5#B/+D[JDB>8D.Y<67T1/)0JB?O;B/`-+)#D(&)K`DU*'<G^YC9Y
MEI8JMPIR*S8"7%.A#'+2019;$:APP,)"2`9-;-TCE[CJW4+(-1D)>6XA%3MO
M2%43/3)NCZRT"N>)2CDWN+EX[+BQ($C?'J2<HT'(8TFWH(%$U7"+/\\PZ\$-
M9*&%$2J\+PHB<V^8M($05")";LA#EKA_W&4`QSH`G!N(XK20$+']DV,!$Y;V
M$KE%'EVOY)V1,BE*<-<`P.C\"D2)T()K;2*WDU`K"*%0B11*RXAXD)-<IJU<
M^%0-H'@`BBTD%+[@%EI`H045V.$(+?)<^I8%MA=$2LB]+0:E"SLW([WG!C89
M7J/^8-V='*#80J`2+A$2D+@,W:(,)*.AI@VAA<C")V)!($2ZCY)`Y=5DRBF!
M]U6\/TRW)@/)7JA.0VC!F8!(>TJH%!`I5$J@'A4BNK.Y&54FK5@#[=YOI,\)
MQ1JX!14,%2BAA*%01A*`IB1P;]=/&;#H<##=DW[OW5()V"CG(>>1\38?=*M1
MU&3L/B.G5.PV8^O-3.(AX99)0"%BH7*`H$C%@UBDI2X1\QZN%&".CRG23B;A
M%DB!VA/L%Q#*=5CS"N0@4BZ4-*D44R$=BA)1E2M(VZS"W2H+ZD1#Y0Y">:1[
M+\A8'NEU2@070L;"1%`EE@#"K=\"J-\.14F-LF*Q<H=0F;,\4N]<IU8L]E2`
M4#V5BRG1>A[%HH"[^Q&*5N":!#"19UDW>R)2GY:(#FJ310Y;)'5F>-IA*]PE
MA)"4WT`)@=!TZ(5+\0+13/F?56$#EFYTXS/J#_93(8'2*JAQ3WE,[^Z>!:JS
M")1<!4(+SGU+`PLD#^AWRJWW@O3>62#1342]#S]L+YV8WR&WA`N44^'4<)K)
M0B+CFCMZSN6'=T['NGV;WO9ULY?F_=3;MRC7J]<WBE]A?&?UZ?H3?RBXXWK)
M'S;V?>'-_'IUKM[J/ZOV;7_J9L]-WS?'Z876:]/T]>`U^S($OJNK[?7'H7[M
MQZ]FS(A]:VA_],V97H)>W\2N_P-02P,$%`````@`]9,'1SBV`("E`0``L0,`
M`!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R-4]MNHS`0_17+'U`3DG2K
MB"`UK:KNPTI5'W:?'1C`JNVAM@G=OZ\O0),JTNX+GAG..7/&EV)$\V8[`$<^
ME-1V3SOG^AUCMNI`<7N#/6C_IT&CN/.I:9GM#?`ZDI1D>9;=,L6%IF41:R^F
M+'!P4FAX,<0.2G'S]P`2QSU=T;GP*MK.A0(K"[;P:J%`6X&:&&CV]'ZU.VP"
M(@)^"QCM64R"]R/B6TA^UGN:!0L@H7)!@?OE!`\@91#RC=\GS:^6@7@>S^I/
M<5KO_L@M/*#\(VK7>;,9)34T?)#N%<=GF$;8!L$*I8U?4@W6H9HIE"C^D5:A
MXSJF/]MLHETGY!,A7PAWD<!2HVCSD3M>%@9'8GL>SFZU\W`31+PR\=ZL'SMJ
MFCAX69S*U28KV"D(76`2\3!A%@3SZE=;Y/0:/8_T_-_T]27]-CE<3P[_H__F
M4F"=!#:30'YMQ(0YS)CUMR;L;$\5F#9>'4LJ'+1+6[I4E]MYG\<S^8*71<];
M^,5-*[0E1W3^9.,!-(@.?/OL9DM)Y]_/DDAH7`A_^-BD*Y42A_W\0)976GX"
M4$L#!!0````(`/63!T>B0)K3I`$``+$#```8````>&PO=V]R:W-H965T<R]S
M:&5E=#DN>&ULC5/;CILP$/T5RQ^P)H2D5420-EM5[4.EU3ZTSPX,8*WMH;8)
MV[^O+\`FJTCM"YX9SCESQI=R0O-J>P!'WI34]DA[YX8#8[;N07'[@`-H_Z=%
MH[CSJ>F8'0SP)I*49'F6[9GB0M.JC+5G4Y4X.BDT/!MB1Z6X^7,"B=.1;NA2
M>!%=[T*!525;>8U0H*U`30RT1_JX.9R*@(B`GP(F>Q63X/V,^!J2[\V19L$"
M2*A=4.!^N<`32!F$?./?L^9[RT"\CA?UKW%:[_[,+3RA_"4:UWNS&24-M'R4
M[@6G;S"/L`N"-4H;OZ0>K4.U4"A1_"VM0L=U2G^*A7:?D,^$?"5\SJ+QU"C:
M_,(=KTJ#$[$##V>W.7BX"2)>F7AOUH\=-4T<O"HOU:8H2G8)0C>81#S-F!7!
MO/K=%CF]1\\C/?\W?7M+WR>'V]GA?_0O;@6V2:"8!7;W1DR8TX+9?VC"KO94
M@>GBU;&DQE&[M*5K=;V=CWD\DW=X50Z\@Q_<=$);<D;G3S8>0(OHP+?/'G:4
M]/[]K(F$UH7PDX]-NE(I<3@L#V1]I=5?4$L#!!0````(`/63!T=C!U$II@$`
M`+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;(U3RV[;,!#\%8(?
M$,JR$[N&+"!.$;2'`D$.[9F65A(1DJN0E)7^??F0%+LPT%[$W=7,["P?Q8CF
MS78`CGPHJ>V!=L[U>\9LU8'B]@Y[T/Y/@T9QYU/3,ML;X'4D*<GR+'M@B@M-
MRR+67DQ9X."DT/!BB!V4XN;W$22.![JB<^%5M)T+!586;.'50H&V`C4QT!SH
MXVI_W`1$!/P4,-J+F`3O)\2WD'RO#S0+%D!"Y8("]\L9GD#*(.0;OT^:GRT#
M\3*>U9_CM-[]B5MX0OE+U*[S9C-*:FCX(-TKCM]@&N$^"%8H;?R2:K`.U4RA
M1/&/M`H=US']V>XFVFU"/A'RA;#+HO'4*-K\RATO"X,CL3T/9[?:>[@)(EZ9
M>&_6CQTU31R\+,[E:K,MV#D(76$2\3AA%@3SZC=;Y/06/8_T_-_T]37](3E<
M3P[_H__F6F"=!#:3P.[6B`ESG#%?_FK"+O94@6GCU;&DPD&[M*5+=;F=CWD\
MDT]X6?2\A1_<M$);<D+G3S8>0(/HP+?/[NXIZ?S[61()C0OAUL<F7:F4..SG
M![*\TO(/4$L#!!0````(`/63!T=%XEF1I0$``+$#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;(U3VXZ;,!#]%<L?L`9R:141I,U65?M0:;4/[;,#
M`UAK>ZAMPO;OZPNPR2I2^X)GAG/.G/&EG-"\VA[`D3<EM3W2WKGAP)BM>U#<
M/N``VO]IT2CN?&HZ9@<#O(DD)5F197NFN-"T*F/MV50ECDX*#<^&V%$I;OZ<
M0.)TI#E="B^BZUTHL*ID*Z\1"K05J(F!]D@?\\-I&Q`1\%/`9*]B$KR?$5]#
M\KTYTBQ8``FU"PK<+Q=X`BF#D&_\>]9\;QF(U_&B_C5.Z]V?N84GE+]$XWIO
M-J.D@9:/TKW@]`WF$79!L$9IXY?4HW6H%@HEBK^E5>BX3NG//IMI]PG%3"A6
MPN=(8*E1M/F%.UZ5!B=B!Q[.+C]XN`DB7IEX;]:/'35-'+PJ+U6^RTIV"4(W
MF$0\S9@5P;SZW18%O4<O(KWX-WUS2]\GAYO4??L?_;>W`ILDL)U'S.^-F#"G
M!?/1);O:4P6FBU?'DAI'[=*6KM7U=CX6\4S>X54Y\`Y^<-,);<D9G3_9>``M
MH@/?/GO84=+[][,F$EH7PD\^-NE*I<3AL#R0]956?P%02P,$%`````@`]9,'
M1VB$/SFD`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULC5/;
MCILP$/T5RQ^P)H2D5420-EM5[4.EU3ZTSPX,8*WMH;8)V[^O+\`FJTCM"YX9
MSF7&EW)"\VI[`$?>E-3V2'OGA@-CMNY!<?N``VC_IT6CN/.IZ9@=#/`FDI1D
M>9;MF>)"TZJ,M6=3E3@Z*30\&V)'I;CY<P*)TY%NZ%)X$5WO0H%5)5MYC5"@
MK4!-#+1'^K@YG(J`B("?`B9[%9/0^QGQ-23?FR/-0@L@H79!@?OE`D\@91#R
MQK]GS7?+0+R.%_6O<5K?_9E;>$+Y2S2N]\UFE#30\E&Z%YR^P3S"+@C6*&W\
MDGJT#M5"H43QM[0*'=<I_=DOM/N$?";D*^%S%AM/1K'-+]SQJC0X$3OP<':;
M@X>;(.*5B>_-^K&CIHF#5^6EVNRV);L$H1M,(IYFS(I@7OVN14[OT?-(S_]-
MW][2]ZG#;7(O_L._N!78)H%B'K&X-V+"G!;,[H,)N]I3!::+5\>2&D?MTI:N
MU?5V/N;Q3-[A53GP#GYPTPEMR1F=/]EX`"VB`V^?/>PHZ?W[61,)K0OA)Q^;
M=*52XG!8'LCZ2JN_4$L#!!0````(`/63!T>N3LN"I0$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;(U3R6[;,!#]%8(?$,KRDL"0!<0)BO90
M(,BA/=/22")"<A22LM*_+Q=)L0,#[46<&;UEADLQHGFS'8`C'TIJ>Z"=<_V>
M,5MUH+B]PQZT_].@4=SYU+3,]@9X'4E*LCS+=DQQH6E9Q-J+*0L<G!0:7@RQ
M@U+<_#F"Q/%`5W0NO(JV<Z'`RH(MO%HHT%:@)@::`WU<[8^;@(B`7P)&>Q&3
MT/L)\2TD/^H#S4(+(*%R08'[Y0Q/(&40\L;OD^:G92!>QK/ZMSBM[_[$+3RA
M_"UJU_EF,TIJ:/@@W2N.WV$:81L$*Y0V?DDU6(=JIE"B^$=:A8[KF/YLLXEV
MFY!/A'PA/$0"2T:QS6?N>%D8'(GM>3B[U=[#31#QRL3W9OW84=/$P<OB7*ZV
MNX*=@]`5)A&/$V9!,*]^TR*GM^AYI.?_IJ^OZ;O4X3JY;_[#?W,ML$X"FVG$
M^ULC)LQQQCQ\,6$7>ZK`M/'J6%+AH%W:TJ6ZW,['/)[))[PL>M["3VY:H2TY
MH?,G&P^@073@[;.[+26=?S]+(J%Q(;SWL4E7*B4.^_F!+*^T_`M02P,$%```
M``@`]9,'1U+1-SBE`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,30N
M>&ULC5/;CILP$/T5RQ^P)H2D;420-EM5[4.EU3ZTSPX,8*WMH;8)V[^O+\`F
M5:3V!<\,YS+C2SFA>;4]@"-O2FI[I+USPX$Q6_>@N'W``;3_TZ)1W/G4=,P.
M!G@324JR/,OV3'&A:57&VK.I2AR=%!J>#;&C4MS\/H'$Z4@W="F\B*YWH<"J
MDJV\1BC05J`F!MHC?=P<3D5`1,`/`9.]BDGH_8SX&I)OS9%FH0604+N@P/UR
M@2>0,@AYXU^SYKME(%['B_J7.*WO_LPM/*'\*1K7^V8S2AIH^2C="TY?81YA
M%P1KE#9^23U:AVJA4*+X6UJ%CNN4_A3;F7:?D,^$?"5\S&+CR2BV^9D[7I4&
M)V(''LYN<_!P$T2\,O&]63]VU#1Q\*J\5)O=IY)=@M`-)A%/,V9%,*]^UR*G
M]^AYI.?_IF]OZ?O4X3:Y%__A7]P*;)-`D03VV;T1$^:T8/XV85=[JL!T\>I8
M4N.H7=K2M;K>SL<\GLD[O"H'WL%W;CJA+3FC\R<;#Z!%=.#MLX<=);U_/VLB
MH74A_.!CDZY42AP.RP-97VGU!U!+`P04````"`#UDP='E-.T4:4!``"Q`P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R-4]N.FS`0_17+'[`FA*15
M1)`V6U7M0Z75/K3/#@Q@K>VAM@G;OZ\OP":K2.T+GAG.9<:7<D+S:GL`1]Z4
MU/9(>^>&`V.V[D%Q^X`#:/^G1:.X\ZGIF!T,\":2E&1YENV9XD+3JHRU9U.5
M.#HI-#P;8D>EN/ES`HG3D6[H4G@17>]"@54E6WF-4*"M0$T,M$?ZN#F<BH"(
M@)\")GL5D]#[&?$U)-^;(\U""R"A=D&!^^4"3R!E$/+&OV?-=\M`O(X7]:]Q
M6M_]F5MX0OE+-*[WS6:4--#R4;H7G+[!/,(N"-8H;?R2>K0.U4*A1/&WM`H=
MURG]V14S[3XAGPGY2OB<Q<:346SS"W>\*@U.Q`X\G-WFX.$FB'AEXGNS?NRH
M:>+@57FI-ON\9)<@=(-)Q-.,61',J]^UR.D]>A[I^;_IVUOZ/G6X3>[%?_@7
MMP+;)%#,(V[OC9@PIP53?#!A5WNJP'3QZEA2XZA=VM*UNM[.QSR>R3N\*@?>
MP0]N.J$M.:/S)QL/H$5TX.VSAQTEO7\_:R*A=2'\Y&.3KE1*'`[+`UE?:?47
M4$L#!!0````(`/63!T<D54U<!@(``'L&```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;(U5S8Z;,!!^%8L'6`-)@$0$:;-5U1XJK?;0GAT8`EH;4]L)
MV[>O;0R;K"R2"[:'[V>&@2$?N'B7#8!"'XQV<A\T2O4[C&79`"/RB??0Z3LU
M%XPH?10G+'L!I+(D1G$<A@EFI.V"(K>Q5U'D_*QHV\&K0/+,&!'_#D#YL`^B
M8`J\M:=&F0`N<CSSJI9!)UO>(0'U/GB.=H?(0BSB=PN#O-HCD_R1\W=S^%GM
M@]#D`!1*922(7B[P`I0:)>W\UXE^>AKB]7Y2_V[+U>D?B8073O^TE6ITMF&`
M*JC)F:HW/OP`5\/&"):<2GM%Y5DJSB9*@!CY&->VL^LPWDG7CN8GQ(X0SX0L
MM(F/1C;-;T21(A=\0+(GIGG13L.%$='*2.<F==E64]C"B_Q21,DFQQ<C=(,9
MB0>'F1%8JWLMXL!'CRT]OD]?W=*3,<.5RS"Y+["^%5B-`FLGD/I*'#&'"9/=
M-]EX339.8+M@XC!I>-\D\9HD3B!:,)DP#SSOU&N2.H'5@LF$6=\WR;PFF1/P
MOG;.9,(\T/BMUV3K!)8:/V$>:'P4>EULV$@LM7X"90_T/HK\/NXSS):Z/X.^
MMA]?#0<&XF1GH$0E/W=JG`US=)ZSS[$=+I_P(N_)"7X1<6H[B8Y<Z1%E)TG-
MN0+M'SYM`M3H/\%\H%`KLTWU7HRS<3PHWD^C?O[?%/\!4$L#!!0````(`/63
M!T?SBZH[O@$``'L$```9````>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;(54
MVVZC,!#]%<L?4!,2:!H1I*:KJONP4M6']MF!X:+:F+5-:/^^OD&3"C4O>&R?
MRXR8<38*^:X:`(T^..O4'C=:]SM"5-$`I^I&]-"9FTI(3K79RIJH7@(M'8DS
M$D=12CAM.YQG[NQ9YID8-&L[>)9(#9Q3^7D`)L8]7N'IX*6M&VT/2)Z1F5>V
M'#K5B@Y)J/;X?K4[I!;A`*\MC.HL1C;WHQ#O=O.WW./(I@`,"FT5J%E.\`",
M62%C_#]H?EM:XGD\J3^Z:DWV1ZK@0;"WMM2-23;"J(2*#DR_B/$)0@F)%2P$
M4^Z+BD%IP2<*1IQ^^+7MW#KZFVT4:,N$.!#B'P3BC5R:?ZBF>2;%B%1/[;];
M[0Q<6A&CC$QNRI3M-*4K/,].^6J[SLC)"EU@//$0,#."&/5%BQ@OT6-'CZ_3
MUY?TU&>X#AENK@ML+@767F`3!)*E$CWF,&'2ZR;)HDD2!&Y_,9DPV^LFZ:))
M&@3N?C$)F+OHAPDYZPX.LG9#H%`AAD[[YIA/YSF[CUUW?</SK*<U_*.R;CN%
MCD*;'G6M5`FAP=A'-PE&C7D)Y@V#2MOPUL32#X??:-%/HSZ_-_D74$L#!!0`
M```(`/63!T>"P;\$O@$``'L$```9````>&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;(54S6ZC,!!^%<L/4`,)M(T(4M-JM7M8J>JA/3LP@%4;L[8)W;>O?X`F
M%6HN>&Q_/S-BQODHU;MN`0SZ$+S3>]P:T^\(T64+@NH;V4-G;VJI!#5VJQJB
M>P6T\B3!21)%&1&4=;C(_=FS*G(Y&,XZ>%9(#T)0]?\`7(Y['./YX(4UK7$'
MI,C)PJN8@$XSV2$%]1X_Q+M#YA`>\,I@U&<Q<KD?I7QWFS_5'D<N!>!0&J=`
M[7*"1^#<"5GC?Y/FEZ4CGL>S^B]?K<W^2#4\2O[&*M/:9".,*JCIP,V+''_#
M5$+J!$O)M?^B<M!&BIF"D:`?866=7\=P<Q=-M'5",A&2;P02C'R:3]30(E=R
M1+JG[M_%.PM73L0J(YN;MF5[3>4++_)3$=_'.3DYH0M,(!XFS((@5GW5(L%K
M],33D^OTS24]"QEN@OO=]KK`]E)@$P2V4XG)6HD!<Y@QF^LFZ:I).@EL?S"9
M,>EUDVS5))L$LA],9LSM-Q-RUAT"5..'0*-2#IT)S;&<+G/VD/CN^H(7>4\;
M^$M5PSJ-CM+8'O6M5$MIP-I'-RE&K7T)E@V'VKCPUL8J#$?8&-G/H[Z\-\4G
M4$L#!!0````(`/63!T=B+8]4L0$``!8$```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;(54VVZC,!#]%<L?4`-)NFE$D)JNJO9AI:H/N\\.#&#5%VJ;
MT/Y]?0&:5&CS@L?#N<PP-OF@])MI`2SZ$%R:/6ZM[7:$F+(%0<V-ZD"Z-[72
M@EJWU0TQG09:!9+@)$N26R(HD[C(0^Y%%[GJ+6<27C0RO1!4?QZ`JV&/4SPE
M7EG36I\@14YF7L4$2,.41!KJ/;Y/=X>-1P3`7P:#.8N1K_VHU)O?/%=[G/@2
M@$-IO0)URPD>@',OY(S?1\UO2T\\CR?UQ]"MJ_Y(#3PH_H]5MG7%)AA54-.>
MVU<U/,'80JBP5-R$)RI[8Y68*!@)^A%7)L,ZQ#?;9*0M$[*1D/T@D&@4ROQ-
M+2URK09D.NIGE^X<7'L1IXQ<;<:U'31U:+S(3T5ZM\W)R0M=8"+Q,&)F!''J
MBQ897J)G@9Y=IZ\NZ;>QPE5TWZZO"ZPO!5918#VV>+?48L0<(L8=V^LFFT63
MS2B0_L=DPOS\%.1L<`)T$\ZG0:7JI8USF[/S%;C/PN"_X47>T0;^4-TP:=!1
M67=\PI1KI2PX^^1F@U'K+NF\X5!;'_YRL8[G-FZLZJ9;./\*BB]02P,$%```
M``@`]9,'1[T&^8.E`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N
M>&ULA5/;;J,P$/T5RQ]0$T+:*B)(35>KW8>5JC[L/CLP@%7;P]HF=/]^?0&:
M5)'Z@F>&<YGQI9S0O-D>P)%W);4]T-ZY8<^8K7M0W-[A`-K_:=$H[GQJ.F8'
M`[R))"59GF7W3'&A:57&VHNI2AR=%!I>#+&C4MS\.X+$Z4`W="F\BJYWH<"J
MDJV\1BC05J`F!MH#?=KLCT5`1,!O`9.]B$GH_83X%I*?S8%FH0604+N@P/UR
MAF>0,@AYX[^SYH=E(%[&B_KW.*WO_L0M/*/\(QK7^V8S2AIH^2C=*TX_8!YA
M%P1KE#9^23U:AVJA4*+X>UJ%CNN4_CSD,^TV(9\)^4IXS&+CR2BV^8T[7I4&
M)V(''LYNL_=P$T2\,O&]63]VU#1Q\*H\5WFV+=DY"%UA$O&8,)L5P;SZ38N<
MWJ+GR>)K^O::?I\ZW";WQ^)K@>):8)L$BGG$XM:("7-<,+M/)NQB3Q68+EX=
M2VH<M4M;NE;7V_D4#Y%]P*MRX!W\XJ83VI(3.G^R\0!:1`?>/KO;4=+[][,F
M$EH7P@<?FW2E4N)P6![(^DJK_U!+`P04````"`#UDP='GR<SF'8!``#T`@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6QM4EMOPB`4_BN$'S!JYV4Q
MM<ET6;:')<:'[1GMJ24"IP.T[M^/2^UT\:6<`]_M%(H.S<$V`(Z<E=1V01OG
MVCEC=M>`XO8!6]#^I$:CN/.MV3/;&N!5)"G)\BR;,L6%IF41]]:F+/#HI-"P
M-L0>E>+F9PD2NP4=T<O&1NP;%S986;"!5PD%V@K4Q$"]H,^C^3(/B`CX%-#9
MJYJ$[%O$0VC>JP7-0@20L'-!@?OE!"N0,@AYX^]>\\\R$*_KB_IKG-:GWW(+
M*Y1?HG*-#YM14D'-C])ML'N#?H1)$-RAM/%+=D?K4%THE"A^3JO0<>W2R?2I
MI]TGY#TA'PBC<0R>C&+,%^YX61CLB&UYN+O1W,--$/'*Q&>S?NRH:>+@97$J
M\VQ:L%,0NL$DXK+'#`CFU>]:Y+<6C\DB[RUFMQ8Z8L;)(F$F_RS8U40MW\,'
M-WNA+=FB\S\GSE`C.O`*V<.$DL8_P:&14+M0SGQMTJVDQF%[>6/#0R]_`5!+
M`P04````"`#UDP='&SY-U4\"``"<!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6R5E=N2FC`<QE^%X0$6$LX.,K/J.NU%9W;VHKV.&H59(#2)LGW[
MY@0>&M'>2!)^W_?]DTB2]X1^LA)C[GPU=<OF;LEY-_,\MBUQ@]@+Z7`KWNP)
M;1`777KP6$<QVBE14WO0]V.O057K%KD:>Z=%3HZ\KEK\3AUV;!I$_RQP3?JY
M"]QAX*,ZE%P.>$7NC;I=U>"65:1U*-[/W5<P6V>24,#/"O?LHNW(VC>$?,K.
M]]W<]64)N,9;+AV0>)SP$M>U-!+!OXWG.5(*+]N#^UK-5E2_00PO2?VKVO%2
M%.N[S@[OT;'F'Z3_ALT4(FFX)353O\[VR#AI!HGK-.A+/ZM6/7O])O6-S"Z`
M1@!'`023@L`(@K,@F12$1A">!=,E1480/5M2;`3QC<#3BZ66>H4X*G)*>H=U
M2/[_P$S@5)H(9T>L+Q-;ISRIVKPB/Q703W/O)(VN&*B8Q<!D]YFE9L!(>*("
M:QG0M45`'0'\B8B!`?>9U<#`^\S;P`3WF?7`A(\G%%Q/*-#K&AB#Z+%!:#4(
MC4%LJU(SBX%)'H=$UI#(&-SL?JN81(=H!O@^$">3_S@IMB;%)BFS)85Z@S7S
MQ)(GUHA$1T!_(L(P21(&F772FEL9+HK2##ZQA:FUH/3QZB[3_US=S)J4F:F#
MB23-1""(+X/^X=XT%R;7G"[(NSAB&DP/ZC9@SI8<6ZX_[7%TO'!>H3RB;L:7
M8+;21]?9IL@[=,`_$#U4+7,VA(L#4)U3>T(X%J7Y+^*D+,55.79JO.>RF8@V
MU;>'[G#2#7?A>"$7?P%02P,$%`````@`]9,'1P9VZ3V^`@``X0L``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C,N>&ULE5;;<ILP$/T5A@\(6G'/8&82=SKM
M0V<R>6B?%5NVF0!RD1RG?U\A+:Z=REAY,2#.GCTK=-9;'<7P*G><J^"]:WNY
M"'=*[>^C2*YVO&/R3NQYK]]LQ-`QI1^';23W`V=K$]2U$24DBSK6]&%=F;6G
MH:[$0;5-SY^&0!ZZC@U_'GDKCHL0PFGAN=GNU+@0U55TBELW'>]E(_I@X)M%
M^`#W2TI'B$'\;/A1GMT'H_@7(5['A^_K14A&#;SE*S52,'UYXTO>MB.3SOP;
M2?_E'`//[R?VKZ9<+?^%2;X4[:]FK79:+0F#-=^P0ZN>Q?$;QQK2D7`E6FE^
M@]5!*M%-(6'0L7=[;7IS/=HW^13F#J`80$\!D,P&Q!@0?PB(K#)3UQ>F6%T-
MXAC(/1N_-MQK^#"2:.9`%R/U/AG.P>Q47;W5E-(J>AN)+C#48!X1<QVQ1$1^
M@D1:@%,%O51A%Q\HJHAO$\27!)DEB)$@N4V0.!4DEJ"\++(WD-QN`T)(3DE*
M"+F.7%ID3J'(SX%7):5.2:G-!X4K4V(U60P0`M0K4^;,E!F6,IE)E*$8751^
MI7B+7%HD`(4,O#3E3DTY?M%T9I\M)B[+//'*5#@S%9@INTU0.@]?Z7_X@#@E
MF.7+:J]3@)MB<K*'"8$ZZX#)AH4'1>Q6,1G1:20\2PB*,Y+-^PB!*2E+K^\+
M;F\#.I?"G"@+2B'._'*Y30OI;2\AIL@3.F\E!/K7[[8W9#/-;=*4>7<WA/JW
M-W`[''*/!H<@_PX';I-#X?%=BMM-;MJ#XK-=#DJWKO(_YSO.0?G)1D?=;882
M#W<B:,:=J`J!WJ>3NAL7!0]W(LC;G?3*G$%G3@'^S2-FQIUX!A#HKC\Z&\;V
M;,M_L&';]#)X$4K/=6;\V@BAN"8B=VD8[/2\?7IH^4:-MWI^#`8[@=H')?;3
M0'V:ZNN_4$L#!!0````(`/63!T=_;W]D'0(``"T&```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;(65RV[B,!2&7\7*OHUS<P"%2)!1U5F,5'4QLS;!
MD*AVG+$-Z;S]^$:`*@T;;)_\_SF?37Q2#%Q\R(80!3X9[>0Z:)3J5V$HZX8P
M+)]Y3SK]Y,`%PTHOQ3&4O2!X;TV,AC&$*&2X[8*RL+$W41;\I&C;D3<!Y(DQ
M+/YM">7#.HB"2^"]/3;*!,*R"$??OF6DDRWO@""'=;")5E5N%%;PNR6#O)D#
MP[[C_,,L?N[7`30(A)):F0Q8#V=2$4I-(EWXK\]Y+6F,M_-+]A>[6TV_PY)4
MG/YI]ZK1L#``>W+`)ZK>^?!*_!8RD[#F5-I?4)^DXNQB"0##GVYL.SL.[LD"
M>MNT(?:&>#2,=:8-B3<D5T-J=^K([+Y^8(7+0O`!R!Z;/SM::;DP271FH#<C
M]3G9G,*>5%F<RSB!17@VB>XTL=5LG28:%:'./EDB#J;LL2OQ?8'**1!Z7"&Y
MK^""F\1O(KJOT5E-[BB<)H/+Y?>BRHN2?/D8)9U$23U*/%4E=2A.\Y2DD[Q.
M5'D10C!_S))-LF2>)9EA<9JG!9QC<:)\`9/'*&@2!7F4=`8%^6/)YE"<*,H>
M@^23(+D'R69>%:=)$$0SKXH3H6P)OZ"$-]>0$7&T[4F"FI\ZY:[(&!T[X"8V
MU_A+?*L[HVMDUS1ET>,C^87%L>TDV'&EFX2]RP?.%=%<\#D+0*-[][B@Y*#,
M--=SX=J96RC>7YKS^(4H_P-02P,$%`````@`]9,'1Q*-Z,L]`@``2P<``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULC97+CILP%(9?Q>(!@H%PBPA2
M0E6UBTJC6;1K)W$"&H.I[83IV]=7)M,ZETW`YCO_^0R174V4O?$68P'>>S+P
M==`*,:["D.];W".^H",>Y),C93T2<LA.(1\91@==U),PAC`+>]0-05WIN1=6
M5_0L2#?@%P;XN>\1^[/%A$[K(`K<Q&MW:H6:".LJG.L.78\'WM$!,'Q<!YMH
MU92*T,#/#D_\ZAXH]QVE;VKP_;`.H%+`!.^%2D#R<L$-)D0%R<:_;>9'2U5X
M?>_2O^K52OL=XKBAY%=W$*V4A0$XX",Z$_%*IV_8+B%5@7M*N/X%^S,7M'<E
M`>C1N[EV@[Y.YDD!;9F_(+8%\5PP]_$7)+8@^2C(]$J-F5[7%R1073$Z`3XB
M];&CE<29"I')0"Z&R_>D,YE^4W5UJ>,DJ\*+"OK$Q)K9&B:Z330N)9^94!IX
M->+`UR(V`7=:6.*)#LGG#F9RDUC%PM?#,%O'E+>9YG_FILC2*[(T`4MX1\0Q
MWG=N11P3/Q9)O2*I#4CNB#AF>4?$,>ECD<PKDMD`[W_0BC@FOR/BF.*Q2.X5
MR6W`/]]_T$QA1`Q3+M+;3&.8*%X\85)X30ICDD)?E]R8&";)8'8;:@R4PO*)
M_VOI52FM2N3KLC0JADGR,H5>8X,U%BN+ZX49G?!J\^HQ.^E-G8,]/0_"[%WS
M['QN;&*]^7W@=36B$_Z!V*D;.-A1(;=0O=,=*158&L!%&H!6GFSS@."C4+>Y
MO&=FLS<#04=W=,WG9_T74$L#!!0````(`/63!T<1ZA;-^00``#H=```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)69VW*C.!"&7X7R`P2DED"D'%>M
MXPV35&W5U%S,7I-8B5T#Q@LDGGW[Y=!B,Y-&=&YB(%\?D-2_#JPO5?VC.5C;
M!C_+XM3<K`YM>[X.P^;I8,N\N:K.]M3]Y[FJR[SM;NN7L#G7-M\/1F41RBB*
MPS(_GE:;]?#L:[U95Z]M<3S9KW70O)9E7O^[M45UN5F)E7OP[?AR:/L'X68=
M3G;[8VE/S;$Z!;5]OEG](:X?M.R1@?A^M)?FW770)_]853_ZF_O]S2KJ<["%
M?6I[%WGW\V9O;5'TGKK(_Z#3_V/VAN^OG?>[X76[]!_SQMY6Q=_'?7OHLHU6
MP=X^YZ]%^ZVZ?+'X#KIW^%05S?`W>'IMVJIT)JN@S'^.O\?3\'L9_V,B-*,-
M)!K(R4`HKP&@`7`-%!HHKH%&`\TUB-$@YAHD:)!P#0P:&*Y!B@8IUZ#O\['G
MHM],PK'+AP&SR]M\LZZK2]"<\[Z,Q'7/U[V?SGG0#9.F&X&#VWH8@YOUVT9J
MN0[?>D^_,')@MHZ!>>;6,6J>V2$S3_PY$G$\C]PM.LD6B2_+8>[123*//+A7
MUA,3=NU.-[[\M?%A;'R)'F*&!R`]`'KX+<_3P*BQV4<&XJYSA)SG[IA<1G/S
MF2LR<X69&T_FBIDYD\MH;CYS36:N,?.4X2$F/<2CASBB<DW&@AH985*(HH@1
M*2$C)1A),#P8TH-!#YYVW2(3@4K2B#.84S)4BJ&`"F7&4"DVRY7DQ!$1&6AX
MW$=2\QVP10@2H36S#X2@PZ%2Q!RE$+14",GH!X3X`US0JB*`TSZ`*BK2F-D\
MM!((E`)%SB^`T1"*6=U.%Z[`RE61+Q!"<<()1->WP`('XPOD((Z."+J\!=:W
M(J<R%\B)@.$$HE5`.!E(?2-BA-)ND#('!*T#`H4@X?B0=(E++/%$>!)&2,<I
M*%[&DJYPZ98+G**3,XL!K/"$E+\QXPPA#9*;,%WA$BL\41P?=-U*M:P2.X1`
MFN1]PA_`NV40)_$9T),^K092^X8TKD`0$D+ZL[KC@MD,Z$F?UA@9+P_PG8-$
MK]#>UF>"V0SH29]6+HFBE&A?ZR<XVRL`W_J/R64TY\F=%D.)8IC$OA8=(9%R
MVXG60NFTD#,=`:V%$#%F"0<EG%D":!D$)X.I+Q!"AM,J0&LEH%8:SKH69K9.
M*('&NR<:(5:JM$H"JJ3QK&X>)H@CQT#K&:">&;*BL'P12F/-7+,!K3Z`VY.(
MU'Y<CL*TPDD`!&?Q"[18`-9MY'FU+4)@1*J8ZP^@ZQNPO@U9WVX7/$)*@^#5
M)EW?@/5M/#OX+4*?>35%2X'"*C>>;?<6(>BD2S`G*44+@G*U[IECMPB);DAR
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MSU75VLY5=*57P<'F^^FFL,]M?YETU_7X:6^\::NS^U(Y?2[=_`=02P,$%```
M``@`]9,'1Q'W@E6P`@``?PL``!D```!X;"]W;W)K<VAE971S+W-H965T,C<N
M>&ULE59=;YLP%/TKB/<67X,-5`1I[31M#Y.J/6S/;N(DJ(`S[#3=OY^_R!+)
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M#L`^`)\#H+").R&;YF>F6-M,XI3(`S.'!P\:/AD2S9SHW*0NVW).MO"V>6MQ
M#4WV9HBN,"[PT6-(?L9DFC\H@J]%<B>"O0B^39!?$U!'D'N"B`R*8`:%(Z#%
M=9FCQ92N3(?)2R`D1PC=EB)!*>)S+6X3T&"Q-+[8,IA!N51LX8IU&$JAIE&U
M5D&ERJ=*%I0<IL841PG50:':"]';!(""NVJ7([<5()@$0$2Y'@2`RZAZ(6P9
M\)ZI(((B;!KX@&O@;)OK8KPG*JB+N.,#$LYE=D4904'#.S+[HEK:?0?*<1&7
M;=A`X-R1+QG(8P#B_`-A`X%S1PY+2@Y3Q>F$_0.UO]R6=!P&BK@_+D9!)>Q]
M5BT=DP?E-4(0J1:V)/:6K.HE-6])0E'DS8[_\QUSI@2\=%P>=)<3<V(Q8GE8
M;+;O8FD.=$<@C_L?XO#W$7NC7U`$Q!SHSFQD[+&1X+V"R4?O%4S#1/3#1.4U
MD?_XXW*1*+OHK0YLQ[^S:=>-,GD12K=IMIO:"J&XID+W)$WVNAL^3WJ^5698
MZO'D^D,W4>(PM[OGGKO]"U!+`P04````"`#UDP=')"I!X^4!``"P!0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R-E,N.FS`8A5_%X@$&FTN`B"`U
M4XW:1:71+-JU$TQ`8V/&=L+T[>L+T$2U"AM\._]WC@&['+EXERTA"GPRVLM#
MT"HU[,-0GEO"L'SB`^GU2L,%PTH/Q264@R"XMD6,AA&$NY#AK@^JTLZ]BJKD
M5T6[GKP*(*^,8?'[2"@?#P$*YHFW[M(J,Q%69;C4U1TCO>QX#P1I#L$7M#\B
M:"16\;,CH[SK`Q/^Q/F[&7RO#P$T&0@E9V406#<W\DPH-23M_#%!_WJ:POO^
M3'^QV]7Q3UB29TY_=;5J=5H8@)HT^$K5&Q^_D6D/J0&>.97V"<Y7J3B;2P+`
M\*=KN]ZVHUO)X53F+XBF@F@IB%QP9V1C?L4*5Z7@(Y`#-A\/[;5<&(@F`YU-
MZFU;IK`;K\I;%4-4AC<#>M"XPN.LB19-J/E>D^C1)'8FT02(UP&Q%Q!;0)3G
MCRE[J\E<2J>)4Q0E$,)UI\3KE$Q1DW5`Z@6D_XN:N*A.@_("Y=&FK#NOU6[*
MFJX#,B\@VY`UFUYK:I)NB)I[G?(IZFX=4'@!Q8:H3H/TSUR@35D1]'K9Z;7?
M;1+%!80H^]<MO#N,`[Z0'UA<NEZ"$U?Z7-OCUW"NB$;!IS0`K;X^EP$EC3+=
M3/>%NU#<0/%AOA^72[KZ`U!+`P04````"`#UDP='5.Q;CW<"````"```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R-E5USHC`4AO\*PWT+A`CH(#,5
MW-F]V)E.+W:O4XW*%(B;Q-K]]YOD!*S=@-X8$I[SGB_,R<^,OXD#I=+[:)M.
M+/V#E,=%$(C-@;9$/+(C[=2;'>,MD6K+]X$X<DJVQJAM`A2&2="2NO.+W)P]
M\R)G)]G4'7WFGCBU+>%_5[1AYZ4?^?W!2[T_2'T0%'DPV&WKEG:B9IW'Z6[I
M/T6+=:H)`_RJZ5E\>O9T[*^,O>G-C^W2#W4(M*$;J16(6MYI29M&"RG'?ZSF
MQ:4V_/S<JW\SV:KH7XF@)6M^UUMY4,&&OK>E.W)JY`L[?Z<VA9D6W+!&F%]O
M<Q*2M;V)[[7D`]:Z,^L9WF2A-7,;(&N`!H/!C]L@M@;QQ0!/&F!K@._U,+,&
MLR\>`LC=5*XBDA0Y9V=/'(G^G**%PKD64<J>*I=0G3":W/2BR-^+.$SSX%T+
M73'(,"M@DMDX4@$2#42@`G!&@7R7!V3,T;B#$H@DF8CAILCZ/Y'1,./K,!,H
M5FR+E=T6P-<",0A@*S"_#K(S3`JUL`S&X3A4`A1E430.50!E$4+CT!J@!.$[
MFC=S)C4S"FGJ<H(A)T`>(HR1,RO`RAZ+,XS'L<IB\1S/G>D#MK88PBB]HV&)
M,[<$2CA1P%72YY9ER43'>BS$Z43W*XO%*KF)_J][#,T3=#NWU)E;"A]:Y/23
M07+`/(2/R-E>H,H+%8]3U4`E$UKK@4KC+XD%G^ZWEO*]F2S"V[!3)^$?.YP.
MP^L)Z?OQR_DJ6I21X[Q2PPYFTT6^R(]D3W\2OJ\[X;TRJ6YE<WGN&)-4!1P^
MJAH?U#@>-@W=2?V8ZN+#A(*-9,=^W@Y#O_@'4$L#!!0````(`/63!T<$-2O\
M$@4``.L;```9````>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(V9Z5+C.!#'
M7\65!QB[==@.%5*UW#`7`U6[GPT1)#4^LK8ALV^_/EH&0DMI/A`?OSZL5O\M
MVXM=5?]NUL:TP9\B+YOCV;IMMT=AV#RN39$U7ZJM*;LS3U5=9&VW6S^'S;8V
MV6HP*O)01%$<%MFFG"T7P[';>KFH7MI\4YK;.FA>BB*K_SLQ>;4[GL','KC;
M/*_;_D"X7(23W6I3F++95&50FZ?CV5]P=*]TCPS$WQNS:]YM!WWR#U7UN]^Y
M7AW/HCX'DYO'MG>1=3^OYM3D>>^IB_PO.GV+V1N^W[;>+X;+[=)_R!IS6N7_
M;%;MNLLVF@4K\Y2]Y.U=M;LR>`U#AH]5W@S_@\>7IJT*:S(+BNS/^+LIA]_=
M>":-T(PV$&@@N`82#>1D`,IKH-!`<0TT&FBN08P&,=<@08.$:Y"B0<HUF*/!
M_,T@\1KT-1\K%W%CP%1L8$>QY0;!CF(+#NR*@RTYL&L.MNC`KCK8L@.[[F`+
M#^S*@RT]L&L/MO@PWS,)Q^X=>O\L:[/EHJYV0;/->D6$HYZO>S^=\Z#K^*83
MD\%M/<C)<O&ZE`"+\+7W]($1`W-J&>%FSBPCW<RY992;N;",=C.7(^/)YFHD
MXMB-7!]T<G/8R5=TDKB1;XR+_FX93Z@?EO'$^FF9U,W<6F;N9GXA(R(W<V<9
MS\2YM\S;*(?=S*2GI_@X/>4X/05ZD`P/DO0@T</>^)<#DXP3:F0B-W&]3[BS
M4&06"K/05`PU9J'<68S$]3[ASD*366C,(O9<J6;'B,D8,<9(&!X2TD."'LA9
M/#)G(R/BE!$E):.D&&7N'HLS9*+ACQ%I3D::CUXDQP-$I(OA<.^#[#:)BF8A
M4M0D*M9GR),-T-E@7TM2[$?H9(+(QL,ICY"(Y?L!_CPID=,BYA4":#4!<;CH
M%P@)S:TZT,(#J#R2['D;;(2$8,\QH`4&4&%DS/%!RP.@/LC$G?$OA.)YPDV8
MU@E`H9"<%@9:*2`YG/!/A`2P1Y@6#$`UD'..#UH*`+5`>2;[.4+`GA*"%@V!
MK:Z`XX-N=0&'1_@[0F)L&4\I$%0RA;F7O+=Q5<(>!,<"`EM>"7>T'P@E_!&G
M6UY@RRO.<D70C2RPD16Y8!RA4X1X]S]!=[O`;E<>?3I%*(T%>VCH=A?8[HI<
MXX[0^01Q%@^"U@2!FJ!23XLAQ%==06N"0$U0GAO*-X0@U9H;C58/85<2OONN
MA;1G(7F)4!II;QM>(1=_O.]^7I@B!_'0KVZ'-Q:$!'A#(6EMDZAMFJ-MDM8V
MR="V.X0@94\520N11"'2G(67=#S+R,,9WR,$*N*G3$N11"G2K*<O6F4DJHSV
M/'_=(J3Y"=,B(U$_M.;XH/5#)G23O9_O-P@!MZ$E+1\2Y4-S%FV2%@5I^YV<
M$]COTO:QMXVO$%/@[W9IF]AU$[>CA"J3\`9)T:VNHL,%N40(0/J7(%<(QK%+
MJ.RC=H1KFKEKS%#1;&05I<S+I-5(V9<EGEO))4(@XP-+K6LV^=62.A&">06T
MPBFK<)X']\L)(M\_X9,L`7FRF;2RQ#SZ`P=L'&]I[$.49^UU8J&8-52T*BJK
MBN0;-AL(H7C_'A>^>]-;F/IY^$K4!(_52]F.+Z"FH].7J)/AN]'^<26/[KKA
M^GRFN\KNC"+/Z.[,\-$H?`N^7&RS9_,]JY\W91,\5&U;%<,[YJ>J:DUW-=$7
M/0O6)EM-.[EY:OO-I-NNQV]1XTY;;>VGM>G[WO)_4$L#!!0````(`/63!T<U
MW2AK*@0``&D4```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)68VY*;
M.!"&7X7B`0(M"0$NCZLR8[NR%UN5RL7N-6/+APH'!_`X^_8K4,,,GD96;FR0
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M_W\S/4F(9K0!0P/F:L#1@(\&8V"T@4`#\6X@K`81&D2N(T@TD'<C!$:L7NIU
MUF:K95W=O.:2=0D("XW7G1/MV=/Z-OK1]3[K_N&MEF\K+MDR>.L<31C6,R^&
MD=$\LC$(C$2@`R"C8#XU`NO-+3&L#2&E)8:'3K:?G,R&R:=A<B,6-V()AWF*
MJ0/3^%68`)+']A$90'1O_PEY-@CG8LJ4/1,;N0T#R?U3_PBM#91(F&<VAA%I
M&,]#6X0@=)!-DM.6J#M_["`F=8^==4_(`)+'NAN$1R&EA#"Z&X;)=)Y9(Y/P
M>69CF`A(U0VS188Y)'M*:I::.:>/[2$D1>N;NU3D%MD&B-8-\Q6A)(PL^8J0
M9-*2L`B!%#;M!@IBAY0%H&>/E97%#BX8^02`.:<MT`4+^./$189+,N-P#2/$
M0H=T`D''(C`=0@<7$2W(I_HW[X&N)"`=!,%R(VTE%"&(R;4\9)N!A)-J=.6"
MV'T9TK4+$I=EF+C,>:A?EDS9P!\4'DCIB%,,)GKL@H6D;"QTEHW1ZY>!@VP#
M=+\OF:P=A"!R2'S&Z&`8CN-03!BG%>'NBM`+F`D711"Z7V&31$+(NOU`1MBV
M'\@`6%ZH6X02%^GH71>CMUV35SLRC(-E`[!&"D"0ZPQ?[TA%";?XVB(E$NZP
M+6)T.622?J33J6&I`ULX:Z2DM+Q8-P@QEI*/?I@9#BA"AT+/8GIFIF[&MFT%
M,EP("[5&"A*PIJ*A$F"6I-XB)9G+)P0;ZWF)<^H:["9T064I_5$P7;E#U76H
M$)S>\?&9S=QDG`&2#A)PNC;SH>S:*M$`Q0YEE]-EEP]EUZ;;"+F,,_-=.6S!
MR,_;81R$7/:DG*[@?*8X3\=!*&9WXP0?SA<*51_[HZ#&VU77LL6/@+%Y/&]Z
M9MT!Q5W["RS60+1O8+&EVG7F+S8Z^S_WZ*S5/2G5P\/%AH=D#^@>:AS]+'4/
M%;%67_=PLD?H'G,,\Z[*:GG)CNKOK#Z>R\9[K=JV*OHSET-5M4K+''Z)?.^D
MLOUXDZM#VUW&^KHV)V'FIJTNP\'>>+JX^A]02P,$%`````@`]9,'1UZ\SYG.
M`@``+PL``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC9;?;ILP%,9?
M!?$`!6.P0T20UD33=C&IZL5V[29.@@HXLYVF>_OY'S2T#O%-P/9W/O^.(8=3
M71A_%4=*9?3>M;U8Q4<I3\LD$=LC[8AX8"?:JY4]XQV1:L@/B3AQ2G8FJ&N3
M+$U1TI&FC^O*S#WQNF)GV38]?>*1.'<=X?\>:<LNJQC$P\1S<SA*/9'453+&
M[9J.]J)A?<3I?A5_`\L-0%IB%+\;>A%7]Y&&?V'L50]^[E9QJAEH2[=26Q!U
M>:-KVK;:2>W\UYE^[*D#K^\']^\F787_0@1=L_9/LY-'19O&T8[NR;F5S^SR
M@[H<"FVX9:TPO]'V+"3KAI`XZLB[O3:]N5[L"A["_`&9"\C&@$4Z&P!=`!P#
M0#X;D+N`_%-`8E,Q![$ADM059Y=(G(A^/<!2R;DV4<Z1REZH@S6>W!QM7;W5
M$,,J>=-&$TUF-&NKR6XK-DZ!1TFB`+P4V90"6HK,4N3@O@'T&D"71NZ#M)I'
MIX&?-+W18)NJU10(IFEZ6[9Q5F`BNXF<>Y%SES.\;U!X#8J`G)VF\"9CS=>C
M#[J1M-5MK"[/\B(H:^2%1FZS8@8:!4!;#8;P#K35+1!"0=#8"XW=FQ-@L/`:
M+`(>E=,@.).UU8"LO)/UH,M`4-:E%[H,>%1E`+35X+2<9RX=,PYC!JD7VDQ[
MCGI"Y$0%2HMYID&(<1D&!?Q0P'^44R@K6J3Y/2@K+$N(PZ#\-1>XHIN5,_70
MB0!$&FJN)`[*`F=9&-98R7L'I"?F0_R5%.3^RCYY4P<11@%H_H(+;E33Z3Y#
M.0WX&`)_C03(_Z^:[C-4TL6G?9*K-J"C_&#Z*1%MV;F7]E,RSHX]VZ/IL+[,
MP^5:/92O*^HPU4KN72G42N%=06K%M(;)!U9=G<B!_B+\T/0B>F%2-3VF-]DS
M)JG*,WTHXNBHNM=QT-*]U+>J&XNX[>?L0++3T)Z./7+]'U!+`P04````"`#U
MDP='\J=T\2$"``#M!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R-
ME=UNVR`4@%\%^0$*QO^58ZEQ-6T7DZI>;-<D(;%5;#P@<??VXR]94E&G-S&0
M[YSS'4)P/7/Q)CM*%7@?V"A74:?4]`BAW'9T(/*!3W34W^RY&(C24W&`<A*4
M[&S0P"!&*(<#Z<>HJ>W:BVAJ?E2L'^F+`/(X#$3\75/&YU441^>%U_[0*;,`
MFQI>XG;]0$?9\Q$(NE]%3_%C6QG"`K]Z.LNK,3#N&\[?S.3';A4AHT`9W2J3
M@>C'B;:4,9-(%_[C<_XO:0*OQ^?LWVRWVGY#)&TY^]WO5*=E401V=$^.3+WR
M^3OU+60FX98S:3_!]B@5'\XA$1C(NWOVHWW.[IL2^;!P`/8!^!(0IXL!B0](
M/@1`9V;[>B:*-+7@,Y`3,3]V_*AQ89+HS$`W(_4^V9S"[E13GYJDJ&IX,HEN
M&&R9M6/PYT3KB>*"0"T0M,"W%F[Q"3N+$MW6&"U3.`O'X!+ASZ'60RA-[ZLD
M097$J\0+*HZ)JS@-0:E3<1!.JOB^2AI42;U*L&%?Q3$X0_>+9,$BF2^2+/3K
MF!PMM>N8&%=?V/D\:))[DX4J:\_D2R;YU[>D"(H47B1;$'%,6@6/B1<I_(DM
MDOLF9="D]";Y@HECBG3!MG4,QOE]D2H*G8#*G8`*+_Q#6P=5"2X_E(%7-]-$
M#O0G$8=^E&##E;[D[%VTYUQ1G00]9!'H]+OG,F%TK\RPT&/AKF,W47PZOUPN
M;[CF'U!+`P04````"`#UDP='4)+]@%$"``!*"```&0```'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6R-ELV.VC`4A5\ER@,0V_E'(5)A!K6+2J-9M&L#AD23
MQ*EMR/3MZS\H#"9D0VSSG7/NM9%#,5#VP2M"A/?9-AU?^)40_3P(^+8B+>8S
MVI-.?K.GK,5"3MDAX#TC>*=%;1,@`)*@Q77GEX5>>V-E08^BJ3ORQCQ^;%O,
M_BY)0X>%#_WSPGM]J(1:",HBN.AV=4LZ7M/.8V2_\+_!^1IJ1!._:C+PJ[&G
MBM]0^J$F/W8+'Z@:2$.V0EE@^3B1%6D:Y223_UC3_YE*>#T^NZ]UN[+\#>9D
M19O?]4Y4LEK@>SNRQ\=&O-/A.[$]Q,IP2QNN/[WMD0O:GB6^U^)/\ZP[_1S,
M-QFP,K<`60&Z"&`T*@BM()PJB*P@FBJ(K2">*DBL(/DB",QFZ:U^P0*7!:.#
MQWNL?H!P+G&F3*2S)_>7RZ/3GDP?7EF<RC!+B^"DC&X8I)GEF<D>,RO#H,?$
MBR&2Y#'R^M1D?6<2R$Z=[:+;=D/3+K*MY,\-0J=!:`QRX"K2,,LS`Y^'1,Z0
M2!OD7_:[TTAD,@P"GB?$SH38EHA&(@P#(8H!F!"4.(,2&Q2Z@E(39!B$T@Q.
M2DJ=2:DI%XRU9)A4-30E*',&9;:ER!64F2##(#!#\?.8W!F3VYAX9.<,`V.8
MI3>'=$>N<EO0&/1J[2($TW247!LR3J);\&&+$#A[U,NJR63DT"R4IQ-/#4)W
MEKW&\G1D0RUTOP4F+;BZ8GM\(#\Q.]0=]S94R-M:7ZI[2@615F`FK_5*OM@O
MDX;LA1JF<LS,J\Y,!.W/;^[+WX?R'U!+`P04````"`#UDP=')=H/MI@!``!V
M`P``&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q]4]M.XS`0_17+'X!S
M65I:I9$@"+$/*R$>X-EM)HV%[0FVV[!_O[ZDH46P+_',^)SC,Q.[&M&\V1[`
MD0\EM=W0WKEAS9C=]:"XO<(!M-_IT"CN?&KVS`X&>!M)2K(BRQ9,<:%I7<7:
MDZDK/#@I-#P98@]*<?/W#B2.&YK34^%9['L7"JRNV,QKA0)M!6IBH-O0VWS=
M%`$1`2\"1GL6D^!]B_@6DM_MAF;!`DC8N:#`_7*$!J0,0O[@]TGS\\A`/(]/
MZ@^Q6^]^RRTT*%]%ZWIO-J.DA8X?I'O&\1&F%JZ#X`ZEC5^R.UB'ZD2A1/&/
MM`H=US'M+)83[7M",1&*F9#_^B^AG`CE%P)+SF)?]]SQNC(X$COP\+/SM8>;
M(.*5B6_&^CE%31,G55?'NES=5.P8A"XP1<3<)4SQ,Z*9$,L9PKR!;UT4ERY2
M\;:87*PNS]`1LTPN$F91EOXV9C_CFH3+5UEYCDN&V-F(!KZ'/]SLA;9DB\Y/
M.PZE0W3@=;*K:TIZ_PCF1$+G0KCTL4GW(B4.A],MGY]:_0]02P,$%`````@`
M]9,'1V:C%5BD!```[!D``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
ME9G;4N-(#(9?Q94'&%OJ]HD*J5I@&1A@)AQJ]]H00U)CQUG;D)FW7]NMSG"0
M.X(+<OJD7[9:O]O)=%O5/YMEGK?>K[)8-X>39=MN#GR_>5CF9=9\J3;YNOOD
ML:K+K.U>UD]^LZGS;#$$E86/01#Y9;9:3V;3X;UY/9M6SVVQ6N?SVFN>RS*K
M?Q_E1;4]G,#$OG&S>EJV_1O^;.KOXA:K,E\WJVKMU?GCX>0O.+C3`S(0_ZSR
M;?/JN=<7?U]5/_L7YXO#2=#7D!?Y0]NGR+J'E_PX+XH^4Z?\'R7]H]D'OGYN
MLY\.A]N5?Y\U^7%5_+M:M,NNVF#B+?+'[+EH;ZKM64['$/8)'ZJB&?Y[#\]-
M6Y4V9.*5V2_SN%H/CUOS21)0&!^`%("[``1G@*(`)0W0%*"E`2$%A+L`B)T!
M$05$4H68`F*I0D(!B50AI8!4&M#WW'0N$(?LF@W2XP#;;A#W&VS#0=QQL"T'
M<<_!-AU"<8AM.XC[#K;Q$(M#;.M!W'NPS0=Q]]%V']]WWS<#/]C%2=9FLVE=
M;;UFD_4F"@<]7_=YNN1>9Q)-YS]#VGIPH-GT9::#8.J_])G>,#@P1Y:!<>;8
M,CC.G%A&C3-_6T:/,Z>6"<>9KY:)QIDSR\3CS+EA`!SGYYO-DXPS%Y9)QYE+
M@=:50.N[81`<Y_`'Y7%IS2WCZ/NUH.8;6X^C[[=6R[%^[BSS)X_?+71^M>/;
MU:[,:D?*H`49%)M!409V[1GFV#*10$6S*IHRO%N9ZX&)C8IA(!C^!$HAJQ22
M4L(I::,4OE(2"$6L4$1"J4/(,(E8*6:58J.$@4/),"F&4JF$E4I("@094C9#
M2AEPO-,GA@G?5/J!.C44A,(#@H"M9WB[+T@Y"B+H_=K[<)I/"53BTPS`5T6C
MC]IQ`@CZ1%.!=PD@F\!0DH/W"2`3P(BK.*6+G?KD#`-O%T!^@:Q?6#&"8KD:
M;QD0[F_&'5C3^$0W>.,`<@YD+<K*&0CEQ\9[!UCS2"4Y>%.`9/\(W1(4?:(;
MO(%`NK\;MP0!K32)'/+^@.0/2I2#GV:D:5;@<&BTNP9YQ2/7?#/-B*P:74P)
M"D%%0C%^[)'&7J$D!S_-:`95J7"\X+F%4.KWR`\STC`KT::*GU"D"56.)3@G
M2(F[R0\HQOM/S@^"4*S%#S+2("O)=0#Y\<1T?[W?"1+W4O&SJ>S55K+Q5/QL
M*J`<CJWG.4$1.G<DW]3N)L.%72I[#Y$ZN2OBDEAXDG@[4'1Q5^R%V5:.NP7D
M*DA"71.EA%6/W'987V';HNE$&B@5*O'NHVB;H-C+K=E+7!"DHG3LX#4=O`$Q
M#86^JGB;4M:F)-=EQ=N4(IO2CFX=$23?L2K>IQ1M)#1[\VR@KSN(O>LUT!D#
M.:KAG4R1DVEV2Y)2-09*%2KGBCXC,(98NM1X;U2T=='L=<,N-3+0.'#/V26!
MF$:AK"K-NZBF'8YVW.)?:&NU[/<Y!KID($<UO!]KV+][N2;H_>[E`WA#H(ZY
M;8[_Z@O$3?:47V7UTVK=>/=5VU;E\(WA8U6U>9<H^!).O&6>+78OBORQ[9_&
MW?/:_!AA7K35QOZVLON!9_8_4$L#!!0````(`/63!T?5204]W70``&7.`0`4
M````>&PO<VAA<F5D4W1R:6YG<RYX;6SLO=MN(\FU(/H\YRL2C?)8`E(T;[IU
M[VU`I>KJUG97E5Q2=V/0F(<DF1*SB\RD,TFI:,R#_^$\&3CS,A]P/N)\BK_D
MK&O$BKQ05%5['Q],H0V+169&K(A8L>Z7?ZNJ=?1QN<BK?_]JOEZOOO[#'ZKI
M/%TF5:]8I3G\<E>4RV0-_RSO_U"MRC295?,T72\7?QCV^R=_6"99_E6TR;._
M;-++8I.O__VK\?CDJS_^6Y7]\=_6?WQ53#?+-%]'%_DL^C9?9^MM=)7SF%F1
M1T=1-4_*M/JW/ZS_^&]_P'?XO9/H39&OYQ6\,TMG]5__8Y/WHE$_CH;]P7'S
MQP7\.&C_44!XG]YGU;I,`+"WR3*M/W513C;K316]S(H5@+=,HLNB7'6,=0G+
M*Y,%+&N6?HS^E&[KSUUNRA*WX'563>&Y_Y8F)2XK>I6L&S,?'0V&1Z-!QU2O
MLT5:1I?PWGU1-N:YF$Y3^!U^G?&370`+/._355&NL_P^NEDGL-SZX_^M>2PR
MPD_%`DXZ*06BQF-OBXX7?TX7BZ,/>?&81S=I4A4Y@'I559MN6(OE$M#D9EU,
M/\31#>%*]&ZSKM9)/D/0#[)<4.BP/H3#O=OMJK'1@_[1GSM?N$[+K)AU'I*B
MW__Q7_Y+&XZY8>R!OX8O&_M4?U+F;7WVS\/&><.K,WY]D=S7?[U+%E4#\LL"
MD#2O8-?A4U4LLAEAR\MDD>33%/87;G85'?R8)YM9!K\<P@7]\>95=/#B,'H1
MP5;?SHM-!5O?7$HZ=;=NW'4#DJJ"\;]N_)Q4\P@&C:;X(?W+)GM(%O!\8Y*;
M.2#LT3HMEP#+0UJM<?4`;UZLTVC80`"X$$B1JJA,IRF,.5DT;_IT6FY@!\KT
M(<TWC9^OW"S1.OD83<L4MF77>-=ENDJR691^7.$^5[2L8CV':\N+K[]P6ZSA
MX*?!!M6?^:'([_=?]74)E+N$NX-3XV:N\/G&F&D%P$T!_S8+PH%9"L1]FA%9
MWF_(.,K3=53<[3W,%=",_#Z#;9.%RAI&C35\5Q2SQVRQZ'R`MZU]NQ3;%EDR
MR1;9.DN;*.=08Y5L$P((5I8(,I@7!8#C)G%)[U*8QF&./#AN//AS4B*?Z3ZO
M$`/,W$]-Z?9?WR5R#M2R"Q2X\TCN\=$I7/]LALS"OW#6O4A$?H5L^\2A[%@!
MD?%YL8")JW_\[>^$2NMMXW"((\SXZGA2_W5T/(Y'_5$\[@^C`Z`WZ7("UTII
M#E"JX3`>C\[BP<EYDQ3,X.+"4@$^O)]'0,JFR2H#>%O6G$VSQGVY,#C.]WE:
M+`'5YW#-LX<T6A15Q]VNS*)_+TM^<N=H\?N\^7R*?G"=(+;,TW4&/*="$G\S
M3?,$6$\<_9A7*[B^=QF,\<NK`J6[_PX/O(C^T"&H"8/F'V/Y&V5\@CN8<_M[
MQ7Z<O?9R7L"AEA$P#;R'\-JL6"R2$BXW'!,]]-0(R68-K"7[ZU,PM^XU2D\I
MTV2XC.]6<JOX#"\#+/D!L.23V.MH;WFXP7S?/T&@+G&S)H4%&J@#B+33%DZ4
M37$E<#IW*>[;$L0_P-*<Z6=9;),%T`>@J<LV]LU8WL%JOQ6.V02_`OEI.H^!
MM3RDBT)8S_094'^7YBE*Z$3C9\LL)]E_#0?2O/R>>^%AKO;BI1=3^*4B^@)`
M5#OX&N]`VK%4PHZ[LEA&A4.B^C/OB/9D.5`?.%*D.BV("HPV!01>RW/UGU\7
M99K=YP#'=`X,.8WNX9I7G:,=7.4@^"15>@A'P)\05^^23.\<[-0CL[D&EVCR
MN[?`M-JH):U^Q835W<WZ0R^3*IO2:<RRQ68M]_7I^_XS+'B.CR</L+.PY'Q#
MW`.YIR4%^\W739:>X`B7S$/P9]0^JP5C6C+[=<-BW7-)#B[@)F`3WQ*;J!&9
MDVC)Y"-%\A$%^O/>-,CJ8M$O;XC]_O<=C/9:&.TE,]K.5]ZG:\`_`.O;I,R!
MME3=@[^[O(HNUNLR`_V<Q+9U$3$[ZWR'KESS6(D]QE%3C##G&R7K:*=>LV.8
MIUZE73R:)'BT*$G`(;?*S*3RRG.7YKGH`N_;/2/!9!O9YZZ9_D87<"EG,7`D
MHB1Q].W'M)QFJ)7`&EG7;!.]2'"H7XQHM2GQIS5N>2H#X5/%JI5./7^@1R<H
M=]^P3Q^U=?\CD31?;4KD:;PE:F:(H[?I(S_QC-6A8%GDOV[R*9W28[:>1T"R
M@9.`PKC&%T"DALF<\)[I4,PYX)L7Y_%IOQ_W^_U/`=HPHV<M^B>DY+M?9\5J
MNMV3=KG;`>0F]>2F=L%VVO(ZAGCJM=^$:M;EY)U&2*&@_PP\"1'DDV12,K"\
M7A2/[;)GE\A%?.^5E[HBD=$Z:>T5S%F!.(Z"QT.Q>$#\0IM.0\.S$ME%()$]
M.8>*#]%=4?*.M1*R'W,05!8DT=_5Q9T#DG<.(Y9W&CO*#STMX;1!-G4OYT5^
M1/8LD>5@*S+<GL9>."6[2RS<UU;QE+V@%5Z$$*3<APSE`N`C!QO$I2P_-'"#
M3)T]M$YQ]?:G;V]NK]Y^%UU<WE[]='5[]>U-`XRL6A4B'1\DGKP<XJ96:-&C
M!2W:C%SMED(<@ZP2\[+8W,L7.D.'Y&UE]+T%^^X=.L0C9D!W[]#KJ[<7;R]W
M[]!U64S3=":R?]9%,SI8QEY`WV4YO+$;U&^!Y$QI@L:-0:>"X#80E)S'W\=B
MJZH#T;M]7^JT!\?1)+W/<A02Z1!;;_Z.MU.T*'6]]U8O+'&WA.AR\[:^;J,)
ME1,Y9K@["4V]0`LK"&19RZ;LL"HWM?L:ZJIS"K:VAR>TV,R4SKJKT5P;G-\`
M*/[;9+TI"?27&]#CR0@,F_)Z0U^_ZU0[<8`*9:O7C$A`NSV+:3SL)C'&D%]N
MTX_KZ.4"N&Z=IJ,#\NMJE4S3?_\*%*@J+1_2K_X8#7H&W(D%]X[!]5IRU.ZQ
M*]2^B7SB'W_[OU"`3O+M/_[V/R-@'O"%O`9?P(6&L8%3YLDL2_)HH@--TPT)
M`!X"N%+P!7)9V(]95DV+!V'58J&@SVR16"X1+Y`1T=U#4VU*G&L%D!%[KC;"
MZ?GV3X&FY:!RSE-\8@U`O82[@Q>3%@(P?__R)X079L#)Z7+!_N`*%X`]H#XG
M1,+ATMLQ'K(2ML>\WP-%+XUD1VCQBZHP*X#A5]DJ7<":`>#I1G%[]B"$)(=E
M+Z+W;R\`/J#;L(@4:1+:)Y(5;1K,!S]GP&A3TKKQK;6?]!]_^WM%3*]<9TPA
M?LA6V0P./2]6"7PY!5Z'$/_P]II.:)U.YWFQ*.ZWO8B)%0H,_[%9;)V_-Z8)
MIG+VH.8G2R5<,][@V_3#,BN3Z#HXW2K$%YA4GN.)B]T(UHLN<//29\`D1_8(
M$NAB>U0\HOY;;295!MA7;D%IRV'\U$\7\WU'R/@G`DQ7U@J@>\%2##YZ^"1D
MP_X6V].)Y@DP)%Q,.XSH58F`<\%Z$YPT.'<WM3S`"-OU],&/-Q>'C7=`.KT(
MW[NX+[/I9@%W'ZZCE4L59#_$Q:O+0FX)!1X`D<[N4S1N^'G-EKH'_,VH-M,I
MWG8Y*'-19ND*S2BH1@!!GJ#Q0C$[3_$==(R7Z3U:>@KXF*R0$R..P3%-2I8$
M*V3/L\UT3=\ND_)#NA;!;I[!TO#GNXR-')[.,6A3\N-LG)429RZMS&XLI8;?
MTT^,BIXLN4$"D$#<")=9O[9JY`/89:/N-H`D9,I8I&LB`W"GZY,7LE]`1H`Q
MXV7P@HF3YG"0"7RMD+7)+NP<,OMRM<:C0=4#A,TJ$]O0"EDKR#1I1F937$6Q
M69/M%`=F-M*Y=;`=]V4"&HUH&AT;<+?A?:U2_T;&6\8S]%K9\1`=+R!E97=`
M@-!:PV(^Z>2@QTW;_&>['_\$'COL!3`D?M"5#HHFT(IE9G@M7_.YW-)Z-ZI-
M(DZ*'CJU>NB=$Q<JKY'.$\#O20K7<87N\I(4#IJ[G)%<2]KP/>N(@%3P2[HB
MXZT!#^[1-`-<<S?TQSQSFB]]>0%(#LNB"_YC[Z87?7=QP8P$&3`QK6S9#J%H
M6``/S+4`<CPK1*U%N@EXO5@0YP<-<H/:?)F*2H(C)SG<S47KP#W9-S,5:$";
M!;!KQ,-DUFD7"'#/[_D3.XWKR%ET`_Q/$5D%E[<8E,+6X!;C93[3I<X4E2T`
M\A`MLZ0H(J01KPM0W@;]HS\QE?HTW"C3NP4PT5BG15E$Z,`29#,V>,9T`-[R
MQ`L%^7F1P-U'7&:IT)-CI@6(OJ35`U+1]700J(8:(S4`%E.Q:3-PY9&$?;<H
M'BLQ0%F+5"YG#W"Q>E'IA.F,]Z-]8#T/H'XI:_95]K%AK:_-9+\9$[%&Y-35
M9K"Z+"<9%=FW9Q`TO4Z(])JP0''R.:=T!Q)!\4CC5"C-5$_0D`01L*B0J533
M,IMXM,I5L<!_[(_8-:Z\#U;'J"P!'4%@/!@3H/://1`Q+#GQIC1/ZIZS/4HF
M:$UJO:F!S!BS*97W=DI9<4U&$VG(BT4@)]7$')1'%TSAIC*=56KIX0F;5BTU
M!F%_B7R7)?VIW8106X";!J2Q(KB]M8:\"BAX19M*!2(.6HB6*1S_+!QD3N>`
M%A]R_JSG<*GX==+$'F#Q)/UDZLQ,.200R?E/5]\2(4<5?)X!Z\X<^Q<CZA)O
M_018"$9SP.>&NK/C6<00&'!6I/P8[1`]6SRB%('RV@?$9=#X:3\)]F4!,)J+
M@(R++2JT$;"=Q1(4.[CZ%/XJ%A[\#58#\Y0M$Y;HM<0)Q38@4*Z=2%),%MD]
MHRD\E4RJHIR(79.A@C,1X6>:$!8CLUG!I8/-).8Z"6^OW$0`J>=/PU^7NTTI
M#NB(PPD.)B`OOT]7"Y`L6-Y$IU/5]A72J<JXJ21,0']68Y,04OYRGBY(E4U!
MK"RVJ3!V:P&Y0+MHN:Y=+^:3.PPG!W@(*3("5J<._37S/XD.>*A&>SC]M`9G
MJ%O]O=)'X0;_2F>/9[?:@'B)VT_GZ5?5>-DO\Q]_^S^C*F7Z&(UHF0ECTHS=
M`[M6%RIRP25#L1B=L:%MNVPY+12!Q-6*HI>++G/\I/$*,]DC*[ZCG)E-,=XO
M."6&(0GB)DQ`&I,S/R4.#+>K;>18"0#9SPI`9#3YPW36J:JF]0@M-7P=/ZXR
MN.C,JF4'])#(;HH76X\+J3$0LM1?#PLYGH=R^,:6T+*J==/_0Y>3\$EBI9*U
M';5'\KT3/V$]%`S6OJHR7:@Y2M0NGCS8$XFQTK`W_#$3XRSA(JI=)4"V*CC\
M*EDBVP*A64,Q62BL1W"R/EHQT]N4(LL#N0;:G55S&@E>Q$`R5917R5J$");"
M%RCPH2CIC/*BA-%8@+LY:P%T]U;,@T5ZD//3J=&P40?0G$"6'ZW0U%Y5.]3E
M,JN<,>XY!*5^8:_VF.S@ZOK]?TV6JV]>';9L+9V62+2,TR#5`?5'/><(;7T<
M(JGB'QP8W):_TB[HL$#=4=E%"AZ\MUF)3B_Z.BT(B.X$!BQR=9$2IE=5@0%1
MY$;J6$9Z!T>)RDUS]TE_X:E!*DA!Z"0K)2_.0<Q&<W0!XH4[(IOCA-5.N;!`
MK-#5LB1`[$!Z_W$\$7-78H1C/(N0^`%L%SP9WQQR(Z#,E>8M&V^!]M"N-LA-
MURC=P'V_NF.5BH659?(K;!^ZV=9.]"8)2&CV-"G++7[C*&YSUF5"S#@#=$-5
MDFAX;I2>B&ZAB`]P!O(DNQ%0/J(+JL29C-(D/SVP8Y]Y+JQ]DY/->I.3^,HF
M$*_:L)2,SJ@FW`)2M<']]CCZ6&9KV&D07QYSH4%P7)[!5(:(E*EH19608;6Q
M&>J+_,(1:MXPO`3WN2-QY`CS^X?K1D,5W!.5&&M[^]1E=?"A4(I;ZRZ:56<6
MV9W,)OHT^LD:=R^OUJ#(Q]&]CID%TD`2K1^+(WAFU3A`O`6YZM6$_S&<%OF1
M`A.DK!6C"/P(@G9%J;R%)#TQ3$1P<1<9;BD[+)E?W64EBJP("JD)S)?2FFP@
MS%Y2A3:P*;@,E$$==C"O<*R8M1\>2W>A%_V,N-,</JD/KOC7.H/;U';`LLH)
M$NF,1?PBO%1J`ZU0()_QXF6L^G'`8)O<F1#TRM=A"NX+#+%`6MW<004\;LR^
M!!:\T:V7,9L0H4R_%PB[I@Z)!D51A'(3&F47?,F2M=Q.\A:0Q;3D5UR49?</
M>`[)8BKQ\H[TD,=CSTA,&PO>BUY)]&5M'J<QS3+THC'7GE#,9NU)8.KLG!(O
M39N^P"*6!+01ICC_+E)YN'1'%`4*+,%#)*&X76OWJO"ZI(/>RC2L$LN5V51R
M_I^R.]&,([F,0$1R`;JD@KNHP)LML)H@A14@T0QGXH!D/QV:YHY@N"-X)MWN
MV+2>AI@1QN^T:L4>D/HZ[Z)A?'HZCD?G9]%!:/A"*CZ,CX_/XO/A\:'3SMAL
MZ00X/0SU<_CSLC.AI(2.4^%>M&^D`SRJ>;9V_F$@@#<#@5RQ+C=L![(F!W?-
MIR#BH@ND_16?+T;10J@6^!L-9+OPZESMNH=*G\,H0P_FP`%0@-N*Z`T2315)
MO(_`1Z*O?X,-&\G';`GD@<?;2-CG!!4P8;<T$(GYP#,;CV[RYL.3K;"F0$PB
M$TK+PRE#2>):\I!D"_RU%[UKPE"ZC^)28T=RMJ);S&=)IURH9)&SC$!$S,6N
MJUSM%1%'PV1<T/H2<68ILJ'0H"ZSJ@!Y!B6?'UL6;Z!TPP(0FZ5>H@E<-SF\
M*7'TSUD,\WJV+Z,C?E'Q-:#YY8"W;H_1N,68:O&`I'4U^U9?P\W[7]$/.%8T
ML(OZRZ9`VJ70HB0G:AZ)+-,ZKNM1LON'2!._6_7,%,.6?2O$GP<KEDEE-N>V
M0"$>0PH$2EHH#F".0ZW&+0@@-K,9"`U3M.31?=%_.3[<\B()D"X5A;@IW%:^
MFP1[M-P`DD\:@*"189TH+786>GP;E!=4]A-4U3Q%[]SL"J[@(BF=[%L&B64[
MMWIDM[KMWN[8,B+]+..3"\>H+JP\-S!<O=[F!R.Z&HQDG:!]7A%E"3.)F""X
MSOF"L3.NV("_5X%2+YI,'B9^.H21ZS`+23&KK(`/FY)HF(CK9)>0_(E83"8<
M+;2#&HLH@E^+*1<#7;"B0N6VP%-]4K_\.%\[%-?;HD<9^HTN>)F=T7'1"WCN
M-![V,2'DR/SK%F,R@;*AARP:]./^8$A/R$=.:8+'!_#XX-1\^L'LILN"Y;%'
M\4G_Q/WMS$OEAX_CP>C$_7W=PC;I0?R/@>'7SN+3\=#][=JDIO-SCXTZ'<:#
MLU.91_[QW2;!%:;$39U+!)D].R1A$T;G\?GIF%Z3C[IY@P$,<C*0$?5?.S;P
M..Z?G[N_>^])^)H53UQ0;4(DQQTX(/0;8`^$0F072=!2E-UGF.&SQ/`\O/LH
MI8V/1+XCK%\3)22W4FC#2EHC?54[$*]41#5&>NA2MF)MJ^38KO2$BX!#8W3%
MK(HV-57""31)4(*KO>LI*7,!?]V$TYB`C?@UXP`]M;0X$PM(.;-T$=[I]C6T
M28BQM?:^@=L"2%$0'9NB[YGE<+(S\(%:+YSXIPO#O$@6(#]/'/I%0P?/;0C?
M8^BZJSDF1)\TAGS<0-AQKZS[#4,C2];P1X2K]SP&)\ZSA5/C87T.S?)"H^_%
M/&'EEZ;+OM=-=LBD9Q@;\B<VD@<^9Y+YUOM;A8$`$-QG_P14F7:MQ:-LW6<1
MGHWQ<;0=DV68P%K940RZK!IEGX0#3^[%.#X=G=`55#DBG`M'>4,F9HV=5,=7
MRYVW?F14K4'AJ<3%92'L1K!.6-EF](+X#4+;*F)$@2%38^,;62-U:4.5XU!4
M^-K1^BVN-HAR-_3O':@7;(C4AVT,NCB20M?(D_'JX>,N7O]`4WT/.S-AJJB1
M2$R9-9Q8$ZY((N_-3#>[#`)CXE&CTW/B6@<G(":<1IB?>AJ?]4?((H_A_T[B
MX_/^[H&.';.C@4;C`0US<-:7#Z-C_L"2R*T[RGTRG!6)GXC8$1-;:8*I*IN)
M5@\S:F01,_XU3$,O%\GTP]'-=%Y0V`I1_B,4E<DR:*5ML7ER"%"26SFV(;/B
MHMP!6RM3:\P3I[G6P\=JVF+X6O/Y5QGFJ<!HVPP=X_T>$(C?Z1_,!YOBLA\*
M-.+0QI^<]T9#^.WLN#?$O^^SZL/1'2JXCF-3I'6_=WP./P]J(^D&DHQP@#%#
MU2$\.\;GNRZ,W8D7T7GON(]8..R=]:.+^_LRO:=@UGW>5=F7T?*ML^^U/@Y7
M(#X&Z$?G9_$0YM0;-VU-Q:0@."6H[I'7$DSHJLS`=T306KYO"5+B()]U>L^5
MQ6QH4G2@,4CXH(E'.A07B<^GX!3]7G,!:$5<<]!-JQY&CCU9)(MD17U4Q^)*
MX2&.'L%%0AN#H&^7X(:9/\\$`T:;9]6Z*,FH$>1)R77%J3.X54P96-,4O&N`
MF7D]S\WA"@M1AIIX^FT45P\0.JC?P%ET%/K#EA(?P)F%AOHP=9+A7133&B*$
M\3*92QG()"1"4Q5<V)D[]3`45P^)Q6XGK]FP%';2H,S6Q,E8PK%D[#JJ:OR6
M"[!*\X>L%"<V+)UG#=;"!%>"R&EK,5(#A*[?"#W;ER\(&.;4?4'0O1#T?9.J
M61&:P,-?.W:>G8E-TLAQDOMMJ(EI#$YPQ[%)Y1WRJ3?*P=5*N'1/%QQ*N#$N
MI!6_AJ7>AP<@S)PN0!-PT;AG1GHW+^N1]S0UWL6Q=@)J\*UTBH/E3^RD2RGJ
MM#6^IHTCB<??/M;"XV`!%.+OCISLERX%O(Y_WWC_?2RN,0]:4J:!P-96[LN>
MGB09:8H`P#G5J(_`\^2]I:[4#15M0$29IK7(::!@\'DJ`<6O:;>R)>FV^!=S
M@1]WO)#XP#)16[V-R&2.W*"<0;%B+POX$QV\OKAY>8@@\J(K^1UTV#6],"EF
M@7$TF164F5'3C1,7[NS+B?GL.+X=/W)D`TWTB`F`J`%O4(<+];L)Z'+I@TZJ
M;G%V7Y:T<>*[1.'$K<=!B&>R3==F>C)2NS!;#-[!3!"TLLBX.;.B1G(`[DM[
M%#_%4]%>4.S>E3.:C7DMN*T*X\7-C_3+4?\\5A+!U^%2"UBQI>UR`_=IF0(V
M'US<7$8@-6IJFIY*QI(9Z1R`&%-`_>QN:PU:"_$)J(\?S]#2[;5+^>2\*_2'
MZN]N&AS`)=#0:U>OW]_@F:.*R`GPA(^WQ0H8,`"ZY\)P.;"&^TW&>3_5!K84
M$$",<@J(,2AI0(O&V4>\,\=^PO=UZY,9M,+[A]&*?DK+A&XVD[6LX/AHU#XF
M670P/V!=;HA6'6%U695_9_8[MVK-VBO-L3@KG+^,]E@9?7.->7<A&I7;%#JY
M52:DALCL'2L20`J6I-ICX`?Y?R16EB)TIPZK,@XWXA`2FE`\-Y6:1T*;B&$D
M#%5*"E4EXAM]N9#X3^4TS*\P\P.!L;#PIB1:P]8F0B4KCJ*9.#_<P>`0@%N7
MA0;W+8@QD.4*MI007'F"V!=<]LTW..O!L#F`RZV:^JI</C)"[$8+RM]<;)G)
MP<G@];61QJ'M4ZU-M(1IXLC!!4"Y,,8K(@@/Q5K]6\4*]RC!.,VTQ/1608^0
M:.JW"`-L#M;=<QD\=`$=6CL7FA\`C^*.ZPR3RFNL3,D=4$"OF".0`.HIF9TQ
M*0VFK?]XHM%>*I&8.`<@B/^1Y!L45EG%/^MQ[6\5JU8H^*]E\40VVQ(`<53G
M:JAM!,<Y`@&:%T55L[VCAJ%4OQ;[GGY<IV%X%1]V0+HO-O?HHGV">N,^7-N,
M2!BFK3@"$8SO"MQF(`C3M,RC`T=HAD!HQOW#KZ-7+IF01)E<@D1XQ\AM"5>5
M:V*3"'3ATT_9C"U&[G`F2<1;\9:%S$*J@UA**/1=?+.!\Y8#PZO,3YNRNQ+3
MPU-QQDLXK/%D@U`$2_4K2/T*3`+M-%C!/:U@*GLE3$JA5>?'75&LR3]ALC!1
MI)AAH65/4^!-7%/L'!Y5Q9F]$C=>:9B`7B6Y"NY*.YFC/;W22UD'Z%QQ\0RB
MT-)/APU*1Y'LP;TD\#CNT[NZNF_FLR[?:>RS$^T4E4;T4QJL?D>G2+/VL!Z?
MD#\A9;AA[NZ&E\Y%XJU`#V+:3"_3Y2;"R6C(;^D]S&OWD![4RQA<Y)K)H#VE
M>A0=16]24(-*IB!=-1%>A[D_^/NUJ;+0*![D:J5<F@04<V6?GW<]ZNT%Z-T3
M@,+W_K0';=Z1E`RB8IA(=-*+^S)E^[/Q%`[Z_=\I:;0V2!^)%UA1U#;86<+"
M5UTX<+'69W`;@E$>Z<Y+U3,,M*%A2-K4U$53?42KK6SC,&FC5FO%$624;Q:+
MHZ)DC1+IQSUH3WE8@H6.X/N7/S%N+N5<$#"JW-!0;WR>E]2/0]#$;V5LXRA`
M;99+S:?D!\;.KU7/_>I./*X%3(NYPCGLZW8+<5?632SU!>R1Y:LZ>DO*F='N
MQ6#@#'LBTDJ"G#%D&`>D1+^Z\#<4X\]0C&^[:E7LPP,J%8YW9.N)I5!VJ(QM
M\)YR-:H_#O]:;*M,#($^_D8]T)AHX>1T!WPLRHF(C!3KA5ERS@3/66/./@FJ
M!\91PU[<E\5F54DN&]`.5R@H&-"'_(;5M&LZ-L[6[7E69MB^\5J2)I#P184@
M:E$%84_XL(TSV^%55OIN:Z=TY798-VUWGD<=WQV>.1L-?.'3#)K%F(/$L<0G
MJJE:9G.:X8D7Y_'),7NI:UF6/)SQ^AUU>_WJ^<:<XR>)CQ@N,XK/3T?Q"&A%
M&/#,03;RH+OT+T9G@_A\S/$K2175TB5=#B19J;@.&<S1CT?CT_B\?U(O/LG@
MX%0HF$EV"E^#47PR/(['@V'[.Z;2D*-<=\6&.47Z,9U2>+34KV_-@77IE8VP
M$N>7WP?6;C]"G="]O;AY=?'G2"Z<(B'L*>@EPY/`#LJZ9#/)TQ%,HN>TY35R
M3M2P);.V<T%/;,Z.];TX.8D'YX2AL2&OH3M8_<`<0<)()8RA[/"6`K3]WNGX
M=[%UM<*79X/?8;&QOZ8EECL+7+7D`L[%$(#I&9@A!:^,6<7L1>]LOJ^-58=;
M-CQA=/:,PZ0;5]VIQ+8XR?/RBL7Q44\EUGF%C+Z`VW\^&G.H&-H*)VGTG-QB
MGU0L6<9/I!=KX2.\6D[U/&OJM&[1+X[CT9#AVR,?F*%PC&T7)([AUZFZA;%&
MYD!AIFIG+'JVE:\)]3$Z)H2*4MV7$GTCYL$:$^NB+J&(2^.GRD2[5]<X%UJN
MV?+P!$[%.NG`=Q*:&,ZTW99L;,=1.+Q!LU@MTDH@FDB-L(\42@5[^6(0GYV/
MZ(#12_`7D._7*,=XI?'/HUWA49Z&V\(%RH3"MBHF?_9)>GWS9")\7#\%V7O:
M<7*6)8[8C(]'\>#T5&'$&H%;4.&$IY(\SV6_8.RW<+LX:*25OU*M.BE-(4K6
M+!J<C>/1R.V!+WQ#*:^V2'B@D00)3=V$O?N=7:1[%`_/3I]-N4G<P#H[/JHG
M2-^I289/Q`LJY&Z)W41Z$`^&I_^:1!I#I/N?3*.U<*^G";3'P3$:FN<,,$]1
MYL%Y?V^ZK##L1J9/H<ED;^J(2NH6^HTIH$&$6^P!N[#<"ZNLW[1A#U<+<0J`
M"4E[EI:+]D80RDJEL:RX!:&:]5C+RV`+L!_4U]IH\`FA\T4T.AW$Q\>C]N>?
MDNE(YFEYU24![<`#NHH(`.]M=&4SWO?<K:\YJP$&&8ZC)UO518/!2=320R\Z
MB]H;PD6#\2GK7V)QJF7AC_!R#$Y]MOT`]2S8S/V[L8WBX[-^=!AQ&YR\R%OZ
MIKEV9M$!IXP<1JX4NOCM:_W,"(X!1IARLD1-84T6&!Q%R.+W_[:FP(:WK+EX
MD"1\!0N])[PA1#$\.Q`8220`@4'CY(,O.;^S-6-(BQ*C5T]YG<9&N?)1X3TD
MVB>X6X><:Q9H.I6DH5[;?^+2G(5%ST/,!:P9J"U+\J_0U260L?>QLORBJOL>
M=-N(+I#RPI7_4E>^@@K9X//H*-(F,C:U48JJ2N&3EMJL,7E-"^\UGF%'`F?5
M\450'#\6P28`W!^PJ16(Q"R0[H9]<<!QD2-W6"H7A4\/1KVSWPD.["YRX6[_
M,TO>V"HTW[_\28:+VTDKQ[Y3U;ROX3;X2C/D%]^"DKV:8SP;W':X?$!FPB>N
MEDMD56^*&9\`"&GG\>!L6'OL0@S'5_D\FV24`@O#'</.A<]-I]-7;R]@C_J@
M$0_D]OI'7CB2@W%>_GM/)TL-*,0@DCV*[52%UH[SKTU2*<7@2H"\O_[_H/Q.
M[#,P)[:VC@@0:*_#`"(2@9*\K9S.7>KO<6<=G:;-AK0:L[E$-0@.Y]B3"`%Q
M&4J]'U%K<`?)K'LG2;92Q02QUQ6KZ&$9VM05D>@2'(#"/%!BBRFD\4*X3$V,
M99K.],]7R&!EJ+-*S2YKYAWYJ?>V8YJB,YFGQ^H]K+9Y6MXC,W.V%:3#:-HS
M+LI]:U/1F6$V<5A>Y-Y6O>%=,7#+",:X**J=+;ABRA,UZCF:"?C\:V24X;)E
M<JB21TI!-"X_&S@U[#B&1VA";166W(DC@-/AO<<Q0B=?[:197$?]LKHEN7:6
MJ6]?W8L2>$["HJ2VLFN7X!Y[R=U;B]H21R1GJG\ZY"RD`*A9Q@5ND-]%;,#F
M:--]-(:=\^Z1[N1K^P)W(3])TB@P^ZR*MAA2H6').J!-?_1)W*P3N@BQ-I^9
M/[]/J)TJM6IUF[3K`RD\,TEH91!F)LPQR-B2*)O]UY298L%"!MV/+(X2_@,.
M4S%`?PFZR_R&.V+2ZGVY5R<42=$P<7SB,M?)!ZS.C=4,78#S9ZW0+\\)2PW/
M2JQW6@YZC@'-C$^^Y4\H\_#==[$'KCSWD^.T2$^$497[-^U3$'W`!>"X_-LM
M(;?MR4IY:,$7A-R4X.0_7;M]LKOS78ED1Z,-,45H/*;\HOAL,*`4]L%P2`EO
MP_$@:FL3"CK,.!X/434Z&(SBL_$8/XW.X_$YYK<=#,?Q\/0,/KGV6?C"V=D)
MO="/QZ?G],((=!L:9#2,ST%7/8R:'3!KE94.^KTAJD[X=\1_3^3?I_#OUD`-
M3((/^\[&)D@4)_.=9EVL0DOO,S?"0QHT1/RLV(QQKP';-(!MX6!+'&SM52A0
M$D+A;%Z/947!;$,.VNFSIZJ;,Q@7VPAL9VYD*V[N:@0<O2I>10?)(2/E"=55
M.$'4',?G_5/Z.^@/7$)Z=#`YC(8GY]'P;!0=@_Q]/#R)7KZYB0ZH[QS^-^R?
MP#%AC%<2':2'T8"2/<?PK98LZ!1X=_7^C8;Q:-!':PE<@>/X#-8*>#X:1<]K
M7>Q7L@C>DRI'^JI['-=[UC^.3F"=@_AD?(H0G`ZBB^DF6P-I:7MEJELQ..Z[
MK0BFHXT9GF!8$V[@472#LF"Y63;A/;@[A,DC(`^#P7ET=AII2_%GK1J`A@T[
M@?L[C(?G0_CWN'\6!7V;GR1/;<(#452^"#,UQ>P\19ELC]Q1AY?')Y@8/!J,
M_-FI,4+K".,IC>+3\0G@Q'!\[#:]\1SB(VP`GN5P.(CJG?3BQAO'\0F<_G%\
M>G9L4,<5NK``G,:CT0GLV<F)OP`M3P((I_US!.!4%=M9#0P\@E%\PJFH,#<<
M`FZ%$E*V580I4=^ANI([T\HK;+^Q5H43EXEV:JRP#ONJK8\T0>#V3V^.OIT4
MBX2BSM#G-V#W=S_TQXD*X:L@>:,)GA:%_#Y0R*D;D50V[!5%\8?2H"?:H`_Z
MKVU=HQ;4*"JWC:)\<RC.4DM!;F%HN?65:Z)%+DNVLW&L]FIN>F@IS#&U=6DZ
M+V[)8&Z$LS?4#6P1W>K\&?EPJ`],N"\HSH/:>J_-:;2F^V:%_WHQ&FO;5W$\
MNLH%XO_,O&QMJ2$`YD_&9VE:TP+U;IDN8,`IH9'IHWXGR8=H:R&'Q+TN#+O?
MOBHW]T$`J#O)$*U>%U)TD%ZP'3T+[J;U^A7U<G()[@@9I8U<T^8/HOD&5,FH
M2N[2-1IB!-0UYN7T$-\PG^:,L&U4\_[FG/<T\[&Z#N^<Q+XL9FS7H7Y%*^I8
M$G3Z620J);M49TDN4F1U&2<MN&>;E"%N:-(75[[.-UC&34HA&BSQS9P(6(91
M`VU=:6[V2V$"(%+M-<JR;/EDI$#?,:8>N:[;+T[B\U-!HW<N\6"H/3#"K9NY
M6]F\M`$\U.9(2_]+B8BG(4,G':,T8?@8!-/!N:^H8:`V.$X!X>(]"X)Y.)PP
ME]K&:`R"/_,TF55USQHHY-AKC6MMKHX>B_*#ZKMTQL74ERH?8A&K6I2Y`4SG
M<!!*FDJV9I>C&G-\RM?Q;[K)?H/-O@K%&)"#S6TGSC!G-4;K`%&LPUIBR8.K
M,4FWA4!6IS.Z4_ZJD#'!7X.0Y!@W9-VD>1>U$1W:$B`(SOA>,^XIC$3I)YO9
M?2H1Y*S`ZB$%I!7)DN[*N*_[0D4\9%5*.M&$7KI.771P[Z;K0IR[.VZ(+YF"
M);!\G:79+'IQZF;4:?RU3X/M.OIND^5IXEI2!E]>:*@)MZXSU2<#!W\LETT/
M-1B#JJCG/F'#U#E4H:78K">`71]P>W[&\*^+.TS;%21&B?MST5C/2(YDB+4K
ME`QHN[3@6C?VY^KM*W1)+;.J,B[TRH:U>E9M1Z-J*]ERLL&</QH[;$\0&QZ9
MY-:WAR83O>UJD&!3"_E)J2PX<@1*VDC37G318AEA2[#+L@I`\XXL=,&A\+LI
MV>NJTW)9@J";48(_N+E,'1TWO-29[!Z/VSZXDL1<)H0E2$JW$&>::7C6+/KT
MY"1D@+5EF'&-WLG`#_ERISQ<K7.$(AGEPP7=1BPHXN^0'D5&6=9F$;Z/(8!8
MD>S'I3M-`\%>]#-G_E#)VLU2>/5'^CSE+'))&W(&XN#X@Y.=HD,%#;&;!G92
M(R.[]-J:!42F<ZE@7E`ZV183U;S_$)0PHW?M-I92`"BYAFE(AV.5WOL5`&`9
MQP>$B?^FV%0+LB]GZ:.<DD<:VV7-^[!-2B7<KNG\:+-R3:`N=I;S<NG>V9JV
M%3T]H$.:4F/>V>+VF)=;%5(,S)E8")D\)CE?2KA]M<(D4NP/-1\*:'_G(AS;
MX/7RYSV,EXMY'*1"N)V!B)FLYR&IJ^6P^-Z6ZLL`O%BQV88]Q;\6&44A'C53
M%4+S2)O:1=7L`3D?$[C=J(>^6SD9]4;S@[VMC5]VJJRN%B5=7W7P?X8)2*,N
M(=,-HYPCU]E](A(OL0D)<,KBGC(,>5SL9^N@Y':MGB5<&".9FU1Z.GB6K3U(
MQ3I"RIB4_JX5NBM`>N:J*[.4NBMOK9[)A-05?FEI9,,),%S?V#6O1912IZ$`
MI=?:N=JLUV^2UD("J&T<A1#4%$QJ$"*LE]44HXTP7PE*1N[1-#8.#Y"FH.YG
M6L;<V8["0AW<)8V;_A`KD)5RV(1D6@FY];7?PQ*>/KDHMA:E>6IZSM;D36??
M0BMI%;TX.XF'*B,W1/3$6(PIW6OILF-9:FX>43-6EUHDLXTUYDOC=L1)/W7A
MD$:O_*@]+O"!5&EE;[6[R?40OWH%Q)EK'H]9#?&Q2%O$A_7LO+/3MYH7]&5K
MA.""*Q:`![_QEA%[,\PE*#I0.9$2ZF%4IG*JXJF&/W("R#+MN%V7/=R.RC>@
M(CFU,T61*I_^YFT)OXGFQ2.&,QLBE+DZLXUN@QKJX;%16^\]UE:"DK7T_]GK
MZBIC4X^?F+0`ASU<R&&!*'%*9/*Y562)N]/UQU@3TYBBAAUN?@S0XB1^OG82
ME.TI1NR+>%$'0T^*6!M,:I5G'*%W8]V)&UH[XK#5#;"B*!>S1Z"5,7>-H,(^
MKN/BIS`$#3^EW!B,Y+(T/UARNI`X448T%FLR1R79D)65%!Q6ICXL6I<)WW%)
M(ZRW+FDDA36>5APAB$`L%D[S:^=2*COO:L2V:;EV32U!30FV*2B[9DV/21\2
MG!>N8PZ9=@0_,?0_,XU]UX97`&-DOQ[9U[F!#88"&>N/%=AM;U+5_M?;'1'<
MK2U-IW1/..:4RX/3"-C[*J420V$#W-:Z^WB]^%:W%B.6X7A3Y*;5BJ(1<Y&X
M+%PKC^;R%O>K1MHCO],/(OBP.=;X820=?9%O%\DRXESS*2%4LJABR4I'$8R?
M<#9=]7/=6@ST3_.O\#25).-TW8L%EG$,[>:<U/[&.:GHLJX$#1Q?%?O]SH76
MI%`MX(W18,P;O2>,TX`8Q+C6[%'7Q52#3=8-7YZ,()M6/R;]GN]&8/:^NKIB
M$S<'?__P]NCV]GU_2)$^V;KM1&BOJRD*/%7]>**#[X&!_'5>;-`'U(M^6,]D
M^^4%)[#C/@T';=9TFP\06JXUC#3TLSA8D'CG'+TV3Y=B`P(E/*5E_71S'5,4
M,>GEJ-?-*'Q*)7"]NTOJBLIK#2]I6`7,4R.L>M/B)`]V+1:CL`=<JR4%*P`Z
M>H_)_`DFV*G(Y@_;M-H-SCN4>WO1]\K[]0&6*&`W29/#ML&+1-,OU&715KL&
M]&4B1VT@A+07V<1J@P86=R__7KFR9=0U"..C9UMF,O)T4T_S$#^DFH!%4;(>
M&PD-TAE%6%/^#VD;DNKO,\[U'!C,.5P_5^.;Z10*4V;8=5%\D'BCS(KI$B(M
MG9:]J,1O8J04AJ)(D[`Z4<>-]$GB/D0NREQ\JRLZXC:Y1S$*+TLL9K@X>K-%
MC+@!>CR9T%UZ^>:&KE%(-<5!-6#:T^]T4%$R9I+K6K@JI0AR+708)K,"+Y7\
MTYV-*9Z"F'RU3+3=-R`U;O3[MQ<$;97!)X)W60!SWT@YN*4V9@ME)VR7\_:Z
M=L,KV!AJG48FY^@^S5-I(,3R;X_@X,9[%+FIG<B,QY$<,&OJ4I3-G`E'DT31
M32#*)(].,8-S[>A)G9:<*<-=,WO84]\*J38SO6Q\V`T?\ZS<("93@4@II69^
MY477UAO*8:IVC;R6A]0!-V7JTU-\&A\*"MY4G`3V#X>L1HPAXA'Z_4,0'HD]
M:7R<<6)1<IY197Q="3SE"9KE4J-PH57AB$W._O;B,E"]3*19I!./\_2^0':6
M1DDK_45#IQPJ[;DSR78Y-9@6I@_%XB'U6Z@8,R/4T/-PI55]K&MP_6IL``=Z
M).L>ES^T"JF%0#B6AI;R'3%[I5V>>6H1*?82N\9R2LY+B2#I"53S;(7[T6CC
MUUZ-S"^.DVK9.C@IUG.I90&"%!8W,<RBC3(SE#T*-+'BX*N:H^YF@^7OC#V.
MME0#5[HE1'E"90Z7P(O%JYKRF7,I*2AUP^"38#UE)@SA]B0AMJZZN%%**#68
M2SX$XV7&&!/UAUZ+8O_]%LZN^)@LX#"3:$!;<?W]@`V55[545]\&@U6X>^H@
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M4<CPCD4F9)59_E!D4R'RE.84PN++F?+[R+Q+Y1+B_@K2DZBEI.^;A.`0%]!<
MHI*,54&JJ,L5D_(7XLE"8/R<8GD6)R&7M,_6W&Z4PM^IC!.Q!VX*+NF9ZKJ%
M=Y$ZSV:D]I74'+W(Z[/T@,O:Y?M?M*"[;)<H-9QO=A="CC]8P+6FLVC'8L:O
MDV1M\)`N4@G6<\A9$P::!U)O<BQ<WR,25R0EPX0V0S`,\;GWQMA;S5DW2S2X
M"M1U/`5!(%4>LZ&DWMRDGVF>+JP?T\`Z[7*FNGE5HQU<P3U-Q'^+$U,R%Y6[
M<N6(52!M,=Z;2C<4"HGT+G1AM=CC@]3G6D;LF8A.G3I_NB>/D#(F7'\44P'-
M7J8?0:<C709+J_F'T%TKY5:W'=>M9I_7HFVN!EK`S9Z`%C=1?/,4$T`L#)',
M5;D+3,YFB]46*N%KLI)$:ZQ/,;"'+(:<!$113W@ES!B=2G(J*:[;ME!UYPK'
M*/.ZC]C%I'?+@OJ("H,HK),8B)7"6\5`KZLDM>EN\:8$=D8S$?T8FAF_1R/C
MRZRHIAF5]]?*F3X*"`$@+BE\@)T"2@,J%ZK%,S<$5(WZC#CAK<5;!E+^LF"U
M<NO$2:H@]I=L4OP__S>:BHHI.9-NW^#_WCFQ_YR$Y>'.D%>&*W`"NMI$^%FB
M[-C]RW-ZO0GC\%S&GA5HDQF@4*U&YO4\6R1`2E9SD&VG<\R8IY+J.4I?Y%1!
MWADMMLO5'-2/I$(=>I%N/J3+#&.3M>\]E4)$^E,2GUQ5Q/H>J3#`+*N(Q,^3
MRHE+Q(&=__>QP*>76`^5>G*["7B+2<;3=4HKOQ7"R5NP-!T92/ZRAX/6@.@!
M@R\SK,V2JEV>&PDX@=80'-N-4>:<A$UFB9VWA'USH$[+;?-R[N#,&14P5D*1
M!.G`RS+YD#TD/3E]<E]K<AOP&G<I,U^>:R11MS8K5#/G$JY[SG;2<NFXC3+"
M2;I^1([&LRDA<L880-B;=+66W`PU+#L@FC':[+16S9?,#V1?,!*[\.[B3C?6
MMP/=-[4TO#:^PJ,4GL,!7@PX(IG-CGR`FA:C_.Y@S_DPJ^W%>.#'YE)/)I=^
ML3WTJW@.[%H,9=@[_AV9+U6=409W>WW9,&NFC16)S:(FC-@FE1AD[QHC3K/4
M]:13CUQ[Y65L&NRJN%R;*BX7`KCI95L?8-_W/B^K#VNE[5MF9N\'ZQ4WV8XF
ME*J>I_=4*M-MF<Q<0P@_]XMH&)_UA_2W/QZ#M-OI^0<`45L;Q.>8V!>/S@>.
M79$37!\XBK"7W'59W+$NBI31_G[2'U/^T]AG/K'<G:&)5[CQZ&3,PR3;LD"%
M7]_&E%,`^70D'M.VC3L='T?#X0DEC9T/,8'I/!Z!&-B*7)CY)J7U\_OZ$S=8
M)4GJ,/]>FQ71:Y^%+B<]/R6++!07?;P[!)`S2#CQ1`*3.-R-0^]*5!`PD7BR
M0&GM3JSU@#BG:J8)BX7&7#'/ERP=]GO#8Y]\&_M2%3C0/>41BXNFDN(7`SB*
MXZ8%B,P_:G!B54-`9!_8J'\T`S'-AX*XNA=AO@G6I:+A;9V]6DK*<!B?G@TT
M`'PJ)4@X=N@(([#7)IX@@,-5.=!@CK6+)='T&2YT<Z>'9>.[B6P1AHL'N8;Q
M&"*#-1;.-?,J-J(S=D"F@L=V-\=#+%E(N]F*JJ>4V$S1I:8:P27<(,`*;%/9
MS&$V#],3GX>WIU&O!8`I`X#%DQ08^IQ):9HF3^"82:!8KK0K!5OD;&&DLE]:
M:"F[HU0`FXN-ZDR>EAQTJC5-,%2'XGJ,81H&)`:6+5L:#6/\8%05@'=I?1%9
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M#U:?4AS@>QHVGKCU3N5K/US%PR31P5<@P'YU6/?<!1.]3M%OLK`3%M:Q!%KR
MX/S\W'O,4?GS[G*4D.F?,Y>%-#QU#2]J61GUA"M7&-RV)^^/8R4#M81<=7T6
M0.F*?#-=I,4:;0J-`!@-$DY,[HEI)T!W&@%''#\%UL.ZBO/7A;OU!J,LR-B!
M+GQC%N$?&JZXH5@7.H29($(R+_(C'R5I`N<3^`G6+E[>9+LHL'Z,/VT,*(7!
M?LP12^'#6]H-M'Q%%\"&BWN"\$<)4^"(95Y'1[)SW86/.6%O+\(I<[0Q;DQ[
M\Z?&<'9+-$M4S@@QV4K\`WD>U,RFOTX33GBAJ`6"HM*Y,72O1+;BFL+2E!)M
MD(N'@FRHSENUIFA(;#CB0J$D#52L5!DU9-2FZF15!&QB"?+N2`(TN$9TD"BW
M:*!+X/5&=Z)LN?$DWJ72>$#D4N.=IB`!5EGK)!!CUYR91.<-_)$RW&,B:76<
M@CNJVQ1,IL%.$\G(I1;Z@A99ZKT7JY">=80=4!B-WA*0/$*$DA)'QAJJVV4[
M2Y@8^B"S)]Y=Z4+>[T7?NN+>@>UO%'<#UC#[7)3H,]E47?91_=W%;>).X)A-
M%%&+3T@;'*;0S$&U.!Y9"F:WV9!PMWRW3Z`QU")P1M8C7V"Y-5/=&38IKXJX
M/E&*[U,X[KDR$1+6*`C)1UA&EQH*=+/>S"13&%.POG_YDUYZKC.!>K_;GK^W
MH("/$=0('=9X&:\5"ZM6R:">H1[@M`K([O2<$V+&+2M([$+SF"_2:E885DO0
M;&.S/I?N3E'P>O&:P5^:R.4:%(4QJ(0K.;J1*A%%7X),FH$Z<%DL-LM)EC`I
M?WE)Z'4I/)`;@;$[KK5Z@HNDK[85".-5+:\*W25T;Q!R4@ZY.AEL,TQ%^$:6
M"?<<XEDMKM2[E+;XDGC-DB;:QY'O^^@E&)0KSB*3(41$J\]"P$G$!>SZITWG
MBNK7%6G\[$[P'CN$Q'!2%^/K(RC@6S6B]H)X4F1KF+3A!\9F2M,/]?5NZDQ@
M1K-R24_6U9_;4RL(YZ*8%EC[^<ZN8UA'8*$%>FM""X`3A^'-&HE-YLR%RRDW
MGON.F$EV+0H)0'1?%M@3O&,"?+S=6:EG8G/5L`'R0@*2W`*$_&%1$`2+92EB
M`Q3%QMNN)54$G$"L=`'*P<*#H%KR13K6H.DB<A:4B-.(\ZHVU&:B=<\I?(4I
M.VDQ!!,.PX"2%28(UW+A](@W=]F"W7,@SHKWT5`)&T5I649A<D1/U("F0]W8
M*(S+19(ME6RAX(B%^R1&:2DA^<#RCWUY!WYHMD!4)[+F10"7<<WV-NQ&Z!HT
MFNI[$F"`Q@[?K%KT73<$BK]BMC.O]FA3R))6I>F'RB>%\>VIN%B;FJ,`4K$[
M-8*QO%&`@[,S1EQ.O<<E:GDX'#AG=VQE(@VJZ1QDP87#F3"\^LG0:)]<K45N
MBXIK1Y#9IUG_.AP_#D,6;/-2P_<H1)'OQ`<@^7.M&>1M"R2.!C-C9U]J)`R_
MXA>HOE;K1L$7BX5^4]P"F[8MWP/,J</K>FP>!?D''0_#$KNF9*@K6!B$8^E%
M"Q]\N2#?-@=8O"K3CZ`\-8J0-.<E_NWS[MH;-/J95INRVB32X%%:"7@+K@W/
MUY*P)-Z8C-L.$*A$>+4I[Z@VJ,Q6I9*E!ALK%;NUPHK$;TZ3585%-*H*Z`HV
M;*\_%[.\CBYX5W\@+QY-@J&KZ1KF`@<6PY:>F@1_X.(:6>6H:VOJ&^`L!VC&
M5*7=M7-[,73%>/`7=P[<*A*X.3?X]JX*+^/5HD?4=""B)C4^XH@1@_/A^.@1
MEUTDR8":LK05WC$CX"D:?_FM\\#6Y]7,U31'+X]"R<]*=`!ER7$=KTE=&H6?
M<"J-(VB+#W*64;8U4X8^2JS.Q(I&+KA)P%*YX9X+C[ZED+!F')#7U8@8!-7.
M:\TTP[Y+U"_":9.>DIAHJ6D7O5!!/FN6*._N)\&M*D:'ID>E+0SK&5:MSWC0
MCI*M$&1$GJAYX#%%X26=V:['3A]SY#=012K?-1Q3CU0]-*%;N)Y[CIZ:^CQW
MU\(RKQDTS%;Y$&"TK6K+`T?`LS+L,-&Z)%=S).R8T.Q<SQH'5\X"64E*,-7-
M0+Y&'X8I2M4Q=-C)\3'U"A1Y+7N#='C"5C8NP;R3HZO.@BORA3O\N3RKWTV#
M*[FB$:ZN<NLDMJ1`&_KVE!59%O4U,J;7Z:14M;#.F6IR?M.*P/D7+1R/3DW5
M(VHA*+;%V%H=0;TYXD'I$AAEB4,RN-Z0A%^NL%$<AG7"?GVMK2$<G\'2NET\
MB%7.[R\OS5>DV9".RIC<B-K/G*)0VQ2N%N6`-9&M:E,;&).5MAJB\$*V+K7L
M5V#4;M%:0UZ%`FD;PPI%Y_TB*E?>D#>K[W*LXYX/[<!5LDC#R,6N\42-C&O&
M.R&ARVQVA'0`;039/3KYF$@ZUNGK1"$A0&\M3XW"8FT*Z=JW#9,[9E++O45*
MSIRCTN]B&R(GU.->0<3EH>\U89$U<3T73,T-%WOGL9M<T:9[U!0(74'Y)'(O
MR)UX96WW3UW&P`/_C(MI!4>A+$&`Z/-NJBBD3J]2PP-.^`'$NZ,YB'AD#"W(
M33!IWV0R4)!(LD*I)\6X0JGIR2%B<MLI,^CVZNUWL-("2Y!6W4DW51HU'!JU
MA@'1DB)RO%'<6K*/):VFW=O4,&6;:I&U2^DE1Y=F4,?>3FDQ,7O;*@FQ](U>
M77N3-"`L?L:-TKM?15I_<R+YQ.VU(YY_WXAN_3,O'9*0[DMGKYH+L@J*HA,(
MKZ6@Y$7'7=JMR]4X9H<E"^?1PI5==Y:O5E.<#JI`&>1"PDN>F^+.3QM6QT26
M*G6E@*FFCU;RM&J6!`4U(WV"(?!G!ZVQS;O)`4ANJR=*`LL\&!PT1:Y1UI18
M_]XB46.?<#G"7]'RB6>C0.;FI@0$N>IDN386L[7O9UTOW(`@!1L5I#09'?K*
M[T&S$A'^VV7-+BG9A]U.6<FY)5L.!'-.Z6!:$I/N`*.Y!:/6/07Y=V5;?O##
MG-^Z"])@2VSPE_>&&6BU3EI`\S64=,(Y_7$S8IY.BSP*;60!R7>IV>=4_I/A
MK6,%;&L02<\E<ZI&E:`ZM*2:)%XT:UP-5@DM3_(]0$43,,G-&.B$5U8O['*#
MRT%;(NYJP.LZ+JJXCMJ>HJQ];ED21(ZB,N2!F"G[>:I\_]=MK$ID*=L/BPG"
M-\I_SER1YBXNX_=J+YGQFQ:Q\.FAF\X&.V(H(%)4I&%J>+5JPF)0<?33)$;B
M&4_QL+?IIBQ^0ADBS'^)+EZ2.\S]3DZQ*QLH_\D*E9\S4*,H:N`3=*FV3.AF
M(G3<GB="?L8"XW)F184<F,J350F<1':7SH%&R!E,?7-`JWD=>/OXN\N71_U1
M__`I9:=.8LE$XW3),%3%$RSJ>,_4@AF-3_'C;XDODCHYI6TQ)T>U$A?I0T)&
MM$;W2)9GN92^+]];%8M4>S>9+&<BFLU4:KO7Y"QHHF/']C]WNPX&Z/LWD;U4
MDX1+7[6&^#@:92=^R.C,.12FDDQ<0$?/R@^&9IY8J38A']U'>_5S9I]8R6]_
M>`+;S"[<=?XR1`W"52KCY\)C._9Z[^5:*M!2F:TN6#P?[B:`[`=ZQFJX1,Q,
MBG0#%H1+X!2V=G^H#<">F=)\GVDB\7OF"9VSD(2E[9]4$H3AC'TA=@Q5[BH^
MWVWI\#M$#ZJ&UO\\^X8DD^O0#=$F"Z-XDD`ZI%@/XYEAFK],T5RHSH(IA<MG
M2>S-L#HVUDARAD4\8E%&&UM(")MB3#*5:K(X:DD>&G]H_4UK.SV8E+.%I"L_
MSE/!L52;B%#NN7M1'!O-EG3Q#E68Z\0(GVP]X@FE/HLDZ`WEO>@"P]TKV"R*
MT!-GD%15V=$^L^8^?)3N\IS<,<$O.#`[>L/NIPM/>_E".0^'.%<X^4'2BA'6
M)<>NI&V]I9K.V]"T9X2!C/9DEQV-JB8^'@7:,SM8=PI*G%CB1"6VXJ2S3Y69
M:NCO:F!6'3PLDAK"*?5ND+K*0'``?2BIUX?GKN<MF80(M[J7FZ;'-DM-XW)8
M6F5C,)1>#3V]NMRNBTJ#<"5.[X?UC(1!^DWC<'V0F(NQV&G/VTNL.[!61*$.
M&)%09E.)HJHQ([<AS.%<FZ2`Q\U3=."ML^K0\F%,8/06>#8)!Y:BH)C"S%B0
MT+G[YPEPRB/@&&2?H29-1^B:BC0PK-*KCG9[JE@6W?[P_CS&_S]%NO;^ZKNC
M*V?I(]*$M54Q.1C^X'WC<*!?-_<^=D$<IZ9-JEN<=(J"]PL;ORK`U7T\C;+B
M(K8$*&RD%6,FV;75\.UBD^9_33CTGY")T)(%"RM72*=0?CRF7U`DJ(\N`2Z+
MEGD/VL_8BP+9^K>3`&H<KW''>*U-U_K):=-`JL4P``.[G!._G3:+LWHDX=PG
M9"T-^WKC$L4MRQD,?'^:IT'<)6NP5AQ0?=/+3XC_''!E!_6OGF,"_A2G2B-?
MTU3*O?#51JX+&!Q/[4`_-3J'MCW]R\6DHD#J>O[+'U]R.?$[,TG,[VVC7^1O
M=_J,?UW\THS4'&OJNQ^CXJ+(9WI"^QPITQW:2SDP)-P9#ASDIBN<I8;DB<UC
M9&":8C7X=&9KLD@*FQR'!.2:/FRX7#@(V%T.Q>W=]*+O+BY<9S(.4,N6[1!*
MEK,V@8E!;@G;ZE*'%\T^,E4'V1!,G;7;!M8873.5=-$BITA"&T%T6BI"UJL]
M<AB<W_,G=IIU(Q8GX&ZLB["C3GOFPEB$]+#5MP5`'J)E<AMT#-=XC>:.0?_H
M3YJ]^BFX(>$++IT(K02^%%+BJLZ@9X.B(/Q"L=@E!N+?.<W.]V.ANF0<5H%A
M+XNMR$<*@5:(U;37>MMHTD<QW_,.R$9''ISJEFQ%-8VL-3RG;>!/ZA$>EEK@
M^+"U6VU&#OVN=M@ZX=UFP8V9%">?<TILGV7&DRS3L.BWN:1*G+B3.%5?8J7#
MH95@IP0O[HW886V9O;"::ML#'>$ZH@K&!-C>8X,T7SH`""?V)Y;7`5D*AOF$
M;;8F<9>G65LZ8]Z&G%D9]2QJZ_"0U1VZ>W6`YPQ1HI136Q8[F?I;X7)%/567
M<*]U*EV>S"8T:L8"B:W:2\U?%J:+DM2!U\9)=>GS,]M4^%C+S)7I9P&@T:.B
M8879\2R%UYJF[";3[9'=7)35I36=1<I?8AZ_N5#(`'U-&BP;5"RS:2`("4K`
M:C`+NV5"YQK2DCL,)=?F)S+K2WJCD#:IBG)"8<:J>V#Z2D8B,O6>X#K#+L!M
ML:4N388*R(T&D'K^-/RU\]T=V?8P/I@<-F[A2SQ_M*!<>BFJ>L9E?)]2'6T6
M:A\3Q+26KZA0&L8-'['XI^XB^1F(!F=G,7WG+^?8UF*RC=+E:E%LT[1J6$HN
MPF:Y`?O>86`Y<-6ZWN6719D>^EOK?[I-/RQ!NC[4<&>*)`SAM(-RY"T_:G1B
M8-P:C"E:E*ZJ\;)?9CUZ^*+:$8]97UVH^-1J>K):$,:DEBVG10GGG!=,/HY:
M>[R65YCW'QE1W)5&K+4T9ACL"@)-3HNPZY0X,%S6MI%-`ZNP<B#246KHFA6N
MEZ-M];/*,$K6^6'-(?G""')<87^&NNF.R]3=MF\)+8O+A0155OBN$SY)-![Z
M%P/#H96*83T<--ZZJC`S`:U8/'FP)['4-Y\FJPPWGX)HM.,O68!A/F[A.?/E
M%QJDXKNBF)%M`$_H"I24G*N,<8^2YW#P8*3,CR1AJ;?S1H9\9DK@J@]+"UJ0
M%&12S)YJ+J.-&Y'HVY1:#:5FQ/`Y&U<-`,W19OF1]JKH;I)49I4KC_@<2E6G
M!%=[3'9P=?W^OR;+U3>O#ENVEM!`)'B^+"#%8DT6D`F/%A)T-W/B+F`"7,._
MTB[HL,"%L.RCU'+Q[SF5?FIZI`$UG\"`16ZC@DV"3^<RI.UFV^Z3OL938RHU
MMF5#"'AQ#N*GFWX!%32%;\U`L4D*$;%>*JH)GG'&,5Q4GHRO)#5F1=DPS5LV
MW@+MH5UMUFQPW6!.-ANJ2^Z3RE58-"M"5`V2U+3ON%9+<:2\.2M:)B?<E3.C
M;K3DL/%*GH1O29<OM`?2DYS\IIEEF5)]BL0C.4\J'+LL`HSK<D'V=QMR+WI5
MCK4"K&K4A%M`8N^)QU$M7C4#&=M'[9OJQKW($9%:21B<BSU"M40(QP%XPVP^
M.6E)V/C9[1^N>X:"UYV3;&M[^]1E=?")Z=9?-*N^8=B"1&;SX9,SJ7[W\FJ=
M)G!\]SIF%H@9"2;E',$SJ\8!DFM1[0B$_UB)G'QF@854UHIN'#^"H!T&3C#3
MDIYFW*4-$Q\RW%*\1=H113+'$10N`"T%=4.A0Z0(7&!^S^6`I;!2K090(]\`
MW]1=Z$4_J_^QEF=3'USQKW4&MZGM@&65K5A$JD@17BK-79%ZH[1X&:M^'%2B
MRIE,G&^J7OG(WA?M6=;<004\;LR^!-Z^T:WWP5@UB#C%<0\0=DT=$@UMDF8$
M,L`6+C?"_A6ZG0W9XELM[W4-"'7#Q>;VER>NPM9EKF!=U/D#'JKO4>WH&"[-
MYS(AM<.D'E<=.)3C3%)D+WJ5+3:N<)F?QZF)ME<U7L-I_<DJHT"@N>9?MVDU
M+`BR,Z22^@J2R$&N@G5V-$,X@+]XB*2O6]?:O?Z/$2B`-5N9ANT`6K2B$F3Z
ME-UI]AH1'U%5A!=;@3=;8-5?%)>)&(<ST9Z:Z="N>03#8?I>NMVQ:4'?ZZ?J
MHX9]'LPZ[Z)A?'HZCD?G9]%!:#5$EC",CX_/XO/A\:'3(=GFZZ1!/0R1`,UY
MV9E0[$JDZ5!6\KZ1IN+2Z,+SK]^1UWB'?Z([_(:I`UMY][YE[36^7@>DP5O8
M,#6_W+")S5IS'&52=W'[*Y3[QM8++M*Q-D2(6HPYU;9&H4(%V.&M(6%S8%HH
M<VY%6P`AK'+EFQ@^DM;]&](8XF.VI,(M.)ZTJBTFN`\B(=!`I)E@E_?ZHYN\
M^?!D*]PTD.S(.M7RL!29(@G3Y6KVHG=-&$KW45HON+8"E!7I&U@5*@QQ]M[:
M]I'<.E7`E#-22BGC4L<KCH5V:0]P>ZB1.'KIJ9PBE8=JV2D/I1N6$@_UJDX*
MJ6V-$6LHA'S.8J14$+D`%K@>Z;-%\\L!;]T>H]V0,=7B`2D8:IFOOH;[_;^B
M'W"L:&`7]9=-@112H2VI[P/A&DE9TSJNFSH1W%!7.V94/3/%L&7?C$-=)I79
MG&<)]0[LM"90TD*I-)(_#C7LMR"`F".YQ\J"P[MR_9<3'5I>))G7U9TB`0!N
M*]]-@CU:8M&I20,0URF!*+YSHN#;H&^AX2-![=+SC<[-KN`*+K"_6&N#U)U;
M/;);W79O=VP9,1A62\C+9K0MUO<;&"Z@VQ^,M&TPDM68]GE%^O:U"KCYACKD
M@C1O=Z\".X0H7[5,8(<P<AUF(2EF+1OP85,2#1,-PY:BCFT\XBYJ+`*/SR>F
MD";L2%*Y+?!4GS1&/\[7#L7UMNA1AJX]-E9%EUI7EK14),$P"MW&%_#<:3SL
M8XWQ(_.O6Y@7IB<G)M:IP>H[^(1\O"6S)CP^@,<'I^:3K2G^LXIK//8H/NF?
MN+^=M4'X8:H6X/Z^;F&;]"#^Q\#P:V?QZ7CH_G9M4M,_O<=&G0[CP=FIS"/_
M^&Z34&A\.K/>)F3V[#.&31B=Q^>G8WI-/NKF#08PR,E`1M1_[=C`X[A_?N[^
M[KTGX6M6/#&51];VP$V;4`WL@NN7W6<8C[/$K'\I4C8<'XD4R4'E/F4@-+MA
M0DE^?T23F(T2'42+S5;S-%W[&OXB/'?6[V_J:>$B*@PN1G3EHHA-S=H5+=;H
M#"JE[KUZTM?8.20".(TYW(A?U%'5&X><50@S:M-%>*?;U]`F(<9!*PSI=<[M
M3SZOI7P<NJX#WQF36`_?8^@5K3EI1`4V3HTU1W)Y^X+?,&UEOFOUGL=0X^YL
MX2P/I>D4EQ<1.ZG4HF+EE[9>X)UD1[J9.,8F-2%J\<DNU75?0S80`(+[[)^`
M*IWE4CS*UOTWX=D8?T_;,5F&:4NNU`M:=<)!!>#'\:G4?7$=&8.Y<!1;^9?J
M(S:/KIEK@PI\Q1UL^#9["+L1K!-6-G/Y*C6M(D84V%X9\TBZ:DYD-T]5\'K7
MBA\\NJW9HF[[UPK]>P?J!=M.]6&,+?"6D&K3\.:$:JI[UD29!H]?B7LL.IBE
M_.FPN28W"I#G-+O/G7LX.L#2=(=LX0E6E.:SVEIN=K=X01XU.CTGKG5P`F+"
M:72(S#8^ZX^011Y33XOC\_[N@8X=LZ.!1N,!#7-PUI</HV/^P)+(K3O*SE6;
MS=^K)^VQ6@5+$^\6]$2L1X)AIY-TCJU^'U(Q5=ZV&:!>+I+IAZ.;Z;R@B""B
M_$<H*I,QTTK;8J;E**TDMW)L0V:EH&0]8&O+VKL\>T-;?*HCRZL,D^AAM&V&
M00+]'A"(W^F?;[4SPD.!IB+:^)/SWF@(OYT=]X;X%_LY'%'BH>/85+.HWSL^
MAY\'M9%T`TE&.*`T^D-X=HS/=UT8NQ,OHO/>,393&0Q[9_WH0ONB=EV3\%V5
M?1DMWSHK8NOC<`4P)0KDQ3.LP-QHW*(W\)([U6VQNTT80D5?+)X=WJ(#3W7@
MM1]'`B*5<KM'7DM@*9H*'3QSWX+<?M\2:,:!6NOTGO/6;7A9=*!Q9/B@B2D[
MU+IIKGS]#"L\E+VHL0`TBJXY<*I5X>-VC;Q(30>IC>IX:2G,RA$^N+%HS)![
MTB4AOH4+^DPP8+1Y5JV+DJPG;C[*NI:"V3!U!M>721"KM(+@#3`SKU"Z.5S_
M+8JXE_`*&XG7@YLC[]]SSF4^T_`M-LGX8-XL]#O<!?*[Y*D4TQHBA$%*/E%9
MZH@P%FQC'SKH3CT,R]9#8OG>"88V%H@=6"@<-G$REI`Z&;N.JAJ#YX+DTOPA
M*\7!#TOG68.U,&67]@_<+K8BZ>XW0L_VY0L"!KCR!4'W0]#W3:IF974"CXK&
MMN\\.UJ;I%&ZH>RUH28N-3C!'<<FG7DIWF#%Y:^-'X%7?,`;<M@]77`HX<:X
M\&;\>H$=$((#B&M9S2'@6F3=J`DVSU:.O*=-Q5PL<B>@!M]*IZ%8_J39<M.T
M:H\]:N-(84EO*4;0P`98`*5[N",G0RE(RIR24\>_;WQL0RR>/@\:OFLE0SZO
M4/ZSIW?(*INFBP"<4XV("1QIWOG[@[I:R;/<[)N3/@;)04#-J"F)I!D_)QAV
MFM:B\X.QHM=T"E+W!?_&40Z3=[^0^"A!T;N]D<N`?$--G3'P[V4!?Z*#UQ<W
M+P]];F$EOU-A<;+3%K/`NIO,BM6ZJ=PGOA&TRQ'SY<'YUOW(T22^UP*J\)NJ
MDG"CMO[*VH6;CXYM)2E%8<M:*[<>!R&>]=9U','IR<KN0K`3UZ/;C<MIO,T$
M%*KSW)HI0C%LM!>:;BA6/^D0@=NJ,%[<_$B_'&$Y^J`I^*5KMT&FPDLJKX>E
MXPXN;BXC$'O%E.1.1:J:Y=H##*Y4=K>U%KF%.#4TK@+/T/(#7^>!W"[D-M;?
MW30X@$O2XBC.U^]O\,Q1Q^4VW(2/M\4*&/L)]DO>:V%2=.A^DW%N6;6!+04$
M$*NB`F(L8AI$Y)('>6>._83OZ^8S,RBU`:9>?&Y*R]QN-I.UK.#X:-0^)IFD
M,'=D76Z(!A[=;E>IRM4S^YU;M?8`+,VQ.#.BOXSV6!E]<\V'<&$QOKTYG1P`
MN_8<X8XU(2`%2[)-8+`-.;!<$WE7M%%ZPR6YANTTZ],VC#J&03%47`FY$K$P
MY0+X''.K'(SY(&87(3`6%FGSBZTJZLEV5(6!B8HX$K$83)FNR\*WJ*5<9NZ=
MDQ&"*Z\1`XG+\/H&9\4J+_4!7/[>=,/MEH,`$M]A`\'9,O.$D\'K:\/&0^.M
MFLNDD(0C!Q<`Y<)8WX@@/!2:5XS)K!B$C;&Q:5DFSLH<$DW]%F&`S<'Z"RY+
MC"Z@0VOG`_0#X%'<`8E-.+6L,F:RY`YKASG+PH#[AYZ2W1P3'V':^H\G&F&G
MDHX)U`""Z#HIT,-G()T@=JBXMD*%8BV+)[+9EF2*HSI?26TC.+84"-"\**J.
M?O%(]6N)#,""TS"D;2IMQ`WIEL9&3U!OW(=KFW4+PW@>>^,3Q9!@?%?@-E/'
MRS*/#ARA&0*A&?</O[;M\E!$"IH3L-\UR7D/6;2Z$!L:*MEDAQ4K?3B3)'NN
M>,M"9J&U%PTE%/HNSN7`^\Q1_E7FITW9WYK:^BD<)&9<\50`<^U7D/H5)'ZH
M:;""^X*;HO)>"9-2:-5[<U<4:W*PF$Q?K3!E:`J\B6N*G<=&RDQKK'ZE<0YZ
ME>0JN"OM9([V%%XO91V@=\@%9(BB3#\=-B@=90\$]Y+`XUA;[ZOKOIG/NGRG
ML<^`M5-4FD5!J=;Z'9TBS0IWEBJ4&U*&&^;N;D?C4"U[R>7-^7(3X60TY+?T
M'N:U>\CU:>4R!A>Y9HIH[V&)GO4G,_=O*<*AD;?_EEQ,_&-W#%RL_NTW&M:`
M_7!=&`/GX_]"HSP[).Y+),*72(1/BT1HI$A[=YH)WX3[Y2;_9!3]XF?[%_"S
M-:J52%\EA/W&I,M>2[KL!2;WQ1$UH8?3$:/33RY@ZL)XNSX5,[YXJ?YI7BKB
M;2-`C3<MC8->9L6*2KJ*_?]UF*2,OW/)5VZP>=C)`"T2N>SN"Q_U@#5XMO:+
M3T:5RUI'FFSV-36:]L'QVFXB0\^J:RB)%'MT.HB/CT?MS[=G4/ODW/-X>#)L
M>=5%D0;NAS`!8!`/AL@41V>#^!SXT)7-\MJS+\K7S(Q@D.$8E0<J,-EB<Y;A
M!H,3%6&"%N!G:&K@[%2RZ<.DG/PX&)_R`4E!MEKFV>@<.?VISS`;')_$?=A,
M-XEV![)17'8=!Z/X&"[#8?2.X,R+7!N0!T^19'X&J,:<_A#(`:JU/JEDG7PT
MW.&`X!@@Z60>U]V)R.__+O2]JN>F-K*._3:!C'DM:>9M-0T^&<E?F,Q7LAGY
MPL)P$K`Q@`+A$U?+)=+0-\6,RWM%@[-SD$B&M<<NI)O9E:].#,,=#_NUYZ39
MQ`!H\N!\(#OK'WGAT*&SM,.%;=\$*$=5A)#.^)C@3]V=6XJG?\/\\%OBA\@@
M@R^(D1#O\)\0"IH]B$S^C@H_JK4.J>]X3*0[/AL,2'(<#(?$B8?`6<FJS\D_
MWH)[`,K^>(BH?3`8Q6?C,7X"X6Y\CHSW8#B.AZ=G\.EM*LEJ^,+9V0F]T(_'
M(`/@"R/`31ID-(S/@=8<DDHP9<=#>ZK70;\W1-3'OR/^>R+_/H5_MS(#E#V#
MG@]`G+V1%2?C1G]!!XANW<?>'3,L-GDNJ>ZF3ZY!%^>TZY$P?.+S<*--5NH4
MHEIQ)=P@"0[2/7I5O(H.DD-&DA-2+TX05<;Q>?^4_@Y`]M((T>A@<A@-3\ZC
MX=DH.H8[<SP\B5Z^N0'Y\U"D\R'P^U<9VBR2Z`#$T0%)A6/X5B7WSISUG9VW
MA_%HT$?N`RAY')_!6@'O1B-SP'?4(F1WT7V_DD7PGJ0=-3K2X7K/0&<\@74.
MXA/@*P#!Z<!UI6U[9:I;,0`91K<BF(XV9GB"H@QNX)%K&]R$]^#N$":/X+H.
M!N<1J&6\AXOGK1J`A@T[@?LTC(?G0_CWN'_FCF,_<E&_+(Z7";UAL<A?@M@:
M\_YITK1#W^,35#1&@Y$_8N7)6@L%#W,$RO,)H,YP?.S.IO$<HBWL$Q[Y<#CP
M7+O4E=;?.`8Q]QC^__3LV&"8"U"W`)S&(Q`%SN*3$W]/6IX$$$[[YPC`J?*L
M60T,/"F0KUDXA[F'36&`B"3:/YQD<VTDFPN1;*Q:O@]IW'NP?]:I`WF=F6IC
M*JV]`.P^ZP_I;Q_(Q/O.@B+<"A[OQ3F2RGAT/G`M8?%^N@>`GL'^`K>]`T&`
M/?W![R?],:'*V"/)@A3R#+OG"+\8G8QYF&2+C;/\V\A4`61@;RQ'MHF:IX"H
MP^$)7</S(9[U>3P:GK4?-1I<WKH>BDZ`2:@1$GW]SK#Z5UBC%L#`\P%X&F?^
M,Y5IB]Y1F;8;$T?WZ4;'IZ8<!*)/_=<WR;;G8KI_O(&K_Z(Q`N!.S^&./,,J
MSJXGQ^V/O$&GTA,3`GJZ9\8=SY#)\968'']Y0^C<B'YX8])@KIS%K0'3D-U6
M]:]_<#1DQ[N=)XJ:GO/_MKEO&N5=X61=NOD-&GX97;\-TK/1*K[Q?J&V*@47
M['?]'U'[";3I(K$UL`9*=.S-6)TX>N'#IRRM>F/R\XRQ4#$6>7K'X5JK^!7E
M-\;..MMUU@Q$HZ[3DR;7_><>=L[=_<ZH\QVS4PV<$E-.YX9W6F&-Q^;WQB#<
MLN5`]3(L3BGAY5W0[;+&MN["WI;6EHH9I=#Y#D-85R2T,[ZB^K-S(0TC;.<.
MAR'\[\(0?FO4?/[6#H8[*;(Y4#-/[,V/SMSY'M"W_C9:/7_W["%_\K;1MD')
M7MH8E:RG>\^%-M;H-:I?5VIC;8?_^+PQYN"3%H4<HC$22*JS9-L\D[-AZ_=[
M6',/,A^$[E3O9NWN9QAY&TBYV\:+`#"E;]?H?SOS;EW4Z";@Q.7[(^;R#<$W
M77EYHB%")"!"#`;M/P9&5"6LP.ANO'7VO;?.=E%>L=*2SR)FI@EX<T6&WOV>
M?==]6)T@@B@,<D$1D\]HFE3=4DL[@P;A+UVH9;OFC;FTA1B_E4!LE`C^#.P/
M;MN^0.IJV7[-.Q+]+*;R&S65/PEW8-V3X&%WZV74HJ1/J&7$QHMQLUMD"4:F
M9T&3`"WCMP/%412JQ/99&]>.E=?.9]"UC_W>Z;A);5N)X+A=<OVME@]89XJN
M5NA8""S8-UI0E<IOBIAJS-ZL95_[I;<<U5-;2JZ2WQ[EGE@H1G+:E;;=L'U7
M\CZHB(IO9_X:MV+&>R[UVBGJLM<"4>P)(K`OB/I]X,?=DX!>2@U70?[W;'/@
ML"!1D6G;\WVO:2LU,YOX$U?WZR877:M\S8Z;'SH<-UW+'?;;;YF10%3H?R6Y
MXJVRS6#4.VM>X59@]V,)K8X3'UM,=B7R16DM-^MB?469YA=4"F=//TW09?JG
M@@Y!+YGW>S66W6\52KNXG(=0C_P2"^\VA`C"5'-[^,[$]GJ]IR4^P5+J6K#Q
M']]*Z'/+HMI??^^C=P,G;L,S6-.4+]B)&W=A:%.M%3_K9^&)LQUH/LJG(XP3
M-&N8HS$@;>8!L[O[V`2>)YL8FK;S8K4$#.PU\;Z\?7\XGA]TT+@2'L)&V$$[
M8=\7ND^*2&@L,:GF]>_V<O9WNDG:7/Z=F'FS65*6J$?RVB5M,@2+E7OM4Z#V
M=.&Q]=9W;GC=8=\I"C1=]EV/BM>^ZV>W49Y:>*NE=<P_N2M[6T):7>X-4F<]
M\`UZ]Z0+?"_M_+,\W_MKQ:S;,GJ,6RWQ`]:*^SO-]$WH'^#-DZYAR^XWWV&;
M>36T-U!K!6\.A^T_DJ5_R&^.6J'MG[7_>+&YAQ_/Z<=A<]@%+&7<O@G<4*0+
M?W_2CB].[.>DAA@#"VS3'918I;#PA=1;;K<=?\Z(.ZR[W<.*P9Q)U#I[H"]K
M.:/2V_4V^=BX"V]N=K"7CKB*N-5,5G=$-WX7+VO7=*T9<]>F=<UUJ_55_##1
M`"3N-FN<^!,[J<$O@R9%=EY\B5AM#(K^;L,/G1D:F.[-9D5=SEX91^?U(ME!
MMZ]=25ZE'%A[8^8Q8\_99^XU9.(W)'._R[M-6K5AW.3`0%QC-%P1CAHD5V`=
MM]L_O3GZ=E(LDJ/O-B"\@93X]A4*.,N,'+2J@GW&JMVZ=L'=($XK203_UCD0
M='A,-7DG;=7;]]6%#'0R3FQ=_Y%+9/%0'4CY!HOL;I:17Z0)16+UK_[*MQ\E
M&6KGP!C+TH;E>TQ(6$&S5-WCO\6D(W*3NE/IN@._#!O[<YLLN'E9F:S2S3J;
M=A^_`MR&@![(;F-&OETD2Q<LX%BK'>^Z0"4$2->[S9K)X1V\L-;F55UC?X?E
MG)UG$PN)_)B[O/YVQ'D:G!8.^Y=LTHUI[R5TJ(-H:92'VS(7_./U[0:A[!TW
M%6J%&"452['PWTC)%ENS&/($*!EG,_^4CCE95+$X!+Z2W[^B;LT@94BFV(EV
MUK/Y8=*Y(FG9.&Z?]"1(!^OBGO+]>."OO(P%``3P^M3R&+,)-UB,>5-*W;R@
M%:MOU,HE@KT5#DO+K[70U[54D/E^"S)B\1&N&+#H:`!;</W]X*M#RMULZ^[K
M>FC=DY-YAEU'),?/0Q\[N"DH.RRN%&U6=V6!+FD,W]8F9`5UU#[6CMJU0B=4
MI=[E1)OV;BXXC2(%=%8JC:V;I)V*7-ZVI#_.J,;.8TK%4%R?-C>@RYJM]>G=
MJX$PE1JG-L`OAJY/.%4W2]0KQD<7%K27YN6NFWL/F$K)^-&^S4GT:Y'EZUH`
MY))R"DTY2M>UJ2-;E;6)DAL8:R(A/`4S,3]T50J-KM"+PIS%,#EXEF*P>,D%
MD-N`]\4"FD@5^^KBG"G)$.U8:^P*3U3V?LQ,'D#[^;M+XF'<,<W3#1E#O'-S
M[@"#*V=PO8(%BFU209_R=RML&XP,.ZC2]UB4'_!:I!_3*=OO*?GTH8"!9[YC
M=@B++Q?`[R-+*+5QFF3LFUI\4G/>%U9%<";)FHL$3$D\QR@V!,,W<-+V4PR9
MH`X!X^>,I7@O"S5<BBI;<S^".=;SH?`9;EQ#6H/4YN;R5?0NDN49[AW\1`V?
ML!M;.$LO>A,LW_^BA9ADNR0GF0K"4/DG`SG^8`'7FBE4F$`?:M!C+<R6<A0?
M/2+(Z>HC,<%J'DB]<4O"]2,\(G'&/[5(U")FA@L^]]Z89J;FK&L%:-:%K_!2
MQ]-HQN4S\/D-U0G/I?$3@2WF/%@_IEZWT0%:@ZE*5-5H!U=>2A-Q4^'$U!&(
M.C"ZX$"FQ';7-+[5-9RR?42UDI2OPF'OM,=G3CU/O.`,['MX)E'S-0)H2NND
M>W():CFC"?X/L'ZSF>G'K%JGTO34/!1M7#V#;<=](ZYE%5XNNNEJ[P;\[`EH
MJ?490TH^-V)BB&6Q\@D??&5W6.M\%E,I5R4]H:2$T13C.4BLY1I`KC.?&:.]
M$(5P?J1YV[;(>924,#6^7;=B.4POD^%&1%:<"J63'GRE7X%`AB*AJP8P:I,(
M<7`WAHJ'N>I$=?&P"<9.@5`K,M1E`#>AM#CS9;>Y)4B4.`K!/>[JIU860-"Y
MS)[<O"U7_2\6Q?U6$,)5^FOIZH@,9\-A;,D]\`8X3Z"%O>B=7CT!*;QUQ+]6
M3D)MW#/J]4S6D7"3N5N>B#"+;)41QUMNM*XH0J-[\OM=#2'9WD0-HX.#HPFH
M8;&VQ['(52.,VO^2JES).EF88?1=BJ;H!;VP-+S7<V-;U9EHYQ2[=&%#1-O,
M\<X0D)BJR9^=Q$.5FTVU+"F.8P@!%;ZFTAF\Y50X8M8\(6I'&IX%]>@@JB?<
MVVV)BKDJY3H](75ZL!8T?,V=:;!X7R!4BA8(P^PLK3WS=__%X"P^/I;Y<%0]
M/"X.8I,\4\5>5AL$&0+!3'H#A=?"W("B`X^U,T\'XWFJ]:7L/X9IV''A$-LO
M>@N;<E)]TM$.'?1_LB'_1IW$O_KIZMNO#K^)YL4CK+(TQ"=SO0L:S<&;'$D[
M93_65H&ZB;3!W.O::G%5%6'N-K2=@+X>+JQR!N2(]=?D<SL3]**+-7$>$A=-
M2[4::KCYL9\1UU7B&\=V/4,M8E^OE1J.>S+$G<>36C%`1^#=6)1+@@UOI#$D
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M1!KP_16:'IR]$/UC*$(>?/6J>`7"L*EUZ9PI+"%O0%Y0?V:'P70:P("/H%>$
MRM<]D/;@AJ36IN_?7F3V]D<;C-S_JY)>?T59&LR3O&`]&(N'>?I%=9Q!D8P8
MV(>LW.!]N&.S%\M.7KL'.C%/O&"@(,?*9)**U"#]G4-[U*,/;[])9U05^%8!
MR-CF<U\FRYI`BUQPD7$<AK%MBF0U&L>GWBR:>4)T)PZGS)>.MHP2@U'=R?A"
MYJ$LN8+)0#0A2,W+L$JISYU+)ICX'>`Q+-3[JMS<![7,W$&&"/6ZD#:C],+%
M#'LRHDC$415?O7YU`:BDC280*JI^>DT;/XCF&]`#HRJY2X%@.##7:$CI(:JA
MH"LN][H>QN5[C=;K4`[E2!(6EN0H9-):B=O3[M^*W)XT@.L$(#5R%4]=X=06
MQ#OXZH>WU[`ZHYMP?GA@E5H;[-#*I@+HTCHR,^<E)3+($8G8@0?M9=SOFY%A
M0B)",IME<EPO3N+S4T&?=ZYVYK!+?=7+V+RKRYIC52WFF7,?/PD9:`D#T1(0
ML\>C^&QP[@W^!FJ#VU334,)C`Y&%]<Y<6J(CGX4_\S295;8O%6E9Z1*.-^&N
MNJLCLK:)JD/G*T8*2M?"&(UZH40#F,[A()1*JQGU492"NK->4P_[C3;9;[#9
M5Z$4`]7!Q#*%4\S%@%@XG8NU#B6>;N9)NBT$M#J!T:WR]X1$$7\'0EJSGI?%
MYGZNFQ\2G#9JPZG%KRY8Z7S`V_W2-H-6&('"3S:S^U1J((J`+&<4F@B`&NFF
MC/M.-<URMR:GI8+05*9*F.G<WDW7!7K]=E\0G^,7V%P`5:(7IPUEV-B(9;."
M\(,#LO8$7UUHB<NO#F/;^S50!V*Y9GJ:P0BD>^:^VJCI,JH2<[%93P"O/N#.
M_(R*WL4=UK)7.P+J7Y^+P7H^SDXP/'84``^C<:-;8S,J'YNA)9X"/=FS9SL<
MF=*SY62#):MI<*Q731(QW??8\$6DFKXT$E8DUYM.[T@#S8H]F@E1Y)0-LG?H
M%[J0C@CUO%%3)#@`36W,W*4!9=!-R5XBG9;='7IB7$\5?W!SF=1.-[PX5;K'
M0WN%:3S.QCT6CJE:Z*^;BKZG\L&PCL6VK@<].079SVRK=5RAMZGS0[[9,`\7
M'HS#,2KF7%ISD0<DO8/-69/O9QJ([62VR%G38U<X`%B1L,?N/F-$Z%%`-?:<
MQG;1($HSCV:%;,IAE'%#]3)''YSJ%,OR)F5N%$IW,1XX1]XMO+9B`9$)7"I8
M%S1'MXU\U<X0@A(6HU^[;25_%]6%90KBZQ'_WI\,O?4K3"\&<3))$+IP16%0
M;A:HFC]DZ:.<D$<74.U2M%8BC_7-,4PM\"EZ#H^`"'!'>T+B'=8^YTS)UK2I
MV$0OF2Q,DS^^7-0U0W>8%UL5TH;/J7J$2!Z+G-4YW+Q:IQYILZGN!*_;#%L!
M]B+G/0R8BS\,!$&XF(%4F:SG(9F+.\Q;?(\F:`BN5JSMLM^`W7EE>I3Z+KTM
MCIQV)2L3;_QCLFVHRR]+;&:R.'JS13_D#8@RDPG(L2_?W(`<&_C^(Q6_-7JW
M4_Q&*R=\J5$$W))&3'OAD`0FS&7]'-270U7OF(I$D>&G6J+=A^XY4!E$-]`1
M`=0J@[\`[+)8I$#BF'XNA=;5O)K8D/OM=4U!K+(%^:J8K4;WJ01SJ"6T1S#`
M)L+N4G\"P72K1Y%XR7W0LYE#5>GR0C*0N!5X=(I-H<AM.D'LY>Y.3&`-;3I3
MWVR]-C.];#3SAN(\`S4,9J3.,.+V-K_RHFOK#>UR:G\?>0D'*3QNRM2G-#CX
MR73DF6$2>,"<=<=05S),AQ6*0A`>Z6I+,H,5T7$CCHQ1.W<)MGC*%+B0&ML[
M>I>.F*DJ4'RVJ!\F0%E*+(FJQM(\O2_0XY]&M@B77PZ2<SE4VG,?@]4AN+'>
MD3X4BX?4;Z%BS(Q00\\#:$\0-(##!'<O"6/<<*1'(F/<H*0>2Z`@,)"N/0A?
M$K-9HD4H4Q&"N)<I;BSGY+0PA$G/H)IG*]P18SU7ST=;PP"_NA3SW(0,3HKU
MG&-$<J"5OX^*R4),%#;<R+R+,#8HG@T@;*%&&AG9%2THOXL-0PUXM]9.K4_R
M;U]1=RJN.7"QP(Y^H7V(JPY$/H2;;MQ*Y!KG<U-+U>XS"!F4MHT&C4@$<.\\
M)[02$&/;?A=.3E?%=Y\--`VWNXP@VU4WYNKW&C9CC#Q75U=LT.'4K1_>'MW>
MON\/`?4NRDFV;CL,VNIJBBIE53^9Z.#[)+__*ZCDAQ$Z:WY8SVCWY7%UXN,N
M:29'N$MKDZ$76FK@MJ"`4^,7#A!T[N3<KF">+H4RX?6B1?UT<QT3B2*R@!+-
MC%F#>.;54K&D\G>\T%Y7=`D0CDW`(=LHDMVR6(P@'G!M<!.L`*C=/45'8;MA
M)>_^J/T-"T\[](GWHN_5-Z@/L+<1=I-$&/B(K95$/U3S7%N[$9`425YH`R'T
MSJ`C:;5!M4+F1&]6P4F<\"":5)?I;,MF`WFVJ=-Z>!]2#L<D&28QB$A(D,XH
MA30Q(7QLB6I0'0825*/2=95F\HFJEAEV710?T-[(C4.\W8CE/=BPS$9AZILP
M$K60((-&9[`,LUCFWJ+GY>YR:I<(M\4-"ED/D7$NARZ:J`_(7</%4/0T]K%J
M=09X1IW4YFH&Y+M9Z"=+3;]'6OHR*ZII1@WMM(*+5_!Q<HHOE0A*]HWJ#:S$
M!L-S-B*ZV9"+IJVT)58`V-JR8$EJZWA_'$F8/-Z$8HK2U.V;Z`"#@:H"Y-?H
MIRPO@$5.0%QA!O*R3#YD#TGXU&V!H2-`,0Y9!Q'^*-ED.^W>O)8@<"+1DBKX
M6:QM'#$C(?U.PD![G/+Z('(\F6T6I,=D_J2NY]DBF:6+U3Q+8#=@C(+:@^48
MZDS>:(Q3C1;;Y6H.ESBI4-Q<I)L/Z3)#YT1482=3\I3>4ZQ?2<+#JB(/X2/U
MO()[2Q;0>5*YV&2Z>BYHYK'`IY>8+(:Q<D=N`CX:TO9UG13HL,A6!>^RM=*K
MQ\<>*@K.T0-:83'#.T_5J<E-\9R9UL3V&>%'YYQL0F*7M?M]6'-O"6WS0>6#
M,T>@,;!,T,LB$0IO=/P4\Z/9O\!=W`7.G#X[&(G]W:2^NQ8T"3?Q8@Y2+EUH
MI\:43=+U(^K+/%L2&O3(Y7"3KM92>U-9K@.BZ:GA2!^5$5G+1UG<Q,=+H"P`
M(CM++6Q%G2DE&F*WJSB\-XY,OCBA."8:X,6`?1-,DOD$M2:NDM*#/>=#'_2+
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MEWAL>_*VU.UO;][;&7+2Z.#;&++6R+>]441+-]_6K<<&X-*\`!OD/;-OW?"X
MO5H^66`>RPQ)TE,MDCH;,]F>]AB`9IZ3ZLS1Q6-2SH)&-NT%GD?M]:-_@ZG?
M:3/%[[C=8*8@X#<M339]J>IKC@GF7C+>(2ZM22XVZWE1(JEM!;J]09@;DNZL
MMI+""2Y-'ZH6A')Q@MS\Q+W9VD_(S?)ZURQQ]#9M!$L1RIU2]PARIFA(%[X+
MR`],AYI?/@,-'=EX3P1(FN1US'S&,]>"T2Z-3>')'M'<F.)D9]^2H%=$QS/4
MB4*C_#J>L=T?QY<7KQI=M=()7,'_M[:SV6T8A`'PJ^0!(FW:-&VG'=JFVVF-
MVF[3CAR2+5+72"4Y[.V'P?P5G,!^KFTPR(`QQO#=3<IPH!:7,1G>_PE4ZY1O
M;B+UN*#JZP28]=7D-QEZH\8-`3Y;'&1:^?L$L`&7"?UN/V%QXB`T[UE^<RO!
M@*@EY2Z47[R)GV8;8L,>6QVEW*A3K,K$+_6:]8PA`IS[?RI;/W)_'IW96O=E
MGC7QFQ:4I@E+)W"C+/M\S=3(6)V$-W=0N=)S@T2K(FH_@VA6^3.5R9&!PC+J
MV#%P^EW$2)YH2C]/S7CJ7Z`;DK0"Z(/03/R';A)K`LB;V'SL,>8.@V7=I#,X
MOX9^`D-)E*J.#*E4>3A#"D'O.BY`DI:L;V%4D`7!2XU>?Q1S*+(4=`ZI)H_$
M>U8X<`C1WD0U"AO[D5:>ID+4A-]N$M=KB(7"=4#E^Z;9WDA7F?M5KTX6+B3<
MR/.MME@(Q[;C'Y"7+NQ`YZO,7H*L8(]&3X9>=JH#W%BQ3P:H^AWD&@YE')B"
MI(MBT^(T6IM#NWV]#.@7MS&>I+6.1T5RE6,=#B%49#M0G,W+\8JT=!'=9P\C
MDP''AGMN5HS7<<'Y</\-4$L!`A0#%`````@`]9,'1^=_,3>Y`0``G1<``!,`
M`````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````
M"`#UDP='2'4%[L4````K`@``"P``````````````@`'J`0``7W)E;',O+G)E
M;'-02P$"%`,4````"`#UDP='#'72:8X!``"I%@``&@``````````````@`'8
M`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`#UDP='
MS/14PO4"``"A"@``$```````````````@`&>!```9&]C4')O<',O87!P+GAM
M;%!+`0(4`Q0````(`/63!T<2V&D^/P$``&D#```1``````````````"``<$'
M``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(4`Q0````(`/63!T>97)PC$`8``)PG
M```3``````````````"``2\)``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#
M%`````@`]9,'1T%A2`%+`@``W`D```T``````````````(`!<`\``'AL+W-T
M>6QE<RYX;6Q02P$"%`,4````"`#UDP='*8PQ2^$#``#E#```#P``````````
M````@`'F$0``>&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`]9,'1RVEMY)9
M`@``?0@``!@``````````````(`!]!4``'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+`0(4`Q0````(`/63!T?S2Y)+[0,``&$2```8``````````````"`
M`8,8``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"%`,4````"`#UDP='
M[B28@<D!``#,!```&```````````````@`&F'```>&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L!`A0#%`````@`]9,'1R)^KIMQ!```&A0``!@`````````
M`````(`!I1X``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(4`Q0````(
M`/63!T?%Z([D)@,``)L,```8``````````````"``4PC``!X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"%`,4````"`#UDP='LM)/U:H!``"V`P``&```
M````````````@`&H)@``>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`A0#
M%`````@`]9,'1\*;Z0B1!0``E1T``!@``````````````(`!B"@``'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+`0(4`Q0````(`/63!T<XM@"`I0$``+$#
M```8``````````````"``4\N``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"%`,4````"`#UDP='HD":TZ0!``"Q`P``&```````````````@`$J,```
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`A0#%`````@`]9,'1V,'42FF
M`0``L0,``!D``````````````(`!!#(``'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"%`,4````"`#UDP='1>)9D:4!``"Q`P``&0``````````````
M@`'A,P``>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(4`Q0````(`/63
M!T=HA#\YI`$``+$#```9``````````````"``;TU``!X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L!`A0#%`````@`]9,'1ZY.RX*E`0``L0,``!D`````
M`````````(`!F#<``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"%`,4
M````"`#UDP='4M$W.*4!``"Q`P``&0``````````````@`%T.0``>&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+`0(4`Q0````(`/63!T>4T[11I0$``+$#
M```9``````````````"``5`[``!X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L!`A0#%`````@`]9,'1R1535P&`@``>P8``!D``````````````(`!+#T`
M`'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"%`,4````"`#UDP='\XNJ
M.[X!``![!```&0``````````````@`%I/P``>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+`0(4`Q0````(`/63!T>"P;\$O@$``'L$```9````````````
M``"``5Y!``!X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!`A0#%`````@`
M]9,'1V(MCU2Q`0``%@0``!D``````````````(`!4T,``'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"%`,4````"`#UDP='O0;Y@Z4!``"Q`P``&0``
M````````````@`$[10``>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(4
M`Q0````(`/63!T>?)S.8=@$``/0"```9``````````````"``1='``!X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L!`A0#%`````@`]9,'1QL^3=5/`@``
MG`<``!D``````````````(`!Q$@``'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"%`,4````"`#UDP='!G;I/;X"``#A"P``&0``````````````@`%*
M2P``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(4`Q0````(`/63!T=_
M;W]D'0(``"T&```9``````````````"``3].``!X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L!`A0#%`````@`]9,'1Q*-Z,L]`@``2P<``!D`````````
M`````(`!DU```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"%`,4````
M"`#UDP='$>H6S?D$```Z'0``&0``````````````@`$'4P``>&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+`0(4`Q0````(`/63!T<1]X)5L`(``'\+```9
M``````````````"``3=8``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!
M`A0#%`````@`]9,'1R0J0>/E`0``L`4``!D``````````````(`!'EL``'AL
M+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"%`,4````"`#UDP='5.Q;CW<"
M````"```&0``````````````@`$Z70``>&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;%!+`0(4`Q0````(`/63!T<$-2O\$@4``.L;```9``````````````"`
M`>A?``!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`A0#%`````@`]9,'
M1S7=*&LJ!```:10``!D``````````````(`!,64``'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"%`,4````"`#UDP='7KS/F<X"```O"P``&0``````
M````````@`&2:0``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(4`Q0`
M```(`/63!T?RIW3Q(0(``.T&```9``````````````"``9=L``!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L!`A0#%`````@`]9,'1U"2_8!1`@``2@@`
M`!D``````````````(`![VX``'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"%`,4````"`#UDP=')=H/MI@!``!V`P``&0``````````````@`%W<0``
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+`0(4`Q0````(`/63!T=FHQ58
MI`0``.P9```9``````````````"``49S``!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L!`A0#%`````@`]9,'1]5)!3W==```9<X!`!0`````````````
M`(`!(7@``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%!@`````M`"T`+0P``##M
$````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970766080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 2,802<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_AccruedResearchAndDevelopment', window );">Research and development accruals</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_AccruedLicenseFeeAccruals', window );">License fee accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fee accruals</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrent', window );">Deferred lease inducements</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll accruals</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );"></a></td>
<td class="nump">$ 6,920<span></span>
</td>
<td class="nump">$ 9,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_AccruedLicenseFeeAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for license fee accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_AccruedLicenseFeeAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40010-112707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40019-112707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41614-112719<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Lease Incentive<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516590<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655968269792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Black-Scholes Option-pricing Assumptions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">69.32%<span></span>
</td>
<td class="nump">85.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.59%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">146 days<span></span>
</td>
<td class="text">182 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_FairValueOfWarrantsOutstandingPerWarrant', window );">Fair value of warrants outstanding (in dollars per share)</a></td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="nump">$ 12.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Aggregate fair value of warrants outstanding</a></td>
<td class="nump">$ 3,606<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="nump">379,500<span></span>
</td>
<td class="nump">398,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_FairValueOfWarrantsOutstandingPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of the warrants outstanding per warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_FairValueOfWarrantsOutstandingPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655971216752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left"><div style="display: inline; font-weight: bold;">2.</div></td>     <td style="width: 5pt"></td>     <td style="text-align: left"><div style="display: inline; font-weight: bold;">Significant accounting policies</div></td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of presentation</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the year ended December 31, 2014 and included in the Company&#x2019;s 2014 annual report on Form 10-K. The unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the financial position, results of operations and cash flows at June 30, 2015 and for all periods presented. The results of operations for the three and six months ended June 30, 2015 and June 30, 2014 are not necessarily indicative of the results for the full year. These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of Consolidation</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">These condensed consolidated financial statements include the accounts of the Company and four of its wholly-owned subsidiaries, Arbutus Inc., Protiva, Protiva USA, and Enantigen. All intercompany transactions and balances have been eliminated on consolidation.</div>  <div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&#x201c;VIE&#x201d;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Replacement awards </div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&#x2019;s acquisition of Arbutus Inc. (formerly OnCore), Arbutus (formerly Tekmira) shares were exchanged for Arbutus Inc.&#x2019;s shares subject to repurchase rights held by Arbutus Inc.&#x2019;s employees &#x2013; see note 3.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.</div>    <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount.</div>    <!-- Field: Page; Sequence: 7; Value: 3 -->      <!-- Field: /Page -->                  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Goodwill and intangible assets</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Intangible assets consist of in-process research and development arising from the Company&#x2019;s acquisition of Arbutus Inc. &#x2013; see note 3. In-process research and development (IPR&amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written down to their fair values.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. &#x2013; see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.</div>  <div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income or loss per share</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company&#x2019;s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants. During the six months ended June 30, 2015, potential common shares of 2,774,398 (June 30, 2014 &#x2013; 2,558,925) were excluded from the calculation of income per common share because their inclusion would be anti-dilutive.</div>  <div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value of financial instruments</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The Company measures certain financial instruments and other items at fair value.</div>  <div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; text-align: left">&nbsp;</td>     <td style="vertical-align: top; width: 2%; text-align: left">&#x2022;</td>     <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td>     <td style="vertical-align: top; width: 92%; text-align: left">Level 1 inputs are quoted market prices for identical instruments available in active markets.</td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 0 4.5pt 0 0; text-indent: 0.5in">&nbsp;</div>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; text-align: left">&nbsp;</td>     <td style="vertical-align: top; width: 2%; text-align: left">&#x2022;</td>     <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td>     <td style="vertical-align: top; width: 92%; text-align: left">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 2.5pt 0.8pt 0 0; text-indent: 0.5in">&nbsp;</div>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; text-align: left">&nbsp;</td>     <td style="vertical-align: top; width: 2%; text-align: left">&#x2022;</td>     <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td>     <td style="vertical-align: top; width: 92%; text-align: left">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#x2019;s assumptions about market assumptions that would be used to price the asset or liability.</td>    </tr>     </table>    <!-- Field: Page; Sequence: 8; Value: 3 -->      <!-- Field: /Page -->                  <div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The following tables present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</div>    <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 1</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 2</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 3</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; font-weight: bold">Assets</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 56%; font-size: 10pt; text-align: left">Cash and cash equivalents</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">207,205</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 8%; font-size: 10pt; text-align: right">-</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 8%; font-size: 10pt; text-align: right">-</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">207,205</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Term deposit</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">Total</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">217,217</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">217,217</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; font-weight: bold">Liabilities</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Warrants</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">3,606</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">3,606</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Contingent consideration</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,136</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,136</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">Total</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">8,742</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">8,742</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" margin: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 1</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 2</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 3</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td>      <td nowrap="nowrap" style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">December 31, 2014</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; font-weight: bold">Assets</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Cash and cash equivalents</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">72,187</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">72,187</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Guaranteed investment certificates</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">Total</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">112,161</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">112,161</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; font-weight: bold">Liabilities</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Warrants</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,099</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,099</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Total</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,099</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,099</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The Company acquired a term deposit in May 2015 with an original maturity of 24-months and it has been classified as a long-term investment on the balance sheet. For the period ended June 30, 2015, the fair value of the term deposit is $10,012,000 which includes the principal and accrued interest earned as at the balance sheet date.</div>  <div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The Company used a discounted cash flow model to determine the fair value of the financial instrument, related to Monsanto&#x2019;s call option to acquire the equity or all of the assets of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial liability was nil, and there has been no change to its fair value as at June 30, 2015.</div>  <div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">Contingent consideration is a liability assumed by the Company from its acquisition of Arbutus Inc. &#x2013; see notes 3 and 8. The Company used a discounted cash flow model to determine the fair value of the contingent consideration as at the acquisition date, and at each subsequent reporting date. The Company&#x2019;s preliminary estimate of the contingent consideration was $4,736,000 for the reporting date of March 31, 2015. As at June 30, 2015, the Company has reassessed the preliminary initial fair value of the contingent consideration to be $5,136,000.</div>      <!-- Field: Page; Sequence: 9; Value: 3 -->      <!-- Field: /Page -->                    <div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The following table presents the changes in fair value of the Company&#x2019;s warrants, in thousands:</div>      <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Liability at beginning of the period</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Opening liability of warrants issued in the period</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Fair value of warrants exercised in the period</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Increase (decrease) in fair</div> <div style=" margin-top: 0; margin-bottom: 0">value of warrants</div></td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Foreign exchange&nbsp;</div> <div style=" margin-top: 0; margin-bottom: 0">(gain) loss</div></td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Liability at end</div> <div style=" margin-top: 0; margin-bottom: 0">of the period</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td nowrap="nowrap" style="width: 12%; font-size: 10pt; text-align: left">Six months ended June 30, 2014</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5,379</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">-</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 11%; font-size: 10pt; text-align: right">(6,607</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 11%; font-size: 10pt; text-align: right">7,803</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 11%; font-size: 10pt; text-align: right">15</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 11%; font-size: 10pt; text-align: right">6,590</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">Six months ended June 30, 2015</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,099</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(341</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(801</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(351</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,606</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The change in fair value of warrant liability for the six months ended June 30, 2015 is recorded in the statement of operations and comprehensive loss.</div>  <div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The weighted average Black-Scholes option-pricing assumptions and the resultant fair values, in thousands, for warrants outstanding at June 30, 2015 and at December 31, 2014 are as follows:</div>      <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td>      <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">December 31, 2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 78%; font-size: 10pt; text-align: left">Dividend yield</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">0.00</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">%</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 8%; font-size: 10pt; text-align: right">0.00</td>      <td style="width: 1%; font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Expected volatility</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">69.32</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">85.22</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">0.59</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1.00</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">Expected average term (years)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">0.4</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.5</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Fair value of warrants outstanding</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">9.50</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">12.80</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Aggregate fair value of warrants outstanding</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">3,606</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,099</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Number of warrants outstanding</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">379,500</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">398,250</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Foreign currency translation and reporting currency</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;">Functional currency</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The functional currency of the Company and its integrated subsidiaries (Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The local currency of Arbutus Inc. (including its subsidiary, Enantigen) is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic environment in which Arbutus Inc. operates and expends cash. Foreign currency monetary assets and liabilities are translated into United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><div style="display: inline; font-weight: bold;">Reporting currency</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the Company&#x2019;s functional currency to the Company&#x2019;s reporting currency of U.S. dollars are unrealized gains and losses; therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.</div>    <!-- Field: Page; Sequence: 10; Value: 3 -->      <!-- Field: /Page -->                <div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent accounting pronouncements</div></div></div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition &#x2013; Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December 15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &#x2013; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970661936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Pro Forma Financial Information (Details) - Arbutus Inc. [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Pro forma information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Gross Revenue</a></td>
<td class="nump">$ 3,440<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="nump">$ 8,122<span></span>
</td>
<td class="nump">$ 6,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax', window );">Loss from operations</a></td>
<td class="num">(14,420)<span></span>
</td>
<td class="num">(13,844)<span></span>
</td>
<td class="num">(39,491)<span></span>
</td>
<td class="num">(24,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,886)<span></span>
</td>
<td class="num">$ (10,479)<span></span>
</td>
<td class="num">$ (33,940)<span></span>
</td>
<td class="num">$ (32,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinessAcquisitionProFormaEarningSperShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma income from continuing operations before changes in accounting and extraordinary items, net of tax effect, for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655964603328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Summary of Acquired Identifiable Intangible Assets (Details) - Arbutus Inc. [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 03, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_CyclophilinsMember', window );">Cyclophilins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 35,124,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_ImmuneModulatorMember', window );">Immune Modulator [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">189,182,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_AntigenInhibitorsMember', window );">Antigen Inhibitors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">35,520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_CccdnaMember', window );">cccDNA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">130,191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 390,017,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 37<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_CyclophilinsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_CyclophilinsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_ImmuneModulatorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_ImmuneModulatorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_AntigenInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_AntigenInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_CccdnaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tkmr_CccdnaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655892160864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Collaborations, Contracts and Licensing Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 13, 2014</div></th>
<th class="th"><div>May. 10, 2010</div></th>
<th class="th"><div>May. 31, 2015</div></th>
<th class="th"><div>Nov. 16, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Apr. 22, 2014</div></th>
<th class="th"><div>Jun. 21, 2013</div></th>
<th class="th"><div>May. 08, 2013</div></th>
<th class="th"><div>Aug. 09, 2012</div></th>
<th class="th"><div>Jul. 14, 2010</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=tkmr_PADCoMember', window );">PADCo [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets', window );">Variable Interest Entity, Nonconsolidated, Carrying Amount, Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities', window );">Variable Interest Entity, Nonconsolidated, Carrying Amount, Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax', window );">Variable Interest Entity, Measure of Activity, Income or Loss before Tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_BMSMember', window );">BMS [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_CollaborativeArrangementTerm', window );">Collaborative Arrangement, Term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DicernaMember', window );">Dicerna [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_RevenueRecognitionPerformancePeriod', window );">Revenue Recognition, Performance Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MilestonePayments', window );">Milestone Payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember', window );">DoD [Member] | Increase to Support Development Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialContractFundingAmount', window );">Potential Contract Funding Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember', window );">DoD [Member] | Increased Funding for Stage One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialContractFundingAmount', window );">Potential Contract Funding Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember', window );">DoD [Member] | Contract Modification to Fund The Company For TKM-Ebola-Guinea IND Submission Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialContractFundingAmountIncrease', window );">Potential Contract Funding Amount Increase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember', window );">DoD [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialContractFundingAmount', window );">Potential Contract Funding Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_OptionalExcercisedContractualOptionAmount', window );">Optional Exercised Contractual Option, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember', window );">Monsanto [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ApproximateOptionPeriod', window );">Approximate Option Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MaximumPotentialTransactionValue', window );">Maximum Potential Transaction Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 86,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ExtendedOptionPeriod', window );">Extended Option Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MaximumPotentialTransactionValueForExtensionPeriod', window );">Maximum Potential Transaction Value for Extension Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_NearTermContractPayments', window );">Near Term Contract Payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="nump">$ 626,000<span></span>
</td>
<td class="nump">1,647,000<span></span>
</td>
<td class="nump">$ 1,171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_TalonTherapeuticsMember', window );">Talon Therapeutics [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialContractFundingAmount', window );">Potential Contract Funding Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Contract Extension [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialContractFundingAmount', window );">Potential Contract Funding Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_AlnylamLicenseAgreementMember', window );">Alnylam License Agreement [Member] | Positive Outcome of Litigation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Gain Contingency, Unrecorded Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_AlnylamLicenseAgreementMember', window );">Alnylam License Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_MarqiboMember', window );">Marqibo [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,130,000<span></span>
</td>
<td class="nump">$ 667,000<span></span>
</td>
<td class="nump">2,292,000<span></span>
</td>
<td class="nump">$ 1,408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_AccruedContractRevenuePercentage', window );">Accrued Contract Revenue, Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna") On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.  The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months.  The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Option and Services Agreements with Monsanto Company ("Monsanto")  On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.  In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from MonsantoThe amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.  Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_AccruedContractRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of revenue from accrued contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_AccruedContractRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ApproximateOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The approximate term of options agreed between two entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ApproximateOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ExtendedOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the extended period for the option agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ExtendedOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_MaximumPotentialTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum potential transaction value between entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_MaximumPotentialTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_MaximumPotentialTransactionValueForExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum potential transaction value for the extended period for the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_MaximumPotentialTransactionValueForExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for milestones reached in an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_NearTermContractPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments which are near term in a contract agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_NearTermContractPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_OptionalExcercisedContractualOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of an option exercise that was embedded in a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_OptionalExcercisedContractualOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_PotentialContractFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of funding an entity could potentially earn in a contract agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_PotentialContractFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_PotentialContractFundingAmountIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in amount of funding an entity could potentially earn in a contract agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_PotentialContractFundingAmountIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_RevenueRecognitionPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the performance period for revenue recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_RevenueRecognitionPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the amount of pre-tax income (loss) derived by the reporting entity from the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph d<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5747-111685<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the assets in the reporting entity's statement of financial position that relate to the reporting entity's variable interest in the Variable Interest Entity (VIE), where the reporting entity is not the VIE's primary beneficiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph a<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5728-111685<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the liabilities in the reporting entity's statement of financial position that relate to the reporting entity's variable interest in the Variable Interest Entity (VIE), where the reporting entity is not the VIE's primary beneficiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph a<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5728-111685<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityNonconsolidatedCarryingAmountLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=tkmr_PADCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=tkmr_PADCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_BMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_BMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DicernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DicernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=tkmr_IncreaseToSupportDevelopmentPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=tkmr_IncreaseToSupportDevelopmentPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=tkmr_IncreasedFundingForStageOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=tkmr_IncreasedFundingForStageOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tkmr_ContractModificationToFundTheCompanyForTKMEbolaGuineaINDSubmissionExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_TalonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_TalonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_ContractExtensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_ContractExtensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_AlnylamLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_AlnylamLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=us-gaap_PositiveOutcomeOfLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=us-gaap_PositiveOutcomeOfLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_MarqiboMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tkmr_MarqiboMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655892538224">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember', window );">DoD [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">$ 4,907<span></span>
</td>
<td class="nump">$ 4,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember', window );">Monsanto [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">269<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 805<span></span>
</td>
<td class="nump">$ 626<span></span>
</td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_BMSMember', window );">BMS [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DicernaMember', window );">Dicerna [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_AcuitasMember', window );">Acuitas [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_SpectrumMember', window );">Spectrum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">5,830<span></span>
</td>
<td class="nump">4,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,440<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="nump">$ 8,122<span></span>
</td>
<td class="nump">$ 6,241<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Contract with United States Government's Department of Defense ("DoD") to develop TKM-Ebola  On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection.  In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. In May 2015, the Company and the DoD signed a contract modification to further increase stage one funding by up to $1,000,000.  The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKMEbola-Guinea (the "Ebola-Guinea Amendment"), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.  In March 2015, the Company and the DoD signed a contract modification to provide up to $2,250,000 to fund the Company for TKM-Ebola-Guinea IND submission expenses.  Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June 30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.  On July 20, 2015, the Company announced given the unclear development path for TKM-Ebola, development activities will be suspended and a joint re-evaluation of the development contract with the DoD is underway.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Option and Services Agreements with Monsanto Company ("Monsanto")  On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.  In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from MonsantoThe amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.  Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Bristol-Myers Squibb ("BMS") collaboration  On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA ("siRNA") molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company could use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the four-year agreement. BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.  Revenue from the May 10, 2010 agreement with BMS was being recognized as the Company produces the related LNP batches.  The revenue earned for the six months ended June 30, 2014 was related to BMS batches shipped during the period. In August 2014, the agreement expired and both companies' obligations under the agreement ended.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna") On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.  The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months.  The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">License and collaboration with Alnylam Pharmaceuticals, Inc. ("Alnylam") and Acuitas Therapeutics Inc. ("Acuitas", formerly AlCana Technologies Inc.)  Milestone receipts and payments  In the six months ended June 30, 2014, the Company earned a $150,000 milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.  Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. ("Ascletis")  On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam's position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement. The hearing date for this arbitration took place in May 2015, and a decision of the arbitrator is pending. The Company has not recorded any revenue in respect of this milestone.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Agreements with Spectrum Pharmaceuticals, Inc. ("Spectrum")  On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. ("Talon", formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the "Talon License Agreement") for three of the Company's chemotherapy products, Marqibo, AlocrestTM (Optisomal Vinorelbine) and BrakivaTM (Optisomal Topotecan).  On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.  Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three and six months ended June 30, 2015, the Company recorded $62,000 and $119,000 in Marqibo royalty revenue (three and six months ended June 30, 2014 - $41,000 and $87,000 respectively). For the six months ended June 30, 2015, the Company accrued 2.5% in royalties due to TPC in respect of the Marqibo royalty earned by the Company - see note 8, contingencies and commitments.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_BMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_BMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DicernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DicernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_AcuitasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_AcuitasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_SpectrumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_SpectrumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970687248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Business and Future Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left"><div style="display: inline; font-weight: bold;">1.</div></td>     <td style="width: 5pt"></td>     <td style="text-align: left"><div style="display: inline; font-weight: bold;">Nature of business and future operations</div></td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Arbutus Biopharma Corporation (the &#x201c;Company&#x201d; or &#x201c;Arbutus&#x201d;) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (&#x201c;HBV&#x201d;), a disease of the liver caused by hepatitis B virus (&#x201c;HBV&#x201d;). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company&#x2019;s expertise in Lipid Nanoparticle (&#x201c;LNP&#x201d;) technology.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Effective July 31, 2015, the corporate name changed from Tekmira Pharmaceuticals Corporation (&#x201c;Tekmira&#x201d;) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (&#x201c;OnCore&#x201d;) changed to Arbutus Biopharma Inc. (&#x201c;Arbutus Inc.&#x201d;). Including Arbutus Inc., the Company has five wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (&#x201c;Protiva&#x201d;), Protiva Biotherapeutics (USA) Inc. (&#x201c;Protiva USA&#x201d;), Protiva Agricultural Development Company Inc. (&#x201c;PADCo&#x201d;), and Enantigen Therapeutics, Inc. (&#x201c;Enantigen&#x201d;).</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company&#x2019;s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company&#x2019;s ability to fund these programs in the future.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=SL51803626-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139656098447888">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Deferred Collaborations and Contracts Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember', window );">DoD [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 563,000<span></span>
</td>
<td class="nump">$ 313,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember', window );">Monsanto [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,746,000<span></span>
</td>
<td class="nump">4,245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,336,000<span></span>
</td>
<td class="nump">8,666,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_DicernaMember', window );">Dicerna [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,296,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">709,000<span></span>
</td>
<td class="nump">1,271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,605,000<span></span>
</td>
<td class="nump">5,779,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,045,000<span></span>
</td>
<td class="nump">9,937,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,650,000<span></span>
</td>
<td class="nump">$ 15,722,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Contract with United States Government's Department of Defense ("DoD") to develop TKM-Ebola  On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection.  In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required.   The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the "Ebola-Guinea Amendment"), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.   Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June 30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.   On July 20, 2015, the Company announced that development activities related to TKM-Ebola will be suspended and a joint re-evaluation of the development contract with the DoD is underway.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Option and Services Agreements with Monsanto Company ("Monsanto")   On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the "Agreements"). Under the Agreements, Monsanto has an option to obtain a license to use the Company's proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto's research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.   In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from Monsanto The amounts received relate to research services and use of the Company's technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.   Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity ("VIE"); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company's initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. ("Dicerna")   On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the "Agreements") with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 ("PH1"). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.   The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months as at June 30, 2015 (December 31, 2014 - 28 months).   The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company's performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DicernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DicernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655895109328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 207,205<span></span>
</td>
<td class="nump">$ 72,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (note 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 6,332<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Accrued revenue</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Investment tax credits receivable</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">215,702<span></span>
</td>
<td class="nump">$ 116,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments (note 2)</a></td>
<td class="nump">10,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">12,469<span></span>
</td>
<td class="nump">$ 12,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(10,433)<span></span>
</td>
<td class="num">(11,199)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">2,036<span></span>
</td>
<td class="nump">$ 1,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets (note 3)</a></td>
<td class="nump">390,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (note 3)</a></td>
<td class="nump">156,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">773,820<span></span>
</td>
<td class="nump">$ 118,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities (note 5)</a></td>
<td class="nump">6,920<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue (note 4)</a></td>
<td class="nump">5,605<span></span>
</td>
<td class="nump">5,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants (note 2)</a></td>
<td class="nump">3,606<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,131<span></span>
</td>
<td class="nump">20,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion (note 4)</a></td>
<td class="nump">8,045<span></span>
</td>
<td class="nump">$ 9,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (note 8)</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability (note 3)</a></td>
<td class="nump">156,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">185,319<span></span>
</td>
<td class="nump">$ 30,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issued and outstanding: 54,303,402 (December 31, 2014 - 22,438,169)</a></td>
<td class="nump">821,660<span></span>
</td>
<td class="nump">290,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">27,844<span></span>
</td>
<td class="nump">26,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit</a></td>
<td class="num">(232,739)<span></span>
</td>
<td class="num">(205,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(28,264)<span></span>
</td>
<td class="num">(22,313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">588,501<span></span>
</td>
<td class="nump">88,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 773,820<span></span>
</td>
<td class="nump">$ 118,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.5(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655961286224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common shares in conjunction with the private offering, issuance costs</a></td>
<td class="nump">$ 9,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970356560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Concentrations of Credit Risk (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, Net</a></td>
<td class="nump">$ 6,332,000<span></span>
</td>
<td class="nump">$ 1,903,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655958063664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=tkmr_TermDepositMember', window );">Term Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MaturityOfInvestments', window );">Maturity of Investments</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">$ 10,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements', window );">Wholly Owned Subsidiaries Included in Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774,398<span></span>
</td>
<td class="nump">2,558,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_MaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_MaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_WhollyOwnedSubsidiariesIncludedInFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=tkmr_TermDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=tkmr_TermDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655893473776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Contingencies and Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 16, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2004 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Mar. 31, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Blumberg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ResearchFundingPeriod', window );">Research Funding Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ContractualObligationAmountOfResearchFundingPerYear', window );">Contractual Obligation, Amount of Research Funding Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment', window );">Research Funding Agreement Right to Obtain Exclusive License Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments', window );">Research Funding Agreement Right to Obtain Exclusive License Maximum Development and Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments', window );">Research Funding Agreement Right to Obtain Exclusive License, Maximum Commercialization Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Drexel and Blumberg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">License Agreement, Maximum Development and Regulatory Milestone Payments Per License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense', window );">License Agreement, Maximum Sales Performance Milestone Payments Per License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | NeuroVive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License Costs | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">License Agreement, Maximum Development and Regulatory Milestone Payments Per License | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense', window );">License Agreement, Maximum Sales Performance Milestone Payments Per License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementEarlyTerminationFee', window );">License Agreement Early Termination Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Cytos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">License Agreement, Maximum Development and Regulatory Milestone Payments Per License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense', window );">License Agreement, Maximum Sales Performance Milestone Payments Per License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Enantigen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_MarinaMember', window );">Marina [Member] | Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_MarinaMember', window );">Marina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_UpfrontFee', window );">Upfront Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tkmr_ArcturusMember', window );">Arcturus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=tkmr_MarqiboMember', window );">Marqibo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_RoyaltyPayable', window );">Royalty Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_RoyaltiesPaidOrAccrued', window );">Royalties Paid or Accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 3,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember', window );">Arbitration With the University of British Columbia [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PercentOfCostsFundedByTPC', window );">Percent Of Costs Funded by TPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_MaximumContributionForProduct', window );">Maximum Contribution For Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 9,323,000<span></span>
</td>
<td class="nump">$ 7,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_CumulativeContributionForProduct', window );">Cumulative Contribution for Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 3,702,000<span></span>
</td>
<td class="nump">$ 2,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_RoyaltyguaranteesCommitmentsPercentage', window );">Royalty Guarantees Commitments Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,136,000<span></span>
</td>
<td class="nump">$ 4,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ContractualObligationAmountOfResearchFundingPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research funding the company is obligated to pay per year to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ContractualObligationAmountOfResearchFundingPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_CumulativeContributionForProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of contributions from an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_CumulativeContributionForProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_LicenseAgreementEarlyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of termination fee if the license agreement is terminated prior to the first commercial sale of any licensed product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_LicenseAgreementEarlyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum development and regulatory milestone payments due per license under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum sales performance milestone payments due per license under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_MaximumContributionForProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of contribution for a product in an agreement between an entity and the counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_MaximumContributionForProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for milestones reached in an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_PercentOfCostsFundedByTPC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percent of costs funded by TPC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_PercentOfCostsFundedByTPC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of commercialization milestone payments due if right to exclusive license is exercised under a research funding agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of development and regulatory milestone payments due if right to exclusive license is exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment required to exercise a right to an exclusive license under a research funding agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ResearchFundingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information about the research funding period under the research collaboration and funding agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ResearchFundingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_RoyaltiesPaidOrAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of royalties paid or accrued of an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_RoyaltiesPaidOrAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty payable from an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_RoyaltyguaranteesCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty guarantees commitments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_RoyaltyguaranteesCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fees due upfront from an entity in an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tkmr_ArbutusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tkmr_ArbutusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_BlumbergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_BlumbergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_DrexelAndBlumbergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_DrexelAndBlumbergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_NeuroviveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_NeuroviveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_CytosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_CytosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tkmr_EnantigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tkmr_EnantigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_MarinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_MarinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tkmr_ArcturusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tkmr_ArcturusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=tkmr_MarqiboMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=tkmr_MarqiboMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tkmr_ArbitrationWithTheUniversityOfBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655971110400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Changes in Fair Value of the Company's Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="nump">$ 5,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_FairValueOfWarrantsExercisedInThePeriod', window );">Fair value of warrants exercised in the period</a></td>
<td class="num">(341)<span></span>
</td>
<td class="num">(6,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_IncreaseDecreaseInValueOfWarrants', window );">Increase in fair value of warrants</a></td>
<td class="num">(801)<span></span>
</td>
<td class="nump">7,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_FairValueWarrantsForeignExchangeGainLoss', window );">Foreign exchange loss</a></td>
<td class="num">(351)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Liability at end of the period</a></td>
<td class="nump">$ 3,606<span></span>
</td>
<td class="nump">$ 6,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_FairValueOfWarrantsExercisedInThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of gains and losses from fair value changes included in warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_FairValueOfWarrantsExercisedInThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_FairValueWarrantsForeignExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gains and losses from changes in foreign exchanges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_FairValueWarrantsForeignExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_IncreaseDecreaseInValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase decrease in value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_IncreaseDecreaseInValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655894811472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not involving cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,377,000<span></span>
</td>
<td class="nump">$ 792,000<span></span>
</td>
<td class="nump">$ 2,705,000<span></span>
</td>
<td class="nump">$ 1,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not involving cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,046,000<span></span>
</td>
<td class="nump">289,000<span></span>
</td>
<td class="nump">4,525,000<span></span>
</td>
<td class="nump">629,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">(14,886,000)<span></span>
</td>
<td class="num">(6,081,000)<span></span>
</td>
<td class="num">(26,875,000)<span></span>
</td>
<td class="num">(24,065,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">147,000<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gains) losses</a></td>
<td class="nump">2,639,000<span></span>
</td>
<td class="nump">1,391,000<span></span>
</td>
<td class="num">(4,418,000)<span></span>
</td>
<td class="nump">1,332,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of warrant liability</a></td>
<td class="num">(2,024,000)<span></span>
</td>
<td class="num">(5,813,000)<span></span>
</td>
<td class="num">(801,000)<span></span>
</td>
<td class="nump">7,803,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in non-cash operating items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,738,000)<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="num">(4,624,000)<span></span>
</td>
<td class="num">(178,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInUnbilledReceivables', window );">Accrued revenue</a></td>
<td class="nump">$ 1,304,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">$ (519,000)<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
<td class="num">$ (298,000)<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(7,351,000)<span></span>
</td>
<td class="num">(943,000)<span></span>
</td>
<td class="num">(5,343,000)<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">334,000<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="num">(957,000)<span></span>
</td>
<td class="nump">12,744,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(16,671,000)<span></span>
</td>
<td class="num">(8,010,000)<span></span>
</td>
<td class="num">(35,641,000)<span></span>
</td>
<td class="nump">1,145,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Disposition (acquisition) of short and long-term investments</a></td>
<td class="num">$ (9,944,000)<span></span>
</td>
<td class="num">$ (42,992,000)<span></span>
</td>
<td class="nump">27,419,000<span></span>
</td>
<td class="num">$ (42,992,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired through acquisition (note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">$ (383,000)<span></span>
</td>
<td class="num">$ (246,000)<span></span>
</td>
<td class="num">(524,000)<span></span>
</td>
<td class="num">$ (581,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used) in investing activities</a></td>
<td class="num">(10,327,000)<span></span>
</td>
<td class="num">$ (43,238,000)<span></span>
</td>
<td class="nump">27,219,000<span></span>
</td>
<td class="num">(43,573,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net of issuance costs</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,177,000<span></span>
</td>
<td class="nump">56,477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">939,000<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="nump">1,559,000<span></span>
</td>
<td class="nump">2,072,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Issuance of common shares pursuant to exercise of warrants</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">974,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">960,000<span></span>
</td>
<td class="nump">234,000<span></span>
</td>
<td class="nump">143,780,000<span></span>
</td>
<td class="nump">59,523,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of foreign exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">967,000<span></span>
</td>
<td class="nump">1,924,000<span></span>
</td>
<td class="num">(340,000)<span></span>
</td>
<td class="num">(545,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents</a></td>
<td class="num">(25,071,000)<span></span>
</td>
<td class="num">(49,090,000)<span></span>
</td>
<td class="nump">135,018,000<span></span>
</td>
<td class="nump">16,550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">232,276,000<span></span>
</td>
<td class="nump">134,357,000<span></span>
</td>
<td class="nump">72,187,000<span></span>
</td>
<td class="nump">68,717,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 207,205,000<span></span>
</td>
<td class="nump">85,267,000<span></span>
</td>
<td class="nump">$ 207,205,000<span></span>
</td>
<td class="nump">85,267,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised', window );">Fair value of warrants exercised on a cashless basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Investment tax credits received</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Acquisition of Arbutus Inc. excluding cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued and exercised on a cashless basis. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655961237264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - Scenario, Unspecified [Domain] - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">54,303,402<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">54,303,402<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, no par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655964555056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 1</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 2</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 3</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; font-size: 10pt; text-align: left">Cash and cash equivalents</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">207,205</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">207,205</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Term deposit</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">217,217</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">217,217</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">Liabilities</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">3,606</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">3,606</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Contingent consideration</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,136</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,136</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">8,742</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">8,742</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 1</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 3</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td nowrap="nowrap" style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">December 31, 2014</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Cash and cash equivalents</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">72,187</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">72,187</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Guaranteed investment certificates</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">112,161</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">112,161</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">Liabilities</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ChangesInFairValueOfWarrantsTableTextBlock', window );">Changes in Fair Value of Warrants [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Liability at beginning of the period</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Opening liability of warrants issued in the period</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Fair value of warrants exercised in the period</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Increase (decrease) in fair</div> <div style=" margin-top: 0; margin-bottom: 0">value of warrants</div></td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Foreign exchange&nbsp;</div> <div style=" margin-top: 0; margin-bottom: 0">(gain) loss</div></td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Liability at end</div> <div style=" margin-top: 0; margin-bottom: 0">of the period</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="width: 12%; font-size: 10pt; text-align: left">Six months ended June 30, 2014</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,379</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">(6,607</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">7,803</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">15</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">6,590</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">Six months ended June 30, 2015</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,099</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(341</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(801</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(351</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,606</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; font-size: 10pt; text-align: left">Dividend yield</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">0.00</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">%</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">0.00</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">69.32</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">85.22</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">0.59</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.00</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Expected average term (years)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">0.4</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Fair value of warrants outstanding</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">9.50</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">12.80</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Aggregate fair value of warrants outstanding</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">3,606</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Number of warrants outstanding</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">379,500</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">398,250</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ChangesInFairValueOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure on changes in fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ChangesInFairValueOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655958504752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arbutus Biopharma Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001447028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,328,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655964566688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Consideration paid:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 89%; font-size: 10pt; text-align: left; padding-left: 10pt">Common shares issued without subjects</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">371,553</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Common shares issued subject to repurchase provision</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">9,262</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Common shares issuable for Arbutus Inc. stock options</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,127</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">381,942</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Identifiable assets acquired and liabilities assumed:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Cash</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">324</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">116</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">147</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acquired intangible assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">390,017</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Goodwill</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">156,053</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued liabilities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(3,580</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Other noncurrent liabilities (note 8)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(5,136</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Deferred income tax liability</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(156,017</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total purchase price allocation</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">381,942</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">$</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 89%; font-size: 10pt; text-align: left">IPR&amp;D &#x2013; Cyclophilins</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">35,124</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">IPR&amp;D &#x2013; Immune Modulator</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">189,182</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">IPR&amp;D &#x2013; Antigen Inhibitors</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">35,520</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">IPR&amp;D &#x2013; cccDNA</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">130,191</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Total IPR&amp;D</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">390,017</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended <br />June&nbsp;30,</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended <br />June&nbsp;30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Pro forma information</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; font-size: 10pt; text-align: left">Gross Revenue</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">3,440</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">1,811</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">8,122</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">6,241</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Loss from operations</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">(14,420</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(13,844</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">(39,491</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(24,278</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(14,886</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(10,479</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(33,940</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(32,962</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Basic and diluted loss per share</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">(0.27</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.23</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">(0.67</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.73</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of characteristics and cost, by total and major class, of indefinite-lived intangible assets acquired as part of a business combination. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. The future benefit is not expected to diminish over a stated period of time. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4922-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655895207968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue (note 4)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">$ 1,144<span></span>
</td>
<td class="nump">$ 5,830<span></span>
</td>
<td class="nump">$ 4,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,440<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">8,122<span></span>
</td>
<td class="nump">6,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research, development, collaborations and contracts</a></td>
<td class="nump">9,690<span></span>
</td>
<td class="nump">9,298<span></span>
</td>
<td class="nump">20,247<span></span>
</td>
<td class="nump">17,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,662<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">10,378<span></span>
</td>
<td class="nump">3,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs (note 3)</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">17,860<span></span>
</td>
<td class="nump">$ 11,234<span></span>
</td>
<td class="nump">40,548<span></span>
</td>
<td class="nump">$ 21,622<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,420)<span></span>
</td>
<td class="num">(9,423)<span></span>
</td>
<td class="num">(32,426)<span></span>
</td>
<td class="num">(15,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (losses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="num">(2,571)<span></span>
</td>
<td class="num">(2,728)<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">(Increase) decrease in fair value of warrant liability (note 2)</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="nump">5,813<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="num">(7,803)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,886)<span></span>
</td>
<td class="num">$ (6,081)<span></span>
</td>
<td class="num">$ (26,875)<span></span>
</td>
<td class="num">$ (24,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">54,255,804<span></span>
</td>
<td class="nump">22,063,438<span></span>
</td>
<td class="nump">42,297,517<span></span>
</td>
<td class="nump">20,938,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="nump">$ 3,223<span></span>
</td>
<td class="nump">$ 3,774<span></span>
</td>
<td class="num">$ (5,951)<span></span>
</td>
<td class="nump">$ 1,616<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (11,663)<span></span>
</td>
<td class="num">$ (2,307)<span></span>
</td>
<td class="num">$ (32,826)<span></span>
</td>
<td class="num">$ (22,449)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 23<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e1043-128460<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b,c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655958445920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left">5.</td>     <td style="width: 5pt"></td>     <td style="text-align: left">Accounts payable and accrued liabilities</td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; text-indent: 0in; margin: 6pt 0 0">Accounts payable and accrued liabilities is comprised of the following, in thousands:</div>  <div style=" font-size: 10pt; text-align: left; text-indent: 0in; margin: 6pt 0 0"></div>  <div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0; text-indent: 0.25in"></div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2015</td>      <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">December 31, 2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 70%; font-size: 10pt; text-align: left">Trade accounts payable</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,802</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">2,044</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Research and development accruals</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">1,914</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,391</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">License fee accruals</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">250</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Professional fee accruals</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">604</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,294</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Deferred lease inducements</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">364</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">250</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Payroll accruals</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">491</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,873</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Other accrued liabilities</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">745</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">226</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">6,920</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">9,328</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655958083104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Collaborations, Contracts and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left"><div style="display: inline; font-weight: bold;">4.</div></td>     <td style="width: 5pt"></td>     <td style="text-align: left"><div style="display: inline; font-weight: bold;">Collaborations, contracts and licensing agreements</div></td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The following tables set forth revenue recognized under collaborations, contracts and licensing agreements, in thousands:</div>      <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three months ended June 30</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Six months ended June 30</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid">2015</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid">2015</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; font-weight: bold; text-align: left">Collaborations and contracts</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">DoD (a)</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">1,862</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">861</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">4,907</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">4,101</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto (b)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">269</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">283</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">517</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">526</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">BMS (d)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">206</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Dicerna (e)</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">179</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">406</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Total research and development collaborations and contracts</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">2,310</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,144</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">5,830</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,833</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; font-weight: bold; text-align: left">Licensing fees, milestone and royalty payments</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto licensing fees and milestone payments (b)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">805</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">626</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">1,647</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,171</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acuitas milestone payments (c)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">150</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Dicerna licensing fee (e)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">263</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">526</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">-</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Spectrum royalty payments (f)</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">62</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">41</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">119</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">87</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Total licensing fees, milestone and royalty payments</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,130</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">667</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,292</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,408</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Total revenue</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,440</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,811</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,122</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,241</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>        <!-- Field: Page; Sequence: 13; Value: 3 -->      <!-- Field: /Page -->                <div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The following table sets forth deferred collaborations and contracts revenue:</div>      <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2015</td>      <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">December 31, 2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 70%; font-size: 10pt; text-align: left">DoD (a)</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">563</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">313</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Monsanto current portion (b)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">3,746</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,245</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Dicerna current portion (e)</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,296</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,221</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Deferred revenue, current portion</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">5,605</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5,785</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Monsanto long-term portion (b)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">7,336</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">8,666</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Dicerna long-term portion (e)</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">709</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total deferred revenue</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,650</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">15,722</td>      <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">(a) Contract with United States Government&#x2019;s Department of Defense (&#x201c;DoD&#x201d;) to develop TKM-Ebola</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">On July&nbsp;14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company&#x2019;s lipid nanoparticle technology to treat Ebola virus infection.</div>  <div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to $34,700,000. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (&#x201c;FDA&#x201d;) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (&#x201c;LNP&#x201d;) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional $6,970,000. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by $2,100,000 to $43,819,000. The additional funding is to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. In May 2015, the Company and the DoD signed a contract modification to further increase stage one funding by up to $1,000,000.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract&#x2019;s budget this would provide the Company with up to $140,000,000 in funding for the entire program. In October 2014, the Company and the DoD exercised an option to add $7,000,000 for the manufacture of TKM-Ebola-Guinea (the &#x201c;Ebola-Guinea Amendment&#x201d;), developed by the Company, targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>    <div style=" font-size: 10pt; margin: 0">In March 2015, the Company and the DoD signed a contract modification to provide up to $2,250,000 to fund the Company for TKM-Ebola-Guinea IND submission expenses.</div>    <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company&#x2019;s actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company&#x2019;s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management&#x2019;s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At June 30, 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>    <div style=" font-size: 10pt; margin: 0pt 0">On July 20, 2015, the Company announced given the unclear development path for TKM-Ebola, development activities will be suspended and a joint re-evaluation of the development contract with the DoD is underway.</div>    <!-- Field: Page; Sequence: 14; Value: 3 -->      <!-- Field: /Page -->                  <div style=" font-size: 10pt; text-align: left; margin: 0pt 0 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0pt 0 0"><div style="display: inline; font-weight: bold;">(b)</div> <div style="display: inline; font-weight: bold;">Option and Services Agreements with Monsanto Company (&#x201c;Monsanto&#x201d;)</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the &#x201c;Agreements&#x201d;). Under the Agreements, Monsanto has an option to obtain a license to use the Company&#x2019;s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto&#x2019;s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction, following the successful completion of milestones, is $86,200,000.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2,000,000 for the extension period. From inception of the contract to June 30, 2015, the Company had received $18,550,000 from MonsantoThe amounts received relate to research services and use of the Company&#x2019;s technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity (&#x201c;VIE&#x201d;); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company&#x2019;s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company&#x2019;s initial investment is not significant, and has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADco in Other Assets. There were no significant assets or liabilities for PADCo as at June 30, 2015. There was no equity income or loss with respect to PADCo recorded for the six months ended June 30, 2015.</div>    <div style=" font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"> (c) License and collaboration with Alnylam Pharmaceuticals, Inc. (&#x201c;Alnylam&#x201d;) and Acuitas Therapeutics Inc. (&#x201c;Acuitas&#x201d;, formerly AlCana Technologies Inc.)</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;">Milestone receipts and payments </div></div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">In the six months ended June 30, 2014, the Company earned a $150,000 milestone from Acuitas, subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;">Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (&#x201c;Ascletis&#x201d;)</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam&#x2019;s position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement.&nbsp;The hearing date for this arbitration took place in May 2015, and a decision of the arbitrator is pending. The Company has not recorded any revenue in respect of this milestone.</div>  <div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0">(d) Bristol-Myers Squibb (&#x201c;BMS&#x201d;) collaboration</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (&#x201c;siRNA&#x201d;) molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company could use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company was required to provide a pre-determined number of LNP batches over the four-year agreement. BMS had a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">Revenue from the May 10, 2010 agreement with BMS was being recognized as the Company produces the related LNP batches.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The revenue earned for the six months ended June 30, 2014 was related to BMS batches shipped during the period. In August 2014, the agreement expired and both companies&#x2019; obligations under the agreement ended.</div>    <!-- Field: Page; Sequence: 15; Value: 3 -->      <!-- Field: /Page -->                    <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">(e)&nbsp;License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. (&#x201c;Dicerna&#x201d;)</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the &#x201c;Agreements&#x201d;) with Dicerna to develop, manufacture, and commercialize products directed to the treatment of Primary Hyperoxaluria 1 (&#x201c;PH1&#x201d;). In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of $2,500,000. The Company is also entitled to receive payments from Dicerna on manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of up to $22,000,000, in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee. The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. Revenue from service work orders is recognized as the services are performed. The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately 28 months.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based, in part, on the Company&#x2019;s performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0">(f) Agreements with Spectrum Pharmaceuticals, Inc. (&#x201c;Spectrum&#x201d;)</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (&#x201c;Talon&#x201d;, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the &#x201c;Talon License Agreement&#x201d;) for three of the Company&#x2019;s chemotherapy products, Marqibo&reg;, Alocrest<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">TM</div> (Optisomal Vinorelbine) and Brakiva<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">TM</div> (Optisomal Topotecan).</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.</div>  <div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: normal">Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company.</div> <div style="display: inline; font-weight: normal">On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the three and six months ended June 30, 2015, the Company recorded $62,000 and $119,000 in Marqibo royalty revenue (three and six months ended June 30, 2014 - $41,000 and $87,000 respectively). For the six months ended June 30, 2015, the Company accrued 2.5% in royalties due to TPC in respect of the Marqibo royalty earned by the Company &#x2013; see note 8, contingencies and commitments.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655958138544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 207,205,000<span></span>
</td>
<td class="nump">$ 72,187,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">10,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">217,217,000<span></span>
</td>
<td class="nump">112,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Guaranteed investment certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,974,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Guaranteed investment certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">3,606,000<span></span>
</td>
<td class="nump">$ 5,099,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">5,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total</a></td>
<td class="nump">8,742,000<span></span>
</td>
<td class="nump">5,099,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">207,205,000<span></span>
</td>
<td class="nump">$ 72,187,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">10,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">217,217,000<span></span>
</td>
<td class="nump">$ 112,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Guaranteed investment certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,974,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">3,606,000<span></span>
</td>
<td class="nump">5,099,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">5,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total</a></td>
<td class="nump">$ 8,742,000<span></span>
</td>
<td class="nump">$ 5,099,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Trading Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph a, f, g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655968294896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Collaborations, Contracts and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three months ended June 30</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Six months ended June 30</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Collaborations and contracts</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">DoD (a)</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">1,862</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">861</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">4,907</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">4,101</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto (b)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">269</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">283</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">517</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">526</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">BMS (d)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">206</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Dicerna (e)</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">179</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">406</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Total research and development collaborations and contracts</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">2,310</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,144</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">5,830</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,833</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Licensing fees, milestone and royalty payments</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Monsanto licensing fees and milestone payments (b)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">805</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">626</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">1,647</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,171</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acuitas milestone payments (c)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">-</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">150</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Dicerna licensing fee (e)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">263</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">526</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid; padding-left: 10pt">Spectrum royalty payments (f)</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">62</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">41</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">119</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">87</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Total licensing fees, milestone and royalty payments</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,130</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">667</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,292</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,408</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid">Total revenue</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,440</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,811</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,122</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,241</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2015</td> <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-size: 10pt; text-align: left">DoD (a)</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">563</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">313</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Monsanto current portion (b)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">3,746</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,245</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Dicerna current portion (e)</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,296</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,221</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred revenue, current portion</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">5,605</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,785</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Monsanto long-term portion (b)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">7,336</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,666</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Dicerna long-term portion (e)</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">709</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total deferred revenue</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,650</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">15,722</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970730544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Contingencies and Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left">8.</td>     <td style="width: 5pt"></td>     <td style="text-align: left">Contingencies and commitments</td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;">Product development partnership with the Canadian Government</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The Company entered into a Technology Partnerships Canada (&quot;TPC&quot;) agreement with the Canadian Federal Government on November 12, 1999. Under this agreement, TPC agreed to fund 27% of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of $7,179,000 <div style="display: inline; font-size: 10pt; color: red">&nbsp;</div>(C$9,323,000). As at June 30, 2015, a cumulative contribution of $2,965,000 <div style="display: inline; font-size: 10pt; color: red">&nbsp;</div>(C$3,702,000) has been received and the Company does not expect any further funding under this agreement. In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement. These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date. In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay 2.5% royalties on any royalties the Company receives for Marqibo. For the three and six months ended June 30, 2015, the Company earned royalties on Marqibo sales in the amount of $62,000 and $119,000<div style="display: inline; font-weight: bold;"> </div>respectively<div style="display: inline; font-weight: bold;"> </div>(three and six months ended June 30, 2014 &#x2013; $41,000 and $87,000 respectively) (see note 4(f)), resulting in $3,000 being recorded by the Company as royalty payable to TPC (June 30, 2014 - $2,000). The cumulative amount paid or accrued up to June 30, 2015 was $9,000, resulting in the contingent amount due to TPC being $2,956,000 (C$3,692,000).</div>  <div style=" font-size: 10pt; font-weight: bold; text-align: left; margin: 6pt 0 0">License agreement with Marina Biotech, Inc. (&#x201c;Marina&#x201d;)</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&#x201c;UNA&#x201d;) from Marina for the development of RNAi therapeutics.</div>    <!-- Field: Page; Sequence: 17; Value: 3 -->      <!-- Field: /Page -->                <div style=" font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0pt 0">UNA technology can be used in the development of RNAi therapeutics, which treats disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">Under the license agreement the Company paid Marina an upfront fee of $300,000 during the year ended December 31, 2012. A further license payment of $200,000 was paid in 2013 and the Company will make milestone payments of up to $3,250,000 and royalties on each product developed by the Company that uses Marina&#x2019;s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">Effective August 9, 2013, Marina&#x2019;s UNA technology was acquired by Arcturus Therapeutics, Inc. (&#x201c;Arcturus&#x201d;) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus&#x2019; UNA technology. This triggered the accrual of $250,000 as at December 31, 2014 related to the milestone payable to Arcturus upon the dosing of first subject in a Phase I clinical trial of TKM-HBV, which occurred and was paid by the Company in January 2015.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">Arbitration with the University of British Columbia (&#x201c;UBC&#x201d;)</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at UBC. These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Spectrum.&nbsp;&nbsp;Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to $3,500,000 in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. The Company is currently disputing UBC&#x2019;s allegations, and no dates have been scheduled for this arbitration. The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related to both the likelihood and amount of any possible loss or range of loss. Costs related to the arbitration have been recorded by the Company as incurred.</div>    <!-- Field: Page; Sequence: 18; Value: 3 -->      <!-- Field: /Page -->                <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">Contingent consideration from Arbutus Inc. acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In October 2014, Arbutus Inc. acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&#x2019;s merger with Arbutus Inc. &#x2013; see note 3.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">Under the stock purchase agreement, Arbutus Inc. agreed to pay up to a total of $21,000,000 to Enantigen&#x2019;s selling stockholders upon the achievement of certain triggering events related to Enantigen&#x2019;s two programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The regulatory milestone payments have an estimated fair value of approximately $5,136,000 and have been treated as contingent consideration payable in the preliminary purchase price allocation (note 3), based on information available at the date of acquisition, using a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The Company is currently undertaking valuation assessments of assets acquired and liabilities assumed from Arbutus Inc., which includes a valuation assessment of the contingent consideration.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">Drexel and Blumberg:</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In February 2014, Arbutus Inc. entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In partial consideration for this license, Arbutus Inc. paid a license initiation fee of $150,000 and issued warrants to Blumberg and Drexel. Under this license agreement, Arbutus Inc. also agreed to pay up to $3,500,000 in development and regulatory milestones per licensed compound series, up to $92,500,000 in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In November 2014, Arbutus Inc. entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, Arbutus Inc. made an upfront payment of $50,000. Under this agreement, the Company will be required to pay up to $1,000,000 for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate&nbsp;net sales of compounds covered by this intellectual property&nbsp;in any commercialized combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">Research Collaboration and Funding Agreement with Blumberg</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In October 2014, Arbutus Inc. entered into a research collaboration and funding agreement with Blumberg under which the Company will provide $1,000,000 per year of research funding for three years, renewable at the Company&#x2019;s option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, the Company has the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted the Company the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the Company elects to exercise its right to obtain such a license, the Company will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of $100,000; up to $8,100,000 upon the achievement of specified development and regulatory milestones; up to $92,500,000 upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate&nbsp;net sales of licensed&nbsp;products from any commercialized combination.</div>    <!-- Field: Page; Sequence: 19; Value: 3 -->      <!-- Field: /Page -->                <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">NeuroVive Pharmaceutical AB (&#x201c;NeuroVive&#x201d;)</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In September 2014, Arbutus Inc. entered into a license agreement with NeuroVive that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#x2019;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, the Company has (1)&nbsp;an option to expand its exclusive license to include treatment of viral diseases other than HBV and (2)&nbsp;an option, exercisable upon specified conditions, to expand its exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which the Company has not exercised its option.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of $1,000,000. The Company is also obligated to pay up to $47,000,000 in clinical development and regulatory milestones per indication and up to $102,500,000 in sales performance milestones per licensed product and indication. If the Company is acquired by a third party in a transaction that meets certain criteria, then the Company or its acquiror will be obligated to pay all remaining development, regulatory and sales milestone payments, regardless of whether the applicable milestone events have been achieved, for each licensed product that entered clinical development before such acquisition. As describe in note 3, the acquisition of Arbutus Inc. by the Company was completed by way of a Merger Agreement, which does not trigger any of the aforementioned milestone payments. The Company has agreed to pay NeuroVive tiered royalties in the mid-single to low-double digit range based upon the proportionate&nbsp;gross sales of patented licensed products from any commercialized combination. If the Company terminates this license agreement in its entirety for convenience prior to the first commercial sale of any licensed product, the Company will be obligated to pay NeuroVive a termination fee of $2,000,000.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0"><div style="display: inline; font-weight: bold;">Cytos Biotechnology Ltd (&#x201c;Cytos&#x201d;)</div></div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">On December&nbsp;30, 2014, Arbutus Inc. entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to six different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&nbsp; The Company has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">In partial consideration for this license, the Company is obligated to pay Cytos up to a total of $67,000,000 for each of the six licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of $110,000,000 upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&nbsp;net sales of licensed products in any&nbsp;commercialized combination.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970747984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Financing<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left">6.</td>     <td style="width: 5pt"></td>     <td style="text-align: left">Financing</td>    </tr>     </table>  <div style=" font-size: 10pt; margin: 6pt 0 0; text-align: left"><div style="display: inline; font-weight: normal">On March 25, 2015, the Company announced that it had completed an underwritten public offering of 7,500,000 common shares, at a price of $20.25 per share, representing gross proceeds of $151,875,000. The Company also granted the underwriters a 30-day option to purchase an additional 1,125,000 shares for an additional $22,781,000 to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was $9,700,000, resulting in net proceeds of $142,177,000.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970696928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Concentrations of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left">7<div style="display: inline; font-weight: normal">.</div></td>     <td style="width: 5pt"></td>     <td style="text-align: left">Concentrations of credit risk</td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time. The Company&#x2019;s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0">The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at June 30, 2015 was the accounts receivable balance of $6,332,000 (December 31, 2014 - $1,903,000).</div>  <div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">All accounts receivable balances were current as at June 30, 2015 and at December 31, 2014.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6442-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655968394432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of presentation</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the year ended December 31, 2014 and included in the Company&#x2019;s 2014 annual report on Form 10-K. The unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to present fairly the financial position, results of operations and cash flows at June 30, 2015 and for all periods presented. The results of operations for the three and six months ended June 30, 2015 and June 30, 2014 are not necessarily indicative of the results for the full year. These condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2014, except as described below.</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of Consolidation</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">These condensed consolidated financial statements include the accounts of the Company and four of its wholly-owned subsidiaries, Arbutus Inc., Protiva, Protiva USA, and Enantigen. All intercompany transactions and balances have been eliminated on consolidation.</div><div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&#x201c;VIE&#x201d;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does not have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Replacement awards </div></div></div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&#x2019;s acquisition of Arbutus Inc. (formerly OnCore), Arbutus (formerly Tekmira) shares were exchanged for Arbutus Inc.&#x2019;s shares subject to repurchase rights held by Arbutus Inc.&#x2019;s employees &#x2013; see note 3.</div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.</div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount.</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Goodwill and intangible assets</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Intangible assets consist of in-process research and development arising from the Company&#x2019;s acquisition of Arbutus Inc. &#x2013; see note 3. In-process research and development (IPR&amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds the carrying value, then such assets are written down to their fair values.</div><div style=" font-size: 10pt; text-align: left; margin: 6pt 0 0">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. &#x2013; see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the goodwill, an impairment loss is recognized equal to that excess.</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income or loss per share</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company&#x2019;s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants. During the six months ended June 30, 2015, potential common shares of 2,774,398 (June 30, 2014 &#x2013; 2,558,925) were excluded from the calculation of income per common share because their inclusion would be anti-dilutive.</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value of financial instruments</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The Company measures certain financial instruments and other items at fair value.</div><div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</div><div style=" font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;</div><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; text-align: left">&nbsp;</td> <td style="vertical-align: top; width: 2%; text-align: left">&#x2022;</td> <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: left">Level 1 inputs are quoted market prices for identical instruments available in active markets.</td> </tr> </table><div style=" font-size: 10pt; text-align: left; margin: 0 4.5pt 0 0; text-indent: 0.5in">&nbsp;</div><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; text-align: left">&nbsp;</td> <td style="vertical-align: top; width: 2%; text-align: left">&#x2022;</td> <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: left">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</td> </tr> </table><div style=" font-size: 10pt; text-align: left; margin: 2.5pt 0.8pt 0 0; text-indent: 0.5in">&nbsp;</div><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; text-align: left">&nbsp;</td> <td style="vertical-align: top; width: 2%; text-align: left">&#x2022;</td> <td style="vertical-align: top; width: 1%; text-align: left">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: left">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#x2019;s assumptions about market assumptions that would be used to price the asset or liability.</td> </tr> </table><div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The following tables present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, in thousands, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 1</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 2</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Level 3</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; font-size: 10pt; text-align: left">Cash and cash equivalents</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">207,205</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">207,205</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Term deposit</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">10,012</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">217,217</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">217,217</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">Liabilities</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">3,606</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">3,606</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Contingent consideration</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,136</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,136</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">8,742</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">8,742</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" margin: 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 56%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 1</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">Level 3</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%; border-top: Black 1pt solid">&nbsp;</td> <td nowrap="nowrap" style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right; width: 8%; border-top: Black 1pt solid">December 31, 2014</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Cash and cash equivalents</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">72,187</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">72,187</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Guaranteed investment certificates</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">39,974</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">112,161</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">112,161</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">Liabilities</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Financial instrument</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Total</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The Company acquired a term deposit in May 2015 with an original maturity of 24-months and it has been classified as a long-term investment on the balance sheet. For the period ended June 30, 2015, the fair value of the term deposit is $10,012,000 which includes the principal and accrued interest earned as at the balance sheet date.</div><div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The Company used a discounted cash flow model to determine the fair value of the financial instrument, related to Monsanto&#x2019;s call option to acquire the equity or all of the assets of PADCo, as described in note 4(b). The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial liability was nil, and there has been no change to its fair value as at June 30, 2015.</div><div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">Contingent consideration is a liability assumed by the Company from its acquisition of Arbutus Inc. &#x2013; see notes 3 and 8. The Company used a discounted cash flow model to determine the fair value of the contingent consideration as at the acquisition date, and at each subsequent reporting date. The Company&#x2019;s preliminary estimate of the contingent consideration was $4,736,000 for the reporting date of March 31, 2015. As at June 30, 2015, the Company has reassessed the preliminary initial fair value of the contingent consideration to be $5,136,000.</div><div style=" font-size: 10pt; text-align: left; margin: 9pt 0 0">The following table presents the changes in fair value of the Company&#x2019;s warrants, in thousands:</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Liability at beginning of the period</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Opening liability of warrants issued in the period</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">Fair value of warrants exercised in the period</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Increase (decrease) in fair</div> <div style=" margin-top: 0; margin-bottom: 0">value of warrants</div></td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Foreign exchange&nbsp;</div> <div style=" margin-top: 0; margin-bottom: 0">(gain) loss</div></td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Liability at end</div> <div style=" margin-top: 0; margin-bottom: 0">of the period</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="width: 12%; font-size: 10pt; text-align: left">Six months ended June 30, 2014</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,379</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">(6,607</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">7,803</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">15</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right">6,590</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">Six months ended June 30, 2015</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,099</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(341</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(801</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(351</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,606</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The change in fair value of warrant liability for the six months ended June 30, 2015 is recorded in the statement of operations and comprehensive loss.</div><div style=" font-size: 10pt; text-align: left; margin: 10pt 17.8pt 0 0">The weighted average Black-Scholes option-pricing assumptions and the resultant fair values, in thousands, for warrants outstanding at June 30, 2015 and at December 31, 2014 are as follows:</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">June 30, 2015</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid; border-top: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; font-size: 10pt; text-align: left">Dividend yield</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">0.00</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">%</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">0.00</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">69.32</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">85.22</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">0.59</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.00</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Expected average term (years)</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">0.4</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Fair value of warrants outstanding</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">9.50</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">12.80</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Aggregate fair value of warrants outstanding</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">3,606</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">Number of warrants outstanding</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">379,500</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">398,250</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Foreign currency translation and reporting currency</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;">Functional currency</div></div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The functional currency of the Company and its integrated subsidiaries (Protiva and Protiva USA) is the Canadian dollar. Foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The local currency of Arbutus Inc. (including its subsidiary, Enantigen) is the United States dollars which has been determined to be its functional currency, as it is the currency of the primary economic environment in which Arbutus Inc. operates and expends cash. Foreign currency monetary assets and liabilities are translated into United States dollars at the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&#x2019;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0"><div style="display: inline; font-weight: bold;">Reporting currency</div></div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. The translation differences from the Company&#x2019;s functional currency to the Company&#x2019;s reporting currency of U.S. dollars are unrealized gains and losses; therefore, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: left; margin: 13.5pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent accounting pronouncements</div></div></div><div style=" font-size: 10pt; text-align: left; margin: 4.5pt 0 0">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</div><div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: left; margin: 0">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition &#x2013; Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to propose a deferral of the effective date of the ASU by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017 instead of December 15, 2016, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.</div><div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: left; margin: 0">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &#x2013; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent on the impact of this adoption has not yet been determined.</div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)-(d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.3A-02)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph k<br><br><br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02, 03<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655964066176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Financing (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tkmr_UnderwriterOptionsMember', window );">Underwriter Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_PotentialProceedsOfAdditionalSharesAuthorized', window );">Potential Proceeds of Additional Shares Authorized</a></td>
<td class="nump">$ 22,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 20.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 151,875,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,177,000<span></span>
</td>
<td class="nump">$ 56,477,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds From Issuance of Common Stock, Net</a></td>
<td class="nump">$ 142,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_PotentialProceedsOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential cash inflow from the additional capital contribution to the entity if an option is exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_PotentialProceedsOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tkmr_UnderwriterOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tkmr_UnderwriterOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655970782256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Nature of Business and Future Operations (Details Textual)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_WhollyOwnedSubsidiaries', window );">Wholly Owned Subsidiaries</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_WhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of subsidiaries wholly owned by an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_WhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655892655984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jan. 11, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Subject to Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter', window );">Business Combination, Acceleration of Share-based Compensation Expense Per Quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Common Shares Issued Without Subjects [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="nump">20,347,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business Acquisition, Share Price</a></td>
<td class="nump">$ 18.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="nump">$ 371,553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Common Shares Issued Subject to Repurchase Provision [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="nump">$ 66,196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Pre Combination Service and Included as Part of Total Purchase Price</a></td>
<td class="nump">$ 9,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Post Combination Compensation Expense</a></td>
<td class="nump">$ 56,934,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Related to the Expiration of Repurchase Provision Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Arbutus Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,287,000<span></span>
</td>
<td class="nump">3,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Pre Combination Service and Included as Part of Total Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127,000<span></span>
</td>
<td class="nump">1,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Attributed as Post Combination Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,160,000<span></span>
</td>
<td class="nump">$ 2,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares', window );">Business Acquisition, Compensation Expense Related to Vesting of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member] | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair Value Inputs, Discount Rate</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business Combination, Acquisition Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">23,973,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="nump">$ 381,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_StockRepurchaseRightsExpirationRateShares', window );">Stock Repurchase Rights, Expiration Rate, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">381,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">390,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">156,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,303,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,303,402<span></span>
</td>
<td class="nump">54,303,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business Combination, Acquisition Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,303,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,303,402<span></span>
</td>
<td class="nump">54,303,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">$ 381,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,053,000<span></span>
</td>
<td class="nump">$ 156,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of compensation expense related to the vesting of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinessAcquisitionCompensationExpenseRelatedToVestingOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity, of which will be attributed as post-combination compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount per quarter of acceleration of share-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity, of which has been attributed as pre-combination service and included as part of the total purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_StockRepurchaseRightsExpirationRateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the stock repurchase rights that expire every three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_StockRepurchaseRightsExpirationRateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 23<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e1043-128460<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 37<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=tkmr_SubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=tkmr_SubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedWithoutSubjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedWithoutSubjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=tkmr_RelatedToTheExpirationOfRepurchaseProvisionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tkmr_ArbutusStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tkmr_ArbutusStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001171843-15-004476-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-15-004476-xbrl.zip
M4$L#!!0````(`.^$!T>IM&Q?B]\``/D9"0`1`!P`=&MM<BTR,#$U,#8S,"YX
M;6Q55`D``X$7Q56!%\55=7@+``$$)0X```0Y`0``[%WK<^,VDO]^5?<_\'2W
M6Y,JR^9+#]H9;WGL<<Z7F;%C:Y+-IQ1$0A(2BM0"I&WM7W\-D)1(BN!#HF1/
MXJUL0HL`^M</`(U'-[__Q_/<51XQ9<3WWG>T8[6C8,_V'>)-WW>^/G0O'BYO
M;CK_./_^O[K='["'*0JPHXR7RF@6>@ZF5_X<*__\</])Z2KJ\%35[SXK7T>7
MBJYJO:XZ[*J#;O?\^^<Q=<DI_[<"]#SVOC,+@L7IR<G3T],Q__G8I],3756-
M$^*Q`'DV[D0E3VT_]`*Z7-40I1FVCZ?^XTG\$FIJ1E?5NH:VJA92"HS(ZL5O
M>44S6]'!I+@.O"@HCI_M67%Y_J:@`O$>,0N*JT3O"K@AS#=U;5`FMJA$4L$E
MWA\EI?GK,6(K(7N(V*P8DWC%(6E92)[O>>&\F(83T)-@N<`G4*@+I3`E=E*/
M$;N8$+PH(,."!964AS<%%8+(+AVPRPRX^ZL?K@GP/67'MC]?E?YC3C/%`OS'
MG%"TF"$ZYP4YA9[:-]2D1LBZ4X06JTH3Q,:"Z?C%263Y:4AA0*6ZL$[@;5*0
MOW!RYA>7ZY]$+]-%28-N]+QA$4^&**U9EG4BWJZ*LJ)RT*IV\L_/GQ[L&9ZC
M[D;[C#2I=?Z?_Z$HWW.JITR\NL<31:`XG5$\>=_ABNDFLC]^9DXG?LWMZGV'
MD?G"Q9V3J!WHFJ<7<^PY\/_@VD53Q?:]`#\'][PIY[=$):H6/_:[7*'$>=^Q
MNYK1.9\@E^'O3S;:63=_*4:,X)HP&[F_8D0_>LX5C(5-*`&A;E?3P3(B4K(V
MUU2O?#N<KXK<03_RG6OXC35B4.^<_Z1')*4-RFAR6,TI:IUS_FL1S56#FQ0C
M.%L(5E,C>M&O6:J91C=ICL"<FI"R.N>:VOTI2X,WLF[ZHQ>08'D)OU/DWL!@
M]/PC7C:A`?I2H=^8YD#5AQ&EPC8W2/KSN>\]!+[]QP.,7YC=A@'O;WPRS]`G
M,=&!&*0<;),Y=(#WG9LOUPF&84<)/1(5%V--EXDF.^<]T]"'IF9F@)50WD`9
M6?T]7O@T@/</`0J:F5>O<_XK9AGZA6WF*</XC^DEF,'4IXT48G;.+VP;N['W
M(]I)D\\TG*=ZCZ>$@=J\X`N:-S-K($O'(9?.!^*+*0DIESY=I&EGF\\3_]EW
MP4-"-(+82,K]SOD7/TTIUU:>U"_8=7_T_"?O`2/F>]BY82S$M`G)09ZDI,V(
M-)\B3D$O-,3.I<][A@U4'K$78NCT-M@#FN)"NX]HKNW>B`%H_0'T.V/#]!<A
MA2E+/59U&-)JD=U$^(G`*X:O,18_`-T2:#&:OC4TK12:V,GKAF(Z!!^,N#!3
M0NO)1-B4H!E-1VE9=(TT^9XJ(7^N]V",4K/BV"2Y">L>,Y@![-D%C,@@-==?
M\!&TEIJRT,R!#)IF:>8&MF*ZV^.K%)TYE(K.L+0M\"T6U'\&4@&^702P7(MF
MMLW^)18<FI%^O.3K)$P7B`9+/DQ</!/6_>Q[#(8-_S.>CS%-0;>&,)_>F;\F
M`(L)IZ!]"!GQ,&,7]K]"P@@O`S/"`FP!\>>/S_P1WV.7#Y\C_V=8Y,`@?3N)
MYHK"$0(60&;*#'Z[>$+4X?.L@!X/BV+"B3"QB(O?"J"D:]QX=L)NT;0GN)?;
MO&:E;'XWILNE]Q&>@N4-UQE4$X.><TOY?]'8Q3\C-\07C)$IC(@704`)\`9/
M[,YG`6`8$P])X!3V,Y"U45MPOY5C^[!<*2GE%%3*W.C+9-[K6X99*O6]">LU
MZ>C0G4`Z[YSK6K^\%[R0/NZH?^V#A_0148^[@`M,15?[@!BQ^:A*7$ZH<+0Q
ML_Y("P(<#+5B`78!5S?K47?58WT@EV=-QO8D'7,M';-%Z>B-I&.\5NEL^K*M
M2,=H(IW^:[8=;0^V8S:1SF`OMI,:J%8K0WB.9W>HS]<&&P,8.$X_A>"#259%
M@[4E64UD]1M?[F+N+CZ`_XW`.1/%DC^`16PC%E1/PM(Q7QM:QN:8OZL0"N2*
M=I]&*$[A>L#T$18EH$N0EALZH@00OYV,_`"Y=R%XW(#SCD*A%_"-A)E&Q1["
M\>_8#D;^/5ZL4/F/A!_,5&NN)].<I??U3<V]I)B_!:T?W-N2KA4U31^\Z>^5
M]-IU?^4O8%R5&H5T6V!0LKI\]:IFV4'_'MO^U"/_QLZ-`Y,/F1".`R#@(!(Z
MA<8]YQ/\3%S@`#-X%\[A1UL<W`+=I:CA.:L-I%71W?5:H@/I1&?TAOG%S2&9
M3@G\<H:\*1B;=XT(%;J]G?R"*-_H92/>P`B$\\$%PVNTI=SOG/_=#<X<\JBP
M8.EBJ$'8PD7+4X5X+LCU3)E`<]T)FA,7?@S(''3AX2>%^G/DQ6\9\'^J:.HB
MZ/Q]&ISQ%@..20$OP%T@)[H^`%3YWVR![.3OF.;8IPXX:[;ONFC!H*GDZ>Q,
M>2).,#M5H"LLGL]$\XIHGR:5'S$-B(W<+G+!UD^5L1\$_CQ5DGNBG*HG=G;C
M6CG<9PH76=($W[7%]$R)<44MGBH?7`3BU8ZU1:`PWR7.JD3@+U:ODY>1*-!\
M<>:-V4((Y21PTK!D4/9,]N6DD9CV4D&!,L93XG$_6_$G2C##RD+L([[)*3B[
M!<^8"\9=R0M$]!3W=H6(D1[ZYYO4,K#XR*@\\J$Q(R[\C*E-V+<A,<]_HOPV
M2?3?@X]6V:E`F2,*?30JKYXE?R8$5%$'YE>*P4-0WL'T*IZ^XX*>@#($K]#>
MBMFF;6\H,]WBFP+;42#?#P`8"K^@QGV,'*N[Z._=%!'O.\7UV3>@N=>OJ<ST
MB3UG9_UL3KP2#9T$M+;G!;P#NU,*WJW#73J?GBIT.GZGJ^:1;@R/]%[ONTZ!
M[F-'3_O;AE.9U8&+)T&U9B7],"&BUZ;R0)Z5.92<,2YRF$7^+_2P8JA'_$ZK
M*3?E=MFI;+2%)B2X_J>ZK4II4C*=1:WUCHR!]1>06I-&&XBO^Q<070V#JVQL
M+;%W_:.^.F@1WG=_9FD-CH:J\69C#:6F]=Y$UE!D_:.>I1Y$:KOZ+K_,2("+
M')9J)[`]A;=%J]2;*;'B0_+:>!%P<"F6=(4=2:0=)=4J<93>%'+@+E3+!WO3
MRJ&[R3O#U/;/28G/]Z8&H8:A^J:&5Z`&H_>FAI=7@P%+SOY+SA)IG_=$',6N
M=O7B';[X2+O^L7+Z+)J?S@(3*""/^((7GHKK9B-,YYNGSVI7[74U-?U8&'_P
MX?-#+O1@`"YI+QUZ4$8X@R\*PPF1>SL&F457TN:<Z.TD":RX#D4XVAVF/`2Q
M,*!#[1J:!*L;<J33^,;()SQ%;A2BU.BJST!5A_*P%55-W3W8@J>T1,)YZ`JI
MB7;X51"H?NW3.^H[H1W4NS,@9<*0,J%;_5Z*B0H8!T1<=,/*1OS*QT#5MT+\
M\3D02ZKR:)P>[P(KE#VIA95$X^C0);2>>A5#+**;@E70L3\F)Z(WWFB&2^.&
M,K=UY3=H=,D-Y<YYOZ^F;C'5!-,&_')SR,&77P`RM9;1IT)AH7C\:ZUXM]R]
M9[-^1(%UW"OAH1!1*TP4!,7EF:A_\5_3CX=M<)%4B,\]/\;'GC\@XGWR64'X
M6:..(+UYJ_4*#*D"2ROPFW0$0V)3G?,N>)8[,9#<$[B*;PG<>#D%[BAX211`
MYWPP5%.7U2MA[`:YD;"E5S^[L)K:#G(<<GLQI5AX1A\1=9?</8JO*U[C@ANR
M9AQ@4#@1?<$AOW?^B'?V=315JB,]X^O48**$Y<_HF<S#>2IJ]L)S[O&4S^,^
M77XF+F:![^$[M.0O&8P6<1.%DM&[^K!8,E<4/V,7&F_1&Y3.HT:O3$+;\WPP
M06J:U,3V(4AI`*E6:FK?@"`/TE=5J\@E$@ZR.?C6)<B=$HD$+Y>!SUH8Z:0!
M'/V7D]X#@LI08<)CW#P;O^Z14#I76'J=H;`!L_N7W&%F5WDDB?K-B6S_750K
M";Q1Z_31[<3U&04A!;BWDQN1W4^4K+5-L"Z_"D#B/M$57OB,!!O[!$-+ZYS?
MZ<G662'=#"[!5,W-%AX#;D3XHD?Y(H]OMD@710-M8*T%78KA4%B+'`<Q[UF&
M;FR-]<X/>'00<D?@L3-D\_+"BV\O7XLTFE"6>J!S/NSK:4.OPMJ`+9"%V)=B
M>]@*DS,J]9ZSZXOFX-.<Y[MYD0:U];H5'K6^9-J$T8%ZJ)(O2YXZ*,=8'ELS
MW,9Z\6I$.S<2A2!*JF!#5^K)8;<(6E^#UNN";B5"'CCL2^<0(Y,/:T<6,_L@
M)2Q>4!L&^;`@YC2/6SHBU(;]!2/*IY_D7*("O6:VV,VEKJ$V[*7QRS"FV?`]
MT/3L&DS#LV$HN*5)5"T+J$CF")49<>)<!F4[P'4RR:38Z&^1RFVO:#<SNTBW
MKOIE4<O]E`+:PWM`G17'RD9\RSK.R^FL[@YIOR?9:C^(SJ+#*?#5G^WX9?I`
M<[$^S&QX$'OE7U6.%P/IZ61V+5X;8XJO.,7C[>329P'CYZ_8^;`<W5TV=4,S
M.2>-]`B7S3FYR@PEI9Q&EW@X"2/Q`;%,U"I/.@-#]=:B[DNWW8QXVRA!7XIL
M!Q8,X53*]BD2%B0.0++3/O(?P@7/'9O:A[ES45$VA[P`I">)?6MP"/[%**[K
MN_'OQ$3`$7K@Z4MO/5S=R^0^A780S=?CO(P#Z0!I&D/-.@`+2?^[YV=HL=<J
MEBJQUHJ3@J8NPB1T1GZ\,0$:O`UFF+),LJ&HT&J-4RT9^6ZZF=TKV9MH>M&0
MN8-V2Q91O4-PH(OO7UC%'(R0Z_,;!!0M<!@0N]J'EQ^F:<-]J&05Y[WU.GX]
M^G!3O)VD[#9CEY]]ATR(+=R+D<]!@&!XYC#D+<&>1S]^_CCV7?1#2#R,;KY<
M/83C.6%LG5*L>I@>R(_I&\@N$4F1#.^H;V/L,&#3<4CD6$3Y@B["8.93GC%&
MDNE6[Z4?LVFGOO*/63Q1`L*5)AC*&8HN'=9T?3#4"IBM@SW-<US\FOISD7W(
MLS%W2U;I7K_@XNM:.5;+>)`;.W],W3"J`R:%/7=S;K7'>\_O<H[\VW&`"+_5
MX(:,/.)X.W>U]S>?<T<1N>3?PEC+E_*'O%5H27?"<J<G^^6_)4'7/@U[.7E+
M^]A0:TO<M:6PJ]2_+B84Y!@W]W(RE3J4NXLTRZ)<8/*[D9$(6I?&^GRJSY.N
M&[\6<[FQ*QU_<2#.1A9?!$U.INI?D:RU3YVZG=T71TR:OKJ,6@/'KJCK[H;*
M40]V1.TOD<O3L]TAXMS2.&U;+?'&YT.W-$F[%^],_XN,*_8]^7ZZ=)!)K4V*
MP6V@7\9IY^3I+G>"*D]@:>2A)D@:0#1;D:;\4Q;U(4Y#Q+>\,.8I`><D2,Y]
MB[XV4N-^8'83R))N`JT_/%(/1PJX\('6.67%*,G`;R;1=MX]"G#)9QC:3VYM
MF9O?5TEN_)H]`WR[F-/:P%/,QL-\_M+CUN=&9>8DW60TTK/5&E$*YB\SWW67
MMT^>2/O+B$.`IB3E9?FE\&%?EQA-8C`26M5HDO2@-]YJ:WBUB;05U,R&41JJ
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M&G<S>8I@><>IZCKI3,$%UKN=>(J#>VN$.V^)H!5Z=?(@5G`OHI]KP9&FG*DC
M@8.QNQUO5]@6GJ)B:)L)`F7#V(Y9B>J(K3A.?5M#W-&*&P2S'YZWEN&])BPO
M+JJVC+\XG:C<6QFHM?.(C2AR,)_>,W-^A5S*LI5M#)O-1-ZHZ3HI+TIH%.:A
MK#/L"RKZT5#5#\!-"Z)K3P7MRULF7-7<F$OVDS/OE<Q2*Y3)UK?PNYW4-UA1
M_%'9G9VH]IVREH?MVGU0.[(V78Z7QO\M3('ZD6%I>T9V\-FO'N`D"FN"\99=
MZEM0</=%47T+$M)[ZC?2`=J85>ZH/\'BTA!R=S#]/_5LTE??YI(M.I)VI%N-
M!??GF$NN\`13RO=%Q55!XCFA'1W,O'6K=7;`_ENW>IN?JN8GM*2^Z[Y-2YN&
M8#;WU-_ZC]B?&1C?2`]J;UJJM6LO0B1JG$&^V/E,:>+8DK2QK=M]VPA27QXQ
MJ\Z"7I[[_9Q&;<O>@34I&57T_@OS]4IF;6FJZ]ZASWZWI5C5VAY/(-HGG?[2
MC*57>8Y[9+WMP>6`VCV4*HOU9AT9^O!`3-4?78HO'F6^F[C*L+[C%;C2>W3B
MG'+KNXM#4QH`IP_C_-<U".^`L.INXM"4QIR"8VCNAO`>VY@\\K+YT+0Z=U=Y
M/)KTMF_?,(K%EZ&Y%:R*;,H<EC3Z7+/B)+B[PMK^NJS\AG0]F=77Z/878N4I
MB^H)4(:1=_;TCO,UWN'B\5":A>2\KV[TC!+2N\&L[,$E"4=T:R><45)^[%SA
M!07B(@``GETL`A!@>)W[X/5%08G0Y@)\P"7/W\`#YW@VDT5Q8%NE"<MS'&BJ
M:6S81RLP#\5\9=^0IT?0-,VR#LN\6+'SF'"*9SR)P2.^\6Q_CGG2<>B'MY,1
M>FZN8%.>M[6K#_7^AM$V@=,R+U7Z,E7I9-#5=4.36NL6O*RBQ'G0V8UWB18D
M0.XV\I=G"!\,\[-^,=4MH56+4^XQ]75UN`VTW\,X#^?(E]00$4UC)%(1S7EN
M@RC6"4?15CB.>XLB%%/1BY+,D@4!7*O(F2C)$Z?B>QQ2%,95C&HS&"HK*DN>
M+L12^SE)[5<(KT_D)6*3=MB!R#SZNL7&P_-XP@7L)&D71&*J0UIA+L.O/&F$
ME>2B:H/#G*Q<6+KQ852(_T->_'&&DE:#*W_[PG/[XMM)W+@H=(_%8#[R1S.\
MCI+DGXI*(BCO>.)I[FM%H925@9KRCSSU##TW--<20DYP7D`<XH;\6TL/V.;)
MBF%9+`+W'>SP=!Z\B3"(^?B(J$>\*0]R%40*LNXT_"H4>*S#S9#$)!95'PQ,
MPQJF>&P#[T%$4)XD,"\">3BNWNL-+1YYO$\1,(9KAI/FO%/YX#DPAOEP3$&E
M'N7J(,J27)A#;3"L27G[A75?[IEHO4%^-R=-K!&.2D'(D_]I6M_4B@11@F.5
M6'*],R9/5K`J_&&Y>OQ?@BF_-[S\Q.\,BT%Q]>[&`[-DXH56X<W`3"(7[P#^
M*6"K`/NN+);@DV>]/@2^)`?''E4P*,EUINE:7SL,BR7XY!]QW!H?S)J$9^"*
MMIEXSA??)?8R^G>S,.F53Z0-!KU]!4V_M?B7;+%.K'(2,6R*@YET;'(EM,P!
M6_UJXB7\!FX[L:-ZHC_QL.P%.#,\+0IW2F1G-_GG+1E.AV*#'PY^?^BA$%87
M4;H@AWO!XDD<5G&'69DD.2V`WBJ[Q@P]8F6,L<?!+Q"_8$D\$:1&';X.49Y(
M,%.FV(/AUG67_`U>\-;0:O2`F@3:7;B8);'I7ST!1"R^Q(\7<U@,VDAY)X[#
M_OL9AA#[[.OQP['RP\7%W?I'Y^P[D`(%#`%4F!=CCJ/D`2%0=Y='BN,KGA]`
M)>$>*@!4<59C'U,H7YARSGC+R/-"?B^[H.%C)9)DBA2;^:'K@("@$21$`R+]
M/?3$%QTBV7!^XQ22:SZL,X"Y5D>%$CA#P`!`Y1MD./`%4M[PDG]`6'R#5=F(
M_Q758IZ=*`>`!$E<6C`.6O9IH`#Z:Y_.P<ZZ/PJ^M[0?BB<NMH.CA+Z_(!X7
M#>@<^CF*<G`>"96@]4I80*?8=A%CJX2<?'RP85&*Z%(!$<2=29G`=`:&)U(>
MK!"(#]-`G2-HA85N((R,[_3&+?'V>:YQ9>+Z3_!GH&1"P\5[80V`:R'V*5A"
M$#N1/(H;3A03S"B.\C4P\JS,H>/.6*RH34KI7T`1X`AP<TVXA0&27V<64H#.
M&'>AA'Q"<!("5&X.B94VT5*4*T*TP]`<_@4CBI![%.NVZLC<`^#Y)A"W1!^(
M.)C9E(S7]A6;J2_^J&_A,5.Q==8R[R,%/_.QAH-9PQAC8.2X[N"Z[?/:I:KG
M*^7\J\W=E231/8QJF`715L\M%9L]8Q<+;PV<-]!*+MO;.D&Q:OQ_>V_:W+B1
M-`A_WXC]#]A>3ZPZ@I0)\+8?.T)]>?1L']I6VQ/O)P<(%$78(,#!(37GU[^9
M655``01(D`0O"1,STQ0)5.55F5E9F5G5HS;K9\OT:Z;FI;0+YX_=QY._&'9Y
M+HCF;([CE.YG!@-]G`W/[D>D@Q.<]G[9!KF"S!2LRW3(K:5767F3+V,TO"3*
M'4U4_^5@TYM(2&Q!E#&[DUK3.'"H]_O=T]$XS`_VF5I[?IFJV):T.>YTSX[L
M.<G.)+3DPGZ=;F\X[@RVH'LE6CUK^N^EH8U1*3.Z`Z/?TXVC\R+M)?EE^H>/
M)C89GYX*2O2,WM;UG31O+T.0S@I!>*M`?2TA*@"]&?$`KP.;F[<>]8.EGO0[
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M7.WR]:RD=M32#:.1VKVE=M`R>L>1VI-X0\7=WM`B3`-_KIR7'7:'>IB>'/L-
MGLK`E=YK]8PU-F!GN%_7Z*8</JQ21IUN:]3;9GNV)RF>HX1UQZU<RYI&PE+J
M&*#5AJ/:)>Q@7O@>02JLZG5!_YX@1+6^7OYP350./7U6D8]&@Y/@OHU^VS^6
MLSL^QV1<&9<ZK=YP?'BL]C(YI^72Q:RX;K<U7K=];E;<.:RXKM$:#]9L%P^V
MXLYGTX/Y81;O'X_E2MCC#;=!L`'2Z&#]1;NGG6MCV#BGI;3I[@O/R][\=*X'
MC725TF98OW2I6C=M4T5_K>;-;I?OLC%9AE**[@+'*JYC.]_LMY+BT398B'8V
M`4L?71OK4^%2(FRD5YA26W;8X%6SF,0<PR;O2Q*C>\.`'^SMS/0>\`K4--49
MVZ5\CP*3"BW,8'D;L7EQVQ"9H=2KX1+?;-9F>0EB6^_U<L6WIZ##.7*BEW*B
M5Q\G2BLEVWHWWT&EX42M%UOG.%%:E=WNCGMCO>%$\9K0ZU\3I77I;:-GY`KT
MSYL3\$8*Q+&4>VG1`RCWT6ACP4@Q\+7A?!@U6MX'3.]@-OQI<3Z,PBKO%];M
M4K^^4_.Y?M50WKNCW37&`^/0.(O4G".MY$$IA[N]+?@K@*X!R\.LW?)^+".]
MNMFM#\O#K-;25I0CW:@NM[7R\@"FN[3GY,#HU<1+V#Y.P"83=.F[HG]6]1YF
M-907KFE8-N@7V]G-P->*=*^\E5:VEUVO=!%V!\5\.R8FJWHG`WO9TM*^AS]Y
MCOO+JRB(V:L?#RE.:RA;NB3.0DB*FHTIP)<%"K8E+3C?H6,+M_M;8'HAOWA,
MK[4"<,U:+>_!W!WIXUZQ!JZ"P&%1+U>U)T4(MTC,BS)CW`0!;J.H-<%7_/1E
M^B6.T,<*17.IAUEAKZ8.MJ,J8_%[SX398#(19?S('DSW/7P5+;<2@6&GLZ[Q
M5J=3[$_5@_:N))7W#2Q+PK/ES>4'XU%Y5]?>L+M1\6R"Z#`H;6AV."YO::F?
M)4K'E.[2S<*9TJ:&7H#=3;T`1Z5*\BR(\MGWK)W;2(Y+U5D=N*6@'13+I%6?
M@E>95[VMSU%P14LE5^X<ZKY7#A-YB[)VY"]^TM0O9!K(`+\KJ`A7;N$I3>F`
M04M.*PNN\)%9]OWR(]<JY%MM%-==;4"4N]=GM;1*(6_YPW4"^8D%#RS@/<J$
M<M;>./YB9F)U(NCI:^T*#V(9=M?Z`DLC8/C['?W>H@=>KT%3/1`NN[MHQ]YV
MG:+C<`%%#0-_\;3_-KT8VXSIO-=4OY7I3D4%JM3R*O(U4Q.$O'D(&/E.V/W*
MY$T>8,;./V1S*Q]T?61ZN%YX[@_O?"=(3P2GCFVPMWF:^:Z[;/M/V$0GC">@
MBAR`IZ4E5E:["AGOMJ6-7E]G1WDR0P!K$3B/L%L"YO%AJ)N>E338LF)L#>9[
MU`G/AW6$??+0$OG\E@[JD.;/@?W8JTO<EH$`FQYV16O[`=YE@$U+`_8`BL.C
MIET+>(P:>I%8_?/-'[Q7VES(&@*V6`0PG:U-EN4-Z8@\0`-0P"'"^`DMJ-95
M6J9A2[%X/J>.8LD#/?Y`EAS9D<O;P6$?.>V1>NDCEKPGLRD[C.`3RNV<^'L\
MQ^\#5JW'7H4F;%@:@^_C,P1#ZF)=URSC!UL\R.T(MV`F;X$X`Y93^TC11DYT
M6403]\![Q*5(@IA$,Q\DPQ2B>7/_5AMU8/5)DZ@I-C%LX2,XQ(3Z:T8S,TH8
MGVJN;^SON1.8KS5ZA$F.!JUTFK018:CR#'ANNDL<&IG/4#2214`=][`_HOBL
M8-$2[?E<WJX/S73@`%3X)K4UI)[W\L4%"!?U^0.B8`[B(L3>A5$;S3V0J$6O
M9`;TJ(D.OB^4B,/[#V77$^*EDC:G::ZUWSU87"4<X"A8J@O$F2JN6`>2S)F)
M[HB-K1/Q89""OUF$2L=BV)%/?*V.C6+-U0$V[@M3$H@N1>)EU$62-*XSIS-+
ML2Y-V5=,]!?T6+2R4!.!"QAV`$4(0^W!]^TGQW5!,R@`611'PA7,^+4`]*S#
M73S1Y5$JS&2T'\:M07_0`J<TMT3%<+)U8>A\;Y>W?;RH]2Q%2@B:">3'BVP`
M?:/;&@^[K2XH98M2H:1,DOJ7#R9*]8?N2&^->P91SPRS$M8"J^>`$G="(GK@
MT.J$.3JM;F_8&G<&N3D$.$\\XPK-)*5<T8KIM@9&O]73C>)W0'[*3<04,X%1
M/;'OS*(;!OB88@)\.6"*T(K>6EQ>LE:$+Z,J0"=B:S-P+D#J.9035FY1/M_<
MO[OY?YK0%'+U`)4I44PJ1S(F\!N*I9]?DZLFBFPJ<2-G4DFQ$SLKHKB!7&LP
M_F$P:.EC6F,MQ5)0>GC[W@*_@(6$+OXR]VWF"GD3-AE$Y^_V%%LE.2*%3PN$
M2>U<#WO_:&F//BI3VLS#ER,=OC*U_[#`!V_H$202N+UTF,O-/C@\J!\L2MYV
MIC1.CUJ3AM?:%TZ!/&5:J">,`9?TU`9&W!1P10/ZK6VE]DP+^;4XV;:]^)R)
M_7C5>;):1UE#G$W<@"@CRWF%(?@!]->XVR/84"OR]L5T#<]_^)26<F6*5(Z*
M8J:&N#@2P^M=B(:%+!:F+IJ!87N8T:J+'V)@!XC4B,,J=<N,:UZ.]`_]5M?@
M\!5"$O!S`"G0++ED9A,DB8N5MTLJC%E%#0H"O@%'@N\#BCH\F^`ZV-R'$Q`1
M5/.%ZR^3&^\"TXI6'/Z-BB>[\:")F/0'RM%<81#AK=`^RXHAL@+='(E'XB5C
MJV]RW9C+4@J7\"01('B+F:`[<./"_AWC@`(B\%'(___NS/G6Y`>]-1IWB=-8
M$O%OV'5%Z)NQZ106'+H[_Z][60;S9K6;=$LQ1](^,MPW"'L*ZUW=&W(SB&[)
M1HMSGU)X5;F38+?RPB)$A`2#(:AFHAQ[_6Y+'PXEC`PWA5I7-J^FS:!'.A?&
M_@S:@+=C+O9H."7_5[NM?4!%^I-V!R[VS]H]06LA-?6?-0J"_@13M-MIA"?W
MWH_X8N8!]3_G*P=YY3:-`VS>CDL+]#RP71_U6MUN(A%I'V^\40M5`&R\0[82
M(@BQO3#L76D+5&Z6R]]99WB[+6,TW-KN)FW#R0#3+*`#,+2M49`AMS.!N9*9
M.<J%D"<HEIM8O:4;P_,TL49+'W1VMK"@^7G#]421$XTS;%0L5M(;?9-=U<>=
MRE95PK!>F':PJ)>BR9&,YL-#P!X0G:R0EN^-E>!?N:4O"`6N6Y7IKHG'`XJD
MG=^(D&R84W##K<)9H49;@$`:<A[HP-L!2!U@_%;<Y>#'(8P2_G1<=@HSL/4I
M1'GWV?*CADV'#=O6CQ8$]*M56F4.HT!9.?9/^7."G2O1=@:JGN'2FK2C@5=T
M,K%GGX[R<YW1N$H/I[2U!OZE\.QME>#!!GKMU"QKJW&J=,Q:0Z+J;;.Z0[W5
M[W?K!O3PLE*?0MA.5#;L()Z?%J&HR[-0(+MT^\'6"5L("!E0W'B4.WC;DK(0
MI.TX?=A>%_5/J/:BU+,-#4Z"W3GK+(FV<6WT]U8H=0Q:R`X^D&;[,2R0NJS=
MWC,I9I!O"(Z&VMFKPKT$Z1+,VL4YQS7O@&YMYD7.U"&+57$SV^R13B\&M;DX
M>5_&#&>G9^\FE5]5G1N]"V'G$;8Q=WC-K&/+J"0_>O<I=,[7_>G97O>JUO7!
MA?#_4,M9="O`]#R+.8^4)?KLV#RZ$"8?99%C\F6TY)EU8,8IY_3YL5SO;=H.
MG@O3#[>RA9/F>)'I/3BI__;\N-W%TS7]4CA^A&7^FTB[?'ZLUC$%=&,@^EQ8
M?7"SO3"7?&>&Z7*6%<0LLR-[?OR_ZK;ZHTXMH+V^X`7^A?QR+ZV*4[?A5Z(Z
MY1ERO]_2N_7X[`?C_I$/%]XQ61M`O8BTR/R>",-R6TJ]Z$.$*[(M&]V(@_3.
M/G?U4Q#I_T;I6KD:$M-U?6OE:L5=1*\Y4S@0:M6]'OE-MG8TGVIZOCEDQ6E9
MF)6ULB?"XA=,NYO+1#Q*_^+;"DK<2[,RA9ZE=&K3FO&LO]R7F'X9:FGA6L2L
MF>?\&W/",`D3"S_!?4M23BW?\^>.!9-Z;(IEJ-GT,DI!%/D$><@I[0TQ#=$+
M(`2OM3OU3T0MJ;B3[H*H&N/E%;(6<X*Y+=',#Y-D6'/.W4PE;3-4JO:RN762
M?I3W1J4@IOU7'%+E(1\.A@CH15`<S`P\(*DH'YR;2R0YD,YAF*,;+S"IGCW$
MKAGY@4A>!W1:F$(Q]WFA#&_N'RI5?F'H6PZQ,,F/%6G7&0Q23EMF.-.FKO_$
MD_4R*?)&A]>:<.<ZY9K,VLX^K7>O1_\0PJ">F:R*6G)\0KF,8<0%L@V#47$>
M\HXJ@`@]I3#XZO;N*U$<__?N-1;YBB%;Q>F#/$]O`@,\O?ADP=V,X%97(N_N
M[-8T_+87V]+2J#C[BD$\NK>R55X?/[M4UXN6*JONS]K;I07+:@9.\L9,FY-E
M\6T[\C;I?+"/VGCV=8;9?'5D*ZR1BMOY'!/F/_DVMSO/;P.MC\8M?70I>7IU
MYS*4<_Y&-/>X]6;.Q`'6/\/0&2SZOE%/Z.SL5WI%J[9&(BS+>O?YYD26_.)C
M*7JWT]*S%Z">!+_3:Z+5)E"[A%DR@KJM4!:`<+)H2P5R'"X`LV'R;0\4#TJ`
M.L,T\IEU5<'&_E7!YQL-NG%S2TC)80R8C(K`+MYRL=7-U)$=:6PV=3RP1&W7
M>10)CZ&/$17/CY37)@RC0^;<!WWR'^Q@<_OU3IELPJB7JY8;C8(<HHW'PF6\
MA#70S`E,XWNTYY==CM+`1FEX@$VG,'W(PR*R]C4!2=:+8GL@9RXJ7K'!1A(*
MB4,VC5W>:".)%\%L"]$/8`%/8;D["^9A4<L5ZCR0(S)%J`@6[,3@8!-Y'EL3
M39WX)*9L/X"4I)926!H!Q`?=C*X8!4CF"Y@-$;V8,M8WDHCYGDIJB:@Y`4ZT
MJ-D#Q=IX'QE^R)TKL.:A=1X2E'V59.^>@(D08"@:<U3I\X3-T-SJ'9ZN-9E6
M@`M`AB@IO`,OA4N/`?8L3'NV8&@2NPEIYC024Q;VTUG3+HO+60Q3IN3!<23^
M"GD4!,0(2F,CT8L!%P,L5&P-JH0Q:1"U^E>=@,MK+K+(X7I0R('ZP&9V#&M%
MUO;@21R0?N&'3*Q*\5RR*%L:P)FLU71-D/@G`D]+!/_KQ<`N6B`7LP:HE#OA
MG"<N0U_A<KZ17Z9GG]*I+]L\L+0$OI76P*==<PJ:@5%?Q!]ZK<Z0:KQSW1QM
MQR9V8:1:XZW(Z$J)2K7W:^<]%OMJ8F"N#%W+J)K8,V/;03XM`I]:\YE)%QO9
M6@.HPGB.2NA\U\J;L]$CV-%7]'I(!DS;-CKI'94:;P/!Y.HNZB^9"EHKP]R6
M=A?X8-;,Y(/V^_T-7Z5IJT\SI')[P<^)Z(5(/0-LKG4$".0M"-4T84`^3S1P
MF#HA["^VP,D))7FE'DA_Y,>MI$]`)[C+C%(1YA(MM0"DF"+D`CSYL8O=#!Z9
M[!$ISET<_JIH&XIH1N;?\,`"?%LF>PONAV&*7G(>L]+,KR5UI&#T#&12M&I)
M'+?<L0K7I;;/)#EH[`KC%!S0D$2%R=]$)QQT"?J+Z+6(<09TF8ZLB9_+P4H-
M0:Z5C=2VIR3#\E.2#9LT?BPD]".JMD]<I;TGE8;S3`+M1_P9U5L*$NBYR\3R
M'M3V[CCN$H2I-8%J[_ALA0A*]4FJ'--58DW%<"-:U@LYD=P6KZW+MPKH>D14
M&Z[NQM6+B.+*^AKA_"@NST&.DK9EPK&JM1NX3@[7<<[@Y/T9@\KY`;\%N/<7
M%S-N(.:ZY(-=?:)=ACY`AZ7JIQ"M7F_3>6T=R-1`N0.GPM3?T$IOC?1-QY,'
MS]AYT=(]:NG&ID241KIWD^Y!R^@=4;I/[Y\5`DR7BE.L-HU_'6O_O:\C>;`9
MU'J77JNW?4)050R>8_F9WFV->O7T#-F2/,];$KOC5F]CME`CB0K%#-"2PWH:
M6UQ0):1@SF=QCGC2,-[N.6RUK[SZ8<A:B=%H4\WM`:FPM:)L<C`EYSJMWG!\
M)/SVMV=GP+G+6IG=;FN\,4#0K,PS7)E=HS7>V"WY!16:RWPYQQ)%G2[5OE*N
M$%Y/1*V3&X<Y%:#.]<9^QXV[G*57/3V#FFU;AJJ#1@JWDL+A@:0PK]+7UP2H
MG__KQSAL/YCFXB=YUZ]RU>\[)\1;+N.`?0,PWKB^]?>O__-_:-I_K7GG+O`_
MX,GG;7H`^E[4^G\),"3W92IZT[%[Q[.8<C'L.S."/R-,<\5\<9CR*YO^\LK^
M$P^[VYUNN],3'P?M;N=/.;DRPLUW)VR+1+];S_I$MS.]TFQF.7/3#7]Y=?OY
MPRO-L7]Y9>F#P7C<'[VB;&":QPG]GJ$/VW%HO_JUUQD:G4YG+7EJ0747@HHS
MM+.AY!"&TLLHN34-M\!N(_&^)I=_J9VL;RBQ3[9(O/'LCVG[K!O>Q!H;'<,/
M[^&11].E=%>5DDY*R>Y.Y&MW%3D<]KMEU.L:O4UB6"..!Z0G+Y;A3XI>P^]Y
MJV%XGOJ9\=\.2N9>&9EU?7`X,E=%_4C4_YKT^CTLL?MEQ!X=A]0*GH>CK.R_
M]LW\KOSX.>W,=T`*#TIUKMX?=/3AP<B\">G#D?LVR=:N67;SCH%1JI#'G4.2
M5D'P0JCXYP<J:OR(-8WIP!R*-\M/YE]^\!;+*NEEM?'*1O$N-XI]_8!F\9FS
M@'<Y29J<;.1"N<T<C?711B>Y84,Q&T3+D;3CR$9&E-K3;K^/;&CXL)-&LBS;
M,S<2?U"Z"KH=?:Q?-O53RZW\QGL,'])]Z931M*]W#^>.ER-[.`++>Q?N7!.\
M4[[EXF7[AW3`RV6V=S@'IA35C=0-[WS7L9:%$0L=_JM$+-+(@SX<#E_]BA$M
MI>[.=L*%:RY_TAP/'`W9AF-JSAT7OL0&"*'FL2<M\.>F5Y+NUXSX4D?<IFIS
ML(BTCJS=K`)8)O1=_37Z$;Z+``J+O_>5454N:1'SR0SLL#3(F_]<`[(%LV,K
M%3JI:_/^(0MSJ?[,OELS,&6BKEE\.6.NK4V6&ILO7'_)V&IO@!N\Y2!(.C]L
MW4'B"N.*U%ODB_?6#]CKM!(\_>D;^WON!.9K>4GK$PM8#N#R2^7%.\57_HK^
MLQ+/\E%2"F3ZD(6,:H^9UKT^`!=O0EG4;<NNMN6D;*D,R#?,B*A/5;8E3%`@
M(]A+-^UN;&K4DX//)9ITY%\!>BY`IJS44`!1@D=J-YZ5#0Y#MII<N<"])3KY
MRBEQ8#^,BD966H<$B2'$Z;!5#_-"_K"X*BWMJ`)?.,%2=G[@%%BY^UF*!,A+
M2/V7(MET)=].XA`<_U9,9*47L96YKICW"\#E(&ZVAC\5.&%]6I8?8`X=-20`
MM.@6XT(Z!<PUTY[66&#/)\]0N<5GUBQS@=H.?Z2^T:128`69,':`?8E\SQ9=
ME^)<5Z!#?%[K+`G/)>OA4'1=>$H?P/K<9.5RQ<7IE;@X@_&@4Q:-TKZ'/WF.
M^\NK*(C9JQ_W`*"7`M`K`*`L%%,?`$5.7HEG.^B4QB3RQR5K0-B/6/H:8I5M
MU#<3RZ,S&>5`YB9Z:P;!$@2=NK,5;A?6TJI;?K1DX!%G?Y5<FX"H!>Y>6S?:
M77T-W*4\'AKZ:'@BL&EWM@;L07=<2NZN80P')R/W!KA[I9MQO=OK]D]%[^X&
M,1GT2@/U@]%0/Q78O4T:K%<JW:.^,3@0V!_`.Z.'T[R.4H7R9_+PFV7R\9\.
MN%+@SRP_8N-!"D<DO]UZBS@*Z0=]0V1B,"AE6F6=5(!+W218`W]I*/8LX!>Z
M]:`L')<&EZJJYR-08`WXI6KZP.#?T=[@5GBT[QC_MYI#6&IS2L6Q;?0[0[T"
M-L5@U8E0D8-9BE"I<+5[X\ZX<Q8(;>.P=H?EUK7?T4=G@5"15UN*4&GBG#[H
M]VMC$)[2?)G^"PR=Z45?@J^X<_X".BHR^>:OBNK.GNP/>^IB^3X)7*?-M[JP
M>1B.^QG`-TR_+[`%6BH/[*`<V/$(%O?.P&+_MXD?4,?`&WR%]T(MR/BL)/D'
MBL!OU>1N)2+"XQ_MR%_\I*E?R)**`7Y7VO]N?5D$#%J2G%N0U2MK[?OEN<:[
MQ8Y[JW&/7%;P:L,6A;SE#]<)I")KOA>V2)X"TQ*W<KF.Q3RZ7<U\"!AO]+H&
MJ:+BE7R>\XYALMYU/Q<HRW4^#37L9XUMMF>R&:P:'HP]FPY,M\6VQ=O>^G$(
M3X2YJ[HDCA?>_+%*Z2V_Y_3PU0QUMT';M\5B18AXJ\FB[KDOER;W)?V$ZRAY
MVZ=R_<`7QAV!@;NW,=SF6KD+ZF*X)5K/JS5EP],+;TR9]<'(%4D<D^=7:7<F
MX)T3+`VI&E(]0U+5I8%K['6:[FSP+X5G[_QWVI6YJ;"YZ0U)W3DWML=H>D/N
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M(36;Q:*`5FM42VKGBY/+'A#NT/'I\]LR-@NI_F249C6=$7B-A#82^A*2S7;F
M\<>DMFC*6-C2YH[+PLCW&+G^@;\TW6@INW(U.X!F^5W8\FLD]`R1."\1>"8&
MXI@)86[&:I"I2`V'-!9-VE@VA[:S=853LPZCGP<'3]%YP3*IMP:])G%LMS#F
M<.N[QR]CYU#9&MQ8L1.98:'FMQK-WV3P[+7"FHRR1A[/21[U_M;G*L]W(R#S
MQ3+[@%JRQY[/*C,&6Y\G->NLT?N'/!S>?BO52.3A)?)L_/R=TX?O%\R*@GB^
M<EZ@74V;A.+CP*!&3"Z``"LSG)S'9Y*MV-L45F@2BB]^A>IZD_)_P4MTM"ED
M>CD9Q<>L/E+2C]WC9AV<@>A>EGYJZ1NS2,^!!HV&*G,!!Z=74<TJ/?`J-5K&
MN''U+WB5ZJU>9W1R[$X4?J@@9ENY%**W^DO20IMZ81U2^71;O5[C(M2V/`_`
MRC*=,]*;",-S796CEFXT+L'EK<I!RSB#N%_>$Y#?9"]*R5XSPK_[7^VV]L%A
MKOV3=F<^L)^U>[JDV$)(NC]K=.793UI7:[>SV"GO_8@O9AY(_X./[G@_RWC]
M[2QX.4NH\=M9;#9E0<#LM370TL]XGC>N%,O8L2^@.+.K"C+@B+M"6EI]-Q:<
M\KZ"S-SOF$47.&I=G?`[NZL+FJ/]IM:CON$NN-:C4N?Y8:=RN^*7U&5>-_9J
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MB'"W-=A8!W]`W&M/,#D>>X_%R[+N!:WAKIE!6V-59X8)_KUCZ@=/^L@-8#OA
MPC67/VF.YSH>*Q*](AP$1%GH3@7;E?E:>RL24K0G)YIIOWN@CFWM/C(C%FJ_
M^:#(/2R=(2S^]W>CHX]_#K5W;&$&$;7Y]Z<:QB>\D&E7Z4,6'@2F?]H_O]9@
MJR6N!]"^_=]/[?<`A7D0BO1(SF2JSA=/^^_87:9<T'N4DM!I:=&,`?;SA>DM
MM1`&`KS-)#^'DP,?P2--`-ZT'TW/8BGP+<WTM*^?;QQ\*C`7+`:3I\'_N<Y_
M*"TH'3Y+/==9.+;FF9Z/5'0LEP$VULP#@_BPQ*FB@)F11I-HCTX0A\#'*;/0
M0;X^$)EN/8+7`?8[8!87,Q,8"KS%+R5)6MH4##=2*=00<OG[M\#TPJD?S"G-
M"=[^Q&PT_MHWB94#LK0(_(?`G&?)_@1#,8#.P?0FP#Q@%G,>F18O\*\?NKW6
ML--I=3J=:^W;S`D3^!`0I+%#*5<TI'KW!`"6L`G>L=R8GK9@5I?1/@.>6,!D
ML#H(4N5EP!(X"$\#=V^]1Q9&SH-$[#-[TMX%,?RV6+CP(@V5"$IV[7SP?9LR
MONB%&WL.4X413P7++I4/[VZR2X7GB7%8$1#MCMBA:[-X#E"%YI1%2RT!/@J`
M)-<:2/HG<ZF-2+R[63J;G@=.EP7013,0+96KVLRTM0ECGC;W;6?JX#.^%L8+
MW))EJ`HJQ0OY`(X7,>!FQ(AC\)M8';Q6W_&*9#R#\\?/=UF<47YBEU.'ND":
M7CP%\.*`UI(B22@*"O@<:L$+X#6LG9#P9+`J,!,0BP$C$'J&S)&",T&::)A+
M)UC[PZ`U'@I1`TK>+`+'U0R#IR_EB6DGBF%5;V3@`4I.XP#U0P):!<A^,%HZ
M%WM:!;UN:Z2/Y2I@*M3*.L"37@`0-#&R18475TCL`:-0F\-,^,^,F3:F(`+%
M.</QA8C-@>EF`.HP\A?M)S_X6UNPP/&%V/@6!9YM9#"0Q>"4\'%I/SIV!C`Y
M1P)A./-C%]Z,0-9@WG_'#@QT#2N,A!9SX&HE<DI@A:Y"J^A(2B)GW5:XT-37
M,/`W00A0`T04?R&5&+S(.'Z9-3UA2U\0,*\R)4/3-1Z13"7K-ZL]HQELUQYF
M4D2R*K1(?Q+G0*6AC@2Y0,WTAE:D[V5@S-K$26S#,H`'0)*?2%*D4&7,!:I:
MR<5>1_(1Y5&B)\T!0`(2)JT."=H7*_(Q*7']BF;?66`Y"#`H"$%H,O^V]L,P
MF5%.DZHIEJ%;^[<8'"]3N\*'5,67^?4&"&9GW2O0A2U)3H`!I%8!M"74A>1W
M9C`T+D"(@(4+WPO)HDHHY7F1'T<36!]_(\'^!99-NYD&P+]CK8,*0V<'(NV`
METOMJQ^D,`G9,5I&/]&O*#DK^G*%D;>?89YX,G?"$,=DWU'3@C&J?YMQ*"7R
M._AN0<ZA4]%VT!XX\TD<H/`C$2P_)&O.M7Y+\:30=KJN+P@,@I_H>WJG1>QQ
MT$UT:!W!F[@@P;.;,G:MW7"E,V$`GH?C"4]RZH2H39;,##*@H1,V)Z_*`8`P
MI3X.:(IDVH!^E?).`YCX0S(7PZ>GZ:^D]&#=8@^!TO%,6-4`D!5S,TDM!7B<
M")$S[;_BD+ZW+-CP`A[NDEOH0K=_XVQ/C@N:U)E.@4W3P)\3LA)U^=!$ZE(Q
M7)9'R;(`@9<A=8%U(4QLBA4+(8Z7%B80[\#!"]"0PT!VC-\"K"'M1&S0J[#$
MX%'G$4P+.F3_`KT,*@5=W'D\%_[;=_I,M0=!R$7-G(,72@8F(Q`97EL@+L`@
M3XM7Y%5[-`-'I4$.>0$BMR5,R.*U]D[XD,I(2#EN"%LY4"1_N6L3)11&47``
M0BOB6AD4/W@8JUMCR2\:X"^`A+O$3S,'[\@+.`B.%_MQZ"YQ-H<]";ZE\A1J
M'KC588BN6!PFP,?<0WY$H8RL61NTV9Q%,Y]+>::@(+NT)[#'`KQP^1!]P>]S
MS(F;+BRQ^CQ"5Q";XQWZY'6@]_C@@;81XI7*%FI"(DJ6CAQA?)7V%LA1[FC:
M,-TY&AS<#*L1`R!C$2G3G=0#H,I=&OC;19V2V2R9X*ID+$DKZR4ERX>O>_"*
M07;!J-A2&K2_?%B%0/DV`R\J-M7%G+UHL2AB`?J)%M"3N2RT4>L*K7K[%UKM
MQU0E,'&F4;?](919!A*<'8?YLDBVS/<L>'1`;6@W#P$36W&2B23700IQ9BLN
M?\WXH.<7J\Q`="@?"=<^>/2H=S&$4KQ32,@I_4[86G`N)(07*WB5([`A\,$X
MP5Z5CZLR(F5;AA776NJYI8^T4C!0R6;V*OXDPIV`[*I+D;4X9.5N`'H+8%DC
MQ-L&VP"&=*G&)+GCPYT@]`Q<EPD;"B^R(!(QAA!WFYKY`'N*V,4MT;7VY5%`
M+J"31I>;!U!2B?D`&$$'TJ;Q.]DD%T<%3PG=M3`7-D2-*7UZ'FI2XD?<#UP5
M:\2T]+K:5!^WLDRFN>;FWUA^&1!=DYZ48D\LH8(_Y_`[/8.NFT"9SDY$U$IZ
M10L_0EL)%$35GD1:(XRDFA3H;:D%IA@QBBWT"*:QF]N#)QVO`'"@YP^C0<NX
ML/#&2A#(#(`0W+NB$+$YYW81*,P#'JLB11&]K/"@*S('6&9`&=*#">.2;6!^
M.T^CA^FHU]H'<L3!+BY4^YO87!AFC=^%H541TK:U'_11JR^VG>3>2Q'[EGC&
M8?HT7VX\)BY$-I3:!.4S3N/SA4M:6;U^R1HD'14PU;<SD[)DVF+PF`*(;QM5
M,_K=(&')<)P5Z(FKXUZ,U!5KU2S[R)\'3]D)9Q1@>)K!HERV_2?4^V$\"1W;
M`:79TNYNWKWU,YL_>MMFF-WD>#+P3H_1WI'V,E3535LM#,:@1HARQOF/V_<9
M8_"S-O.?@$.!HO^=4&SY0/(#=/8]-G4LA$M*B+*>K@4,3SG<,$C"`M2BU72D
M].\?&7?PQ=$0K,(4+MQH@!GP:'F9N)-VU8B:14%@+DKP$5#'Q_`9`75(-?7P
MEZ#N#=I5T+/.'#S@=%.7$^MD_CGH%&OF^]P`RKB>HIIQ[R<0L3!HG.I\'H$T
MESG;+Z=*QL*=#E*)OR!/KT!._,"UG\`ZM>!9RX4]''Q-AF!O6^QX8K,&/CC2
M)F-N,[@SM-)DI$@&^3;/2>P2/P=R8-OBA%9`]B0KP/`=F+*06,*-F+!X\K`S
M1$R(0?B(##(6.P@RJ+#Z2QKLC`M6Y)J`BHQL.W1*1Q(*V'E^1(X9Q?_P.`]G
MQK7H^;B!=_&`BPY$A,2"-9T[$;<+,GHBS30X)WZ(H5W*$PY#'-]UYHYR9J*&
M-%(PO"0&'2U7M0*/HZ$O1=$+]360=(M6SA<ZS[BA)4`C`!1/^'^>KZ*7+))`
MPRV]X_(M)2XXOL[1>N9B`\EPG"AB[0%0/JPK'`@Q)8.)L60A0WPT-!6!+<*#
MY)8XWX6-U;@MR,ZT]7:\('^':^UVY"]HWY5\(;-+9#HPWA6D?10>+S]"5;IO
M<(1N7&_IFG,\4`WFID52;+J@SFX]ZSJK><6CJR>S\K:B;^I"*'B?/Z:^WR(O
ME07@G-RX;TW/S)Z0XQBO:S-R@_VWJ)^29JJDV19BA21NU$$VB8,D$"-R$M:*
M6&Y[)L),)CA;PM-*&\*2SR6XTB+C31$/DF[)4Z[!^:'[RFU48@0A0OD%(K_G
M6BES<'][>\L/Z6G9W'S\W/[V[6O'J,]3JH'7-\'$B8J6"HE\:.&&(\RO&^WJ
MG^!7_&?FQYA'=*U]C.S\*A!O'CZX,,@G_0#C#+TH&8)V62+M,YMF`#8)-UFY
M=)P$>_0B//+98+BY.%>R8XL13_^XOP-C(P/F&&>U'0QVREVX-!ES=)($=;.V
M(0G3DJ^86D.//2F-CLTDEJ#RJ25.\%/`!999#,"./[``_<\?^LGN)Y5T']Q!
MGNV2%?;L3O=:^Z=T0N4#W-D%:E+X$CY:KBFD*<DX44T@6NDEBS!^35:P"(2L
M[4<W91'C$<B*9B:WR0\=X<*@F9HS>\F]'?'::A@G!?V1SK7GC,*ZIK(02!X8
MGNR$E/3$(PZVR*B0[$D8<IWN51#P&6@C9!@)`3>8Z/DKXT>^_S>FU5@4.$GW
MP#QZ!$1T0F73*=^$D?!HC9_[KWH72-K$3G,_3AQ9>8F^HA$=A>S;ZJ)*>=BK
M*OW*?JV]"1R8TFU_6J(@WH/W,9EDE<:;3_=9LYNQY`>P-")U2N<VI5.:.H5[
M7OA2,L6)E(!2@;<!>*C!.US&B:RT\%?N/X=S=)]I&PCK%27FZ^>;+$5"![[*
MTF3N@R<=N]S9FXL3RFRZ`'+\X^>[G#H+@>>8R,A3";0'V"Z&W'_E^]!K@@R$
MP_(]U&1RFZ7FRU%J$(SU"(2UD_,C(%.2&2)B97QTE.=P9HK-'KQ@IH<5B4Y1
MY=BB_93<)V4R]?!E)9=T)0'3#F)<K0^X=>%Z1_V5(YW#-[OID>&:;AH=0E6(
M1`&*R%U.`C\YX^D1MID)`2?K4-DJD*;,5AUD07@B1X1G2&72JY`0;26DX,74
M9`MF1BY/\$R0*?$9C)ZV^5%XHJ$(#0Q+F;"##(!`R:;48P\^.BY,,PN-#1ZW
M"J82S9.#X;)D%:[XV:/O/K*4A%)B;!(-R8^:72%:U%^%VJ.I$:[,$L]9403M
MB0XK$>ML1$S%21A\_J4,B2O4KSOZ]6V6'DD+Y[;2UJLGI"C)[T,$I82$,V>!
M_%)B*#+<"3[W3?P0@V"DSG5**M!^CLPR@.W7C$+1I@>;%]48JR:\R$QR<+<^
ME>S7<2K9U`$4GD6RUREXZA;Z72ZO[SY>+'#WFET\LIRSPJY:/'J$LT;QHP.R
MY@&RG>N^XQTVH`Q>Q&=0OJ23]4'1]C1)5),TSA\8;J3W]L>'61:EEK.EYBZV
M9,[Y'`.;@.-_F*+@*>%'21/&\@29*7HGHL[_7((*\;_#`H6-KJ9GN7[W3SUW
MI'E+"4<AF#7A,$FM)@*-#[![B4I"@JT$&THORX5HXP4H?$R+,,/DQ`<!_<%H
M]=-:@DS:&\BJSX-U+L=2!G*32`?9$#DK0)O=-I)[(P]GY":AA:;CB8%G!__*
M_.1DP,1],*T9[ODDE/E$VH`]H&OG`X73@SY\4!YA)6=8+7[V"E0"U2L8FAXS
MIJP5E^)0WM8'#E:KA,PR!26;;8+ATH@Q);<G=XP@W)6'&`P].IITC$`R1,ZA
M)Q/48*8PS!RJ*1[TQ1PC9;:HZG$/D^%[C!B$A21.(\&KHM_2>.6$LY"E#?30
M&H[@BH;Y'0S,*&N;FVN?Y*]82I,%GL*X9IK-IUS9U9$YMBP!@V_"08X\VW0Q
M"D#'X@2<"4\O3*HU";&R1JX4VH)0`@%L@V1VIN,]^HXEG"0&:RL'BY_,S=^G
M.D6.$/E*E+UF.@&?GV?]*=@1..1%X6F;1=%R/`)RU#S->"%$G$,FT^00F'1.
M<2(M4A$IF]AVD%NP[9JA3VQCV)[<*Y(?%+J_8;<F,T7A730TMDTQ+)1'2N+,
MS7(-/J^*?OJ+2&B4Y!(1&CI9HYP^!7+\005</"OCG"(+(6]+Q%-`529*R1+A
MO-8RKODJ0T*>BYSWP5-!"I@\K,0:$N2>JS@MVZX;Y113X75^,^-38*503L&1
M9M(XQIZ#'BM&$07MPGCR%\9<`'\8O/R0*V"`$(]3A3G=03MGM+J<&#@QS$/+
M`'./8R^29JCD+%]N"0752"UG4W$*SKV%/!<EYA@CL?6X2#6MQ%E918N+',`C
M`^`\*HF6RG+VW0DC"JD`/Y2',"^4[YBC98E6R!W.M\0)I%@\.=]@`[3(:Y&H
M3`G2Y!#@6FA)FUM\WJR(A#S_%(5>`B70P`MFX8$C%I#0*2'HJ=@EH:,EK(Q1
M&H_D417\<N5@)3QV7O`!PILRP#E]O9)^F5QJ7&%_))\MW2#5>4:"`1':IW0&
M)?N4-,)DYI#ZAOHO<P9:A`X]57($^D\\`'WC^*'EH*2)]U\K528($GE#PM[S
ME`JIZ\/5XBH.U,KF:J72%$:&G];F3UDS-O=YY'"9;(5:6([T;V?"DPIA[?V,
M)R"^A6'$35MO<5Q]W>VR>:;_P0@;&\OCBY\2/^1G;:6)"JQJ&HLKM$\9L;C"
M%-30GX,W\8?C@2%Q)_`H/[%^$YA_.X_F^4#XS<>=B65ZKP]S!OHEB6*-:1MN
MK*V&YE*3R=4#JPJ.2\`-KJACY%FEG/]I4!$K'>7>-;,Q-FW0D%@&X*2+YF[F
MN"98]L4,]LC6#,;P0U2G'N[9*',(75G-7<X7,W_BFB&&K%T6_\WF#A:R@PN$
M07ET.Q_('0B(&8N0/-&G&:8Z`5O)XYJ98;+)(H<XR29]\O'I.<B(AH:JG4S`
MQ9UVAA)/2E5SG87/&:=6:<M=F[I0,/BN/6(5+IA$$`29:F+RQ!6Y#58,JQ*B
ME'-.XNQYH5/<(X!7YQ08DW1WK(^2&#YF9XN5JJZ)PY][[1*9\]"8NGP1D7!2
M$JPEC@3`,TU,BI,4J^A=41V.C_&EJMD^X_;7G$XI38&.B(-YXIM*MWG"HB?T
M?_ELT@V01S.[URDHB,":O&>+2-P+(L_E$T16.Q3P]%D9JZ8##3JQ4$(98K<`
MR`C9N=8^R+5(&IXB,VM3E+*:(3FO^6%`@14:X`>=5]_S,UHNH_)F8>EA7U6<
MKZ>UM1]Z>CKVB&J*Y<$LR+6[?)UBL0WLH+."&!XQKOO_H+->&>>1ONJWN[<K
M9\!L!2-QRI#;_J3&L?LS:"%<S:"H1BU1SO8`%MQA81)%%`EUUV6A7?7S?_T8
MA^T'TUS\]#8-`#VRF]0M?N>$EDN)>-]@K;V!9?SWK__S?VC:?Z4O)E/>>/9;
M%:2"=PEF^.,KFX+\_HF4;'=T^*_X.&AW.Z]^K23G4Q/T#WR)&^>0#GA!IYM>
MR14*[I87.=61'3?`[TJO?2*02KNVP:`EC9D*>C[)&Q7ZI=V<1M=%79Q61N@K
MY"I_N'"&M^N$,3<>_S/;P"[?/^ITZ5AW(HLH6U(81![H.]"(RO$Y>-&V8WIJ
MKZ9#IU>I.SQ&I^B4V^MK2D+C4KM+P0TYF*;8'/P[]F&0N[?I'Z_SY[$9U#XP
M/"9P%131G*=G+>#>Z>/Q.,VU0*\E3;1`O4=_VDFYOS'\1QIUSM00YQLN+`+'
M#X1W8LW$A5:=7DO&E7)MA^01N0\T]+W8<ID?X9YE)2M,%J&82J6T%P7.)$ZS
MKQ!P/+D8MO0AMT"5I$EEJ.SOR@K[T@G!N'K[P[C5-2CA`8S/S6K*,)X%J.7'
M*JC\;&4\Z!\6PFYKV"&;_#H]>5#""MESH,3QX>5E%':0SJ?L%!(7"`L=3"E%
M"R*MQ1;)@3Q6#2("G,D9WT2^L&H@-;TB\L*37X!2TYA:A2@)%IZ="$?2W]V9
M:KS;!_5:4JJ"<E99R<GP?*]-64)51$]V`A+#Y2FBIK2A3PD.8HH1!5_-)=DQ
M##RZ*!H""$5$Y,F;2'I!(O-HELB^YR]B0HL(+F$^`H:`D`.RD5`KG2$=68S(
M_HV1<Q&"DQCP>+JKI/$4Y1\D\L//#_U-["2/*L-3\A63+W(>)$X<JKO%?;U2
MX9)E()!N6VAB@%@HH[08H<A_W=$49=*\53^UCO&J^\T9#W2C"ZU=)4YJ[VKZ
M^G5+"5D"L7AREY+M$]BKJPL#Z,(IE@(OO.BK%9?>$+H33>.JK)*<87&3<-&Y
MZL]PG+9X/XSY26X&5FZDA&.3+"C%I^=8H`[N#P@MTI:#L8#I6#O<)&\D:\D_
M81(L!?HP#;$H2,B?.&#$<R4[PQ!AH9*H4*9^"Q5K6L.E5%2;\!/(FLB&,Y>N
M#]M5)=42R]U@L-\]W'/`A\^DDC%$IMUXL,]^R%+A]WR")Z\1Y=0K:7*83WXL
M;D>T+JEJ>-([==.F&X<X]TD&!])F&>/AB58<\DYV5>B:G))AU"U,8FR3I<BF
MI7-N>4@B?[5,WKN%<F#!.?T,CI68&XNM`NRU%TG7F:84N:N>.`^G$[LDA2.B
M^C5P0D3YP60IV]V)6+F#&SE>`R9+]L'P\]S4:5ND^S**!!TDX3+-='975$$F
MAQ*UH1!L)6%GRB/R/W1%Q$[)3J0D5FX4\E?+&N"O)JZ=G#>3]B.&>S)%.RK>
MO+"[XC.FA?YK8XK=I'<8D5BUR73ZOLCNW$K28BGQ.Z_X\-PA*ZO<H*C'9))N
M`9,]R&RU2#S39*:U_@)J\7[=AV[O2<)0669B\-U6!7Q7`ITW`>84Q.'&DR;Y
MX&J]'M(>9UD52AGUS%J!1#8)EE"<A6$5C9B",Z4PCDI>/HKB$U8'@S6980S+
MII:BB>06=Q5-/%;J)43'L60!_LE`P&9R`TU=/BDM/ZTNT][*Y/C[*+9%ET1L
M._3/-W](Q<7;$F/QS`J=QC\7"%U:*R23U]%U,5V^I.0"H(WBRF7/^;:BF>4D
MW:B$L<G!N.V'(H^>QWEEW@1U,I&H9IO>RI:+"J))CU(JRY9K?K4N0K9Y*2A3
M;3*$*Y0'TJKR,$4EI,K]*=;U1$X(DNJ[\7SBF#GWYLW;9YGT^U9L?6'-PK:3
MYS`5MC].:OG#91BQ>9AKJH/)&Z2C469ITQJ!*:(J?2"=W(8KSYG!2F5AFN"R
MQ)?$WM=<U7PM63OOJ@$\#**--*7="EG*#H]X#0A>^#!<S?"0R;JP8I.S^73?
MC9`H;G-25YIFQ\*W\AQ(*:%+/ZE%ANBP870FG<NF6T7R)(CSSHA-@"S,B"?T
M^KSO`09"EJV5M!HU$SHY[<R4O5"<`L@QSFW5L^%0;+'K$LE!6>4V1@!.*UME
M*VN3Z9#&39J7*AF0)=5F/$5+&`;4?;"/?BB=`!\O3OJ2;%);%H4LBER1HYX@
M((PB-OI&L/A>BKP0JO;A9)>-TP4XF;!J4K6:03Q38$G)4HDO(7M8"%Y0FY"5
M,I,PQC8YQ32GF`^W]Y2?2##A,!S0_&G5.>>R90H-DCIX%.^IX_*\'3]R1/*6
MHKC5HCC5W_&5KF<#&8"20]VK2;=O7=.92U.+^]L'%LK,^;FHI0</N9_V9>8/
MV2ZN2#+%J<><M/%<T%J&1\Q'TW%%4YSD0@&13XH-0=-0H8B")$/@+IT/H[YZ
M342A]/Z0L;_#M-<.7^34JC;--P)(,<>!L5SE,=9"\K(_5Y8A.WQ]Y3J\(JY<
M(#G0'D]K"Y4,T]":P:[,360\6Q&\L9HW[=@I/,^%'_)>S]2U`]Q5WW+(I`@K
MG1V_E4U5E>F)3C81@TJ[^!K^&ZS63-YDD(87:1N7F1F0H?-:_!6_N`8LPFBE
MQ;PJCBE1UD3@Y,',UI&-T6DC&\_5$7R;1B)S!3S4+R"8Q%$LVJ&HF2@@%>\]
MS#9Z$/IW)4DO5<_9!]^XE(/X(.[28-^9^UQ\QY6>]*ODHYU,VA++CR-*/N<W
M*I@!KP5*";:(@S`VN1[&[FV8[0#?6;1[RASJB*[^?*.G=!TL`4&#+198UF!J
M6CQK#&<+F>@;!4(S<V!A@Q(0#?=%/9ME+D+L`!Z&8*W<Y>IS+1XTP?S.I$.R
MYS\IO;\$0/E^B(5)F^"SP8Y5],50$2E.7^G6:/&/+SUIN*V,SWEN9@ZUY/$S
M3Z.C;7UR,0;^D@A5EL0A^.PD?3CG#-0")F`E>_A<QKH\%Q2A!'Q/9*DK9J%D
M(DQ3%$)"7C\>%1;>-Z$,A4*J)#%^2W+&\@#(GGG,"T"J)+C\69&R2=VX^+T[
MDWS8`7["J61R9U$-1?X$&MNR8FA"1IP]X"[@R,!=;M.IUZ6U3_Q&U3VKM1)I
MM)+LN^*RV$II%3D1F9*2'_HMO3M(`JNI<Z`4OEAEQD<&EAQ97,BP39N''FVR
M+'C%EG)MP157`J];J1NI^(Z*,RK*,6SA=BEVK27:LU/;GXF,O7.KR;C>"T.U
M?D/QJ#*A,7GK"6SCL"6.C%LJ53B(SP.O,+'25J:R8D1$,=6"SX14:=$IIN+2
MKC?V4I_,064,^THO$JPI0BGI32]?ITHT'LL.V!2;^HD517$0?OT.;-?$O2CY
M,Y;T,C"L.!-7%[DLDOT^N`W)A++EA0EH#2?\,)$N([#J;[IPE"*DS*9"!GR0
M\&FS]U1\>)-%;A-3HPP449O^P>_Q'%=9WA-+VBWS:E/>?71U$K6Y;=$JNQ@R
M[^C:<N<RXW3^='X.^%$V![>8=#<)9(0\[YKFHERK)RN\I\JJY\X5AHP7HFV0
M)^LM]<P]C"=M/BCI7R5ZR--%^"4IHHAS@=<)8W$HK(&?-,NRWGV^21U-T)"E
M3BB/P?[S[5OEJXMV"6]YP9_0_RO=%9PDPI?C)[^F)Z&S4MHK#V5UY<S3`3V#
M`08J7.2GD@6LSF1C%D2@LZXIAFB*_--L,*E:K>8B/0FV\P+2DN..#75@GD6E
MED*6C2?BOZW<Z:]P/.:.W4;KB?%^YP'[@W'7(G&0TWMYT'QZ8.KYU!@UR4U!
M@_)F6$I;#L)H(B*A*V$J$1)-J5BT!DUP3N.)!!'1PXM;3!Z[0?.ZTHP\J79*
M%R9CO(GF7\*YM<`]\*D3B%C2V+_OPM=2FB^T205FKI+<0AVJ^W5AHS/%LMOI
M1Q$$3X*D\K`#)_P;=M7M&>RLZ?S?I]2D2;%\T*$(;946N"UC6(0F[@;EQ39"
MQU*#FF^WGW\#3'V\W#0L[^L2,FTEB2K,D71NVDQ-"%&S./JB<TMQAO=*&H=R
MQV1.GZ1[W*1%1'[AE6YG386VA5L?'O1P@<JJ$I!9A*VURB`5Y(Q6D/HKE[3K
MA,7=M--1ME<>I(0/J4%0'Y9KD&>B-W9TZ[[*D[VWF9,]NDQ3)#??%.N30[JH
MIXE\YMS+DD-/)$V2]UVB:KE&7(W.9"Z0470"FGI*-@,Y3J;-7BV*_J>XD@8\
M4/:D1@@*@Y*BW3[=@9"Q$YFQ\.<$;"7+)X$"H/V+":\`@T]\]X>-/2QT6()<
M[#=]SS7E`;%PL$C_B),6<A<Q5I;,3<T_A*JFS`[EE)7R=CBC\NVO$:0,Q8IS
M[W/I_?D#:/P[Z4@YIT8[/&7."7A?%\PT$4V-J9`G,RUM+J:@?T(*E,O;8T,+
M=*/<W"8/\ZSI=9!F2"+W+-E,/@5:>>E2QF;+_/$);P7<6NUB0-RBE*2BNQ'0
M_`:RLRLO8B%X\U(!9,WT,N!W/X0K]U[DH:58DIGN"E;6"(_AJ3X%OVT'J2E"
M-TKC4&`(K5VY<N>Q*,<@JF9\E9(5*W+/BIZB'KD4P.`E'\EQP")@*1"V=!]:
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M6[I=Z4I'W<SEC-1!GE_]4UA6E-@X%8)'AZ2`%Y:$HHLB"&CJ"EX911.VI/GG
MY9JHV%4;XG$_#*\]JPY8YE1FG5@GR7HH-23&=.<9=R4+`UY$_<IX7RN+M>"N
MJKR'NCW<JP#RI*XML.&=_6UQ%3W(118%WHVJ.!F3'QYSY\U6;BV[Z-WQ7A'J
ME-VI^DX"U'(/5S&L(9RNWC#9^V']<E%^P?I`<\I<>E!&F3K[A9=%,U,Y](I[
M[V2K9,S,#HD*)I2D'F[)Y@P/#Y-*[<"A;IRM].PX*2H/2-CX^"B=(J"V0D):
M:PRO/*5;3M3EI>IOC+T3_JLI`O2@&=BN:)?Y-&-B>5##2:`*[WV:O"BR1]+D
M`%E4WEH3SN/W$`CK7\CB";7>%+NA]'2?6B'8+`1B4<V>R!H27?&SV6T9:<VE
M,3Y1Z@(_X"9^/9E+'D_\Q!.6;E)#PG5!DCTB$E?(C9;](A'6.2\#@.%6J;J:
M1)H]65%<'(=HLNX8@VZ^>VIGXGT\T;/:9N$AP.S09+O`0]+,+E*7%;8+^760
MW&P8EEAF3=S%B^0"&\$O*@;-`W)$70?3_A[1K*#!%,(M\UU7CX"*PLXKJT15
M6FH2NU1<20/OYWZ\_G89^:&L`Q?E?A\C.[M%H8>>Y?9$J0!,YTAOL5M[N%1I
MUW&EGL8)-8^Y[H%CB<JBG$.4"#3WLAQORL23BI,R8YCE%CGA:]47Q%X-Z2$\
M/UK-G%9DNC+;RBD&)GC^OPEX:VTP_70T`+/'81L3HS19+!5*G8U']W2UD?;M
MX]=Q"_]_B`;JZ^UO[=ODV(EL#-YXBFT-X1]4G+P>YJ_X(4V&%VF&87J<F2#'
M@<#W?;606`"'&48)RU:5:X%WGU%&BN^L1'_7$1V^=6/F_<<DS/C"(07#W5S5
MRT5]ECS>HE_00<V/+HHHW()YKXJYG3JF3K3!'SW`DCEKSS3GB:VH?,ZPU03;
MP7#U\%$V"8<%59:S4%^D$6=-99["M0C#ZMGUBDYH%:"CZYT$G\T@KO.!><0R
MXXVD@5KIE,Q`X-=X)>%.QZME21?IXQ6#E^IGM:/A-HT)5YL:^MX]YEF_-1<.
M4/V>,O[QI#``Q?G!#SY0-ZG;$,]]+);I:^@HS0S_O'D")_O;<L%NOCMA6Y@:
M&OD++>'P$]FE/]]@ZB?XXC>I;ZN^`;:)/_B*[B:<P\[JEU>WGS^\TAS[EU>6
M/AB,Q[W!*^I-3T!\GP2NT^:%"J]^U4>];M?($F<K!$OI\]F_,P.*"Y?2H`SD
M84?7^PK(3NCW#'W8CD.[#<+:SJ+0*80^G7XG"'MMW6AW]740#@X/(:?]31S-
M_$!(>ADE%<"&9=S6OH<_>8[[RZLHB-FK'_>8-B&/,NVHGFEO>2;;+C*CEXIY
MO]?M='N=8D%7Y]T1N`KB8I0"9QB][D@?C`\%G-0X537)GTEYZ3TH8A,V8_38
M/7=EO_E?F<S?7Z]YAMU.N5#\VAT8_9Z^-T>^*-57N\A,=Q^942;?!\P*TM/;
M1WIJ`O-4<H06K'SU;):C*NA7-U3MK@(8B$>Q%7CUZ\B`!\`-*U;^Z_5^=:.4
M@Z9;!HTQ!DAZVT&S"-@,.V(^,F"I/V>?6?1E^LW\7MBKN9?KU5P*XZA7!F,;
M;.J@FX>Q#(H]P.VEX/8V@EOBB`"X1K<S/`*T!8VPRZ$M<4H`VJXQ,@;'(:Y>
MF;C#<N(:O=YX5W`]3'WD6\6O3OAWTV\\.I=^X\.M`I7*506K&[O#]BQ/)8@'
MT6`7C%%VD*;<>/S/P_4LYP"ETV-TPV;3HOO0>.`K]GAY*P;T,<Z/)TMX[R8/
M+00>G=5C-V,U=_.1R5;F.'[LR99@&#JAL)*2<8A%'S&_F"YSK)&K^Z9<-A\L
M/,L1D'=/3@J$^<&6I28GT^P3TZ4=-`]X+0+'P_OC>"-A41P9`O'FV+(Q6&I`
M$9,W?4PZUE#*9@&*2?B"RQ?>;![P5`5,\>-8'J(9HQJE3$Z3TH)#I!@/)7(4
M0AGIFI@839H@G7@ZYMS\"W9FO,57$>DPH$L!U1+T\:Z:M&^[J3;GQU=EK(TD
MZ(EX=I@[@9`@EAD$2TH&21+\!"NQ51`OKU093NB+[NQ<ID#<2;ES890_RF])
M"A3AR[=1IY-`T4VO5`8I4MCJ=GD#YZO5]GIM/.T>=[H[M?>M1JP;S.$OAU&4
M$@MQ$GT`LYB*.R!7H*\4--ML4U>L<.C3O?+PQAU\LI;;6=]D^Z,/AX-#V>)F
MQ!<YXI%O#JGT&OT(WT4`A25O'"&C)^+BF155MF3SGW=$>IS5TB'O9">/0B0<
M6$24Z.KD)N#D"N6L6LW>[,<S!\'PXO?H`CS-P%8MV_Z3Q[L6@@5R3%X>FJV;
MOPM\L&9F\D'[_?Z&'Z4E74NNM1O*\8I88,FLA#3WAANZ1&VFB2NB047$^TY8
M*KE75&0]=,U=<A42);"A9!C)3(F[FW=O?='_@9HY_#M&RS]GT<RW-]_[S%]W
M>'^!P!$=.43'->H2M\R>]O]Q^S[;KS?I`^10BQ;*@*&3''[)_(1YX(V"!`3+
ME32O-<]2'[$H=8.4YMI/O):$VC[CSC'D=2Z4,.6'O-$A-O4VR6M2KE'#B_C\
MN6-E3K2$V`%:Z.X53)C47\A+[#B4$;E)U.`I\7WIM&T2^L&$7&MY)HZM1ATZ
ML+6HQSAU#4G:?KB(MPJTS&P!D*Y3_LB<)COIG"V3FWI7D]>5;NW:YW/&U)<:
M[A43S]M6R[NC]PH,E1WYO/K5Z.KY0%IVXFW!VB8`5';.\^I77>_E(VK[@;5-
MI$<O#9WT1]W:J54YHI,)^&?`ZHVZ^=C>WM3*R=:?;ZF)3D`IEY_-.3]:?>>_
M6XTO9Z`>EH?-]-'`.+#H[0YUJ0B,!OJ!!7-WH,L%9+P23JU;;G>'>EP*M=ZI
MG=:5Q/H3J&DP)OXFT,>=4K4ZR`=8CR/:E2'72R$?U:Y**LEW9<A+3X7Z^FED
MO#+DI2=(_973@^/(^9M/]Q)H!<RR0Z0-N09UB7`Q4&4.S)Y`597.8J#*3-O^
ME*HD>`I0I3)7:L>,SFED[IUCL<`S-P)>:LOTX6E4:PYP!=0R`W8DV:Q&T5&G
MU%CU:A:%RLY!"45'G3+K5(FBL>E^2;>5I:D6XLK9+\$]"QX!$J[+^36#&Y)O
M.IW^FFR`?C$U,V"=$/(B]6Z9-F9[C(O]\360O\,JUX#91;)`,'?:G7Y;WT:!
MY=)3RMU#VHJI\.:`V1+27EO7V_I@RS66@W:-ONW7"NVF3>RH5RJA>G?0KYEP
M:U-G1KW2M!2]/S2,G4%YLUQ_:?H61R%MPSB+E(0)W@L0M.EL<1'"4/+3SX59
M!NOS"WB.@O*D79KY(.:560UO7+QB1E]$&H6KBBH1Q"G]AG$+,BKVG0HH`H3S
M?GG5W2J10XT;4UBR$B290[XM\#X&DKMAM')"F9]=)EQ4D:V?Z2ZBAP"K-]KR
M9NN'R971Z;6,[JAE]/NO*\A?C?)5JZ@6)K`<8G!BWUF"OCM0]1&O1DIM"=2^
M:^%?,R=B10L@T>7_*+@BOA#(=_X[[<I\78ZK3!`K&G'W9;+5J"6@_[!Y>&.'
M\5-1Z`^ZA\5@/TK50NQ:*5M,QJZ^(QF/O*IVL#`E,,K079+:(PKHM*O)FI7V
M_*U0MS7L#<X#ZO,U0""`O6U\PG.Q/152*JKXD7Q'O+IRV%XKI[:MR/IA#FP+
MZIX\%3J]98S7K,R38GVH7>762!V/;Z5,,O33X7,^]E4&;+2`1VQ:>77QDHUL
MOS7H;&,_7J21[;>&HV=I9+/^I^M[#VW,+FP\4%',U.IV&P]TP^(8M0:#;8AT
MB79D*V>T8!DU[N@AW=%A9WRF.#?.:.J,#B_8&:UN82M(3YD47/<S<O"->C[9
M.>?U$'HD-_'N8I$.=)A`;?VS*A+:;0WZG9-@7*,F.0XKC\"W$B:!)VX8A\>E
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M=TNK6HQ!;;2I7%!<KK'S18#ET+P77:_N6$`=(=^8H6/=>/8[QXVC7,?4"J*4
M3:<'>:G<"+C=N3:&*<0;X-H3B?42F$>B1"N7(#$Z%A+K!3>/1(EJ+D9BT#LB
M)];(>QZ)DOU,$1+ZM=ZO"8E].S2-FPY-S8@GZM"D=RF$=Z(F3;P5*3:+H7:+
M>'48+5`UZ+?N\XY(]S(XEP&!G64LT[5BWFZ1W\8@[F+@),`[)!]9@%=9>G3?
MK[@S9H[W$I*BH8N;10/E:TUJN=P\25\=?@4-;S\X00V4?S)TZ,))[-?#6_=D
M&T-ENTB&V)Y87&K"^S8]F1@EQ39)(=T>T[81(.>1I:`YG!AE1$A[*>&]AF$<
M+,4TO*>2Z'84\_8^NY%)L_D%E]30B-_.S.]Z"9-[9_C@$GB%%FKC(`=O6:#2
MK,Q,1%QENI:&[5]GK`W/L.4:H@&-4L#P?A-X(9KA55S8+S-32-1*`<GC.=6,
MUG#8:W7'(^U*?:FGI=SK_@Q/]?NCUMCHO^:]">G*))PHN>Q'<D5<V*8P3IU2
MFS#+C$,2&B?@!*3FF$_4:0EO4<\(0M65MW^OI`U6-&=RB<5?IN^_6S.,\W\%
M:?SBO37#&=Y#`O^\_W?L/)HNM5#;9WLS*`]"CW,N_#8PU8G-%MNC07EP6A\;
MO;-`9XO]U:`\8-WN]CIG@<X6&[1!>0R[W<^%+/=`9[YP_25C7WG;8"7PL//!
MUZA?&B/IC;-QG(VS[PWLQO+D?FG`PA@-N_M`^\%T^"TT-]1K]Q-91&9_\;XR
MC.B`=L-]1+A3P;+>;PJ65X^;E<05\01U;J^MGOG`T]9:]KL-5!_Q0C5M39K0
M"Z/$FD2'%T:)-26!+X82:[L`G"1+MCC?FYN99Y#8?%*@3@]!0Y:&+)=!ED,W
M2.@/*M>;OY47L="-+"S=[I1C?YXE^Z/J%?M&9]@RUA61U5BU?UJR;3'H%O1K
M-Y1K*/?\ENI9%VY=9WWK;UBM9;.%'SI1C5N-?7/PCUC14WDN)1F_T^KHVR?C
M'P2IAC55%6/#E88K#5?.2HT=JSHQ+2L\U<9RC3-3U8/1P8/1A\T>NPD]O"2R
M7,#":5JV-BU;&[70D*4AR[GZ?V5J3\D@:53H^8#^LA=%0Y:&+.?O?/Y+Y%T_
M`S:MB4Z]0*%]!M38?\_8;0TZ!VSMUQ#BZ`Y@<=("/.5X#R)Q.71L%IA;]<5M
MEG%#C8M9R_V6OE53UX80%^.2[7S^_\'Q3,_"2CC'"Z,@Q@YM6U#F91^@-<>:
M#5<:KC1<:;ARUL[_Z4__&T^VH<;AW-E1:]C;IF*N(<3^^JJX`S)^?GX5P?L%
M7C;;$;78Y$1EPTKV=QT0U&`[SPTF4<VI9-[O7=1\CE1J9.>,9.>PN:F-[#QG
MV5E3.'^.5&ID)P.3YS\%YN*75_S?O'-S/%EZQRQJFJQU==X&[%CT.\<0<W'>
M4]/UX`SW4@U9&K(\6[*<.FE@^TX'YQXX&1HM?=24%CVSR&)#C<M:)9>4-_!;
M;&+Z)Z.>Q(\LC.:41(6P3@'::*N$^I=]!M<=M\;#PVXLFN/1"SP>;;C2<.6"
MN')Z-?9R\@GV]V5T'9R9P38=9\_4K6N<W(8:%[Q,FMX!3>'K)6B#)MS9D.6\
MR-+T#FA4:+,H&K(T9+DXY[/I'?!,A?894*..ZM+.>-P0XN"$.%T:0%-;>ZBY
MFB!_PY6&*PU7&JY<J&O?E-F>C0/74..BW-F&$`6JJ[C,-KT1>-LK?LLO"([G
M_%+Y]]\7S(J8_<YY=&SFV7B3<^'%P%WXK_KQ31PZ'@O#&^O?L1,Z.-C-=R=L
MWP23.(K#6\_Z1*4D?^)5T-'R%D8,6!C=PM0`<(#_(JYOEM^6"T9OOJ6+XNGV
M]9`_=A]/_@+HOOE?V2(.K)D9LKO`?W3PRG@^NGK/<D^Y9GF<N9O[^R1PG38,
MP5[]VBFFYCIZU$C%-7>+J^`/SQ'\S%WB*[=<9\'OG0)\NMSIDF17$=?>JU_O
M>O]?->H@GJ>D2C+;FR7IH;>N"6_AHQ\<8#K[Z#PR&XAF>@\.D$GJJCS._2[@
M;'2.BW3Q_>9<:,<`C]X;O#L>0$5+*@6HUT&`1L9!`/K#=\T(#_26ST;E&V5*
MYWJD5R-AEBBU$K.RYN^78C$`%$^+QS8F8%#.C;YQ(#R^.N'?'P+&I.@]&]'6
M2XG9Z0Q[ZXE91)0:25E9L(=K<.B/3X?#-D(]*L=A@XK9`H-;;Q%'X3LGM/S8
M.X`,[V6_2R2T7^KQ7>O=40%I5I$LH8;8Y.!IPIWO.M:2_W^RQ]G*S`^-;@>L
M*NZNZF]<U(SX(D>LTNA@;@8/#ORE=Z_[BTCK:)WJL&42AZJ_1C_"=Q$`8O'W
M<$UIC[BH-'^J30O.ZT(U[K#N\X[X]S+H?YLQ#>SDPO26VIPO\Y"*ZDS'*P:/
M"I']:,8"0(S-X>](FR987=<$Y5B%T0>5!RI[#I358&)ENA;]+1&(0P`^^X`V
M<UA@@JE?PNP`,:D\?!"K"`7&CO>@OA'-`*.Y^=V9`Z1\/'@>V>5/0A8\4F\T
M,1#2`L!:?33V5A^>++4`B[=I0IH%7YC[850P\H1Q*)]FS-/,1]-Q\==K[<LJ
M#$'R$:CW-XNTA8E!=V>!&2_:DQ^[-H$5^0)#$T9$BZ(!15R15+@D7'`L&[O9
M^`N8>V(B!+XGQ[7-R`1043;@^RFL3YC89@L&_^?A00+X5"R\UGXO0%Z!,AG6
M3&VS9D[\.!+,LR(_V`^9:PT%.YJ!M0?!`GQ"9(J87S!XF=`8QA*RK\H!0FR&
M(#:NZS^%/]4DV!WQHT,T@[^O^XY7%)]4IDK;\:GM]_+M^00PR2%804.^54!+
M&_05A%EEU[Q_[!%ISI\'1?XB`<)8._#__FYT#&/'H?5#P3PN!5HTHU/E_]^Q
M#SNJ1+`#!U8+5TLH"SA%5M'*58^J"A8%^(3BW?"Z>@A[5SE-#44CL2])8HT"
MC<W-/>A-3\JP$%['L]S81C/E1#.04BGTI&)Q`,40H*"C?B\P/<RA"6PG@-VY
MN]3(4LN_KK7;:=F+L(/73-I^!+!`8EA`Z"=PKX!@U^8QF-?)"B!A/`EA=Q6!
M<P/SD=F)7?[VM7;C:>P[D)E6'B$8EJ_=$(R_:P8<NE`%SR$"'7WE&GS=7H^:
MU?OR5F]77;U%3NB:58@.X),#JR!@4Q>6'DB49S[0MC^AB#[^.2SPV\2R4'\@
M%<#]-<7/HH53`L#AE\8XM_/AOAVYXSAZ"."Q$%U9QP,ZS>EF)L4S%?N,%6(P
ML1-0%WZB`85G:6?W2>3^`J'%F3'ZQ$[80G41S?PXA-'@+QP3]2!U-RG?V/A<
M/>+7'.*(63//^7?,PH3NZ08JC*V9,DZ17YO*9#U]H'=M`UTI579S9M.)NF7N
M-2W0#DCL_?*J^ZH4A)5<B3J@VMA#^8518ION[L^;$FOZV[X82OQW#!JTVZ'.
MK/TSR(!L6J1>4!Y<0Y:&+,^6+`>KC5+OZJ@&Y`[M4I5MVZY<+1]B^[18I5]X
M118;G6'+Z*R8I#W`VP_GPY%MBT&WH-^:?/.&<B^><A>[5"^IP2OE9]ILX8=.
M4[1:59CT3JNC'_;6FJ8:[P*K\1JN-%RY(*Z<7HTUK5RK[R<-'3P8O;F]H0D]
MO"BR7,#":9J[-IT)&[70D*4AR[GZ?TUSUT:%7LRB:,C2D.7\G<^FN>LS%=IG
M0(W]]XS=UJ`S:`AQ<$*<^HY7>,KQ'NA.0]\+'9L%E,S;+.-SD-Z&&O6NY7Y+
M[S9*[?"$N*3S_Z9Y=7.L>1Y8-%QIN-)PY25QY>6<_C>>;$.-P[FSH]:PMTW%
M7$.(_?556AG-_RSI49,T]B@:^CSK?_<+LVRV&FIIR8F*A)5<[SH@J,%2GAM,
MHG93R;/?NX3Y'*G4R,X9R<YA,U$;V7G.LK.F3/X<J=3(3@8FSW\*S,4OK_B_
M>=_F>++TCEG4[5?KZM1LH'<L^IUC0+DXRZGI<7"&.Z>&+`U9GBU93ITBL'U?
M@W,/DPR-ECYJ"HF>61RQH<9EK9)+RA+X+38QV9-1`_='%D9S2IE"6*>\46*-
M>YWG?>+6';?&P\-N+)K#T`L\#&VXTG#E@KAR>C7V<K(']O=E=!V<F<$V_67/
MU*UKG-R&&A>\3)I.`4V9ZR5H@R;<V9#EO,C2=`IH5&BS*!JR-&2Y..>SZ13P
M3(7V&5"CCEK2SGC<$.+@A#A=&D!327NHN9H@?\.5ABL-5QJN7*AKWQ35GHT#
MUU#CHMS9AA`%JJMB46T%CUW6W>+OFCZ4UW)SI95>*JR9UK]CA^X)UB+E)AR\
M$OB3N:0+)^F6=<WT-!]H`CZ^"X-'<8!W-_M3S>BUYP#.C-]%#&_BY>@3QCS-
M<LTP=*8.#H[WI;N^]]"F2904.KPW&,"9F"[L'9@6SAB+KK4/XKKH!0L<W]:8
MAY>]9V[!;.4O)A;7$6>1"+4?^!T/K4ZGHSW-'&N6WJU.$P3PI[,`G!!ZT[*"
MF%+\8!B`4&-FX`GPHU4X-=N,V/61&$57*IN:[806&"Z\%)[RL:>N_Z3-?9NY
MV?N6BZDS+=BBM;2`N6;$+VS^Y'NAZ44^B6MRV3284%?S%_R69U_*#(V(^>`H
M"(%&STS32[9#_.ONYMU;OX4$!(I;@3,AZFJ>'S&M=S5Y?:U]RP+Z1(\*+&Q)
M=B0T#A<PRW_P'`2$WU-M(H^`J0%P/,!.=IPG-*J##P*JZ\B07D..$WN.RX>%
MAP"_1)(]7[-FIO?`$'L'KS-/A^2RD9'-0XI$6<,^E'53O54=[T0'`DZ6ZAWB
MVC3PYX0!\3`D2B)5;H))',6A=NM9UUK*_.[/6L@8L2O4ND2:$2=NK6)IE2&5
M+CP57F1QEOUA/`E!$G&`(DDHO$%]`6+O`%!FL-1@K3MS(6-K`4(I^:'7&G8'
MI%'DM?;927&43WA)NBRCZU]K-ZMBTLIP!H4M8+AR0KH\G913"F&Y,)?""H2?
M,.T'ZO6&T-8EEANNLY>WV7,%R]=-B(M^%?1"OCR):'GV6OJ+N3!^VTNB+8;&
MIKE0OFYJ?$Q5803K`"370Q$5DL<=BX9.T<]?%HP(DYH.()%<@V!50NX0-53+
MQKHSNBPA%_O.`LL)+X-B)47GQ])6;E&C(/Y\1QJ;9`)N;<`[01/)M"N;\4^O
MI6%1S8.VR]@KS,P;G(:!^S,0]G4,P(!UPOV"'*K[\._JP72\U[#)#"^`<^?/
MJ8SYA/WWWOQ9-;PE'#I&*+?>*Z)+UJ&<Q*@\R[WS71/!E-60QYI:DQ=TX_5F
M:JJ!N^YP3>#NV5!MFT&W(%]SQ3J-M7&PE&)7@]:@LZ9B>FOP7C]G:@U;H\Z:
MME6-C!67Z/0;DFU)LD&K/^X<A6H'R]&ZH(R`:M[,&BEN<C@J+H7:4C<VG'`V
M#'F92367Q)5C+).K;N^P[7TW^7P-&X@-HT[#AC-@0[??L.'T;-AP/^%Q4R^/
ME[\D\C%6CI5%]%XYSI)G].%:=Q3S)S"[)+#3PYLP,B/&LY2FFK\0Y^H\T<GR
MYXN`S9@7.H^,HLZ'3@3B]:.8;0'["1-P)UZV[ZV9[[)0I.>T%X&#!]X\_V.1
MPLNS%,+8C9`Z*<URQ^PM(E=RGN7'$1#!LVG$7/J"3,!8Z1FLF0&EQ?"\@,LY
MN3_1N4#9M/1%MFCX#$XH"J!:T4MU`%IQKWAIQV^UT6=CI^ZC=H<Z?9KOA94B
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M0_32S<-#P!ZPAJXPK/_2U\6&PYX7O3#.O/W6,6^K^1Q3:/@`Z^:TAZQUBG/]
MTRO+=#AN]==YZB?&_?Q/SH^:9-4=XY*LEUV'.42O^_-__1B'[0?37/R$;N@?
M:&T_,3.,`SKVO@/<K"7__V^`SQO7M_[^]7_^#TW[KY77OM!9\UM>[7WK)=__
M9CK>1S\,=:I3AT&^LNDOK^P_\5BOW>FU.[KX.&AW.Z\TFUG.W'3#7UZUNZ\T
MQ_[EE:4/!N/>0'^EQ9[#WW9"OV?HPW8<VJ]^-3I&K]/I%&"R$:3Z4.FEJ/0V
MHF*4H=(?Z=V3HP*LT"MSI5N&RJBCGQR37HK)9J;TRC!I#T>=FKC"BQ_?QD'`
M/%A18)A#T\(A\(4W;`J_?S._[[=0^L-21(S^,,>4:@#5A,4V:Z0_*L=B:(Q.
MB,4VRZ,_+L.BUQL,3\N*ZBNC4\H*W1CU#XT%KJ/?O8"!*?T/-I?98VWTUZ!B
M#+KC+5#)0E4G/ENLDGZY46SKW?$V:_UP^&RQ7OKEEK'7T[=9]`=E3]65TR^W
MCL">KG%P?,(;SZ8_79ZWF'/DJO%*H#,TNAW]U:_H.RIIC;83+EQS^9/F>*[C
M,>$&3\VYX\*7D3-GH>:Q)RWPYZ97<BC?C/A21]PJ*;9[W5?R82O!EMDL5W^-
M?H3O(@#$XN_)MA666&1:E"XK2H--^W_)1ZKNQ$Y*CP^Q1YK"="O!O2.LO0RH
MU#%L==Y<2S#13#*D4_&'@-H38I,WQW;,P`%1N[H+_,AY-.E!^?GW^YO7F,A-
M`YF>"0][FHU)P@'UE,PR<>Y[+,+>:J)=(8[DIK<<41JS9#1O"NGG1TW:TP6B
M[9ML;()-T!Y-&(DG3I>TCM0^^UY[2S!@M)D31GZ`8<=T/@0@Y-WN<&K'CT.>
M[9YMKB9/75?@!:I1*S_`,9D,Q/J1>=CC$$!BWQ?,"P4HPL!<:^_E^]A]1<#N
M8P\[`ENTVJ2$>OCLSQDVBL0'DJQ\W@^DKMSY55$#2Y>3LDRKPRL.(K()I2T1
ML65+>^^97N0\,"\1J=_!F`,R]U@6$"82P+N*)KTBE>:5O`$?]8M<%7AJBLE[
ME%*?O-PZ6`3@4V!G0K#2_MRQ-.8].H'O43D"D)//FL&%5RBP,&67'5(WQIID
MOQA](=T906RD_PRD?T>;\'4K4U;;.I5ZGSB!LY=(6TCK:=7>7FLWKEM1B/@$
MJU*[1E2_<ED(6U(2^"0^-HJ5S+WBO']=/EU&_K(R@`-;#(B"7P.J#UE9$W4Y
MM.A7`1=-E&VE@ZGRLI1ND%?>K->TJ%?K&KHH:RQ(NJBJ3H_M3*<,"0^$H)ZR
MI>T\BVP]+K.RYU=9BRC]?GU_G0H!@!VGF[3\XON9M^_%8`-OL:H"B^^J=5Z<
M@]EJ+I6?KWFC6=O')KB:`P!;7$J`-E8LJ`$`WB8+'#=KR%3M?@:3K:SM`X;P
M=]T)9C>4N.%,N@Q;2]QW<G+=S%%J,MM&!_>*7=PK&OJ?V1=AW;U9?L9&X>SF
MNQ.V[[`C-U#W2QPAI;Y,/\*?#P3/)ZID^?,K"QEVS05@W\%R<_T%&KL;/,!\
MH/,('#P`C+[Y=RP`]LX!XR_(/YCIVW+!Y[EQO:5KSC\Z%B[3FX>`T;M\#G6S
M?OOY@[);'X]*`Z<8X\ILUC=0*$=.YL&B=P&I&QO<`EA86$;XR-X+B[)7M+=;
M&C$9#@;9",,&./8$>IO@;K<T+J(/1\,C`KU-++=;>D"@=[K#T7%)73EXV^V7
M0=T==?<AM>_;3PX8W!5E`(0$?=#]\PT:$Q:&-VG?;KX\N<<*ZG+CBNP/2DG>
M'W3ZV4,9"=$6<*XE77=8J@]JF+W7UHUV5\_,5W;DH7T/?_(<]Y=741"S5S\6
M3P%LN_4B4)3.Q&4WY`7M%>[3AP!/$^YK1CQ-N&]PNEA?LF@I`I6L*;&U.'!8
M;Y#O<N"'%`,C5YC\519B=H@3SFAO#2#.3032H1[>"_#5T:_'O0(&SER765$,
MGO<BP.``N/XV=ZSD'2?@E;M+\HG%MB;7N#J9NJXMJHK@;9ZX_/Z"D-HM.-C*
MP`>/'7<$W"_DCGCJ&0+<#NU8UF]`MK[I0NM>PZ^;I[^ZO?M*`^#_WKU>%18B
M;/86',>SV13O<F!M%XRKS9LH!#2Q9LYQY_,?W*EEAM8F#%UFO!@E\VZ\$!L_
MW+ZXC&,8:.8$!A61HO1"%M]R:)-7B@Z;@MA$(>*>QX,N`.)3XTYR&N/%*8]B
M-Y5`C=M04T._`==B&Y<9[*6!H9H/^UZ$PPF2FS;LS$`ML;4UQ:TR`"26B>!F
MC,LTE8D`;#=\,K[MHJ[^&(!C7@'Q5:!3:!=QQ*-9,#V@.A57O=#M*7/S+R`?
M[O3Q&1NVOQ'?$)MRRQ<$2_PF24M>G75N+BGH!X*(URK1!M2#;SV3[V$TTBT+
MOG_!2Y7XDW..(\@^J9VIH(*%E*,6&31E"^G)"1U[RI4KTQBW6>G-*R&/)C`[
M+(!;@!3&2.]43I\")XHP?ND_>6*##NQ2&H4<0@4DRA9V_>JM(0A]2!<(+6*0
M56SYCHU-6"))R>4[(<P@`G?PK<>`B@E'D)(VC`FKCVBXRJW*^B`!%..\R+5D
M'<MH"K]#82JF#=,8Q,K2]L*(F2`9#W),AP+/?S&,+/AX$=>3#Y:)+59D@TZ;
MX+\>ZG1:6BT0!!=)I9Z=2*3QVI5T!"'1?A!RB7[R8Q?5`;_+"72"ZR!M<8%Z
M#^)>)B>`60D45#$@)F')#3YIU`9]6'E-4B)X)FV,6T4W<$DJ7&O_0K%<'=[,
M#RY%NW"&A*C%@#EA<DD.LXDS(DB?K%?9+"?$R+O-D1=CY=F!<37/8RBJ9K"4
MVB0/4V8IPA`NFH)5"DK`6RNSSWE&)A]`C+D*$;4@J@+"NJFS^HA"U:(OTH-'
M*AZDQ73Y:C,CL4R/&.*JOMW);I-X=.Z;^9V%7X%?SB-O.[3UIK`\XZ:?S80J
MG'`GF)*M8BE,I3&@T6`'F.A:C7?B>HU;[T;$BN_,)3Z.X0%^2=Y');Z^5U;6
MJ#1&T1YV^WH>A1W@.PR.VV1JC4I#&>UQKWNV*&Z3O%4>/VWWNV>,XS897:/2
MM%2],SHBAB7Z8ON$R-($57W8K8K0]KID'?C;K*KANM34;E7-42_\VRR98:DU
MZ0UR10U')'_EU3`L-3SZL'[A><>F#",16]L=!>`R%;4VQ+HC*%L)<JE>Z0\W
M$+(`EKHH618<1H#+%,>!*%E=0Y>J!%TW#D=*D1ZPIR-4JHV[W4W:(`?(WG!O
M([WC4IKW5KWB`\.]C?H=EZ?/CRNONQH)7EG(Q^6*UQCV:A:5.]A!FXXMWQ+'
M@>"^T,G[31*XW4/NRS=5^G@#,E6@.PR&6[G_I0QK&QM=X].AN)7[7WJH;XPW
M.0,G96)UT[*F1-#8I.?J0/%W#\R2BPM7^DQ[+KSAN@*5SB8]4@!.+1ALY3B5
M\\0P.B="8*LM0'GP8[,3?4`.5-\$E$<V-CI<%>#/QO@^L^C]=Y&OO4]J1WE6
M#-@;/6_Z-\-0!]1%*2%EM-W@93^R,,(`+@_XW<J^@OO5%9>7>N<WVL73[PKD
M5F7#I>K`6''HZH5RJ[+@4O$S1GEGH'9:5DX=*\^^ZJV8ANV@#)-"^7=.:+E^
M2&>7)>OAS^3A-\ODXS\=%N`9]O(CGE]37EGRVZVWB*.0?M!74\PR.()(E"N"
M\;`,RR+X3XZK(7%5L"OS.BNJCZU@7T/D4LVQ'Y$_<B."UR0[CTR$57GR<T&2
M\J95.2I7<-U!%LAU$^\#XB9*CM:IM\ZN()9$7JI9TG%YDB00-+=[*XVKK(5A
MX_G7N#1XUH6WNUN#`$[Y?>1;?\]\UV9!*&HFMJ9-3R_/S1YV1SGO=-/\^T*[
MB8H]O3PI6Q_E7=&=H=UY>7;+@V/Z0,_%^E<GW!Z@S6)7:CN,CM$9[`I0@=H#
M]QA>HHJ8$K+M8SBZ&XSDH)SRHV'/*,-S'1[U(E\.>3F+3@QY#?9^$]N&>BG;
M^IUQJ6(^'O+ED!NE;*L+<BH->DNYM44^LI'ZR$;;&/WYEM+L@H491,O/YIS7
M&;T+V'>&B2AO7.JV^""JF#ZR!]-]#W8W6FY5\`#.:'F84,_;=P6%[9#3TPT`
M?`35<33D2G<]M>'6&:>,&Y?B]IG%@?\(;M'^.!6Z'I9)^0"=+;$*MS@:.'6I
M7"DK2^0T+#QKV(CX-O&)<G6G4U.]VH#:)AY1KLD&N?Y?>Q.J<O3!*.^D:(SS
M1G%/0E4.-ACEFJ_7R?N>]8I4L9+XY'NAZ47^!BL[ZI1N@$:=_D&E;D^X2S=-
M`R/ON]8KF7O"O68;T*MS214HW;T`U]<D)@SSVY=C2/B-!3LU,UP)&XWT,@6Q
M-FQ4FP27P[53.*LV"2V'JVSGO#>]*@E@#JY2^2NO7SZPS2[Q,&&@P#,W@ET>
M*Q_D0SO'T*\YL!5`=SJKJ4TZJY*SO,E!K6J_JO"6DW.G:NC:I/,>J\^">+Z1
MGJ7F:%"S*U5).JN"7>Z7]FHV196$MS+8I:ZKOA)J/H;T5H:[O$)C&Y?%]QZ^
ML6"NG)$4QL3Z&%E*'TIV>_CN.[;`-BR;=GBC-1EFG4[N7+\`KMT`WS>2N>FX
M;S`H;RAQ6*S6@%3NSQX(I((\@\%NRM8/0Z4+SCMS;CZP\-Z/'V81L:9$(>@#
M]6/:!>BM&3(9@'&H^8CO_<N)9M]F['?/>60!".[RR_1-`&^$L[<^1J8<83K^
MO(\G(?MW#"B_?U2%/O?]QHA.>4E!MY^/Z&S"/TLNW@KIR_0+=>G#+DR5]O$'
MZL$1\?1_YKH+T\;$E%]>`>;X=[@P+?EWV74AO)277TZN?B$OR!C@=_*>Y4YG
M\9VW5M#X?];?H`.#EMR>D;Z\<A-NO_S*C=VZ1^BK18WBMHY2(/H*><L?KA-(
M+E)8Q3D1W7:H>E54@_N)H*U!1;U[)/T[N7]$JZG.6Q99OW'\Q<P,YJ;VU@\6
M/H=/N\(BU+3TVOIYI8^#_3,V-E`?$2.JC[SF5?Q)B]:)G,QB,8E82B:;42TT
M+QRG0GH00Y#ZENR(0)^1F)8_G[/`<K#7'!748ELZWKQO`="3C@UC["^7=**P
M9H'O.98V8_@$*"OM#7!RRG@SOBL5BW^^^2.#`<R)X.#IO2S.Q=8%@6:9U)]R
MLLR,^N@$0-2U(_)";J6[(F@]7\$2)EPX"T;-&J:^%8OV`J;]:'JH!S0/2.-J
M7S_?\(XAHI$>E;>;"R(L0``_.Z^!_]3?4#81+.S&@7U&8,&'6(VO?706CJU]
M-CT?'2O'`I640>;CY[LL@R-FS3S?]1^6F?59FYR^GTY%VXG_CMVEUM5;&NKB
MENBRP466:1YX@!IOP&ASGG]C?\^=P-3N,@(79L5<14V\D$//U]:N%&QR"=QC
M6T`II.AIYKONLNT_>6HCY65+^^*]Q1X%R70MT1=7A94_DP558E\(\NH0:I>%
MG'S>)AUXU8=:F8X&V'5AB@@7X^&P\*>D"32`D1'.56#$D[F55_;^%765+AT%
MFTZ7C'3S$#A6[((V!MVCG-,D:!4,>O/NK9]7":"&DF;$N)P3V(J8E3R9)?-!
ME@NJEC"V9*^.**MI;(8MB*D+C:?Y$]FDB/?I$$T3M(`]8!=-'SL`+Q:!_XBK
M!GLR!+(G,WQIQU9$WP(0?S/>(\6T9@[#_C"!/W6X.Y-:/*[U+/+.XJ1'I^@L
M4]),"%>4:!<K6D"HNC\9)`,2-D[)H%G>A8C.J:GUJ:#8-,;>2Z)U#RG4D*U`
MX0O"@4+&U@O8-M;QA&:.P,Z`LXDFR0=7V$M`3!_)#:<2Z);Z5V`'#-@2AM04
M!69;!&@9(XTYU!<5T?%YPTX:F'L6I30$NCP$YCS41&O;3928QIS2U-Y%O"KZ
M3_&I2EM+I&[XJE^=\[M9!#N+V1V>^8+9?[/\'4S<K?=!TN@F)=$^!Y`#HS2T
M-AYD-P[5(:H/DRU.+0=&Z=F0D:M#/`4F6YQU#HSRW76/-^T\/5NJGI$.NN5I
M,>.^T3TD+CR@4.-B*3\-:^N=KC&L@DP!4/4AL\UZ*3TP^[7=ZQJY/@JG0&:;
M)5.>M6H,C5R4]42,J;QBRG-:@3']8:4ELRLRPAS5MF3ZXS7%>H-![@BY.E#U
M(;-5R7AYW1Z_.?+$N&Q51EY>PM?M#WIGP9CJI>7E(7*]UZ\+%5XG1(WRJQP:
MT1T0Z&#R['+T*GT/(R\4XOW*T$%F]GLSP/W%II/P?GG[\;8Q&`U7D$R!W1./
M-2"5BU#-(%6_<'=-86IOE.LLMCM(6UV<6UYJ.NB,5M;9[A!5OQMSS36EO<Y@
M"[X]W21=)&%!>?#1(HD/"^]@WOKJ/J/IY=V,^"*O[L/:<HKN)$U:%YGU=>"&
MWMF+CCY0HVJ@-W70A'];1/=2X/@U4F$8\]`_QD7$%LYTM51CX"5)GFT&=JB]
M\>$?[>K#S?V;UQB%X=?;A.)W+601O3#Q;8>)/K#4P]GV%U$Z27()7Q+6PW;,
MO(EU&GSF-R/]SOO/TD1/&-?'XY0X#$7OXV2L"7,Q7A>F[93%93HP0T!,<I<2
MUS#!)X$0`U5+%BG34QD]?CTSX2_LWARQ``DCQ_7XU6L)P2CU0?3(#E@8N[P!
M<!H4XPVUB188;*])!(388PS,FX2+NB1+]E#7/IE+#/_W.+F1\Y*,-_>_:Z(:
MHB5OL.+'%;(\0'3)?AN'$1BF(-2N;N[?:H/.0)P;)8+C\)L8/9N'_"W7#)SI
M4MY4!_1=8">)*5&6-XM%,5-O4(N24R<>L)P#J>7OR30X`%WU]-O-S1V]=OOA
MZSV*)?:,B/AY%2Z9;_["L1#0BH@A.H##0^S8_&ZO&+@.,BJZZDI`!/`D):(S
M,E^(CJ=QRO33";^F#_,@O3)HB!%3[-Z?3JE>!W<?3R*!01]V"85C9IM1`V)A
M%,1TAMC&]`9Y\:6M?I>@+P/@@<*?I!E\JCA4_O*EYFF,2F'2IK]A0AUBX<(1
M%V#1=6!3T"[8I1MH[^#1(;82IO!OR()'!R_<0FE)Q,OA#:QY4V*:,&!3O*1`
M-"H7K9EY)!O>5"X\XU#A\:$X"YB(+UUQ,8*\$8W?J^:'O*^Q"@LGB@D<M3E7
MPQGUP(:1S`7ORPR2)D+?5_IK`"X*?-F)WJ60-3,!("`I2;IL+2TN2Q`MS!D_
MK;XR5@<@H>37/<[I\C#07%RC\6[RP'A^(P.`L^0Q?N`,KF.E![-0G_*V-_$6
M1\$2YX2@%VX`2E<Y&"3-\.B+0V^\$0)I9.*E`BS`$RHA'ED%+[]%&(`XL.\"
M-8S7J7ZC8YRG5+Z?)"W3`9`54S`',#B^%/*._70*9$Y!6VOO0/'C;DU#(`'4
M(6!#W=%QVOR/`]D_?)H]7L`&V:"\_]OT8CQ1XJ>AHVN-:KKD]7\+O)0S$LB3
MBB=AM/#B+@Z^9(T?.``DWBZ9)01OR@^::.;[(<N>J^/YI+10Z@6@U,H^8MF&
MW9S9EV9F;N('6,:;+`VRZHXO@^0X*G59DHU\F%5NO_DH$J"\,!M8NTJTHP':
ML==Y_9.F-*#`RP#Q.=ST<^Y._)@4%Z_ARQXVW:2'33Q7BRX-`*G/3,F9&2\X
MG[.F;L'C&ZH>%]:)YDUO=LA?8Q@N4)NE\S/LN8X3/,V8/%SC-T_@.7:$I[9`
M(ML'Y%.<6`%.R@&:E<'IP1<%MT1&870E_`'CESQ.?3^B6PWLA*8A>G&@=E75
M"&\BEBUY?0CX>/R(3]P+PPTL7J`H-()8T8EF2MR\U`$+4_8KCNT57EF"M\6:
MX@QR(G]ZO:*PZ:::C'HA\/B%"`(T>+A<P6RE0X;<K..CF2E">3<0_#5/OB-V
MTJR@>LQ`:'&AD9%@B0K*Z@[;9^(<UC4];F+H9=)1I/^Y8/*WI#KQ<NJ$'I0Z
M):./<K<2'[%;_[9AC5Q0!.38#&=?@CLSB,0?RFURGQE^*:\/YIVVZ.=L!U?X
M(9XS6]^R5_"@OU.OX$/#7!0N4V#>*8_W"'2N?/K4+V^!.]('>NXHK5;`C\[(
ME2BCDA5>=CRZEI%)Y/V]O*)XKPAPK[QB;#C*I32L3+TU9-L$@GOE]>=Z/D5A
M?\BV*:[NK6F:UN^-ZJ=9Y5!UKS0]Q=`'AK$39'6=-?3*P^AZKV>4B%I9,+T2
M>%N)6ZE2:H][N<2+>J#;JIM@>2I%U^CEJOIJ(U[U-H+ER1%ZOYL[M=D,'G7+
M7;DW8X^N;Z7+8I@[[EP_]7Y@;N[\5IZ2E>?PMF"^5:\^3^E>?IEX]B[Q&_NO
MF-<:@4W\,OUF?J_A2!?@Y_$19I?!N.F4MSR)K=T?YVX5.@P=SH76:VA4KMB>
M.XTJVZ;R"R6Z1E[W/R,2;6,?R_OW=X>Y_I[/C$25K6!Y=WS8U10H\`.3Z,Y<
M\AZK?G"'M]PR.\2CR;*ZT>USU4J5[WB<NY]B,RC[@[Y59EJI3NP9XUQ_I&/`
MOLWNN;R=<=L8]G+)FT<B?.5DS4[Y95BU$?[+E'J5WL*V'$.Y)8WD@,[=MM%7
M/JXI&#9*5S:VERZ$N@B*8GB_^2*H<"?N[[YS32^"M8Y>$R^YV"L-NU.Z7>WF
M.I%7AZ@^3+;)P2[OPV7T!B?'9*M%7'X7F%&L.H_,D^HKNKP#:6[?MS,F_%:5
MPMM4=F\U/"@WUL-<PXX*`-0`\>8K8->$ZG+-#W>`6%6PX@99F"CV[#V+0,H[
MKN>NTUD'PC[`;HBFEQ%U;1!V:W)5CXV7M\(Z&KG6Q*Q+[XNH3BYA$+],WU)Z
M$%G)/<WSFK:@?3V?6;T1F#I@KUXC5<[O(T.]?IWLUOEL-^)5+V,JOY@`/^:U
M^!$H6+UJJ=P!&/3J@YQ^_D+'Q>'[[UCFC/E;^TELZ6+#=OEE<!<"LC?<6Q6\
MEO?FS)W9'![NK<I;R_NA]?LG('AE$2]OB&9TAN7:;4O`_V5B/^Q(/KEO?7>Y
M5UA.ZCP(^P"[E427.H2YRIU#`;N5&)<:NGRLZ'"4K2ZZI5OF_%U&6T%;O-OY
M+<B?OU7<P91[/;`=7A'7-9/O!^C&C4MYNS7=&*^JL/T!_<QVV1&67Y1I=+HK
M"ZITYGU@W$S*-7O`07X/6!7&XGL&Q.9QOX.5\@.Z,4FH`N]:*/8">*MF_N7>
M3?Z*V\,!O$UF0'G#"*-CY)JE'Y3$E8])NN4.#6S5C-TASE8(*\?+[]C4L9P=
M=$*O/';:-KK&,.?P;@9A?Y`WWO%5'B1M&YW^*'?-W?8@4Y7(GKE`Y6Y6E[R!
M#(!\PJI@;+78R[7I2-?W`F.KRSI*7:.1;N37P];4J'X]1ZFL@Z=9B1K^TG2C
MY39]N>NYXN:3&?S;F13<SI"+$Y4OC5PC[RPF6V.9SX,Y,I:E-C??0'L?-`NZ
ME1\7S?*&/'EAW0_+P]S*5!G+JEW%]Q39_,(4-8=?@GM>5K<5T+U2UAQVG>T'
M='DW],,NF_V@+M]6'W05[`=TJ:790JCOK1FS8Y=]F8KRDU#<@`L+<S4U\AO^
MLDMK#?#SSJ(]]\0/;!:T+=]US44(0\E//Q<VX5[??INW\%:>3#I7KQ0-KG9J
M**@C%,#)SN!O7!-HK"\B+?1=QRZJ613-J;>??-^I@&Q`7>^75]WRSN<;<`[P
MATJ0_'?L,:W;X9U[M\#[&$CNAE%2:B?Z$??RL\L^XU4$$&:$&1X"6+TV2K8?
M_*3]:^9$K))DKB"PJYSM+I_%?=[W'6DO9.H#ZO00G)(L^\IQ\#"Y,CJ]EM$=
MM8Q^_W612"=Z^Q\K1J($WF^!:2>]'4)MP2U>.17DU0E%$ZQHN<JTW6K4$DQ^
MV#R\L</XJ9`8K5''."P.^]&J%G+72MLR0G9Z*VI^#^@.M^9VLQT)8%_+NX:#
M.PF.[#Z>2ZU.4'T*MO)RTEOC56-_&JC/US`9K>Y8OVR;5`U&<8>9-F5L^]5Q
MOOQK-VZ6*LW]SOG*\IZZ_B[PIRP,'1][`.TDQ<]0QP\ZC8;?L";TEC'>AD@7
MJ^'?4<,P9L,W)MWC9,=J,\T7ND*Z@V:%O&2K82X#WW4;8P$#];;R=%_F4FB-
MAMWS70RU&(M*46,Z_N2K!BU*>BRSGP35=.RP?I@#QX?JGCR5OF%OS9'#27&N
M_;QC5Z2.Q[42!6$,3H?-Z6QI&<.IC?JQC@QWF&S30(<)A]<_J[+C:XV-->[:
M`1&N44\<AY-'8%LQC\:MKC$Z/"K5%$5Z;33]M=(-=)^LC++\CC?B0F>E-6/X
M9JG\M5->ASYZKGD=APT,O,VT;\<R\Y^>@:M^"4?*I097R,EH7.4,[F=-2&4;
M_U+XP@M*M7!F!B#GHF\S]G_&+M5A//D+>_*74^<\#SI'U<\YNT.]U>^OV:^=
MT4EG35NW;21!2`#VK@[8(@ZLF<EO]'UT,(S^#'3`N&4,UF0,G)KG^_C;DM'2
M2]"O]<4V_">+ABW2U=O;87ZTN;P;^39;^4)H]O7=CKC/JSR7>FZ@&\-3XG1F
M&D=B:EP;_7UTPI[C%=*=CT&7-+CL4#N!;291;-1(;XU[:Y14?0B=HR)[?B'B
M2_`[Z]L[W-IXU<G4(7-B4CLJS10=]2GK2@D-X^_85[_979S[JBSW(\QP=BKN
MK=''576M\=P/^DL9)_K'T45L="L!KDU^RR1?M<]@3>KZFMC[J=E[@,4HXW%T
M#Z?SN#YO_&*XN"8P>FH>'GJ)\O8>M#29[.WQ##BJ]];LDT[-TX.L2^'_.%YD
M>@].ZAH]`V9VQYU61S]CAAYVD?[F^S;>8/P,.*GW!ZW.NNCHJ3EY2),IZJQ(
MU^Z3Q7*^[+WJMOJCO1/W7E_6\N1I29[O6:(IL[K]O*+[,T<K*%TB<_LMO;NW
MMUL[<X\7T$Z2F1WJ?ZQ%YO>$U\LMZ/("`]=7I/C7F?"ZT#IWY5$08O[F1WA?
M;'H8YEA@)%S7Y_?![B%931S[N''LZGDMU;-1RO)9WF*&!R!(-\,KC8/"&\_&
M6TA+?E8N`MJGG8G^7-->*BWO@O2T$E-RT)3Z33IS\V1)BX_ASGU,+(:76U<$
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MY#<&9?<B6'4<$3]#%]AH=?4]TZ*>OQNLM_1UUXHT6ZXM`EZMT;YI>,]?WGI`
MI#,N7ZJOR4*S)LX1]/-=&"<&JI&\1O(N,7UH9Q;RNY,<[P'OG0E;VMQQ61CY
M'B\O#?B5MUAR^N)OVS@WT%_V2FHDKY&\R]3A1TKQ<3.*G;1YJMNE/G_IB4"C
MSC8U'2]R20T.F9SQDF1-;PVV:B;T(J5-;^G#,[ZS]"!M76(G,L-"Y6R]:.7<
MY&XT.4*-G)V!G.GG?(GB8=UIF0&4\:;WS0>Z]`5C#+8YNGB12Z91S?6<)6ZU
M^6@D[;Q4\P'NY-N<LWF_8%84Q/.5V+5V-6VR.`^>2[:NQK9))3NG5++>FGUV
MD\5Y>2M/UYO\Z0M9>J/F\J6JC=XHY],]VB%UHVJJA;+U=2E^C;(Y)V4S&)Q4
MVS2KK^[59[2,<>-E7\CJTUN]SO;W99^1M:\UY6PKJQ^P1^;%U>\%NEB%LOV]
M[;7HD6ZKUVNL^.YKKEZVE:F/D=[LTY_#:ANU=*.QVN>]V@8MX[11L=TN`:B]
MA7_970&WGLVFC@<.P4<8RKY-[@B[H2O"Y.5A-^&=&43IY01O_?G$\<S,=03;
MW!*@CU_T+0&J#&W5&_Y$"_^0C:M7M,`Q@EFRX>"X<H/`V[NO1"+\WSN-/O[O
M[R#8W9^UMTO+]1<S!\1V3:3J%"T7MQATB]Z+W3X8OC6EM6?4?''/^O0U3+^=
MS_%:AD\^Z%$S\H/*Z_%\SYWUT;BEC]9X-*?F9HT7A9<S]L:+G`?F:;?>S)DX
MP-GGT(T>EFS?...4KT/F%6QBN&59[S[?7+(C?=SP5[?3TL=GXU.?T[T6%>YR
MR\CA?COS4USI=J@=^9[S;G$A\$'1KGL;6./NK&P#>#\S`_;&#)E]QP];;Y[,
MP+Z/X)4O"]I(_F&Z,8T%D\;SQ9[WP^G#%[WSVZP<Q1.1OTA^/LEU6WM"<KR[
MG#8#*BY0:VDUW_A4(XD\_RDP%[^\XO_6NLO>#.4[9K'YA`5:5R<:U7Z15%7W
M[OGE\IX4J--#\-RKNJ6IV!@]2>!]YSPZ-O-L;>DPU]XMB+*B-VN)(-5Y^%#+
M72F=Z\Z:+6L=J/SC)83K=B=C-9J=.$;W_CN6!S!;>_1=<%.WO'%]]Z5TW,.[
MRHMF,+[N;A/"JV&I7(S5&?6OUQW8GDC^ZXMJ?G7"O]M3O$?9P3,E%D9:8$9[
MI=M<^G+H7/</<3'0<U@-^EJ[<.;&(*OZ39C`?&``8S#7KI;,#,(77<[;N=[S
M+N?GOP,!Q7#96X\B2G\PG4![--V8:?Y4>S(Q,R0*-3^.PLCT,"9VWJMB3=AX
M]\4POMZJV<'EK(9MJ%5B`HSKT;,\%:27;AX>`O8`#I`V;=9%4;+P8*N;@E[2
MPNBW.N-M_,;SMP\[GYQ_CBDT?(!U<QG)Q:>N#>H.QZW^.D^]R3,^I_2([AB7
M9+WL.LI9<QT'P;E#YF3$M_Y\P;R07BX\+.YE#XO_O/4L?\[N(S#>",I'W^(3
M?W?"]E=Q7<R-9[]++XO!O:`7LD]TD/5*LYGES$TW_.55NRN.GO7!8-SO&Z^T
MV'/X[$[H]PQ]V(Y#^]6O>G<X['0Z"FD*P=\-Q5Z*8N_@*';+4!R.C8-AN'KB
M?T`,>V48&L-._Y!,U(_&Q'ZIG`YZG4-R<9NE^!OS6&"Z@.&-/7<\)XQX24)5
M)`=E2/8ZO<&Y+,9]D1R6"NMH?"[+<5\<1Z6,[!MGLR#W17)<AN3`J(N12BW/
MFV6Q11;&^#=RQ6^].Q8XOOU;X(=AH11TVT9?_4AC?%LN&)'D=P]\D:<`MMF!
M&'>5"K>?/R1D``MIZ`H9OD\"UVF'"&@(JDFOQ.R]D"R@XEW@6"R#O*-@O`85
MO41LVPMPT+*H&9UKHY]#C.8M@&>R&>%)'F&008??<\=QK967"<8Z+-1?[[J=
M=SE,ZH"X@!#AEW2CN,J?7ELWVEW]SV2QOO]W[$1+!,/WJ-8-L8(_Y[Y';NAZ
MT1R,>Z-1J6@:1J\[T@?C'.(JA%LC(!5K;0CTNX-2!/J];J?;ZQA;(.`'T3<6
MS&^]1Q9&O&%>&0X*$-U2UT/['O[D.>XOKZ(@9J]^W&4ZP?-2)=LM=PFZX_&P
ME],NJU/F@((MDS-U+-`B-Y;EQUX$9+J#79;EL'"[]-5S2%I=V1C.S>#!\7AB
MG_J%W%P.\+N"=%;^G_71)QBT9.>9OKR21=(OWZY6(5\F)$&O&=?JOE7=Z98"
MT5?(6_YPG4`J8J:9B9QI"R%H:S!0M^OIWW++SO]6`-H<&I`B\)/6N\:4]H[6
MV0>S2J_1C_!=!'!8_#TPZ$Z(,<,%7N[J160G5NA0\'DOE`<*PM]F,#&H$C.V
M'3PBAC5NHY='GRC08N+74\<S/<LQ79A/:/%0FYF/3)LPYB'X"]"R-B!,G`UL
M>)K!DHIFV@-W)]TE_L(6=`ZM,#]P8-R%RX@,T8QIOWL$"%D+^O)F#H;3,K6K
MM!S)^OGWZ_MK[;>;F[OT2_OGUT"%@"=U./-BF+%M&H<09G>7+<WV-<^/X"7+
MC6VF`:`:L,]R_3`&GF@!X[4#-++I>3$,5S3PM<8IJ4P5SOS8M8%`,(A)I`&2
M_A5[5'?.:8/XHATTO66*Q_AG`#-EQP8F($*``(`*@P4L\@E2'!C/]S4&[+2U
ME<QE>DW@3*"50B*>)L2!RV!*-(#^@Q_,0<[:_Y?PWE%^`C9UF16UY/S^`G8;
M,#CP'(R!R?VJ%K'$M/^*I;6DSG?,<LTP)&W";SWV`,4P-(,E:&2YG.A`"P0/
M!T\A6/BA@^^T\$;EV(U(R'SP9=7[D\UPIDU=_PG^C+1,8CS]3M(`<"W(IPOE
MA,SF]"@>6#(FFF'N$0X3.M\U\'JB62@8M3J3^@TP(F`DKA);L*)`/9NH\,CD
M$I+3RPFG,8"*XB"E=!LN37T7Z$#CA.8<_F^]%M=,E$0?)K%9:`7.))4O(:8^
M_5%=P@520CHKB7=+8]]1UR`P*1@3!HA<'T2-'MENW&6TYMN$A,>P'N,5Z[&-
M-$D]2R+`I6>%PWR!Q728YL#/3S,0P67;?_)@U#">A([M@.AC/\R;8!)'<:C=
M>M9U2[L+?%@&9O)!^_W^ID7#O0=0J%[Y6KN!M4`FPA+314HW$'IX8KIHOE0#
MQUQGCJ5B``"/L*0$KT^@<I1-Z`'*#NQ52+1P$A\>5]7=S;NWOA93@U"D(*.=
ME39GL`*%*I*#S&@I8.:7@V2,9J#7^.O@@9C:(Q"4?.PD)1*FP+$R5O>/V_=9
M>XO'G3/'F@%L.`ZJ)H0#K/H<5?$$;#^H"N#6,@O-^F=QV3I89\CX8\0'>M9_
M@E4.&F1N_LUH<Q02UPB;N0]0*]H)/8[I%`P,)PTPS9\[%JIL4"%S<E"$X`%:
M,$]0,"$=6.&$P`/FD#0@E"BS7`OY$^`DC[O!4^8D](.)!LY#R`14P"7FH&E&
MFX)K!7V"!6A"("]Y19.L2A7J$4"Z3OF3ZK!I'-!@,"RJ4ZUW-7G]+%3:5P;/
M6:0E-!,#)Z%V5$>X8'XTMA17:%-41[;9E3^#B9EA]$=X`_S+&4.7;ZFQ^<+U
METQXL(J6TF[`6S#1BYJN<?^P8I5[*2OO7Z'T,G1KOGAO_8"]3K5@^M,W]O?<
M"<S7''Y0H;"F<P"K@V9G%^^`IOV+5@]*_R(.X.50K(@4S_)14@IDV@B$C#L"
M6O<P8GM#'AM2%JT04F\-,5L9NY-1C[#^J1(]FQ,5%$@)[BBB")9G3'L;#7UD
M,1=WQE9>X1YJVTKKCX$LP2.&9\VL='`85`S0]CBV\"FY<4NGQ(%!"Q:-W)**
M.B1[`@KG/P@M!I^4LP/&8_R:_\BX?F,8OEP*/U=00(K"(O`?20%+H4#;#":(
MI6I,A1SYD>-YG=O8(D(3L4*BID7Q12G;I)II43AA&",A(A566*7J'A&H%$8\
M`E9`JX"YY!APE.$+,7F&TBT^,QB!!6H]_!%<(=@8HF*!=63"V`%`MO!Y%-6<
MHVM42*[_U6YK'[`J[B?M#C9)/VOW1',+2#;\6</L`_C4U=KM-(:5>^U'?"_S
M@/J?R[0?O_F^_>3@5I%VMK(#`/`.6P`<.Z8"W`RYMQL'(BX"/A4X6$XX(_;B
MI;0F@@E;7MP]F9'8;/'XA8L;8]QRPQJ#M1>A<J*S<1HKPINY**)"6GW!G6^Q
MRQ)+54Y]&"U[FR>PNM0<KPU@XP85=Z)TN$\(V^GQ/D#N\+;V@3_?S0Z6617X
M=?/T5YD&(Z]7!89(*V,,7%$Z29>)MHMM)KCN%1MR6*^@@O^#`8!L#YT)PY-6
M=.$R[\8+G[,+58K+.(;@14Q@4-\C&(4)`!!\\(I1PY2BPZ8@.!B$6N4+Q9GX
MU+!18-,8+Q5X9!S!!&K<U9@:GO3B>FSC4H-M$`4GA24`*P@2#*XZ`J(.)`T+
MCB>"#UAN@LXREVHJ-P'8;OAD7'E.&,@4;NU@<[5*?!7H%-I%C.YTA!L>!JA.
M><2+[U_FYE]`/NR;'"4!$=H4"6?`,H-@B=\DIGQUUKE)WK@#@H@A/W(./"44
MI9%^$?L'X(%X<LYQ!-DGU2.MOH64HRT53=G2N!,)N,<>1AA1OY-#'\5D%V3`
MB<<NF!T6P"U`"F.D=RJG>)H)E(;]RY,GS!"P*_5<PL,H@43E@N7E\:]0^`RT
M^#"LG;H*Z-PD7@5G`BZN!R^QG)K'@(X)3Y"6-NZ2ILG&-,>ORAHA`10WP<BW
M9"6K$2S7F8II12P5V+RZN+TP8B;(QH,<T\EXRJ86/?E@G]AB13IPB7DRE$J+
MJP6BX"*I5"]4(@U"KXP@9-H/I.]"^T@1G=9`*[@.TA:7J/?`]]I3)\`-,8)"
MH0[N]^2S_(6+B@@"#?!,$='`'6XB>MP721Q('L'A8TDJ7&O_0L%<'=[,#RZ%
MNW"&A*C%@#EAXOXRFP<0_.R*1?91I!*W^S9'7HR59P<,%GM)U%CJDSQ,F<4(
M0[AH#%8I*`%OK<P^!Q<OEJ078ZY"A!&#2B"LFSJKD7#(G+</T@*B1ZO-C,0R
MK4\UZ-U3'J7QC":TH80X:&GN<1_<\\L>():!0;)KNE;,]PJ)+4`.<B(H]9E>
M4DN0W;4H!077VCO'I0UG;IXDAF4[TRE\2PX6:ALK_R3X7Q8WV8R'R=9%)/C^
MQU^D4=*DS`'M+VBLMHT`@;%.07,X,<J(D,8MHX!6R5),P^.70M_$H5@\NY!)
ML^-`3B(<8_+:W-#/*C()O$(+-4B'NT2>@I"9B8BK3(='66T8K@W/L.4:H@&-
M4L#6GP*U4D#R>$XUHS4<]EK=\4B[RAX496RAT>KW1ZVQT7^=!(+XP5_B?4NN
M"$=;89PZ)3JS)O!#.!A$0-K_/\F3SJP@/!/5DBT738\UP('%^S:3F[>.IV74
M4'IB8"S8)\)VLAA`DCZ?AXXC-J<@66I+#G2&X:<AM9SQR@;>DB6N6+<9^#.X
MUUF*/3$X_R$^2/M<CC/M'],W^"&`^=V9`Z1\/)15/(.=8!!,>)$T$.V_P0-<
M>33V5A^>+(6CE=E1T'%#P<.,0TD[&_/1=%S\]5K[L@I#D'P$ZOT-SB]&_AS+
M69!:Y6N*5ILO'6:/N[YD7L`KIBXNR38TC1`DUD6,:YN1":"B=,A%CR[P`K6-
MA_4TX*;#)D'[O0!Y!<ID6#,M;($=*^@_P3R+_--]D.&>*S\@=Q&?D*LCFE\P
M>)G0&`^"N/2K<D`;6WEN'?Y4FVAWQ(\.40W^ONX[7E&-46:R-'--S53+9[()
M<)*JL(*&BZN@;LA8VY#^]8^M"J96QRE,A!.#&VL'1[-D&'L,KQ\2]G$I\!]1
M(#5=71G_CGWT2*3(XRY7!/%H%V?EE;#4!SQ1BAP._J[PPX^2\M9)K4DCTHU(
MNYI1H.RYKP`JUY-"+J0[R1K#(!V(L5P5I)UQ`,6&R%R=`JLE#L5MV+=;>%1/
M1E[^E6R%"UZD&`[E(@<FCY&CB\$="H)=F\=@F2<K@.#I5&1*CS[)B\*WK[4;
M/,\Q,12;[@M*%W<(?H-K!DD<*@6/HC8G7-H&7]C7HV9Y-\M;+N^NNKR+'-PU
MRY0VK3S&2\F:2C@\=U2SXA.*=:/^H(0N%1^.!X>+`=AV[6P\(AV=^(@TG^3%
MW53:62`622HI\(;2E&A+GCK9Q<=DXB@`>*4JHD0C"R?9SF[Z^)D/*-PXH)V-
M"$G3,:(?AS!:V!*GJ11[7K='$Z&C1UGZ#@2P9IX#1`\3-J=[03J_2,?)N>@)
M><6?6]=_K-%(I0IH4YF'VKN\8'ENW=UAUY[8YS+W@:ZZV@R:<#<:FJS0Q&AH
MLD*3;D.3*@W^RRQK?4V7JM"^N&/839K`4YF/>RK0+3VUW7IGG0EXYP1+0ZJ&
M5,^05'5I5J7/8P&4<I<\J-RB_BWF'"75;GC"`>YX<II53H^=>OYO-4Z5AH7E
M`V[1]-_H#%M&9\46[@MH#20X,"FW'7D+FK9/#6M#S<NFYC-8YJ=WIG=L8XI]
M0C2;48UTW7NG[<3FL`T@ZY]0:1>-=RMNVHT?';V&73MJV(93#:<:3EVD"CS.
MSJO(.Z)KC$^_9][D2E7UGW3PG[+7!>\,4A-2:$AU/N"]^$5WZIW*G@PH/C.H
M<;S:E\.&&>I8(8=&XIP6\`O4+PVIGC^I3N*YEJG3CVE24:.?&_U\62NI(55#
MJO/5SWNYS?\2U:3/CX^;(GV-I#\_"M6T;5ZYK[$ASG&)<R+7M3C%Q:?>+IA/
MGVF<=WJ&-OJ@H="9*(5^2^\V&O.$Q#FU,[ESMLB'@E83V]*J.3)M#K<;3C6<
M:CC5<*K)%6G\[3-V*1L*'<GI'K6&O:W+61OB'&Y'(K_)-BDI;ZN5M!HJFB?_
MEIB%,#B/.O\:PE&;#99:L'7*9@!*V4-M8-1@KL\2,%&*K52@U-.OX&SIU<C3
M6<K3$5*K&WEZ0?*TJ4_&V=*KD:<2P#S_*3`7O[SB_^9]IN/)U\K=G$>EY-D'
MWHOSXYJ>)Q>WN6M(U9#J?&`Y.:E.$DTM2P+9L<_)Y82$AD9+'S7E>2\OWMI0
MZ#FML-.[HSOF@?P6FYB(S.AVCN2"<KR0A*ZUCK:O&VG.147"YK@U'AYAS]0<
M8S^38^R&4PVGS@*?YZ8"3[*C.:?\D)H\*5T'5VJP=0/OLW<T&U>\H="+6F*G
MWJWLR8#BR/OY%G4WE>G/+4;:D*HAU?FJY:9S2*.?7_9*:DC5D.I\]7/3.>2%
M;`H;"AUIV]QO=<;CACBG(\Z)7->F^/WD,?[F-*;A5,.IAE,-ITZ#V5EL2L[D
MG+/QMQL*O2"GNR%.C77P_&^U$K[";D,6R^/OFCZ\'L$_'5$Z_VW&M+?^?&%Z
M2\VT_AT[`;,U$P9)KVF#[8?VR5S2I<[:DQ-AKKOF`YU@?^+"X%$<.-%2\Z>:
MT6O/`9Q92-GP\.;,#+4)8YYFN688.E,'!X=?-=?W'MHTB9+/Z7M:!.!,3!?V
M/4P+9XQ%U]H'/Z"O%RQP?%MCG@V#9&Z:;M'O4],)M$?3C1F"@M]DD0BU'_BM
M0:U.IZ,]S1QK!I-;;FRSD$\0P)_.`G!"Z$W+"F+*-X5A`$*-F8$GP(]6X=1L
M,V+7668=D%5Q2&RRG=`"\Q@Q47LP=?TG;>[;S-4B'U!'"CA`J6+Z3`LVF"TM
M8*Z)`\(`GWPO-+W()_G]W]^!UN.?0YC)=35_@6TN\2$A-30BUCZ@*`0:/<.G
M,:G8#/^ZNWGWUF\A"8'F5N!,B+Z:YT=,ZUU-7E]KW[*`/M&C`@M;$AY)C<,%
MS/(?/`<!:7&>(9>`K0'P/,"^G)PK-*J##P*JZ\C@BM.D)4WL.2X?%AX"_!)9
M]GS-FIG>`T/L'<!,&9)+1T8Z#RL490U(4=Y-!2%@`O#7UB9+PEG*T33PYX0#
M<3$D6B)=;H))',6A=NM9UUK*_N[/6L@8,2S4ND2<$2=OK8)IE2&5+CX57F1R
M5@#">!*"+.(`1;(@@,V*]0($WP&@S&"IP7IWYD+*U@*$<O)#KS7L#DBK3(6N
MRDZ*HWPR`X!+U*CVK[6;54%I93B#XA8P7#LADI0KJ!3"<G$NA14(/V':#]1P
M$J&]SIL6+IS_J]W6/CC,M7_2[LP']K-V3Y2T0$#'/VM_X%0_`>_;[=+7?L3W
M,@]D_[/'$ACG].'4=T&RD-"\LPN0*,3**TX)6J4AJIA5,A7*P),XMFCA.]',
MCT']V>%/Q80ZR\XRJQLB&!H@\'YYU7U5R6NQ&%J\*H7NIRRRWW_NT]'E8ZJ5
M(UB2(-@>2K`03.[G-!138?NR8$2BU)X!L>1B!5,7<D^MH5\);!\RZB\A'/O.
M`LL)+XUV):TGCJ75W*)69/SYCK14R03<5($;A;:<:5<VXY]>2ZN4L2V[C+W"
M5G7$AI5ULQ*VHPS`@+7#W8L<OOMP\NK!=+S7L#<.+XJ'Y\^SC,%EGKTWIU9-
M=0FOCA[W5GK\U!6X*UFC<B:C\E3WSG=-Q(=6HSB;"K`.@-C&D>L:9\<X964*
MJS'+[G!3S/(94G+KD;<@Z:;#@V=(SJJ"N7'$E(I7@]:@LZF_P=:`OGY!%!RV
M1IU-;?0:6:Q4OM9OR%@#&0>M_KAS/$K6Y4JM3]Z[M"2/:L[5)H%O4G5V6S6U
M9>A4.6MNF-3D4UTVIXZVG*ZZO2-T1*_D@C:LR;%FU&E8<Z:LZ?8;UIPG:ZK<
MJWO\+-Z39*N)W)N50WUQ_*&<$<ILC'"M:XR9,IA)%-CI.5@8F1'C.6E3S5^(
M#`J>UF;Y\T7`9LP+G4=&P?K#IWWQBFS,K(%]#B97$'/;]];,=UDHDK':B\#!
M1`.>Z[-((>89*6'L1DB?E&JY-(<6$2PY'/3C",C@V31B+E5%)MNL-%_7S("2
MH'A>QH5G3ISR@*5L;OHB6Z!_+N<]!:"M*+,ZH-UF8WORP[%=#CAKH]3&NQ&.
M$U.I,^7[$LH-S@2\<X+EY*2J2]*W/8@=CBJ'/M\YCXX-#HJVQ#3*/0*K*XJX
MOMCR!AV_<T"\D$I5#`K-UKGN[!.(KHK4/\XUN%\+M0]"VFIT/(D9*@'N_?<%
ML]#5?O1=\/IQ([&WCU:_SW>JSE*#\75WZ[M!ZUI?%VC?1OUKHYZ[5`^V:.IK
MYD]O?G7"O]O3@+&T<@IVSZQ90XI*[6]=5OB"EY"^V0)=DMG)&AD9SZ%2Q:LE
M,X-PZ]#HLUXJF]("CP[])2P9T##/;3M5Q(62J@8E<'DI2VGKBO7**VA\W=]:
M>U[B$JJKL[EQ/:K'VIPZD:D:E#</#P%[P!K5PL.49C%M?0K7K*;+[.EW]#O-
M/L<4FC_48CN#(_/:);]^&)2U/1RW^AMW&N=`A0O)C3A^6EYWC$OW`"P\ZS2)
M[G5?R1;(C60[X<(UES]ICN<Z'BN2QNJOT8_P702`6/P]60UIQ4'`/&NI1:#)
M0E=TZ_!LI1.&?$3%O>SS&5#D0^Q9B(7I;H1\+VA[&6"II\7JS+FF%:*]4D@A
MMH>`VO5@RQ/'=LS`8:%V=1?XD?-HTH/R\^_W-Z\QV84&,CT3'O8T&],G`NJR
ME&7DW/=8A)U&1/L>',E-;UN@1`_);-XFR<^/FC1K"403%%DSBVTZ'DT8B:>6
ME#13TC[[7GM+,&"TF1-&?H!&/YT/`0AY[Q><VO'CD&<$9=M_R&C,"KQ`-6IL
M`S@FDX%H/S(/>_X`2.S[@GFA`,4D]L%\[^7[6-@K8/>QHPN!+9I/4=(1?/;G
M#!LGX0-)YA(O,*TOOVA5V%S?RLE9IO7/%0<2&87RE@C9LJ6]]\!G<1Z8EPC5
M[YZ#/+C'Y*DPD0'>:2OIGJ2T<^(-::B#TJK(4YLHWK>+>KGD5L(B<.;4J<?R
M/7_N6!KS'IW`]RAI"PC*9\W@PO.X6)@RS`ZI.U%-TE^,OI#OC"@V\G\6\K^C
M9?A:V:35O%:E]B=NX/PE$A?2FEJUO-?:C>M6%"0^P:KDKA'7KUP>PI:4!CZ)
MC^W3)(.O./]?ET^7D<&L'.#`%@.BX->`ZD-6WD3^(BW\5<!%<T%;Z>JEO"PE
M'&26M[`S+>I?MH8NRCH+DLYBJOMC.],I0\(#(:C/6FG;J2*+CTNM[/E5UB)*
MOU_?7Z="`&#'7L!`M/X#8.<7X,^\J1T0C/&V8RJP^*Z:$<LYF,U[5?GYFC=?
MLWUL#*<Y`+#%I01H8\6"&@#@;;+(/^(B!Z9J]S.8;*41&?Z]I@V9WMF_#]G)
M_<M=/>ZO#'MI2/E$&5B`V8//%B4LKW8..:Q>^D""[<RI&2+^V](\]E0.'M?\
MO&&3Z$68WG-PD[YUCW$0,P`+_<:'?[2K#S?W;UZC['!I#,7O&B@S>F'BVPXU
M\@0-14G(MK^(5AL>FJ%<_>&"6;PC*0/1A_7WR(0B^]US&<@G3?3DA(RZ&<;8
MAB_;HF_"7`=TGI@4?Q&RSWM3`KKN4N(:)O@D$.)B68+V3*=_<D`_X]<ST(*:
MB;U50?%A?TXQKL>]I81@U-J45E<@,KS#7,9ZO,"-F,TSQ.LSI)VB+7!]`]\F
M'6=[G.3(?4G*F_O?Z9=V9]R21H<K6&R&&0"A0MZF]FT,&GK.0!M>W=R_U0:=
M@>@PF@B/P[=05!0`\FN!ZG2F2[4;+*;73XFZU&OT/RAJJN-#W2P?F>LO@%^@
MWL"K2GY/IL$!2#O_=G-S1Z_=?OAZCZ*)S:!(?$U:-M_\!;BR`&A%Q!`=P.$A
M=FQNCF/@/,BIZ&@K`5$:I<)G:M?*%R,H=TZ9?CKAUWQ75670$/6WY8=1.J7J
MQ=W'DTA@T&]WB\?,=A,%Q+#S+%F_]K?E@LD=JZU^EZ#/V0>62>%/TF8V51XJ
M?_ER\V!_$*%=EWQD84(=8B%`':5.P90'9D%US:D]VH/OP\H%+H8L>'301J*T
M).+E8*Q#,^<X/Y\03*O++-F',M^&4_%1.%2,\@%"L2.B+UU.TL2)X:Z0#]H(
M@5%AX40Q@:,VYVHX\V/7QI',Q<)UN!)D#NG-*_TU`!<%/JH_5#HNN1K4-15(
M2I(NG0O1<5GTU&3VSSCKE;$Z``DEWZ7-R=Z#]N):#:DH6I7"<PC.DOM/P!E<
MQPD[5IK[R@:GA()%I+L&#T*[`2A=I5\J:89'7W0L!HXMD$8FL!28&)A)%^*L
MDI??(@Q`'-AD:9A\P4F)*S&1[R=)RW0`9,443`(,3AD;2@]'<PH:.RV+02`!
MU"$U6&:FC=/F?X2USN5!.KO2O,P92*+VWZ87X_Z/9_"/P$%%Z9`>^P+WTI%`
MGM0\":.%SAL'7[(F:=B=(X1#A`!--/.!<-EFOKAIEU9*W;>3<QV)\JBLW;M$
M4W,3/\!2WF1MD%UW?"DD'FWJNMS+BK$PJ^!^\U$L0(%9+/"TJT1#&J`A>YW7
M/VGO0)#`B8X#DLG?\;D(G'7.X8D?D_(BGN<V`3>BR@WC;C[J/=%^.CLE9VB\
MX+S.FCM8+)AQKNIR8:%HWKGI@?],MT[E=A_A`C5:.C_#<V.<X&G&2,OPCMD.
M#QAAU1F2R/8!^10G5H"3F8YI97!Z()PL049A>"7\LF/YU/<CZB5N)S0-T9L#
MU:NJ1W@3L6PES<G#D*)&0MTYW,CBOD=H!;&J$^V4N'NI(Q:F[%<<W"MLA(Z!
M'JIP$^$N^NGUBM+&U[(JAL#S8/6[2N_[<B6SE1X9<M..CV:F$)W[,7/3F2??
M$3MI5E`_9B`TN=#*2+!$#67UA^TSKD!@:^-Q,T,ODYXB&\`%D[\E58J74RGT
MH-0K&9V4"RA>E^UW_NO'.&P_F.;BIWO0`^#T6R"2Z6;CS@=<8+U]`PC>N+[U
M]Z__\W]HVG\E[T3PU2VQ[5T<X/-$%MJZAC=I'_*09!;&^,JFL*'[$VU4N].%
M_ZH?WV`$`41.>?'FNQ.V1:@2]LB?B*VO`#'+F9MN^,NKV\\?7FF._<LK2Q\,
MQF.C_PKV]@Z?Y_LD<)UV2,"\^M7HCH?=KMY7,*X*?9U(Z_!?\7'0[G;^3+0C
MCZZ@?,#B`K$GU-^2VTPS;L*]KX].C/MG]D0_E7';Z"L?RQ`9=F`)EB(R['?P
M/Q7Q2`"J#8D#<L\X(=)?1!CKF`AW!J4(ZR-`N2*Z!/H6J-*/7W@)^/NDR7,%
M@?WSY@GV3;CI(E3)=CX%#FA8,=IZC(<PT+@4XZK8%D)_$.P/R/A.*1FZPZX^
M&!V<%A0A/8EY4F7>"?V>H0_;<6@#YB-]W#.JK/(5X&M$N4:FM[L9[38N1[PS
MTON7A?B-;3O\4.+.=.Q;[ZVYP#CT)B(8G3(BZ+HQ/#,2K$&C>U(A/IJ!SDEP
M*=8Z?JS.ONWL\_8HKT%A>#H4CN)A9-'ME*+;'?4JXUK=O]@.SS5LTD\`]TD<
M@QR_2O$VQOU!9<3W=`L.18@=;4;'*"-*6X=-W=E390UF_5)MU.^/:T=LYKO@
ML(<BAT&%W/F3!S&-=E>O39I[HU*/QT#D"A9R!L)#8;";&/;&I:Z+,3`ZHQ,A
M\Y5A/)C9[\T`CQ@*=F`Y+$HU3-OH]$>#DS'%$J=#S":U_5;-)^&I(1M1*]<3
MAM'5NX?";`U$I0[3:-3I%GC\>P)4NSWJEOH/(P,>*`C)'`6#'0U)=U2Z@H>C
M7OV27PV9+5=POUNJ5=M&UQAV"^S&<9BR]PKN]TI5;-L8&0?031LM=*]47?9'
M(W#7]H3HLQ^Q](@O.6&HY%7\6BE';&K.'1>^Q.2KD,ZN`W]N>B4]B-PM^RU6
M*6?*W)BTB%;N3!K@=Z7=&=<7[,&@)?4W!:4]LA-1O[1H9W!=5*RS,D)?(5?Y
MPX4SB"/AE0J^HCK%?$G0VH-L>6P]X-EW955)VV0C>GX`2X+>^^*)*VJ-?M%M
MM*;'<_AL?OA)5WOS5J@NH[QS#Q:1B!5'S-,6\<1U+,W'I%)QM^40R^OHEER1
M)L7CH2U,_#`Q]\2B$_`?C,ZUT:?D4'H`+Z06&2@XT$-`J:.!;S%F4[+;#WI?
M;XV&?;K2-G/\"*O=AQ=,NH88L8G3<#8>*G<[;=M<*E=9+V*@`%[3A]D\B072
M])9NT/`"9'%LJC[R@V&TAB.='J+#ZT<\<P88\`,PR?7IBG.1JY.!PW9L.M"4
MES'R;`V>1"'2G4(Z!YU*R6II:54&TM()PZ37*U!FRNAOO!R8(7WICN)Q:\BI
MWQ*)@E32X8&^B'+4[!DM?3A<N2"XPMEJ5>67U9F_>Q/'=9F-B:W.(RZ(\"UE
M-4?;:_-NOSP$:V3=P_)I=P=OD[O8'92:/W!==@+O#S-P\-=;T6R)9XK<8!8!
M_/N&14^,>7_<OK_Q;/X3M]-?`DS!?D,)X-_,[Y6V_H53.2Q\LWSKFB!R4Y$0
M\&4J@$"?@:Y\WWQHU"NCBT*2>E"M0K[/OH<Y>U@-BL[.6S,(,&WMAA+\;GC]
M1*D/=4@RE>Y_-I*I`DI[4^:C4DYR$O*4;L;V(X^"5Y9&_Q*%^R!Q7]&BAE^4
MGMG;*Z]1>2QWT,G&!M?-O`^,&S78J'2'U>^,QWO""/;BGD61RSB#WIKA#'O\
M4`A,R9,KE:WDX3?+Y.,_'1:@8[/\B&G:)$W);[?>`D"B'[H;=BZ#X?;,J8;.
M04BQ!H]2!IX5'C*F=$"6#LO/($IE^82D6(-'J5DX*SRZF_`PROG1'9X/'KT-
M2VQ8G@`QH)A_77B(2R%N>,4D[R?S94IY(XJJ?6.&C@4Z^)WCQE')>4:O_#PC
MF]S1&Y;G'O9[1K\_ZO04[':"\#!8]E(L"QB8Q[(\;<LP.H-NKSLZ3RS7GTWE
ML2Q/0>P9QGC8UX?GB64OQ;("+]=DC';`H>EWNO5@Z3K>WS_)'/2/\(?VG;X*
M?(S$S*)H\=.//SX]/5TC$-=^\/"CT>ET?\2??\0'7XGGH^4"GJ=L:)N!TL#!
MY?"P?19/S0+$YW\3CB/,V^!?N^:$N0)UY6L^)C9[B/S@U8^9,27(-X&E46^<
M7UX9\CTPLQO`%T_\.#6MJ"V'DJ]C\5H!,/XOKZ9M?6QDH8.1<I"586L48VN<
M$[9&;=CJQ=CJYX2M7ANVG6)L.SMBJQ\"VTX>6WU7;`?%V`YVQ+9W"&P'>6Q[
M.V)K%//6V)6W_0-@:ZSPMK\K;X?%O!V>$V^'=?%6[Q5CVSLG+=6K34OUB['M
MGQ-O^[6MVV(+9.QJ@0ZR;E<LT,[K=E3,V]$Y\794&V^+?2EC5U_J(+Q=\:5V
MYNVXF+?C,\)6`68_;(>C0N]"^7I+;#OU8ZL"([#M[(IMH;U5OCX';%?L[<[8
M%FHIY>MSP'9%2^V,;>&Z5;X^!VQ7UNV.V(XZQ7YR9U<_^1`6J+/B)^]J@3K%
MWD5G5^_B(-BN>!<[8CL<%_)VF)>54^YO56#VV]\.QX5Q*>7K<\!V)2ZUZVZ^
M4[SCZ^QJ@0X1N^BL6*"=>5NXXQOF5T9E;+N'X.W*CJ^[*V^+=P6=7>WM07B[
M8F]WYFVA3A[FQSOMNEW1R3NOV^)=06=7[^(@O%WQ+G;F;>&.;YB/A9R6MRL[
MOIVQ+=X5C'?5R0?14BLZ>4<M-1P7[PK&9Q2[4('9UY<JC,(-\_OET_)V)0JW
M,V^+=_/C77?S!\%V93>_,[;%.[[QKCKY()*\HI,W2G+2HBR#6V:S6.6X.`\5
MGRY@H1\'%GX[=V%LK.1@7OOW^U>_R@Z:O!]@MF_X;YBC3HWS_T^HO6,+,Z!<
M==ZK<$IMW:]>O?/?O7JM=CO]]G\_M=]/?-?4M"^>]M^QN]2P?9[1T3O9TH'0
M><"F@28=XZ<PX",P*.];^$CMYY(AL3F9]O7SC4.=Q\P%BR/'TF*\C?D_LOVV
M&!Y`=IT%IM";GH^@.Q:V6F/6S/-=_X'WT<8FJQH']M$)8NR"1XW6,,,>>TI2
MOS'1;W)!!0"BKZ$$N84MNK%KGAEJ.(G\_1LU"\4J"E$'\(G9U!'\FP0`<V$7
M@?\0F/,L63`KG[G.@R-:PP64Z(VM^O"O'[H]F;`O>KQ*^!`0RMU/N^0+EDBF
MI9S)E`E@I89H6[B`R4!N"%+E9<!2W$G@`54>61@Y#Q*QS^Q)>Q?$#YG.;PDC
MLP+U`1N48C$"O7!CSV&J,!+M3Z]>?7AW`Z*$OTNHJ/_M'1%>UV;Q'.8/S2G#
M>BX)9H1]D*^U+[PQ\(@$K;NV1D7E'U6K4+>XN6_SIL]`Y#!>8*O3#/VP4YUH
M&IM<KB*:.4LY35KG%@C>U:N/G^\`.Y0)V?D<,0648M0G5-B=BJ?#DI:V`E`.
MG^RLYV%_X%!4KX01MC/'IH01]KZGCH="&";+?#W*H#4>"O'YDC1--5I*DTOU
M+AFY&%?7:@8>H-DT#F0_?P*M`F0_&"U=5/Z@9/>ZK9$^3JMU%*@5V:8BFCE>
M(\`[+J;PHM1C9WNJL8&9\)\9,^TPZ0,I6N=';`[LQ9Z'8>0OVD]^\+=LI$C\
M]2WJGD]M=H$L1KZMI`*8G".!4+38=;`'H6RI;%-_6M&W>J5^:B\BIP16Z"HT
M!14=<7(2/7$*;)*8EA'QJSPBT3TRLRXF;.D+T/(*1I(J72?4D#)=`UE=$\T"
M/WZ82>)G%4Z1MB&:@"Y`C0(4Q]7]AF1=-("4,(*&G\0V2!5O!,G[\4H>930J
M:B-)E%Y'D@79*W&2&A.+R:B'-"EFXML7*_*QF^;Z!<*2MA"PWM+",1`5[8=A
M,J.<)EWU3!"+:-7^+78\9FI7^,RKS%<WLB'HJ]<M2:R5)O8ML<PD-S,CH*)U
MO+1)JYLV$[5$W9(?1Q.0J[^1,O_""]IOIGB/!;>%H@IP3PF6_!'L,/!>-JD!
MD!DK*SH1)(G'[>=WV#U6%+<E5XH`D+RA:]8\J\,YJ`F<^23&IN4T.%;0H<;F
MZUTMGT.MZ9(3*20U6>GT#N^2B@U.38=8#F^B[&"'5L:NM1MQ&TK2_UGX!4IW
MZ`QH:%+G9".QC[^+O7`#?DF*G);?4"0YQKO/X@_)7,RSY2S)\"AB,%WY>-A<
M5E[&P6QQ,1OO?DZ]5?^*0_J>^D8#'NXR4TD)2W#C%'1W`;]%A/>L1PPEOO*A
MB5S@8K@L8Q(9HR[>@61)UMMC4R`.7G/@)>Q7FM:BLE[P[O&A!@"&Y.S9L-@M
MO#.#2L7(Z/Z+M_A%UV0>SX6-_DZ?+7Z%BN@/S)NZ4T-RA?49KEK8S=@,1`EL
M5L$^\@O9$L1S&`L0N8)C0NJNM7?"3U!&2GOTMG*@9*\CB!*R4B-BZJ++-4C:
MS_G_I)RAM_Z"Z;E7PSL(FR+MW?%B/PY=[)K_Z+`GP:%47+#<W&)AB#8VO1A'
M:0(/Z\J:M4$)S%DT\[D0_W<,9JS;*:HR3B[4`+N*1`6#CK5:Z;I)NBZ[*84Y
MLJ%/1D_I)T^"E$H1;[%/UEXE7NYV,F0C]R!X7^)D;V,4`IRZG`\PH">*C,$1
MA(69\2K-:)95<ZVL*4PDDZ^C"5[E$"YXIVZBN?:7#P(.^+5%LVUE<:@C%6^R
ML-,RU1R;R^O_^C&S$ZVX/=4/NCWEK8T(TWMYP\+-0\"$KTVX?`)S9M(M@X+X
M5Z_D5^!P$Z-DB^MNF9^;C"$M&-A]/G4RFR#W*AA@KOT':F_.QWV5`OCJ];5B
ME=+O6^F$*&$9E\&?8%,0F`EV4_SJ-!]OH,II.]2$H$#H!C@;5@/HBZ6ZN^6:
M/+F$CKEXZT3,E2!HBTBXRR'U=C<?P,S'+KHCL"MX%.`*D*1NX0L"!"99,+QO
M.7EIWVD5NC@J6`&Z_""WJT7IE<:?[X^4K1`W;)(F_X=:R3/R-^C^J,(%T<HR
MCB:8FW]C`PMJE`]K:YGT=5=!@3_GV$@?GT%;)/"DZV+%KDMJ_(6/G<?1^4TN
M0$^N`N'W@^'=8N`G/$D=%\86*KYI[.8\W;GC@K("3QT`!R+^,!JTC,0]7]D>
M4/4/U\D4$*!^\)SDW&%?Y1#M];*\0%U&M_EAL3\NE80DB?N5]TQI]#`=]5JC
MBYQ0-RY4U9*H$QAFC>+&[;4(8(`CK(]:?>'ND2<@F?<ML:=A^C277AX!$<*0
M7+*"G(_3:$RZ+)05X)?(,2WC@&5N&$GO?$%EPUUED(8V*"F\TBX$AB7#R?J+
M[+@9]U-=Z%EJD'T%R^6$,_*3GV8@/<NV_^2I-[6"(T^%S:N7;F0NVX"M*CU&
MKAHY%-3`Q1$%S/(.F:M7?]R^?_7Z9VWF/P&6@:)\Q!V:\L[,"?,8..L(07)Y
M3BJ(UV*VIQP6Z-6S`%=SM64K+>LCXZ951-!`?%.XT,2#.O)X1PUT45UU5V71
MOIJS@_?WP<?<Y$X7<94A_"7H>!-1TPVZC\Q.?:B<:"3SSTUY[PE?<:(!1ZHM
M6NE5HA;NPU,UQ'>A9NYRL43!)V.ACX%4XB_((!](A!^X]A-H2;K4T(WI4CW2
M3;L9`L<3OA%S:7^0T?49A!F:"%*6)&+<JW(2_<@C9TY`EV@$+&U#(I$,J)M5
M2'S@RE1H7AFHI9L4B2OXB-QT%ELGZ;BO_I)N?N."!9??GLC@A4-A2WX)++\G
M(DQO?.!*@5\@@9XQ78U$T20AF]1,)1+W<0CE*VT$F$->#PK(TAVE#D:>YXX2
M<%+W"BD8GG+1T^I*3Z_/HFV!^AK(M$5KA+=;Y4T::`2`XHG1#7(J>LER"#(7
M>^+2XBO:I-MH,VH\&8X31:RRW&VL9%,PH"`$AX^6W!`I;4KH?!=F2..:,SO3
M;GZG<5"_\Z/PO7@PVL7=;:"$MF]<;^F:<PQ-!W/3(NDV7=!M_&[D5^)W$<V^
ML8!X0,=OZE*03_+?7M$=I7.&MZ#<N'A==O:D`)\&7_:3="*XPE@(<4S,NCRS
M6$OQG/LK=C8F]DOBMCEQ5;B5%B"VR#[179O$;(D55UT\5)^^*4`2(PARY>5%
M?L\7:2;<?WM[RT/[)$4W'S^WOWW[VC'`S-X$$R<J8@:1.K30Y0KSG-&N_@GL
M_<_,CU]K:`\^1C917SPN]PE()4,O.D.0M[_AWCP;LZ<F26&8.UI*`$'[X?%K
M?F9L+D)@=FPQ0NJ/^[L6-;FBR`3N;6UJ-"*=?ZE"YF@>!:)979&]:S)5B=CO
MC0]"9$TV*RK)6B(<G@(N[[C+8`#*_($WQOJAGSB,*:M]<`3X<5"6VUFW^UK[
MIW0_Y`/<H0%JTF86"W5=4]Z%)P]JBFX<F[.(M&(1"&'NHB$G7,088!)SHL$4
M5V/"@ZBKYLQ><CLGGEW='*;P/E+\>LYH9V\J@B@Z96$31SH*Y!L=6YQ)2)XD
M7.!`SF#I(7/L]$9C].2482/?_QM/GO@57.D6@6]%L;(Y5'QR^2:,1%<O46B[
M^.*V1$=SPRTB?EZR..7M2@F)=]32W8-JZ3<!7K7LMC\M43SOP49-)K"JWWRZ
MAP6=5=OR@%#G.K!3>D"(#CY\*>G*+\P67FV!)8"YU"T^77$KN=S"7[G/$\[1
MY2'/7#2^^_KY!D`-'?@7@)T#_N"5<:LL6FGF;Z@%]GS\?)?3,R$P"(_(>>!?
M>P`//N2.!M\$7!,,#O5=HJLSA>>KGO32`1B,!7M<QTZ":>+J:3JE$3MJ/CI=
M_3DSA?\-+YAI3"E9[*K06>3B2M<U<\:,+RNY`RM'^W80XXJB6ZK%-9S*KQSI
M'+Y9EU1N/;OI3A=U%!(%+XT3/F@"/WE-:;C>S`1_DD6C^'2DPH1=$.LH"\(3
MF4A^#I@Y1$1"M)7]G$<M!7!FY/($`Z1,V79B8*7-P_ZI%D$T<(MM@G\?`(&2
M?8+''GPTJ2R)(V6M``:<!5.)YDEHO.QHB6MD]NB[CRPEH908FT1#\@.,=.:2
M6APFL_9RU@A'>J)`*[]$5]V7JR`(PRFOL.6+1"&6..>4ZDPX-I6\T)[@4W).
MC#!)'H0S9X$443:.<M-?=$EDBAUH$D<>7TS\:$8A(=,#A^[_J":KR$)P&'?4
MNKVC^<;O<L>V]S'>Y*K$1HG![QR\G=$L=9?%[Z`'04M_!I'GUQ<.BMS5Y(A1
M@I$/T&X$:5VX-@MOJIE:ZI%M2^:HS'$O#TO@/TQ90'2DI"0;8(Z1/!6_$X&6
M?P*-`_^[Z8)$F9H.)+C[IX[!XELO=RFPE%ZQH99-2XNVOJT$;CJ4S,4?X@6L
M13P',,,D#LC;JLKVJUF]A9X(MDEE\LYA)14IV6_0\I:S`K19SY@,A0S929>H
MA:OZ"?;U^*_,9T@&3!2Q:<W0K950YM,#`O:`1M('6J:!57Q0!C:3R&:+![B!
M2K#:!.O2L&[*1"WPEZ;+SP`_<+!:)6269R[9XY4Y773)E".C7(PL?ZDJQ<A(
M6LC,>O*$$V8*PTRH5?$ZA(Y+_-OLY;LB`$1=00N!3\,*JT+5TGBVDK.024;T
MT!I<6\E%]*&Z/KC"\XFSQ?Q/%DD*XYII-H=!LW*7"1.7@,&=>7X?N(M;"`KP
MM_BELB'F.J+Q3&YO15Z0FT3G'^"JR=-RQWOT'4N8&;HL.PM+>ATW?Y^R3J^%
MG1*'H5/3"?C\_&Q6P8[`(3LD&R$'%#ETU"/T>"&$AT,FSS41F'1.<0(@#HPI
M:\)VD%O@&L[0;M-%VV2@2'ZPK?3?X%'*0WQX%]6R;=,&&#M.TU%[;I9K,/0J
M^NDOXMA9DDML[R@@2X>P"N3X@PJX>%9&"<1Y2EX?BZ>`JDPD:B;">9WU1U89
M$O+<D+SCD0H2OU&;0C3B*EM7L8+;KALE^*WP.N]P^;13*Y13<$68-#"QYV!,
M!D,0@G9A//D+-W&`/]X'7!HF#:CU+5G!,*<[R+M'R\6)@1-CJRR*W2;7XR9.
M<<$QBG1;!=5(X65/$@L.1H0\%YTK&B/AO.44H!+^8!6M!.*67#_]"/@KQ&3?
M84=)&RK`5'D(#^_%_=O+DO66.RUIB4"Q$,N</=L`+5)1)&I0@@@9,92REK03
MR@&`0F$9FQ89C`(/4&BPJ<=@,&9X400W;?5-*T(9HS1>P#=2=&]T/LH7)GD1
MN_FK_8/ZJ_E\@7N,<`1Q>?16/B"B@KAU(5>T,RAQ1=.MFYF;ZQLNVDS@-YF%
M?E+COO_$J.\;QP\M!SDGGGRM)*7AY&2LA3GB!T52%84B;Y#/N>(>\^1C&`/^
M7CTXA8W.W.=[ZV7BS+8PZ>_?SL3'F)UOX?[ZVR?M"C,C0G\.9N0/QP,-XDY`
M?_%0]YO`_-MY-+-/??/1X;),[S7/FQ$[IC&Y]\;:7&V.2^84&?0/J/B`JR:1
M(<K3!SBLZ9X3<TBE_YQQPTT;A!]S;YR44W<SQS5!!RYFX)%;,QC##W&E>.@W
MTM$<&GW-7<X7,]B[F2$&(%P6_\WF#B;4@['`$`L:Z`=2G`$9^$5(-OMIAF>)
MMA.2;9J98>+HD>N09!`\^?CT'(BJH>)I)Q-PUI!W*O&D4U_76?B<RFIFN?0<
M5:9B*$5[Q,QA4''`,'G"8_+S(NF**XI2V0[+.2=Q-BSK%-<J\&RS`CV1>NCZ
M*(G(8):-$"]5B%#3$_LI`<(2(12PDLD"=I(<++TK<L;32S732^;-Z90.'"C6
M'<P3.RE-^(1WB!>S21V:A+)`8N_9(N*;TJX\'$B`6*TNX&D/,FI`P1N*SBB;
M#>%U`"""LK#ID))*"Y3V3FO/S;+K)HE-_3"@K0\-\(/.\^EY\)ASD&]STJ#O
M5<7Y>EI;^Z&GIV./**U91HR!Z^[R=8K%-K##B@YB>,2X[O^#@M!R)R8M\[>[
MMRO!:;:"D8CWY-RH-BQ,%'!8NZ.62%Y\`/WJB/V!<K2[UGJ5E`AWBYM4='<M
MB#Y``Q(5&"I',_(-0RH71/>*L>V=4\O)W@JVNS9SZQ:WP.KN6A!]$-X:M?&V
M&-O>.35/[:U@NS-OBQOC=L^H`8D*C,!VUT8&W>(FC-U=6W(<!-M>7=CVBMLD
M]<ZHE8X*S+Z\+6XYV=VUV/T0Z[;;KVW=%C?&[>Y:['X0;`>U85O<@*1[3@U(
MNN.M);DL$J`8KZ;8O2EV;XK=FV+WIMC]\HK=FW+SLR\W;Y]YO7E3R]W4<C>U
MW$TM]W%JN2L7<Y/%+*G/5NQN:HW.LFA;V:&=:]%V4[7=5&V??=7V2R_;YAN7
MBZ_;;@JWF\+MIG"[*=QN"K>/4+BMG(5<7'&*UI2G-.4I37G*AO*4ICZEJ4]I
MZE.:^I076I]2Y)-I5^_`-/'\83W)IDU>>9W7FDU1R]D7M>2^^PA_\._1B75^
M(F%T[%]>.:'?,_1AVS+M5])!YH_,00V`<OA5//'3VYMW__5C]B<^43KBVAGB
M<-,,O]_O-@/]V5[`\R43\+_P@3W&IY82X=H9^"/[4JD-@M%>,Z?MH`46WV5&
M^AS/&?5727[<EM;TQH_K1E2F>\<\G_;SZR;<1)G\C*N#RE\5O,O(B>%#]IU3
MU/X3MFF]=J?;[NC)QZZ>(R;?)>>Q@WG@^ZF#G@\6J63W@2&SKA_\QQ_?WO[?
M5[^"CZSW>L..,9)`I2_G$,C,)6;B.CT_/VC`('H':_O7%`<Y2OI;[B5P2#*O
M=/5T8EMY07ZK3"V_$O1;1U*]T^[TVWI'_?@6#1H+4%<N/YMS=@,*O?WFT_TG
MLBDGH'A*2$9GBGGQM`&,[Y@AY40<1O"HYSQ`_<NK.&P_F.;BIR*L7OT:_3T/
M?DIPXQ"L#+<BV5DX]A,(2?8M!"+_2JT"88!P\C4&'^&_7;U8(#YA-RGSV<J$
MBMY)Q$+P81NQ$/PZ&['X\UYN&.]A=P`_^/2(_.,#N-N6&4:-#&TY92%97_V:
M_%Q(WT:(.WHW%>)NH]M.)Q;=[<6B>T"QZ*5B`1\'[6[GXMQ*B<,V)!6X'HFD
M?[[!="X6AC=IT30MMIM@$D=Q>.M9E[W@2O`3:RZ/Y4G6W?D+2:$Z%KU_+UL\
MUNCC#'Z-8%07C&93V@A$1B#$Z>NS%8H,?HU@;"$8_KOG*Q02MT8@J@N$3&E[
MME*11;`1C>JB(7LM/5O1R"+8B$:A:-Q2#F,2:OLH"OI(0GYC'@M,]\:SU4+K
M1_:>WPY[V8*S!O$TQEB)`HUD;2U97T5F/!!62=U\.7)5`?]&J@JEZH[GW'X)
M1/&9#&1CT[K+%IPBS-)(=HI?(QB%@E&\I&[2-"O9I^:;?\=SF#[X`94,A&^6
MWY8+$8/CMQ*)//,D=>ZR):L6TL@@WCH"-:)Y0-%\%DJN3E%LM.(ZT:-SQ!=R
MP'>D,],U1^DW`2:EQ\_X\":#X.6LMM.+1A.L?XF"H7?5CTUL]I2BH7>WM-#J
M*P<0C1Y^[&-R:VEF5B,:1Q*-WC:B(7AV*-$PTGV#T39&)>8D8-\91B3?N'1!
MRH-(0OW('DSW/9'B6>4;K;,\Q:38)$U59K>9\U..HF>6X61LO_%`H3J4[/:>
M069A[[SV<CF2-IF%9['NSEQ(FLS"1C"J"T:36=@(1!.L:`2CR2QL!&)+@6A"
M%(UH-)F%C6B4BD:367BQF847+%E-9N'99A:>N50UF86-8!0*1I.^]7S3M\Y,
M],:IZ(U+W>O/+,9^IH_LY9[\Y4CP,D[\QMO+ZOAPLJIW,'M!^5@<8'[QA]0O
M\&R:Y&$[2<V\4K>D*FEZ>EL?-)'ODPG&#FEZR+&C"$9IY+M)N&D2;G:5W0.9
MWWZ:>]R_U(2;_O99N_T#>M^K)&T2;DZ_[IZ/D/SYV<1K"[Y,12Q.1"OI6L)O
M_K<91GX=?M_'E^E7MHAAFVV&[`[W.<BVKW1M1R-PN_42+2"^F'5'%C2KH7`U
M-.EGC6!4%XPF_:P1B&83W@A&!<%HTL\:@6C2SQK1J"`:3?I9(QI-^MFEII]=
MMF0UZ6?GF7YV_E+5I)\U@E$H&$WZV3--/SM_T4N4_?M_QX`A7O7J>_!G*,*Z
M5CR/*7I.-,:?`S9#ICTR;BTN6]S6HI_:O,IT:*1L%RFS;3HH,MT[T[%OO;?F
MPHE,]V5(UCK<&VG:09K@S[GOW4>^]?>+D*`5?!NIV4%JOC*\SYW9[\W`<[R'
M"S_)K"@ZQ4@W\E,H/W^8@6-.7##W$0M8&+U'1!T&;N=;UPQ#X*$E\@K>IQF#
M=S?OWEZX1[X+WL(!5[!OA$J`HP_4CQ^!E`]$OK=F*/O,3IR(IZC\RXEFWV;L
M=P^\S"`$"GR9O@G@C7#VUL?T3">YGCB>A.S?,2[X1_B_9$N8^_ZR!7&55FE6
MT;84VR2.6RG;8N(KUQ@7<>%T"R)-MJZX(`Z6GPUC=^&_RL>+S'%%P+<DJ?K*
M@4G:Y+B>18[K,Q&2/[E'*9V!VS",F?TEP'_125#"D6)?,C/A.?X8Z,&_&$;N
M"A(O&Q'<S?A498<`91>F-"OF9"L&W1D_C@2/+GQ3>L&+I)`/S;K8;UU\,)W@
M#].-@0$W8<@BVD[2HQ\<SXG81_#A;6":Z3TXP"9ZIED".RZ!4F*GVY2-5&\$
M7H[=4P-#-T]F8*?7BW$F4CSVRP(Y+*CW[/WP#!VR(KU*C3IE^V(V`-O>1'#(
M2%1>BI^[=#9"LI.0&'WEXX5&9XS^UM8C?>7`),U9C]\]FP5/`=CA(*,N+W75
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M3:=+]RVDKE*16$CF4XGT<'N1/L2M5P[*<0>7B]X<\AY>"AP/>`WOIT1/<!>_
MU,7085OO-6=Q1V8H$OV@#/V*FP,1$/CNS.490DU!!OG0^^\1I_EERTE"K-0&
M9*A6I^VI,[11PH9G)M)&NS,"FU:LH[Z9+NQP@3KF@L618SW?6$()IB=@MF#(
M09C=)1]^M"DB5>P?@[,8,#-DW_S[>+'PP55*5]B=:UYZNOBQ`TTE;C)-6)'4
M)Y!.(4&'DLY!V]#__,UT/%2^#NALSZ)V/_R")=[6"/?!SB/[$D=XDO9EFO9F
MJ=4*W[C>TC7G'QV+KG1Z"!B]>]E"OI:TJ7W>2.-SM=EKF7::Y8(B?:#E`K:B
MJU]$D4:&)`3V04C2:W>,ME%FWYJ;5E_D3:N*[`GY.)3L=2]P.0JP#T627MLP
MFOC'D64<B7Y"AF[8/]AX8`H."%AQ>/"!??$N/*7K''<.I41^?A)Y,96J69*H
M&2B'($F3"G<B63\D8\>EZ?J?68RMTQ[9R_5J<R1X"=[L^'"RIG<PX:+L3/V]
M!U,Y#\Q[YN*V_A@]1X47('$D%0>5N.+3[Q>_97]Q._4325JS+;U(AE)'^Z88
M_C2,59NTU\_8TF+V)I[;Q'-)/@XE>T:I[+U=1G[X<N5-0?\ER)AQ6!F[P#.#
M0Q[AT=B-+3^=K)^"L8W7_;P8VI1K/0?6*IW;DX__!!ICNL[R(R;K\)[Y\K=;
M;Q%'(?V@7S;GJV&N-+`O)T$C&WG"&(UL&(UL%,M&MY&-[K.6C?5WX3:WOI_I
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MPPP<S,B5B;SO$5"Z:XP2&X`'%ETE]F5*O_"NB7<W[]Y>N(.X"]["@52P?WY"
M,;S,)(;A?L>B\AO\?_CS_P=02P,$%`````@`[X0'1P38"9YL"0``:WD``!4`
M'`!T:VUR+3(P,34P-C,P7V-A;"YX;6Q55`D``X$7Q56!%\55=7@+``$$)0X`
M``0Y`0``Y5W=<]NX$7_O3/\'5?=,2XJ;ZR43Y\:QG8QG?+%'MMM[NX'(E<6&
M!%0`E*7^]5V`E"W;!`F2$H&;OOB#V@7W!^PW0.K3K^LT&:R`BYC1D^'D:#P<
M``U9%-.'D^'];7!Z>W9Y.?SU\Z>_!<$WH,")A&@PVPSN%AF-@)^S%`:_?YE>
M#8+!^)>/X^.;WP;W=V>#=^/)^V#\2S#^1Q!\_I3$],=']6-&!`SPEE3H?T^&
M"RF7'T>CQ\?'H_6,)T>,/XS>C<?'HRWUL"!7GT;RB6&7^/TH__")],W0C\>:
M=O+APX>1_O2)5,1EA#CH9/3[;U>WX0)2$L142$)#)8N(/PI]\8J%1.I)JX4P
M,%*H_X(M6:`N!9-WP?'D:"VBX>>__F4PR*>.LP2F,!^HW_?3RQ?WE/`CC3E9
M+@A/CT*6CM34CW\^'H\4]0@EEY`"E0%E$N\1$"%`BH#0".],9G$2RQA$D`(1
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M:PIAQCEJF@%50VX'\!A]N`.>[DR_"8J9LG^Q_T4X)RC!=R9O0<H$R"R!2ZJL
MPE[EV@U2!78G.)WR<,`X.IZ3(294CQ`_+&217>7C$!Z^B5HO4X."8B2R--5C
M!C$&K2W_G+.TB8-GG7T(RF.%=^(;WEK5M476QTHV=1EL/PKMT^)VF(+.N8#M
M/+SS3<F;!-!GD)]&95GUONN.D&%B3`7FT?B78$D<J1HRF)%$U52!6(!*OC-*
ML@AG([(O-5H.W%MUT4F^7@N*,&09JLX-V2BG@=$!K_`,HAU;/$.S0U"F$J/Y
M"/WG#5LAT8<`QCV4\SM(.UQ5+$Z`9*G25(C.8<DAC+72XM\):$^%TY\R+N/_
MZNLWG"V!R\T-ZIW$SU387Z:5H/<ZO-,)NI8+X!@0$,<"C3%>84Q$HX4K)@2N
MY?7\CJSKYZ')*`[@1NA`<"5(<D/B2,7\92Q)8H)53>U`?!WI*IL7KH6K\1)E
M-'^*ILIW1L-*:'L9TY=&RZD\PR1Y@\+K!*E1D\7`ZP`:2U-&;R4+?U2B,)#U
M+_`YS`'5(9K""F@&U:943>Q<^%I[J:5W!P%#U$XV9HVDCJU_0-\8BQ[CQ!3?
M7G_LH@>J<@.<.-A)'(VMSPI:%Z)+0A]BE</KH(;)S<4Z3#*U(5@S[TU8G;9R
MZ]NU7HB),4B[[P5+,,8*%8N,NR"V;$X!57M^GRK%/VEC_(;#$E/ZB_52M1U0
M$7398I/!-N!T`<M08'[C6'X9$=DP>00&W653*#LL_0.9JFUP"M$%X10]O'C1
M-9C'86R"8\_8/ZC;!>/2SO*K2!T(;ALI?(H-]Q0]?J*2Y6WB4^.FZAG<[4:B
M84[5EH"XSJ0Z+A29-X9M6'S>:7P]YZQ#(/%IZZD6G46R[M\64@6>>A]F"^?8
M!S@M.C>V^/[N`SY;]V<+ZKT/H.RW6%ILU`<'PV65E+V$>8!-%9^\9],9:9*A
M^W1&X]6.Q"&.FO07[$I5M7NT[B^ZE8?IIITH_\)<&:YNLO<7PAI9^YLBUB=;
MKVA*E1R]JL_G?7(`=MAL-F1\\@IVJ%J?5_%4.2U6SK1SXZE*EL;7/2U.SWI8
MM3AVNVL^A:<:8'L\,."3K56TS7;`-VUM^F1[=@BM#@_Y9(=VL*I/2_AD?I;+
MU.7HFD]V9[VQ61XF_#6W-L#J>O>>G.Q^(A`!FP<J[=<2Y`]8AKN:&"2HA'L\
M^MWYSJ[/AN\)0)^'QTL"_FF(RBETG)B"=D)G3!@WTIH/X.30W6O_67-XV(+#
M!0PJ.0E5LU77!$;9R\E<G%U[;I4:A"TCZ5_0IZ=NKI<ZY5T03'C%)7VZ_@T3
M0Q5R)P88S0=P`))Q#(LTK[W"S1TG5*":H+A*N"\PQ\_-%M&0V\&Y0OU^BT0U
M`Z(TIK&0RONNH-C,-,"RY'+Y)';N?BZI!(Y7##CJR%T<'0O5#-8X*P-5_^*B
M>W_.K`W"EM+T+^IUGEC0AT))3>(:Z1R*7#O'%90.Q*ZHOLP.$9V)_J^H3*)_
M9[EEUN0<A[V9BR-F`K"F47OZYVC="=,;!M7NV(K'!13MG4PZ^_IC/T__O)&2
M6;IAGPKO*A#5B:]/?1&S9V8VJ;%/"V(%I5&6Y5/_T0I=`Z?E4R_2"EO;\MY+
M:RM)*5B=%V]A:X<[MF2)I";Q\VEMRE/J,BRF?-`G9UB+QJY,\\D#UD)JU1CP
MR0_6(VS9W/')SFP:FJS?6L0GPVTX/16-`"]W<4(B%L$\88\'VZVIN(-?NS*U
M@O:Y^Z*/O*MTBD/T%15R)[4R-??K.7QY7\,-\)A%:"<<B(!SR']7X6HX1/]`
M+^9S"-$M7*Q#'02FJ%G7M%QV`]`V0SCIABI9;CA;Q6@+7S;W:%88\;`$H"$F
M8Z?H[U=5CV,W'\`;D'F.U@%DQ0#>@'Q*J]N"K!C`P6.Y9)._/8]QE#,$B(1R
MCO6/@=HSN@-UQPJ'W_1-8,T'</)`]?.L"Y&I=^M=SW<.=)FPV?*YA:1%R<L&
M<;$&'L;B.=^H@%3)YQ92<5Q^*U7%$_RU+'[VR5MX]==/,=HD:%XUEKIA;NMH
M6O0Y?)\"VT#B4V^@1:[&6KLMGZK^_0&O]G">]?/VA-DB[/JDY:TJ3-:]HO%)
MX0\T![4%CT\&<*`YJ*V'?&IY=YV#]DV,OMNC^CN"W@>D>&(P6.:/#.H3V21_
M:/#%MP:U^\:D]C?H]\N2NLIIUQM].UWJRA]/SVCJHR9?`?0%DKRN(.R(FQ1!
MU0*5;]]7"%7-X.[-Z/\G+X`OA+SC)*IY':T%AQ,8:F8Q?LQ!"/TP'JIW_0)9
M,#EHB*/?8AN`XB"(M<)9\SDXMZR"'@9!%")>0:$Z-2^_M&!Q='BUJ2>P8_*S
M<=/&BYG?*F#V%CYE]"TQ-PUG/B7P'9>YB8;[E+-WA&WOHVQ!]_)&FFZ@&X89
M6^2]O'FMNV'7)<^V<'_V%VZ;_,BB!"T^4#_4=_OBE?\!4$L#!!0````(`.^$
M!T>T]HIU1CX``&_X!``5`!P`=&MM<BTR,#$U,#8S,%]D968N>&UL550)``.!
M%\55@1?%575X"P`!!"4.```$.0$``.U]6Y/C-K+F^T;L?^CU/LOM=MMCS\3,
M.5%7GXKI+M565=OG/$U0)"1Q3!$R+]4M__H%2.I2$@$D2!!(JO%B5XNXY)>X
M928R$W__SR^KY,T+R?*8IO_XYMVWWWWSAJ0AC>)T\8]O/CU-+IZN[NZ^^<__
M^/O_F4Q^(2G)@H)$;V:;-\_+,HU(=DU7Y,U_7SY^>#-Y\]W/?_ON_</'-Y^>
MK]Y\_]V['R??_3SY[J?)Y#_^GL3I[W_C_YD%.7G#NDSSZI__^&99%.N_O7W[
M^?/G;[_,LN1;FBW>?O_==^_?;DM_TQ3G7Z-B5^&P\(]OZX^[HB=-?WY?E7WW
MU[_^]6WU=5<TC]L*LD;?O?WOCQ^>PB59!9,XS8L@#3DM>?RWO/KQ`PV#HF*:
M$L(;80G^K\FVV(3_-'GW_>3]NV^_Y-$W__&__]>;-S7K@BS,:$(>R?Q-\^>G
MQ[M37L1I\3:*5V^;,F^#)&$D5RTL,S(7DKIE(*?@1][W_SVH66S6Y!_?Y/%J
MG9!OWO8G*J*K($XG*[*:D:PC>:UM&"<T7I&4KXM)W5U76@7-F"9WR=K+PG)&
M)KL>.U(L:6E`'I-Y4"9%?R:_;D=(\);:8U)Y7P7Y?15GP7H99*MO0[IZRW>S
M[_[R_KNW%=%L,R@(ZZ^8I+0@DQ\G01C2,BWRR3K8!+.$3((TXC]F)8G8\@YF
M<1(7,<E?@RM^7V63;<L5BMX-"]$RKL1IS/>K#^R?36D.QBKNFCSRI2#LZ&@V
MN"V%"0W;AKX:]GF0SZJQ+_/)(@C6%5UO25+DVU\F]7GSKMD[_V_S\[\N&@H?
M:@(OTNBB)N_#GKKK.`\3FI<9>6:D73)"?M\2G`0SDOSC&T.MU?`3?G#0K!F>
M8>&W$',QRXLL"`L!1$`-^S">0I(&64P_I?F:A/$\)M'UJ[WT"(2R_(@AM&]P
M5J%LMP&VE9`[]F<NPB`LZ)#H+6,OOL1*NMO*.B3]F6\Z*II?%9(1NS\2+K+P
M#<V8,/^/;YCX7Q^M?^.[`(G8*<7VMVUSS:G=2Q:99W2E))MJ#0;KU2(VH:@A
M0-9*-^V\TH%@WQD'^VJW,HW5[(`V/]*T8&?835*1QL0BLN!_://@0!<2P#[=
MW]HF<,O*M#R8;5I3%TA@(<'RRE3C@U!.#0M\>R;\_6V+,&Y:)XEH6%9_<&&<
M_3\N-I,XG=-L5=DKX#H(L"%;.H<6.?HZ1D[";Q?TY6U$8D["#_P/SID?#DYD
M]M._+A@-$:?C-@D61X>Q\'M7H0%*U%699;Q+-A6#Y'](D-VDT35C7`M]JJ)#
MDWK=#&--P`-AIT%TRWX[%L9`9>T2R[D%(_6DI"U":QZ)1U]:SA:1SZP?"6V'
MGX<FZ:;:1ZY8KUF0W+$=X\L_R::%-FDY2T32U8JF3P4[7Y[89DGR:5EPLS0W
MU8LI!E2R1'Z][SR2-<T*UCN7-%I7$J2X'9)OXX1D5VR!+&@FGA2MI>P0^$@6
M,1=>TN(^6+4M*5DQ.R3^2A,F0`59S2;Q>`O*V2'R-Y(D_TSIY_2)!#E-2727
MY^5>A#PA5E%^Q-:E,X#@#63>0.8-9-Y`Y@UDWD!FVT`&D[F`H+Y'!TJJ_P!1
MO4>$"F8+`0+[`1$PI68"Q/0C.DP0O1`([B_HP$F5(""JG]"A`FE+0'0_HT,'
MM[``(?X5$42Q20YZ,-N[VH&CD1@_H;`P"1P@TS,4&":A`VC^AT+#)'E(;HDL
M7Q<R)2!B&@R)^%\Y3>*(>WA/9D'"/9XG^9*0(I^4:5!&,?^P#OCYNR1%S,9$
MPZ/13#^V+AM-4FO3W_'@-+JG#T'V:Y"4(HN(M*Q]*\[)07I1%DN:Q7\RSBD!
MB&H@@%%).V`(KTLC(%]\RZ139<3VY#.`X$WBWB0NH]F;Q+U)W)O$O4E\2)]1
MD*0S,LNXO@0T,B.YAJHP,BNYM@Z!0RW?%Z!S]@]&]9(FC+'YA/Q1<H_8P13U
MWCT[5MT-T6\U>#&**K8$R4,01W?I5;".BR#Y^&K2'X<H0NK8ET<OHG^7><'9
MGS]3`8W5(JQ/!?Y?;FBYHGDADKA--&F?$3?59&.[SIJFC'2I/B<M.T+2$:FA
M1_3E$,U.5L=KU%XMA:NEZIF$+G!*OA?13@<0;AU<.DBTTU:'6@_OA=?KXF/2
MQ<V)3I:UHBKOR+M)&A1E1K@@/RMS!C3/JZ#`>5G_O.99JA@%NOE6]!NVFF^E
M*WDV598S23AR7S%Z.I^>L/2(>G'!$5\7G0$$1*K&*.5S?^,U4M7"WWCAE[3]
MC==7(65_-5E25$*0"R7A^TD>+U*V=L*`IPRI\[C$Z6*RIDD<ZN=B!+=G5270
MI`JF"9SR@O_RKV>2K:[)FN9QT7H#(2_D<Q]VA'&7OI!:5^=.^!)Y3%S0-=%-
M"%+\9[4Y2*^OX!7/"A0"=<4KCYB4Q_VN?K';U!^:/5V5I5:OLM>,O69\SIJQ
MZEA$)WQK'($4)G6AU/PEXR(</?C1:5=E](8<;\@9WI!C%:.IY>E-5MYDA=!D
MU45&=F'&>L]`9PMVRGV.B^4DR&9EP2#,8EK5YR\3A1.>`I=DR69"TY!FY/57
M33.7L?ZLFL$,4]W+3'91]WZ7AF(KF:B,CFX@[[[RWIBN*V.LD@YQ80,$-0[V
M!R$?3^7LWR0LGNDC69=9N`QR\I#1ES@7V5%ZMS,(C-_87*-ET5`AX;)F50/$
M/I*$^[P_T^<EN?FRCFNK_'3>PJC'>+&4$=^S*0-@6H993*ZRL`/7]\]!%BEL
MMZUE[)-ZV7@5781_E&Q(J\.<_YD1(K6D@>N=$23W1L(V$L533%':'?EL>YS%
M:;6MP%_BTJOL-(V"]&I`6,[?E_6*4KEC&B([;HOZO)UFE0LKT](N-XJ=6+<Z
M-H"</D!D#KSZV0)TOX'?!G$=27N1YX1+3@%?2]$T?21AF65,([T,\CC_E-)9
M3K(73OY=NBX+]IDI,7$25_O>Y::J?I4$>2YES-#=>09V[`[13#PD3K)+*LL[
M@,"M"N1#_$(BMO:#=!'S!YN:@9*<P.!Z+AP.V!X6K^K$=U7PQ3TM+A).`J-1
M.E5UJIX=,/?K:>L1QS1F'HHN64F2DNX\*&YI1L(@;_?S@A4>L?O'&4!POP(J
M<Q<[#DG$(P79U`[JJX&,[;"5Y3:_W.S+/`0;_EME!MG;0M+H(0E2GC]=SH4!
MN_*,T^P*P<SS[D7>O<B:OP;(K(;NMA1NL*6@*RN4+BFJH5&,(L#:Z[V,+,Y9
MM;Q&]2Z!4$Y:QWY4AC+K&9RJW0RRZ&:OMMF5]KD]1CFUM4<2/`M41EUTWE@&
M9X.N%X3=C6`@7@"OSX!8#67;-+CI*:U"Z/8W+8,C->E<@G*ODPT@-6'-1+>E
M@<0S'=LA$*&AA+(&%Z_$F0?=LAW4=D;UW`Q1+N3VP:3#<K#7DC?T9I_!!0&\
M+42W.`:_,#_DD=XU),JUHA[GMDEAY3(=8XC-UQ!&Y&3[Q,\6DZ9)_&AM*/[X
MN8!B=\3/)H.:D]DCT\<>^MC#=GR:L8==?-==Q![^,`EID@0SVB3UXN]I5*#J
MK+-)'/+EG"XFP8(=1M59O24:&&W8HP>K\86]Z>P749BDFR18?:AZ(1?;+B1A
M?9`*!B*S+C\^B8DX^6@D"*]F^PUGIRI<4%K4(#$?:51%$O.9\4QORS1Z7A(N
MS`;IYI9FS__\>#.C2?!+R19]<'=__53.5G'.26J..&GHX#!]&(!_S697E@9B
MVEL+F.B87DLZ/?YHH,.[-,R8_$6>Z5.Y7M.LN"8O)*%KOJ:XXB$9/\VJ!HF-
M^"1A6Q*;'>SX79!I*HF:!%<R0.#'(/LCGE$Q,:T%3'3,-NX@+60]MY8PT/7#
MQ?65I-^6SP8Z?0X2MEDL"3OE2%G$H62:*HHZB)D]T/^9>G]/TV#_RS/[*V>;
MHC"VO6<K7PE<]YZ:E5ZZ.]>F\U^#+*XUV5K;OTD+IOM+75B[-''V0!&,[%Y<
M?B$'\Q(>X-NA!1<P2\[^=9`5&VY^E#CMRHKZ6-^.,'YADYV+R$QD(2G/W'.Y
MJ<U'DH$`U7$-I2%)NB,`:HP<AOM][&/P)5Z5*^FQVUK&/JD///LCVRNG91'2
M%9G./[!_+M3)B<'U[$-ZY)N^9"F??'=$HI2_+260D^E^V>W]OW;&J^/S4[JG
M:-<_8X@81C,G`:.5Z20'YH\#F6YKY7JF#R3C>=IN:38MF#J:*]-U&&U[5*Q1
MYL$PVK9GS4G;[A>6CWA&%?'LXT[/(>YT&&+YMC&='^PP$CY+R]HGO=725.G-
MQS:IV@8E0=:GJ3.(%>X/'YWK0R?[*U7=>Z#T;NTU>M2D)7>T8<=J(RBZ":ZO
M2E*Y`P3*N2T=&&I,ZT3GF=9]="7>#>@B+'N@;'>GL(O0YST`YCWHY&V"<C\Z
MD]=DAAA<H(\.$"F^T&>`]H-NB79U--E']0_IYH=RA<N'F7;F;:]UCR^66'#%
MA6X%M-UR'<"0W)&BG)VG;#\>$P.S#5^@[@"W*?AFJM%KD>,=7.INCG.J&QUS
M,Y/)4#X?0\+-H!J6S.<8G;0ZS-K1"%<!<N0OZ'96#:\S=#LFQ-'L`*JF0Q'*
M31$V7,+Q!7BQV95(!]W"0-$#"(UB0^QEDN`5R[NY3T&A*<OC1V+<2H\?LHM+
M-_Q<&<IX@A^YR8,9/UK<NIE9.<ZGU_#I-=KQ::;7Z!PYM@=N+\?&7R:LBX#M
M9.EB2PPP=T9+3:LY,83]]\IU\8G5S#YG,3N5E:]7J\HZB.,=SU._9Q(!Z%V@
M4;E`C_OM(L^XCETAF'G>^=X[WXN)96?5DB9,7,CK?)+W3(*!YR+0KG\&ONH^
MB?F191<F;:*\S1A?#G-\KNOX/$>_*D]*?YOA<BU[2Y^W]"&T]'64RUS8^7[B
M*6/9KE-L,\C2^23,2!07DRS.=P0";7_`UJS:`[5H@MD(327I.B#KD9&BDX0,
M7M6;\%S;O\X`@C>D>$.*$4/*2*P,7JO"KW$XTJJ\^N#5AZ$=!72E.Q>:P\_5
M8Q,[?Z?JP0E6:147E3*OJ3D`6[.J.6C1I*\YY"3\=D%?WD8DYG3\P/_@//KA
MX#1F/_VKS06P.8=%G[N*"P.09$IRA)+V@2R"Y-3G\H`Z00D=PD0/HF2SN%FV
M_"WTYR7YE,8O),M95]/Y9<;F9[Z\HDFYFL62!RIZ-&,&!'\4]2X-I12VEC'2
M?5B462EQKVDO8:#K2\Y1DBTD;\>TEC#0]=6FH++G5DX_&^CT.B-?2'*11FK@
MBJ(&B+E)`[8DV58K)D)0Q$#G'YEX*'LRINV[F6[=/#ER3TK^?OF+Y.D501'[
MBN@E])W)(]T47.^,(+DWT[21*+9Y*$K;)_]J+]ZQS>Z50[^.=;9+(R[`^E<B
M7!J8]_&G5T$NX[ZXH&NB3X,NI*2+8C1&",#]5ON0T:@,BVGV1+*7.)1-(%E1
M9X3SS;&A)Y<.@;+\B"&XGT;^38-S>M-@:^N^I1D)@[S],598X1%?5YX!!`13
MR=^XGL.-ZT#$EK.<_%$R0FY>3G+B'-,L*^N<=$58G*(T"O+E.XRJ_(@AZ&R2
MR#T/E#<3:&XUA9=.%'0[@,IO0L9U"KW,&FWLP->5]EYR<X%J3H)&QWKN>WPY
MT]5&#72S5VW),)>OR^YDE0[&Z:!!#2'H7)5Z)-04WB$"0>)+B8[/2])08GL=
M`PG*Y>C8#W0,3XC(W$B`,/&E95?=%*%;CLK[H0.EHI]3%,IU*ADOX:BJU%\@
M4'Q9WD&F%G0S6&U?$4,<S3Q5#8U\%`W,5GR9LT&^*^AF*]PK:KOQ2KWN4$Y6
MU<@H!A'@46578A_V)36(9Z==>6A0O%*_1KM'YZ`XA2[#F$*Y-,VO>(&8T[OP
M8^QMZL$/\2M,:&[RT,2/MI_>A1^?"7G=K*3GHV-]=&P[/NWHV.[>]7OL5N)D
M\WB15F\[L+^#,.0G`Z-ULJ9)7`64;O_8$JF.E=5MT5:\;#>Z;&;;N=A1]=#0
MH@@94%=P$%T3Y'$^G1^1MJG_JPI+T:OL+G2(+?!9G-;)FFKB1("4%5S$U*0Y
M(R&JJ(&-"Z2*?2`W09:R.9(_D*S*R@?#`JQE'\YM$&>_!DG)U/Z`'Q!\U])9
M/-KU'4"D&6';\%699?Q%F<-7=-A!6?TS.5PD2LA]V[//@E\HC3['"3=GW:5%
MD"YB)MY=Y#DI@)CU&[`/\IY\/MC#,YJR/\,Z@Z;.C.[:C(-@F]>$*,YM1>D1
MAP2<`00?U>"C&F0T^SQR0^OCH_`?^AIL]MY2YLA2!A(0T%G)5%13?<L%.HP`
MPFD_>P:Z*:L'&6XJ0.>HJ3FV0-,..D<,/9A=U4UT_AAZL+6L1.A\,O2P=C0<
MV76+,X_:C.T(R(6?D'*AGXG%\F55E?+T>^5-3L'E0-WLKKK-6DWSVHVX7J_)
M7BWYHS?Y7;K;':;SWZH7T(N\$K1%QKN.M1W:V^O3K-G\HFGZ2$*V*3#V5N(;
MV.RNV<R(361G``&!E2]<DJA,V,)H?U*J>J&G>2Z/SZ_Z+:H\+U?U;])%.&PG
MWB3J3:*=3*+#$`M:"?HSV=MOO?W6VV^]_;8#)-EF@\ZD*2"VS4#02<1%-X9B
MP+UT%W3V3/7`#BD>NK`-O&?\R!8DFWR.B^4DJ),\368QK>H'DS@-)W.:L4+)
M9D+3D&;DZ&LGVX'I;JW:%H8AWJ;?;$NPQT/&$V*L@KN4DUY-6Z7O:;=61JP#
MGP$$3&I\RP3*+S<'_X(KZ_I-N01^ES;[$OD0OY"3:Z(F\"JZR!^"K-B#.[@X
M@W-F@+Z\-<-;,[PUPULSO#7#6S.\->/\K1G]Q2QTXZ@#>C`):H3VCUXZGPL#
MQP^3D"9,%J!UFKF\>OZ5^W;43[\F<<CW[W0Q";;)'CJZ0_3OR*H1PQ2Y-LT6
MUV1.,K;2'LD+24O"-AYN8UQ4U,%?<NO8RHAU_C.`@,EL<;5?."_D8/)P+[A[
M;N]K_WSH+Z?IBC!8CUZ3]YJ\U^2])N\U>:_)>TW^:]+D!Q8IT`VWFC>]]`(7
MJNV/6[_V?+(.-AQ?I;JQ'QD/N0H7S.*$D=#5P;]S^U85V9Y4VM1?O4*'4Z%K
MXGGRAWK^L!WPHIX]'_:31U-CZ]ZD5\F\2N95,J^2>97,JV1>)?N:5+*^,H,+
M'>3=)`T*IA9-Z'PR:^X&*_E[7M8_LZVXN6"*2!'$"9/"&?5EL)O50&6D?T=6
MM1)3Y/:*2/YMR;3XS?1S2B*>$#R.8K;]D6,I"5)TQ(K&&4!`H"MY%>$<5`0O
M=7NIVTO=7NK6@`27#ER(G^HT+_VDSL[M(TMV,YR,^9&+N=5SK7?I"\GK-SS:
M)$QI09T35D#(,\E6UV1-\_CH!<Y#(H2%#!`@6"1W:9B4$7<;O8W3(`WC(-FM
M.!U1'-2.?4GE@LVT*$Y*?D_XQ(.;*S7UYDM-["W;::[H:ET6E;(SG1]GB;M8
M\;DJ$'",MHWB[8O=RS8%S_H81XT2N%7P-1[%@+9D'_9^>1^_4'6$2ES0-=%7
M;%TM:!;_6?&T=3O1KWA6H-RKI!]HNN#;N?C8`90<L5'@#""XGT3>KN'M&O;L
M&JH##]WMA<;A1F$2-DJ[C61<A*,'/Q3M*OS>#.?-<,.;X:QB-+4\O<%Q[`9'
M#1L(NMA:V$`.8/(`<L+><PJ`\0<8"X&P[#V7`!M@I3(*Q&7O:008KMXF*A?7
M!_TSN?6[7ABL_Y'EPQON>N*BIH8='.)+`5$9`W<"3=.'62&5=(@+&R"H)7\#
M/U"8%%:MS9LO_$^VNA(VPM$S_97M46P)-]DN6Z\KS+0X#+0;]E>QN6,B&NNJ
MN,OSDD33C/^?BTG;!*WQ@HD9%T61Q8S_51X/FA>O]K$3.$!&#-Z_0;8=='@1
MAB1I=NO#1*<MA##!X_^505:TSVC3;1N$&_0?I8P<X'HBV4L<DNK1IUI8V^:#
M>:9%D#R46;AD.!\R5DC&*@QT&6`SHV#%.J_6>$TYD^/_3<+BF3Z2]:Y3^A+G
MHLN(WNT,`N,W=L;1LFBHD.SFFE4-$+O;8Y^7A"VA>+O(6ACU&"^6,N)[-F4`
M3'4*[KNK>]F3\LC($Y])VI5-$'PZ+\7\519V<)&?5+VQ!2;;DT4W]5J5'8#C
MN;D5U]&M9=QY#1R($4V&,2*]90/7.R-([B\0VT@43S%%:13D:T@=<)0=&D7(
MC/R8\/N2[]E;7:;^VI4I6HVC8`Z3ST.2%L&"3.>_4J[5[;!L<R+"F:'1&`KP
M]1NG+=*\5AT43FD'%#9RWQ530%5[&+P!%"!?F2"K+"9UMH]W<)C*)E``;4G'
MN;TEF&8?:%Z]KET?HD]QRC3#_>!=LZ&["`\M<&JF&.T.*P.;E#"#<ZY#/RA8
M]DA"NDCC/TET%[%-/)['P6EZW/0PCK5Z$N<PEZ[&=F.R-_OL:^P"7$.]"M9Q
M$23U`?](<I*]D(C-B=LJ1K22`U+A^=*Y':>0I6ZGPG).208(=XK2",B?ED7.
M)G_$]F4HAI8J]H'(%8?+C4*GUZV.#2"G3ZHBZU8_6X#N30'`-_\^I73&=VA.
M_EVZ+@M^G*4A.ZFJP^UR4U6_2H(\ES)FZ.X\`SMVAVLF;A\>Y";8D&EFU_$+
MTV'2B-O``8R!5,<%D#O7=`!V6`T7H%\I4ZDKAYF.8];>``Z0CW'^^RU3=+8;
MO"9$676'``\W!8ETHBSO$$*UU>4\[RGW*(0,B[B&`QCBYUJD&@BXGGU(OU`:
M?8X3D8'A^+.+:$.V!N/5`_L/K0V`][2H+P89$Z5'L4[5LP/F7EZXKU)53>?-
M-:UDQY*4=!>'>$LS$@9Y>]@_K/"(@RC/`(+[%=#NMG"8%OURT_[@]]YK((T>
MDB"]#U;R+6'(KCSC-+M",/-\!/(Y1"`/12P-?Z]M7M<EMTC4@D1MGSU\@U&(
M0[,^&HBUHM<9H;#Z&421@YR(T(62P]W3*"@L`V7DL6IH%*,(\&WSP>06YZQ:
MYJ9Z_KPH)ZWC<'E#$;@&IVJW2T-TLU?[:I#VB5Q`.;6U1Q(\"U07C^B"[@W.
M!MT(''2A^%UXT>(FT0.KH6![@YN>TK*';G_3,AI3DX%-*/<ZV0!2/:Z-9$L#
MB6<Z]E^[*24,+EY)Z!*Z93NH_?-(=U2%TJ-<R.V#28?E8*\E;R@7B<$%`;Q9
M1[<X!G?J.N21WETWRK6B'N>V26'%X0MC)K6O(5N<D^T3/UM,FB;QH[6A^./G
M`HK=$3^;#&I.9H],GV+2>LXZDT%YZ.Q>,*Z`@IGLVKF,CWB?P'.[5H(A)SLH
M;MNN#F@,;D?7!R#:OXP#K<(-`@CV)V1@ATBE`63%S_A9(4HR`43X5_P(.R>3
M@8HI%HVA(!YTBWR!HL4FE74-98+BQ29O=0NW@Z+%)H'IQ>!!46(1MI"F\H2R
M$8L0YSB?+I1=V*3`+ED8H5BQ"($#YA6&L@*;$`C/W`%%B$4([)/,%6I]P2;L
M]<SK`X6-1>HSGD,>R@!L8F#+G@9,.`=%C$T4;$%L/K47E#E8),@3.5D55@\%
MB$6VVY9J#UB'HL$F>L&N$OIF1MQSQ]X;.3],0IHDP8S6VU`^X?=161`6^82)
M&).$*1MLETH7DV#!D%3WYSU?Q3'88\TV2^_@&*>[W\LW8<A61'35T-#<8NUO
M.[9=O7J!!EC'0+K\BR3=),'J0\44<K'EB.1U'$@%$X2MUQG]$K,%2VK/P=J4
MWDJ2O*@!8BX_/HDY<O+10(=7^QG\0@Y\8EJR*H'+&R&KGI$W?$6H7@R1%C5(
MS$<:,0$EK*4S>ENFT?.2VVO60;IA.__S/S_>S&@2_%*RDR&XN[]^*F>K.,_W
M`JWT]9!A^C``_YJMP"P-Q+2W%C#1,;V6='K\T4"'-\W^J]H'9.4,D'&7AAEA
MFN\S?2K7:YH5UVQ?3NB:KS/NAB:91II5#1(;\;G*#CLV29^JR_54\AP*N)(!
M`C\&V1_QC(J):2U@I&-V5)2K!R8J,,TF2"J%CBUQ-F4J0;^=%E@="^2Q,=EM
MJ>*ET+T5$Q!BIOX5-"6-TV;KVT#"0B8(8%)?D!:RR=5:PD#7]R3(^*&[/3AD
M+%"5-4!.O14&R<T7=A:$<;X7*IF46W]\_5;M(7W:E0T0_'!Q?249MY;/)CK=
M+I,MOF;_$[,&5F-PTK8;MCZ)QS4-D-JH*8WMJ#F"*YV;:=7BK4JCF@$BGX.$
M27!+PK1)4A9Q*#FT%47MYV@Y](V_2*-[MC8/)/W]#B_/K=BQE:\$KOM,5)7/
M]D[9F,Y_#;*X]O*NKUMOV*(N-M(475V:.'N@"$:6;[PD6P=9L>$Q*Y)L7;*B
M]@F_)O6%1[-5"V@6E'*0HI6-]N[1\S`F^>6FCBV0,!Q4QS64AB3ID@#4&#D,
M]POYB+A/:<:$EXP[`K4)C)JU[,-I;+FY?'D+2MDGM]%MI:=^:QG[I#Y0?I'T
M0J9E$=(5F<X_L'\NJL-*2CZXGGU(CUQVDFRD)]\=D2CE;TL)Y&2ZW_3VKC^[
M2Y]C*46ZHVO7/V.(&$8S)P&CE:E$![;H`V5I:S5XIHTZ?DNS:<&TX5SYVI/1
MMD?%FM.H9'.L$44\>]8<M(U@8=%-D!0;N2S57LA!UE^?_1Y3]GN?@]SG(!<1
MR_>XZ?Q@.Y3P65K6/NFM5KG*Q')LOZOM=1)D?9I"`GQS$3+5COW_DA2?"4E_
MO;MA1U[]Z2ZMU+W*+?&2L#../`=?=%C1N7$LS+FGC,HTITD<58'P099M=I=6
MM0.R%C\TVAL%"PY<KLWQH:51&3-&DJ"__U[1-W&,'G2`$W2GBQVJNCNW#!.6
M4J[7Z-%N+,.00<[@`E!?(J&;X/I&HEWL4KL7+LJY+1T8:LR>9'?B#CJZ$E]6
M:*C*&%"V.\_:1>@?&P$^-M+)J1?E?N3XZ1%DJ<J[N$(#D>)[;P!@*D"W1+MZ
ML.V?TA@RJ`/E"I</,^W,VU[K'E\"?\'E-;H5T'9_?0!#XOV`<G:>LOUX3`S,
M-GS9\0>X)\4W4XU>>![OX-+@0IQ3W>B8FYE,JNM3N\+-H!J6+.X'G;0ZS-K1
M".`&<L10$@B#.ZN&-R^Z'1/BP'L`5=-5$.6F"!LNX?@"O(/M2J2#;F&@L"2$
M1K$A]C))C+#EW=R_^Z(IR^-'8MQ*CQ^RBTLW_%P9RGB"'[G)@QD_6MRZF5DY
M;N;?M!DT$9TA;R1T<MQ@Z(4^2.BL#WU8T,\]#YT6`\@I"\],9M>.:P:==O(*
MNR85,R!UDIT`\:%*8]XE4PH0)Y8<Y7WR^0"AHDI6#DH)"14ML*0F[Y"*#`H1
MB_@$S.,'A85%+C*2DPT*&HLDI)'C#`H-BV2S+27-B0`%A46@$>CP\CP54)!8
M!)IM*6FR&B@H5%*,(J$B%!,6B042*@O%A$LTT4KNO8=H+]7\7R:L"Z;`\!SI
M_5+(`UJJ85I*#0^FIU?*]]T)_Y#1D)"(OS`017$M?#<OGY;%DF;\@8UMOZVI
M&W4:,)%LLNGNELWI[;,VT_G!2SCWI#T;ID8]`V1^8B.3?<[B@F2UB"A)XJ@J
MZR"MX><@BQ09-%K+.$A?U)PDT_GN85L^M*]>)S[.7`2HX@"(:H**T$#KC3CO
MP1E`0)"ZH?6ANP-SY^5F7Z19(]4B;S:E7UC!(K]K]+Y?,IH+<R@,UQ-"MN4B
M-/L=,HUXL(TR-].077G&:7:%9,&^>J*U#7;+&Z[6B9RIU_KLF//[9QE;\VX/
MUK[/F>-SYB#*F;,309F@4&9,Z:MG:ZU!W9//U2<QXW4J(P-7?9QNG_5N;GNZ
M`)4V=`9)0B2:EF57:8!Q:4@1AFHIS)9Y`W,C;Q]+ZD*4L>NU=-8A^U]5"+MW
M(W>YELW.<^]B.>S-T$#:RTA=+OM*<2-UL^PBI8_,C5)ED1B9WV1'V_K('">M
MF6M'[7"I?[\Y,K]+_6NQ,7I;ZM__NG!K^(D_!,^=++;OPM/Y),P(FW>3+,Y_
M[^GJT+%UJ^X/O6B$N408NB,/0^YJEC^2D,0O7&(]]3P`E1WQI>890$!PS>.O
M!\[A>F`DQF1O/,-O6')D//-6(D>2-T`\<"&,_LQ%L7U<_21((_;+:A47E9[0
M4QCMV+I58;07C?K":$[";Q?TY6U$8D[7#_P/SL,?#DXQ]M._;L2O#HL^=SUF
M!R#)E,0%)>T#603)C>C5%DD)`V[`%]DL;C29W^)B^;PDG]+XA60YZVHZO\S8
M?,V75S0I5[,X$'L(]VC&#(BR*/.[-)12V%K&2/=A46:EQ(&ZO82!KB\Y1TFV
M$'?=7L)`UX=AK[.DR9961S=-Y]MD'4T0\`/)_H?]NXV^'LV8`%&NRJ2*JJ_H
MB-D<8=W?TNPAHU$9MCKJ0^N8(&]34,FT:OELH-/KC'PAR44:J2>7HJ@!8F[2
M@&U[['@3$R$H8J#SX_2.-T&6;'@@9IQ6T_26'&MGNM4&(+*)D#W,D9-&CV3!
MYRS--B<1;FQ1-4U`L/1O?3C(3P'K_"!UA!FH'5HU`/$CTYJ.G^HX)+;MNYEN
M3W,!'O4K2A;8L^.*V?!=&%3!!&&BB-!7Q,C#1GL1<$_*C+ZPTT8\*((B)H+9
MZHA*?@^1%SD_ADETN7E^N&HC0UG8`$%'$L%NL3[&BV7Q3*<SIN^D-U_"I,P9
M/YIUN9LKJQ6_M@^2^,\ZMRMD;.WTZ)@UX/W<-(>T.W;%J$_K><;VFH8<8VQH
M;]8\R-80!G5!$X14L><Q.T.#.)IF3>1V*R72DL9(V3!FMQC6)27,=;TH`^Z+
M0$A^M;?2G(:MMY`$K&DB,KB>D@+A]O2K_0N22[:"4I+G%^$?99S7QE/^)UMP
MTCLV<+TS@N3^^K"-1/%=G**T._+9LILU"MPNL0O/.9K'$<E._&:K),W3>9-0
M/J]R$_T7.P@4J,UV@IE9VU25F]X<.6G)/NQ6(Y8`F+2L"]+%";I/*%<]A6J3
M\$:`DN51:"OB@M#M6Q)7/+VYF+_B@JZ)/DV@+"5=E&]YA`#<'Y\\E>U!)K'K
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MH`M+Z?$XN=`QSFYRCK..B`/$%2EM!BU18C(#"<KEZ#CFS^;+TUW7HRSTP6X.
M&8,K4G53AVXY*N_G#I2*?H$\*->I9+R$HZI2?^UF##)YG$!,+>AFL-J^(H8X
MFGFJ&AKY*!J8K88R/QF<K2!_,'2S%>YIN'NO3Q;%A'*RJD9&,8@`+T6[$ON@
M8A`H4LZN/#0H7FE(BMVC<U"<PA!,RRJU-&V'IOD5+Q!S>A=^C+U-/?@A&C>]
MXH=L\M#$C[:?WH4?GPEYW:RDYS,A#9BB$Q`JA\YR!\D\"HO;12>-PY\+AT2)
MHQ.^`?#T4I&@$[LA2ZY#]*-=6P>F1YI1):B6Q=("\6#)0`T.3P;BPI)X>B^(
M*V/2H.>U18NP>LA$P<I0,*BD#T-OTV,1/7;2OUZ<$A0F%C'D6)L;(L(7RA,L
MLHL^3P0QOE#@6$2:O<8K"DR%(L(BO`R:)`S*#%1BC^DT8E`FH)*5>F=UA*+&
M(DD-DP$(:DU`)70Y2`<%Y1,J><YF8C$H@[`(A]WR:.Y1VLM!_GXR:Z2825`9
MZGEODR#/25&GXTX:T86GYV9[8IK/29:1:)N:>XL`F)3<5'<UPRQE*3=+-"QM
M.<Y4T5N)-]C?Z=RPOXK-';_-8BNX?H5OFE4O0,T24DG\%WD>+U(2712UC8_]
ME3]DY$!LWMX1IA&C.BFCJD20L</VF19!\M!<G[UZ^.Y5EFA$=)EB<_Y:LW@D
M(5VD_#&TNXC-S'@><QP7U21L[M4B1N>'_51DW\H5^[%Y_*`Q9+$RC>GGH*B0
MIRZ(,)%XNGYVK'I%KA[ZIW+V;Q*R<VE_&?O`/3SX'9DD0W6/=@:!P9U::5DT
M5,AR:^M5-4#LOB\^PK<T:_:APW='Q?3JU\:1"<[G[?-Y^VR1KW&DP5%V:!1+
M7KZ]?>UY+W2]4T#7:0(UT(M97MDH^N,];@D%[,ZBQE60+]D'/J]?@H2<)GVV
MV^G(F5FR"9(6=4DF&Z^#F#^=7NFU:30MEB2KO]G@L2XM9\3Z_<MEUCG=TO6X
M&7M-ZFWO.?AR\/&>IF$-VP*#H22,F]%,J`C216QITK;T-F[V[:?#P;=JF[/`
M377GXV8N4]K7)"LV#TE0V>KYR;UN>1K!2=^C8>TOE$:?XR1IGT*DT)=1A^C5
M/COE2M7E1I%-3+<Z-H#*5%VZU<\6H'LSR78Q"8`<?QYQKLPS@.!^NOATGV>1
M[A-YFL-^!V'?("0]N`!G`>WCCO:YQ;$,'Q9MKSV2X%E@*'4$OKR+7TOJB!$E
M`H4.C;7<$?8\P@SN8;IWZ.B"$COSHNLMMUT.G'7NOU%DQO/9*`QC_+KR%M@0
MMLPN8A_W[R)42<,;`*V<V061?+5W]HA!-S=Z\@BI:RTZ<=#P5-3W4$+'D<Z;
MTG#7/V/8P`9!WY_AG3R>QK`9CHK?W;R?T&T-YS0,0M<H(-?M!?F/G.M`CPD@
MV^WE$1@YVX4N54!&V\M;X(#1[3?C0,[8RW]@D3,8PL:`_+>7<F'D6P#4#Q#(
M=WM9'D;.=ST/81>1X]^+(J!7),A+'OX<%)-Y$&>3%VX1Z!@PWK,7JW'B1FB%
MA8>;<2ZIY^$MHZ@RVES'.5^5C-(M24=^)LKR]OUCA"0I7$_!]5#XXD+32H%B
MP#025-F$W1@4^/\.C`KPR:E=WS[$'3&7F]V?_Q6S(<C"Y>8#SQTC<4S3J^P0
MW%VZ+HN\HNB=],5G0`T<,+[7AO$]1ACOM6&\1P/C8WV$KEZMZ=WTEWK3=FKC
M*X#JWIGX+GTA>;'2V^=AE>R#.1#3]<41O<K8P#$MAVDE3*SHA.ZDM@-X-%WP
MS%P'<TL$15QRQ'$%9P#!_6[F0R/.(C1B&&)_"WA:Y"*_I\43*8J$<'+N^(LQ
M2_C1UZV1,X@#Z:+[H+OP[R:'MG%!I2^A=*G5',,VW-VE6G3>"(-,AE:M$YT'
MP"#06S55NZ/NW>:]V[P65OP8+>W99F>V]R4?UFU3\^H$G1P&I__PB:%NMPOH
MAK@3>*71`YV,T0DF\'H3'5CHHRWZ)D9T:U<3!#6C.Z-;Q=W9T/M*&-WL[\Z+
M3F9I=*Z]G;8ZG4L4R\Y%3'"+N%=[Q/_*:1)'[$LTV1>@<_8/&OZ^I`EC=3XA
M53C2I$R#,HJ+?5"6VL/(6%>VW(P,$VS5UR@,Z]=>21VLP#:@=4:67`EY8?LP
M?Q].>CVM7=^!+U(454,=)/R)37ZVK.,B2.2P('5<0/EWV>P/SU1`8Y7,8!:P
MV<C'@@U$X_%8QPF2)L"O?F6Z\8/D!5X]BGC"#3O=.O!NJK-@\+4IG0_"<JY2
MX'$FTY2-""#?G:#L"$EW?YMX3XIZ5^,/C`I(;RUCGU31?LRINJ49B1=I'385
M;JH85B:3<&$IC:I_)?7C>KN5ST!-Y\_!%P'F83NSS[Q'[@2<DN@FR%(F;+8_
MD0(K[.`*MLIG,RT+)H%4K\");F%%Y1S>&A^M^QQR\2VKXQT.SN_6OCJ'ZP0'
MUV56/_;)Q(IZ.A^DC!`S7K,^,HCWY'/UJ1.^D\K(P,E2J<,K(@-UF$GLY@M_
M8S,7O@;4O2$TH.MD(YT7HK`Z+H`=EV%[75S0.BS"TWJX(!E8@NIV'$%N[$JU
M'"3#U%KP##S1-$1!=)<G<B6=@HT0N%U/I`-SDN@.I/>CN_\!CZ2&>1'=Q0X8
M)$0K1G=M`Q_";H9OC.Y$9M:HV<W(>PL-ZW:@,/V@VW6@`R67<=!M-T#7+JOW
M+T`FV4O7I#'V/=1F(&Q[R9-ZP8:J*D#4]A(C&1CL[GEP[.4?ZC^X8\CV8V`P
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M^1C\FV97"3OF9/GN]%M`!7-/XGVPDJ_FCJU\)7#=;V4^SY+/L^3S+'V=3U!W
M/H;0N7]T/64H4"=!Z1;29?A@HP\_JNS>W/H7J/T+U&?Y`G7?_0M@S4#GC=`7
M,\B*A\Y9H?=))33=V1U@GQ',9P33PHH?H\ES!S]:N]*CV>7L'1M1OE[;]:$]
MFP\[A4M&#<DGC$\'SQ71^:18D@FKOP[233[YW&14ZORR4[]N+#_M9(+87G>W
MNSP]T_DVE]7.U>XN?5XV+I=M]WB:50U<,>YZW/;7^&K<?*GY^`M;@RV)#3K5
M-7$CFH89"7)R3>K_WZ5'[&J]'856&K&U]PP@>(.U-U@;,5C[AP'P6>>]6HQ?
MB7*D%GO%R)%B9"'3*A8OY>[2-3J;*P"HIL`+A(@EO*N'[F%92Q=D`9T%29"&
M9)(O"?<>-I</5=6PX^RG,/(LYSI5/EM_]?H=[]-LI[HM.$@2VA#Y2$(2OW`Z
M[TD!PR6KX@3(-L3^FJPS)GM4YCSV=T*:<)*+%<V*^,_J]X>,,@&VV#RP>5>P
M;SP`>+V2@C;:O%,&R0)R%*D;.[:")I&O"):\M`/R*X.SB-I7'UT1I]@EVLHX
M)A7TGKR@+`KO=56:_WN:AM)1,=*F@\S+K2^W7!173,+;,.)E^:BUZCI-*BU%
M(2AFG^!K,B=L.D2/Y(6D)9'O`O+"SHE7KA=E>7<0V.EZ($B"D:BJV0?T"Z71
MYS@1'<W'G^T36(LUC''D0.854"LMZX+TURX+3"YC:G!2\B0^"K[K5+4/[&`.
M"^AO*>&43'8&@=,O0JLY!23?^3$IN:>T*"1!=04'(,;YOOU#1M9,I;KYPM-,
M<2-(I39"-`B-FBY@"13\7S+Q6P^P2HC`L#U?%\I!%?</,;RRVLSC,!;!@5<<
ML1?%&4!`X`BRI%D!VX=E1;T'B_=@0>3!,G!B<%M$*\0Z=07[(#ZE3-),N(5A
MJRTJQ")U!7<.4$P0>(P7RP+PG!"DBG=N\LY-WKG).S>9SI"LON=!%Q`MIUGY
MR+WTN@/=,(+!JB5L=,YH8&QP-PMT?FA@C%!9!IT;&A@AX#X`",Y>+G$P.&T+
M'1"JO03B\-78&Y2]=.%@4$I#,1":O1SA&E,3;FH%HK27'ESGC!C`*PTJ#R"4
M?N!F:2A(A%*/_LTL%"Q",:@?((0R3YOS'CHI%:9(0:])T6E3`,);)'%M1VYT
MBI4>;HCS%KJ9JP<1;H5$IV3I`34T5>UI6+VFJLBM#9VJI8?2H/<N.DVLVWC#
MO!G1:6B=UR[R/:GKPWLC$1L`A+>_P#L&HZL>.%#`##KA0`^CKE,0PN6H-:1]
M0KO0R0]ZV`V]!6KSO4<=>'K^Q'NP+D.A=P5RGJ&+FW4JR2:?,.F\2M:UFYL3
MQFN3L=*]>W8<3&V(?IO1UBV2[4'*R4=2[4I7-!?ZVNDWX"34ZWA#543;`FJ@
M@J'PO]*HZ0)66E&0-SJD$$-[,1>!8'N+OX#8MB+V"=W*3P\DJQ[T5,P257'W
M`"Z#/`[907H=)^7!MJG`(:CEX`6@7;*;ZK7GJSHKYEVZ^WV;(>6=`)E^`PY`
M"A\6Y<1=DCG[+MYX-6L[")HD*3O6$VZ+CE9,IN!+I&"[:G,7+X`%K.4B3G%[
M`UT?"W=I03+VBP"'JKB+$+.0<U!Q>`A*V2>W]=G9(V(E3]/:)'5:RZ_IHIFD
M(G*%Y1"0K#CQE.4=0E!.$TE)!V0/^M3T,7(+[UI;9UX-@;M.`.<NJ)*+4,"<
M!%G(?6&OV6Z;T,H-1'X\@NJX@%*=%J(%>/S9'8&*J2(J-N)XQ#.`@""DTD<F
M^LA$86@9X7X9)+IX86+&@MR7W"8^G5<:]8&S!DPE[]<8+O"'KBJ*C;=K,S[^
M;H!K9A]_Y^/O5*?9><??R>5`=%X?0G)?^7K(;@70C1,$DM16A<ZS`X*H75%"
M!P6VB(`V(W2K24TW[:20HUMC6D"U#//H9JP65/&=)#K_*2U<73T0T'E.::%6
M6-W1^4UU`R<R;:.;L<"S0\-FB^\`@1'_*EX.<EN([P#1!MKIUAK?::*/NZ,_
M`KKEJP]=<DF+[F"!;4XP]Q]TVY*2;`E$J;T1W1$*?$&LE\T1W?!VA@-D"=3Z
M#&2,O;@MV&S0]OQ$-P%T$!R+6@/["*"37#KR"NSMC#%`(0SRY62>T,^#!2)(
M>D`5<*"DL]<3ZCS&D[]"R53L-(R#9)K5(2QW*9M8Y>HX$%;VL..6JL,'P0=H
MWL7;5]L-(V_P5!OS,WTD;-S"N$HEMM^'GBG/%O>0T1>&*[K<?*H>O=PIOQ=L
M2WJI8X<4[R=9ZM;1^T/<F).1Z)9M=0>&'0$O`#7\,TJ#0ZM?;3U^\U0+H;P)
M-T!OV>:Z76&5;8,OES1J-JW#I;-_HU<5FF.H61\&(XXBF<])R,29[3NTC^S0
MG*;MLTX`I$L3/K[$07P))^Y3RK:*)/Y3Z(W4I0ETD28?7^D!>O$FK^NZ>MAK
MK\'RKKG.)/;D`]1``T/J#@JJ<P90W'NWGKZX#LDG)L;:HS%,X"$OZ8&K8@"V
M34G491`E=3%!DP>W@>MA@+13,YO$-0KQ6+\!#"";_,S;86C-TPP&K-,8!O`M
MN<7!6"5UG<1JMAE*6M0R`3[]!C"#5*S4[@VA`;U7OCN.K*0!S""[C2R@(32@
M6XR;>F`E#6`&V6UD49J"1Q0YW]CRIME#D!7-/P[LT(Q*]N.*IJ0(LDU]@&]-
MUH<)P_*\7)%(9*L9IA/[S&+Z4W5S<4LS-@]#0J*<V^W5KSS"*[H#]4P;GBM?
M`!"`@S?@`.0KKC?/K3R2>9E&DH=XE54<`V$+@@DL9#H_2",*02.KYQ9214IM
MT17>P6K7<PNIN?/=4@69;J(JR#(D2,VZ&C5''!A_!A#<6S^W_HT\]&'%YX?L
MGDY>V"<F\(D)%`&QHPY5!]\MH?.-A%TF0>/ZV@X0E#'ZD`%3CR^B:/T!1KK#
M#;!=T#[7A,\UH845/T:3^Y+9Z>LS:PP;9M'7D(I.LN@!R&B0'+;L#W9=K=%-
M"VOP3>8ML/B2J`/V0'1W=(O-!:.Z>WVB"U=VPKYSB?6&;?1='8_0;=D=@$C9
MH'(&1+<IFV:`TD<)W6YKF@-*KTET:]XT!_1]\M`EA1AJ7X#[0Z-+L##4.NF3
MR<]>0H%^Z+OZ3:%;%[T4?K!/'#HQH0>@`[;H^N2@$Q;,L`$<A(Q.5#`[#72]
ME]#)#6;8T=5;&-T!V6MO!'N"CV5OA``Z7!1ZWF)CV1I[<`'@8#:6#;('%^2.
M:6/9$C49T#4T!IVX:(8=W?,+H#LCS#"D>TX0='K5D`R1IH%!QPE@RCJC&5'0
M"1/&X-&A,V>ADT!,LDX_(@&=*#($.X:,*MHST$KVP)069/)^LL[H9$ZS53"9
M;U?()$ZK7XK:0ZL(XF0WUNJ<@=W:M94IL`]UO?(#7F2SLBASMH9:0QBD970\
MG@7=7S:O`!Q,5K:T;SG@)NOOTQKTBKBAUNP[<;?0W"Q-(@UB`-<[(TCNXS/:
M2!3'"RA*HR!_NT#N]MN,(ORX6R,HP.9[0G=9A=GAS)^CBM.2[0_-Q0<K6:?_
MW_E+-/=D]3E]\X5!8X(#VZ.S3241*YX^=DD*+L9#XL&UZ^."*$_[HU%SQ)%T
M9P#!_6'CX^E\/)V]<!R0L(+.+@,7@RE(F[$,$!9QI!H:Q2@"9&B[1B,?1.:#
MR+2PXL=H<HF:G;X^B&S8BX\^ZO`8CE,(&#D[Y/H-NF$?E@=VU'UTMQ[#,K5_
MQ*(]3XSNG#!JXW9QK?/#)*MW`/;_D"Y2'K,U*5,V`).0)DS1HLT2X.\EU0_$
M3X(TFB35V^H,VB18L%.R?CJIVPW0D"18O2P:'DB_>Z6PC(L@EUPJM14P<:/T
M\4G<Z<E'`QU>,X9F:2#NM+6`B8[IM:33XX\&.OS(9E.0%E3<:WL)`UVS/2WD
M;A'BKMM+.'AP:+O:Y&9@43$7!)?\@>=UD!6;^V!%)/8Z65'[A'^H=C*B8+2@
ME(O\@>LR"Y=!3BZV&^\Q/Z6&:NWZ9PS1O6V^F4ZBE7+\V8$Q.TAVDYZ)QXH[
M745IM^0_D>R%K>)<#X:DUHAOI<X`@OO%ZR_6_,6:O2L*M=2$S@RH+VM0N=Z!
M\@Y&.C#4F%B"SL#9?71E^ATZDV-WF`(S`3I38H]E*K9)H(O5ZHY28F-"%X#5
M':7,\N'O]?V]OK_7[X'1N(Q@=@[[R_UA+_>U#`KHQ'@H]:^4%9E=&IV,IS^*
MXQP]Q:A)C=SXEAX<6+L=U<7=]?>361*$O^?ADGW,)[3*?['.XK"Z2N61DW5&
MC([WTEV;MWKGW(_(7O?)+?'/T[)@]*41Z_R!9,VO;5>#NG4=W,$EC'L[ZJ;9
M8[Q8%@<TBN[C@-7L`]JQ_&(_*WBZQ;!@HE_,,RJD$<^6(0"F6QT7P&>2K3H`
M.ZR&"]"O-`D*'B2^Z3AF[0W@`/D8Y[_?,I']C@OK)"\T(<JJC_B2Y@P@^'LF
M?\\DHQE\SS0,L5M1Y((=9?S<SM7G/:3*&5R8>=L??KN8(]N?-X0Y,J%TD\A'
M:B_J*LJBNR#L#E<MUJ*[)^P_MJ<:&+IK0CG('N8.(%)L:0?A(A$0X$_(`.K9
M>-Q$]43-BPG'D2<\WF0??;*-5^D:N-.K%\NQ.09H[64N]4$I)H-2OO)`"\&#
M*$<T2Y]-<4AN_7*<R&-<7M@Y\3R7IP[]I^7/.`KD*X"(P(;I+<K>HNPMRCYR
MP4<NX+$T^\@%'[DPD%^_=P7WUT&CN0[RKN#^!LR6(19B*4!WDG2")C(BC/1Z
M"_B>KSV#^8^3H'EU>;*NGUVN[,)!_?#R)-F_R-+15MZ]`ZMF\KYD]DQ0U3QS
M77G.WQ)2_1`DQXHIK+`!0W;3QR/)"9N4_-6P:S9A$_KJP=46HN05[*O,D!?%
MY3;9#BTXA_F<!9'"U`RHX00&Y^Q#1N<DYR)0D+#IK1X@0"7[8&[8MD4WA&W3
M"=MHX!,.7,]!DJOZ37>V[Q3Q"VFFCAP-I(I](--B23+=G0!6:<06Y3.`X(WB
MWBC^-1G%O3D*OZG&>R=_7;89L&@],@.-KIXW,@N-CFX]4G=C'55I9,[&^OK&
M2'V,-=7#D3H:Z^A:0(@_(X/8V;"DMA(WO_/_S-AR8+_\?U!+`P04````"`#O
MA`='*0XN'-E6```@B00`%0`<`'1K;7(M,C`Q-3`V,S!?;&%B+GAM;%54"0`#
M@1?%58$7Q55U>`L``00E#@``!#D!``#EO7MSY+:2)_K_C=CO@.NYL=..*-G]
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M_?GN>I#FC]]#B^]S^@C3]#%ZH!G'++I8%739_UU6%`>?`8X?`<>;?P(<_]#7
M6[7;T'_[IDS7FXQ^\[TQTEM:I"RYRBU#[N_6"?8O5514+M"?=FP9_SVKHLPN
M\M,N;6/F&Q:UC/FD2\N8/U/+\G'<H3V\"*#5*4A%=!FT^LA_JAM"AR.;JJ!7
M;^&=CNE+1;D^JG?-MF\6'PRB^GU=G(%J>OU/[UX+F/";_[QD\79-\^H\YYM%
ME5:[ZWS)BK78WQLR`J;L0:F]A)6!EF!%/>"#(6OV>Y9UN:G$I%/V%[1DVR*6
M2I63!B5/\[.?OWSS[PUMPHD329UTR/_K]WNTIV,Y+QH^1T4\@:UN\7W,N$;=
M5(?C6A9LK<-DILTYR0@.XGA.U$3E,ZOH/?N0YOP\D$89WYTK"H0O:16E67G/
MY7`;97U"H_<E1GS4*+@6)$!![AEI<9`6"*F1D!J*?Z'2G`1FP%E#0;L]O[Q@
MG^CZ@19]TM3S9XS(=+IQ+1>"%/E-$OO_QZ?>-M*DWAYZ=N@1Q'=TP__*/RN)
MH+X@$7E>L2S;G;'GG%^#RNU#F29I5.Q(%,=LF\/=B.\[)"IYTZ>H2*.'C)*4
M_YYW5/&;E=A6H<7S*HU7I%I1$K/U)LIW)"U)SBKQJTV1KJ'3!W[A6J8Q$/C.
M_UKI$S$V-1N&4E\V*^NL\U/ZF*><#1'_N68SOYV>;5C&64/+]H>^96*C/\RZ
M,J'K>B&VB#J`]G@:%,V__N7.RIPQZQ/A0++Y>N>W_DD\%>PBRN*-ZM26C&L1
M]R;H@.KMJ+1+0/.0==P$C@F\P:RXDOIW9VM:/'+M\9Q6J[.H>-A6V_+L(66;
M550(DUM\!B=X6H"VS6-6T*._(E:%;:)65XTM<%Y7U3N)&2#7B%M('%$#5Z+M
M_F5VZ\VZ:$RN1S?S;;A>[^@3S;?TCL:,[Q5P6KZEA;A)<[Y*@V3?BM/X#+-F
M%+IW+?6J.+3O-4[&5@T8,T<O.P('Z0!9D`X4,J?Q&=_GQ"VK,[B-`")N9D7-
MB&*/.,#E2V=%,2RK72GW'\YB?DN.'E@A)JCD_YM71117Y5F4<PQI3/,2CA[1
M8T'E502CSLW)6%7@>#A>5?8/ARA;D!QC"W&/<':*VL*D3ZIF6S-IN+XN]B">
MZ'E1\"D5Q.YIL>Y;*"KM,1(_UJ\7O3L&0%LAV1T-0M,>`"`=!`LR@P%94:V<
M*VO"EB0B\<%@HSVZ`#I5:7TP;:ZZTJ)_:B[IY=DFVL'V(G8?_LMB2V$7BA[2
MC*MYG(4(W;M5G:F-PJNJ_%,#KL;&H=7(.L!FIR'Q,SNI&`VGRYT)-2I+VFKG
M/8@UC<IMP9%%U=DR2HNSIRC;TK-$/MMI6E2-:%@VL**P^+6W2HCB5-D";/!%
M%:`3X&IL,UH_IC.M8(FU,'WNUE*\`EU7GJ5Y%P1;GG'-?E:_5I9GST*7\T'@
M%I,9$<NK"0?&[W*J,:9YNW+8DL-KT#7@YKB<#.=:83W9F$#5!=5U0"YI_-TC
M>_H^H2GGUIL?X`=8;#^<O7Y3N_'^`__5?YYSL`D`_I!%CT<K9?#OFD)^TH]K
M^6R)$:#F5>*&><8F&>%NXWS(HOCW,EXQ./BP#5R@-D4:"T-!66[7&VE,P&V8
MN,XM;Y1Z(/QND%UL!]`ZR.:X.R(G5F%7-)DMS&ZXC,H'P9IM>?8811O8$O_T
M/<VJLOG-F0P+:??&^M?_>5NPF-*D_,`Y]JO<I:]>:!&GY<FM5N<33>E7Z=JU
M3*M@T+$0N1G3$RT>F*[=ZYK+G'AL84MP>ENSG)2KB']`-ML"_E21BA%:HX)6
MC<+VNEZU!(QA.&RH@7Z&N*OG(JUH<2.7\+";Z%1;C'X8ZM/UTNC0)35AO#NI
MO4$8&TRWG7')7;H,8!R=E!2FQ3F_^N,C*\L+)MR9:![O+J-UQ*\#7]CV<57]
M`G>!`26B_!U2DTSV[TN=3`+!Z!0'HT,\IP`*TH&Q(#40(I$LB,(`'>D0=?EB
M:+;Z76EW?-/BM%;G>7))GVC&-K#W7;UL:%[27CV$^!*YVA0HN%YO#002Y0GI
M@"`U"D6%Y4@<=::`&?#5G=/HP[9,<UJ69U'\MVU:BO"N`6-JQ4]@Y9(68$_%
M7+EM$;/L)&H&RJ]S:(-U#[7O4:`#<W[W<VM2H.`/:G-J_6J%ZYQ?Z&@;%M?D
M1KADX.P[H`^4OD%J@M&^7:\!2;P3]=B0)[])`&$V?S5^,Q03W6WXY78-H7!@
MRQ>K`@0^37B#="F"Z\Y2?O/*'U/Q%"W7"FZS-R=D>:/'`_*[R=<XV;)!V06Y
MQR@ASG&#MS#S"IN[K>ETM]0V!1,!!]'9L@ETYJ#V8?2X=:79J^5%I$C=[XKA
MH`2"%E('T1P7B.X4*JP&U+S,XDQS_I(./4DH?&'W/`,]!SS-`/E9G64..#U]
MDCEEGU\).\^$(-#D"SR#O(]*FERP-=RJ!;SZ@CT@;'H?(^5.C8@O(Z8:&HPE
MT]4X$>;,%@H16,X@,UQ"NFB(TD`=K3Q-L6-F/'87H%1'>9W545Y_YZ<Q\0Z#
MB/S`G(M<`K`<U&0?J-]PIQK_'KY`KQ4$-;]#F5/Y48B/<BT4WH]Z!;^@TDLJ
M_[W.+ZDTKM4AE<,'/K7O\,>^\?Z=)X6KR35!L:$.>XI<9FC6N5,T24WV>&7`
M>MBOCF8]X72)$0W+Z@*%Q:]&:"`>(N0`6WPUO#GN^V9SK;"U6YC`&43$8182
MOOM0,7$AEH]24-S\5H[!Y-H,BYO!:>=3])*NM^M19XW>-LA3S$%?KD6U)A;6
MSZ*?>TR))1;RTY9]J4K+\X=2[-U]6Z+Z5]B\M..]^\A)6PXDI2W);PT,O]*B
MRWF&9*=G!S&(Q!HQDI_\'>OLU?3CW*4+"(4T=I]RC$VRP=DNHK=[N-DU@NX6
M<]HB-+:&X%O"N&_H:0N3;<&3KZ?<&$+Z]/3Q[7ASL.6=KQKKVJ3B_Y"6<93]
M;QH5'_AOCC<.A9:(^->!'KW53I!T"1`F@K+WJ-@IGC(-1OG=)3[32K[3@O_[
MP#[1VP:Y4QSTY5RET(ID$*@`&0;KY(.:V10MX:X&:O,H@`^!5O\!50VMHPVY
M7T"9$C_\;<HR%Z3:MMS3UGAC[O3I>VN6I&>Q.?=QMG=['F17N"#M)I;W9GDA
M(GF_5"S^?6#35O[.0KAV;__.*YO4``C,-$F'PIP7).=;$_]MVR)FY=2%PMN0
M$3OMX;B[X=T2"1%0@@=OC\O<0`2W`E?#K3X!I@Z^;6+,C_-R:W]G8?7U]A\B
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M)]OC[S;]_7JP*`C"XCC4D`[[U#3-8Z;-.+]2)>).'H[C3CJI_=_O]DWXN0Q^
M=?X<%<G5RR:5RK6W`I:S_I%2:PV'KYN[-<"8&WY`;B%,;H,Q81W`Y&%W$#M6
M@R8"]8+L<2N5]'*TG=A?+,SYG`91@C=%O8..^%2--353?0==!M)ZX3RO1OEZ
MJNY&F.7Y\LZ'%I6KF^(V*JKZ?\Y%3B%1%>XSA5^N64ZKJ-B=BV03YW5.BH[Y
MX1QR!-/DS=#%WPD1K-'`*ACW5J\6&5@=SF7M3W*=Q]\1^A)GVR3-'PF,@32Y
M0L*8(-Q,,?,S;YZ#^4%_W'.2(_MT;QML:'ZW+^<""\0(4`NY'?>SCRGQQ*6U
MXRJOTFI77Z3OZ(85D+L3?"][_2M4FB.L'F/=NI8/29LT!I"6.I'DO1L_E%C,
M=/GF7H9^8=DVAZWN0YKQR\&@\`RT0TO-47^>Q*6E2B390&(RQ$RFS"'W@B&H
M7D05?63%;E`L>ENAA>*@-T\B(6B2AF@@@>AG(U/DC8\7%]!Q(P\MW3\;O*]`
M-]Z>58!8L+>4`X:Q*2X$,%N>I,OI&#/*VIKQ_MB:L3\.Y<DMY_KG:$U'[>@N
M29D8,RU#<KZ7\0L*W\ODH3FHT=[IA!X;W)S.DM\UIY;^Q6ZR%\^I70;(8DSH
MQL@1AO`V,XT2;D?+2R$/C96L,W:$^B>:TR+*P-4H6:=Y"K'"4-Q:I7B#UK?(
M!:!$P_6RJ$$($_0AC'F4<-";"&;$7>_Q7Q=1N;HMV%.:T.3][F>N*J[SZ_R)
MEG`C/X\Y7&GNZ\]D8-X1/I),DZ#SI*V??[GZ<G_]^2=R?G%__<OU_?75EU#Q
M4-BY8/88[-D2K.#:>9F6<<:@V#.X&0HOPR&;L5EO6.LRCJHW=^';CKMPC8QT
MH)$]MO".G*8SR"Q/BWMKU:\TR_XC9\_Y%QJ5+.=KM2RW)V<+Y?9H"]9`OYYL
M64#]['<@3QKZ1`((9->:8C/3YIUAFI%?5RS+=C?/O/<OVX<R3=*H.`V;4&F*
M23`RT*5KZ1BCK5W&TMH8$%<P29L(XF0>H\#5XKQ?49)OX?P+K_%E!P%YEF-D
M8HP/.ZYO"!7+(T"%SJDEP'2X.8NS?1VTT#W`Z9WI1SJP>Y;O(>3+0*..")F?
MP=EXD<D;A-_+I@8$B^[5%MP8T_Q;PAI8)%(<M=][S9@\3M]G)IGN=]'^2M/'
M5463\R<.ZY%^%CODS5+8<<N;;556_/0-:,>OX]AND`M8EYSK9=S@(9$$U-$T
M!X&\0<08/3?,%L-]^]32390FM<V+7Y]NJA4MI%]9[0$R(,4:7Z(];B<IN'?`
M%1`(E1BD(RX#&$26)`ODA:O.>F;`3[^B^'/.+^P9/`S$-'V"V_R$!$Y_@!2\
MX8X]F'.$Y29D=0$%MC)]7H6Q..Y1P0EC5)I4/C&T'?9U[<U`6+3$@]K\1MG;
M8]B;YIEGYY,F@>@]8!IR&^EMA'7X..C,M;SLR]K])N@%<M/H9R!3XXIQKE_A
M==_FC+TII/_*=<[/:\*:<L'RDM]39&#4AR@M?HFR+;U9_AJ!@T<UF(+(5?>X
M;,+68'@Q$%K$JVV."\.K'R6O<OH(1>+TS`8`@3P!!KA7/=<HVGQ(_!";DT@8
M%KC"+LE#5*;Z5LJ@(H2W;"[[>0-)Z.!6FB?C;/J.U./F7Y"$+E.PA$8E$17H
MP0H#R5*2;2&,,G5:4U*MHHI$RR6-*[(O$59?(@@KNJE]R,.VDA\DC.0,/BBW
M64727%J"A";?R,^D:4BZCY708I]*-8!!UL76QEP+F]_S`YBY^-4+_@'\7`Q%
MG8+J@H/<<9$1F`>.%5K?(D\;2C2<YPT1@7Y\(0KQIGL<&(.NHQ')1<:/(46E
MMS4/#FY!'NACFN>P<?"-"9\0V>F(KW)-530R7@K6%+61.CIHZBTI9L1CWU[R
MK*CN:;&63D%]M2I4FJ*]U$^[='YU`9IG%2?*%6%+E;R"BE3D[;>!_,U'6,MT
M^.5?37W(V'.M=?>.97E2:^#NH\S>PV;BZ<-6MP;*S82\^SHK^9G8);MGR;\$
MVQBMS!1SQ7Z_"^*.EI33@CW_DC[1C&U@C8Y7I%?Z!BG*HWT[+_12$U_P^T]+
M>T$.ZV-*G=_4QPQ3#49I`AB*JYX-VMU7FHE-=K0MUH3=UZ>O]('REAQF'QQG
M)M/BD%^1N1+6AIOEU4N\@JBSNZBB-WG_N75`DC!=(`5,AY1S=U5II^$WDR4K
M:/J80PX:@8KPO8T2^7,)QJ$8=U-U)*RH^6(V)F$.1A29H>PXL[26+66\"ZLF
ME7Y2OGSH=##9,T'8&C.B9%-#M+6BSF;1HB1QTA*APFJ_BU96>6K?[28.,1.M
MD4MQH%?GT6>"+.F\K88IL*O*7*;)L5GX3O=<(0=D2[\#N[[3/80"^T[W(++H
M.VUEO,@R?2>^T\L&S$P]IL>D<-IC>I+5?I?J^VV9YK0L.QD,2P[Y`RO6T7@J
M"8TOD8M3@8*O5:D`!;,<G8P05:WIIP)*?8;,3*$C3\R`A4'3LKS?=3+,J$=4
M(WNQD]9EBIKS?%M'>5,6H"0ZD!:'H=,BR#IT`#5VPH;3L.C-@N<T+5&:7[`<
M7@IH'N]D@9_1M%T*7V!3L@SW[#P1"Z=!.K07I"[3%#2AE@JK&8)_GL-@:@^J
MFZ4HM-<4%[R`<J0#,J;R"3;P9:1K7T>2,0RHNI%6QX2IS=HXR;&E+,.ZK\^J
M,"A7D3PJ0L0P7)S/.7]?W1L*6<K%O^7K?U^@[3T%._N%M*JWE0#EP_#52U5$
MK$CXO:;875=T7?*;S\WR/GI!7!Q<0W%P$W$%>0Y7&U=CLWU7FL\<H"Y?`%Q6
MI&8MX-G=P9PO3<5+G9^Y]GRZ83#()WJSK6!P-\N/_'\?Q6A&<QPJ?X<]YTSU
M[SR\MP9`:@1P-MAC")O74)WY#,W1^1P2^#+9KSR$9N_]WH$Z/J`S!QUZ`,BV
MXC,<+4I;@=$^FQQ+``W5+V**:F6$DV$6X05;/W`M)2J[M:IO"?_`KVJKT,VR
MKBU$OZ2<=YV!04'4\[C:1MG$8K5.QW!16\/C>_%;`VZR203D'N+*WZ`F'=@+
MPH$3@9QTH"\:\Z\H/U;#)R7@)]WB9#""!5%AI.,=ROZZZMG)'$UW\&-'SV`F
MW%%PG=@[@(P0<Y\#AQ%!E*1[XG/1SBJ3,*ZBE3D[1ZF=>ME#]N)4;KV][+7;
M?P?/P/8_EX<]['QIB_@L'O:$#7O%LH2K=AG,/2#&PPW1.56.._1UG#NEC*K1
M;0$_.H#Y?93!H\."7-)8&!7(NS<+`KFOPPY%.S*Y'<C_N\TI>?=:#.)/H0:!
M<'"[AT](V2'^C\*=>4JHG&7M&5RF3)U7?O>@-D_$)QJ!QP,\K]VR+(UW\K]3
M&E;[>^2.I4S']48F,LL()*0#A>M5`8/\5O\;6I/JSPLS9K9?R14GEBGQ[&^$
ME,'#SGQIS$.JF-W9%#<F;3.K:$D$X3"6S(&)9VI<">G@E=+R?>T8-%(Y7.D;
M*TY>1WU[=O/BU/>.7N$JC:NQ>]#1:Y2'<S2`7T4%Y.$I;PHPV#NW@^/).36'
MZ\.:EU5<'[\[X[@/7KJVD3=C@,QSPJOD#V$L-UA\VC9S4RDP3&W:Q(,F'[8B
M!3V']Z6*'NE-WE_M4N\C3!K2R<X]Q&9*`*1&`,9N(C`0#D+1"<3/R/`Y+Z,U
M."G!>DW;\2X[XRW%>%DNWK^B-FU+@!R2ZM+&<(SVG(6C7O"WM!`%(-2L"HI?
M87-MC/?N/+U&HT4X?2(`S,YZH,I_AF2JX39^R2Z'M^N3/V*VY;83Y^%7[!*_
MQ1J@Q&VE4(Q=%JKANRDM-E$1I/#9Z12S<8X$OV*5<CFH7Y*./K!WS:D[]O;X
MV"4]MVU.@>_C)]Q>9GHVX,L433+Q%M]P.YD3S_-$_&_6Q3IIT#?M#VO@Q])U
M;O"O<V`UR$@7FDBCTP4W-Q$WGTYF?8[\+A!1Y8FOV4U!5S0OTR?:B7$8'-#A
M>,Z3OVYE5MJ)Z"NWQ)!+RPTH]]D/UUN@_41E.EB)@T0M$(RM:BZL0%BJVOT'
MPPU'NXMC<6=^)\YW1EWA/CKTP'/\9W2>7-F-+\-T0P^S./%8T;XC2H7FK*/5
M7_P::)WE$CZ21S;%"L\Y,47M5.%<<U)I=&")J7R"S7DYTK5SQ=FM(KNH_R5L
M#X"\2IL_3U0%\#$XC"J4(Q0(%M*$Q@?:01$FD:6*.#$,&ST?F)NJTW7>[W(B
M-F"R/?;8.M2O<P-M32_,D6J2FTR;1>%=]RGG="X>)9:_,`!\#?9#6E9E_0)X
M7"K03F<6'?FGB08,AU5`9RDVU@D?3-[M#X,;6G1@I9;X2`N0J/'"8VR#AB1/
MA#CH3HMIC5`:%5"NYZ)^*&T2\_0]R$RU157O'.C3]1H<):Y?0-+:*#`NFIPX
M`>JD(4]F,!#<NU2;W.IYE<8KP@]3)(?AU<6P.B_Z)'HLJ'!H#E$?<FHE,"U^
M!E?K\J&W2&.-++:GW]A3TON^`^KB/0A+*M=D5-8TJP!!%(;E3WOV2-*XDAQB
MI._"A&K6"=LF">]VB$'"J`@S<_0.`OY,+2G61F4I]D]]/*Y"Z%0,)[.REIR&
M\T'LBWKR:>WOK87\#M!QO2U\.0C7E%`(8#E,-!WXW5Q_6D9#/)5X;7@G^Q2]
MI.OM^I:3RJLTRCKO8'U5M;6^P=S1IOKV<E>;`J%]U;$_*L09K09!6A1=IQ0R
MEX'AW;77]?@V[?@Z%6')DXB^?:#5,Z4Y@090YR/`?4YY]3`4C_TJLO,X+K8T
MN2W8DA^;.:(H^T!I4]%Q0'NI?8146>.=>\C[TY(E2TI)!'"B+,RS@"*C&8Y[
MP?UC+UA>IDF=8E:L"EF>03$M%:(G>QZU4Q3=O_=VZ)--E"9A2L6:3,:XFZT>
MAP.X%]9K[6,:/:29T$;CVZ;:1R;N?H.=NY9&05WNE30AV9Y^.`>U:48?.YHI
M<F^VV^8;\_WRC;^-\HUCF9P)9FO1R8<;?@?4W+?]-X;[_1NK]V5X8+FD&T@9
M/AQ--M@(<R,^Z<SU9BR>]VJ*^#`S"[!Q5\%SDM385S1+2%21J*E?R<_D:5[R
MF]]6+()JQ?^XBDK1X(4K'GCY^X[\NJ+P^">>`9NNTI)L.+T51,PN^(>49#3G
MPD9>P<_QMJS8FA;?DBW\4E@82]D]_'G-<KHC<903EF<[?@<ESVFU2HKHF=-9
M<CJBE:`':*#C!+(%/.S(8_HDJFZ2#9=D"DVXV"<DWPJ+,EN2)-J5)&=5&M,`
M=]EA06=J8A!<&=[1F#WFZ=]I<IW`]7J90H:?\[*D>R>(GQA+GM,L.\^[RIVW
MX=*9?*9359D]4;6G<FVB<YZ)H(.01`(B/T=*C"+.JG.8A+\#O-G<=)R(P;B6
M=#>W?I?R1TA><)V#_U+Z1&^C'0QC_/ZD\@ER$8UU[3P8O*G%F0$(KN"2;4P5
M/'(<B;D2EQF&==Y#`X[#AIH`H(G]7N-+?*#`%`4/\0)[".%JC^CPFADP\*LX
MI_3NUU#P'(IL\29/4=;C;NF7J-]3BB*X@`G8+(["4AJVH'S%Q/5PLE_3@4YW
MP9B?YU"S-1MMJZ]EW6E77QO%"`1D[)V]$2'"9N=_6-`\)(1<*K]&4'2^@N09
M=^GCJE+P"E7Y!+E8QKIVO5H:VN15#IY@;U'>E'8'@-!?YX^/!7V,^`"6D"5>
M^JFP)7EN1L<"AZ@J20_#<-38=ZWX6_K`ANWPO0UP7FF=CER+=4T,;WHW1(LS
MNW<+`T4/7&9)E`>-F^F??#;-HZ_XKB?-)K(E[X7RHQTDT_=QXYL@/8=[WP#$
MK_+V-S"6X'=`:SS&:%)95;PD14OXZ[\83JTK5]=#I8GT[FPJYK<V$M\743)A
M\E?X`N]F.M2S\_=YH`7.4E+8-Q)!*`?32?XR!-/^("KXMJ#@65GGV>#MI9^8
M^)MOG:R"96Y*>@SS5Z^UQP8W*S5N=Q80>KT&0&B=KT:\ZS/I,JK`KJ]-RRNM
M5!]J7WWB#2_RYUF^RZ+UQS06A)I+X_#%7ND#S$5_M&/76TY-G-3424L>;PJP
M/)X_B&E`37R8/@\]GX>31*0HB+);ODRO\XMHDU:#1;4F6F//P?V].E\J+5D1
MNW*6YB26E,.<@R=XRS09YE>.FD0Q]ZS6#;<%V]"BVMURGE?U(^%F/7S-TN\`
M*6WJA'P=#]418<YT3L;[HQQO+AX=-#-`="N5L279U'#$B8RJC=31$D3((#-G
MM&DT092Q_)X?JJ(-W59I7([$%(PW1446]'?IW'X!9$F7KD&4@:TAX,/.\[J\
MC0@$Z)2X$2G$.N<<X?0O6HG@\Q`E<*9DB.EPU5#T[VA)^<>KNO[8K<A(TR?X
MHPTQ8M_;H9>\$KV4M67>$G[$1;RAW%;]"SL"W)J]HQO^5Y'X+SVYF,#R+)I1
M-K7^9+8D&=MSV")F&4?-ZJ`Z4(+--R&O-^,KAJE/@N$2?__IR[`^._DC9BFW
MG3BO3/7I"UY)&:#\JBNNG4XQ&^?(UVOVO^93E#^FGA[;>ZC-P'3?0?4U&N<[
M\$.;WXTX:2UB?`^?'$39R0&T>;&%VNN,@=2#6)`/:9Y6].QC^@1=J++W*S#7
M]ZT_1P;Y05'P[)^=15!YNW;MNRF$8Y]"L13%S[">VA/=>W/7GL"!\MFV/C9,
MNN\VSKS/&S5XXD]E\6)8OGHVZ(]Y!EAYJO?[=HY_S$:_+F-K>@5\2!Y^V77Q
MU!IOTRH:L3/V-D`]I78[<OX>)(D9/)2:H?VJ[VG]4\ZF.1,Z:?)$(/;T!];2
M(OL*N^Y2_N__\.>W;_[Y7\2[2[4+D]1"@<6C*8[-HJV1.8T_L.+JI8*X+E$#
M9\#NC._%1=[C4VJSR(1\"LMZ"F$;(W>3+9DL64%:;%ACN(_Q&UO**\7\RL`1
M\<0%B"&-56T[;WX?-B`(O:!54S%/S97G'#DGF2@G%.;T!]C\.(,=.\]3(LEU
MTT"%T90*O&7Z#/MZ+>:Z/D9>:<_`FA[<L\G+8$);VBUR&>78/AOW*;_+RY&Q
MW(_3UB?&=7Y>C<6=][9`70L.>G(>>5Y3,P@]-\1K[H85S=T):T`XF`(',=J^
MI/%WC^SI^X2FH.A_@!]`J'_HZ'?^J__\2!^C[$HPY?PE/39"C[30%.N>GER+
MM2!')#WR&U#T6QYJC'E,@2.>O<&'-M'/=-#_6^$3K,?W2-?>?+Q',*"\NJV.
M"?'DT7_N6)"<5F(+C?DFO,W`.QP28!<T3L5^',:O6T6V&(:Y+G=3N93OZ&,*
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M^X/()5M':7XDN$-_1A\[9#>>3AN_26K^+4^]+&-3?#`\4GR(TD*\B+>>MN75
M"RWBM`27]OL5'3YE:'Z*.7@HDO!R%E'$HJW>[8_Q,&_`O?[.]Z$_OS%M8(&Q
M'M3^9BXC-GZ4B-8R1Q\?[B-?8C)S%>0_IR6!%=I-^1RO^-<4@E+C;)M(;ISR
M*,`12'=!,I/Y^'H=&IHZ3/?12^>/GSES1U-4AH`P`_>&*:A?HY?#U)A".SM8
MY+FQ+FBKEJ6BL`*IHI?61\NO(2;H0G3D"*$WT]Y+O:S32F3;X=@O&!\7UWMY
MS`%>IF7,M>.VH/?TI7K/Z?\^L&OB.L$7A-$@YMRC<8]&'"<.\)`](/(;0"("
MD]];A^$D,3N<-[S!7.=Q`:4)+ZG\]SH_.LOTW5V4/\+<6B8[=RUY#0`XF?;7
M*M$^LSL8$_ZTGC;C2^A^H"=C#'`"5Q<KAN.KX5JYV/&EN%EQ-9./1!8.M\*L
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M;"MM)=_?!""B;+GT/%RD;2EZX');D&1OF^7W[OU[[X`Q+<3E6U\@F2';31=@
M'"=Y-&)TZOD[:A%U^G&]3.(XOOQ\;F!B,L)J7N/G8=<:D,21M:3%4QIS46<%
M>2S8=B,<(LITG<*JZ&T:0O;[)(5-LM1W2H\J?11<OHA*VA.H.=T0G<+CN$/G
M89LM10(D0T1N*G"3J;/(ED]=LZU^8`5-'_.K%ZE*?HK2_./I!1GUK9%7W00-
MUW)3DR6TIBL<KO#>9-9'8^I.-NQ-UCU2'#$AQ(ZJ+70GGF-:O#=]\%VOMSG]
MQ)51!D(_?*08;8AZV.WKT/ECKB!*6JKXXX8E^/]5SQWCXL34F6R:&3;GVHOF
MU_DJ?4@YB;$<L>--4=EB^[MTGC=6DB5[N@8I9&T-X;_J2I@2*Z;#:`_1LFR]
M9KG(:?I%)$$?SH>O]Q$^CG:D<U]!M0("$1@61*(@-S/(&:\Y!0S'5\^W098_
MWM-B?9T_T5*ZR0U=!X=;8N^#ISTZOQ!RDF<5I\D/N"W1^AGX+2K=@)5!(&(`
M]R/I4`YSLQT1#*;!J&"930?M'R<MS'.7^GH#ZY!$2;4)8G0%A4P5M/L$J_W&
MF0&F^)7<>T[M9GD.U]I'$=,^8L,;;8N4YMX^7<LU$(4#9X>L.&M^9OE9U/E=
M)YUR&=+<-\YXIL7-D/9A@-<;2JW:W(JM>-^M=XMQB)AK9=X.6HZ'&.97E*ZB
M(N?GV_*6%N+0.Y$[?*HY4I2&NG5_UBQ+"$0FL;S0B"M+$#F:9"S3Y99I_MNH
MVA;\5G2S'+YW3#=$9</MZ]!3'8P>RHA2#U;PHZI92,J@A6<P`IR%2\:+BUKK
MZ9J2!UH]4YJ3M"RW$5]&XDBQ[A]HD'(38]+/U!GJV2MR?YB!F#M^1.N<T+H'
MM%[SL&$O6!]'/6K.C<H=.`KGW)"'%.P\,4O,#V8V:)\8]W&DZL51%#XV-S:,
M$'%_CI[-55Z%U?VW?&7^&1Z'FG@,$6A1IB#JLK;9-62AYUOZ-==/-+DIX%]P
MA!.@SLLR?<QI<EY51?JPK?A/Y2TKJTY4!X3C4;YZ1(\O\.-Q*K=@]#&'-Y\X
MO9P)?0Y(^Z`V;VZ;U"COC&A!Y)A(,R@B1P7/G,VX%K67<3.T!=D/CD0E@>%U
MZYZ3[@#)'Y/]N.-WZZTM"TZ2M!Y*25Z5VW@%S.Q>ELL%V11-EI?F-WQBH"Y'
MSN=_E6[:+KX5AW@Y<6G-$5(Q$LG@M4[!CH7PD%ZEG)Y(-OW`C_T'\[GA_#J+
M._,9=^>32I8%N`X$V:99<'&TI%PC<^`%[>#^(KT<^'GUNDZWQEMPP;Q9BL>,
M6[X$5E%);XLT'E6Z<\!EHHQ#XO>1**?=C)H-IMP^_)7&%6PN!=W4<,`#YBDM
M)Z.F_C",G)/^+>B!^JT'+N[-S=!%.SYXV/OE8V,S?B(8\%]DUOX8:ILS@&MM
MFA_K[8(>J.VR(P=I1PXVM1Q`W^*MFG16,?\@H&J?A3(X5OGS$7%3_]2"X]F6
MG.J(8^I`&Y1'ZE%?[JV&@AYL>M\9.*$:H[:2T?^AU1;=4;T"#U5:9#MRPT^.
M?(-XG[);OL6LHX5H\&T(I],AD6%*'+5O/.HY4M]1$?9\SW[AZS;-'V^6T@U1
MT1R$Z-&2@4>#<BB3C09$&U8`IQRQ=JSKLX&0&B<H^!HIZ.&OA#4&05>/CX7(
MSM`)O^JS*?#[1,L?V`*?]CR2QZAY&!TPF\&(&0$]:88;YZ\KEF6[FV=^5OFR
M?2C3)(V*%,+/Y9GD.O_`SRMYG$;9%S[G=-!'P:0?S":)H>=E:\0`TU[U?D:/
MV`8E,"*0D2ZT_1T4DE8TZ,CL>6#E%)=OX<`CKVZ"/TSPI^SRIUNN`+XIZ`:2
ML,B-#WZQ;)E6MN,)L!4:+71F;>[LUU7IQ*+<TJ+^;=]6I_NMI<HJO31"E5;I
M!6.CTHBE42*VKH&J*NPHYBKADAL5TJ=1G$>T`F8<#]O*;G6810=^T\L,8$#]
MAWD44QE?A"/55!28[]>_IMWTOL0TYSLC&PEN&&V+])[I[=/U5M/0"AFP,,Y,
MIL4ASR)3X_@Y+S<T3I<I348C%B;;8T5GJ%]?XK,@'=)AG0*G><RT&6=J_-UL
M"O:2KKGT3E6IG6B*,@7W=^GE$#-`6]\P;&L,B"-*A[9AT5IKHS"P!W4&(T)X
M^6%#%JHM9:7:I/5,KYZ9?/]*P^13F%@)3(>I?M5"<\3YS*HOM*HR"B]4UQ`=
MM>KQZQS0%;A.D`I$CYBO2&(]5)A@8]?CEL4@^;FEJ/0VG<85>$>BBJ_(QS3/
M.U8)_1J3?@=\E>LF`^X.E^;)_`>*,=,IU1ER="Q";B?,#D?#',LA\5H<E=5H
ML,]X8\,#^6&G_D[C#5W%IWC'1_$!UO:<P\?XY5>&KOGI*G],VTH4GVEU]0*&
M4KX-_\18`OZ[`Q*E\RE2OE1(N"^HUF`@D0!1)[-Y%Z:FB1;7F0DK/8<T"E07
MHV5X>]M@PQ&[?7FKF]`EBBI^8(8:G3>F*>TC5T"8*,C>R6=*O#$T;-SR]<YO
MB%$&Q2TA-NW#5AATSX6O09]]0^T+C)ECO&<OUHYQ"-KF`MLC0AQ96PBDP4!J
M$&0F@[*1CWA9#RG*:X=?$K-MEI!-@S7;$1H5.;P21_QO-2>$O01H![".**XC
MAN"Z7_764PEW(I19X0NDZAOIV9<B'(&`48M61X38/_A=D9;@4Z;O?.)(6ZI(
M#T,PT/?M!.K.WT<OM+RC,4V?X"X^>!T9:8N^?_3TZ?["T>08(57T0N*")BF_
M=10M@$#WCC'V,BV>^16BVV@GUB&_=-\6+*8T*3_PH4WG8U7_$"E>TP1\[<?3
M2##;LM7QF11AX]O;ADE?6/*J$VSSK73\9455EVGHR5T;IH2CNN@Q/+\-KT5U
MQF7A-RP#E7Y-JQ7;5E]D_.98F7&]3S$7)442G@)<ZR3;=>AEC80T4`S*2+D:
MI7E^>ZCL%Z7B/:?VMH_[@GV?:U[40;_E`JX?PDT?.JF_7-/B$5S">-M.6-*F
M$Y9$7LG?APA/TI5F9C)YP;(QC=OFAAN:9UGR;*4[I6R8X#F<O6Y&^9Y'+'=3
MK/+M(,EO/W(Y7FX+Z;>9LD0\_'VFS^(OPPZ3&M^B'2@5:/A:*TI@,,O'T2@1
ME_OK)G6EC"GK:C!(7)/_=9N+W'E2.XGG_(+?>BKX8$D!^H+D5%C@VBR8,8/8
M?OZ;_^?'Q3^_?KUX_?IU()]4'7EE1M-C_;19:\E[=M<F";EM<H3H'#W5^[%S
M#IVF%^10^F6?=64/C+3(;)Y177#`VX%U(CO-'^+\JK$DA@^SNK,\"S4O!X#4
M\P,?VU7T1T0":_HC-!95O?$X$;I>0&DV1`FF]H)NZF0M"$=$5`;K5V4/B=ZT
MSA[ELYU\,(*R=%L>JU@XU=@@0\QII[Y2Q4B1JDD;YXRQ,0[;FK(9:2E&6KO9
MA\L2,R(_3(^9GCV@DK]N:S/M9S[2J%Q=5W1=@OJ$D:<9/UA7\G4%"E_<,W!)
M%0HUH<G[W<\EQ#;?\*F)(++[G-])GL25>N*=V1=9K)^68WC.7_,`+<E9!6\*
M+'N"-0.C^$L8)RI?D\U"S:#?-3N9L[4\SN#V6:1K:-*MR+\.K$R[G2/7GQT0
MO@ZI=M!B#K&A^.0U2^CG-M>(2D8I1WN8Y67!W,[AS/:CT822V'U(J5-7^\\H
M\=GL.Z,HG>PWEOD2,!OQ/'<9-:'7V5TT9LRSJ0QVM_<1/XAU,\EU:@J]W^V;
MU$XHY\]1D=1WJY]$0-UU';+\4\%/>4-V-7>4L$8X^XB\6>SL0T>9]^;`08PM
M$$"=/0"JPUR;W0JY#SO2;5?#)P+_HK'Z+(@<`[P,--9$!7:Z,B`Z7&/,X[3[
MW0.;B()ME-T\9'4AV(%=;+0M<A_J[=/73M)+'+,76!H%8C5W*!/5,3A:@./B
MP;2XY=T?OZ!\O5Y2^6_'+G,1;=(JRB:,C?H=X#WW%0FY7D.?:47B%6QZL/WG
M?`+!!$98`X>D8`T+8PY$3`<SY['AF]+^K@V'Y`^LT'IDTO\:\^JD3L5YLH2]
MCX>H_+'D%RW+3U,N!VN<=++CNW$R_M`/5@A99(8\MU$*H>27V$ZQ$3#C/^;I
MWVERG4#TY3*-VBP#Y[+(3'*>)QTG3_XW/JG)>1Q#6&;)#W_BBQQ^4_`K<*=I
MWQ(.!@)=<,$G6'\U&GR."E>[8*9\/PQEND?DZJOQD(T$)**7(@E)W>?[*^.:
MS33$/;QJ>'C$6#F4)G%Z6S*G$T06JF1$D!V0S4-0[%?TN2T@*],ZNHH*\&OY
MPD^RC7DBC3FBRS2#2EN#^LBH-TN5?!2IAJKBHPC/1ID:9YQXHL4#TWX(`:IB
M?TDD79*QLI/EW5;N=Y^,P"<DV12,"%<R\G#"%XB32(4K2(<[<&2/ZAR)4%TP
M71[NQ=V*A+QIYW]+LHH26<@0J@%E5-0QK.3GW6R33??S*/^CNWN,E/Y!S;]?
MH]+>._R\R31S`>J`%E!&<O<Y6M/1;./:WR--2LITW$=O[*D2(!LV$[D^_YDQ
M4PWUO[P@1]G52TR+.!5O%'M3J_CC<&XO[8\QVEV9B!=EKHQ&6V4Y'"?BD:!!
M0ZY>:C3DX-U@(UT8YC=6.Y>B-E-8E-=6,4)K1O`&7&\^<^T+1J6DKB6USQ(6
M0''JKT-F-A&^'QP/M\&1,BUC3='/C:==!M!KX:JUC/*4Z3#*-(1&7H4;";VC
M3S3?TELNN+#>'X_386E]@PJHF>C;3\&-"1#ZX3761X4IP5%;I=HDE#6,!9G5
MR*PHFTT+`!1.(5$16(.M<:[1+4%BB517$$.QV:\J:?/6"WN;?!R".K"QM#ZO
M!]2*ZF=(%3/5O2_GEBD<&#\7^V/#%AUL76D;&`O2`"'3HW.D7)4EBV%9:JAT
M&]>&>_9ENX%:J9=\/6=L`]O>+6?RB(.!YJ<8%:Q(PGVB2@D#8D!K(*2#A`@H
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M@`@@VD<R3H_7XW5J5`8GKE73S#;.Y2>M)%<O_,P\E:YOM"DN(U]OE^[-V[55
MKZ5KDE+/TA"LW(7:4C&T@1,DB=VXH#`=UGE60:R@Z6,N<]_&N_N"7W(BD5/T
MIRC-WU-^S8.""D,:2.]KK`)2H^+\,"1A<$FK8VH>.?62O`*'*EJ&*<FG.P',
MD*N!SD>?^*5\6T@;1?O+_YG2@B-9[49==%!]F)Z45&CY.[N3EG)8;QW<5/0=
M&/3YZSEK0;RBR3:C-TL5_^)[^$M;_&A`CFUTB<U#8$#:>8Q9C0U>\MK0A-M.
M:$+SL-E!2'X3&`F`)`)EJ.*]%J:4N9BG\,:6=]K&EG?.C"WO0AM;WLW/V'+,
M[0EC2R\+PQM;FD>\RQ0R_N6)IK%E[','+]-=,G-XH>[BL?U2;396%R_6#:)Y
MV5I&15#Q"7N8UX:VELLTID4>#5M8>AM@["H'';E>&S4QO`G%$*VQX:09P*TH
M`A#3;97&41;BH;9?`-@TG^9D)8'4L3_G!8TR"$!$F4KZNW!B+SDDY4V/:&!"
MZ1(W8S:I_+@G",X2AZ:C5\)V]"V1MJ,9FHX&!%+9?C3&<;]K]Q+VO3@=2YK5
MUP2Y]KI=.==#'5IP_]T4D-FGVHE[+S@#"+^5,#6@^SC*5-@4_NKY5OOJ^=;9
MU?-MZ*OGV_E=/8^Y/7'U[&6AG<"(C_Q\DI?T`Z7B%_P(U7?(G6QL$`IQVJEK
M4:DIDB6M4UEPFMC``!OH<8?ABZ@H=N"H^"1N?)$HB"="LZ-,5,DK5Y16))&E
M]`AK4^"!BZ2H<)GPY@7;/JZD6Z5H"?MND[T#(L>S'EZ%"R@8$4"F-R^>H]&B
M<M7D\(":TIT0\X$]6N$+;&S:<,_.W_`A=5]4TVZ%KY,,AKS*&1?"=V%>(E5X
MSA",#.9=V^J2R[2,^3E]6]`["DN?;QL#<J?YM;FO[1B5`"ZW8W`,/6_MCA3K
M@!O:MU9)JOI=;-49Z+GT5,SU-P02T.2&*^`",C87=`7^,4]T7YKG,ZUNEL..
M*,A>L(6A]*@Y+_>VAT,8X!$99UI`PL@0IN03<E:8)58;GO)O"Q93FI2@GYI*
MS#?+NM@HN*MSJGT'?IWO,&=_E?Z]A$*K`-&^&[@9'>)%J`%"``GIEN)N:A@#
M&BC*.9=!XNY"[3A%!'3:&6=3@UCDJLUIB$P;6FN)H;GK.^T4E+"D29T9J^QL
M<I=TF<;I4`YS]0_1B::F"+@W:@HR@=))*;.7X7D6R,+Y?G?J*2<,9"/97?0^
M-K5[CA+Q:0+M^$N&RP*CR?L^*Z@&0TV/2C+9!&RR955^V.:B?N;][47O^6BJ
M,>I0--2IGY/0$'7]DX&]<6#./)(ZN8%##J=/)`"H-11X,#8SO\BS#0QOV1U>
MB./-Y%)@>JRT%!UU4/9%)B2[6=YQ3L(>\D&F'>"(_C?__[X5;M"-2525!CDO
MNP("%SH<R^G8K14]:A(8P@ILP)$:'62:(O/E`3[K\#ZY8=$,N<G<(4/8UILH
MW_&;5_/.!/9]!B])(A/QCG\"_Q_QUFD!+TQ%M0L8Y899U,<1<.B9,MS?ZI>M
M-N'KI^@E76_77Z*,EIR>R`W-N?`IY?]?L9S6Q>'@;_6G?=N=O5XQNY\Y=2^;
MH3E,[7TA!&<06V7SI-[B7)`:*1%020<K:<$V!1_%G\G7Q"+\3KJNV5(*MFPZ
M;%FW;-DT;$FV,I-[\PH/1R;(YM[\?]2,.<!>:G''8(YFTG/$')CE9!7B2Y%"
M2M;>E"[K^[?AP>*]FI]C(^$4R?AZ>U7%@ZJ=ZVRLF(*XP@1=U^N6<-IRMK71
M1GV\KL+Y=&60F3+;S6&HD_/L/$_NZ"/8,EFQLW,H,NC=XN$(@2+D(0D!U]9)
MP`NG[!Z:NHD@P25O#]K3Z<D+S\Q/4<D1GXH]G_X8QRF3O6;B6&4\Q;,X7LE2
MGOCSU?#W=@]8IW0"G[!.`5D\8MD8K>4SEH0TWT/6B"!.G[*F^.V[^$:=>K[.
MXSZP(H>:H8MN'';G:WT=T\4L(W/LJ-)Z%U`U[X$5=5P`:-"V;$"88:#,]-A!
MN/(C'Y)KILHIW^&%2PKA(#44&0XYY+\SWA@=<MC7J0<_'4&UK9\AHP]^T"H=
M:7L(B`5P/(X%B27U0'&3HP+"]%CF=R7TE(`<<2V::(U<"P.]NEX,#=GN^2BD
M[]`4<YDFQ\(+D@P5&J_&J?R=1>$ZZ#^$F-5G<L@&'#2YGSKS)X1OA*.6[9U7
M49'MH'Y+7;+W`U4R9(Y\9L-"V=-]$--C#PYC^YB5L=DP%A*!A'2@D-F,SX:C
M2=49&$0?UW6K3VQUX'32M.5GH`V_#@M?$VB\3(NR$C$`4*DRRL2KJRS1N6MZ
M@D]8L@U2A%-G70Y9\R8GS'#+.7)I:>G>I8^KZI[=/(#K^-5+G&TAGJE&5YL8
M+UK.IW\7X$YLBWV[E1^*F(W.+3(O>Z3;(6AO/W/C*&)G/G$"W&_18A2P&<EQ
MD'8@S7/-_L7G9#`]#SU?/7?-'WSV^B$^8=C`BP]7'$4S#[2=@$:/<.U!VW+5
MS8/0B9-CR)<A3]LA"R`S`563\NN7;0VE3=BWHE(&.'M]I3P2KQNK0_YZUEXX
M=X4_"K-M*C-]/P9UK?:5J2S]_=&&YD+*20@%]O.&<SJO:D#6U%-_M]Z4SR'Y
M^:J60YQ^]C)3WOA6"S5>\E4QR8;-:EL/O-ZI^3;>Y#IC[7X,UXN&@U'>LW?_
M<2XA`UN*T7X]-LV>'=(@+*%^N_Q"BR>.#Y+XG#^4XF5_R`U-[2NL\]EX[^Z+
M],W,%4.5VPS)0M,DK`54&]^6P^4%^EN@TJT>].0\H5=-#5]AP!2O<;1].P2^
MQQ?11I08")+[M%\$F`*?/&^(VX>2*SQXD^"KI[KGQ$<?NR?;8S?!H7Z=5_)J
M"1-!F0#IL&_:TSQFVHPS+:E2\*-0QF]9[[,MB.SC2'&5\::H,BO]73KW-1-D
MA49L"!L47[$U!OR95T;\I^!0W3.T$&58)D2%Z?#.4,*G!=N>//L58W/9#2VR
MNT5(*9T03ALRZ4R7CWA"3K2VI\=]>$(.:/%PKI!3W!W7X*%=(;_PI2JN]3?+
M#VD>Y?`Z>,MJ3[F)N[+&I^AHK6D2S@6NP0`FI!8%:6!PT:N!!!(_G5E@)JPU
MODT_I)6T/?R:5BN^Y_^<IT^TX"1W-\OW!:=<KBX8[+'I2$4_@VYP]W)M<NXO
M[RTD`IB$+]T>%8AIC8LTP$SN^1[&CSLU7.<BY8C@0T&S)JM5U&'/LQI[@I@-
M\&+,;,V-[](7PD0\$78XT`I=RN*@-W\E*P[(XDI3&")'A1Q*JO"<L:1P>]P_
M;XMW;[:+,KZ$-@A?`6OCPGMGET1I/APIZB'!9HJ\,52_5US'5^DCS8=5ZT`3
MC-H\ZLKUNFO)X16=,6(K^6/;6W`+)X!N&I(#IL*J,)%<%XSK..EA#[&[?`/C
M+.4_E6E"I88\+PHHC"KVK3OXZ69YLZV@O$=9YZ]^7`VH)#=$#&/$[(#QI1#M
MHL;HG=!\0ZBM-AJO@WE!]JC)`6S2Q;T@`CD<=AOLBWWR^2D..H[@L[R.>L+]
M7$RRH?[]3+<%>^+'\V'].]`$HW^/NG*]S`6Y7\!-!JU_C1%;,#VWPPB@=(<F
MGZGPQ[/-$-+9O(]*FD"Q+'YB'2M]/=X8:Q?L[=2])9#%OY\]`%DA,PW=,':_
M<;XR/6:99O7?56S$3:;GSZ@L_/MNG+M*`2G\9F:$U,)&)N&_3UE%XU7.,O:X
M(Q^K$+[F?5//IK@TH]1UXH\W&^$Q=]7X[`\^B&`[<I',KI?@+++:]2*SGM[.
MTO@Q>>Z`?JTGNEMN]X0.%6&Z[6J/67+^'!7)@M2X%Z1!#F7!ZV1Y\TN+-R[;
MJOGQ%"9L%AN#N!]8V!>F^W&01'R.N\(P,-MIQ</M"=<]52^%U)/-MH`_50=1
M"+P5V\PN"::"Q"JF')_?6C]TS>@]RRJUM>--X^>4>^)+HW;@]>-(<WIHU.!5
M,">:BZA<?<C8<ZGN/#/XB;G3S$G77IUE@#H1Y&?D)#/,[7[GF`D6&EZ</T5\
M8QSQ=NG[.^;JW.W'M0Q(6OC+LQE6W.WY<[2N5?,VY]H]5`6TWNEFDWP)MML)
M-;YB6<(/1%=_VZ;53GW;F_[6?/\;IN%U(^S"^$<B@<QH2U28B?Z]496]?N7S
MH#A[#D\Z]]'+'84XW2$/:95/D-(XUK5K(;S.GVA9"2FLHA<2%S1)JY(4-*;I
MT]3MRI'<*;&:8?CG5\I^X;MQ])#1:]`7G,M7><7E_S-G`+_2L"Q-P!_Q(BJ*
M'01/BQCTC_R#-$NKE`[)H9U.D9)J1MR7#<$,)<:@X)LO".M"`Y$T&(D$N2!'
M,!>D`5K7R5T09>XXVA`LR3QS,V%^-Y7/M(+[QBV\](KRVS^7-+G.;S;":X&#
MC:OT2:"<.&?A.T)N'OH$76\8-[=7=^?WUY]_(N<7]]>_7-]?7WT)(N`&<\'L
M,=BO()\G?]W*DT=YS\Z31(251-EME'+,%]$FK:*L8Q]LK*.B]/R`2-OH$BG<
M)J1]Z443C!BMZ)<G5BWN:0YY3_ZZS>/#()%-D3YQU<`_6%*P5R](VO013[/)
MT>YA1>R9BWF;_7G[O"SIX'9BW)^_4[:D.^,#M@3HZ6R-Y8;G8[4*3^9SHCX2
M;;/#=-\,F0:/QG&QA5I$,B?9>9YT4D+V&<Z5/D`%A(YU['J-MGG_(!KK("LI
MH(HR_>RMEH>#L[ZWB^<)WH9)5(H*$UPC/T294+_EBM**)%(Y$_:0I8]U$K,T
M%]6T$MZ\8-M'4.11W1)XM(EV8@$O6;'/V'?*O.;H'"(05$E0F?YT&:ZX+QL:
M5\5V/?PVU=\"LZ8.>W)NFJ^IX5^H3/'B/3SS^IU*QHKMWZK@3!OEG;(K[:&6
MBOTZ@&`/B`=3X*'?DV7_8NKXZC75(._9+2T@YOP#*VXX;XMR,HF:U;Z1)TXK
M&+QJMF["\@Y.&?L$2,%7JL8JMG:)=C&#C&YV)YPYG<6O9IF]WTUD.++:M_]E
MML?P-2VS<"F7[$ZWG44V-(=^%]FO%+(ST^3\B1;1(_TL$I;=+(6#]<VV*JM(
M)'-^'Y5I#(-,LVTUZ+=LUAER&>&(.L^L!^3DQ4$2)*_2QIXX49#8T1HPG!QF
ME^-SL`76+R"[][1ZIC3_Y?J*HY5_DHX#-\5'5I;O*5^WX$2@91C$=F[52J@+
M(JS)4!>M/?NA>SY9-29^HE&Y+<2]KD&^(!(HX5H7H)('@95,LLFK21&]*";M
MBV8S.(LP(1G4)`X'@\Z0JA^ZB`\4!&81#RB06(__0X[/2VS/<P1'RJH,?HK0
M$$'5,+X>OOM=CS\QECRG&621YIL*GZB4;R_R3>*696F\NZ<OU7M.^_>!=:G?
M`7)]JA-RO4X;).*(N\=2OV(MB(1#?JO_!5Q$``MS`43,$#-G^RS4B@B?0VB5
MT^\<1)?.0:?L@=B.'OT:-,J<M$B/R"F&AP;7(1<PZ+Q.KGJ7EK]?IF6<,3BF
M3VD/G4^12U"%A/MB4AT,!$"0/0KR6V@-H34+S(2UGATK^1U(F*#2)_J%QMM"
MO%N+,FP)32!(`C).;.73XLWR*BIROK1*OK;$Z4PZ:`QY6-KL&^MJ:0.#-Y]+
M&V!1SI=AN(309%VD9`^5-%@)+%O200O*K,$+CP\R2\J"J##+E0NFU77!G$ZC
M<3QR72F>;X'IPQ;H?F#%;<&2[4FL@?H'N(CED8Y=+_!I!(BH9JOC02S%IAQX
M%P+A&,A,AF2S8G?<'2,\749D(W&=>,H\2!.CJ/8J#(SB#GSL8!,D&%QE:3']
MR0B0+?*V2..AC/^G#4RR0HJ.O%U!6XJHNZ8!7FQ:,J*`UF7&RL-Y/LY2V<,,
MT\R4VS74BN<*5EVGJ7Z#RF$YT;<7S38%0C_?I?51(>1[#^)0Q2T-5)S]@>&U
M7,6J*!O0<:4\1[<Z+$2F3]55PU"\-=P';ED%G(FR)I_`S7(?_"0?+LZWU8H5
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MQ'6H$V^@\^RLW0/Z]5F9DOM'Z`Z4@_3Z\WJ+UI\:9H'?L]B+90["@P6GMP>/
M=&!W[^TAY,N.K(X(8V=V.5YAE-*[7G,X\G*YJ0%!+8Q76X[I6WB<21M8G;C\
M.>FA,7F<UC^33)]AGBXX]#T<UX^ZHW_;IF5:T2^T>$IC*KVW[FC,'G/1BW#D
M&O(T\4369;XO`WBSR@EF,`YG><.\\A;SE#:G2G#>%I-N%C%KL^CYP3I>T62;
MT9OET,FKY+=?D0&I_\_W_*<R$LGERGN(;9HZNWN@B'U2=X?,>9J7&KJH1#%T
M3RB%G8;C/XL'KQ+=(?#+A(CA"WVE\"$Q+(`8>#[]Q,+%I[R56:+X$.K\2LIF
M<T0/V#.).B77*ZN!TF;7@C44230DV\,AKW)64?*G"4MG@/'JWUIZYLF5.D>(
M%+/`-\,']CNVB[)J][B-(`Z%4JC!O4[E$8'K>'"JCQZ/[P.(+S%/ZFH4O+RE
MJT'1?D]V-4+$V;B&0GYJL9`.&#+#0>)>RYMQ[N&(4*UFG)L64(#';LTEQ0P8
M;&7;X'L27!UNBGJO&MXFAEKBMX7C'CUN`\>DD2O"?`3H90Y:'FA#GHK0@S"H
MF[WW'-R[UQ7M`#?U`)LC#EL&=;2;6`A,@ZUV='Y]U!C1[4<M#'1XW9-/75V3
MQ*HK-&(#W1L*,GX)'J^[W3YU;VC'U@$99@H\,UQ?/V\XC+SZ0'O7UNE?,>MJ
MWXN7-;4GIRV<)D@1:ZDF1WQ#M;&&EG`:3;:4;.M!'"ZBXQBH`(NJ1WC9!/-,
M0QO3C)85RRE?J>)$V[>F!ANA0AB/._,3MGA,53^NSQPW)CRQH4I"`L>MOH:>
MB#59-RB@TF($EM,9K+=AP69JS//M#P5)3\0SV]@[\E`SM&?387>NUZO,?B+,
MIVR?:/,OY$\_+-Z]?K?XX?5;\NJ2QB)#.GGW9D$XMWX@9^3MV\4/[_Z\>/-/
M/X9Q(AUD.U/EI5]IVM=!G<@C/=P0*5&G'3J7J7W-U]!IFD>XR=19Y%=4/D1I
M(>3UG*_-M8A<*:]>H%8!37YA8"3(^`'J+JJ&MB3]#I"BI4[(E[N).B+,@Y#+
M\2*.*P"'"#RD`VA!&DADCXE,#]G1"D0((S/GN.\\>74]\HLL*LNZ*/G('C_9
M'IT7;Z!?YT[00*\M,Q]RPY]F;5\=^7%^A?$(N!,ETL&@\YE.O?WWMC5\Y3_H
MTYN[8!]QD[=[PU%@TDTUK@E[T@LR.0K'+_G]`M+S9C_"KV#7+QG<*F\JT[>P
MOM;FE[%NK^Y#2CKI-A=MR5AY4U-.U^QX2)CL&')<@OBBCF!?$`D@]"6R5VKZ
M[Y+#?/-]I8P+&I647\_%O]?YS_E#FF50FZ]9Q,.W3(UOT1=/!1J^%(L2&,R"
MLCW*'^4H<_HH(JUU58]X'2[H$\VG?..=W;AU)(L9,=+S*3]]S--E&D=Y56M+
MR!@,V;I36D[Z5VM]C#W_*Q%Q[O6\1T'V,$B#(WPPI.9<,#,&!SXV#:84TOC"
MUO')7]*@HR-4U!(.7NY"A=UCYXYYY'@YE?Z)[`;3'YA=5WLZ]N2#?KBW-<3#
M[&P*7#Z]\TVRSJ]H06X/R&UT"&ZG5C=%[V.DR*D1\9'C168%:W',KDB*YG0P
M,QX'T[2?V6U4*#X2G[8UUZ[[/CWKU9R13520)_$&,:,40^/\[E>O0TP,?:D_
MM<PIW^F'/[5VI3\E$>Y&?XK%SH7>:(R&]WEI2BX41^3M3C\B6:-7^BE6^EUL
M=]).,G5V'6J&7$3'W;E>,#6].A3RAS`[\B`/F2IC@FGW;BZ!$LIS%T\T^<"*
M#]MJ6]"F3M:TYM?KQ_Q4H$;/UW:M#<SP=</5Z(W?/6I@30;?!IKPVY3@B!H+
MW)^=-"6V_UR%F0B_:[VW_B^_#;_?";\`8?"KR]_(RL##GATF72%7/(:DZT4_
M4&A:6DB"^8883<Y4O6@MC@=R*+S.-]NJA*1]<`A3\2`<_L+49?"T9^\^@J<0
MC)P";8S(S`M0(EB0!L,,O/Y&!*C/S6^*AYX/@4?+N;]0_"5;1VD^=/Y#=($]
M^FF0"J0`=OSX<X"2_";Q!,J*BID<9H/C(8,/+OBJ>H0G)('ZDPCM&#0IJ7YH
M)3BACX"_8(4RK#!J\'HP=&&:@9Z?"45%\W9WWZ<+'GHEG&J/?20<ZM>;7^L0
M`)1OJ[W1('+GWL,G85XW)Z6#:3/)=X+JY\Z+5L%R_F,LD]?IO')BNT$GJ]8C
MYWI1<3P'CD4'B&;W!HJ>+&9K!D+E+FU*=="DCN<]?XZ*1!B%;F0H#RQ-H:HZ
MX3V:Z4IM$C'.4&H#C,^DI`)OG42X1DP$Y$4=R7/3Q)2UN+NA9O-+16I5&GJS
MC]J?8L_+,\K`#"M>6C[3:N+I:Z(U=L'T]^I:\C^F,<U+4!F0G&2QSY(@PM\[
M27\44C^XDN0)?C--)H;:^M]O.9]I69[',M4VK('WN\[_J6_P^ET9;^/J)'UN
MU@TJTH6U@,H5G5_,;TM&S%_OQHN=%,_>BS7*"[9^2'.A!M0+*.E]C/5>5"+B
MW'NQ$>8.C%E53-*<"V;&X.!""O6/N6:$6&B^KM*$%N+73<;FG;K$JO9D3WRG
M*/HR\B"@8<P_7CB`>(CJ6](+LH=&#K`MB"(3_*UO9<D=7^QZD^%WY?\4I7M\
M\>[GO*`Q*Q*:G(O$?0.K7/$KY(J>Z-W7ZIV`@5FIUD>&6)6`@71`+,@>!E$9
MFJ/UIRI3#,G.T&[;MP6%I,V7=$F+@B:0M"8OH1;"3;6BA;1.#[ZZF71FS;5;
MA6@X9V\5=';<ORWSP<0AO(9"J,0@2P<Q@$$BA1%[<P_7DM=1AW%]YGL/A)29
MVZE$!'7&"KH".],3AQ^S-1U]8=?^'A\FJ4;'>=3DS<4U.:^J(GW85L)443%R
M&T$Q&/*;A!`L=E)S)I@Q>PWS"7_9/OR5QM4]NZ,;SNX57S&]PJ;6&)-?>+!3
MYX8Q21B$9T]:48#<C@-9RH5R>2F%%TJY'UK1H@F0KW=:8)@>]TQ+/5"QON[9
M_8IR/9`6M=?5GJBH=%M"A<?T<565PVO!L"M4\0@<2??!00(6"!O?M\@>&5B<
M.RNK!4<D.OQ2\\8(XX58G[+X*CS@$3W@T7Z)RF+2@D>%`!ZB4(2A8#.;D^3W
M)";TKE2U_'A8'Q2G0OO4/D*>N<8[=[VR!762"O+D5<;X43E0RA-%)C,<YSQ+
MV4:8\_+'!M208`VUP\K2<7^^;MXGA#&7:@OHL9Z*[5TYC.@/B@%3YH[I)0%<
M4_;[MMRN]WLZQ%C(V+S>2X/NQZA+A"H1+\5+E-'H7S+<C1-;0+Y[Q)-X%MTS
M($!J,G7.:;C&1SLXQY6"`9WSFSRU\;]%E3SD\;/>$RUV_#<%I63-\FH5XE"G
MOPB9V11X?I.B.=__,B@3G*S3/`4E#X40Z]UPZ$U*[2OLF]1X[ZXWHIJ\K&I]
M`"#,6XTBKQF2@8&R]7],<WK-?YQ,TW_2T#0_?]NA<S-90Y'\!C2)(!HX,_\I
M-_M2\@^P*)1#XW6>T"67XXI^Y%*<7'/=DS^F4-U</$$(-[2")N?E;514>V>U
MCEN`NL>C`UK&+I$6,?GTF=S#/LL`-]D#)Q(Y::"3".H(%]6!JV77.VUVGI4N
MY*37]=+9Y/O.Z9.7+$L3@4@MTDKE$W2FGN&NW:?QZ]">7<24$M,9AI-^Y:UY
MM+Z/7AKGKY26GSD#M@6\=P[(G.IG2+F;ZMZU[#7T216]D*QQBJNSD[T+8Z%4
M9CG#\M&W.U)%BW1]R__#D@M65AQ7=9Z!K/!=>S1AA<ZG:%>C:1+NP_X%!B)!
M@)LJAT$X#M(""9T.0&,>F`ES`R4CDM%R%RL^*[2\SMO?@Y??1U:6;P8$5+\#
MTU1%DX1<"^NKQB_J6Y+4GE%0SW<)F7]D[EU^9GV.B@)*+AQOJ6]1=8*<#-[$
M]4TB4!AVV'Q'ZD+9E_Y(D]F!5JX\]7_B8KCE^N\FOZ.@\M+\423MGCI28[LQ
M7<6*Y%ROY7VZKD5S`VTP$;"X-ZB(S.\^DTLG>M(&:GGJST1H?^[FN-<YZPV>
MH#2^M>:MW4/#VTD^Z!.K'KM'G8TG>>@Y6TP$&5)OEHW3\W#:T9&6V)POISTZ
M3^LB2().KXF&S!4ZQE&FP2:_$B,S'%!Q[!\0E;XF2!GI=N7+':5+$W.N-<.,
M>&:O"1(%Q(Y$N7?&F0I+##U/;OGU(Z_2*(.@+7#<^K#-$Z[F9;A6L_WVN9WH
M?8GQ.5&CX,7A1`V*MON%JQ$BUD`+A3182`VFCD`DLQLESL/D?@4WU/T-/9*C
MXRIM68\WR@D564%)S+990C8-_FQ':%3DXBO^MYI-T6-!Q7-H`+<3S47(#&;$
M<*-I*'UB29N-]9X!73XA$(H3Y;L/K+C_CT]7#RR+?MJF.8VN/U]^V3ZLTQ*<
MF!O/N^&0`5<T,)N7;2P>GIND.'<!@SL]0":P:&K0A*,F'/:9P'TF@1..G.RA
M-Z=#@Q"$\/PS=F!K=XCU$4MAHQ'N;0U+ET,L+?<L;2YP`7899^N*>9GLV2=N
MF7QNM-*GOV0N_AXJ.YE+XBZ4VJ[^YS!/E7:FRRR#B>DCYX`:[T%R'L<THTWT
MT3[W(JQ;OB;%[^OE>4N+_V\;%56_^K;=-T9MV\+@Y59B"ZRV<@[')6LYC[IX
MC].L=C&WABZ.FGQ]_++BA5]?D:!@Z-\D$.!8=,3!LL/!N,O!^N02X.!B?4=A
M3B<TC.M3DY]4U>=IL+VAL]-)O][>1@I)>4%R*@P!-7U^\2\ZAXFIJHS.1X?8
M^WJ&V`((ZL4U+$0][EL3O/.[;*[^MN7'*UC5+.=01AVU1MLBETMOGZZ7BB1*
M6JIA_:[&V<JT>!4HKN4(63GR<*CTC6FT2U_?OH4J:.%!-2[W1<%,LRZ0#]#[
MG?#B$!6P1N1KLKVI5\]QO\[35P$U6<0LI$1-\[7/\6:<6;/T)OLY9P]0,E:6
M5=ML*_YGSIXT2\6AMSNB46WIFIQ;[S1M6%Z704AU[7Q>]1W8#"?+=TQ46ZAY
M-$_A8#MT]--1?^ZMN?LBW&$3#0ZSLK^`=OAGAP_#L7^C0J/\'7;WG.K?N3.O
M#"W].!!:&E3,U)G/T!P-<3MNBJM"Y7B^^1:B@CQ'^7YWS]&,G$5U/S>Z0T^3
M\70#:@OP`MV01U9M]I_<M75YZMMEO"TDJU[P5.TCM)/X6.?.<YAL(PC,H7QG
M3%L@)*9%)9_A@[F+*W&\M\3NW,J)CB\+6!0*%D3USYULB'LROC=$B82P@C18
M%O4F&=[^J#$IRMOD$*<])TQ/$E&M*\INHY0?,BZB35I%V7B2=)5OL(G1Q_IV
M?HUNB1.@?@:E.B3]P+G0E1C.4%ST+&Y#9:`G$L,J?X<5NZG^O5APPJA@==ZJ
MU/.>0U;8BZA<G><)_`-[\%.4Z1T#M;_'6EU4Z?@*YU$&A'D>=SA:Q',YP!`)
M_6+X@>X!A3%":4L<,V:LWS5YE`AH8K^?:(U<;P.]^EI=`^0Q:\G:2!`KYSR.
MP4<,PF<$C#30U7%*1I@FNP)E+I=YU2&=Q,!:&&EIFKU\WZ/W_.5[TD89S$U&
M@,AA#H0(B"%AF]H!,'`F\QZAZ,ME/L0GOT)_1RM^WZ7)553D'-3X<\5X8Z3H
M]W?JOJR+I$H:LF'ODQ.<97KL"AYSTRDZ7A=*&8NXU^_`7C3-`"'GE\M.0?I8
M9%932^_G?UP6??[W0VZ**H6+^4?(W'A(D!+#0SVX2%W3V#TGGUKZFQL_LAQV
MZR6!(9BQ986?P&\I`RSM?449X]-L_!K>[SY%?V7%I'^C?@_V?1V.*07V>GC8
M$8%G!EZ2B-E1<X889_ELI'@/\G.T'G\,1/;BP'.GAUI8B5X<R#.@"NSSB)PJ
M13^?2?X?BW>7"1_Y3_R7S:_X?R!HC__F_P!02P,$%`````@`[X0'1^"P@H41
M/P``(C0%`!4`'`!T:VUR+3(P,34P-C,P7W!R92YX;6Q55`D``X$7Q56!%\55
M=7@+``$$)0X```0Y`0``[7U;=^,VEN[[6>O\ASJ99Z52E<JM5W?/DF\U7EUE
M^=BN9.:I%TU",A.*4'AQ6?GULT%2$BT3P`8)$B2,E\0E`L3>'W'9=_S]/Y_6
MT9M'DJ0AC?_QS;MOO_OF#8E]&H3QZA_??+F=S6]/+R^_^<]__OW_S68?24P2
M+R/!F_OMF[N'/`Y(<D;7Y,U_G]Q\>C-[\]W/?_ON_?7G-U_N3M^\_^[=#[/O
M?IY]]]-L]L^_1V'\Q]_8?^Z]E+R!(>.T^.<_OGG(LLW?WK[]^O7KMT_W2?0M
M359OWW_WW?=O=ZV_J9JSIT&V[U!O_,/;\N&^Z8M7?_V^:/ONEU]^>5L\W3=-
MPZ:&\-)W;__[\Z=;_X&LO5D8IYD7^XR6-/Q;6OSXB?I>5H`F9>$-MP7[UVS7
M;,9^FKU[/_O^W;=/:?#-/__O_WGSIH0NH1&Y(<LW[/]?;BZ?C9F1/]9AXFT>
MO&3]K4_7;QGTW_WX_7=O6>NW0'E&UB3.9C'-R.R'F>?[-(^S=+;QMMY]1&9>
M'+`?DYP$0(MW'T9A%I(4F"W&?DC(\A_?9'^LD]GNS8R\_^C\XFR[(?_X)@W7
MFXA\\[;&[28A*;RW@/<3_%"U9^P,RGE)('G*",STZGOL:(RH+\&'_?+O*Q@Y
MO:,780SS)_2BVQU-Z?P^S1+/SW:#1=X]B<KW*/0J28S87*1)!2*/Q/K*67KI
M?3$-\W2V\KQ-`=U;$F7I[I=9N8+?5;/Q/ZJ?_SVO0+PN,9S'P;Q$\-,!P+,P
M]2.:Y@FY`_1.@)`_CMC4]+;AV6\@AO,E%7I,G(W9>W.,W/HD]I*0?HG3#?'#
M94@".)*\,.:P(6UO@(7=ZH:]CES"GRF/=FY#@T3O`)T_A5*ZF]H:)/V.;3DR
MFI\U$A%;/[7FB?^&)B`>_>,;$*C@R9(D"6QJY1A<<:`XM@I"8,!"I/D;6W,D
M@',!-L4=%5[BOS@+G[^H:O%VXR7L_/,?PBC8]5XF=*U^SE`<-##PI&&1\-B$
M`G]26P=&(ZM4>7-%X_)N(KC()PEGQ^YOAF2@TI%/9N!XR2QM)4?8LGXP$B#5
M+!,?L/O[VT:E2K=V&5`_+_Y@2A7\/\RVH#<O:;(NAL1KD\@7#:<]*A&$TQ;K
M@DQ*_&]7]/%M0$)&P@?V!\/F0TUT@9_^/0<:`D;'1>2MCJ06[O.VTA66J-,\
M8;/_`J:C%_T/\9+S.#@#X!KHDS7MF]2SZC.6!%P3.*>""_CM6&I%M1V66(86
MCM07+8<BM,2(__6%[88B\@[&$=!6?]PW2>?%/G(*HR9>=`D[QM._R+:!-F&[
M@8BDZS6-;S,X8VYALR3I(L^8/939B/D4(SH-1'ZY[]R0#4TR&)V)*8TK"=-\
M&)(OPH@DI[!`5C3A3XK&5L,0>$-6(1-@XNS*6S<M*5&S84C\E48@1'E)"1/_
M>W/:#4/D;R2*_A73K_$M\5(:D^`R37.2<(F5M%<AFF.PWNV%('660UZ^E'3J
MIFI,>V<5=%9!9Q6<@L:*7]+.'NCL@<X>.!U[H"$D&DV!.`'1NEDAP4*HXZ'!
M>#]U,'!F(C0>WT\=#ZFNAX;B@QU08!1T-"8_V(&)4(E%@_&C'6"@E&0T*#_9
M`0K>'H=&YN>I(\.W^Z(Q^,46#`1V>;P@-GFI%.5,P>,Q><D4Z0?#(S)Y\53@
M91W<Y>Y3T!5B`(3]E=(H#%AP_NS>BUBP^BQ]("1+9WGLY4'('I3\/Y`LA(^I
M$-^M9YSA'/8ZZ57WY[<W0=;.Z"MZ[26_>E'.LT0*VPYO/7TA7LSS[($FX5\D
MD#/`ZS$"-@K1$<W"\]8C()_OJ57IXOPWK\Y_LUCN@X*O:1H6Q[@X/T"EJW-,
M.<=41P$-,\N<C\KYJ)R/ROFHVNAZ2C*>=9-##9+NIL1)FP445++7X;925O'&
M8CDY-*!+^`?0_4`C^![IC/R9L[#_WFPIG4<V;EW1Q,&0]I9Y$!2"(XB07AA<
MQJ?>)LR\Z#-9W[^(P53J8R`K/_@]3[,B=?..<F@L%F)Y?+'_,EO8*4TSGAK4
MY94F,\+/B^D&>\^&QD"\T&X@;&M0U3NB*\5HJZ(^SORA:OZXK>U@);)X^X>\
MK[,BC$-\07TK9T;@H2#?<JP#1<@R;24G6*<]8C%"G+[683-"L\MH2P7HE$`'
M5S&+FF/O9K&7Y0EA.M%]G@*S:5JDD2_S\N<-*Z@'%*A66U-_\<#5UMH2Z*JM
MN7)CDAXFE<NK8E(OEHL7T_>(?GY#YTU_=>JD<SI/4OAW-=*<O]GYFYWBXVJD
MC:Y&FDR\,J/NO9^EX2J&->U[K%Q86<<MC%>S#8U"7[VF-OI]`RMWBG19H]-Q
M2+PCR?J,;%@86J/O4-QHXMJ8)6R85"HOXT=2VKE8)II`2>`W-$UTE9H<_E7L
M-$(/.KZCTY3;L'#8F>?[C?FZVI=EY?C5.CLS@#,#.#.`,P/(-#S9L64+$@(^
M*4X*?(5:OS,-O5;3D'BYM!47K8LY=X8S9SC39SAK(^&;,:9]/UN39$62V=<P
M>YAYR7V>`1/W(2WZLTOY_!FK2TF2:#NCL4\3\ORIHK%-VW@#&^,TT]W)6#<O
M1[^,?;XAC-=&@R&N>G41$[38%&9A*1W\QAH(JC)@:HECM_G][\3/[N@-V>2)
M_^"EY#JACV'*,YMT?D\O;/P&<XWF646%`&7%KAJ(G8#!^(9$+&?FCMX]D/.G
M35BZ,!;+AF]Y$ZX>1/AV?)4&9AIF(I]<:6,#J3-?O220&%X;VPQ/ZDD52#?W
M_\S#*NF=_9D0(C13HON-@R7^=Y"T-D<^;'/WL'4P@O"7GZIU-EI.1FC1Y[:;
MN$_($C;,)^-=QJ`Q@A9?"@"+I(C4!JWV9"O9=U6[CXU!1A\B`1'??7@&+[RP
MS&2?IREAXH/')EFPB&^(GR<):(\G7AJF7V)ZGY+DD9%]&6_R#!Z#LA%&8;&O
MG6R+[J>1EZ9"0/H>SB"`=:($<U[:W@`+81QFY%/X2`*8JEZ\"MF]A-4'$AP,
MZ'XFW->PY,)U6=*RR!@!#6`>,1*`1N$45>EJ+D(=E`&6I2^8:(*6YCSO%S0A
MOI<V!]+@&KNP@38L,`T=ME82L'P\F`^5&32!55OJP2?;0YMK;UO<$,/4HH-N
M%`?7D1>SFQS$W/<XE`M)<"$)+B3!A23(?&<H0X(M<,B8I2C+O"UN9Q>;H!*;
MH&*U?3VN]W9V"5LFC3+WM(LSR)9]1R-JJLX_6Q9F&PB11FKK*C-R]RZIVF_+
M-B5BE.ITG]JR0RD'*HKL+VA0IG(M'7=!"9S#MBRE9A:I6B0-&HRI7,K'G1%(
M$[XMLT/.;AT;-9^`+:*+"P)7W%F&LQ;;`B7"S-,R(,@6X;B+_M#.4V_+W%+;
MX@?QX=L"K41-:>]U1@,TE7M_72:,RX31EPG3)OK23";,AYE/(\"25J5NV,4+
M!5ME1<TH!)$Q9>57O!4<X(5,M",;F?O2882!LUTZ4]HMOR6*MY&W_E2,0N:[
M(01))I@.&H+P3S[?\HEX\5!+2D@)^SF#4Y:\(FRJD9C/-"ARV]C,N*,7>1S<
M/1"F-GCQ]H(F=__Z?'Y/(^]C#@O?N[PZN\WOUV'*2*H.7V$B2S]C:&#_#&97
M$GM\VAL;Z!B8G@D&/7ZH8<#+V$]`FB1W]#;?;&B2G9%'$M$-6U-,Q1-\/\6N
M&HD-V"2!+0EF!YS=*[*(!0DRZ$X:"/SL)7^&]Y1/3&,#'0/#QNW%F6CDQA:O
M(SOL>GYV*H"FX;&.&F9>!/O9`X&#F.19Z`M6DJ2I@0RNFC%H'@=7-/8.O]S!
M7RE\(&XR:,>W&$C+81KQ_@Q:+'_UDK#4H4O;Q'F<A=E6&(+9YA4F\H_VDMXC
MJ7T>?(95BS>88#-GL(."DVV9C5(0BREJ.O$L)4O8,)EL]1%6*Q-306P@,:OG
M<+(MC4N"&87J8YJ5BB3AEH;H,3P;G[VG<)VOA>=.8YOA22UOT7XDBSP#)9PL
MEI_@GRMY.4=TO^%9NF';O6#NOWANB$0AO@TM#)"Y#X?9FS".CR+AXE3N;X+%
ME'A`(XA^-<VP)C/L#`!W])HDK*`*J&:+#,3@5)K&JO7=DX)&F@"K]=TN\\LE
M,`GHMCJ!J1]BV1I;+&O+48"SL.WPI#?JM(6`>ZS]EMJN@+,NKW))9R[I3-LT
ML@6K3DA0F2'4EL@0^8R2VX-LF3%"3JG8T6G+?$!A(/#UV1)+B\.AV?UH"P8N
MBU4YB[65!]B6O4,-(J3WV9:X8/EB0N@VMBPF,:N'I-0^PV%>3_(8QP9MRV1Z
MR1Y%>3Y>3ZY8#[9A:R:/5FB.=RYA.*(M)QM*5!8%6]DB__0SEQ3">U]/-H9"
M2($M.Q6.Y1I&BEYS6^0AU':$BB^T18_O9U\2!.[:`IQ+J&XA<7.#26R1MV4;
M3,>`%%LF25?_2_<X8EN0E%I+M(27VX*6LIR$CNJT16'3+@_T&&B%QORG<6/N
M$LQ=@GD/">:MDT\.>`V99?[C;%D&]<2K'3G([/&&G@-GA7,IZ)3M/8%<P2_`
M7/(U"6&;D%YX*&MK('%O.E>ON5RG<>4ZV1!X[:[<<!'K8KI=Q'H+8F&'>J`1
MG'5I6;.-'<CXE&'E_B[`VP5XRV456T`05P+&B9BV6+-<#*;SQUA5X'8J+C]G
MIW-V.GUVNI82GQDKW4^LX"'LH-FN_B%=SGSX#&$V2\)T3R+2<H=\V\#6/"6J
MK+'PZ2HF5$/N!M!2*9:$[SIQRY4E;#@#G+,C.3O2M(049V1Q.K73J9TBZ!3!
MT2F"Z@*P&1WPYZ+H_3Z&KBA\#YW68=:F]C_R;0/K@$I4X73`NA"3$O_;%7U\
M&Y"0T?&!_<%0^E`36^"G?S<%L%8""^]Q6[D*2](GLO*BEV&Y-:HX+32$F\R3
M^[!:'^SFWKL'\B4.'V''@Z$6RY,DS,+TX91&^?H^%-2C[_`:/4PT7G-^1*'@
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M`R'GCX1S4R:JK7'2)7E*DM:C(%^\L\C:.Q_LJ_?!2JW+4X=`Q"!%V89?CX_5
M%1]_-BU$AN/7$X$M5^!LF11"3G46XAKY1H$K,<GU+]A2N,4%+G4)7!*IX[9L
MGJB%(O+]HH$8>15(^5*1F5]M62<"/FO29K=8"316(R_MA]A@,2JX+5-'QBP?
ME]==G1CER;5EDLB8W6TRPL`36R0TW+5!F#@@6PYB%"+".!E;#A<4$MP@M:FK
M<A*KESC2=>K,NV2+;G8.1>>W+9*&JS2M2P)I&2QH"T)B'5`MJL<63-HK-ZY6
ML4M]>P&)2WV3I[ZUCP0>/`DN#5=Q<>D`_.WY/CM-@=K9AD9AD2NV^V-'ICP1
M3O6-PR7#M:.L4U&4VN"MR:@G-NAXGX':Q'NJKBM:)"'/\@X&DAR\-$P7RR/2
MMN5_9=D!:IW-97#`WG4?QF6IH)(X'D/2#D;J]:1`0E!0@_LNF"[#,W+N)3',
MD?2:)$6U.APOR%[#LW/AA<FO7I23S\1C9U]Q2;3"XE'N;X!%FA#8AD]S$&%B
MH*AV!PW(`,4_H_HBD;+<]7W#0_"1TN!K&#%[[R6<VO$J!*%ZGJ8D0_*L_H+A
MF;PB7VM[>$)C^-,O(QU59G3;UQA(VWA.B.3<EK2>*/FN-)C+:7`Y#=/2W?5I
M2RY@G8>"B[U[K7XL9SEM83E%2A>VK!V9+$C5S3VV0(/@EW:S'=FRT:@AA;?F
MV!('K3B3D$8[6Z+4U-!I:W^P)8)-#2TE:Z,MH6UJ$+6T6]H2U:,(EAZ+IRVQ
M"6K@=;,G#NYT+JJ2OI>JXAE3+E1+L*J^=N!:K.W(Z^2#/GU@MQ^EE_%^/UHL
M?_/8G4A96NAO/&MUR]X:JOXU&6Y:P2?SG7?X)D8\:*4X4ITGP2*^(3YLF$!K
MH22@'6F*KW%F[U8L/)`@CV"Y--\X5ER55-WLQSY*>4"E:;XN?Q,NS7X'<3X"
MYR,84=TCU$H8RTQN02S.OS@M4Y?F$]<Y89P3QCEAG!.FLQ-&O//:LF0XAV&3
M;:J5*F#+$N+CU$GWM<6[()]&?>H?9LQ2W\_6)%F19/8US!YF7EF?;G8?TJ*_
M-PMC?[:D"32*MC,:^S0A1T];F:UT#SNP6:L?\K6G7O1"*\K&U`]`)E($:BFE
MUPDK-K7V+F-&>C&EI(D0[=[B+%"=+%`-J*<GV]J_\'8F]5>99/P2MH]E&(<9
M^10^DA=^W2HG.IBGUUZ2'9BK.<CQR/0PEC/$.4.<,\0Y0UQOACCM8HDSU#E#
MG3/4.4.=,]1IM["TE;QM648J6/4FB[\>TUXG3=V,[>[#S*<1X$C+&K]I<>\U
MBYDK[[R.0CAW4N9F]';EPUH&F74?:&#[G"Z"^['(=:<.98/3!<*06LQ9M87<
MD$<2YP3V>^9^6!74X2\G;?D69W7K9'PZ/<RV1U)#G`4T7S%EJOEQ/?19,0BL
MMQ&=(<H9HIPARAFB>C-$:3B;G>G)F9Z<Z<F9GISI2;LYI6>YTI;5)H>TDR)F
MQJCRPRX^.YUMO"WCL#B1X4=`D9W,WGT8A5GKA+W6[Q_8A-*1SGXL)ZV)0AE,
M.K+L#`<M#0=5+F]Z78(.F^R\A/S3`7%%RT#[5SK5WZG^3O5WJG]OJG_[4\9I
M_$[C=QJ_T_B=QJ]=X^\J+YK15=_-8B\#!7I&E[/[*GZA.$R6>?GSANSLRP')
MO#""(P7HS[U(46GM/M#`VJLN@CNIL5=`R1V]"&,O]D,OVJ_-LW+$N^<#UE54
MM9X:*M#\]D"C:+OX&I.`W8H5!B&<(<WJ,Z>IJQKNE$"G!$[KI&RSUS@EQ"DA
M3@EQ2DAK)41%B#`C5LO+]723IEN_?W3%&_N3G3\S\3W,MBRV_9&DY?V23>)H
M8\-VPNCTQ?@[DJS/R(:F8?;\LODZ5=Q&_>D1E[$?Y0%+3'@)AHJ2(7R/20UD
M#@LC"*.<103<LI(RA<7@_*DD]P*VQU.ZWN3E"ETLCZM)S]=L:7&D4"WO-@E.
M0[K)_IK8C!6Q#X-*&]]96Q2N892]R23CAQWI;OO\&NHCOO@-31-]"JMK19/P
MKP+5QDU%O>/P3'VB\8KM>_S#1-#2F3:<:<.9-J:ELCK3A@:M578LV8*$@$^*
M$YI?H27#F;M>J[E+O%S:BH.VI)H[8Z`F8Z"2LM_?VAH=9KW:!?I;A:/#$6\^
M1(.B?$'<Z$!14(/1J"A?!#=:5#38G\RX-+H7/NOF\NAM_,D5_NW/93(OJ8%C
MDV_[Y[718/JO7ETO@2VE@]]8`T$-%7W8@4CBM)@4YT_L3UA?$7SAX([^"OL<
M+.2JM'>C5Z+;&[4ZI1I(.8>_LNUE#+LG#'R9ICD)%@G[/Q-$=]7OPQ6(6?,L
M2T+X`D5)*)IFS_:S%PPAH>AM_%Z`JPTY]WT25?MVO;)[`RD@//W_W$NRYEFM
MZ]V],.QU_U()J7%V2Y+'T"?%];&ER+DK+W9',R^ZSA/_`3B]3J"1""R3=&D%
M&FA8P_#%6B]I!VWF=^)G=_2&;/;#TD?@EN-*Z?R>7MCX#<XZFF<5%8)=7;'K
MZ_+-[X^%NP<"*S[<[0D-W_0F7#V(<.[X*@W,%`?W8;ARE`,I-T`>_QA%=]:Z
M/!L6$1]A:6,#(091,1KL!J)#A!=#@.IL-(*"W9\B<9,WMAG%U1!5A4TB],VB
M^XV#)?YWD+0>!?D*L@2>2X67CB'@ADMY>DSZ5<XVMYVF4CYM"POJY2.#!V1O
MGUD+5F2Q_)4RK6W/S:YX+AX.Q,M&QG[Q99HD=52?,3#S3.7:TU@)2J>@8LKV
M,OD+1L;F,W-C47JHM+"^4XJ=:W[%R%AM*,2\\V8LDD\T35D"9WF0WH8QZ'Z'
M#W@&GV_N-R@!?0\W?@BKHDR]8Z<PSLA`NR$^7<7A7R2X#&!##Y>A][*F>ES/
M$2[N^JL78%?8=G2,9A+`2OMGRMVIMPDS4*J+`_^&I"1Y)`',BXLB^[:0"V+N
M6:/\GI$P+0R.Y;8S2C)"W..T'@GF)4F+/$MA"02P0V.YJ'4QR8I8H3C92A1B
MU>YC8Y#1)U295;L/SR#R9N$O,;UGVQ<C^S+>Y!G;[6,?-O)B[S_9%MU/(R]-
MA8#T/9Q9`'?WY#)[E`]R]UGX"/)I'#"3(`(047>3JUQ$(PNR:,$:ZS96EGZE
MH#05P0\MO]OS%XR-S9LP_>,"Q-C=KJ3(9%/W4;!8WQ0$9XZTO4$6BJTN995E
M66P;YL.\[&'T6_#O<!)*E^A^P[/TD=+@:QCQ5,C=8[-I>K`2P_4U_(>6IIXK
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MU%20862+<-Q%?V@786;+W%+;X@>)/;,%6HF:TCZ"``W0C^,&R!5*TU.!2&_*
MQ2LLI(8,<7]%I=$$\D2+Y,976#ZM?5;A*ZRJUCJRH3_+P]2PDD9(]"<TC!:J
M?A+5T4#^9#.0_.1O-#X_VXQ/AT(1:`!_L0;`MFD2>%G5'@6@?=X,'BU[1/NV
MV6%XK.P1]E73S?`835^N'VW%0OQ'F+Z^8+SP*!YL>Q2.=I7C\$A-7]_HM?0K
M'DA[]`V58@UX?*:O;W0KGHE'RA[%HG,I&;S-=_H:1@\ESO'PV:-R=*FSAL?+
M'K5CH$I8>&BGKZV\T.CD50[P\$Q?CY#5'L!C88^8C_,K=R^#>,!VR.MO/LQ\
M&D7>/2VWX!3^&6>)YV?I#,3*602*->S0(%UZ*^"FO.VHVX4W&D<<^(H;[91W
MN]3&]V%=!*<5#55@P\$)O1NJ2B1&]=%:5GX>Q=O(6W\J8"'S'2:"JV\P'700
MMMDD]"F$A4O*X.W24]A(4G-3O=>0?+[E8_+BH99[+/:S^)'4XDH;"FY)VVN^
M)Z2<E^=L7<BN`A$VU4C,9QJ`F.67$BJ]R./@[H'9*#=>O(53X.Y?G\_O:>1]
MS.&4\"ZOSF[S^W68I@>50'@M2#]C:&#_#%9A$GM\VAL;Z!B8G@D&/7ZH8<#S
M:A>6[05-[;1._\O83XB7DCMZFV\V-,G.8'^.Z(:M-1;.+9A(BETU$ANPV0J'
M'DS3VR+V*19<'H+NI('`SU[R9WA/^<0T-M`R,!P8^?H:1`;0T+RH4&MAD<.D
M*52.9EK$?;3.,]E@\%7VVRI_.:B_12\3(:BR&8U)E0#1>)_.BT9Z20`9T(LS
MT11K;*'C=B?B)>SXW1T@(A!X;;5B,:'KILK]VXO.G^``\\/T(`_#..7#\@;@
M)FK1G;6B>ST_.Q5,LX;'.@;=K>P=A]6FS0='W$,O(L*A=N>,.I&[GEJ)K?2L
MRGA720^%Z2#V"7^'17332N:=%X'X^4!`(29Y%OH">4/2=/CR6O7TN'D<7,$:
MK2DJAZ-)7"VTY5L,%'IG.4)[E6&Q_-5+PC*KJ'3UG\,,S[;"`H-M7F&BHGW.
MZ-EX2;9EZ8R"$GRBIL,3?E89/ZM%S*'YJ)7)`G4?X3OOK^SV0Y*>;,M$+0'D
MJ#ZF6:E($BX&1`_C;'R)$S@)$A8$U70"(WN9G&*592\5KXFC5B8)KG0<X9G1
MV&9X4J\I<S`\DD6>^71-%LM/\,]5L;<+R4?W&YZE&W;R"G:?%\\-D2C$MZ&%
M`3+W43%[J_KQ:2G<'I7[FV`Q!3W7?P"QK6;[J@ET.W'_CE92]`5-%AF(L*GT
M,AFM[YX4--)K:+2^VP`T=.M%V59\(#UO9+2(L`4EU%TE<%<)G$<LVQ(6R]KN
M(<!9V'9XTAO5YT(C.E:T2\5:P%F75XV$\>W<!Z$2_G]"LJ^$Q+]>GL,)43ZZ
MC`M!LPB4.2%P))`[[TD%"N67F]RRFSFXHD!GG-(H#(I\=R])MGL;9!G.IX0(
MXGT3`Z$6PJ@/B=I+7:'\DGE7*/\(A>Z[KRU8=4*"RGQ3ME2SDL\HN6':EADC
MY'2?2-$<TF;+?$!A(`B>ZJ^8TAAQ:([GL@4#=_.&\LT;K2+9;-D[U"!"1M&A
MP1EY+5/Y8D*8!&Q93&)6#Q=I]!E?C,9R\@7O.9XF6R;32_9JO`O\FVC^)U_?
MO@</D#631RLTQSN7,+_#EI,-)2J+8HEMD7_ZF4L*>65H("=?05HA=,N6G0K'
M<@TCQ=@86^0AU':$B@"V18_O9U\2)"#9`IR[!*:%Q,T-&;-%WI9M,!W#SFR9
M)%W]+WNX6T?ZVX*DU%JR:]@I`<06M)3E)'3TO"T*FW9YH,=P2C3FRF42QZ;2
MN$MQ7D"B+5JHO[W-)NP$\47]2?03`[!K\%Y_9\CH@%2NOM.?!6*<V+3(D.Y/
MAQHG1&HY^?W9/Z>(#J\80'\BU3A1:EWT`@V4)26HD>7BT+!,O]YTJ^I&>&%S
M^I(ZNK08'I3IB^":"DSA(9N^T*U4Z@D/S/2%Z%TK25D!/"33EYTY=CM9J0@\
M1-.7G7>M)`5:\)!8(C!+*^KA$9F^<(Q+$,<C8HL4K%AE^@#0D)7/?YPMRQRY
M>-6QHCGB30-7*D=3U*D"^81J/NZ%R.N$^H0$K$)_$(2E6EM=IYQG#S1A5VLT
M4:ST`KV5#JL!+V`9[B[C62QK]_=<D>9BC(A^6@G]`A,I^9J$L"F5>HR@?J"L
MK8$"@E^]))#4@6EL8Z#44W7T+I;[.Z_9QRTN3>=0+NIB,C%<.DEY_,CZN2HM
MW5AHO).OYGTXV1Z:5).K6!W5:OX(#;/TLM++/R8TY99+T3^2T6\O8R?E\7/8
M7.*`);I)BW+U.90AX(J+7$7L-M[T.CB9]_+I>G^,^>$BPL:"O]K?;Q0D5^/)
MU7CB$UL)('#*Y0EH*.5\+67H*_*U>,0''M/9[-P74%@\7.PN$*]\:6U8;7R1
M*VGSPC+C2MI(]!9;0&AFD2JIF[;$[[JJ$RX#I?V"&4Z]Z"\D<K3KC2/GOL+(
MY-X4G5<8J=Q=5'R%T<GM5(E7%'TL-[R\HG#CUH;G5Q1O/*!)]]7&*;=Q/[ZB
M<.4V_J[7%J3<QC%L)D3C)W;#.@L:V5VX3I<S'\`/LUD2IG]T#-MH^?:!0SDZ
M46E=>(<F7[_OL_C&](;X)'QD2MO+&`IA6^===OXAYQ^:ED'0>1*<X=@9CIVU
MTX@^@I(BS`C9/S,!\U#K9>;%`?RR7H=9&=_?3<AN^?:!A>Q.5.*$[/I)GA+_
MVQ5]?!N0D-'U@?W!4/Q0.[OAIW^?\V]QYCUN*UQ@2?I$5EYTSKO!2M!"0X#Q
M/+D/*S7HMS![N'L@7^+P$98\#+58GB1A%J8/IS3*U_>AQX\][O`:/4SD69Y>
MQKZ0PL8V6H;WLSS)!:'9S2TT#'W"$"7)BC]T<PL-0]?3U>^CJH1GF>2V6.YJ
M+E6I_]<D^1_X=Q-]+5ZC-<+^-%_G45$'I*`DA%D"!%S0Y#JA0>XWI@'(^N@E
M<)M1P=1J>*QAT+.$/)%H'@?R"29IJH&8<]`LLA#.$3X1G"8:!C^N<'SN)=&6
MY0.#OE-\=7*L_&&[:9TE+PHQEXG>]8)G<7!#5FS>TF3[(N40EE;U"@PW[=\^
M!-.W'@Q?*UJCAUF%MVIE\C/H0<>W&M7);7JN9]B7A72/QN55VNTX<`$W?C<6
M=M#[*8X_>2,YLFS>3B1<D3RACW#R\#\,IXF.P4=HO>9E^)69L<P'DV8IDQ](
M<+*]NSYMHH[;6.NG.Q)F]OO+3;AZR.[HXAZ@B,^?_"A/X>-56\E^<J_7+,S$
MB\*_REKIF*G8[XBC`0=]#.G&"#VP>:B^;)8);)`50=J`>/[:/MELS/#A-]1+
M2E&+((3CWPN#15+EXC?2TMBR!V*V`'F#XZ&A11^#KW*/Q9,0DIX>+#J'8@0"
MHB0]]29/EY.3(Z$?GIKT/)[`:HI)FL[]/_,P+8)/BC]A\0D]D.A^XV")[]:3
MM#9'/LS/^TI9V]?S8:6BTS`@R8NX[>)^@<6RNM4D+8II_1?LG!*N]0PRA@DL
MYV17R'?;&9/]FTPRWFBXXK#6V-8L\?S;(E[0+KMI>4C"*[E#5)>AWL0DQH>+
MC4[9;1M\A/D-31/]LOZ]D'1>N?Q!&:!L!]G77SOSUB!6I+<T!RFVV#!YG,CZ
M&2[IP8P9B^26)(\PO0632=34&.'LWH^*GE0XGZ3MAV=!^<*<(Y9:7K@S*(O/
M:JWQ^!`69#,1K7=!$^)[:=9H"L,U=J&&+M100+?5H88]$9O?I^3/G+F\'LGQ
MA:#'-(O:&B==4KA,TGH4Y(MW%EE[%Z?JXE0I(@!IZA"(&-S77Q6&#[V>.%2Y
M-6#JLP'%Z6Y:B&)>7D\I!KG.:<ND$'*J\P[BD6\4J,7!CTSI+^-_;$O#)7<T
M8()0R6W9/%$+110>W%\]B+$M%9D9W)9U(N"S)FUV"Z?OKT+&V&8-2@VW9>K(
MF.7CTFF2*!?\&-LD0049V#))9,SN+T@3Q<S;(J&ASE]4"H,M!S$*$6$,L2V'
M"PH);G[-U%4YB=5+G`PY=>9=0GHW.X>BO]X624.V8W3T^=LR>Q`22,LX5EL0
M$NN`:M%5MF#27KGIC(QRD;ZQ*3BN/,ASJ0V5$]+?PADG*.@TM_Z,K^,$1BF#
MM#_->)S@J!8[Z$]/'B<^[1*;^M.A1X<2+H"T/Q5A=(`@DO3ZDUS&C(8L;Q*-
MRO2K"BME#J%Q^67RN$A2-_$BG26"KL:[XZ<OY;;.Y<&#-'V)]]CRTD\**A[1
MZ8O)ZHAR$UCQL$U?>L;D:^+QF+Z<W'.E+3R4EDC8^NMXX2&T1"S74)P1C]GT
MA?:^ZNC@,;1$P#=2E`EO];1$=QBV/!@>WNDK(FU+@!XP&K):^?>S^TIRG7F%
M&[:P,7AI2K*R;'=4B:NLC#><!W%:?IM=">\=#\CRY;J&&[B>N5ZR.]TB9+C>
M]4[/\0X^^W/X*]M>L@@'V`7*&R`727$3UGU$"BUQGJ;A*B;!/"N="/!7>IV0
MFK*TBS6)`Z`ZRH.BA9>`J'%',R^ZKD(JBFL3FU@>$UVZ8$Z?ZY,WQ*>KF%U(
M=QG`S`R7(>-C7DS"*FXB`#H_':8B/,O7\&-U64)E;X8VE8VUUI2+Z9!$S.*?
M-6)8W<!67.97?OW;_/YWXL/Q=HC1N6:ACBD[P_A5MCN\IQ<V6%H`S;.*"E%]
M<+6N&H@]C,4^\@5-JJVH?FDNGU[UWAI(/FSU/6WZ=0Y['VP<)?]<%<,Q5#&<
MMSH+\5PJO'1\50H/!MF[PVIZ)V%>Y16C9G1^GQ;&G>[\'K]I%&RWEE).O?0!
M'K"9_>A%Y&7=Z&$&'=ER:<]9GC!ENFP)@O7&"X/SITVA&L?!(GL@2?EL")2Q
MM%@)_N&BM,&QK@UM"[1GE87JSGNJ/;RBL5\R/@#$,A):ZE+CPQKD"R]>A0/-
MW-IHMDS6PYRH/2OVNP'PY`]NS00%U7]#DFQ['7F%VX&=XYN&FQ8&'7N"D_<C
MI<'7,(J:YQ')U&76/D8='DZQFG6RE=0J5.T^-@:EM0Q5NP_/X&Z.<1C8/1Y#
M75U7FM:5IC5;FG9:A3<&LNJZ@J1'*+0[U6S!1YE[VL4C9$V2L:L5U*96T.LH
M?ZMQ2:FZA_M+N9T(A&W]OK8`YTJ)NK(\4RBL,O)Z;VWVGVY&!%N0&W.1$4-(
MO.13FNVEX!_O#RX#\=!=T!#O6ATB3&S;]EN".]+@6%LD-\U37SV^R)9IWGK?
M[<_'8_L>W0MRW3]6RQ"I_A:"^UJ#A5KU=RRXC]A7#%=_.I#[9KV%@Z`_VA1*
M34S\HPE"SM"?:0H5,`Q\)EYD!1I7?#F,7TI<8[("03:XLQK>D60'HK\BOB+'
M:_J*AL,]T5\/7QO$?;V!8\K1WU"Y-HEQ,XZ![Z9L\AFR4,1[7MC2FGAISF*6
MO&RV],)D]EA4V6M7'Z+C*`.7A=!";:=J$-S(LXZDH7*6M;`_9,1BN7HO@*+"
MP'T6IFQC`4J/V):VGWT_0B8D\?'H?J-(&)`53^0PV>)-)J.N*[,F^U_-M(F?
MH.C^)IG<DW.RW?_Y7R%\AL1_V'YB%;L$,<]JG0TR=QEO\BPM*'K76.%"H<<X
MV'BOS,;[,;+QO3(;WX^&C<_E0;I^MJKWTU^8H-'J'<.S>AD_DC1;JVU[N$[#
M,U-3`M3/9[7.8V,.U"70$>&<;<7=OK=)P>H3C5>L1%]M=O&8>=G2Y6ZYW"V7
MN]4/L;]YK`A]EE[1[)9D6408.9?L7KP'_)FA]A+<<IY6B&._RKS+4#M"H8WF
M8@LZBKPWH2;3CFP)?-,+5:,&9DNPI5ZH&K4\6V:5RR@:0T;1R+,^-*PG=>."
M+9N12YE1"]U6=#]8%7R-Y[U^^U];V[Y5D="MH$/89WJ,-&:I+Q,`">W<M$XF
M$NY3;<RP5FU6B@!07286J[:M]B!J\&!;M;>U1[*ER\$6Z;[5H:#B61L\#LVG
M<<!RB`+V5TJC,&!AGC5#)EW"/ZC_QP.-X`NE,U(DN<[RV,N#,#N4MI<'HVD;
M:KB(-,TDX\+2-(4T^7Z^9E>UD3(Y#/8^@.<!N`D?X0!AM\T*G?C*_0U$;05!
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MB`4`RVI`9WE2WNP-LE*Y5FN%F?AS"MG?:+R<B,@K\K5XU(K#?>?1LB>Z]T/>
M<;1LU2N%GC^QRZE3[DUVZB\:(=MEA:[6"_)%][&RV'(Y/N\[5N9:+,9#O[$R
MI6$I\M]CG.EGPH6(JV<-C<KC'<A&2>03CUI`28TNNI6'@ESYL0X4(<L4;:VS
MSJ^.Q47!KFU=M!@6(XPIRA9/I?H$:N?O0>.E7/1LY'@A[._6;48C#,O<E'IF
MYB79L#$4N,@GJ16YOSDR=F2D`GV/(3?#!R\A`WH']L?V=]J-%N+NEJK^CKRI
M@8:W*:`QFT+130T3K=':A`8)7T%SHB#Q+7)HC/#U*2>*D<0[@@8*7PIRHD")
M[=9HG)3++4X-)[E#$2^L3B$HO_NDTH/5%&+O<5@-$^J$1]8>Q4`8.H<'1%F,
M+Y7(\S@8(RC2:"<\,,JB^KB!D7J=!L\SJ*[N3O/UVDNV+&[>JPK^SL):+>!9
MN"_<OZN=TJ[HK8ZA!JY\JX_D3N5OYS#<BL27\4-X'V8T:0[OQ#15\<ORB.'<
MD_R,"N%=RIV&/_7](/;X0S<]US'L%O:1#>P"X?$=O<\&Y[;20,+E>IW'Y#,-
MF$N`)GPJA`TU$,(MKJ1CN=09Z74@<_5_I??5<JK](N^Y-<T2/Y18TGH4%9EU
MW&\C8;_GVW0&+>$:QF%&/H%:4:.H)/]D^]G[G2:G$2P_4>5C]3>,BLT#B5?>
M6KR.6[[%5=I\=>D!KM+F)$.H!A!:7(3>$0JMSP];(&H#`$7J*Z\G7`8EFMHR
M963,4I0:;\ODZ+*`$*JV+;&=76!"6:5LB?/LM"%SK5>V3"-7LG4,)5M'OB4C
M#JB6QC%;@J-;;C):3!&V;-1C#J(>K=M[(".F&6_H>\`'*`)RPKA^"P0H[-D#
MF4'_C1=OT]G7J@1DZ^L_NPTS^/V?.LCMY`'=5^E;+'?E-_>!K9?QW4,57-WD
M1$)V?7'I;R<7V7[0W9!5K,WY4PGE1]A4&\HRM>JKP[48^PGQ4G)&RO]?QD>(
M-;H9L9WZ=#EVG9LH=Z.>!>`L^,Z"__HL^/;<E66PN($)=BTLBM#S+N]\,\Z2
MXRPYT]&Q1YZ.V^UXZF$"_5+"%I,5*TEP-S8+12=MSSKS.A\B1;W-.FL?8O(H
M:=[]F91'G='039P<W+['N3?@WHN\V">S](&P<!M]=RC(7FS\Q@0<@0/?CT!S
MF%'7WK8P(,<!_`)SO&XY+I/5>#5R6[S!P,4"%9$WQ"?A(Z/SBF0XOD1=C#"R
MJT]T1F#:^F$Q:>'OB%19A/,U3;+PK^+WZX3"AI9MKV'>9?",I4%MUD*FM;Q^
M%O\T"HQ$J9B2@O4MWS*:^S]X;(E;&R"_\%GQJ"TC,K\W39YDJZBW&0VQDMKF
MPK:C2`N174YV16-?^%VTO-/`E2V-UW/.LU.0_K9`O.@J&Z6^1F^C$7+!:38\
MP6>5[G!#'DF<$_$^(&YLG'CI>I&V-\<"G+`U>1+-B:S;\`Q]I#3X&D:\X_GX
M\?`$EJ(-`$=JHB^'6F%;$Z0_#ZL"V>S\R8]R5A1!@KM*U^$9J\UA#OVU%B8%
MD'J\41R@ZX/+NHV$)?'N_[+AN,B6R(/R#@:8>'G;-H]Z?LOAR;Y.R`:4J_,G
M5I>2640*!1*C22CT-,$61]O_F/!ON\-U&A$SL/.KL@)=3"[UXX+>SXPXR]`/
M>0SA.[IHJE;7U=$DPVU?HJ8N#$SUGK<+4/9C/_2B:UIE)Z"O>9-V=?%MML:W
M=;G-QN#NW^)2P_'=9/@E!MDS8I:'G18I$93D'<Q%#()H<!.N'C+$3:68+O;$
M`K;:;UV$'P\%%^'G(OS&%^$WI@@C!5^7+8"(6:U?(:;N*;)E^:`QDJMEML0P
MHB'!A\78$L2(A@8KD]J2#X\&!N$F0F.B?#/*2#%1MO2B$5*_%H5F7C1LN"M^
MNQ&%UJ`A4;X%9:231NKE0".B?-W)2!%1<2^@P<'?<?(\/6.L:ZBOH$Z\/*A>
MBV/$>Y**'P@/D2TRLWHD!1XC6X3HKCBHWT,XXN74'.-KBZZ),U!@@R]LL5(@
M^&W0.9533&R91&IP8<)0;;%;J"&#=[?T9[PPL!6K@22/8[/%@-%I6?&"B6VQ
M9*B!HS'5HC]#QY@!5(M8[\_R,:7MJ?6^-/)#K>WU=G;+C`A^Z^XM80J1+8*A
M&B:HW$][%I$*-*JAL+8XMQ0G4)><Z/ZD1@-GEAIN\HC!_J3&T8.CFOQS@,IL
M&9-]@Y25JV,F8:^\`AOTR:)RW7YES")V7;&^.B>=1S9>"$43!T-62FG0<&KU
M[V](L2N>TI0;XZ_^`B/YV<<;NJ1,AJ"'R:AH`5F2\&B%GB;8B@L*TLH(P>7A
M>;/9.W,DUUV.''*;F@Q/Z$[TNR9)<:6Z9)[(FIMGX,1+0Q^.U+,PRFM;IX0/
M3B\#%X#NRPIN"G-262CV,M[_OBL-]X[#F?H+##!95KLK[1[^]B[QXA0F$9#+
MB#LA2WC.WWP5>QNH=D!B.-HCYK$)UF$<LB62P;Y:A3UQV$+V,E4;86^>D>P0
MDM8FR-^%#96D7<89`8&/3[^XN8FD=I]-`,GI=]3*Y.$'DL-!+>:0^ZR-29EI
M48KA\:I:9SR"7[0;%=&212EM;Y`%Z51I:&D4>X$-B'\TP;9>_"LJ5:#@][S<
M9"2*1K^#&0*O9('%D"%G+ZJ3B1($*?$2GR64G,&N&]$B'DY\RJ/ZF&"E.#5X
M2W#WV&S!AY(&R63A-7/%'%Y=3017.J#?S&_"HHE(,'^$\WE%KG)VE^QB6>C3
MM1`CG$+>[67C8KX>8"79K=J^QK[T>)G>Z#+B>2BXC'B7$>\RXC'!0V+9L#\L
M8'._IT/?8<-E]EF\D-AETM]"&2TD$CM:?X%"!D(6,'CP5#_K]E#ASH$TH-FR
MG<K9I:U,&K9,&B5\E!P[M@0B*B'$=X7;$G&H!$?;F!FK8@V5$),Z9ZR*-&P'
M#=][8LN>@SS*%;P)UISG.)Z?);1CW.#6G.?*^+0*0K%EH;6`JV54DE49J>JP
M":,D;)&-<-LV+O+0E@U;RJT`&:&/I#\9<8R3IIM[Q9;)U!H%)))8_UQ_0O@8
MYYYR2+TMTTV%\6.YO.=0I_[D50/B1$N<%7)7QIETYGOIPVP9T:^])9<)1AA9
M$IF44ERRV$O$BFOJ62$&=LOZKES](BF3$R]CF%[Y^KC(Q4'(7^YJSIP_D<0/
MTQ=A'[I?;_;JY?VNDU8L%8?"';TA\.G\L*@6?-C,[B@K/WV=T$=@+3C9?@'Z
M+^.]G68.^]ICF1@JN<MVH&$-W07++)ZP^U[`GE>S?G*P0/2P\$K;V0>;F?MA
M;,R!@A526#-^0KR4G)'R_TH\-K_":,XHVX'A`-EM(87=C^T'<5!MS/6]X2Q,
MF5B32Q,%=;W6I6[R,Q^72^*#X';^Y!?FM!L0#!9Q\[SC,-+F%5;G1!J5(\0V
M94;?EQCVBRC\BQM&J_(*H[Q*G.*?";,O<)A4ZFL\7_(3&YIIE_PH=$2/T;`A
M3&%`]3'"RK/S]C+&%%?E\]CA96-B'G/3N;2KT5WD)8&[BH)MOJ.@[YA8$^<!
MH_N-@:6]]ED599/GEBN^8`Q,5I>>[#Y#X^4G:(8Q+QO9DFRX(0C-;D-?H]RQ
M:Y\:K"@-*@V'1?P+3"J%>"HE*[;]BT;#]$%U;?EM&UXPPF_;0&6[;XMXT6B8
M;K!^JC';\(+9^RFPV>[;CM):K%QNQ""II35LD5Q[25;]HV:J!BKAQS6-2>8E
MV_(PWUFUZP4CTS1?DX!G[>AGD.'!`G6J<&Y<T`3FH4](D#+3?L,U8$<`R#L:
ME2%VY-W1"G;NU4H2_N0O,,OG,^RKRQ!OR#*/`^Z70W0QS`@L"Q!=R&)9J[6-
MX4;4SRQ+!2FE993KKT7W,UEWJDY<Y2'>T869<,==3+(BS*D2&D<5>KJ2*&U8
MJ$(L60;.FH$J<A2)&[MZ+FI$P]Y9>15EXBNFBRM,8[XPS30#'%&SR]4K.4(!
M[>2R!1(,P]@TZJ:#VY;D*T6<6GA_;4'*%04:0U&@D2?G*2XG!9>]+0BYLDD(
M/I]G(78R!MN"5@<<>#F=EI]3PFDU;/RZ+9-P,-3TUF<9^8PU@2K&.-3#D?M+
MB6],5BR?:-B4-1,P=PJ)[2''_M7AWS[XVCJ!4W@>MHUNZ^%D,SE'6\`@!!$1
MLMK#*683@I@@/%N6JF[LI#'%EITPNO%K%>]J2Y&3OK9"?**"+24[^EK6C3'U
M:-!^5*XR09*A:R9W0ZY]V.3KJF[5-9;6,AFP`QPU4%O$`=IBS]`#(+JJ@F5F
M"KW3KT689G^;GX$Z17K0;)]<88LTV.DD06?<V&(G[X!#?0VKA?#V=WP8N2]#
M/X:HF.'^;`F6H"B+5'X-QX<B?.WS+FTY/O3@V+YB3'^FA,E.RBXUHOHS,FR*
M\4':2#)[0)543D.C^5,[-,_C<:@PO6#YPU`+?8SRMMY"9Y;9<;2!0P<H&6J+
M[4<GZ.J)F;8X`OM`L<_,[`/N`]5JCFD&0LELD]#9DB9K;[;<+<I9&!>_L)%G
M`3`31OM)(J_0W.Z]P]5E[D)?IVK,\^0^S_(4EE]C`JBPC4K&&&?XD^I6LMJ$
MA5WA@C%<W4!QNQ'?0%$GM/W;VJ7E<I@Z?-:N'[C.G+ZW#I_IU_!AJCV("%-U
MT?W&P1(_\U+2>A3D[Y;*Y6'F2#)BV[UD%,RF!T+W]T'`4<WN+@[C'':*RIL,
M+<M[M_8AAE6\0WEJGS\!:R![P+)+MH4X?WQ'A!RRWDDQ67-`Q"^FQ@ZZ_UB9
M%!=61/0TR9@-I14F79W`)?5/TE^H6V!S>?]'**#D*5O@D#%+47J:+98HEZ\^
MAGSUD4\2Q))IJ6/:8HIT^>IJ+IDNNFY_2!F)/6D)A1A,F=IC6114OQ@.94FP
M+*BJWX\B-%?T%UTU,20U&_+->+`^S))J%TN(3U=QD0:>Q_`!9SZ-X'BCU3)D
MUW`6$*0S+PYF4>BS*U3CU<Q;@?Q1IA.T<W;U2<+`?K'^6>GF0O/S,/-2@?^L
MJ8$.Y]GG6_Z@+QYJ&/`,`$UBCS]H8P,=`],SP:#'#S4,^!EFDQ=GE#]J<PL-
M0\/.YK.P$_[0S2WZ=%SVN0)1/L[^MX!!K\?<T2AV#APW,WD)Q"D3#TD")W^V
MO?+61&"0%C4=GO!/Q0P@$JB/6IE$^H9L\L1_\%(RWTW98T2%/ACE_B98+%#F
M3:#=8Y-?X=:+]K,!!'=9:6AQ:[/DWY+D$:9WJL:&H)?S0SH_I(!NYX<<C8G3
MH%#E7)9'*,C%(ENP$')*Q5J;+0XH%`8B'=(6/Q,*"(ZQHC^CZ`@Q$-A.;,D6
M1>$@L);9D@2&PD%DY;%EEW2Q'&.(Y5!.YAW7:NEH^+#EH'4!'6H!'4K&COZ@
M,5!]#\LYQ9NBK3N0T%/G]4T9R521F-+[FRGCAH5GU#83H/!^=A]Y_A^I_T!9
MX65:%$_:)*%?6'58+G!93JEE\$';UP\<6-"-S$Y!`PU%!!9Y!O3%`0Q^39+J
MUR8O*;9O._^)JF^X+8@HOV^W+S2H@S0"<O8?9)'<A*N'K/99>,Y223>3/K#]
M/)L?@&:ULOT,%(Z0E8")`U:JB<,:MOM86;PCR;H%:ZS;6%GZE4:PA49AMFWY
MW9Z_8&QLWH3I'Q>@^ETRI8^DF2*33=V-^J"=U],LT<[KV2NQ.^%E#N<`._92
M^7$IZH);JM,R:?0D'3GGK#,SNY3!Z=A/39@V4):PMC*^75:@SE")Q>K^/!23
M`@LCGO<7,3`IJ$2Z:'_!!*.#J).UK+]@@]'AU$:Z[L^[/%IX5&UUIG(/@PKM
MXRA.%KMYB.3<Q7ZV32_L-,K@&80:J.UD[W>I<P.DS@DBG3M]?V2*FH8YYE*Z
M$(1S[DD\HOFHE4E#[A$IY:WAO"2<YL8C(I_5F%;AX-#>I=4Y?X'S%[P"?\&T
M+*/]GNO.UGZL1KE$J+I]PB5"N40HK4E`(Y\0SADW!F?<Q#/F7,Z'\UFV->/B
M%.Q7Z*%$Z^VOT"$IL2:9,?7_,//*NIWI;.-MV190Z"3P(V#%ZC3LK_=J:>5O
M/\#`!OZNA'8L`%B,4B6^7!!2_.`UVX^EC378P:LQ;@!IF)CLLLTSF+81W:Q?
M&NWP'?HTT+?_?BC;?-?I,:1)IBK%FUZ7A,*WV$^9/95B"[+"&XXO`#;(Z%WB
M!1+3.**'$388MM<)79(TA5W-BV!5RS\1HM/PS)S#?DVW!,ZGJ+C8%3OET/T,
M%`!D%UU?QK#=9N$CJ::.F!M,E^$9660/)%'="W"=G*_"^2J<KV(*AJ/>Y!SG
MIG!62)<2,!WSVACK8J#E<^LF2",LJJJU=59I*2HR*X@M[@ST\D$KA?U%\8\1
M&;Q"UE_4_AAQ452[^XO9'R,X*JHO&IF?E#T:-/.B,7HT.E@),=Z.Z@G[SSTL
M7OCE?P%02P,$%`````@`[X0'1Z0/8#*1$0``#K\``!$`'`!T:VUR+3(P,34P
M-C,P+GAS9%54"0`#@1?%58$7Q55U>`L``00E#@``!#D!``#M75MSXC@6?M^J
M_0]>7J:W:MPDG;ZFNGN*W*:H[31LH&=FGZ:$+4#;MD1+<A+FU^^1?,$8&VPC
M@MGP%"+IZ'Q'YY-T),ORQU\>?<^ZQUP01C^U3E^>M"Q,'>82.OG4^C:P.X/+
M;K?UR^>/_[#M7S'%'$GL6J.Y-9P&U,7\BOG8^N/B[HME6R?OST]>]6^M;\-+
MZ]7)Z1O[Y+U]\LZV/W]\%.ZY<*;81Q;HH^+<80&5?/ZI-95R=MYN/XZX]U)@
MY^6$W;>CS#;4<6:?G-IGIZU8+.`<X!7)1;E*\/6RH(M)O@QDY!3'C\XTO[S*
MR1$@]!X+F2\2YN58XQ'Z/1%Y>'AXJ<48GT#9D[.VRAXA@>/B%!%'Y*O064K#
MZ;(&RB@-_'P=KN1M.9_A-A2RH13FQ$GD-@LM"PCBY".#C!Q<0LYX07G(R1&0
MWWV^A$CB[S[A:#9%W'_I,%_)O#EY>W822P3"GB`T2X3&2(RT"5%&.V1H6@GD
M<.9AD2NC<_*%5(/D"^F<'"%ELINA2^3W-^TP,UV4K&$)H4(BZB0L>5QAU<.9
M+GWZX<.'MLY-B@HWKR!4>]K^X_;+0'?8EH6DY&042'S#N'^%QRCP`'I`?P3(
M(V."71@R/.QC*I<*I+(EXA,LOR(?BQER<$E'?O[[WRQ+#QW$GS$N+;I2P?JV
M#D><+\Q!4H]NZ=;.I4,;>U(D==F+NEX"BE:[(J!5QM0'I.NJ`VA#[RU`M%8*
M8)Q\L$]?V:=O2\/8/$ZO:YM<P>0_>U%-/3PK8WH9+(F0_E4'0[8O?V@K+[<I
MGJ@YMIQO/,Z7I.KXIL2L4(TFC'XUQ92<2*`445)R\3_VHI)Z8+)361D@L8SZ
M82^$:W,D/=Z7<8H64?_9L9SRR9GR2=UFR`EGRK1$2BSZO;5#LK%;&1BQC/JQ
M]<"Q$JR4HD0LI'_5(<7:4*;^'*-2ZDPQ&R+1,FVRD`I_UFF5_""J9">)!53O
M>)-5B2AE4LOKM#AU-B-TS*(D2%2AU7D<M-_AL:6#K7/$'35"KP_)VC/.9IA+
M`A%#*N[7%4PY'G]JJ0C8CF.C/STT>@E!7%QD1<'R`*!G"!#!WI<%O%A6C=F?
M6@+:U<.1U4]NCH.\JN:`B!-XVBL--<K%XZI&@0BAI,$VS3BN:A.("%@;U/*4
MJF`(!2P"*Q68OZ1>9M@N<P+]`U'7AK]$SFW5%[FOM;0L)??MKEMNH1'"+%][
M@C%&N?!:N+`JLZ;_?')R8MG65:0K_;-#7>M:J[6Z"[4?VQE=*S`"@=T>_:Q_
M9WI')!R56">XS,#R<EDOYTM&J;%;RWG;8=3%%"I2OP3SB*LCW1'R=#PCIAA+
M80<4!2[1@?-6WJ^JS10;3H$"@Q@%_+Z,<:A?"0[K(L1A#30.Z\6W&,@_CP0I
MZ3)[AF#=**=8$F@%\;1\R2HW19]7V]+'>M%?0G;D4]:E20%AL[&MIDVM7.AY
M`B@"B*8@1NZQ[3&Q\Q&I/AQ3G#LKQ[FDB+#8V.HE0"T`"B530*TO`/0XII5Q
MNO*YD,SY/F6>B[FP\8]`!2I/1;K-^DVQ['5%EBF2#5+(?K*N-;0CKXSX]4EF
MS_IP3+'NS0Y8=YQBJ\UI#A)3>^RQAZ>=2O/4FJ+5VSI3YB4`LFX`T'$(4TZD
M3&+[U*9(!APKAXT"02@68>0S#L+D),S8DC)5M9EBRCNU)4"$`[$;:(!_O@(0
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M`D1)@#QS?KRU`1>B#G0:$P1(5V?*PZ]R1P.UZ+F)=3US)[Y3@S,,?3(>J]6"
MDV-8T]F<B.\F'+M)A2EGG^4Z^UVXJDWIUTM8K=^Z`_W/G`#O]>P,'0%3%9W'
MN_4^D<;B@4TJ3!'@=2X!WH<$6.B/]_EC_<^7`!O6BJ96IJ75F"+"FRP1-BQ)
MK1?QK^>^8MBX?V!+%1$]S5Y%K,L4+=[6W;*P7@PUDN?.CJVW#0RRQQ@64^S*
MWR`UM9-QI&#MO06#I-M"NRF:Y>^[UMO@.)*JZMZ#02Y55VJ*0OE[KE5V/H[$
MJ?H<SG:Q1,0#7^)'&2#O:9\"KF@W1*57^=NM59X*6B^N0FS6,,3VW#FU.2S>
M`96J*S7%H-/Z0?F1.!D?(B%P$HHLI@\?(]6V,+=(>XP(M^^1%^#8HV;H4T^U
M*1)E3QLG'.IH6%$`M)B^;B-8%I+6#<"R?E.P$D8=F>1,$9V`_PA-NPWF&3G%
M^C`OHG-A/R#.D0I@C%*IIFY37,J>(DZX=!GBL@A-<P8F.,"ESPT#KI^$]7L$
M[,BFQ*,C#SG?A3/5EP:PF5(TX\31"R4A`G^V%*2885%%G:;8DST=G+#G0N&Q
M!R$@B']4S7:$2`U3,:(C;8QM\.P@3C(/RA3Q5O:\#6\_'8.M#!$6*R[G1T"$
M[L\%49"$"4&,,5>!D,%!;FL,IKB7/46<4"]9^G42?$4AV7"![S@$)@Z&:<%'
M?*ZB'^UBY3WBJI>`QT1O&1%03R=$[QZ%CC=*L"WTFR+7NR)R#4)L*@+K1-BL
M;@H;C%PQMIAT1V+%CIUQIB<J%)^Z05[ZI7*S+"JKS!1EWA=1IL^9I:8Z%)__
M05[ZG?8C/[9XSK&#:,L$#%.<RM\TK_O<Y1A-91S-\3VFL,SGV&$32OZ">4;?
MYUF?`68(N`-<AAAY=I(WRBE"WH68X6^,V?JF,&_#U"-#`5D8/6<\'YYFB[T?
M\\4H">NI-L6S[$T@"<^N(E@97D7GZV)JQ6P\,JGR<U^#)*JAU11_<C?GJSUM
M/E(G>T1^%^'6NNI-D2'_D/;2B?QC=%3M`/TNJ%!5I2EZY!_AWGB&_TB9:D?N
M=T&9JBI-429_XWOCJ?]G19F/[>P-H5'*\DVB^A[1Z.YTS2IUV>*?T8P<1W11
M/-?'7/5'-,$M??GIIU:)<D3%B>J*1@DE6Y8(1D(2&2@`OW(6S#ZU]/7RYP2(
MU;+"JQAIX)_/PDJZD*RL:EEA,4@FS!WJ8N%]PC)]3VJ1)>%"!]]@K!/TK3%+
M)N06J(,]3/$9!:KQ>19^="?;IU8XLFYIU1W0`W%GVJ'N%32]QV:J6,:RPD)-
MLPZ!?L6B&%#*VH!()&ZQ/\)\8=UR8BV>Z6]3G+O,1X2N8YH;A)-0-=@>G7O(
MCYB5++`S9FPHU$"S8(2%`;9+IV1$).-9OQ1F[\V4!?39C+-'XL,D%CZ-[^L:
M$NB%V?6[2HS+O!LX-&\H]SN1T^$4?Z-$?T5'SGOC"P[3C9C"*CWP1P1E7%1+
MM(%,#)]L=ZFS8E\VO;'@]85=(=NR'6E-@2::X\B`!RLV9%*;!_SB=K",.9W0
M0+BJ5V(^R6#.INY_K(W/`83'`'3PJP[,P2RG9:\?U4]\ASUUV]B0_8:%"MQ[
MXP$L/7`2G6U=RPZ#'!>/\F.<NNT37M?7I1(#=MD5`J*W'E=_E0GZ[&%'J$/;
MV.W$'T1R.Z+/A(1&&1&*"MIG36ON4F?3`LQU;=_G3#\EOD:<`H,&4*7FT`42
MQ%&A,_$"??E?84N6KV&+)9&NT5C?3'D0%@M0+)2-N@\`5TN[%<]"5/3O`'&9
M&G[,U=?X_HJV[SL<IQIJ@/D]!/]`$(A7O,#5):`U>N,AK-.]?@!+-VBX/B?.
M2C_>,Y9F]V^Q3,C%D]'T@:'PD%!\E@@,3SV#T"=T(3%Z9!$]L8`RR99!ZC:D
ME&.>6''3O%`8NEPZCDLS2Y%,VO[#ENC$?Y>J\_ZZV_3&\?%^_0*DVCJ\\"`F
M3TRH(K&%@3*N9GL;%\]N[W%'(9WH$D/,_<2J]64:N"!6&[TPA.G`+QS_!L'H
MO]B10W:'9\G0Q>Z)^M!LAH;U9)NW/%@U1*WP62`C>\0FNXN*-]'4<-/Y^E&J
M,RRK+BW*;JXIM\S5;S^J"H;L)J#N<(JCUXP@MAS^Z_9ZQ#ST:P"S/^I^O0(O
M^42(12BUXE[C]39@A(Z,"I#7&WED$H:;OIHJ>^-XLUO9"$$XA);_@?^S[5%-
MU/P$6S6>N0Q\_=SI'FL+5/`&RL%S,"2Y@9/L^)<HMY=HH5ZGF#L>FTTAT,GN
MC.7F-+!7SR5;09Y.:A[D*PCL>39&RR8V$#:[RD!.)301;G@!*43TU_HC:]WT
MA^-B"]:6J=^-`1.,;N9MXO@1>X`V?X.R.+MY[KFF*'R&M6S":O+^YT(=W,`R
M/>]I5D'>_B+W!'7.0NGZ$7.'"%@C4PA-E@TI7[QQD]LZDWN!5#-_%&M$J6ML
M+BJ_R]W$,L%)`C4&"O$&)A,('<.W^G\%HJN/:JV8MKE\X_Q9.&9T?3^@&.)L
M%7\QOCQR%&7N?_SH4F@'6-I>X?!OEV9(EYA0HN`!>2NR9L@&P4Q]RSEU,*8/
M*C-16_GBS9O,8NQNM*R!SC90)[-Z0,A<(]<5W#]AL^=DKA'WYFI/*MILO<')
M)GFYHOM?W*T<_4&/Q`_\%,<@;+K#DW#PF-\2#PL)NOMHKD\UPF0055%D^58U
M-K:!!@A@`U0=%L,H4;]AJM6TMP8I[..W"$+ZS*(MD]:\@0D`_B`CMH)Z*7'_
M`\ZMNM-.GXOJTGM@A>;#`FY^9@-B[(C:Z_>+-A7:+=6KV-%G4CT[0YZ^,P+X
M!'(Z`LF8LJY<X^*3TD:"4Y)M[.6U42W)QCYC7QEX$S-S,AKGSN*ACH%/J,R.
M==G4_0]V7S'B*D**]\FS;EB3?SC>^(H#]2#O/A/_KB8WP!^,JB^!)A=7]'A\
MS`-LT]N#ZI.=Q(W.V:S;*$G,-%KE`7D=1L@A2\Q.7DZ-W@@:QB]%Q:U4LG3C
M]F$5<I$'7:1M*RQQ0/9T(I'-=J5*[LN^Q)YP-Q9YUX].U(W2#R5GBP>2L5E5
M!`[F*%"_<W69F0Z7D_8_]D8OL?7&ETQ(H39%L'LQ'_8O$\!K"NSPI;=RX.-X
M,.9*M*FS3*V-I9K&IY+VQ5M9Y>Q,E6[<=+9J,"S.'(Q=T1MW7)>$0T-X?J<3
MR"GCZISABMTEA1IL?F3`#6>^/M,*E:J.IT\OJ1=DON(%J\N5;=HBJ'"L3%YN
M&$[Q]>.,Q&>J<PZFW9')-'O$J[[X_L?@S)&<9-].`QVRW@BB,?7<R`L$!.[1
M%EVRJ>'[:L)$'OE+:RI<7.Y<R_ZW4+<QL?2VL8GVK*+L0)OUVVS,81Z*#-FJ
MT5:J:ER3+.]6%64V8+\TNKH@.JP?G9B('PADK2A3M`DVL3GRU%L"?43<'H_>
M'DC,*,IMVLR8L6<>O0^Q;$<JM;%1:X1T$B"UD8*Q2-U-LGJW1NG2>UIL%`8L
MB^/D"M8-XQM?=:XDT;Q'68,9=M3F6<:H;.K^XRG=GHO`+XSW%D'A'02*RZ_?
M5A'88FLE=+]QMZR^PI'QT)H"S6/9$'E,G7;C:(8!AY/I0\79#30%<XCT9DR0
MS&TH>1G-@Z]O5GW@H)#G#F=K\O<_!D0Q8^J@S%)*8R?_WZ?,\^:]!ZK?S1+$
M)8BGWKPLSJYO$8%I=X+YMB%Q`;3X%=LN7;-97U-V7S87=IG4E\$-?<$L;)\=
MU-NX1R!K;*SZE:6-C5:YPD-JK;I?.-O8:K4K/J36*_N5^(VM5;JBPVF=[3\-
MM*'5#"@XI-8T]<WYC:UJ3-$AM6[I#\%L;+[R-1U2^VSS!::-3;95Y8?3BG6^
MXU*RUVY5]2&U8,W/3VQLOKKU'E+;[>+C,AL;=B=*#Z?5ZWSF8D.;UJKR_[+%
M2@Z.=6H\B/;:M&J(?ZQKH0IU/%F;A+>RPY(;^PC^_1]02P$"'@,4````"`#O
MA`='J;1L7XO?``#Y&0D`$0`8```````!````I($`````=&MM<BTR,#$U,#8S
M,"YX;6Q55`4``X$7Q55U>`L``00E#@``!#D!``!02P$"'@,4````"`#OA`='
M!-@)GFP)``!K>0``%0`8```````!````I('6WP``=&MM<BTR,#$U,#8S,%]C
M86PN>&UL550%``.!%\55=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[X0'
M1[3VBG5&/@``;_@$`!4`&````````0```*2!D>D``'1K;7(M,C`Q-3`V,S!?
M9&5F+GAM;%54!0`#@1?%575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.^$
M!T<I#BX<V58``"")!``5`!@```````$```"D@28H`0!T:VUR+3(P,34P-C,P
M7VQA8BYX;6Q55`4``X$7Q55U>`L``00E#@``!#D!``!02P$"'@,4````"`#O
MA`='X+""A1$_```B-`4`%0`8```````!````I(%.?P$`=&MM<BTR,#$U,#8S
M,%]P<F4N>&UL550%``.!%\55=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M[X0'1Z0/8#*1$0``#K\``!$`&````````0```*2!KKX!`'1K;7(M,C`Q-3`V
M,S`N>'-D550%``.!%\55=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(`
'`(K0`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655895082720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, December 31, 2014 (in shares) at Dec. 31, 2014</a></td>
<td class="nump">22,438,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2014 at Dec. 31, 2014</a></td>
<td class="nump">$ 290,004<span></span>
</td>
<td class="nump">$ 26,208<span></span>
</td>
<td class="num">$ (205,864)<span></span>
</td>
<td class="num">$ (22,313)<span></span>
</td>
<td class="nump">$ 88,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">373,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">$ 2,956<span></span>
</td>
<td class="num">(1,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common shares pursuant to exercise of warrants (in shares)</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common shares pursuant to exercise of warrants</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares in conjunction with the private offering, net of issuance costs of $9,700,000</a></td>
<td class="nump">$ 142,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">23,973,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="nump">$ 380,815<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,951)<span></span>
</td>
<td class="num">(5,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, June 30, 2015 (in shares) at Jun. 30, 2015</a></td>
<td class="nump">54,303,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, June 30, 2015 at Jun. 30, 2015</a></td>
<td class="nump">$ 821,660<span></span>
</td>
<td class="nump">$ 27,844<span></span>
</td>
<td class="num">$ (232,739)<span></span>
</td>
<td class="num">$ (28,264)<span></span>
</td>
<td class="nump">$ 588,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b,c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655964564480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">       <tr style="vertical-align: top; text-align: left">     <td style="width: 15pt; text-align: left"><div style="display: inline; font-weight: bold;">3.</div></td>     <td style="width: 5pt"></td>     <td style="text-align: left"><div style="display: inline; font-weight: bold;">Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</div></td>    </tr>     </table>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">On January 11, 2015, the Company entered into a Merger Agreement to acquire 100% of the outstanding shares of Arbutus Inc. and its wholly-owned subsidiary, Enantigen (see note 8). Arbutus Inc. was a privately owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The merger was approved by the Company&#x2019;s shareholders on March 3, 2015 and consummated on March 4, 2015. Arbutus Inc.&#x2019;s results of operations and fair value of assets acquired and liabilities assumed are included in the Company&#x2019;s consolidated financial statements from the date of acquisition.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The transaction has been accounted for using the acquisition method based on ASC 805, Business Combinations, on the basis that Arbutus (formerly Tekmira) is the acquirer, based on managements&#x2019; analysis and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and the relative number of shares issued by the Company on acquisition of Arbutus Inc.. Under the acquisition method, the consideration transferred is measured at the market price as at the acquisition date. The excess of the purchase price over the preliminary value assigned to the net assets acquired has been recorded as goodwill. Acquisition costs are expensed as incurred. The company recorded $9,656,000 of acquisition costs for the six-months ended June 30, 2015.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The Company issued a total of 23,973,315 common shares with a total value of $381,942,000 as consideration, which is comprised of 20,347,906 common shares issued without subjects and 3,625,412 common shares issued to Arbutus Inc.&#x2019;s founding executives and subject to repurchase provision. The fair value of the common shares issued without subjects has been determined to be the Company&#x2019;s NASDAQ closing price of $18.26 on the date prior to the acquisition&#x2019;s consummation, March 4, 2015. The total fair value of the common shares issued subject to repurchase provision has been determined to be $66,196,000, using the Black-Scholes pricing model with assumed risk-free interest rate of 0.74%, volatility of 81%, a zero dividend yield and an expected life of 4 years. Of the total fair value, $9,262,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of $56,934,000 will be recognized as compensation expense over the period of expiry of repurchase provision rights through to August 2018. The Company has included $5,324,000 compensation expense related to the expiration of repurchase provision rights from the acquisition date through to June 30, 2015. In July 2015, in conjunction with amendments to the the employment contracts of Arbutus Inc.&#x2019;s founding executives, the Company amended the repurchase provision rights period of expiry from August 2018 to August 2017. This amendment results in an acceleration of compensation expense recognized in each subsequent period by approximately $1,893,000 per quarter, effective Q3 2015.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">As at June 30, 2015, 3,625,412 shares were issued and outstanding which are subject to repurchase provision. Subsequent to the acquisition date, the repurchase rights expire at a rate of 453,177 shares every 3 months commencing on November 30, 2015.</div>    <!-- Field: Page; Sequence: 11; Value: 3 -->      <!-- Field: /Page -->                  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The Company has further reserved 184,332 shares for the future exercise of Arbutus Inc. stock options. The total fair value of Arbutus Inc. stock options has been determined to be $3,287,000, using the Black-Scholes pricing model with the same assumption inputs used by the Company to determine the fair value of Arbutus options. Of the total fair value, $1,127,000 has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of $2,160,000 will be recognized as compensation expense over the vesting period of the stock options through to December 2018. The Company has included $190,000 compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to June 30, 2015.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The aggregate fair value of consideration transferred to acquire Arbutus Inc.&#x2019;s outstanding shares has been determined to be $381,942,000, and has been attributed to preliminary fair values of assets acquired and liabilities assumed as summarized in the following table, in thousands:</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Consideration paid:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 89%; font-size: 10pt; text-align: left; padding-left: 10pt">Common shares issued without subjects</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">371,553</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Common shares issued subject to repurchase provision</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">9,262</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Common shares issuable for Arbutus Inc. stock options</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,127</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">381,942</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Identifiable assets acquired and liabilities assumed:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Cash</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">324</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">116</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">8</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">147</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acquired intangible assets</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">390,017</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Goodwill</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">156,053</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued liabilities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(3,580</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Other noncurrent liabilities (note 8)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(5,136</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Deferred income tax liability</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(156,017</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total purchase price allocation</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">381,942</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The preliminary fair value of intangible assets is estimated to be $390,017,000 using the income approach. The income approach uses valuation techniques to discount future economic benefits attributed to the subject intangible asset to a present value. Present value is based on current market expectations about those future amounts and includes management&#x2019;s estimates of risk-adjusted future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights and includes estimated cash flows of approximately 20 years and a discount rate of approximately 13.8%. The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;D) HBV assets, as summarized in the table below:</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1.1pt solid">$</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 89%; font-size: 10pt; text-align: left">IPR&amp;D &#x2013; Cyclophilins</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 8%; font-size: 10pt; text-align: right">35,124</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">IPR&amp;D &#x2013; Immune Modulator</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">189,182</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">IPR&amp;D &#x2013; Antigen Inhibitors</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">35,520</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.1pt solid">IPR&amp;D &#x2013; cccDNA</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">130,191</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Total IPR&amp;D</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">390,017</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>     </tr>       </table>  </div>        <!-- Field: Page; Sequence: 12; Value: 3 -->      <!-- Field: /Page -->                <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">All IPR&amp;D acquired are currently classified as indefinite-lived and so is not currently being amortized. IRP&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts, and will be amortized from that time over an estimated useful life based on respective patent terms. The fair value of each IPR&amp;D asset will continue to be evaluated on a quarterly basis for indicators of impairment.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">Based on the preliminary fair values above, an amount of $156,053,000 has been allocated to goodwill, which represents the excess of the purchase price over the final value assigned to the net assets acquired. Goodwill is attributable to synergies expected to arise after the Company&#x2019;s acquisition of Arbutus Inc. The full amount of the goodwill has been assigned to Arbutus, which is the reporting unit management has determined the goodwill to be associated with. The goodwill is not deductible for tax purposes, and is not amortized, but will be evaluated for impairment on an annual basis.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">The amount of net loss of Arbutus Inc. included in the consolidated statements of operations from the acquisition date, through the period ended June 30, 2015 was $4,072,000. Arbutus Inc. did not earn any revenues from the acquisition date through the period ended June 30, 2015.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>    <div style=" font-size: 10pt; text-align: left; margin: 0">The following table presents the unaudited pro forma results for the three and six months ended June 30, 2015 and 2014. The pro forma financial information combines the results of operations of Arbutus, Arbutus Inc., Protiva, Protiva USA, and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014. The pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014. The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.</div>  <div style=" font-size: 10pt; text-align: left; margin: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended <br />June&nbsp;30,</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended <br />June&nbsp;30,</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1.1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; font-weight: bold; text-align: left">Pro forma information</td>      <td style="font-size: 10pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 56%; font-size: 10pt; text-align: left">Gross Revenue</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">3,440</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">1,811</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">8,122</td>      <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">6,241</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Loss from operations</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">(14,420</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(13,844</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">(39,491</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(24,278</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(14,886</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(10,479</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(33,940</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td>      <td style="font-size: 10pt; border-bottom: Black 1.1pt solid">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(32,962</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Basic and diluted loss per share</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">(0.27</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.23</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; font-weight: bold">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; text-align: right">(0.67</td>      <td style="font-size: 10pt; font-weight: bold; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.73</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>       </table>  </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1497-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1490-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1500-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1524-128463<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4922-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4934-128472<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4926-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1383-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655958108816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Business Acquistion Assets and Liabilities Transferred (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 03, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedWithoutSubjectsMember', window );">Common Shares Issued Without Subjects [Member] | Arbutus Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Consideration paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="nump">$ 371,553,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember', window );">Common Shares Issued Subject to Repurchase Provision [Member] | Arbutus Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Consideration paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="nump">66,196,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Common shares issued subject to repurchase provision</a></td>
<td class="nump">9,262,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_SharesIssuableForArbutusStockOptionsMember', window );">Shares Issuable for Arbutus Stock Options [Member] | Arbutus Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Consideration paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Common shares issued subject to repurchase provision</a></td>
<td class="nump">1,127,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember', window );">Arbutus Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Consideration paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );"></a></td>
<td class="nump">381,942,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Identifiable assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">324,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">147,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">390,017,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">156,053,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,580,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other noncurrent liabilities (note 8)</a></td>
<td class="num">(5,136,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred income tax liability</a></td>
<td class="num">(156,017,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );"></a></td>
<td class="nump">381,942,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );"></a></td>
<td class="nump">381,942,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );"></a></td>
<td class="nump">$ 381,942,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity, of which has been attributed as pre-combination service and included as part of the total purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinessacquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accrued liabilities and accounts payable assumed in the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tkmr_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tkmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 37<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 37<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedWithoutSubjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedWithoutSubjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tkmr_ArbutusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_CommonSharesIssuedSubjectToRepurchaseProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_SharesIssuableForArbutusStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=tkmr_SharesIssuableForArbutusStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.2.0.727</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>144</ContextCount>
  <ElementCount>217</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flow (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Nature of Business and Future Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations</Role>
      <ShortName>Note 1 - Nature of Business and Future Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies</Role>
      <ShortName>Note 2 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc</Role>
      <ShortName>Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Collaborations, Contracts and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements</Role>
      <ShortName>Note 4 - Collaborations, Contracts and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Document - Note 5 - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities</Role>
      <ShortName>Note 5 - Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-6-financing</Role>
      <ShortName>Note 6 - Financing</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Concentrations of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk</Role>
      <ShortName>Note 7 - Concentrations of Credit Risk</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Contingencies and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments</Role>
      <ShortName>Note 8 - Contingencies and Commitments</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 2 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-tables</Role>
      <ShortName>Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 4 - Collaborations, Contracts and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-tables</Role>
      <ShortName>Note 4 - Collaborations, Contracts and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 5 - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-tables</Role>
      <ShortName>Note 5 - Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 1 - Nature of Business and Future Operations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-1-nature-of-business-and-future-operations-details-textual</Role>
      <ShortName>Note 1 - Nature of Business and Future Operations (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-2-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Statement - Note 2 - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-2-assets-and-liabilities-measured-at-fair-value-details</Role>
      <ShortName>Note 2 - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Statement - Note 2 - Changes in Fair Value of the Company's Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-2-changes-in-fair-value-of-the-companys-warrants-details</Role>
      <ShortName>Note 2 - Changes in Fair Value of the Company's Warrants (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Statement - Note 2 - Black-Scholes Option-pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-2-blackscholes-optionpricing-assumptions-details</Role>
      <ShortName>Note 2 - Black-Scholes Option-pricing Assumptions (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-3-merger-with-arbutus-biopharma-inc-formerly-oncore-biopharma-inc-details-textual</Role>
      <ShortName>Note 3 - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Statement - Note 3 - Business Acquistion Assets and Liabilities Transferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-3-business-acquistion-assets-and-liabilities-transferred-details</Role>
      <ShortName>Note 3 - Business Acquistion Assets and Liabilities Transferred (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Statement - Note 3 - Summary of Acquired Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-3-summary-of-acquired-identifiable-intangible-assets-details</Role>
      <ShortName>Note 3 - Summary of Acquired Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Statement - Note 3 - Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-3-pro-forma-financial-information-details</Role>
      <ShortName>Note 3 - Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 4 - Collaborations, Contracts and Licensing Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-4-collaborations-contracts-and-licensing-agreements-details-textual</Role>
      <ShortName>Note 4 - Collaborations, Contracts and Licensing Agreements (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Statement - Note 4 - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-4-revenue-recognized-under-collaborations-contracts-and-licensing-agreements-details</Role>
      <ShortName>Note 4 - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Statement - Note 4 - Deferred Collaborations and Contracts Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-4-deferred-collaborations-and-contracts-revenue-details</Role>
      <ShortName>Note 4 - Deferred Collaborations and Contracts Revenue (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Statement - Note 5 - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-5-accounts-payable-and-accrued-liabilities-details</Role>
      <ShortName>Note 5 - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 6 - Financing (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-6-financing-details-textual</Role>
      <ShortName>Note 6 - Financing (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 7 - Concentrations of Credit Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-7-concentrations-of-credit-risk-details-textual</Role>
      <ShortName>Note 7 - Concentrations of Credit Risk (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 8 - Contingencies and Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/20150630/role/statement-note-8-contingencies-and-commitments-details-textual</Role>
      <ShortName>Note 8 - Contingencies and Commitments (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Condensed Consolidated Balance Sheets (Unaudited)'', column(s) 2, 4, 5, 6 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Condensed Consolidated Statements of Cash Flow (Unaudited)'', column(s) 1 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Note 2 - Assets and Liabilities Measured at Fair Value (Details)'', column(s) 2, 4, 5 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Note 3 - Business Acquistion Assets and Liabilities Transferred (Details)'', column(s) 2, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Note 4 - Deferred Collaborations and Contracts Revenue (Details)'', column(s) 3 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>tkmr-20150630.xml</File>
    <File>tkmr-20150630_cal.xml</File>
    <File>tkmr-20150630_def.xml</File>
    <File>tkmr-20150630_lab.xml</File>
    <File>tkmr-20150630_pre.xml</File>
    <File>tkmr-20150630.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm139655968291872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">June 30, 2015</td> <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Trade accounts payable</td> <td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,802</td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,044</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Research and development accruals</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">1,914</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,391</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">License fee accruals</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">250</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fee accruals</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">604</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,294</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred lease inducements</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">364</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">250</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Payroll accruals</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">491</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,873</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Other accrued liabilities</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">745</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">226</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">6,920</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">9,328</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
